

# ERENUMAB/Aimovig®

## CAMG334ADE01 (HER-MES)

### AMNOG Analysis

Modul 4A, Anhang

Datum: 26. April 2021

Status: Final

## Table of contents

Tables .....	8
<i>Demographic Data</i> .....	8
Table 14.1-1.1 Double-blind treatment and study completion (Randomized Set) .....	8
Table 14.1-1.2 Protocol Deviations not related to COVID-19 by deviation category (Randomized Set) .....	9
Table 14.1-1.3 Protocol Deviations related to COVID-19 by deviation category (Randomized Set) .....	10
Table 14.1-2.1 Analysis sets (All Screened) .....	11
Table 14.1-3.1 Patient demographics (Full Analysis Set) .....	12
Table 14.1-3.2 Baseline disease characteristics (Full Analysis Set) .....	14
Table 14.1-4.1 Headache and migraine frequency history (Full Analysis Set) .....	16
Table 14.1-5.1 Prior Prophylactic Migraine Treatment Category and Failure Reasons (Full Analysis Set) .....	17
Table 14.1-6.1 Exposure to double-blind test-IMP (AMG 334 or placebo) (Safety Analysis Set) .....	19
Table 14.1-6.2 Double-blind test-IMP starting dose and reason for dose change (AMG 334 or placebo) (Safety Analysis Set) .....	20
Table 14.1-6.3 Exposure to double-blind control-IMP (Topiramate or placebo) (Safety Analysis Set) .....	21
<i>Efficacy Analysis</i> .....	23
Table 14.2-1.1 Proportion of patients with treatment discontinuation due to AE during the DBTE (Full Analysis Set) .....	23
Table 14.2-1.1.1 Proportion of patients with treatment discontinuation due to AE during the DBTE by Age Group (Full Analysis Set) .....	24
Table 14.2-1.1.2 Proportion of patients with treatment discontinuation due to AE during the DBTE by Gender (Full Analysis Set) .....	25
Table 14.2-1.1.3 Proportion of patients with treatment discontinuation due to AE during the DBTE by Disease Severity (Full Analysis Set) .....	26
Table 14.2-1.1.4 Proportion of patients with treatment discontinuation due to AE during the DBTE by Prior Treatment Failure Status (Full Analysis Set) .....	27
Table 14.2-1.1.5 Proportion of patients with treatment discontinuation due to AE during the DBTE by Study Center (Full Analysis Set) .....	28
Table 14.2-1.2 Proportion of patients with treatment discontinuation due to all-cause during the DBTE. Sensitivity analysis (Full Analysis Set) .....	39
Table 14.2-1.2.1 Proportion of patients with treatment discontinuation due to all-cause during the DBTE. Sensitivity analysis by Age Group (Full Analysis Set) .....	40
Table 14.2-1.2.2 Proportion of patients with treatment discontinuation due to all-cause during the DBTE. Sensitivity analysis by Gender (Full Analysis Set) .....	41
Table 14.2-1.2.3 Proportion of patients with treatment discontinuation due to all-cause during the DBTE. Sensitivity analysis by Disease Severity (Full Analysis Set) .....	42
Table 14.2-1.2.4 Proportion of patients with treatment discontinuation due to all-cause during the DBTE. Sensitivity analysis by Prior Treatment Failure Status (Full Analysis Set) .....	43
Table 14.2-1.2.5 Proportion of patients with treatment discontinuation due to all-cause during the DBTE. Sensitivity analysis by Study Center (Full Analysis Set) .....	44
Table 14.2-2.0 Documentation rate in the diary for Monthly Migraine Days by month (Full Analysis Set) .....	55
Table 14.2-2.1 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the last three months (month 4, 5, 6) (Full Analysis Set) .....	56
Table 14.2-2.1.1 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the last three months (month 4, 5, 6) by Age Group (Full Analysis Set) .....	57

Table 14.2-2.1.2 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the last three months (month 4, 5, 6) by Gender (Full Analysis Set).....	58
Table 14.2-2.1.3 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the last three months (month 4, 5, 6) by Disease Severity (Full Analysis Set).....	59
Table 14.2-2.1.4 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the last three months (month 4, 5, 6) by Prior Treatment Failure Status (Full Analysis Set) .	60
Table 14.2-2.1.5 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the last three months (month 4, 5, 6) by Study Center (Full Analysis Set).....	61
Table 14.2-2.2 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the first month (Full Analysis Set) .....	72
Table 14.2-2.2.1 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the first month by Age Group (Full Analysis Set) .....	73
Table 14.2-2.2.2 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the first month by Gender (Full Analysis Set) .....	74
Table 14.2-2.2.3 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the first month by Disease Severity (Full Analysis Set) .....	75
Table 14.2-2.2.4 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the first month by Prior Treatment Failure Status (Full Analysis Set).....	76
Table 14.2-2.2.5 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the first month by Study Center (Full Analysis Set) .....	77
Table 14.2-3.1 Change from baseline in Monthly Migraine Days over last three months (month 4, 5, 6), Mixed Effects Model for Repeated Measures (Full Analysis Set) .....	88
Table 14.2-3.1.1 Change from baseline in Monthly Migraine Days over last three months (month 4, 5, 6), Mixed Effects Model for Repeated Measures by Age Group (Full Analysis Set).....	89
Table 14.2-3.1.2 Change from baseline in Monthly Migraine Days over last three months (month 4, 5, 6), Mixed Effects Model for Repeated Measures by Gender (Full Analysis Set).....	90
Table 14.2-3.1.3 Change from baseline in Monthly Migraine Days over last three months (month 4, 5, 6), Mixed Effects Model for Repeated Measures by Disease Severity (Full Analysis Set)....	91
Table 14.2-3.1.4 Change from baseline in Monthly Migraine Days over last three months (month 4, 5, 6), Mixed Effects Model for Repeated Measures by Prior Treatment Failure Status (Full Analysis Set) .....	92
Table 14.2-3.1.5 Change from baseline in Monthly Migraine Days over last three months (month 4, 5, 6), Mixed Effects Model for Repeated Measures by Study Center (Full Analysis Set).....	93
Table 14.2-3.2 Change from baseline in Monthly Migraine Days over the first month, Mixed Effects Model for Repeated Measures (Full Analysis Set) .....	108
Table 14.2-3.2.1 Change from baseline in Monthly Migraine Days over the first month, Mixed Effects Model for Repeated Measures by Age Group (Full Analysis Set) .....	109
Table 14.2-3.2.2 Change from baseline in Monthly Migraine Days over the first month, Mixed Effects Model for Repeated Measures by Gender (Full Analysis Set) .....	110
Table 14.2-3.2.3 Change from baseline in Monthly Migraine Days over the first month, Mixed Effects Model for Repeated Measures by Disease Severity (Full Analysis Set) .....	111
Table 14.2-3.2.4 Change from baseline in Monthly Migraine Days over the first month, Mixed Effects Model for Repeated Measures by Prior Treatment Failure Status (Full Analysis Set)....	112
Table 14.2-3.2.5 Change from baseline in Monthly Migraine Days over the first month, Mixed Effects Model for Repeated Measures by Study Center (Full Analysis Set) .....	113
Table 14.2-4.0 Return rates in the diary for HIT-6, Headache Impact Test, by assessment week (Full analysis set) .....	128
Table 14.2-4.1 HIT-6, Headache Impact Test, change from baseline to week 24, Linear Mixed Model for Repeated Measures (Full Analysis Set) .....	129
Table 14.2-4.1.1 HIT-6, Headache Impact Test, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Age Group (Full Analysis Set).....	130
Table 14.2-4.1.2 HIT-6, Headache Impact Test, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Gender (Full Analysis Set).....	131

Table 14.2-4.1.3 HIT-6, Headache Impact Test, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Disease Severity (Full Analysis Set).....	132
Table 14.2-4.1.4 HIT-6, Headache Impact Test, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Prior Treatment Failure Status (Full Analysis Set).....	133
Table 14.2-4.1.5 HIT-6, Headache Impact Test, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Study Center (Full Analysis Set).....	134
Table 14.2-4.2 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 5 points reduction from baseline to week 24, Logistic Regression Model (Full Analysis Set).....	149
Table 14.2-4.2.1 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 5 points reduction from baseline to week 24, Logistic Regression Model by Age Group (Full Analysis Set).....	150
Table 14.2-4.2.2 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 5 points reduction from baseline to week 24, Logistic Regression Model by Gender (Full Analysis Set)	151
Table 14.2-4.2.3 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 5 points reduction from baseline to week 24, Logistic Regression Model by Disease Severity (Full Analysis Set).....	152
Table 14.2-4.2.4 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 5 points reduction from baseline to week 24, Logistic Regression Model by Prior Treatment Failure Status (Full Analysis Set).....	153
Table 14.2-4.2.5 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 5 points reduction from baseline to week 24, Logistic Regression Model by Study Center (Full Analysis Set).....	154
Table 14.2-4.3 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 6.3 points reduction from baseline to week 24, Logistic Regression Model (Full Analysis Set).....	165
Table 14.2-4.3.1 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 6.3 points reduction from baseline to week 24, Logistic Regression Model by Age Group (Full Analysis Set).....	166
Table 14.2-4.3.2 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 6.3 points reduction from baseline to week 24, Logistic Regression Model by Gender (Full Analysis Set).....	167
Table 14.2-4.3.3 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 6.3 points reduction from baseline to week 24, Logistic Regression Model by Disease Severity (Full Analysis Set).....	168
Table 14.2-4.3.4 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 6.3 points reduction from baseline to week 24, Logistic Regression Model by Prior Treatment Failure Status (Full Analysis Set).....	169
Table 14.2-4.3.5 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 6.3 points reduction from baseline to week 24, Logistic Regression Model by Study Center (Full Analysis Set).....	170
Table 14.2-5.0 Return rates in the diary for SF-36v2, Quality of Life, by assessment week (Full analysis set).....	181
Table 14.2-5.1 SF-36v2, Quality of Life, change from baseline to week 24, Linear Mixed Model for Repeated Measures (Full Analysis Set).....	182
Table 14.2-5.1.1 SF-36v2, Quality of Life, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Age Group (Full Analysis Set).....	183
Table 14.2-5.1.2 SF-36v2, Quality of Life, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Gender (Full Analysis Set).....	184
Table 14.2-5.1.3 SF-36v2, Quality of Life, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Disease Severity (Full Analysis Set).....	185
Table 14.2-5.1.4 SF-36v2, Quality of Life, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Prior Treatment Failure Status (Full Analysis Set).....	187
Table 14.2-5.1.5 SF-36v2, Quality of Life, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Study Center (Full Analysis Set).....	189



Table 14.2-5.2 SF-36v2, Quality of Life, Proportion of patients achieving at least a 5 points increase from baseline to week 24, Logistic Regression Model (Full Analysis Set) .....	216
Table 14.2-5.2.1 SF-36v2, Quality of Life, Proportion of patients achieving at least a 5 points increase from baseline to week 24, Logistic Regression Model by Age Group (Full Analysis Set) .....	217
Table 14.2-5.2.2 SF-36v2, Quality of Life, Proportion of patients achieving at least a 5 points increase from baseline to week 24, Logistic Regression Model by Gender (Full Analysis Set) ..	218
Table 14.2-5.2.3 SF-36v2, Quality of Life, Proportion of patients achieving at least a 5 points increase from baseline to week 24, Logistic Regression Model by Disease Severity (Full Analysis Set) .....	219
Table 14.2-5.2.4 SF-36v2, Quality of Life, Proportion of patients achieving at least a 5 points increase from baseline to week 24, Logistic Regression Model by Prior Treatment Failure Status (Full Analysis Set).....	221
Table 14.2-5.2.5 SF-36v2, Quality of Life, Proportion of patients achieving at least a 5 points increase from baseline to week 24, Logistic Regression Model by Study Center (Full Analysis Set) .....	222
Table 14.2-5.3 SF-36v2, Quality of Life, Proportion of patients achieving at least a 9.4/9.6 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model (Full Analysis Set) 240	
Table 14.2-5.3.1 SF-36v2, Quality of Life, Proportion of patients achieving at least a 9.4/9.6 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Age Group (Full Analysis Set) .....	241
Table 14.2-5.3.2 SF-36v2, Quality of Life, Proportion of patients achieving at least a 9.4/9.6 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Gender (Full Analysis Set) .....	242
Table 14.2-5.3.3 SF-36v2, Quality of Life, Proportion of patients achieving at least a 9.4/9.6 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Disease Severity (Full Analysis Set).....	243
Table 14.2-5.3.4 SF-36v2, Quality of Life, Proportion of patients achieving at least a 9.4/9.6 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Prior Treatment Failure Status (Full Analysis Set).....	245
Table 14.2-5.3.5 SF-36v2, Quality of Life, Proportion of patients achieving at least a 9.4/9.6 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Study Center (Full Analysis Set) .....	246
Table 14.2-5.4 SF-36v2, Quality of Life, Proportion of patients achieving at least a 11.2/12.5 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model (Full Analysis Set) .....	264
Table 14.2-5.4.1 SF-36v2, Quality of Life, Proportion of patients achieving at least a 11.2/12.5 points(PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Age Group (Full Analysis Set).....	265
Table 14.2-5.4.2 SF-36v2, Quality of Life, Proportion of patients achieving at least a 11.2/12.5 points(PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Gender (Full Analysis Set) .....	266
Table 14.2-5.4.3 SF-36v2, Quality of Life, Proportion of patients achieving at least a 11.2/12.5 points(PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Disease Severity (Full Analysis Set) .....	267
Table 14.2-5.4.4 SF-36v2, Quality of Life, Proportion of patients achieving at least a 11.2/12.5 points(PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Prior Treatment Failure Status (Full Analysis Set) .....	269
Table 14.2-5.4.5 SF-36v2, Quality of Life, Proportion of patients achieving at least a 11.2/12.5 points(PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Study Center (Full Analysis Set).....	270
Table 14.2-6.0 Return rates in the diary for TSQM Ver II, Satisfaction with Treatment, at week 6 and 24 (Full analysis set).....	288

Table 14.2-6.1 TSQM Ver II, Satisfaction with Treatment, at week 24, Linear Mixed Model for Repeated Measures (Full Analysis Set) .....	289
Table 14.2-6.1.1 TSQM Ver II, Satisfaction with Treatment, at week 24, Linear Mixed Model for Repeated Measures by Age Group (Full Analysis Set).....	290
Table 14.2-6.1.2 TSQM Ver II, Satisfaction with Treatment, at week 24, Linear Mixed Model for Repeated Measures by Gender (Full Analysis Set).....	292
Table 14.2-6.1.3 TSQM Ver II, Satisfaction with Treatment, at week 24, Linear Mixed Model for Repeated Measures by Disease Severity (Full Analysis Set).....	294
Table 14.2-6.1.4 TSQM Ver II, Satisfaction with Treatment, at week 24, Linear Mixed Model for Repeated Measures by Prior Treatment Failure Status (Full Analysis Set) .....	297
Table 14.2-6.1.5 TSQM Ver II, Satisfaction with Treatment, at week 24, Linear Mixed Model for Repeated Measures by Study Center (Full Analysis Set).....	299
<i>Safety Analysis</i> .....	343
Table 14.3.1-1.1 Overview of treatment-emergent adverse events occurring during study (Safety Analysis Set) .....	343
Table 14.3.1-1.1.1 Overview of treatment-emergent adverse events occurring during study by Age Group (Safety Analysis Set).....	344
Table 14.3.1-1.1.2 Overview of treatment-emergent adverse events occurring during study by Gender (Safety Analysis Set) .....	346
Table 14.3.1-1.1.3 Overview of treatment-emergent adverse events occurring during study by Disease Severity (Safety Analysis Set) .....	348
Table 14.3.1-1.1.4 Overview of treatment-emergent adverse events occurring during study by Prior Treatment Failure Status (Safety Analysis Set) .....	351
Table 14.3.1-1.1.5 Overview of treatment-emergent adverse events occurring during study by Study Center (Safety Analysis Set).....	354
Table 14.3.1-2.1 Treatment-emergent adverse events (TEAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade (Safety Analysis Set) .....	381
Table 14.3.1-2.1.1 Treatment-emergent adverse events (TEAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade by Age Group (Safety Analysis Set).....	396
Table 14.3.1-2.1.2 Treatment-emergent adverse events (TEAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade by Gender (Safety Analysis Set).....	410
Table 14.3.1-2.1.3 Treatment-emergent adverse events (TEAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade by Disease Severity (Safety Analysis Set).....	424
Table 14.3.1-2.1.4 Treatment-emergent adverse events (TEAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade by Prior Treatment Failure Status (Safety Analysis Set).....	444
Table 14.3.1-2.1.5 Treatment-emergent adverse events (TEAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade by Study Center (Safety Analysis Set) .....	458
Table 14.3.1-2.3 Adverse events leading to discontinuation of study treatment, during the study, by primary system organ class, preferred term and maximum severity grade (Safety Analysis Set) 610	
Table 14.3.1-2.6 Serious adverse events (SAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade (Safety Analysis Set) .....	615
Table 14.3.1-2.8 Serious adverse events (SAE) leading to discontinuation of study treatment, during the study, by primary system organ class, preferred term and maximum severity grade (Safety Analysis Set).....	616
Table 14.3.1-2.9 Adverse events of special interest (AESI), during the study, by maximum severity grade (Safety Analysis Set).....	617

Table 14.3.1-2.9.1 Adverse events of special interest (AESI), during the study, by Age Group (Safety Analysis Set).....	618
Table 14.3.1-2.9.2 Adverse events of special interest (AESI), during the study, by Gender (Safety Analysis Set) .....	619
Table 14.3.1-2.9.3 Adverse events of special interest (AESI), during the study, by Disease Severity (Safety Analysis Set).....	620
Table 14.3.1-2.9.4 Adverse events of special interest (AESI), during the study, by Prior Treatment Failure Status (Safety Analysis Set).....	621
Table 14.3.1-2.9.5 Adverse events of special interest (AESI), during the study, by Study Center (Safety Analysis Set).....	622
Figures.....	627
<i>Efficacy Analysis</i> .....	627
Figure 14.2-2.1 Monthly Migraine Days - Boxplot (Full Analysis Set) .....	627
Figure 14.2-4.1 HIT-6, Headache Impact Test - Boxplot (Full Analysis Set) .....	628
Figure 14.2-5.1a SF-36v2, Quality of Life, Physical Component Summary - Boxplot (Full Analysis Set) .....	629
Figure 14.2-5.1b SF-36v2, Quality of Life, Mental Component Summary - Boxplot (Full Analysis Set) .....	630
Figure 14.2-6.1a TSQM Ver II, Satisfaction with Treatment, Effectiveness - Boxplot (Full Analysis Set) .....	631
Figure 14.2-6.1b TSQM Ver II, Satisfaction with Treatment, Side effects - Boxplot (Full Analysis Set) .....	632
Figure 14.2-6.1c TSQM Ver II, Satisfaction with Treatment, Convenience - Boxplot (Full Analysis Set) .....	633
Figure 14.2-6.1d TSQM Ver II, Satisfaction with Treatment, Global satisfaction - Boxplot (Full Analysis Set) .....	634

## Tables

### Demographic Data

**Table 14.1-1.1 Double-blind treatment and study completion (Randomized Set)**

Disposition	Treatment Groups		
	AMG334 (N=389) n (%)	Topiramate (N=388) n (%)	All patients (N=777) n (%)
<b>Completed double-blind treatment</b>	334 (85.9)	231 (59.5)	565 (72.7)
<b>Discontinued double-blind treatment</b>	55 (14.1)	157 (40.5)	212 (27.3)
<b>Primary reason for discontinuing double-blind treatment</b>			
Adverse event	41 (10.5)	151 (38.9)	192 (24.7)
Lack of efficacy	1 (0.3)	0	1 (0.1)
No longer requires treatment	0	0	0
Lost to follow-up	4 (1.0)	1 (0.3)	5 (0.6)
Withdrawal of informed consent	1 (0.3)	0	1 (0.1)
New therapy for study indication	0	0	0
Technical problems	0	0	0
Subject/guardian decision	4 (1.0)	3 (0.8)	7 (0.9)
Physician decision	1 (0.3)	0	1 (0.1)
Protocol deviation	3 (0.8)	1 (0.3)	4 (0.5)
Death	0	0	0
Pregnancy	0	1 (0.3)	1 (0.1)
Study terminated by sponsor	0	0	0
Non-compliance with study treatment	0	0	0
<b>Completed study</b>	373 (95.9)	366 (94.3)	739 (95.1)
<b>Discontinued</b>	16 (4.1)	22 (5.7)	38 (4.9)
<b>Primary reason for discontinuing study</b>			
Adverse event	3 (0.8)	12 (3.1)	15 (1.9)
Lost to follow-up	4 (1.0)	2 (0.5)	6 (0.8)
Withdrawal of informed consent	2 (0.5)	1 (0.3)	3 (0.4)
New therapy for study indication	1 (0.3)	0	1 (0.1)
Technical problems	0	0	0
Subject/guardian decision	3 (0.8)	5 (1.3)	8 (1.0)
Physician decision	0	0	0
Protocol deviation	3 (0.8)	2 (0.5)	5 (0.6)
Death	0	0	0
Pregnancy	0	0	0
Study terminated by sponsor	0	0	0
A patient is defined as completer for the double-blind treatment if double-blind treatment completion status on the eCRF page is ticked as not prematurely discontinued			
A patient is defined as completer for the study if study completion status on the eCRF page is ticked as not prematurely discontinued			

**Table 14.1-1.2 Protocol Deviations not related to COVID-19 by deviation category  
(Randomized Set)**

Protocol deviation categories	Treatment Groups		
	AMG334 (N=389) n (%)	Topiramate (N=388) n (%)	All patients (N=777) n (%)
<b>Patients with at least one protocol deviation not related to COVID-19</b>	37 (9.5)	51 (13.1)	88 (11.3)
<b>Protocol deviation</b>			
Inclusion/Exclusion Criteria (Study eligibility)	16 (4.1)	14 (3.6)	28 (3.6)
Withdrawal criteria met, but subject not discontinued	0	0	0
Treatment deviation	24 (6.2)	30 (7.7)	46 (5.9)
Prohibited concomitant medication	5 (1.3)	15 (3.9)	19 (2.4)
Other	0	0	0
- N: the number of patients included in the analysis set. - n: the number of patients with at least one PD from the corresponding category			

**Table 14.1-1.3 Protocol Deviations related to COVID-19 by deviation category  
(Randomized Set)**

Protocol deviation categories	Treatment Groups		
	AMG334 (N=389)	Topiramate (N=388)	All patients (N=777)
	n (%)	n (%)	n (%)
<b>Patients with at least one protocol deviation related to COVID-19</b>	23 (5.9)	31 (8.0)	54 (6.9)
<b>COVID-19 PD Category</b>			
Missed visit due to COVID-19	0	0	0
Visit done outside of study site due to COVID-19	10 (2.6)	18 (4.6)	28 (3.6)
Assessment / procedure changed due to COVID-19	20 (5.1)	17 (4.4)	37 (4.8)
Drug supply method changed due to COVID-19	3 (0.8)	0	3 (0.4)
Treatment not given due to COVID-19	1 (0.3)	0	1 (0.1)
Discontinuation due to COVID-19	0	0	0
Other protocol deviation due to COVID-19	1 (0.3)	0	1 (0.1)
<b>Relationship of PD to COVID-19</b>			
COVID-19 health status related (i.e. patient's infection did lead to this PD)	0	0	0
COVID-19 situation: Site issue (e.g. site closed, personnel not available)	18 (4.6)	27 (7.0)	45 (5.8)
COVID-19 situation: Lockdown / Quarantine of patient (e.g. site is active but patient not allowed to come)	2 (0.5)	0	2 (0.3)
COVID-19 situation: Patient concern (e.g. site is active, patient could come but refused to come / do assessment)	3 (0.8)	6 (1.5)	9 (1.2)
COVID-19 situation: Drug supply issue (e.g. drug was delivered to home)	0	0	0
COVID-19 situation: Other	2 (0.5)	0	2 (0.3)

- N: the number of patients included in the analysis set.  
- n: the number of patients with at least one PD from the corresponding category

**Table 14.1-2.1 Analysis sets (All Screened)**

Analysis Population	Treatment Groups		
	AMG334 n (%)	Topiramate n (%)	All patients n (%)
<b>Screened</b>			949
<b>Randomized Set (RS)</b>	389 (100.0)	388 (100.0)	777 (100.0)
<b>Full Analysis set (FAS)</b>	388 (99.7)	388 (100.0)	776 (99.9)
<b>Safety Analysis Set (SAF)</b>	388 (99.7)	388 (100.0)	776 (99.9)
Percentage is out of total number of patients from Randomized Set (RS) 1 patient is excluded from FAS due to no intake of active study medication. 1 patient is excluded from SAF due to no intake of active study medication.			

**Table 14.1-3.1 Patient demographics (Full Analysis Set)**

Characteristic	Treatment Groups		
	AMG334 (N=388)	Topiramate (N=388)	All patients (N=776)
<b>Age (years)</b>			
n	388	388	776
Mean	40.8	40.7	40.7
Standard deviation	12.4	12.4	12.4
Minimum	18.0	18.0	18.0
Median	41.5	41.0	41.0
Maximum	66.0	65.0	66.0
<b>Sex, n (%)</b>			
Male	57 (14.7)	53 (13.7)	110 (14.2)
Female	331 (85.3)	335 (86.3)	666 (85.8)
<b>Race, n (%)</b>			
Caucasian	383 (98.7)	387 (99.7)	770 (99.2)
Black	0	0	0
Asian	1 (0.3)	0	1 (0.1)
Native American	0	0	0
Pacific Islander	0	0	0
Unknown	1 (0.3)	0	1 (0.1)
Other	3 (0.8)	1 (0.3)	4 (0.5)
<b>Weight (kg)</b>			
n	388	387	775
Mean	73.3	72.7	73.0
Standard deviation	17.9	17.5	17.7
Minimum	45.0	44.0	44.0
Median	69.9	68.4	69.0
Maximum	180.0	151.0	180.0
<b>Height (cm)</b>			
n	388	387	775
Mean	169.0	169.2	169.1
Standard deviation	7.8	7.4	7.6
Minimum	150.0	152.0	150.0
Median	168.0	168.0	168.0
Maximum	196.0	196.0	196.0
<b>BMI (kg/m<sup>2</sup>)</b>			
n	388	387	775
Mean	25.6	25.3	25.5
Standard deviation	5.6	5.6	5.6
Minimum	17.6	17.1	17.1
Median	24.0	23.9	24.0
Maximum	52.0	52.9	52.9



Characteristic	Treatment Groups		
	AMG334 (N=388)	Topiramate (N=388)	All patients (N=776)
<b>Source of patient referral, n (%)</b>			
Physician´s own practice	198 (51.0)	187 (48.2)	385 (49.6)
Physician referral	28 (7.2)	29 (7.5)	57 (7.3)
Radio advertisement	0	0	0
Print advertisement	49 (12.6)	51 (13.1)	100 (12.9)
Newsletter/Educational material	5 (1.3)	3 (0.8)	8 (1.0)
Advocacy group	0	0	0
ER visit or hospital	0	1 (0.3)	1 (0.1)
Novartis internet site	24 (6.2)	26 (6.7)	50 (6.4)
Non-Novartis internet site	33 (8.5)	36 (9.3)	69 (8.9)
Clinical trial registry	11 (2.8)	18 (4.6)	29 (3.7)
Unknown	6 (1.5)	11 (2.8)	17 (2.2)
Other	34 (8.8)	26 (6.7)	60 (7.7)
- Weight and height are taken from screening vital signs evaluations. - BMI (kg/m <sup>2</sup> ): body mass index, computed as weight[kg] / (height[m] <sup>2</sup> )			

**Table 14.1-3.2 Baseline disease characteristics (Full Analysis Set)**

Characteristic	Treatment Groups		
	AMG334 (N=388)	Topiramate (N=388)	All patients (N=776)
<b>Monthly migraine days</b>			
n	387	388	775
Mean	10.3	10.5	10.4
Standard deviation	4.0	3.8	3.9
Minimum	2.0	4.0	2.0
Median	9.7	10.0	10.0
Maximum	28.0	28.0	28.0
<b>Monthly migraine days categories, n (%)</b>			
< 4	2 (0.5)	0	2 (0.3)
4 - 7	94 (24.2)	92 (23.7)	186 (24.0)
8 - 14	248 (63.9)	254 (65.5)	502 (64.7)
≥ 15	43 (11.1)	42 (10.8)	85 (11.0)
missing	1 (0.3)	0	1 (0.1)
<b>Monthly migraine days - stratification factor*, n (%)</b>			
4 - 7	97 (25.0)	97 (25.0)	194 (25.0)
8 - 14	255 (65.7)	255 (65.7)	510 (65.7)
≥ 15	36 (9.3)	36 (9.3)	72 (9.3)
<b>Monthly headache days</b>			
n	387	388	775
Mean	11.4	11.5	11.5
Standard deviation	4.2	4.1	4.2
Minimum	4.0	4.0	4.0
Median	10.6	11.0	11.0
Maximum	28.0	28.0	28.0
<b>Acute headache medication, n (%)</b>			
None	10 (2.6)	10 (2.6)	20 (2.6)
Any acute medication	378 (97.4)	378 (97.4)	756 (97.4)
- Migraine-specific	304 (78.4)	320 (82.5)	624 (80.4)
- Non migraine-specific	74 (19.1)	58 (14.9)	132 (17.0)
<b>Prior treatment failure status**, n (%)</b>			
Naïve	232 (59.8)	229 (59.0)	461 (59.4)
Prior treatment failure	156 (40.2)	159 (41.0)	315 (40.6)
- 1 treatment failed	115 (29.6)	123 (31.7)	238 (30.7)
- 2 treatments failed	37 (9.5)	31 (8.0)	68 (8.8)
- 3 treatments failed	4 (1.0)	5 (1.3)	9 (1.2)
<b>Beck Depression Inventory (BDI)-II total score, n (%)</b>			
0 - 13	371 (95.6)	373 (96.1)	744 (95.9)
14 - 19	17 (4.4)	10 (2.6)	27 (3.5)
> 19	0	5 (1.3)	5 (0.6)

Characteristic	Treatment Groups		
	AMG334 (N=388)	Topiramate (N=388)	All patients (N=776)
<p>* Differs from Monthly migraine days categories due to protocol deviations.  ** Prior treatment failure of propranolol/metoprolol, amitriptyline, flunarizine  - The baseline period is defined as the period between week -  4 visit and the day prior to first dose. The baseline value of monthly migraine days is the prorated  number to 28-day equivalents during baseline period.  - Baseline for BDI-II is the last evaluable measurements prior to the first administration of study treatment</p>			

**Table 14.1-4.1 Headache and migraine frequency history (Full Analysis Set)**

Characteristic	Treatment Groups		
	AMG334 (N=388)	Topiramate (N=388)	All patients (N=776)
<b>Frequency of migraines over the past 3 months (average days per month subject had migraines)</b>			
n	388	388	776
Mean	8.0	8.0	8.0
Standard deviation	2.7	2.9	2.8
Minimum	4.0	4.0	4.0
Median	7.6	7.6	7.6
Maximum	16.0	20.0	20.0
<b>Frequency of headache (migraine and non-migraine) over the past 3 months (average days per month subject had headache)</b>			
n	388	388	776
Mean	9.7	9.7	9.7
Standard deviation	3.8	4.1	3.9
Minimum	4.0	4.0	4.0
Median	9.0	9.0	9.0
Maximum	30.0	30.0	30.0
<b>Age at migraine onset (years)</b>			
n	388	388	776
Mean	18.9	18.8	18.8
Standard deviation	9.6	9.3	9.5
Minimum	2.0	2.0	2.0
Median	16.0	17.0	17.0
Maximum	49.0	50.0	50.0

**Table 14.1-5.1 Prior Prophylactic Migraine Treatment Category and Failure Reasons (Full Analysis Set)**

Medication category Discontinuation reason	Treatment Groups		
	AMG334 (N=388) n (%)	Topiramate (N=388) n (%)	All patients (N=776) n (%)
<b>Any medication category</b>	<b>188 (48.5)</b>	<b>182 (46.9)</b>	<b>370 (47.7)</b>
Lack of efficacy	151 (38.9)	140 (36.1)	291 (37.5)
Lack of tolerability	62 (16.0)	60 (15.5)	122 (15.7)
Other	11 (2.8)	13 (3.4)	24 (3.1)
<b>Metoprolol</b>	<b>91 (23.5)</b>	<b>93 (24.0)</b>	<b>184 (23.7)</b>
Lack of efficacy	59 (15.2)	61 (15.7)	120 (15.5)
Lack of tolerability	30 (7.7)	24 (6.2)	54 (7.0)
Other	2 (0.5)	8 (2.1)	10 (1.3)
<b>Propranolol</b>	<b>22 (5.7)</b>	<b>31 (8.0)</b>	<b>53 (6.8)</b>
Lack of efficacy	20 (5.2)	19 (4.9)	39 (5.0)
Lack of tolerability	2 (0.5)	11 (2.8)	13 (1.7)
Other	0	1 (0.3)	1 (0.1)
<b>Flunarizine</b>	<b>22 (5.7)</b>	<b>24 (6.2)</b>	<b>46 (5.9)</b>
Lack of efficacy	16 (4.1)	17 (4.4)	33 (4.3)
Lack of tolerability	6 (1.5)	7 (1.8)	13 (1.7)
<b>Amitriptyline</b>	<b>68 (17.5)</b>	<b>54 (13.9)</b>	<b>122 (15.7)</b>
Lack of efficacy	39 (10.1)	33 (8.5)	72 (9.3)
Lack of tolerability	24 (6.2)	19 (4.9)	43 (5.5)
Other	5 (1.3)	2 (0.5)	7 (0.9)
<b>Candesartan</b>	<b>2 (0.5)</b>	<b>5 (1.3)</b>	<b>7 (0.9)</b>
Lack of efficacy	2 (0.5)	3 (0.8)	5 (0.6)
Lack of tolerability	0	2 (0.5)	2 (0.3)
<b>Venlafaxine</b>	<b>7 (1.8)</b>	<b>6 (1.5)</b>	<b>13 (1.7)</b>
Lack of efficacy	4 (1.0)	4 (1.0)	8 (1.0)
Lack of tolerability	2 (0.5)	2 (0.5)	4 (0.5)
Other	1 (0.3)	0	1 (0.1)
<b>Opipramol</b>	<b>13 (3.4)</b>	<b>5 (1.3)</b>	<b>18 (2.3)</b>
Lack of efficacy	9 (2.3)	3 (0.8)	12 (1.5)
Lack of tolerability	3 (0.8)	1 (0.3)	4 (0.5)
Other	1 (0.3)	1 (0.3)	2 (0.3)
<b>Bisoprolol</b>	<b>12 (3.1)</b>	<b>8 (2.1)</b>	<b>20 (2.6)</b>
Lack of efficacy	11 (2.8)	5 (1.3)	16 (2.1)
Lack of tolerability	1 (0.3)	3 (0.8)	4 (0.5)
<b>Atenolol</b>	<b>0</b>	<b>1 (0.3)</b>	<b>1 (0.1)</b>
Lack of efficacy	0	1 (0.3)	1 (0.1)
<b>Nebivolol</b>	<b>1 (0.3)</b>	<b>0</b>	<b>1 (0.1)</b>
Lack of efficacy	1 (0.3)	0	1 (0.1)

<b>Treatment Groups</b>			
<b>Medication category</b>	<b>AMG334</b>	<b>Topiramate</b>	<b>All patients</b>
<b>Discontinuation reason</b>	<b>(N=388)</b>	<b>(N=388)</b>	<b>(N=776)</b>
	<b>n (%)</b>	<b>n (%)</b>	<b>n (%)</b>
<b>Acetylsalicylic acid</b>	<b>8 (2.1)</b>	<b>3 (0.8)</b>	<b>11 (1.4)</b>
Lack of efficacy	6 (1.5)	3 (0.8)	9 (1.2)
Lack of tolerability	1 (0.3)	0	1 (0.1)
Other	1 (0.3)	0	1 (0.1)
<b>Butterbur extract</b>	<b>3 (0.8)</b>	<b>3 (0.8)</b>	<b>6 (0.8)</b>
Lack of efficacy	2 (0.5)	3 (0.8)	5 (0.6)
Other	1 (0.3)	0	1 (0.1)
<b>Feverfew</b>	<b>2 (0.5)</b>	<b>0</b>	<b>2 (0.3)</b>
Lack of efficacy	2 (0.5)	0	2 (0.3)
<b>Magnesium</b>	<b>23 (5.9)</b>	<b>19 (4.9)</b>	<b>42 (5.4)</b>
Lack of efficacy	19 (4.9)	17 (4.4)	36 (4.6)
Other	2 (0.5)	2 (0.5)	4 (0.5)
Lack of tolerability	2 (0.5)	0	2 (0.3)
<b>Magnesium + Vitamin B2 + Coenzyme Q10</b>	<b>4 (1.0)</b>	<b>4 (1.0)</b>	<b>8 (1.0)</b>
Lack of efficacy	4 (1.0)	4 (1.0)	8 (1.0)
<b>Vitamin B2</b>	<b>2 (0.5)</b>	<b>2 (0.5)</b>	<b>4 (0.5)</b>
Lack of efficacy	2 (0.5)	2 (0.5)	4 (0.5)
<b>Coenzyme Q10</b>	<b>0</b>	<b>1 (0.3)</b>	<b>1 (0.1)</b>
Lack of efficacy	0	1 (0.3)	1 (0.1)
<b>Other</b>	<b>9 (2.3)</b>	<b>13 (3.4)</b>	<b>22 (2.8)</b>
Lack of efficacy	6 (1.5)	7 (1.8)	13 (1.7)
Lack of tolerability	3 (0.8)	6 (1.5)	9 (1.2)

Categories are not mutually exclusive and patients may contribute to more than one category.

**Table 14.1-6.1 Exposure to double-blind test-IMP (AMG 334 or placebo) (Safety Analysis Set)**

	Treatment groups		
	AMG334 (N=388)	Topiramate (N=388)	All patients (N=776)
<b>Duration of exposure</b>			
<b>Total number of doses received, n (%)</b>			
1 dose	28 (7.2)	87 (22.4)	115 (14.8)
2 doses	10 (2.6)	43 (11.1)	53 (6.8)
3 doses	4 (1.0)	17 (4.4)	21 (2.7)
4 doses	7 (1.8)	9 (2.3)	16 (2.1)
5 doses	4 (1.0)	1 (0.3)	5 (0.6)
6 doses	335 (86.3)	231 (59.5)	566 (72.9)
<b>Duration of exposure (Weeks)</b>			
n	388	388	776
Mean	21.8	17.0	19.4
SD	5.79	8.79	7.82
Minimum	4.0	4.0	4.0
Median	24.0	23.9	24.0
Maximum	25.0	25.1	25.1
Sum (total patient years)	162.3	126.3	288.6

**Table 14.1-6.2 Double-blind test-IMP starting dose and reason for dose change (AMG 334 or placebo) (Safety Analysis Set)**

Parameter	Treatment groups		
	AMG334 (N=388) n (%)	Topiramate (N=388) n (%)	All patients (N=776) n (%)
<b>Start dose</b>			
70 mg	285 (73.5)	302 (77.8)	587 (75.6)
140 mg	103 (26.5)	86 (22.2)	189 (24.4)
<b>Reason for starting dose of 140 mg*</b>			
Accelerated onset of action desired due to a very high degree of suffering	72 (69.9)	59 (68.6)	131 (69.3)
History of prophylactic treatment failure	18 (17.5)	20 (23.3)	38 (20.1)
Other	19 (18.4)	15 (17.4)	34 (18.0)
<b>Dose change from 70 mg to 140 mg</b>			
Dose change	165 (42.5)	152 (39.2)	317 (40.9)
<b>Reason for dose change from 70 mg to 140 mg**</b>			
Insufficient response as deemed by physician and/or patient (e.g. 50% reduction in MMD not achieved)	122 (73.9)	113 (74.3)	235 (74.1)
Reduction of acute medication use not satisfactory	14 (8.5)	15 (9.9)	29 (9.1)
Insufficient improvement in life quality	58 (35.2)	52 (34.2)	110 (34.7)

\* Multiple answers possible; percentage based on number of patients with start dose of 140 mg

\*\* Multiple answers possible; percentage based on number of patients with dose change



**Table 14.1-6.3 Exposure to double-blind control-IMP (Topiramate or placebo) (Safety Analysis Set)**

Dose / Duration of exposure	Treatment groups		
	AMG334 (N=388)	Topiramate (N=388)	All patients (N=776)
<b>Dose, n (%)</b>			
<b>Day 1</b>			
25 mg	387 (100.0)	388 (100.0)	775 (100.0)
50 mg	0	0	0
75 mg	0	0	0
100 mg	0	0	0
missing	1	0	1
<b>Week 1</b>			
25 mg	25 (6.6)	44 (11.8)	69 (9.2)
50 mg	355 (93.4)	330 (88.2)	685 (90.8)
75 mg	0	0	0
100 mg	0	0	0
missing	8	14	22
<b>Week 2</b>			
25 mg	6 (1.6)	11 (3.2)	17 (2.4)
50 mg	59 (15.9)	98 (28.3)	157 (21.9)
75 mg	305 (82.4)	237 (68.5)	542 (75.7)
100 mg	0	0	0
missing	18	42	60
<b>Week 3</b>			
25 mg	2 (0.5)	3 (0.9)	5 (0.7)
50 mg	30 (8.2)	49 (15.1)	79 (11.5)
75 mg	87 (23.8)	109 (33.6)	196 (28.4)
100 mg	246 (67.4)	163 (50.3)	409 (59.4)
missing	23	64	87
<b>Week 4</b>			
25 mg	0	2 (0.7)	2 (0.3)
50 mg	14 (3.9)	24 (8.0)	38 (5.7)
75 mg	50 (13.9)	71 (23.6)	121 (18.3)
100 mg	296 (82.2)	204 (67.8)	500 (75.6)
missing	28	87	115
<b>Week 5</b>			
25 mg	0	0	0
50 mg	9 (2.5)	21 (7.4)	30 (4.7)
75 mg	35 (9.8)	52 (18.2)	87 (13.6)
100 mg	313 (87.7)	212 (74.4)	525 (81.8)
missing	31	103	134

	<b>Treatment groups</b>		
<b>Dose / Duration of exposure</b>	<b>AMG334 (N=388)</b>	<b>Topiramate (N=388)</b>	<b>All patients (N=776)</b>
<b>Week 6</b>			
25 mg	0	0	0
50 mg	8 (2.3)	19 (6.9)	27 (4.3)
75 mg	35 (9.9)	49 (17.8)	84 (13.4)
100 mg	310 (87.8)	207 (75.3)	517 (82.3)
missing	35	113	148
<b>Duration of exposure until tapering off phase (weeks)</b>			
n	387	388	775
Mean	21.8	16.5	19.1
Standard deviation	6.3	9.6	8.5
Minimum	0.1	0.1	0.1
Median	24.1	24.0	24.1
Maximum	27.3	26.0	27.3
<b>Duration of exposure including tapering off phase (weeks)</b>			
n	387	388	775
Mean	21.8	16.5	19.1
Standard deviation	6.3	9.6	8.5
Minimum	0.1	0.1	0.1
Median	24.1	24.0	24.1
Maximum	27.3	26.0	27.3

## Efficacy Analysis

**Table 14.2-1.1 Proportion of patients with treatment discontinuation due to AE during the DBTE (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Discontinuation of treatment due to AE during DBTE</b>					
N'	388	388	0.19	0.27	-0.28
n (%)	41 (10.6)	151 (38.9)	[0.13; 0.27] <.001	[0.20; 0.37] <.001	[-0.34; -0.23] <.001
<p>N': Number of patients with available response value  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR is obtained from a logistic regression model that includes treatment group and stratification factor (MMD at baseline).  RR and RD are calculated directly (without adjustment) and with CI and p-value based on the Wald statistic.</p>					

**Table 14.2-1.1.1 Proportion of patients with treatment discontinuation due to AE during the DBTE by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
< median age, N	186	190			
≥ median age, N	202	198			
<b>Discontinuation of treatment due to AE during DBTE</b>					
<b>Interaction test: p=0.292</b>					
<b>&lt; median age</b>					
N'	186	190	0.23	0.31	-0.23
n (%)	20 (10.8)	65 (34.2)	[0.13; 0.40] <.001	[0.20; 0.50] <.001	[-0.32; -0.15] <.001
<b>≥ median age</b>					
N'	202	198	0.15	0.24	-0.33
n (%)	21 (10.4)	86 (43.4)	[0.09; 0.26] <.001	[0.15; 0.37] <.001	[-0.41; -0.25] <.001
<p>N': Number of patients with available response value  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p>					

**Table 14.2-1.1.2 Proportion of patients with treatment discontinuation due to AE during the DBTE by Gender (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Male, N	57	53			
Female, N	331	335			
<b>Discontinuation of treatment due to AE during DBTE</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
N'	57	53	N.E.	0.02	-0.36
n (%)	0 (0.0)	19 (35.8)		[0.00; 0.39] 0.009	[-0.49; -0.23] <.001
<b>Female</b>					
N'	331	335	0.22	0.31	-0.27
n (%)	41 (12.4)	132 (39.4)	[0.15; 0.32] <.001	[0.23; 0.43] <.001	[-0.33; -0.21] <.001
<p>N': Number of patients with available response value  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup that include treatment group and stratification factor (MMD at baseline).  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.</p>					

**Table 14.2-1.1.3 Proportion of patients with treatment discontinuation due to AE during the DBTE by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92			
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254			
≥ 15 monthly migraine days at baseline, N	43	42			
<b>Discontinuation of treatment due to AE during DBTE</b>					
<b>Interaction test: p=0.693</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
N'	96	92	0.14	0.21	-0.32
n (%)	8 (8.3)	37 (40.2)	[0.06; 0.31] <.001	[0.10; 0.42] <.001	[-0.43; -0.20] <.001
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
N'	249	254	0.21	0.29	-0.27
n (%)	28 (11.2)	97 (38.2)	[0.13; 0.33] <.001	[0.20; 0.43] <.001	[-0.34; -0.20] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
N'	43	42	0.19	0.29	-0.29
n (%)	5 (11.6)	17 (40.5)	[0.06; 0.59] 0.004	[0.12; 0.71] 0.007	[-0.47; -0.11] 0.001
<p>N': Number of patients with available response value  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.  <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.  The stratification factor is not included in the logistic regression model due to collinearity with the subgroups.</p>					

**Table 14.2-1.1.4 Proportion of patients with treatment discontinuation due to AE during the DBTE by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Naïve*, N	232	229			
Prior treatment failure*, N	156	159			
<b>Discontinuation of treatment due to AE during DBTE</b>					
<b>Interaction test: p=0.845</b>					
<b>Naïve*</b>					
N'	232	229	0.19	0.28	-0.27
n (%)	24 (10.3)	86 (37.6)	[0.12; 0.32] <.001	[0.18; 0.42] <.001	[-0.35; -0.20] <.001
<b>Prior treatment failure*</b>					
N'	156	159	0.18	0.27	-0.30
n (%)	17 (10.9)	65 (40.9)	[0.10; 0.32] <.001	[0.16; 0.43] <.001	[-0.39; -0.21] <.001
<p>N': Number of patients with available response value  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>*: 'Naïve'/'Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>					

**Table 14.2-1.1.5 Proportion of patients with treatment discontinuation due to AE during the DBTE by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1001, N	10	8			
Center No. 1002, N	4	0			
Center No. 1003, N	2	3			
Center No. 1005, N	31	22			
Center No. 1007, N	5	7			
Center No. 1008, N	3	3			
Center No. 1010, N	2	3			
Center No. 1011, N	2	5			
Center No. 1012, N	3	5			
Center No. 1014, N	5	4			
Center No. 1015, N	4	2			
Center No. 1017, N	5	4			
Center No. 1018, N	7	6			
Center No. 1019, N	2	2			
Center No. 1021, N	16	10			
Center No. 1022, N	3	3			
Center No. 1025, N	0	2			
Center No. 1027, N	3	5			
Center No. 1028, N	11	5			
Center No. 1029, N	15	9			
Center No. 1030, N	11	9			
Center No. 1032, N	2	4			
Center No. 1033, N	4	6			
Center No. 1034, N	4	3			
Center No. 1035, N	27	22			
Center No. 1036, N	7	7			
Center No. 1037, N	9	11			
Center No. 1039, N	4	3			
Center No. 1040, N	0	3			
Center No. 1041, N	5	5			
Center No. 1042, N	4	5			
Center No. 1044, N	0	2			



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1046, N	1	1			
Center No. 1048, N	0	3			
Center No. 1049, N	1	0			
Center No. 1050, N	6	9			
Center No. 1051, N	1	1			
Center No. 1052, N	7	4			
Center No. 1055, N	2	4			
Center No. 1058, N	0	1			
Center No. 1059, N	7	7			
Center No. 1061, N	9	6			
Center No. 1063, N	4	2			
Center No. 1064, N	0	3			
Center No. 1067, N	10	16			
Center No. 1068, N	0	2			
Center No. 1069, N	3	4			
Center No. 1070, N	1	5			
Center No. 1072, N	2	1			
Center No. 1073, N	11	7			
Center No. 1074, N	5	3			
Center No. 1076, N	1	5			
Center No. 1077, N	3	2			
Center No. 1079, N	4	3			
Center No. 1080, N	3	1			
Center No. 1082, N	5	8			
Center No. 1084, N	2	3			
Center No. 1085, N	0	3			
Center No. 1086, N	6	9			
Center No. 1087, N	1	4			
Center No. 1088, N	6	6			
Center No. 1089, N	4	4			
Center No. 1091, N	6	5			
Center No. 1093, N	1	4			
Center No. 1095, N	5	3			
Center No. 1096, N	2	0			
Center No. 1100, N	1	4			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1101, N	4	6			
Center No. 1103, N	2	3			
Center No. 1105, N	3	3			
Center No. 1108, N	15	10			
Center No. 1110, N	6	5			
Center No. 1111, N	5	0			
Center No. 1113, N	3	3			
Center No. 1115, N	5	6			
Center No. 1116, N	1	4			
Center No. 1118, N	3	2			
Center No. 1119, N	3	5			
Center No. 1121, N	4	4			
Center No. 1123, N	1	1			
Center No. 1124, N	3	2			
Center No. 1502, N	0	3			
<b>Discontinuation of treatment due to AE during DBTE</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
N'	10	8	0.11	0.20	-0.40
n (%)	1 (10.0)	4 (50.0)	[<0.01; 1.34] 0.083†	[0.03; 1.45] 0.112	[-0.79; -0.01] 0.046
<b>Center No. 1002</b>					
N'	4	0	N.E.	N.E.	N.E.
n (%)	2 (50.0)	0 (0.0)			
<b>Center No. 1003</b>					
N'	2	3	N.E.	0.44	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.03; 7.52] 0.574	[-0.87; 0.20] 0.221
<b>Center No. 1005</b>					
N'	31	22	0.21	0.35	-0.29
n (%)	5 (16.1)	10 (45.5)	[0.06; 0.83] 0.026	[0.14; 0.89] 0.028	[-0.54; -0.05] 0.019
<b>Center No. 1007</b>					
N'	5	7	0.89	0.93	-0.03
n (%)	2 (40.0)	3 (42.9)	[0.09; 9.16] 0.921†	[0.24; 3.68] 0.922	[-0.59; 0.54] 0.921

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1008</b>					
N'	3	3	N.E.	0.33	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.02; 5.97] 0.455	[-0.87; 0.20] 0.221
<b>Center No. 1010</b>					
N'	2	3	2.00	1.50	0.17
n (%)	1 (50.0)	1 (33.3)	[0.05; 78.25] 0.711†	[0.18; 12.46] 0.707	[-0.71; 1.04] 0.709
<b>Center No. 1011</b>					
N'	2	5	N.E.	0.29	-0.60
n (%)	0 (0.0)	3 (60.0)		[0.02; 3.92] 0.349	[-1.03; -0.17] 0.006
<b>Center No. 1012</b>					
N'	3	5	N.E.	0.21	-0.60
n (%)	0 (0.0)	3 (60.0)		[0.01; 3.12] 0.260	[-1.03; -0.17] 0.006
<b>Center No. 1014</b>					
N'	5	4	N.E.	0.17	-0.50
n (%)	0 (0.0)	2 (50.0)		[0.01; 2.73] 0.209	[-0.99; -0.01] 0.046
<b>Center No. 1015</b>					
N'	4	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1017</b>					
N'	5	4	N.E.	0.28	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.01; 5.43] 0.398	[-0.67; 0.17] 0.248
<b>Center No. 1018</b>					
N'	7	6	N.E.	0.29	-0.17
n (%)	0 (0.0)	1 (16.7)		[0.01; 6.07] 0.426	[-0.46; 0.13] 0.273
<b>Center No. 1019</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1021</b>					
N'	16	10	0.23	0.38	-0.31
n (%)	3 (18.8)	5 (50.0)	[0.04; 1.35] 0.103†	[0.11; 1.24] 0.107	[-0.68; 0.05] 0.093
<b>Center No. 1022</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1025</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1027</b>					
N'	3	5	N.E.	0.30	-0.40
n (%)	0 (0.0)	2 (40.0)		[0.02; 4.74] 0.393	[-0.83; 0.03] 0.068
<b>Center No. 1028</b>					
N'	11	5	0.15	0.23	-0.31
n (%)	1 (9.1)	2 (40.0)	[<0.01; 2.29] 0.172†	[0.03; 1.96] 0.178	[-0.77; 0.15] 0.190
<b>Center No. 1029</b>					
N'	15	9	0.10	0.26	-0.58
n (%)	3 (20.0)	7 (77.8)	[0.01; 0.83] 0.033	[0.09; 0.75] 0.013	[-0.92; -0.24] <.001
<b>Center No. 1030</b>					
N'	11	9	0.35	0.41	-0.13
n (%)	1 (9.1)	2 (22.2)	[0.03; 4.65] 0.426†	[0.04; 3.82] 0.433	[-0.45; 0.19] 0.422
<b>Center No. 1032</b>					
N'	2	4	N.E.	0.24	-0.75
n (%)	0 (0.0)	3 (75.0)		[0.02; 3.19] 0.278	[-1.17; -0.33] <.001
<b>Center No. 1033</b>					
N'	4	6	N.E.	0.28	-0.33
n (%)	0 (0.0)	2 (33.3)		[0.02; 4.66] 0.375	[-0.71; 0.04] 0.083
<b>Center No. 1034</b>					
N'	4	3	N.E.	0.27	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.01; 4.94] 0.375	[-0.87; 0.20] 0.221
<b>Center No. 1035</b>					
N'	27	22	0.16	0.31	-0.41
n (%)	5 (18.5)	13 (59.1)	[0.04; 0.60] 0.006	[0.13; 0.74] 0.009	[-0.66; -0.15] 0.002
<b>Center No. 1036</b>					
N'	7	7	N.E.	0.20	-0.29
n (%)	0 (0.0)	2 (28.6)		[0.01; 3.54] 0.272	[-0.62; 0.05] 0.094

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1037</b>					
N'	9	11	0.30	0.52	-0.30
n (%)	3 (33.3)	7 (63.6)	[0.04; 2.20] 0.236	[0.19; 1.46] 0.217	[-0.72; 0.12] 0.156
<b>Center No. 1039</b>					
N'	4	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1040</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (66.7)			
<b>Center No. 1041</b>					
N'	5	5	N.E.	0.14	-0.60
n (%)	0 (0.0)	3 (60.0)		[0.01; 2.21] 0.164	[-1.03; -0.17] 0.006
<b>Center No. 1042</b>					
N'	4	5	N.E.	0.24	-0.40
n (%)	0 (0.0)	2 (40.0)		[0.01; 3.93] 0.317	[-0.83; 0.03] 0.068
<b>Center No. 1044</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (100.0)			
<b>Center No. 1046</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (100.0)			
<b>Center No. 1048</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (33.3)			
<b>Center No. 1049</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1050</b>					
N'	6	9	0.25	0.38	-0.28
n (%)	1 (16.7)	4 (44.4)	[0.02; 3.10] 0.280†	[0.05; 2.59] 0.320	[-0.72; 0.16] 0.217
<b>Center No. 1051</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1052</b>					
N'	7	4	N.E.	0.21	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.01; 4.18] 0.305	[-0.67; 0.17] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1055</b>					
N'	2	4	N.E.	0.33	-0.50
n (%)	0 (0.0)	2 (50.0)		[0.02; 4.85] 0.421	[-0.99; -0.01] 0.046
<b>Center No. 1058</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1059</b>					
N'	7	7	0.31	0.33	-0.29
n (%)	1 (14.3)	3 (42.9)	[0.02; 4.94] 0.407	[0.04; 2.48] 0.283	[-0.73; 0.16] 0.212
<b>Center No. 1061</b>					
N'	9	6	0.25	0.33	-0.22
n (%)	1 (11.1)	2 (33.3)	[0.02; 3.66] 0.311†	[0.04; 2.91] 0.320	[-0.65; 0.21] 0.310
<b>Center No. 1063</b>					
N'	4	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (100.0)			
<b>Center No. 1064</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (33.3)			
<b>Center No. 1067</b>					
N'	10	16	0.24	0.32	-0.21
n (%)	1 (10.0)	5 (31.3)	[0.02; 2.49] 0.234†	[0.04; 2.36] 0.263	[-0.51; 0.08] 0.156
<b>Center No. 1068</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (100.0)			
<b>Center No. 1069</b>					
N'	3	4	N.E.	0.18	-0.75
n (%)	0 (0.0)	3 (75.0)		[0.01; 2.54] 0.204	[-1.17; -0.33] <.001
<b>Center No. 1070</b>					
N'	1	5	N.E.	0.43	-0.60
n (%)	0 (0.0)	3 (60.0)		[0.04; 5.19] 0.505	[-1.03; -0.17] 0.006
<b>Center No. 1072</b>					
N'	2	1	N.E.	0.50	-0.50
n (%)	1 (50.0)	1 (100.0)		[0.13; 2.00] 0.327	[-1.19; 0.19] 0.157

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1073</b>					
N'	11	7	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1074</b>					
N'	5	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1076</b>					
N'	1	5	N.E.	0.60	-0.40
n (%)	0 (0.0)	2 (40.0)		[0.05; 7.92] 0.698	[-0.83; 0.03] 0.068
<b>Center No. 1077</b>					
N'	3	2	N.E.	0.25	-0.50
n (%)	0 (0.0)	1 (50.0)		[0.01; 4.23] 0.337	[-1.19; 0.19] 0.157
<b>Center No. 1079</b>					
N'	4	3	N.E.	0.27	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.01; 4.94] 0.375	[-0.87; 0.20] 0.221
<b>Center No. 1080</b>					
N'	3	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1082</b>					
N'	5	8	0.75	0.80	-0.05
n (%)	1 (20.0)	2 (25.0)	[0.05; 11.31] 0.835†	[0.10; 6.70] 0.837	[-0.51; 0.41] 0.832
<b>Center No. 1084</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1085</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (66.7)			
<b>Center No. 1086</b>					
N'	6	9	0.70	0.75	-0.06
n (%)	1 (16.7)	2 (22.2)	[0.05; 10.01] 0.793†	[0.09; 6.55] 0.795	[-0.46; 0.35] 0.787
<b>Center No. 1087</b>					
N'	1	4	N.E.	0.83	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.05; 13.02] 0.897	[-0.67; 0.17] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1088</b>					
N'	6	6	N.E.	0.33	-0.17
n (%)	0 (0.0)	1 (16.7)		[0.02; 6.86] 0.476	[-0.46; 0.13] 0.273
<b>Center No. 1089</b>					
N'	4	4	1.00	1.00	0.00
n (%)	1 (25.0)	1 (25.0)	[0.04; 24.55] 1.000†	[0.09; 11.03] 1.000	[-0.60; 0.60] 1.000
<b>Center No. 1091</b>					
N'	6	5	0.13	0.28	-0.43
n (%)	1 (16.7)	3 (60.0)	[<0.01; 2.18] 0.158†	[0.04; 1.91] 0.193	[-0.96; 0.09] 0.104
<b>Center No. 1093</b>					
N'	1	4	N.E.	0.36	-0.75
n (%)	0 (0.0)	3 (75.0)		[0.03; 4.21] 0.414	[-1.17; -0.33] <.001
<b>Center No. 1095</b>					
N'	5	3	N.E.	0.22	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.01; 4.20] 0.316	[-0.87; 0.20] 0.221
<b>Center No. 1096</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1100</b>					
N'	1	4	N.E.	0.50	-0.50
n (%)	0 (0.0)	2 (50.0)		[0.04; 6.44] 0.595	[-0.99; -0.01] 0.046
<b>Center No. 1101</b>					
N'	4	6	N.E.	0.47	-0.17
n (%)	0 (0.0)	1 (16.7)		[0.02; 9.26] 0.617	[-0.46; 0.13] 0.273
<b>Center No. 1103</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1105</b>					
N'	3	3	N.E.	0.20	-0.67
n (%)	0 (0.0)	2 (66.7)		[0.01; 2.98] 0.243	[-1.20; -0.13] 0.014
<b>Center No. 1108</b>					
N'	15	10	N.E.	0.23	-0.10
n (%)	0 (0.0)	1 (10.0)		[0.01; 5.12] 0.353	[-0.29; 0.09] 0.292



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1110</b>					
N'	6	5	N.E.	2.57	0.17
n (%)	1 (16.7)	0 (0.0)		[0.13; 52.13] 0.538	[-0.13; 0.46] 0.273
<b>Center No. 1111</b>					
N'	5	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1113</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1115</b>					
N'	5	6	0.50	0.60	-0.13
n (%)	1 (20.0)	2 (33.3)	[0.03; 7.99] 0.624†	[0.07; 4.83] 0.631	[-0.65; 0.38] 0.612
<b>Center No. 1116</b>					
N'	1	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1118</b>					
N'	3	2	2.00	1.33	0.17
n (%)	2 (66.7)	1 (50.0)	[0.05; 78.25] 0.711†	[0.27; 6.61] 0.725	[-0.71; 1.04] 0.709
<b>Center No. 1119</b>					
N'	3	5	N.E.	0.50	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.03; 9.46] 0.644	[-0.55; 0.15] 0.264
<b>Center No. 1121</b>					
N'	4	4	0.33	0.50	-0.25
n (%)	1 (25.0)	2 (50.0)	[0.02; 6.65] 0.472†	[0.07; 3.55] 0.488	[-0.90; 0.40] 0.450
<b>Center No. 1123</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1124</b>					
N'	3	2	N.E.	0.25	-0.50
n (%)	0 (0.0)	1 (50.0)		[0.01; 4.23] 0.337	[-1.19; 0.19] 0.157

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1502</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (66.7)			
<p>N': Number of patients with available response value  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup that include treatment group and stratification factor (MMD at baseline).  † The stratification factor is excluded from the model due to non-convergence of the full model.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p>					

**Table 14.2-1.2 Proportion of patients with treatment discontinuation due to all-cause during the DBTE. Sensitivity analysis (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Discontinuation of treatment due to all-cause during DBTE</b>					
N'	388	388	0.24	0.34	-0.27
n (%)	54 (13.9)	157 (40.5)	[0.17; 0.34] <.001	[0.26; 0.45] <.001	[-0.33; -0.21] <.001
<p>N': Number of patients with available response value  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR is obtained from a logistic regression model that includes treatment group and stratification factor (MMD at baseline).  RR and RD are calculated directly (without adjustment) and with CI and p-value based on the Wald statistic.</p>					

**Table 14.2-1.2.1 Proportion of patients with treatment discontinuation due to all-cause during the DBTE. Sensitivity analysis by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
< median age, N	186	190			
≥ median age, N	202	198			
<b>Discontinuation of treatment due to all-cause during DBTE</b>					
<b>Interaction test: p=0.076</b>					
<b>&lt; median age</b>					
N'	186	190	0.33	0.44	-0.21
n (%)	30 (16.1)	70 (36.8)	[0.20; 0.54] <.001	[0.30; 0.64] <.001	[-0.29; -0.12] <.001
<b>≥ median age</b>					
N'	202	198	0.17	0.27	-0.32
n (%)	24 (11.9)	87 (43.9)	[0.10; 0.29] <.001	[0.18; 0.41] <.001	[-0.40; -0.24] <.001
<p>N': Number of patients with available response value  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p>					

**Table 14.2-1.2.2 Proportion of patients with treatment discontinuation due to all-cause during the DBTE. Sensitivity analysis by Gender (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Male, N	57	53			
Female, N	331	335			
<b>Discontinuation of treatment due to all-cause during DBTE</b>					
<b>Interaction test: p=0.093</b>					
<b>Male</b>					
N'	57	53	0.08	0.13	-0.34
n (%)	3 (5.3)	21 (39.6)	[0.02; 0.31] <.001	[0.04; 0.42] <.001	[-0.49; -0.20] <.001
<b>Female</b>					
N'	331	335	0.27	0.38	-0.25
n (%)	51 (15.4)	136 (40.6)	[0.18; 0.39] <.001	[0.29; 0.50] <.001	[-0.32; -0.19] <.001
<p>N': Number of patients with available response value  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p>					

**Table 14.2-1.2.3 Proportion of patients with treatment discontinuation due to all-cause during the DBTE. Sensitivity analysis by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92			
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254			
≥ 15 monthly migraine days at baseline, N	43	42			
<b>Discontinuation of treatment due to all-cause during DBTE</b>					
<b>Interaction test: p=0.998</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
N'	96	92	0.23	0.34	-0.27
n (%)	13 (13.5)	37 (40.2)	[0.11; 0.48] <.001	[0.19; 0.59] <.001	[-0.39; -0.15] <.001
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
N'	249	254	0.24	0.34	-0.26
n (%)	34 (13.7)	101 (39.8)	[0.15; 0.37] <.001	[0.24; 0.49] <.001	[-0.33; -0.19] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
N'	43	42	0.24	0.36	-0.29
n (%)	7 (16.3)	19 (45.2)	[0.09; 0.65] 0.005	[0.17; 0.77] 0.008	[-0.48; -0.10] 0.002
<p>N': Number of patients with available response value  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.  <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.  The stratification factor is not included in the logistic regression model due to collinearity with the subgroups.</p>					

**Table 14.2-1.2.4 Proportion of patients with treatment discontinuation due to all-cause during the DBTE. Sensitivity analysis by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Naïve*, N	232	229			
Prior treatment failure*, N	156	159			
<b>Discontinuation of treatment due to all-cause during DBTE</b>					
<b>Interaction test: p=0.464</b>					
<b>Naïve*</b>					
N'	232	229	0.26	0.37	-0.25
n (%)	34 (14.7)	90 (39.3)	[0.17; 0.42] <.001	[0.26; 0.53] <.001	[-0.32; -0.17] <.001
<b>Prior treatment failure*</b>					
N'	156	159	0.20	0.30	-0.29
n (%)	20 (12.8)	67 (42.1)	[0.11; 0.36] <.001	[0.19; 0.48] <.001	[-0.39; -0.20] <.001
<p>N': Number of patients with available response value  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>*: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>					

**Table 14.2-1.2.5 Proportion of patients with treatment discontinuation due to all-cause during the DBTE. Sensitivity analysis by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1001, N	10	8			
Center No. 1002, N	4	0			
Center No. 1003, N	2	3			
Center No. 1005, N	31	22			
Center No. 1007, N	5	7			
Center No. 1008, N	3	3			
Center No. 1010, N	2	3			
Center No. 1011, N	2	5			
Center No. 1012, N	3	5			
Center No. 1014, N	5	4			
Center No. 1015, N	4	2			
Center No. 1017, N	5	4			
Center No. 1018, N	7	6			
Center No. 1019, N	2	2			
Center No. 1021, N	16	10			
Center No. 1022, N	3	3			
Center No. 1025, N	0	2			
Center No. 1027, N	3	5			
Center No. 1028, N	11	5			
Center No. 1029, N	15	9			
Center No. 1030, N	11	9			
Center No. 1032, N	2	4			
Center No. 1033, N	4	6			
Center No. 1034, N	4	3			
Center No. 1035, N	27	22			
Center No. 1036, N	7	7			
Center No. 1037, N	9	11			
Center No. 1039, N	4	3			
Center No. 1040, N	0	3			
Center No. 1041, N	5	5			
Center No. 1042, N	4	5			
Center No. 1044, N	0	2			



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1046, N	1	1			
Center No. 1048, N	0	3			
Center No. 1049, N	1	0			
Center No. 1050, N	6	9			
Center No. 1051, N	1	1			
Center No. 1052, N	7	4			
Center No. 1055, N	2	4			
Center No. 1058, N	0	1			
Center No. 1059, N	7	7			
Center No. 1061, N	9	6			
Center No. 1063, N	4	2			
Center No. 1064, N	0	3			
Center No. 1067, N	10	16			
Center No. 1068, N	0	2			
Center No. 1069, N	3	4			
Center No. 1070, N	1	5			
Center No. 1072, N	2	1			
Center No. 1073, N	11	7			
Center No. 1074, N	5	3			
Center No. 1076, N	1	5			
Center No. 1077, N	3	2			
Center No. 1079, N	4	3			
Center No. 1080, N	3	1			
Center No. 1082, N	5	8			
Center No. 1084, N	2	3			
Center No. 1085, N	0	3			
Center No. 1086, N	6	9			
Center No. 1087, N	1	4			
Center No. 1088, N	6	6			
Center No. 1089, N	4	4			
Center No. 1091, N	6	5			
Center No. 1093, N	1	4			
Center No. 1095, N	5	3			
Center No. 1096, N	2	0			
Center No. 1100, N	1	4			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1101, N	4	6			
Center No. 1103, N	2	3			
Center No. 1105, N	3	3			
Center No. 1108, N	15	10			
Center No. 1110, N	6	5			
Center No. 1111, N	5	0			
Center No. 1113, N	3	3			
Center No. 1115, N	5	6			
Center No. 1116, N	1	4			
Center No. 1118, N	3	2			
Center No. 1119, N	3	5			
Center No. 1121, N	4	4			
Center No. 1123, N	1	1			
Center No. 1124, N	3	2			
Center No. 1502, N	0	3			
<b>Discontinuation of treatment due to all-cause during DBTE</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
N'	10	8	0.11	0.20	-0.40
n (%)	1 (10.0)	4 (50.0)	[<0.01; 1.34] 0.083†	[0.03; 1.45] 0.112	[-0.79; -0.01] 0.046
<b>Center No. 1002</b>					
N'	4	0	N.E.	N.E.	N.E.
n (%)	2 (50.0)	0 (0.0)			
<b>Center No. 1003</b>					
N'	2	3	N.E.	0.44	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.03; 7.52] 0.574	[-0.87; 0.20] 0.221
<b>Center No. 1005</b>					
N'	31	22	0.37	0.64	-0.16
n (%)	9 (29.0)	10 (45.5)	[0.10; 1.38] 0.140	[0.31; 1.31] 0.220	[-0.43; 0.10] 0.220
<b>Center No. 1007</b>					
N'	5	7	0.89	0.93	-0.03
n (%)	2 (40.0)	3 (42.9)	[0.09; 9.16] 0.921†	[0.24; 3.68] 0.922	[-0.59; 0.54] 0.921

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1008</b>					
N'	3	3	1.00	1.00	0.00
n (%)	1 (33.3)	1 (33.3)	[0.03; 29.81] 1.000†	[0.10; 9.61] 1.000	[-0.75; 0.75] 1.000
<b>Center No. 1010</b>					
N'	2	3	2.00	1.50	0.17
n (%)	1 (50.0)	1 (33.3)	[0.05; 78.25] 0.711†	[0.18; 12.46] 0.707	[-0.71; 1.04] 0.709
<b>Center No. 1011</b>					
N'	2	5	N.E.	0.29	-0.60
n (%)	0 (0.0)	3 (60.0)		[0.02; 3.92] 0.349	[-1.03; -0.17] 0.006
<b>Center No. 1012</b>					
N'	3	5	N.E.	0.21	-0.60
n (%)	0 (0.0)	3 (60.0)		[0.01; 3.12] 0.260	[-1.03; -0.17] 0.006
<b>Center No. 1014</b>					
N'	5	4	N.E.	0.17	-0.50
n (%)	0 (0.0)	2 (50.0)		[0.01; 2.73] 0.209	[-0.99; -0.01] 0.046
<b>Center No. 1015</b>					
N'	4	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1017</b>					
N'	5	4	0.25	0.40	-0.30
n (%)	1 (20.0)	2 (50.0)	[0.01; 4.73] 0.355†	[0.05; 2.98] 0.371	[-0.90; 0.30] 0.329
<b>Center No. 1018</b>					
N'	7	6	N.E.	0.18	-0.33
n (%)	0 (0.0)	2 (33.3)		[0.01; 3.06] 0.233	[-0.71; 0.04] 0.083
<b>Center No. 1019</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1021</b>					
N'	16	10	0.23	0.38	-0.31
n (%)	3 (18.8)	5 (50.0)	[0.04; 1.35] 0.103†	[0.11; 1.24] 0.107	[-0.68; 0.05] 0.093
<b>Center No. 1022</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1025</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1027</b>					
N'	3	5	N.E.	0.30	-0.40
n (%)	0 (0.0)	2 (40.0)		[0.02; 4.74] 0.393	[-0.83; 0.03] 0.068
<b>Center No. 1028</b>					
N'	11	5	0.15	0.23	-0.31
n (%)	1 (9.1)	2 (40.0)	[<0.01; 2.29] 0.172†	[0.03; 1.96] 0.178	[-0.77; 0.15] 0.190
<b>Center No. 1029</b>					
N'	15	9	0.10	0.26	-0.58
n (%)	3 (20.0)	7 (77.8)	[0.01; 0.83] 0.033	[0.09; 0.75] 0.013	[-0.92; -0.24] <.001
<b>Center No. 1030</b>					
N'	11	9	0.78	0.82	-0.04
n (%)	2 (18.2)	2 (22.2)	[0.09; 6.98] 0.822†	[0.14; 4.71] 0.822	[-0.39; 0.31] 0.823
<b>Center No. 1032</b>					
N'	2	4	N.E.	0.24	-0.75
n (%)	0 (0.0)	3 (75.0)		[0.02; 3.19] 0.278	[-1.17; -0.33] <.001
<b>Center No. 1033</b>					
N'	4	6	N.E.	0.28	-0.33
n (%)	0 (0.0)	2 (33.3)		[0.02; 4.66] 0.375	[-0.71; 0.04] 0.083
<b>Center No. 1034</b>					
N'	4	3	N.E.	0.27	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.01; 4.94] 0.375	[-0.87; 0.20] 0.221
<b>Center No. 1035</b>					
N'	27	22	0.16	0.31	-0.41
n (%)	5 (18.5)	13 (59.1)	[0.04; 0.60] 0.006	[0.13; 0.74] 0.009	[-0.66; -0.15] 0.002
<b>Center No. 1036</b>					
N'	7	7	N.E.	0.20	-0.29
n (%)	0 (0.0)	2 (28.6)		[0.01; 3.54] 0.272	[-0.62; 0.05] 0.094

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1037</b>					
N'	9	11	0.48	0.70	-0.19
n (%)	4 (44.4)	7 (63.6)	[0.07; 3.35] 0.459	[0.30; 1.64] 0.411	[-0.62; 0.24] 0.383
<b>Center No. 1039</b>					
N'	4	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1040</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (66.7)			
<b>Center No. 1041</b>					
N'	5	5	0.16	0.33	-0.40
n (%)	1 (20.0)	3 (60.0)	[<0.01; 2.84] 0.213	[0.05; 2.21] 0.255	[-0.95; 0.15] 0.157
<b>Center No. 1042</b>					
N'	4	5	N.E.	0.24	-0.40
n (%)	0 (0.0)	2 (40.0)		[0.01; 3.93] 0.317	[-0.83; 0.03] 0.068
<b>Center No. 1044</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (100.0)			
<b>Center No. 1046</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (100.0)			
<b>Center No. 1048</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (33.3)			
<b>Center No. 1049</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1050</b>					
N'	6	9	0.25	0.38	-0.28
n (%)	1 (16.7)	4 (44.4)	[0.02; 3.10] 0.280†	[0.05; 2.59] 0.320	[-0.72; 0.16] 0.217
<b>Center No. 1051</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1052</b>					
N'	7	4	N.E.	0.21	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.01; 4.18] 0.305	[-0.67; 0.17] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1055</b>					
N'	2	4	N.E.	0.33	-0.50
n (%)	0 (0.0)	2 (50.0)		[0.02; 4.85] 0.421	[-0.99; -0.01] 0.046
<b>Center No. 1058</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1059</b>					
N'	7	7	0.31	0.33	-0.29
n (%)	1 (14.3)	3 (42.9)	[0.02; 4.94] 0.407	[0.04; 2.48] 0.283	[-0.73; 0.16] 0.212
<b>Center No. 1061</b>					
N'	9	6	0.25	0.33	-0.22
n (%)	1 (11.1)	2 (33.3)	[0.02; 3.66] 0.311†	[0.04; 2.91] 0.320	[-0.65; 0.21] 0.310
<b>Center No. 1063</b>					
N'	4	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (100.0)			
<b>Center No. 1064</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (33.3)			
<b>Center No. 1067</b>					
N'	10	16	0.55	0.64	-0.11
n (%)	2 (20.0)	5 (31.3)	[0.08; 3.59] 0.532†	[0.15; 2.69] 0.543	[-0.45; 0.22] 0.512
<b>Center No. 1068</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (100.0)			
<b>Center No. 1069</b>					
N'	3	4	N.E.	0.18	-0.75
n (%)	0 (0.0)	3 (75.0)		[0.01; 2.54] 0.204	[-1.17; -0.33] <.001
<b>Center No. 1070</b>					
N'	1	5	N.E.	0.43	-0.60
n (%)	0 (0.0)	3 (60.0)		[0.04; 5.19] 0.505	[-1.03; -0.17] 0.006
<b>Center No. 1072</b>					
N'	2	1	N.E.	0.50	-0.50
n (%)	1 (50.0)	1 (100.0)		[0.13; 2.00] 0.327	[-1.19; 0.19] 0.157

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1073</b>					
N'	11	7	N.E.	0.22	-0.14
n (%)	0 (0.0)	1 (14.3)		[0.01; 4.80] 0.337	[-0.40; 0.12] 0.280
<b>Center No. 1074</b>					
N'	5	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1076</b>					
N'	1	5	N.E.	0.60	-0.40
n (%)	0 (0.0)	2 (40.0)		[0.05; 7.92] 0.698	[-0.83; 0.03] 0.068
<b>Center No. 1077</b>					
N'	3	2	N.E.	0.25	-0.50
n (%)	0 (0.0)	1 (50.0)		[0.01; 4.23] 0.337	[-1.19; 0.19] 0.157
<b>Center No. 1079</b>					
N'	4	3	N.E.	0.27	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.01; 4.94] 0.375	[-0.87; 0.20] 0.221
<b>Center No. 1080</b>					
N'	3	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1082</b>					
N'	5	8	0.75	0.80	-0.05
n (%)	1 (20.0)	2 (25.0)	[0.05; 11.31] 0.835†	[0.10; 6.70] 0.837	[-0.51; 0.41] 0.832
<b>Center No. 1084</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1085</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (66.7)			
<b>Center No. 1086</b>					
N'	6	9	0.70	0.75	-0.06
n (%)	1 (16.7)	2 (22.2)	[0.05; 10.01] 0.793†	[0.09; 6.55] 0.795	[-0.46; 0.35] 0.787
<b>Center No. 1087</b>					
N'	1	4	N.E.	0.83	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.05; 13.02] 0.897	[-0.67; 0.17] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1088</b>					
N'	6	6	N.E.	0.33	-0.17
n (%)	0 (0.0)	1 (16.7)		[0.02; 6.86] 0.476	[-0.46; 0.13] 0.273
<b>Center No. 1089</b>					
N'	4	4	1.00	1.00	0.00
n (%)	1 (25.0)	1 (25.0)	[0.04; 24.55] 1.000†	[0.09; 11.03] 1.000	[-0.60; 0.60] 1.000
<b>Center No. 1091</b>					
N'	6	5	0.13	0.28	-0.43
n (%)	1 (16.7)	3 (60.0)	[<0.01; 2.18] 0.158†	[0.04; 1.91] 0.193	[-0.96; 0.09] 0.104
<b>Center No. 1093</b>					
N'	1	4	N.E.	0.36	-0.75
n (%)	0 (0.0)	3 (75.0)		[0.03; 4.21] 0.414	[-1.17; -0.33] <.001
<b>Center No. 1095</b>					
N'	5	3	0.50	0.60	-0.13
n (%)	1 (20.0)	1 (33.3)	[0.02; 12.90] 0.676†	[0.06; 6.44] 0.673	[-0.77; 0.51] 0.682
<b>Center No. 1096</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1100</b>					
N'	1	4	N.E.	0.50	-0.50
n (%)	0 (0.0)	2 (50.0)		[0.04; 6.44] 0.595	[-0.99; -0.01] 0.046
<b>Center No. 1101</b>					
N'	4	6	N.E.	0.47	-0.17
n (%)	0 (0.0)	1 (16.7)		[0.02; 9.26] 0.617	[-0.46; 0.13] 0.273
<b>Center No. 1103</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1105</b>					
N'	3	3	N.E.	0.20	-0.67
n (%)	0 (0.0)	2 (66.7)		[0.01; 2.98] 0.243	[-1.20; -0.13] 0.014
<b>Center No. 1108</b>					
N'	15	10	N.E.	0.23	-0.10
n (%)	0 (0.0)	1 (10.0)		[0.01; 5.12] 0.353	[-0.29; 0.09] 0.292



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1110</b>					
N'	6	5	N.E.	4.29	0.33
n (%)	2 (33.3)	0 (0.0)		[0.25; 72.90] 0.314	[-0.04; 0.71] 0.083
<b>Center No. 1111</b>					
N'	5	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1113</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1115</b>					
N'	5	6	1.33	1.20	0.07
n (%)	2 (40.0)	2 (33.3)	[0.11; 15.70] 0.819†	[0.25; 5.71] 0.819	[-0.50; 0.64] 0.819
<b>Center No. 1116</b>					
N'	1	4	N.E.	0.83	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.05; 13.02] 0.897	[-0.67; 0.17] 0.248
<b>Center No. 1118</b>					
N'	3	2	2.00	1.33	0.17
n (%)	2 (66.7)	1 (50.0)	[0.05; 78.25] 0.711†	[0.27; 6.61] 0.725	[-0.71; 1.04] 0.709
<b>Center No. 1119</b>					
N'	3	5	N.E.	0.50	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.03; 9.46] 0.644	[-0.55; 0.15] 0.264
<b>Center No. 1121</b>					
N'	4	4	0.33	0.50	-0.25
n (%)	1 (25.0)	2 (50.0)	[0.02; 6.65] 0.472†	[0.07; 3.55] 0.488	[-0.90; 0.40] 0.450
<b>Center No. 1123</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1124</b>					
N'	3	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (100.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1502</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	3 (100.0)			
<p>N': Number of patients with available response value  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup that include treatment group and stratification factor (MMD at baseline).  † The stratification factor is excluded from the model due to non-convergence of the full model.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p>					

**Table 14.2-2.0 Documentation rate in the diary for Monthly Migraine Days by month  
(Full Analysis Set)**

Treatment Group	Time Period	n	Documentation rate (%)	Documented days*
			Mean (SD)	Mean (SD)
AMG334 (N=388)	Baseline phase	388	99.2 (2.7)	27.8 (0.8)
	Month 1	388	98.5 (9.4)	27.6 (2.6)
	Month 2	388	97.8 (12.8)	27.4 (3.6)
	Month 3	388	96.5 (15.4)	27.0 (4.3)
	Month 4	388	95.8 (17.3)	26.8 (4.8)
	Month 5	388	95.4 (18.3)	26.7 (5.1)
	Month 6	388	93.5 (19.6)	26.2 (5.5)
Topiramate (N=388)	Baseline phase	388	99.2 (3.1)	27.8 (0.9)
	Month 1	388	98.7 (7.8)	27.6 (2.2)
	Month 2	388	96.9 (14.9)	27.1 (4.2)
	Month 3	388	95.6 (17.9)	26.8 (5.0)
	Month 4	388	94.6 (20.5)	26.5 (5.8)
	Month 5	388	94.3 (20.9)	26.4 (5.8)
	Month 6	388	91.4 (23.6)	25.6 (6.6)
Total (N=776)	Baseline phase	776	99.2 (2.9)	27.8 (0.8)
	Month 1	776	98.6 (8.6)	27.6 (2.4)
	Month 2	776	97.3 (13.8)	27.3 (3.9)
	Month 3	776	96.1 (16.7)	26.9 (4.7)
	Month 4	776	95.2 (19.0)	26.7 (5.3)
	Month 5	776	94.9 (19.6)	26.6 (5.5)
	Month 6	776	92.5 (21.7)	25.9 (6.1)

n: Number of patients considered in calculation of documentation rate / documented days  
SD: Standard Deviation  
\*: Number of documented days prorated to 28 days

**Table 14.2-2.1 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the last three months (month 4, 5, 6) (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>50% reduction from BL in MMD over last 3 months of DBTE</b>					
N'	378	371	2.76	1.78	0.24
n (%)	215 (55.4)	121 (31.2)	[2.06; 3.71] <.001	[1.50; 2.11] <.001	[0.17; 0.31] <.001
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>OR is obtained from a logistic regression model that includes treatment group and stratification factor (MMD at baseline).                      RR and RD are calculated directly (without adjustment) and with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-2.1.1 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the last three months (month 4, 5, 6) by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
< median age, N	186	190			
≥ median age, N	202	198			
<b>50% reduction from BL in MMD over last 3 months of DBTE</b>					
<b>Interaction test: p=0.059</b>					
<b>&lt; median age</b>					
N'	179	183	2.07	1.52	0.18
n (%)	98 (52.7)	66 (34.7)	[1.37; 3.14] <.001	[1.20; 1.92] <.001	[0.08; 0.28] <.001
<b>≥ median age</b>					
N'	199	188	3.66	2.09	0.30
n (%)	117 (57.9)	55 (27.8)	[2.40; 5.57] <.001	[1.62; 2.69] <.001	[0.21; 0.39] <.001
<p>N': Number of patients with available response value  N-N' is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-2.1.2 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the last three months (month 4, 5, 6) by Gender (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Male, N	57	53			
Female, N	331	335			
<b>50% reduction from BL in MMD over last 3 months of DBTE</b>					
<b>Interaction test: p=0.447</b>					
<b>Male</b>					
N'	55	49	2.10	1.44	0.18
n (%)	34 (59.6)	22 (41.5)	[0.98; 4.51] 0.057	[0.98; 2.11] 0.064	[-0.00; 0.37] 0.053
<b>Female</b>					
N'	323	322	2.90	1.85	0.25
n (%)	181 (54.7)	99 (29.6)	[2.10; 3.99] <.001	[1.53; 2.24] <.001	[0.18; 0.32] <.001
<p>N': Number of patients with available response value  N-N' is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-2.1.3 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the last three months (month 4, 5, 6) by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92			
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254			
≥ 15 monthly migraine days at baseline, N	43	42			
<b>50% reduction from BL in MMD over last 3 months of DBTE</b>					
<b>Interaction test: p=0.824</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
N'	92	89	3.31	2.20	0.26
n (%)	46 (47.9)	20 (21.7)	[1.75; 6.26] <.001	[1.42; 3.42] <.001	[0.13; 0.39] <.001
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
N'	245	243	2.68	1.71	0.24
n (%)	144 (57.8)	86 (33.9)	[1.87; 3.85] <.001	[1.40; 2.09] <.001	[0.16; 0.32] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
N'	41	39	2.50	1.63	0.22
n (%)	25 (58.1)	15 (35.7)	[1.04; 6.00] 0.040	[1.01; 2.63] 0.046	[0.02; 0.43] 0.034
<p>N': Number of patients with available response value  N-N' is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.  <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.  The stratification factor is not included in the logistic regression model due to collinearity with the subgroups.</p>					

**Table 14.2-2.1.4 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the last three months (month 4, 5, 6) by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Naïve*, N	232	229			
Prior treatment failure*, N	156	159			
<b>50% reduction from BL in MMD over last 3 months of DBTE</b>					
<b>Interaction test: p=0.786</b>					
<b>Naïve*</b>					
N'	225	218	2.69	1.68	0.24
n (%)	138 (59.5)	81 (35.4)	[1.85; 3.93] <.001	[1.37; 2.06] <.001	[0.15; 0.33] <.001
<b>Prior treatment failure*</b>					
N'	153	153	2.93	1.96	0.24
n (%)	77 (49.4)	40 (25.2)	[1.82; 4.73] <.001	[1.44; 2.68] <.001	[0.14; 0.35] <.001
<p>N': Number of patients with available response value  N-N' is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>*: 'Naïve'/'Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>					



**Table 14.2-2.1.5 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the last three months (month 4, 5, 6) by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1001, N	10	8			
Center No. 1002, N	4	0			
Center No. 1003, N	2	3			
Center No. 1005, N	31	22			
Center No. 1007, N	5	7			
Center No. 1008, N	3	3			
Center No. 1010, N	2	3			
Center No. 1011, N	2	5			
Center No. 1012, N	3	5			
Center No. 1014, N	5	4			
Center No. 1015, N	4	2			
Center No. 1017, N	5	4			
Center No. 1018, N	7	6			
Center No. 1019, N	2	2			
Center No. 1021, N	16	10			
Center No. 1022, N	3	3			
Center No. 1025, N	0	2			
Center No. 1027, N	3	5			
Center No. 1028, N	11	5			
Center No. 1029, N	15	9			
Center No. 1030, N	11	9			
Center No. 1032, N	2	4			
Center No. 1033, N	4	6			
Center No. 1034, N	4	3			
Center No. 1035, N	27	22			
Center No. 1036, N	7	7			
Center No. 1037, N	9	11			
Center No. 1039, N	4	3			
Center No. 1040, N	0	3			
Center No. 1041, N	5	5			
Center No. 1042, N	4	5			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1044, N	0	2			
Center No. 1046, N	1	1			
Center No. 1048, N	0	3			
Center No. 1049, N	1	0			
Center No. 1050, N	6	9			
Center No. 1051, N	1	1			
Center No. 1052, N	7	4			
Center No. 1055, N	2	4			
Center No. 1058, N	0	1			
Center No. 1059, N	7	7			
Center No. 1061, N	9	6			
Center No. 1063, N	4	2			
Center No. 1064, N	0	3			
Center No. 1067, N	10	16			
Center No. 1068, N	0	2			
Center No. 1069, N	3	4			
Center No. 1070, N	1	5			
Center No. 1072, N	2	1			
Center No. 1073, N	11	7			
Center No. 1074, N	5	3			
Center No. 1076, N	1	5			
Center No. 1077, N	3	2			
Center No. 1079, N	4	3			
Center No. 1080, N	3	1			
Center No. 1082, N	5	8			
Center No. 1084, N	2	3			
Center No. 1085, N	0	3			
Center No. 1086, N	6	9			
Center No. 1087, N	1	4			
Center No. 1088, N	6	6			
Center No. 1089, N	4	4			
Center No. 1091, N	6	5			
Center No. 1093, N	1	4			
Center No. 1095, N	5	3			
Center No. 1096, N	2	0			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1100, N	1	4			
Center No. 1101, N	4	6			
Center No. 1103, N	2	3			
Center No. 1105, N	3	3			
Center No. 1108, N	15	10			
Center No. 1110, N	6	5			
Center No. 1111, N	5	0			
Center No. 1113, N	3	3			
Center No. 1115, N	5	6			
Center No. 1116, N	1	4			
Center No. 1118, N	3	2			
Center No. 1119, N	3	5			
Center No. 1121, N	4	4			
Center No. 1123, N	1	1			
Center No. 1124, N	3	2			
Center No. 1502, N	0	3			
<b>50% reduction from BL in MMD over last 3 months of DBTE</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
N'	9	8	N.E.	7.36	0.40
n (%)	4 (40.0)	0 (0.0)		[0.45; 119.39] 0.160	[0.10; 0.70] 0.010
<b>Center No. 1002</b>					
N'	4	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1003</b>					
N'	2	3	0.50	0.75	-0.17
n (%)	1 (50.0)	2 (66.7)	[0.01; 19.56] 0.711	[0.15; 3.72] 0.725	[-1.04; 0.71] 0.709
<b>Center No. 1005</b>					
N'	28	22	0.69	0.83	-0.09
n (%)	14 (45.2)	12 (54.5)	[0.22; 2.16] 0.521	[0.48; 1.43] 0.496	[-0.37; 0.18] 0.499
<b>Center No. 1007</b>					
N'	4	7	1.12	1.05	0.03
n (%)	3 (60.0)	4 (57.1)	[0.11; 11.60] 0.921†	[0.40; 2.75] 0.921	[-0.54; 0.59] 0.921

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1008</b>					
N'	2	3	0.25	0.50	-0.33
n (%)	1 (33.3)	2 (66.7)	[<0.01; 7.45] 0.424†	[0.08; 2.99] 0.448	[-1.09; 0.42] 0.386
<b>Center No. 1010</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1011</b>					
N'	2	5	0.67	0.83	-0.10
n (%)	1 (50.0)	3 (60.0)	[0.02; 18.06] 0.810†	[0.18; 3.96] 0.819	[-0.92; 0.72] 0.810
<b>Center No. 1012</b>					
N'	3	4	3.00	1.67	0.27
n (%)	2 (66.7)	2 (40.0)	[0.15; 59.88] 0.472†	[0.44; 6.36] 0.455	[-0.42; 0.95] 0.445
<b>Center No. 1014</b>					
N'	5	4	2.00	1.60	0.15
n (%)	2 (40.0)	1 (25.0)	[0.11; 35.80] 0.638†	[0.21; 11.92] 0.646	[-0.45; 0.75] 0.626
<b>Center No. 1015</b>					
N'	4	2	3.00	1.50	0.25
n (%)	3 (75.0)	1 (50.0)	[0.08; >99.99] 0.547†	[0.34; 6.70] 0.596	[-0.56; 1.06] 0.546
<b>Center No. 1017</b>					
N'	5	4	N.E.	7.50	0.80
n (%)	4 (80.0)	0 (0.0)		[0.52; 108.29] 0.139	[0.45; 1.15] <.001
<b>Center No. 1018</b>					
N'	7	5	3.00	1.29	0.19
n (%)	6 (85.7)	4 (66.7)	[0.20; 45.24] 0.427†	[0.68; 2.44] 0.443	[-0.27; 0.65] 0.415
<b>Center No. 1019</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	2 (100.0)	0 (0.0)			
<b>Center No. 1021</b>					
N'	16	9	N.E.	4.53	0.19
n (%)	3 (18.8)	0 (0.0)		[0.26; 79.45] 0.301	[-0.00; 0.38] 0.055
<b>Center No. 1022</b>					
N'	3	3	N.E.	3.00	0.33
n (%)	1 (33.3)	0 (0.0)		[0.17; 53.71] 0.455	[-0.20; 0.87] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1025</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1027</b>					
N'	3	4	8.00	3.33	0.47
n (%)	2 (66.7)	1 (20.0)	[0.31; >99.99] 0.210†	[0.49; 22.90] 0.221	[-0.17; 1.11] 0.152
<b>Center No. 1028</b>					
N'	11	5	N.E.	4.50	0.36
n (%)	4 (36.4)	0 (0.0)		[0.29; 70.57] 0.284	[0.08; 0.65] 0.012
<b>Center No. 1029</b>					
N'	15	9	14.62	6.00	0.56
n (%)	10 (66.7)	1 (11.1)	[1.16; >99.99] 0.038	[0.91; 39.41] 0.062	[0.24; 0.87] <.001
<b>Center No. 1030</b>					
N'	11	9	2.92	2.05	0.23
n (%)	5 (45.5)	2 (22.2)	[0.41; 20.90] 0.287†	[0.51; 8.16] 0.311	[-0.17; 0.63] 0.255
<b>Center No. 1032</b>					
N'	2	4	N.E.	N.E.	N.E.
n (%)	2 (100.0)	0 (0.0)			
<b>Center No. 1033</b>					
N'	4	6	N.E.	9.80	0.75
n (%)	3 (75.0)	0 (0.0)		[0.64; 150.56] 0.102	[0.33; 1.17] <.001
<b>Center No. 1034</b>					
N'	4	3	0.75	0.75	-0.08
n (%)	1 (25.0)	1 (33.3)	[0.02; 28.26] 0.877	[0.07; 7.73] 0.809	[-0.76; 0.60] 0.811
<b>Center No. 1035</b>					
N'	27	22	15.43	4.28	0.60
n (%)	21 (77.8)	4 (18.2)	[3.72; 63.93] <.001	[1.72; 10.62] 0.002	[0.37; 0.82] <.001
<b>Center No. 1036</b>					
N'	7	7	3.33	2.00	0.29
n (%)	4 (57.1)	2 (28.6)	[0.36; 30.70] 0.288†	[0.53; 7.60] 0.309	[-0.21; 0.78] 0.259
<b>Center No. 1037</b>					
N'	8	10	N.E.	8.40	0.33
n (%)	3 (33.3)	0 (0.0)		[0.49; 144.05] 0.142	[0.03; 0.64] 0.034

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1039</b>					
N'	4	3	N.E.	3.00	0.67
n (%)	4 (100.0)	1 (33.3)		[0.61; 14.86] 0.178	[0.13; 1.20] 0.014
<b>Center No. 1040</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (33.3)			
<b>Center No. 1041</b>					
N'	4	4	2.67	2.00	0.20
n (%)	2 (40.0)	1 (20.0)	[0.16; 45.14] 0.497†	[0.26; 15.62] 0.509	[-0.35; 0.75] 0.480
<b>Center No. 1042</b>					
N'	4	5	N.E.	5.00	0.80
n (%)	4 (100.0)	1 (20.0)		[0.87; 28.86] 0.072	[0.45; 1.15] <.001
<b>Center No. 1044</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1046</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1048</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (33.3)			
<b>Center No. 1049</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1050</b>					
N'	6	9	N.E.	4.50	0.78
n (%)	6 (100.0)	2 (22.2)		[1.33; 15.28] 0.016	[0.51; 1.05] <.001
<b>Center No. 1051</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1052</b>					
N'	7	4	1.33	1.14	0.07
n (%)	4 (57.1)	2 (50.0)	[0.11; 15.70] 0.819†	[0.35; 3.69] 0.823	[-0.54; 0.68] 0.819

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1055</b>					
N'	2	4	N.E.	2.00	0.25
n (%)	1 (50.0)	1 (25.0)		[0.22; 17.89] 0.535	[-0.56; 1.06] 0.546
<b>Center No. 1058</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (100.0)			
<b>Center No. 1059</b>					
N'	7	6	2.07	1.00	0.00
n (%)	2 (28.6)	2 (28.6)	[0.12; 34.76] 0.613	[0.19; 5.24] 1.000	[-0.47; 0.47] 1.000
<b>Center No. 1061</b>					
N'	9	6	1.00	1.00	-0.00
n (%)	3 (33.3)	2 (33.3)	[0.11; 8.95] 1.000†	[0.23; 4.31] 1.000	[-0.49; 0.49] 1.000
<b>Center No. 1063</b>					
N'	4	2	N.E.	3.00	0.50
n (%)	2 (50.0)	0 (0.0)		[0.21; 43.66] 0.421	[0.01; 0.99] 0.046
<b>Center No. 1064</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (66.7)			
<b>Center No. 1067</b>					
N'	9	16	1.29	1.14	0.06
n (%)	5 (50.0)	7 (43.8)	[0.26; 6.27] 0.756†	[0.50; 2.63] 0.753	[-0.33; 0.46] 0.756
<b>Center No. 1068</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1069</b>					
N'	3	4	1.50	1.33	0.08
n (%)	1 (33.3)	1 (25.0)	[0.06; 40.63] 0.810†	[0.13; 13.74] 0.809	[-0.60; 0.76] 0.811
<b>Center No. 1070</b>					
N'	1	5	N.E.	1.00	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.06; 15.99] 1.000	[-0.55; 0.15] 0.264
<b>Center No. 1072</b>					
N'	2	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1073</b>					
N'	11	6	2.00	1.27	0.16
n (%)	8 (72.7)	4 (57.1)	[0.27; 14.78] 0.497†	[0.61; 2.66] 0.521	[-0.30; 0.61] 0.499
<b>Center No. 1074</b>					
N'	5	3	3.00	1.80	0.27
n (%)	3 (60.0)	1 (33.3)	[0.15; 59.88] 0.472†	[0.31; 10.39] 0.511	[-0.42; 0.95] 0.445
<b>Center No. 1076</b>					
N'	1	5	N.E.	1.00	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.06; 15.99] 1.000	[-0.55; 0.15] 0.264
<b>Center No. 1077</b>					
N'	3	2	0.55	0.67	-0.17
n (%)	1 (33.3)	1 (50.0)	[0.01; 22.89] 0.751	[0.08; 5.54] 0.707	[-1.04; 0.71] 0.709
<b>Center No. 1079</b>					
N'	4	3	6.00	2.25	0.42
n (%)	3 (75.0)	1 (33.3)	[0.22; >99.99] 0.287†	[0.41; 12.28] 0.349	[-0.26; 1.10] 0.231
<b>Center No. 1080</b>					
N'	3	1	N.E.	0.67	-0.33
n (%)	2 (66.7)	1 (100.0)		[0.30; 1.48] 0.321	[-0.87; 0.20] 0.221
<b>Center No. 1082</b>					
N'	5	7	4.50	2.40	0.35
n (%)	3 (60.0)	2 (25.0)	[0.41; 49.63] 0.219†	[0.59; 9.71] 0.219	[-0.17; 0.87] 0.190
<b>Center No. 1084</b>					
N'	2	3	2.00	1.50	0.17
n (%)	1 (50.0)	1 (33.3)	[0.05; 78.25] 0.711†	[0.18; 12.46] 0.707	[-0.71; 1.04] 0.709
<b>Center No. 1085</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1086</b>					
N'	6	9	5.30	2.00	0.33
n (%)	4 (66.7)	3 (33.3)	[0.40; 70.11] 0.205	[0.68; 5.91] 0.210	[-0.15; 0.82] 0.180



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1087</b>					
N'	1	4	N.E.	4.00	0.75
n (%)	1 (100.0)	1 (25.0)		[0.73; 21.84] 0.109	[0.33; 1.17] <.001
<b>Center No. 1088</b>					
N'	6	5	0.27	0.50	-0.33
n (%)	2 (33.3)	4 (66.7)	[0.02; 3.12] 0.296	[0.14; 1.77] 0.283	[-0.87; 0.20] 0.221
<b>Center No. 1089</b>					
N'	4	3	0.11	0.33	-0.50
n (%)	1 (25.0)	3 (75.0)	[<0.01; 2.73] 0.178†	[0.06; 1.99] 0.229	[-1.10; 0.10] 0.102
<b>Center No. 1091</b>					
N'	6	5	N.E.	6.00	0.50
n (%)	3 (50.0)	0 (0.0)		[0.38; 94.36] 0.202	[0.10; 0.90] 0.014
<b>Center No. 1093</b>					
N'	1	4	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1095</b>					
N'	5	3	N.E.	3.33	0.40
n (%)	2 (40.0)	0 (0.0)		[0.21; 52.68] 0.393	[-0.03; 0.83] 0.068
<b>Center No. 1096</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	2 (100.0)	0 (0.0)			
<b>Center No. 1100</b>					
N'	1	3	N.E.	1.33	0.25
n (%)	1 (100.0)	3 (75.0)		[0.76; 2.35] 0.319	[-0.17; 0.67] 0.248
<b>Center No. 1101</b>					
N'	4	5	0.50	0.75	-0.17
n (%)	2 (50.0)	4 (66.7)	[0.04; 6.68] 0.600†	[0.24; 2.33] 0.618	[-0.79; 0.45] 0.597
<b>Center No. 1103</b>					
N'	2	3	N.E.	1.50	0.17
n (%)	1 (50.0)	1 (33.3)		[0.18; 12.46] 0.707	[-0.71; 1.04] 0.709
<b>Center No. 1105</b>					
N'	3	3	N.E.	5.00	0.67
n (%)	2 (66.7)	0 (0.0)		[0.34; 74.52] 0.243	[0.13; 1.20] 0.014

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1108</b>					
N'	15	10	2.83	1.24	0.17
n (%)	13 (86.7)	7 (70.0)	[0.34; 23.34] 0.335	[0.79; 1.95] 0.354	[-0.17; 0.50] 0.325
<b>Center No. 1110</b>					
N'	6	5	0.50	0.83	-0.13
n (%)	4 (66.7)	4 (80.0)	[0.03; 7.99] 0.624†	[0.41; 1.70] 0.618	[-0.65; 0.38] 0.612
<b>Center No. 1111</b>					
N'	5	0	N.E.	N.E.	N.E.
n (%)	3 (60.0)	0 (0.0)			
<b>Center No. 1113</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	3 (100.0)	0 (0.0)			
<b>Center No. 1115</b>					
N'	4	6	0.30	0.72	-0.23
n (%)	3 (60.0)	5 (83.3)	[0.02; 4.91] 0.398†	[0.32; 1.60] 0.421	[-0.76; 0.29] 0.382
<b>Center No. 1116</b>					
N'	1	4	N.E.	2.00	0.50
n (%)	1 (100.0)	2 (50.0)		[0.75; 5.33] 0.166	[0.01; 0.99] 0.046
<b>Center No. 1118</b>					
N'	3	2	N.E.	2.25	0.33
n (%)	1 (33.3)	0 (0.0)		[0.13; 38.09] 0.574	[-0.20; 0.87] 0.221
<b>Center No. 1119</b>					
N'	3	5	N.E.	1.67	0.40
n (%)	3 (100.0)	3 (60.0)		[0.81; 3.41] 0.162	[-0.03; 0.83] 0.068
<b>Center No. 1121</b>					
N'	4	4	N.E.	0.33	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.02; 6.37] 0.466	[-0.67; 0.17] 0.248
<b>Center No. 1123</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1124</b>					
N'	3	1	N.E.	N.E.	N.E.
n (%)	3 (100.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1502</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<p>N': Number of patients with available response value  N-N' is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup that include treatment group and stratification factor (MMD at baseline).  † The stratification factor is excluded from the model due to non-convergence of the full model.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p>					

**Table 14.2-2.2 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the first month (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>50% reduction from BL in MMD over first month of DBTE</b>					
N'	383	385	2.14	1.71	0.16
n (%)	147 (37.9)	86 (22.2)	[1.56; 2.94] <.001	[1.36; 2.14] <.001	[0.09; 0.22] <.001
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>OR is obtained from a logistic regression model that includes treatment group and stratification factor (MMD at baseline).                      RR and RD are calculated directly (without adjustment) and with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-2.2.1 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the first month by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
< median age, N	186	190			
≥ median age, N	202	198			
<b>50% reduction from BL in MMD over first month of DBTE</b>					
<b>Interaction test: p=0.836</b>					
<b>&lt; median age</b>					
N'	183	188	2.22	1.78	0.16
n (%)	68 (36.6)	39 (20.5)	[1.40; 3.52] <.001	[1.27; 2.50] <.001	[0.07; 0.25] <.001
<b>≥ median age</b>					
N'	200	197	2.08	1.65	0.15
n (%)	79 (39.1)	47 (23.7)	[1.35; 3.20] <.001	[1.22; 2.23] 0.001	[0.06; 0.24] <.001
<p>N': Number of patients with available response value  N-N' is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-2.2.2 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the first month by Gender (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Male, N	57	53			
Female, N	331	335			
<b>50% reduction from BL in MMD over first month of DBTE</b>					
<b>Interaction test: p=0.688</b>					
<b>Male</b>					
N'	55	53	1.84	1.49	0.14
n (%)	24 (42.1)	15 (28.3)	[0.83; 4.09] 0.133	[0.88; 2.52] 0.139	[-0.04; 0.31] 0.125
<b>Female</b>					
N'	328	332	2.20	1.75	0.16
n (%)	123 (37.2)	71 (21.2)	[1.56; 3.11] <.001	[1.37; 2.25] <.001	[0.09; 0.23] <.001
<p>N': Number of patients with available response value  N-N' is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-2.2.3 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the first month by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92			
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254			
≥ 15 monthly migraine days at baseline, N	43	42			
<b>50% reduction from BL in MMD over first month of DBTE</b>					
<b>Interaction test: p=0.209</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
N'	93	92	3.86	2.88	0.22
n (%)	33 (34.4)	11 (12.0)	[1.81; 8.23] <.001	[1.55; 5.34] <.001	[0.11; 0.34] <.001
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
N'	248	252	1.97	1.59	0.15
n (%)	98 (39.4)	63 (24.8)	[1.34; 2.88] <.001	[1.22; 2.07] <.001	[0.06; 0.23] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
N'	42	41	1.48	1.30	0.09
n (%)	16 (37.2)	12 (28.6)	[0.60; 3.69] 0.398	[0.70; 2.41] 0.401	[-0.11; 0.29] 0.395
<p>N': Number of patients with available response value N-N' is the number of values with non-response imputation. n (%): Number and percentage of patients with event CI: Confidence Interval OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction. RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline. <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization. The stratification factor is not included in the logistic regression model due to collinearity with the subgroups.</p>					

**Table 14.2-2.2.4 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the first month by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Naïve*, N	232	229			
Prior treatment failure*, N	156	159			
<b>50% reduction from BL in MMD over first month of DBTE</b>					
<b>Interaction test: p=0.492</b>					
<b>Naïve*</b>					
N'	228	227	1.97	1.58	0.15
n (%)	93 (40.1)	58 (25.3)	[1.33; 2.93] <.001	[1.21; 2.08] <.001	[0.06; 0.23] <.001
<b>Prior treatment failure*</b>					
N'	155	158	2.48	1.97	0.17
n (%)	54 (34.6)	28 (17.6)	[1.47; 4.20] <.001	[1.32; 2.93] <.001	[0.07; 0.27] <.001
<p>N': Number of patients with available response value  N-N' is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>*: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>					



**Table 14.2-2.2.5 Proportion of patients with at least a 50% reduction in Monthly Migraine Days over the first month by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1001, N	10	8			
Center No. 1002, N	4	0			
Center No. 1003, N	2	3			
Center No. 1005, N	31	22			
Center No. 1007, N	5	7			
Center No. 1008, N	3	3			
Center No. 1010, N	2	3			
Center No. 1011, N	2	5			
Center No. 1012, N	3	5			
Center No. 1014, N	5	4			
Center No. 1015, N	4	2			
Center No. 1017, N	5	4			
Center No. 1018, N	7	6			
Center No. 1019, N	2	2			
Center No. 1021, N	16	10			
Center No. 1022, N	3	3			
Center No. 1025, N	0	2			
Center No. 1027, N	3	5			
Center No. 1028, N	11	5			
Center No. 1029, N	15	9			
Center No. 1030, N	11	9			
Center No. 1032, N	2	4			
Center No. 1033, N	4	6			
Center No. 1034, N	4	3			
Center No. 1035, N	27	22			
Center No. 1036, N	7	7			
Center No. 1037, N	9	11			
Center No. 1039, N	4	3			
Center No. 1040, N	0	3			
Center No. 1041, N	5	5			
Center No. 1042, N	4	5			
Center No. 1044, N	0	2			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1046, N	1	1			
Center No. 1048, N	0	3			
Center No. 1049, N	1	0			
Center No. 1050, N	6	9			
Center No. 1051, N	1	1			
Center No. 1052, N	7	4			
Center No. 1055, N	2	4			
Center No. 1058, N	0	1			
Center No. 1059, N	7	7			
Center No. 1061, N	9	6			
Center No. 1063, N	4	2			
Center No. 1064, N	0	3			
Center No. 1067, N	10	16			
Center No. 1068, N	0	2			
Center No. 1069, N	3	4			
Center No. 1070, N	1	5			
Center No. 1072, N	2	1			
Center No. 1073, N	11	7			
Center No. 1074, N	5	3			
Center No. 1076, N	1	5			
Center No. 1077, N	3	2			
Center No. 1079, N	4	3			
Center No. 1080, N	3	1			
Center No. 1082, N	5	8			
Center No. 1084, N	2	3			
Center No. 1085, N	0	3			
Center No. 1086, N	6	9			
Center No. 1087, N	1	4			
Center No. 1088, N	6	6			
Center No. 1089, N	4	4			
Center No. 1091, N	6	5			
Center No. 1093, N	1	4			
Center No. 1095, N	5	3			
Center No. 1096, N	2	0			
Center No. 1100, N	1	4			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1101, N	4	6			
Center No. 1103, N	2	3			
Center No. 1105, N	3	3			
Center No. 1108, N	15	10			
Center No. 1110, N	6	5			
Center No. 1111, N	5	0			
Center No. 1113, N	3	3			
Center No. 1115, N	5	6			
Center No. 1116, N	1	4			
Center No. 1118, N	3	2			
Center No. 1119, N	3	5			
Center No. 1121, N	4	4			
Center No. 1123, N	1	1			
Center No. 1124, N	3	2			
Center No. 1502, N	0	3			
<b>50% reduction from BL in MMD over first month of DBTE</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
N'	10	8	4.02	2.00	0.25
n (%)	5 (50.0)	2 (25.0)	[0.33; 49.18] 0.276	[0.52; 7.72] 0.315	[-0.18; 0.68] 0.256
<b>Center No. 1002</b>					
N'	4	0	N.E.	N.E.	N.E.
n (%)	1 (25.0)	0 (0.0)			
<b>Center No. 1003</b>					
N'	2	3	2.00	1.50	0.17
n (%)	1 (50.0)	1 (33.3)	[0.05; 78.25] 0.711	[0.18; 12.46] 0.707	[-0.71; 1.04] 0.709
<b>Center No. 1005</b>					
N'	30	22	0.96	1.06	0.02
n (%)	9 (29.0)	6 (27.3)	[0.27; 3.38] 0.946	[0.44; 2.56] 0.889	[-0.23; 0.26] 0.888
<b>Center No. 1007</b>					
N'	5	7	0.89	0.93	-0.03
n (%)	2 (40.0)	3 (42.9)	[0.09; 9.16] 0.921†	[0.24; 3.68] 0.922	[-0.59; 0.54] 0.921

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1008</b>					
N'	2	3	N.E.	3.00	0.33
n (%)	1 (33.3)	0 (0.0)		[0.17; 53.71] 0.455	[-0.20; 0.87] 0.221
<b>Center No. 1010</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1011</b>					
N'	2	5	N.E.	0.40	-0.40
n (%)	0 (0.0)	2 (40.0)		[0.03; 5.96] 0.506	[-0.83; 0.03] 0.068
<b>Center No. 1012</b>					
N'	3	5	2.00	1.67	0.13
n (%)	1 (33.3)	1 (20.0)	[0.08; 51.59] 0.676†	[0.16; 17.89] 0.673	[-0.51; 0.77] 0.682
<b>Center No. 1014</b>					
N'	5	4	N.E.	5.83	0.60
n (%)	3 (60.0)	0 (0.0)		[0.39; 88.13] 0.203	[0.17; 1.03] 0.006
<b>Center No. 1015</b>					
N'	4	2	N.E.	1.80	0.25
n (%)	1 (25.0)	0 (0.0)		[0.10; 31.52] 0.687	[-0.17; 0.67] 0.248
<b>Center No. 1017</b>					
N'	5	4	0.75	0.80	-0.05
n (%)	1 (20.0)	1 (25.0)	[0.03; 17.51] 0.858†	[0.07; 9.18] 0.858	[-0.60; 0.50] 0.859
<b>Center No. 1018</b>					
N'	7	5	0.40	0.57	-0.21
n (%)	2 (28.6)	3 (50.0)	[0.04; 3.96] 0.433†	[0.14; 2.36] 0.439	[-0.74; 0.31] 0.421
<b>Center No. 1019</b>					
N'	2	2	N.E.	3.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.19; 47.96] 0.437	[-0.19; 1.19] 0.157
<b>Center No. 1021</b>					
N'	16	10	4.34	3.13	0.21
n (%)	5 (31.3)	1 (10.0)	[0.40; 46.88] 0.227	[0.42; 23.01] 0.263	[-0.08; 0.51] 0.156
<b>Center No. 1022</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1025</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1027</b>					
N'	3	5	N.E.	0.30	-0.40
n (%)	0 (0.0)	2 (40.0)		[0.02; 4.74] 0.393	[-0.83; 0.03] 0.068
<b>Center No. 1028</b>					
N'	11	5	2.29	1.82	0.16
n (%)	4 (36.4)	1 (20.0)	[0.19; 28.19] 0.519†	[0.27; 12.40] 0.542	[-0.29; 0.62] 0.477
<b>Center No. 1029</b>					
N'	15	9	4.98	2.10	0.24
n (%)	7 (46.7)	2 (22.2)	[0.47; 53.32] 0.184	[0.55; 7.99] 0.277	[-0.13; 0.62] 0.196
<b>Center No. 1030</b>					
N'	11	9	0.78	0.82	-0.04
n (%)	2 (18.2)	2 (22.2)	[0.09; 6.98] 0.822†	[0.14; 4.71] 0.822	[-0.39; 0.31] 0.823
<b>Center No. 1032</b>					
N'	2	4	N.E.	0.56	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.03; 9.73] 0.687	[-0.67; 0.17] 0.248
<b>Center No. 1033</b>					
N'	4	6	N.E.	7.00	0.50
n (%)	2 (50.0)	0 (0.0)		[0.42; 116.41] 0.175	[0.01; 0.99] 0.046
<b>Center No. 1034</b>					
N'	4	3	N.E.	4.00	0.50
n (%)	2 (50.0)	0 (0.0)		[0.26; 61.76] 0.321	[0.01; 0.99] 0.046
<b>Center No. 1035</b>					
N'	27	22	12.50	6.11	0.46
n (%)	15 (55.6)	2 (9.1)	[2.43; 64.43] 0.003†	[1.56; 23.90] 0.009	[0.24; 0.69] <.001
<b>Center No. 1036</b>					
N'	7	7	3.33	2.00	0.29
n (%)	4 (57.1)	2 (28.6)	[0.36; 30.70] 0.288†	[0.53; 7.60] 0.309	[-0.21; 0.78] 0.259

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1037</b>					
N'	8	11	N.E.	8.40	0.33
n (%)	3 (33.3)	0 (0.0)		[0.49; 144.05] 0.142	[0.03; 0.64] 0.034
<b>Center No. 1039</b>					
N'	4	3	6.00	2.25	0.42
n (%)	3 (75.0)	1 (33.3)	[0.22; >99.99] 0.287†	[0.41; 12.28] 0.349	[-0.26; 1.10] 0.231
<b>Center No. 1040</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (33.3)			
<b>Center No. 1041</b>					
N'	4	5	2.67	2.00	0.20
n (%)	2 (40.0)	1 (20.0)	[0.16; 45.14] 0.497†	[0.26; 15.62] 0.509	[-0.35; 0.75] 0.480
<b>Center No. 1042</b>					
N'	4	5	1.33	1.25	0.05
n (%)	1 (25.0)	1 (20.0)	[0.06; 31.12] 0.858†	[0.11; 14.34] 0.858	[-0.50; 0.60] 0.859
<b>Center No. 1044</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1046</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1048</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (66.7)			
<b>Center No. 1049</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1050</b>					
N'	6	9	1.75	1.50	0.11
n (%)	2 (33.3)	2 (22.2)	[0.17; 17.69] 0.635†	[0.28; 7.93] 0.633	[-0.35; 0.58] 0.639
<b>Center No. 1051</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (100.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1052</b>					
N'	7	4	1.20	1.14	0.04
n (%)	2 (28.6)	1 (25.0)	[0.07; 19.63] 0.898†	[0.15; 8.99] 0.899	[-0.50; 0.58] 0.897
<b>Center No. 1055</b>					
N'	2	4	N.E.	0.56	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.03; 9.73] 0.687	[-0.67; 0.17] 0.248
<b>Center No. 1058</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1059</b>					
N'	7	7	N.E.	7.00	0.43
n (%)	3 (42.9)	0 (0.0)		[0.43; 114.71] 0.173	[0.06; 0.80] 0.022
<b>Center No. 1061</b>					
N'	9	6	1.00	1.00	-0.00
n (%)	3 (33.3)	2 (33.3)	[0.11; 8.95] 1.000†	[0.23; 4.31] 1.000	[-0.49; 0.49] 1.000
<b>Center No. 1063</b>					
N'	4	2	N.E.	1.80	0.25
n (%)	1 (25.0)	0 (0.0)		[0.10; 31.52] 0.687	[-0.17; 0.67] 0.248
<b>Center No. 1064</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (33.3)			
<b>Center No. 1067</b>					
N'	9	16	1.47	1.28	0.09
n (%)	4 (40.0)	5 (31.3)	[0.28; 7.63] 0.649†	[0.45; 3.66] 0.645	[-0.29; 0.47] 0.651
<b>Center No. 1068</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (50.0)			
<b>Center No. 1069</b>					
N'	3	4	1.50	1.33	0.08
n (%)	1 (33.3)	1 (25.0)	[0.06; 40.63] 0.810†	[0.13; 13.74] 0.809	[-0.60; 0.76] 0.811
<b>Center No. 1070</b>					
N'	1	5	N.E.	1.00	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.06; 15.99] 1.000	[-0.55; 0.15] 0.264

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1072</b>					
N'	2	1	N.E.	2.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.14; 28.42] 0.609	[-0.19; 1.19] 0.157
<b>Center No. 1073</b>					
N'	11	7	5.00	3.18	0.31
n (%)	5 (45.5)	1 (14.3)	[0.44; 56.61] 0.194†	[0.46; 21.85] 0.239	[-0.08; 0.70] 0.119
<b>Center No. 1074</b>					
N'	5	3	1.33	1.20	0.07
n (%)	2 (40.0)	1 (33.3)	[0.07; 26.62] 0.851†	[0.17; 8.24] 0.853	[-0.62; 0.75] 0.849
<b>Center No. 1076</b>					
N'	1	5	N.E.	0.60	-0.40
n (%)	0 (0.0)	2 (40.0)		[0.05; 7.92] 0.698	[-0.83; 0.03] 0.068
<b>Center No. 1077</b>					
N'	3	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1079</b>					
N'	4	3	6.00	2.25	0.42
n (%)	3 (75.0)	1 (33.3)	[0.22; >99.99] 0.287†	[0.41; 12.28] 0.349	[-0.26; 1.10] 0.231
<b>Center No. 1080</b>					
N'	3	1	N.E.	1.50	0.33
n (%)	1 (33.3)	0 (0.0)		[0.10; 22.62] 0.770	[-0.20; 0.87] 0.221
<b>Center No. 1082</b>					
N'	5	8	2.00	1.60	0.15
n (%)	2 (40.0)	2 (25.0)	[0.18; 22.06] 0.571†	[0.32; 8.01] 0.567	[-0.37; 0.67] 0.575
<b>Center No. 1084</b>					
N'	2	3	N.E.	4.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.24; 67.72] 0.337	[-0.19; 1.19] 0.157
<b>Center No. 1085</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1086</b>					
N'	6	9	1.28	1.00	0.00
n (%)	2 (33.3)	3 (33.3)	[0.11; 14.58] 0.843	[0.23; 4.31] 1.000	[-0.49; 0.49] 1.000



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1087</b>					
N'	1	4	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1088</b>					
N'	6	6	5.36	3.00	0.33
n (%)	3 (50.0)	1 (16.7)	[0.34; 83.75] 0.231	[0.42; 21.30] 0.272	[-0.17; 0.83] 0.190
<b>Center No. 1089</b>					
N'	4	4	0.33	0.50	-0.25
n (%)	1 (25.0)	2 (50.0)	[0.02; 6.65] 0.472†	[0.07; 3.55] 0.488	[-0.90; 0.40] 0.450
<b>Center No. 1091</b>					
N'	6	5	3.20	2.50	0.30
n (%)	3 (50.0)	1 (20.0)	[0.19; 53.67] 0.418	[0.36; 17.17] 0.351	[-0.23; 0.83] 0.269
<b>Center No. 1093</b>					
N'	1	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1095</b>					
N'	5	3	1.33	1.20	0.07
n (%)	2 (40.0)	1 (33.3)	[0.07; 26.62] 0.851†	[0.17; 8.24] 0.853	[-0.62; 0.75] 0.849
<b>Center No. 1096</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	1 (50.0)	0 (0.0)			
<b>Center No. 1100</b>					
N'	1	3	N.E.	2.00	0.50
n (%)	1 (100.0)	2 (50.0)		[0.75; 5.33] 0.166	[0.01; 0.99] 0.046
<b>Center No. 1101</b>					
N'	4	6	N.E.	0.47	-0.17
n (%)	0 (0.0)	1 (16.7)		[0.02; 9.26] 0.617	[-0.46; 0.13] 0.273
<b>Center No. 1103</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1105</b>					
N'	3	3	1.00	1.00	0.00
n (%)	1 (33.3)	1 (33.3)	[0.03; 29.81] 1.000†	[0.10; 9.61] 1.000	[-0.75; 0.75] 1.000

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1108</b>					
N'	15	10	3.50	2.33	0.27
n (%)	7 (46.7)	2 (20.0)	[0.55; 22.30] 0.185†	[0.60; 9.02] 0.220	[-0.09; 0.62] 0.140
<b>Center No. 1110</b>					
N'	6	5	2.00	1.67	0.13
n (%)	2 (33.3)	1 (20.0)	[0.13; 31.98] 0.624†	[0.21; 13.43] 0.631	[-0.38; 0.65] 0.612
<b>Center No. 1111</b>					
N'	5	0	N.E.	N.E.	N.E.
n (%)	2 (40.0)	0 (0.0)			
<b>Center No. 1113</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1115</b>					
N'	5	6	0.67	0.80	-0.10
n (%)	2 (40.0)	3 (50.0)	[0.06; 7.35] 0.741†	[0.21; 3.05] 0.744	[-0.69; 0.49] 0.738
<b>Center No. 1116</b>					
N'	1	4	N.E.	4.00	0.75
n (%)	1 (100.0)	1 (25.0)		[0.73; 21.84] 0.109	[0.33; 1.17] <.001
<b>Center No. 1118</b>					
N'	3	2	N.E.	2.25	0.33
n (%)	1 (33.3)	0 (0.0)		[0.13; 38.09] 0.574	[-0.20; 0.87] 0.221
<b>Center No. 1119</b>					
N'	3	5	1.33	1.11	0.07
n (%)	2 (66.7)	3 (60.0)	[0.07; 26.62] 0.851†	[0.38; 3.25] 0.847	[-0.62; 0.75] 0.849
<b>Center No. 1121</b>					
N'	4	4	1.00	1.00	0.00
n (%)	1 (25.0)	1 (25.0)	[0.04; 24.55] 1.000†	[0.09; 11.03] 1.000	[-0.60; 0.60] 1.000
<b>Center No. 1123</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	1 (100.0)	1 (100.0)			
<b>Center No. 1124</b>					
N'	3	2	2.00	1.33	0.17
n (%)	2 (66.7)	1 (50.0)	[0.05; 78.25] 0.711†	[0.27; 6.61] 0.725	[-0.71; 1.04] 0.709

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1502</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<p>N': Number of patients with available response value  N-N' is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup that include treatment group and stratification factor (MMD at baseline).  † The stratification factor is excluded from the model due to non-convergence of the full model.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p>					

**Table 14.2-3.1 Change from baseline in Monthly Migraine Days over last three months (month 4, 5, 6), Mixed Effects Model for Repeated Measures (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
N'	383	385		
Baseline Mean (SD)	10.37 (4.03)	10.45 (3.79)		
Month 4-6 Mean (SD)	5.15 (4.20)	7.00 (4.44)		
Adjusted Mean Change (SE)	-5.86 (0.24)	-4.02 (0.24)	-1.84 [-2.43; -1.25]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Monthly migraine days (MMD) over the last three months are calculated as the mean MMD-value over the last three months.</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, (scheduled) visit and interaction between treatment group and (scheduled) visit.            The model is calculated based on the first three scheduled visits (month 1, 2 and 3) and a 'dummy' fourth visit for the mean MMD-value over the last three months.            The model utilizes unstructured covariance matrix in the repeated statement.</p>				

**Table 14.2-3.1.1 Change from baseline in Monthly Migraine Days over last three months (month 4, 5, 6), Mixed Effects Model for Repeated Measures by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
< median age, N	186	190		
≥ median age, N	202	198		
<b>Interaction test: p=0.083</b>				
<b>&lt; median age</b>				
N'	183	188		
Baseline Mean (SD)	10.92 (4.38)	10.73 (4.33)		
Month 4-6 Mean (SD)	5.62 (4.66)	6.91 (4.89)		
Adjusted Mean Change (SE)	-5.80 (0.32)	-4.34 (0.32)	-1.46 [-2.30; -0.61]	<.001
<b>≥ median age</b>				
N'	200	197		
Baseline Mean (SD)	9.87 (3.62)	10.18 (3.18)		
Month 4-6 Mean (SD)	4.72 (3.69)	7.08 (3.96)		
Adjusted Mean Change (SE)	-5.94 (0.32)	-3.73 (0.32)	-2.21 [-3.03; -1.40]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Monthly migraine days (MMD) over the last three months are calculated as the mean MMD-value over the last three months.</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, (scheduled) visit, subgroup, interaction between treatment group and (scheduled) visit, interaction between treatment group and subgroup and interaction between treatment group, (scheduled) visit and subgroup.</p> <p>The model is calculated based on the first three scheduled visits (month 1, 2 and 3) and a 'dummy' fourth visit for the mean MMD-value over the last three months.</p> <p>The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p>				

**Table 14.2-3.1.2 Change from baseline in Monthly Migraine Days over last three months (month 4, 5, 6), Mixed Effects Model for Repeated Measures by Gender (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Male, N	57	53		
Female, N	331	335		
<b>Interaction test: p=0.424</b>				
<b>Male</b>				
N'	55	53		
Baseline Mean (SD)	9.62 (3.93)	9.80 (4.02)		
Month 4-6 Mean (SD)	4.27 (4.07)	5.26 (4.01)		
Adjusted Mean Change (SE)	-6.36 (0.57)	-5.44 (0.59)	-0.92 [-2.49; 0.64]	0.247
<b>Female</b>				
N'	328	332		
Baseline Mean (SD)	10.50 (4.04)	10.55 (3.75)		
Month 4-6 Mean (SD)	5.30 (4.20)	7.26 (4.45)		
Adjusted Mean Change (SE)	-5.79 (0.26)	-3.81 (0.26)	-1.98 [-2.61; -1.35]	<.001
<p>N': Number of patients in the analysis  CI: Confidence interval  SD: Standard deviation  SE: Standard error</p> <p>Monthly migraine days (MMD) over the last three months are calculated as the mean MMD-value over the last three months.</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, (scheduled) visit, subgroup, interaction between treatment group and (scheduled) visit, interaction between treatment group and subgroup and interaction between treatment group, (scheduled) visit and subgroup.</p> <p>The model is calculated based on the first three scheduled visits (month 1, 2 and 3) and a 'dummy' fourth visit for the mean MMD-value over the last three months.</p> <p>The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p>				

**Table 14.2-3.1.3 Change from baseline in Monthly Migraine Days over last three months (month 4, 5, 6), Mixed Effects Model for Repeated Measures by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92		
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254		
≥ 15 monthly migraine days at baseline, N	43	42		
<b>Interaction test: p=0.952</b>				
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>				
N'	93	92		
Baseline Mean (SD)	6.09 (1.02)	6.34 (0.93)		
Month 4-6 Mean (SD)	3.27 (2.41)	5.40 (3.71)		
Adjusted Mean Change (SE)	-2.79 (0.41)	-0.95 (0.42)	-1.84 [-3.00; -0.69]	0.002
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>				
N'	248	252		
Baseline Mean (SD)	10.58 (1.95)	10.63 (1.83)		
Month 4-6 Mean (SD)	5.25 (3.83)	6.96 (4.10)		
Adjusted Mean Change (SE)	-5.34 (0.25)	-3.58 (0.25)	-1.76 [-2.46; -1.05]	<.001
<b>≥ 15 monthly migraine days at baseline</b>				
N'	42	41		
Baseline Mean (SD)	18.60 (3.84)	18.51 (3.00)		
Month 4-6 Mean (SD)	8.77 (6.46)	10.92 (5.58)		
Adjusted Mean Change (SE)	-10.01 (0.61)	-7.72 (0.63)	-2.29 [-4.02; -0.57]	0.009
<p>N': Number of patients in the analysis  CI: Confidence interval  SD: Standard deviation  SE: Standard error</p> <p>Monthly migraine days (MMD) over the last three months are calculated as the mean MMD-value over the last three months.</p> <p>Linear mixed model for repeated measures includes treatment group, (scheduled) visit, subgroup, interaction between treatment group and (scheduled) visit, interaction between treatment group and subgroup and interaction between treatment group, (scheduled) visit and subgroup.</p> <p>The model is calculated based on the first three scheduled visits (month 1, 2 and 3) and a 'dummy' fourth visit for the mean MMD-value over the last three months.</p> <p>The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.</p> <p><sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.</p> <p>The stratification factor is not included in the linear mixed model due to collinearity with the subgroups.</p>				

**Table 14.2-3.1.4 Change from baseline in Monthly Migraine Days over last three months (month 4, 5, 6), Mixed Effects Model for Repeated Measures by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Naïve*, N	232	229		
Prior treatment failure*, N	156	159		
<b>Interaction test: p=0.631</b>				
<b>Naïve*</b>				
N'	228	227		
Baseline Mean (SD)	10.21 (4.05)	10.45 (4.09)		
Month 4-6 Mean (SD)	4.74 (4.15)	6.66 (4.65)		
Adjusted Mean Change (SE)	-6.09 (0.30)	-4.40 (0.30)	-1.69 [-2.46; -0.93]	<.001
<b>Prior treatment failure*</b>				
N'	155	158		
Baseline Mean (SD)	10.60 (4.00)	10.44 (3.32)		
Month 4-6 Mean (SD)	5.75 (4.21)	7.49 (4.08)		
Adjusted Mean Change (SE)	-5.48 (0.36)	-3.44 (0.35)	-2.04 [-2.96; -1.13]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Monthly migraine days (MMD) over the last three months are calculated as the mean MMD-value over the last three months.</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, (scheduled) visit, subgroup, interaction between treatment group and (scheduled) visit, interaction between treatment group and subgroup and interaction between treatment group, (scheduled) visit and subgroup.</p> <p>The model is calculated based on the first three scheduled visits (month 1, 2 and 3) and a 'dummy' fourth visit for the mean MMD-value over the last three months.</p> <p>The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p> <p>*: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>				



**Table 14.2-3.1.5 Change from baseline in Monthly Migraine Days over last three months (month 4, 5, 6), Mixed Effects Model for Repeated Measures by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1001, N	10	8		
Center No. 1002, N	4	0		
Center No. 1003, N	2	3		
Center No. 1005, N	31	22		
Center No. 1007, N	5	7		
Center No. 1008, N	3	3		
Center No. 1010, N	2	3		
Center No. 1011, N	2	5		
Center No. 1012, N	3	5		
Center No. 1014, N	5	4		
Center No. 1015, N	4	2		
Center No. 1017, N	5	4		
Center No. 1018, N	7	6		
Center No. 1019, N	2	2		
Center No. 1021, N	16	10		
Center No. 1022, N	3	3		
Center No. 1025, N	0	2		
Center No. 1027, N	3	5		
Center No. 1028, N	11	5		
Center No. 1029, N	15	9		
Center No. 1030, N	11	9		
Center No. 1032, N	2	4		
Center No. 1033, N	4	6		
Center No. 1034, N	4	3		
Center No. 1035, N	27	22		
Center No. 1036, N	7	7		
Center No. 1037, N	9	11		
Center No. 1039, N	4	3		
Center No. 1040, N	0	3		
Center No. 1041, N	5	5		
Center No. 1042, N	4	5		
Center No. 1044, N	0	2		

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1046, N	1	1		
Center No. 1048, N	0	3		
Center No. 1049, N	1	0		
Center No. 1050, N	6	9		
Center No. 1051, N	1	1		
Center No. 1052, N	7	4		
Center No. 1055, N	2	4		
Center No. 1058, N	0	1		
Center No. 1059, N	7	7		
Center No. 1061, N	9	6		
Center No. 1063, N	4	2		
Center No. 1064, N	0	3		
Center No. 1067, N	10	16		
Center No. 1068, N	0	2		
Center No. 1069, N	3	4		
Center No. 1070, N	1	5		
Center No. 1072, N	2	1		
Center No. 1073, N	11	7		
Center No. 1074, N	5	3		
Center No. 1076, N	1	5		
Center No. 1077, N	3	2		
Center No. 1079, N	4	3		
Center No. 1080, N	3	1		
Center No. 1082, N	5	8		
Center No. 1084, N	2	3		
Center No. 1085, N	0	3		
Center No. 1086, N	6	9		
Center No. 1087, N	1	4		
Center No. 1088, N	6	6		
Center No. 1089, N	4	4		
Center No. 1091, N	6	5		
Center No. 1093, N	1	4		
Center No. 1095, N	5	3		
Center No. 1096, N	2	0		
Center No. 1100, N	1	4		
Center No. 1101, N	4	6		

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1103, N	2	3		
Center No. 1105, N	3	3		
Center No. 1108, N	15	10		
Center No. 1110, N	6	5		
Center No. 1111, N	5	0		
Center No. 1113, N	3	3		
Center No. 1115, N	5	6		
Center No. 1116, N	1	4		
Center No. 1118, N	3	2		
Center No. 1119, N	3	5		
Center No. 1121, N	4	4		
Center No. 1123, N	1	1		
Center No. 1124, N	3	2		
Center No. 1502, N	0	3		
<b>Interaction test: N.E.</b>				
<b>Center No. 1001</b>				
N'	10	8		
Baseline Mean (SD)	12.08 (6.30)	10.73 (3.99)		
Month 4-6 Mean (SD)	7.80 (7.87)	7.86 (4.36)		
Adjusted Mean Change (SE)	-4.19 (1.11)	-2.78 (1.27)	-1.41 [-4.94; 2.13]	0.408
<b>Center No. 1002</b>				
N'	4	0		
Baseline Mean (SD)	7.75 (2.36)	N.E.		
Month 4-6 Mean (SD)	6.27 (2.94)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1003</b>				
N'	2	3		
Baseline Mean (SD)	11.34 (2.06)	13.17 (4.18)		
Month 4-6 Mean (SD)	3.33 (4.71)	8.54 (9.87)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1005</b>				
N'	30	22		
Baseline Mean (SD)	12.26 (4.75)	13.91 (6.66)		
Month 4-6 Mean (SD)	5.34 (3.61)	6.07 (5.32)		
Adjusted Mean Change (SE)	-7.77 (1.02)	-7.92 (1.17)	0.16 [-2.80; 3.11]	0.915

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1007</b>				
N'	5	7		
Baseline Mean (SD)	10.38 (3.19)	13.44 (3.68)		
Month 4-6 Mean (SD)	6.29 (5.34)	6.29 (3.60)		
Adjusted Mean Change (SE)	-6.07 (2.15)	-5.97 (1.92)	-0.10 [-6.12; 5.92]	0.970
<b>Center No. 1008</b>				
N'	2	3		
Baseline Mean (SD)	9.36 (2.32)	11.75 (3.89)		
Month 4-6 Mean (SD)	6.17 (4.95)	8.06 (6.78)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1010</b>				
N'	2	3		
Baseline Mean (SD)	10.00 (4.24)	7.87 (2.20)		
Month 4-6 Mean (SD)	8.19 (1.21)	7.92 (3.34)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1011</b>				
N'	2	5		
Baseline Mean (SD)	8.17 (1.65)	10.96 (3.46)		
Month 4-6 Mean (SD)	3.62 (0.02)	5.63 (2.67)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1012</b>				
N'	3	5		
Baseline Mean (SD)	11.09 (3.37)	10.42 (2.69)		
Month 4-6 Mean (SD)	6.15 (4.50)	7.03 (4.69)		
Adjusted Mean Change (SE)	-0.27 (3.22)	-1.36 (2.32)	1.09 [-9.23; 11.41]	0.784
<b>Center No. 1014</b>				
N'	5	4		
Baseline Mean (SD)	10.72 (6.82)	11.16 (5.21)		
Month 4-6 Mean (SD)	6.34 (5.32)	6.78 (3.43)		
Adjusted Mean Change (SE)	-4.77 (1.21)	-3.40 (1.48)	-1.37 [-6.30; 3.56]	0.507
<b>Center No. 1015</b>				
N'	4	2		
Baseline Mean (SD)	9.00 (3.56)	11.00 (2.83)		
Month 4-6 Mean (SD)	3.14 (2.70)	6.57 (1.11)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1017</b>				
N'	5	4		
Baseline Mean (SD)	8.80 (2.95)	9.35 (2.92)		
Month 4-6 Mean (SD)	3.06 (2.15)	8.45 (5.33)		
Adjusted Mean Change (SE)	-4.87 (1.83)	1.27 (2.05)	-6.14 [-12.85; 0.57]	0.067
<b>Center No. 1018</b>				
N'	7	5		
Baseline Mean (SD)	10.57 (1.40)	10.40 (4.04)		
Month 4-6 Mean (SD)	5.16 (4.95)	4.97 (3.61)		
Adjusted Mean Change (SE)	-3.81 (2.29)	-4.47 (2.10)	0.66 [-5.00; 6.32]	0.798
<b>Center No. 1019</b>				
N'	2	2		
Baseline Mean (SD)	9.72 (3.85)	12.09 (3.44)		
Month 4-6 Mean (SD)	4.38 (1.89)	9.35 (4.69)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1021</b>				
N'	16	10		
Baseline Mean (SD)	8.96 (2.86)	8.97 (2.90)		
Month 4-6 Mean (SD)	6.71 (3.65)	10.00 (3.90)		
Adjusted Mean Change (SE)	-2.09 (0.84)	1.57 (1.08)	-3.66 [-6.43; -0.90]	0.012
<b>Center No. 1022</b>				
N'	3	3		
Baseline Mean (SD)	11.67 (7.93)	8.04 (3.08)		
Month 4-6 Mean (SD)	6.62 (5.91)	5.52 (1.34)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1025</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	19.00 (12.73)		
Month 4-6 Mean (SD)	N.E.	17.24 (15.22)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1027</b>				
N'	3	5		
Baseline Mean (SD)	12.54 (1.74)	7.78 (2.27)		
Month 4-6 Mean (SD)	4.35 (1.89)	6.17 (4.89)		
Adjusted Mean Change (SE)	-7.74 (1.86)	-1.55 (1.40)	-6.18 [-12.31; -0.05]	0.049

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1028</b>				
N'	11	5		
Baseline Mean (SD)	11.19 (2.55)	11.87 (4.05)		
Month 4-6 Mean (SD)	6.31 (3.11)	8.55 (3.93)		
Adjusted Mean Change (SE)	-5.83 (0.99)	-3.84 (1.23)	-1.98 [-5.16; 1.20]	0.199
<b>Center No. 1029</b>				
N'	15	9		
Baseline Mean (SD)	10.80 (2.09)	8.36 (3.09)		
Month 4-6 Mean (SD)	4.57 (4.00)	9.25 (5.72)		
Adjusted Mean Change (SE)	-6.24 (1.20)	0.89 (1.27)	-7.12 [-10.67; -3.58]	<.001
<b>Center No. 1030</b>				
N'	11	9		
Baseline Mean (SD)	11.58 (5.36)	10.54 (3.49)		
Month 4-6 Mean (SD)	6.86 (5.63)	6.90 (3.20)		
Adjusted Mean Change (SE)	-5.53 (1.33)	-5.24 (1.41)	-0.29 [-4.24; 3.66]	0.878
<b>Center No. 1032</b>				
N'	2	4		
Baseline Mean (SD)	10.00 (2.83)	10.50 (2.89)		
Month 4-6 Mean (SD)	1.84 (1.64)	9.92 (2.04)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1033</b>				
N'	4	6		
Baseline Mean (SD)	13.52 (3.11)	9.17 (2.14)		
Month 4-6 Mean (SD)	3.69 (4.48)	7.46 (3.88)		
Adjusted Mean Change (SE)	-10.47 (2.06)	-2.62 (1.87)	-7.85 [-14.41; -1.29]	0.026
<b>Center No. 1034</b>				
N'	4	3		
Baseline Mean (SD)	9.53 (2.85)	6.91 (1.01)		
Month 4-6 Mean (SD)	5.48 (2.58)	3.87 (2.70)		
Adjusted Mean Change (SE)	-4.54 (1.60)	-2.71 (1.84)	-1.83 [-8.63; 4.97]	0.496
<b>Center No. 1035</b>				
N'	27	22		
Baseline Mean (SD)	9.31 (2.83)	9.13 (2.88)		
Month 4-6 Mean (SD)	3.41 (2.26)	8.49 (5.68)		
Adjusted Mean Change (SE)	-5.60 (1.10)	-0.71 (1.13)	-4.89 [-7.22; -2.56]	<.001

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1036</b>				
N'	7	7		
Baseline Mean (SD)	11.88 (3.44)	10.04 (2.83)		
Month 4-6 Mean (SD)	5.35 (4.74)	8.44 (5.31)		
Adjusted Mean Change (SE)	-5.18 (2.40)	-2.32 (2.49)	-2.86 [-9.98; 4.27]	0.393
<b>Center No. 1037</b>				
N'	8	11		
Baseline Mean (SD)	8.16 (1.97)	9.27 (3.00)		
Month 4-6 Mean (SD)	6.01 (3.65)	8.41 (3.90)		
Adjusted Mean Change (SE)	-1.50 (1.84)	-0.62 (1.33)	-0.88 [-5.13; 3.37]	0.667
<b>Center No. 1039</b>				
N'	4	3		
Baseline Mean (SD)	8.53 (2.92)	11.89 (5.27)		
Month 4-6 Mean (SD)	2.25 (1.85)	5.69 (3.08)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1040</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	11.40 (3.50)		
Month 4-6 Mean (SD)	N.E.	11.39 (9.25)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1041</b>				
N'	4	5		
Baseline Mean (SD)	9.49 (2.74)	10.02 (2.82)		
Month 4-6 Mean (SD)	5.76 (2.37)	6.58 (1.63)		
Adjusted Mean Change (SE)	-2.38 (1.15)	-1.67 (1.12)	-0.72 [-4.40; 2.96]	0.649
<b>Center No. 1042</b>				
N'	4	5		
Baseline Mean (SD)	11.73 (3.51)	10.83 (4.92)		
Month 4-6 Mean (SD)	3.54 (1.31)	9.09 (6.22)		
Adjusted Mean Change (SE)	-4.70 (2.78)	-0.23 (2.43)	-4.47 [-13.79; 4.86]	0.273
<b>Center No. 1044</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	7.67 (2.36)		
Month 4-6 Mean (SD)	N.E.	5.83 (0.24)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1046</b>				
N'	1	0		
Baseline Mean (SD)	12.44 (N.E.)	N.E.		
Month 4-6 Mean (SD)	7.02 (N.E.)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1048</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	8.33 (2.08)		
Month 4-6 Mean (SD)	N.E.	3.54 (2.01)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1049</b>				
N'	1	0		
Baseline Mean (SD)	13.00 (N.E.)	N.E.		
Month 4-6 Mean (SD)	3.67 (N.E.)	N.E.		
Adjusted Mean Change (SE)	-9.33 (0.00)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>				
N'	6	9		
Baseline Mean (SD)	10.57 (4.63)	10.88 (2.69)		
Month 4-6 Mean (SD)	2.65 (0.87)	8.26 (4.33)		
Adjusted Mean Change (SE)	-8.34 (1.31)	-3.46 (1.66)	-4.88 [-8.38; -1.38]	0.011
<b>Center No. 1051</b>				
N'	1	1		
Baseline Mean (SD)	10.00 (N.E.)	9.00 (N.E.)		
Month 4-6 Mean (SD)	8.32 (N.E.)	7.86 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1052</b>				
N'	7	4		
Baseline Mean (SD)	8.46 (2.76)	10.87 (7.97)		
Month 4-6 Mean (SD)	4.85 (2.66)	6.65 (6.69)		
Adjusted Mean Change (SE)	-3.62 (1.54)	-4.64 (1.46)	1.02 [-3.82; 5.86]	0.634
<b>Center No. 1055</b>				
N'	2	4		
Baseline Mean (SD)	6.63 (0.89)	11.07 (3.01)		
Month 4-6 Mean (SD)	2.67 (2.36)	4.99 (3.20)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1058</b>				
N'	0	1		
Baseline Mean (SD)	N.E.	11.00 (N.E.)		
Month 4-6 Mean (SD)	N.E.	3.54 (N.E.)		
Adjusted Mean Change (SE)	N.E.	-7.46 (0.00)	N.E.	N.E.
<b>Center No. 1059</b>				
N'	7	7		
Baseline Mean (SD)	9.25 (2.82)	11.31 (3.32)		
Month 4-6 Mean (SD)	5.29 (3.25)	8.09 (4.56)		
Adjusted Mean Change (SE)	-3.40 (1.59)	-3.90 (1.66)	0.49 [-4.58; 5.57]	0.835
<b>Center No. 1061</b>				
N'	9	6		
Baseline Mean (SD)	10.65 (4.01)	9.05 (1.53)		
Month 4-6 Mean (SD)	7.45 (4.74)	5.50 (1.80)		
Adjusted Mean Change (SE)	-5.62 (1.91)	-9.30 (2.07)	3.68 [-1.32; 8.68]	0.134
<b>Center No. 1063</b>				
N'	4	2		
Baseline Mean (SD)	11.39 (3.03)	9.67 (0.47)		
Month 4-6 Mean (SD)	5.92 (5.66)	9.67 (0.94)		
Adjusted Mean Change (SE)	-5.46 (2.00)	0.00 (2.83)	-5.46 [-15.07; 4.15]	0.190
<b>Center No. 1064</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	10.39 (4.06)		
Month 4-6 Mean (SD)	N.E.	4.56 (2.86)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1067</b>				
N'	9	16		
Baseline Mean (SD)	9.70 (4.74)	9.84 (2.47)		
Month 4-6 Mean (SD)	5.09 (4.92)	5.34 (3.63)		
Adjusted Mean Change (SE)	-3.99 (1.56)	-3.05 (1.33)	-0.95 [-5.03; 3.14]	0.635
<b>Center No. 1068</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	15.26 (2.46)		
Month 4-6 Mean (SD)	N.E.	12.33 (1.41)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1069</b>				
N'	3	4		
Baseline Mean (SD)	9.29 (3.04)	8.07 (0.83)		
Month 4-6 Mean (SD)	5.60 (2.11)	5.53 (3.33)		
Adjusted Mean Change (SE)	-2.49 (1.93)	-4.36 (1.67)	1.87 [-5.22; 8.97]	0.504
<b>Center No. 1070</b>				
N'	1	5		
Baseline Mean (SD)	17.00 (N.E.)	12.40 (2.70)		
Month 4-6 Mean (SD)	11.81 (N.E.)	9.31 (3.27)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1072</b>				
N'	2	1		
Baseline Mean (SD)	11.70 (2.02)	11.38 (N.E.)		
Month 4-6 Mean (SD)	8.74 (0.57)	10.33 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1073</b>				
N'	11	7		
Baseline Mean (SD)	11.02 (3.10)	9.85 (3.64)		
Month 4-6 Mean (SD)	5.09 (5.15)	4.34 (3.76)		
Adjusted Mean Change (SE)	-3.78 (1.53)	-1.98 (1.98)	-1.80 [-6.62; 3.02]	0.437
<b>Center No. 1074</b>				
N'	5	3		
Baseline Mean (SD)	7.80 (3.03)	7.33 (2.52)		
Month 4-6 Mean (SD)	3.07 (3.11)	3.78 (2.01)		
Adjusted Mean Change (SE)	-5.47 (0.86)	-4.79 (1.12)	-0.68 [-4.29; 2.94]	0.652
<b>Center No. 1076</b>				
N'	1	5		
Baseline Mean (SD)	7.23 (N.E.)	7.36 (1.85)		
Month 4-6 Mean (SD)	4.89 (N.E.)	5.77 (4.66)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1077</b>				
N'	3	2		
Baseline Mean (SD)	10.08 (3.72)	9.00 (5.66)		
Month 4-6 Mean (SD)	4.98 (2.58)	10.60 (11.59)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1079</b>				
N'	4	3		
Baseline Mean (SD)	11.24 (4.18)	12.33 (1.53)		
Month 4-6 Mean (SD)	3.33 (3.71)	6.75 (3.42)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1080</b>				
N'	3	1		
Baseline Mean (SD)	7.33 (2.89)	10.00 (N.E.)		
Month 4-6 Mean (SD)	2.47 (0.47)	4.68 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1082</b>				
N'	5	8		
Baseline Mean (SD)	11.14 (4.74)	9.55 (2.09)		
Month 4-6 Mean (SD)	5.61 (5.72)	6.21 (2.75)		
Adjusted Mean Change (SE)	-6.50 (2.13)	-3.90 (2.16)	-2.60 [-9.11; 3.92]	0.391
<b>Center No. 1084</b>				
N'	2	3		
Baseline Mean (SD)	12.00 (1.41)	7.86 (3.20)		
Month 4-6 Mean (SD)	5.08 (6.25)	3.38 (2.83)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1085</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	8.00 (1.73)		
Month 4-6 Mean (SD)	N.E.	5.72 (1.48)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1086</b>				
N'	6	9		
Baseline Mean (SD)	9.96 (4.22)	10.63 (2.47)		
Month 4-6 Mean (SD)	4.90 (3.66)	7.74 (4.62)		
Adjusted Mean Change (SE)	-5.06 (1.77)	-1.36 (1.70)	-3.70 [-9.05; 1.65]	0.158
<b>Center No. 1087</b>				
N'	1	4		
Baseline Mean (SD)	8.00 (N.E.)	11.81 (4.95)		
Month 4-6 Mean (SD)	3.00 (N.E.)	8.30 (1.25)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1088</b>				
N'	6	6		
Baseline Mean (SD)	8.17 (1.72)	9.53 (3.08)		
Month 4-6 Mean (SD)	6.29 (3.33)	4.15 (1.33)		
Adjusted Mean Change (SE)	-1.43 (1.12)	-4.74 (1.28)	3.32 [-0.40; 7.03]	0.074
<b>Center No. 1089</b>				
N'	4	4		
Baseline Mean (SD)	8.00 (2.94)	10.53 (3.68)		
Month 4-6 Mean (SD)	3.58 (2.45)	1.91 (1.28)		
Adjusted Mean Change (SE)	-0.84 (1.00)	-3.38 (1.08)	2.55 [0.62; 4.47]	0.021
<b>Center No. 1091</b>				
N'	6	5		
Baseline Mean (SD)	10.62 (5.66)	8.44 (4.97)		
Month 4-6 Mean (SD)	4.65 (3.17)	8.10 (4.88)		
Adjusted Mean Change (SE)	-5.32 (1.66)	-0.73 (1.80)	-4.59 [-10.30; 1.12]	0.101
<b>Center No. 1093</b>				
N'	1	4		
Baseline Mean (SD)	13.07 (N.E.)	14.16 (4.86)		
Month 4-6 Mean (SD)	5.33 (N.E.)	11.13 (5.90)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1095</b>				
N'	5	3		
Baseline Mean (SD)	11.27 (3.84)	10.20 (3.70)		
Month 4-6 Mean (SD)	5.85 (3.22)	6.72 (3.04)		
Adjusted Mean Change (SE)	-6.74 (1.40)	-7.27 (1.82)	0.53 [-5.79; 6.86]	0.826
<b>Center No. 1096</b>				
N'	2	0		
Baseline Mean (SD)	11.50 (3.54)	N.E.		
Month 4-6 Mean (SD)	3.49 (0.70)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1100</b>				
N'	1	3		
Baseline Mean (SD)	7.00 (N.E.)	9.11 (1.02)		
Month 4-6 Mean (SD)	2.26 (N.E.)	2.01 (1.86)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1101</b>				
N'	4	6		
Baseline Mean (SD)	8.65 (1.38)	11.93 (1.05)		
Month 4-6 Mean (SD)	4.45 (1.71)	5.09 (2.79)		
Adjusted Mean Change (SE)	-4.27 (1.41)	-6.79 (1.26)	2.52 [-2.12; 7.16]	0.232
<b>Center No. 1103</b>				
N'	2	3		
Baseline Mean (SD)	15.91 (7.42)	7.16 (1.88)		
Month 4-6 Mean (SD)	9.00 (1.41)	3.33 (2.60)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1105</b>				
N'	3	3		
Baseline Mean (SD)	10.31 (2.48)	11.67 (1.15)		
Month 4-6 Mean (SD)	4.59 (4.86)	11.29 (3.22)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1108</b>				
N'	15	10		
Baseline Mean (SD)	10.04 (4.29)	11.02 (4.50)		
Month 4-6 Mean (SD)	2.94 (2.92)	5.27 (2.83)		
Adjusted Mean Change (SE)	-7.44 (0.81)	-5.30 (1.04)	-2.14 [-4.80; 0.52]	0.110
<b>Center No. 1110</b>				
N'	6	5		
Baseline Mean (SD)	8.29 (4.55)	12.03 (3.81)		
Month 4-6 Mean (SD)	5.28 (6.83)	4.81 (2.46)		
Adjusted Mean Change (SE)	-2.92 (1.77)	-7.87 (2.00)	4.95 [-1.30; 11.20]	0.103
<b>Center No. 1111</b>				
N'	5	0		
Baseline Mean (SD)	6.24 (1.73)	N.E.		
Month 4-6 Mean (SD)	2.07 (1.69)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1113</b>				
N'	3	3		
Baseline Mean (SD)	13.41 (0.64)	8.94 (1.85)		
Month 4-6 Mean (SD)	3.53 (2.73)	6.99 (3.00)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1115</b>				
N'	5	6		
Baseline Mean (SD)	6.20 (1.10)	11.11 (1.99)		
Month 4-6 Mean (SD)	2.37 (1.10)	3.83 (2.91)		
Adjusted Mean Change (SE)	-6.46 (1.78)	-4.20 (1.85)	-2.27 [-9.78; 5.25]	0.506
<b>Center No. 1116</b>				
N'	1	4		
Baseline Mean (SD)	14.00 (N.E.)	10.45 (2.36)		
Month 4-6 Mean (SD)	5.99 (N.E.)	3.99 (1.83)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1118</b>				
N'	3	2		
Baseline Mean (SD)	12.33 (8.50)	10.50 (0.71)		
Month 4-6 Mean (SD)	11.83 (9.51)	9.23 (2.22)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1119</b>				
N'	3	5		
Baseline Mean (SD)	13.79 (6.25)	14.46 (4.32)		
Month 4-6 Mean (SD)	2.91 (1.06)	6.82 (4.68)		
Adjusted Mean Change (SE)	-10.88 (1.73)	-6.20 (1.40)	-4.68 [-10.86; 1.51]	0.104
<b>Center No. 1121</b>				
N'	4	4		
Baseline Mean (SD)	13.40 (9.23)	7.94 (2.35)		
Month 4-6 Mean (SD)	16.48 (9.43)	7.24 (1.61)		
Adjusted Mean Change (SE)	4.46 (6.88)	6.87 (6.90)	-2.41 [-29.42; 24.61]	0.817
<b>Center No. 1123</b>				
N'	1	1		
Baseline Mean (SD)	8.00 (N.E.)	10.27 (N.E.)		
Month 4-6 Mean (SD)	2.67 (N.E.)	10.00 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1124</b>				
N'	3	2		
Baseline Mean (SD)	19.67 (7.23)	14.47 (5.94)		
Month 4-6 Mean (SD)	5.95 (6.35)	11.00 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1502</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	9.33 (3.06)		
Month 4-6 Mean (SD)	N.E.	10.46 (4.42)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<p>N': Number of patients in the analysis            CI: Confidence interval            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Monthly migraine days (MMD) over the last three months are calculated as the mean MMD-value over the last three months.</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, (scheduled) visit, subgroup, interaction between treatment group and (scheduled) visit, interaction between treatment group and subgroup and interaction between treatment group, (scheduled) visit and subgroup.</p> <p>If interaction test is N.E., linear mixed model for repeated measures is calculated separately for each subgroup and includes treatment group, stratification factor, (scheduled) visit and interaction between treatment group and (scheduled) visit.</p> <p>The model is calculated based on the first three scheduled visits (month 1, 2 and 3) and a 'dummy' fourth visit for the mean MMD-value over the last three months.</p> <p>The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p>				

**Table 14.2-3.2 Change from baseline in Monthly Migraine Days over the first month, Mixed Effects Model for Repeated Measures (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
N'	383	385		
Baseline Mean (SD)	10.37 (4.03)	10.45 (3.79)		
Month 1 Mean (SD)	6.99 (4.81)	8.63 (4.92)		
Adjusted Mean Change (SE)	-4.01 (0.25)	-2.45 (0.25)	-1.57 [-2.19; -0.94]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, (scheduled) visit and interaction between treatment group and (scheduled) visit.            The model is calculated based on the first three scheduled visits (month 1, 2 and 3) and a 'dummy' fourth visit for the mean MMD-value over the last three months.            The model utilizes unstructured covariance matrix in the repeated statement.</p>				



**Table 14.2-3.2.1 Change from baseline in Monthly Migraine Days over the first month, Mixed Effects Model for Repeated Measures by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
< median age, N	186	190		
≥ median age, N	202	198		
<b>Interaction test: p=0.083</b>				
<b>&lt; median age</b>				
N'	183	188		
Baseline Mean (SD)	10.92 (4.38)	10.73 (4.33)		
Month 1 Mean (SD)	7.76 (5.39)	8.98 (5.13)		
Adjusted Mean Change (SE)	-3.63 (0.34)	-2.35 (0.34)	-1.27 [-2.17; -0.38]	0.005
<b>≥ median age</b>				
N'	200	197		
Baseline Mean (SD)	9.87 (3.62)	10.18 (3.18)		
Month 1 Mean (SD)	6.28 (4.10)	8.30 (4.71)		
Adjusted Mean Change (SE)	-4.38 (0.34)	-2.56 (0.34)	-1.83 [-2.69; -0.96]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, (scheduled) visit, subgroup, interaction between treatment group and (scheduled) visit, interaction between treatment group and subgroup and interaction between treatment group, (scheduled) visit and subgroup.            The model is calculated based on the first three scheduled visits (month 1, 2 and 3) and a 'dummy' fourth visit for the mean MMD-value over the last three months.            The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p>				

**Table 14.2-3.2.2 Change from baseline in Monthly Migraine Days over the first month, Mixed Effects Model for Repeated Measures by Gender (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Male, N	57	53		
Female, N	331	335		
<b>Interaction test: p=0.424</b>				
<b>Male</b>				
N'	55	53		
Baseline Mean (SD)	9.62 (3.93)	9.80 (4.02)		
Month 1 Mean (SD)	6.22 (4.14)	7.53 (4.89)		
Adjusted Mean Change (SE)	-4.42 (0.61)	-3.20 (0.62)	-1.21 [-2.88; 0.45]	0.152
<b>Female</b>				
N'	328	332		
Baseline Mean (SD)	10.50 (4.04)	10.55 (3.75)		
Month 1 Mean (SD)	7.12 (4.91)	8.81 (4.91)		
Adjusted Mean Change (SE)	-3.96 (0.27)	-2.34 (0.27)	-1.62 [-2.29; -0.95]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, (scheduled) visit, subgroup, interaction between treatment group and (scheduled) visit, interaction between treatment group and subgroup and interaction between treatment group, (scheduled) visit and subgroup.            The model is calculated based on the first three scheduled visits (month 1, 2 and 3) and a 'dummy' fourth visit for the mean MMD-value over the last three months.            The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p>				

**Table 14.2-3.2.3 Change from baseline in Monthly Migraine Days over the first month, Mixed Effects Model for Repeated Measures by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92		
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254		
≥ 15 monthly migraine days at baseline, N	43	42		
<b>Interaction test: p=0.952</b>				
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>				
N'	93	92		
Baseline Mean (SD)	6.09 (1.02)	6.34 (0.93)		
Month 1 Mean (SD)	4.57 (2.73)	6.70 (3.46)		
Adjusted Mean Change (SE)	-1.52 (0.44)	0.35 (0.45)	-1.87 [-3.11; -0.64]	0.003
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>				
N'	248	252		
Baseline Mean (SD)	10.58 (1.95)	10.63 (1.83)		
Month 1 Mean (SD)	6.97 (4.24)	8.60 (4.68)		
Adjusted Mean Change (SE)	-3.61 (0.27)	-2.03 (0.27)	-1.58 [-2.33; -0.83]	<.001
<b>≥ 15 monthly migraine days at baseline</b>				
N'	42	41		
Baseline Mean (SD)	18.60 (3.84)	18.51 (3.00)		
Month 1 Mean (SD)	12.43 (6.85)	13.16 (6.17)		
Adjusted Mean Change (SE)	-6.18 (0.66)	-5.35 (0.67)	-0.83 [-2.67; 1.02]	0.379
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, (scheduled) visit, subgroup, interaction between treatment group and (scheduled) visit, interaction between treatment group and subgroup and interaction between treatment group, (scheduled) visit and subgroup.</p> <p>The model is calculated based on the first three scheduled visits (month 1, 2 and 3) and a 'dummy' fourth visit for the mean MMD-value over the last three months.</p> <p>The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.</p> <p><sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.</p> <p>The stratification factor is not included in the linear mixed model due to collinearity with the subgroups.</p>				

**Table 14.2-3.2.4 Change from baseline in Monthly Migraine Days over the first month, Mixed Effects Model for Repeated Measures by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Naïve*, N	232	229		
Prior treatment failure*, N	156	159		
<b>Interaction test: p=0.631</b>				
<b>Naïve*</b>				
N'	228	227		
Baseline Mean (SD)	10.21 (4.05)	10.45 (4.09)		
Month 1 Mean (SD)	6.71 (4.86)	8.36 (5.13)		
Adjusted Mean Change (SE)	-4.11 (0.31)	-2.73 (0.31)	-1.38 [-2.19; -0.57]	<.001
<b>Prior treatment failure*</b>				
N'	155	158		
Baseline Mean (SD)	10.60 (4.00)	10.44 (3.32)		
Month 1 Mean (SD)	7.39 (4.72)	9.02 (4.60)		
Adjusted Mean Change (SE)	-3.84 (0.38)	-2.01 (0.37)	-1.83 [-2.80; -0.85]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, (scheduled) visit, subgroup, interaction between treatment group and (scheduled) visit, interaction between treatment group and subgroup and interaction between treatment group, (scheduled) visit and subgroup.            The model is calculated based on the first three scheduled visits (month 1, 2 and 3) and a 'dummy' fourth visit for the mean MMD-value over the last three months.            The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p> <p>*: 'Naïve'/'Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>				

**Table 14.2-3.2.5 Change from baseline in Monthly Migraine Days over the first month, Mixed Effects Model for Repeated Measures by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1001, N	10	8		
Center No. 1002, N	4	0		
Center No. 1003, N	2	3		
Center No. 1005, N	31	22		
Center No. 1007, N	5	7		
Center No. 1008, N	3	3		
Center No. 1010, N	2	3		
Center No. 1011, N	2	5		
Center No. 1012, N	3	5		
Center No. 1014, N	5	4		
Center No. 1015, N	4	2		
Center No. 1017, N	5	4		
Center No. 1018, N	7	6		
Center No. 1019, N	2	2		
Center No. 1021, N	16	10		
Center No. 1022, N	3	3		
Center No. 1025, N	0	2		
Center No. 1027, N	3	5		
Center No. 1028, N	11	5		
Center No. 1029, N	15	9		
Center No. 1030, N	11	9		
Center No. 1032, N	2	4		
Center No. 1033, N	4	6		
Center No. 1034, N	4	3		
Center No. 1035, N	27	22		
Center No. 1036, N	7	7		
Center No. 1037, N	9	11		
Center No. 1039, N	4	3		
Center No. 1040, N	0	3		
Center No. 1041, N	5	5		
Center No. 1042, N	4	5		
Center No. 1044, N	0	2		
Center No. 1046, N	1	1		

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1048, N	0	3		
Center No. 1049, N	1	0		
Center No. 1050, N	6	9		
Center No. 1051, N	1	1		
Center No. 1052, N	7	4		
Center No. 1055, N	2	4		
Center No. 1058, N	0	1		
Center No. 1059, N	7	7		
Center No. 1061, N	9	6		
Center No. 1063, N	4	2		
Center No. 1064, N	0	3		
Center No. 1067, N	10	16		
Center No. 1068, N	0	2		
Center No. 1069, N	3	4		
Center No. 1070, N	1	5		
Center No. 1072, N	2	1		
Center No. 1073, N	11	7		
Center No. 1074, N	5	3		
Center No. 1076, N	1	5		
Center No. 1077, N	3	2		
Center No. 1079, N	4	3		
Center No. 1080, N	3	1		
Center No. 1082, N	5	8		
Center No. 1084, N	2	3		
Center No. 1085, N	0	3		
Center No. 1086, N	6	9		
Center No. 1087, N	1	4		
Center No. 1088, N	6	6		
Center No. 1089, N	4	4		
Center No. 1091, N	6	5		
Center No. 1093, N	1	4		
Center No. 1095, N	5	3		
Center No. 1096, N	2	0		
Center No. 1100, N	1	4		
Center No. 1101, N	4	6		
Center No. 1103, N	2	3		

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1105, N	3	3		
Center No. 1108, N	15	10		
Center No. 1110, N	6	5		
Center No. 1111, N	5	0		
Center No. 1113, N	3	3		
Center No. 1115, N	5	6		
Center No. 1116, N	1	4		
Center No. 1118, N	3	2		
Center No. 1119, N	3	5		
Center No. 1121, N	4	4		
Center No. 1123, N	1	1		
Center No. 1124, N	3	2		
Center No. 1502, N	0	3		
<b>Interaction test: N.E.</b>				
<b>Center No. 1001</b>				
N'	10	8		
Baseline Mean (SD)	12.08 (6.30)	10.73 (3.99)		
Month 1 Mean (SD)	7.38 (7.81)	8.68 (6.32)		
Adjusted Mean Change (SE)	-4.67 (1.16)	-1.96 (1.33)	-2.71 [-6.39; 0.98]	0.137
<b>Center No. 1002</b>				
N'	4	0		
Baseline Mean (SD)	7.75 (2.36)	N.E.		
Month 1 Mean (SD)	6.58 (2.75)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1003</b>				
N'	2	3		
Baseline Mean (SD)	11.34 (2.06)	13.17 (4.18)		
Month 1 Mean (SD)	4.00 (5.66)	8.18 (4.88)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1005</b>				
N'	30	22		
Baseline Mean (SD)	12.26 (4.75)	13.91 (6.66)		
Month 1 Mean (SD)	8.20 (4.29)	8.69 (5.28)		
Adjusted Mean Change (SE)	-4.76 (0.94)	-5.30 (1.10)	0.54 [-2.19; 3.28]	0.691

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1007</b>				
N'	5	7		
Baseline Mean (SD)	10.38 (3.19)	13.44 (3.68)		
Month 1 Mean (SD)	7.00 (3.94)	7.51 (6.27)		
Adjusted Mean Change (SE)	-5.29 (2.81)	-4.75 (2.52)	-0.54 [-8.89; 7.81]	0.885
<b>Center No. 1008</b>				
N'	2	3		
Baseline Mean (SD)	9.36 (2.32)	11.75 (3.89)		
Month 1 Mean (SD)	4.00 (5.66)	8.74 (1.99)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1010</b>				
N'	2	3		
Baseline Mean (SD)	10.00 (4.24)	7.87 (2.20)		
Month 1 Mean (SD)	9.50 (6.36)	8.72 (1.11)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1011</b>				
N'	2	5		
Baseline Mean (SD)	8.17 (1.65)	10.96 (3.46)		
Month 1 Mean (SD)	5.40 (0.02)	7.54 (4.32)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1012</b>				
N'	3	5		
Baseline Mean (SD)	11.09 (3.37)	10.42 (2.69)		
Month 1 Mean (SD)	7.36 (5.28)	9.84 (3.00)		
Adjusted Mean Change (SE)	0.94 (2.82)	1.28 (1.92)	-0.34 [-8.96; 8.27]	0.917
<b>Center No. 1014</b>				
N'	5	4		
Baseline Mean (SD)	10.72 (6.82)	11.16 (5.21)		
Month 1 Mean (SD)	7.67 (7.61)	13.00 (10.42)		
Adjusted Mean Change (SE)	-3.45 (2.22)	2.82 (2.55)	-6.27 [-14.98; 2.45]	0.124
<b>Center No. 1015</b>				
N'	4	2		
Baseline Mean (SD)	9.00 (3.56)	11.00 (2.83)		
Month 1 Mean (SD)	5.68 (3.24)	13.36 (5.69)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1017</b>				
N'	5	4		
Baseline Mean (SD)	8.80 (2.95)	9.35 (2.92)		
Month 1 Mean (SD)	6.18 (2.83)	7.00 (4.40)		
Adjusted Mean Change (SE)	-1.75 (2.01)	-0.18 (2.25)	-1.57 [-8.96; 5.82]	0.622
<b>Center No. 1018</b>				
N'	7	5		
Baseline Mean (SD)	10.57 (1.40)	10.40 (4.04)		
Month 1 Mean (SD)	7.14 (2.54)	5.20 (2.17)		
Adjusted Mean Change (SE)	-1.82 (2.05)	-4.24 (1.71)	2.41 [-1.95; 6.78]	0.242
<b>Center No. 1019</b>				
N'	2	2		
Baseline Mean (SD)	9.72 (3.85)	12.09 (3.44)		
Month 1 Mean (SD)	7.78 (6.75)	10.19 (6.80)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1021</b>				
N'	16	10		
Baseline Mean (SD)	8.96 (2.86)	8.97 (2.90)		
Month 1 Mean (SD)	6.99 (4.86)	10.49 (5.38)		
Adjusted Mean Change (SE)	-1.81 (1.11)	1.70 (1.40)	-3.51 [-7.15; 0.12]	0.058
<b>Center No. 1022</b>				
N'	3	3		
Baseline Mean (SD)	11.67 (7.93)	8.04 (3.08)		
Month 1 Mean (SD)	12.57 (7.48)	7.11 (2.17)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1025</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	19.00 (12.73)		
Month 1 Mean (SD)	N.E.	19.00 (12.73)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1027</b>				
N'	3	5		
Baseline Mean (SD)	12.54 (1.74)	7.78 (2.27)		
Month 1 Mean (SD)	7.07 (0.89)	5.87 (2.40)		
Adjusted Mean Change (SE)	-5.02 (1.60)	-2.01 (1.16)	-3.01 [-8.16; 2.15]	0.194

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1028</b>				
N'	11	5		
Baseline Mean (SD)	11.19 (2.55)	11.87 (4.05)		
Month 1 Mean (SD)	6.95 (4.02)	7.64 (4.19)		
Adjusted Mean Change (SE)	-5.18 (1.18)	-4.76 (1.56)	-0.43 [-4.48; 3.62]	0.822
<b>Center No. 1029</b>				
N'	15	9		
Baseline Mean (SD)	10.80 (2.09)	8.36 (3.09)		
Month 1 Mean (SD)	7.21 (4.68)	6.59 (4.33)		
Adjusted Mean Change (SE)	-3.61 (1.20)	-1.77 (1.26)	-1.84 [-5.38; 1.70]	0.292
<b>Center No. 1030</b>				
N'	11	9		
Baseline Mean (SD)	11.58 (5.36)	10.54 (3.49)		
Month 1 Mean (SD)	10.96 (7.91)	7.26 (2.69)		
Adjusted Mean Change (SE)	-1.43 (1.60)	-4.88 (1.72)	3.45 [-1.40; 8.29]	0.151
<b>Center No. 1032</b>				
N'	2	4		
Baseline Mean (SD)	10.00 (2.83)	10.50 (2.89)		
Month 1 Mean (SD)	9.50 (0.71)	8.25 (3.69)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1033</b>				
N'	4	6		
Baseline Mean (SD)	13.52 (3.11)	9.17 (2.14)		
Month 1 Mean (SD)	8.75 (3.77)	10.67 (5.85)		
Adjusted Mean Change (SE)	-5.41 (2.75)	0.59 (2.39)	-5.99 [-14.71; 2.73]	0.144
<b>Center No. 1034</b>				
N'	4	3		
Baseline Mean (SD)	9.53 (2.85)	6.91 (1.01)		
Month 1 Mean (SD)	5.21 (0.98)	6.94 (3.51)		
Adjusted Mean Change (SE)	-4.82 (1.26)	0.36 (1.44)	-5.18 [-10.53; 0.18]	0.055
<b>Center No. 1035</b>				
N'	27	22		
Baseline Mean (SD)	9.31 (2.83)	9.13 (2.88)		
Month 1 Mean (SD)	5.47 (4.33)	9.51 (5.92)		
Adjusted Mean Change (SE)	-3.53 (1.17)	0.32 (1.22)	-3.85 [-6.49; -1.21]	0.005

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1036</b>				
N'	7	7		
Baseline Mean (SD)	11.88 (3.44)	10.04 (2.83)		
Month 1 Mean (SD)	6.18 (5.56)	7.85 (3.92)		
Adjusted Mean Change (SE)	-4.35 (2.29)	-2.92 (2.38)	-1.43 [-8.18; 5.32]	0.647
<b>Center No. 1037</b>				
N'	8	11		
Baseline Mean (SD)	8.16 (1.97)	9.27 (3.00)		
Month 1 Mean (SD)	5.38 (2.56)	11.64 (6.33)		
Adjusted Mean Change (SE)	-2.13 (2.23)	2.66 (1.71)	-4.80 [-10.27; 0.68]	0.082
<b>Center No. 1039</b>				
N'	4	3		
Baseline Mean (SD)	8.53 (2.92)	11.89 (5.27)		
Month 1 Mean (SD)	2.77 (3.41)	7.15 (0.78)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1040</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	11.40 (3.50)		
Month 1 Mean (SD)	N.E.	14.80 (11.87)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1041</b>				
N'	4	5		
Baseline Mean (SD)	9.49 (2.74)	10.02 (2.82)		
Month 1 Mean (SD)	6.06 (4.23)	9.84 (4.37)		
Adjusted Mean Change (SE)	-2.08 (1.84)	1.44 (1.68)	-3.52 [-9.44; 2.40]	0.196
<b>Center No. 1042</b>				
N'	4	5		
Baseline Mean (SD)	11.73 (3.51)	10.83 (4.92)		
Month 1 Mean (SD)	7.90 (6.02)	10.17 (5.67)		
Adjusted Mean Change (SE)	-0.34 (2.06)	0.85 (1.77)	-1.19 [-7.96; 5.58]	0.670
<b>Center No. 1044</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	7.67 (2.36)		
Month 1 Mean (SD)	N.E.	6.50 (0.71)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1046</b>				
N'	1	0		
Baseline Mean (SD)	12.44 (N.E.)	N.E.		
Month 1 Mean (SD)	0.00 (N.E.)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1048</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	8.33 (2.08)		
Month 1 Mean (SD)	N.E.	3.67 (3.06)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1049</b>				
N'	1	0		
Baseline Mean (SD)	13.00 (N.E.)	N.E.		
Month 1 Mean (SD)	6.00 (N.E.)	N.E.		
Adjusted Mean Change (SE)	-7.00 (0.00)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>				
N'	6	9		
Baseline Mean (SD)	10.57 (4.63)	10.88 (2.69)		
Month 1 Mean (SD)	7.58 (2.87)	9.44 (4.10)		
Adjusted Mean Change (SE)	-3.41 (1.59)	-2.27 (1.82)	-1.13 [-5.48; 3.21]	0.577
<b>Center No. 1051</b>				
N'	1	1		
Baseline Mean (SD)	10.00 (N.E.)	9.00 (N.E.)		
Month 1 Mean (SD)	12.00 (N.E.)	4.00 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1052</b>				
N'	7	4		
Baseline Mean (SD)	8.46 (2.76)	10.87 (7.97)		
Month 1 Mean (SD)	7.48 (6.93)	7.46 (5.81)		
Adjusted Mean Change (SE)	-0.99 (2.52)	-3.83 (3.01)	2.84 [-6.35; 12.02]	0.489
<b>Center No. 1055</b>				
N'	2	4		
Baseline Mean (SD)	6.63 (0.89)	11.07 (3.01)		
Month 1 Mean (SD)	5.00 (1.41)	9.00 (6.65)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1058</b>				
N'	0	1		
Baseline Mean (SD)	N.E.	11.00 (N.E.)		
Month 1 Mean (SD)	N.E.	12.44 (N.E.)		
Adjusted Mean Change (SE)	N.E.	1.44 (0.00)	N.E.	N.E.
<b>Center No. 1059</b>				
N'	7	7		
Baseline Mean (SD)	9.25 (2.82)	11.31 (3.32)		
Month 1 Mean (SD)	6.22 (3.31)	12.03 (3.87)		
Adjusted Mean Change (SE)	-2.47 (0.97)	0.53 (0.93)	-3.00 [-6.00; -0.01]	0.049
<b>Center No. 1061</b>				
N'	9	6		
Baseline Mean (SD)	10.65 (4.01)	9.05 (1.53)		
Month 1 Mean (SD)	8.91 (5.09)	7.41 (3.65)		
Adjusted Mean Change (SE)	-4.15 (2.22)	-7.38 (2.49)	3.23 [-3.14; 9.59]	0.288
<b>Center No. 1063</b>				
N'	4	2		
Baseline Mean (SD)	11.39 (3.03)	9.67 (0.47)		
Month 1 Mean (SD)	7.66 (1.94)	6.11 (0.16)		
Adjusted Mean Change (SE)	-3.72 (1.67)	-3.56 (2.36)	-0.17 [-8.18; 7.85]	0.957
<b>Center No. 1064</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	10.39 (4.06)		
Month 1 Mean (SD)	N.E.	6.12 (1.93)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1067</b>				
N'	9	16		
Baseline Mean (SD)	9.70 (4.74)	9.84 (2.47)		
Month 1 Mean (SD)	6.86 (6.01)	7.12 (3.51)		
Adjusted Mean Change (SE)	-2.22 (1.18)	-1.27 (1.09)	-0.95 [-4.06; 2.16]	0.532
<b>Center No. 1068</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	15.26 (2.46)		
Month 1 Mean (SD)	N.E.	11.30 (7.49)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1069</b>				
N'	3	4		
Baseline Mean (SD)	9.29 (3.04)	8.07 (0.83)		
Month 1 Mean (SD)	6.00 (1.00)	7.25 (3.50)		
Adjusted Mean Change (SE)	-2.08 (1.19)	-2.64 (1.04)	0.56 [-3.84; 4.96]	0.743
<b>Center No. 1070</b>				
N'	1	5		
Baseline Mean (SD)	17.00 (N.E.)	12.40 (2.70)		
Month 1 Mean (SD)	9.00 (N.E.)	9.07 (2.47)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1072</b>				
N'	2	1		
Baseline Mean (SD)	11.70 (2.02)	11.38 (N.E.)		
Month 1 Mean (SD)	5.70 (8.07)	20.74 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1073</b>				
N'	11	7		
Baseline Mean (SD)	11.02 (3.10)	9.85 (3.64)		
Month 1 Mean (SD)	6.54 (4.43)	7.82 (3.71)		
Adjusted Mean Change (SE)	-2.33 (1.34)	0.41 (1.68)	-2.73 [-6.68; 1.21]	0.159
<b>Center No. 1074</b>				
N'	5	3		
Baseline Mean (SD)	7.80 (3.03)	7.33 (2.52)		
Month 1 Mean (SD)	4.24 (2.43)	4.28 (3.04)		
Adjusted Mean Change (SE)	-4.30 (0.74)	-4.29 (0.96)	-0.00 [-3.09; 3.08]	0.998
<b>Center No. 1076</b>				
N'	1	5		
Baseline Mean (SD)	7.23 (N.E.)	7.36 (1.85)		
Month 1 Mean (SD)	4.67 (N.E.)	5.52 (3.87)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1077</b>				
N'	3	2		
Baseline Mean (SD)	10.08 (3.72)	9.00 (5.66)		
Month 1 Mean (SD)	7.33 (3.79)	11.52 (3.51)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1079</b>				
N'	4	3		
Baseline Mean (SD)	11.24 (4.18)	12.33 (1.53)		
Month 1 Mean (SD)	5.00 (2.31)	10.49 (5.23)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1080</b>				
N'	3	1		
Baseline Mean (SD)	7.33 (2.89)	10.00 (N.E.)		
Month 1 Mean (SD)	4.67 (2.08)	7.00 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1082</b>				
N'	5	8		
Baseline Mean (SD)	11.14 (4.74)	9.55 (2.09)		
Month 1 Mean (SD)	5.47 (3.22)	8.05 (3.49)		
Adjusted Mean Change (SE)	-6.63 (1.71)	-2.91 (1.87)	-3.72 [-9.03; 1.58]	0.147
<b>Center No. 1084</b>				
N'	2	3		
Baseline Mean (SD)	12.00 (1.41)	7.86 (3.20)		
Month 1 Mean (SD)	8.00 (5.66)	8.86 (6.14)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1085</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	8.00 (1.73)		
Month 1 Mean (SD)	N.E.	9.33 (4.04)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1086</b>				
N'	6	9		
Baseline Mean (SD)	9.96 (4.22)	10.63 (2.47)		
Month 1 Mean (SD)	7.27 (3.60)	8.77 (4.94)		
Adjusted Mean Change (SE)	-2.69 (1.70)	-0.33 (1.66)	-2.35 [-7.53; 2.82]	0.341
<b>Center No. 1087</b>				
N'	1	4		
Baseline Mean (SD)	8.00 (N.E.)	11.81 (4.95)		
Month 1 Mean (SD)	2.00 (N.E.)	10.91 (2.95)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1088</b>				
N'	6	6		
Baseline Mean (SD)	8.17 (1.72)	9.53 (3.08)		
Month 1 Mean (SD)	7.50 (5.92)	8.00 (2.54)		
Adjusted Mean Change (SE)	-0.22 (1.92)	-0.63 (1.95)	0.41 [-5.72; 6.54]	0.883
<b>Center No. 1089</b>				
N'	4	4		
Baseline Mean (SD)	8.00 (2.94)	10.53 (3.68)		
Month 1 Mean (SD)	6.26 (2.70)	8.75 (10.21)		
Adjusted Mean Change (SE)	1.85 (1.73)	-0.40 (1.51)	2.24 [-3.90; 8.39]	0.368
<b>Center No. 1091</b>				
N'	6	5		
Baseline Mean (SD)	10.62 (5.66)	8.44 (4.97)		
Month 1 Mean (SD)	6.14 (4.37)	7.78 (4.86)		
Adjusted Mean Change (SE)	-3.83 (1.57)	-1.05 (1.70)	-2.78 [-8.18; 2.63]	0.270
<b>Center No. 1093</b>				
N'	1	4		
Baseline Mean (SD)	13.07 (N.E.)	14.16 (4.86)		
Month 1 Mean (SD)	11.20 (N.E.)	15.63 (4.51)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1095</b>				
N'	5	3		
Baseline Mean (SD)	11.27 (3.84)	10.20 (3.70)		
Month 1 Mean (SD)	7.34 (3.77)	5.67 (2.08)		
Adjusted Mean Change (SE)	-5.24 (1.87)	-8.32 (2.42)	3.09 [-5.36; 11.53]	0.368
<b>Center No. 1096</b>				
N'	2	0		
Baseline Mean (SD)	11.50 (3.54)	N.E.		
Month 1 Mean (SD)	7.00 (2.83)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1100</b>				
N'	1	3		
Baseline Mean (SD)	7.00 (N.E.)	9.11 (1.02)		
Month 1 Mean (SD)	2.00 (N.E.)	4.33 (2.08)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1101</b>				
N'	4	6		
Baseline Mean (SD)	8.65 (1.38)	11.93 (1.05)		
Month 1 Mean (SD)	9.85 (5.69)	7.52 (3.23)		
Adjusted Mean Change (SE)	1.14 (2.03)	-4.32 (1.69)	5.45 [-0.98; 11.89]	0.084
<b>Center No. 1103</b>				
N'	2	3		
Baseline Mean (SD)	15.91 (7.42)	7.16 (1.88)		
Month 1 Mean (SD)	12.50 (0.71)	6.29 (0.41)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1105</b>				
N'	3	3		
Baseline Mean (SD)	10.31 (2.48)	11.67 (1.15)		
Month 1 Mean (SD)	7.00 (4.36)	7.67 (3.06)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1108</b>				
N'	15	10		
Baseline Mean (SD)	10.04 (4.29)	11.02 (4.50)		
Month 1 Mean (SD)	6.14 (5.04)	8.55 (4.87)		
Adjusted Mean Change (SE)	-4.24 (1.04)	-2.02 (1.32)	-2.22 [-5.65; 1.22]	0.194
<b>Center No. 1110</b>				
N'	6	5		
Baseline Mean (SD)	8.29 (4.55)	12.03 (3.81)		
Month 1 Mean (SD)	6.64 (5.82)	10.48 (6.44)		
Adjusted Mean Change (SE)	-1.56 (1.87)	-2.20 (2.11)	0.64 [-5.96; 7.25]	0.824
<b>Center No. 1111</b>				
N'	5	0		
Baseline Mean (SD)	6.24 (1.73)	N.E.		
Month 1 Mean (SD)	3.24 (1.10)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1113</b>				
N'	3	3		
Baseline Mean (SD)	13.41 (0.64)	8.94 (1.85)		
Month 1 Mean (SD)	12.28 (3.52)	14.45 (4.85)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1115</b>				
N'	5	6		
Baseline Mean (SD)	6.20 (1.10)	11.11 (1.99)		
Month 1 Mean (SD)	4.53 (2.74)	5.06 (2.56)		
Adjusted Mean Change (SE)	-3.52 (1.55)	-2.97 (1.92)	-0.55 [-7.45; 6.36]	0.860
<b>Center No. 1116</b>				
N'	1	4		
Baseline Mean (SD)	14.00 (N.E.)	10.45 (2.36)		
Month 1 Mean (SD)	3.00 (N.E.)	5.61 (0.71)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1118</b>				
N'	3	2		
Baseline Mean (SD)	12.33 (8.50)	10.50 (0.71)		
Month 1 Mean (SD)	11.33 (8.62)	13.00 (8.49)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1119</b>				
N'	3	5		
Baseline Mean (SD)	13.79 (6.25)	14.46 (4.32)		
Month 1 Mean (SD)	6.93 (2.69)	7.80 (3.77)		
Adjusted Mean Change (SE)	-6.86 (1.74)	-5.22 (1.40)	-1.63 [-7.85; 4.58]	0.506
<b>Center No. 1121</b>				
N'	4	4		
Baseline Mean (SD)	13.40 (9.23)	7.94 (2.35)		
Month 1 Mean (SD)	13.66 (10.57)	6.50 (2.08)		
Adjusted Mean Change (SE)	1.65 (5.74)	6.13 (5.78)	-4.48 [-27.06; 18.09]	0.611
<b>Center No. 1123</b>				
N'	1	1		
Baseline Mean (SD)	8.00 (N.E.)	10.27 (N.E.)		
Month 1 Mean (SD)	0.00 (N.E.)	5.00 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1124</b>				
N'	3	2		
Baseline Mean (SD)	19.67 (7.23)	14.47 (5.94)		
Month 1 Mean (SD)	6.21 (8.99)	6.50 (3.54)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1502</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	9.33 (3.06)		
Month 1 Mean (SD)	N.E.	12.17 (1.90)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<p>N': Number of patients in the analysis            CI: Confidence interval            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, (scheduled) visit, subgroup, interaction between treatment group and (scheduled) visit, interaction between treatment group and subgroup and interaction between treatment group, (scheduled) visit and subgroup.            If interaction test is N.E., linear mixed model for repeated measures is calculated separately for each subgroup and includes treatment group, stratification factor, (scheduled) visit and interaction between treatment group and (scheduled) visit.            The model is calculated based on the first three scheduled visits (month 1, 2 and 3) and a 'dummy' fourth visit for the mean MMD-value over the last three months.            The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p>				

**Table 14.2-4.0 Return rates in the diary for HIT-6, Headache Impact Test, by assessment week (Full analysis set)**

	Treatment Groups		
	AMG334 (N=388) n (%)	Topiramate (N=388) n (%)	Total (N=776) n (%)
<b>HIT-6 total score</b>			
Day 1	385 ( 99.2)	384 ( 99.0)	769 ( 99.1)
Week 4	370 ( 95.4)	350 ( 90.2)	720 ( 92.8)
Week 8	372 ( 95.9)	368 ( 94.8)	740 ( 95.4)
Week 12	376 ( 96.9)	365 ( 94.1)	741 ( 95.5)
Week 16	373 ( 96.1)	364 ( 93.8)	737 ( 95.0)
Week 20	367 ( 94.6)	359 ( 92.5)	726 ( 93.6)
Week 24	366 ( 94.3)	362 ( 93.3)	728 ( 93.8)

**Table 14.2-4.1 HIT-6, Headache Impact Test, change from baseline to week 24, Linear Mixed Model for Repeated Measures (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
N'	379	377		
Baseline Mean (SD)	63.65 (4.20)	63.89 (4.03)		
Week 24 Mean (SD)	52.49 (7.88)	55.80 (8.05)		
Adjusted Mean Change (SE)	-10.88 (0.44)	-7.72 (0.44)	-3.16 [-4.26; -2.06]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, baseline value, stratification factor, scheduled visit and interaction between treatment group and scheduled visit.            The model utilizes unstructured covariance matrix in the repeated statement.</p>				

**Table 14.2-4.1.1 HIT-6, Headache Impact Test, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
< median age, N	186	190		
≥ median age, N	202	198		
<b>Interaction test: p=0.002</b>				
<b>&lt; median age</b>				
N'	181	186		
Baseline Mean (SD)	63.64 (4.48)	63.86 (3.54)		
Week 24 Mean (SD)	52.87 (7.79)	54.47 (8.09)		
Adjusted Mean Change (SE)	-10.51 (0.59)	-9.01 (0.59)	-1.51 [-3.07; 0.06]	0.060
<b>≥ median age</b>				
N'	198	191		
Baseline Mean (SD)	63.66 (3.95)	63.92 (4.47)		
Week 24 Mean (SD)	52.16 (7.97)	57.15 (7.80)		
Adjusted Mean Change (SE)	-11.21 (0.58)	-6.44 (0.59)	-4.77 [-6.30; -3.24]	<.001
N': Number of patients in the analysis CI: Confidence interval SD: Standard deviation SE: Standard error  Linear mixed model for repeated measures includes treatment group, baseline value, stratification factor, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup. The model utilizes unstructured covariance matrix in the repeated statement.  Subgroup analysis results are only displayed for subgroups with N' > 0 in at least one treatment group.				

**Table 14.2-4.1.2 HIT-6, Headache Impact Test, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Gender (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Male, N	57	53		
Female, N	331	335		
<b>Interaction test: p=0.867</b>				
<b>Male</b>				
N'	54	52		
Baseline Mean (SD)	62.20 (4.71)	62.13 (4.67)		
Week 24 Mean (SD)	50.88 (7.29)	52.21 (9.14)		
Adjusted Mean Change (SE)	-11.64 (1.07)	-10.04 (1.10)	-1.60 [-4.55; 1.35]	0.288
<b>Female</b>				
N'	325	325		
Baseline Mean (SD)	63.89 (4.07)	64.17 (3.86)		
Week 24 Mean (SD)	52.76 (7.96)	56.35 (7.74)		
Adjusted Mean Change (SE)	-10.76 (0.46)	-7.37 (0.47)	-3.40 [-4.58; -2.21]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, baseline value, stratification factor, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup.            The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p>				

**Table 14.2-4.1.3 HIT-6, Headache Impact Test, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92		
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254		
≥ 15 monthly migraine days at baseline, N	43	42		
<b>Interaction test: p=0.253</b>				
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>				
N'	92	90		
Baseline Mean (SD)	63.33 (4.41)	63.12 (4.48)		
Week 24 Mean (SD)	51.85 (8.27)	54.44 (8.56)		
Adjusted Mean Change (SE)	-11.60 (0.81)	-8.80 (0.82)	-2.80 [-5.06; -0.55]	0.015
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>				
N'	245	247		
Baseline Mean (SD)	63.80 (3.98)	64.02 (3.93)		
Week 24 Mean (SD)	52.40 (7.74)	56.20 (7.92)		
Adjusted Mean Change (SE)	-11.33 (0.49)	-7.68 (0.49)	-3.65 [-5.01; -2.28]	<.001
<b>≥ 15 monthly migraine days at baseline</b>				
N'	42	40		
Baseline Mean (SD)	63.50 (5.03)	64.85 (3.36)		
Week 24 Mean (SD)	54.49 (7.75)	56.26 (7.59)		
Adjusted Mean Change (SE)	-8.91 (1.20)	-7.95 (1.22)	-0.96 [-4.32; 2.40]	0.575
<p>N': Number of patients in the analysis  CI: Confidence interval  SD: Standard deviation  SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, baseline value, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup.  The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.  <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.  The stratification factor is not included in the linear mixed model due to collinearity with the subgroups.</p>				



**Table 14.2-4.1.4 HIT-6, Headache Impact Test, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Naïve*, N	232	229		
Prior treatment failure*, N	156	159		
<b>Interaction test: p=0.202</b>				
<b>Naïve*</b>				
N'	225	222		
Baseline Mean (SD)	63.33 (4.39)	63.57 (4.08)		
Week 24 Mean (SD)	51.99 (7.58)	54.76 (8.42)		
Adjusted Mean Change (SE)	-11.19 (0.54)	-8.56 (0.55)	-2.63 [-4.06; -1.21]	<.001
<b>Prior treatment failure*</b>				
N'	154	155		
Baseline Mean (SD)	64.12 (3.87)	64.35 (3.93)		
Week 24 Mean (SD)	53.22 (8.27)	57.28 (7.27)		
Adjusted Mean Change (SE)	-10.35 (0.65)	-6.45 (0.65)	-3.91 [-5.62; -2.19]	<.001
N': Number of patients in the analysis CI: Confidence interval SD: Standard deviation SE: Standard error  Linear mixed model for repeated measures includes treatment group, baseline value, stratification factor, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup. The model utilizes unstructured covariance matrix in the repeated statement.  Subgroup analysis results are only displayed for subgroups with N' > 0 in at least one treatment group.  *: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.				

**Table 14.2-4.1.5 HIT-6, Headache Impact Test, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1001, N	10	8		
Center No. 1002, N	4	0		
Center No. 1003, N	2	3		
Center No. 1005, N	31	22		
Center No. 1007, N	5	7		
Center No. 1008, N	3	3		
Center No. 1010, N	2	3		
Center No. 1011, N	2	5		
Center No. 1012, N	3	5		
Center No. 1014, N	5	4		
Center No. 1015, N	4	2		
Center No. 1017, N	5	4		
Center No. 1018, N	7	6		
Center No. 1019, N	2	2		
Center No. 1021, N	16	10		
Center No. 1022, N	3	3		
Center No. 1025, N	0	2		
Center No. 1027, N	3	5		
Center No. 1028, N	11	5		
Center No. 1029, N	15	9		
Center No. 1030, N	11	9		
Center No. 1032, N	2	4		
Center No. 1033, N	4	6		
Center No. 1034, N	4	3		
Center No. 1035, N	27	22		
Center No. 1036, N	7	7		
Center No. 1037, N	9	11		
Center No. 1039, N	4	3		
Center No. 1040, N	0	3		
Center No. 1041, N	5	5		
Center No. 1042, N	4	5		
Center No. 1044, N	0	2		
Center No. 1046, N	1	1		

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1048, N	0	3		
Center No. 1049, N	1	0		
Center No. 1050, N	6	9		
Center No. 1051, N	1	1		
Center No. 1052, N	7	4		
Center No. 1055, N	2	4		
Center No. 1058, N	0	1		
Center No. 1059, N	7	7		
Center No. 1061, N	9	6		
Center No. 1063, N	4	2		
Center No. 1064, N	0	3		
Center No. 1067, N	10	16		
Center No. 1068, N	0	2		
Center No. 1069, N	3	4		
Center No. 1070, N	1	5		
Center No. 1072, N	2	1		
Center No. 1073, N	11	7		
Center No. 1074, N	5	3		
Center No. 1076, N	1	5		
Center No. 1077, N	3	2		
Center No. 1079, N	4	3		
Center No. 1080, N	3	1		
Center No. 1082, N	5	8		
Center No. 1084, N	2	3		
Center No. 1085, N	0	3		
Center No. 1086, N	6	9		
Center No. 1087, N	1	4		
Center No. 1088, N	6	6		
Center No. 1089, N	4	4		
Center No. 1091, N	6	5		
Center No. 1093, N	1	4		
Center No. 1095, N	5	3		
Center No. 1096, N	2	0		
Center No. 1100, N	1	4		
Center No. 1101, N	4	6		
Center No. 1103, N	2	3		

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1105, N	3	3		
Center No. 1108, N	15	10		
Center No. 1110, N	6	5		
Center No. 1111, N	5	0		
Center No. 1113, N	3	3		
Center No. 1115, N	5	6		
Center No. 1116, N	1	4		
Center No. 1118, N	3	2		
Center No. 1119, N	3	5		
Center No. 1121, N	4	4		
Center No. 1123, N	1	1		
Center No. 1124, N	3	2		
Center No. 1502, N	0	3		
<b>Interaction test: N.E.</b>				
<b>Center No. 1001</b>				
N'	10	8		
Baseline Mean (SD)	63.20 (3.68)	62.88 (5.82)		
Week 24 Mean (SD)	54.22 (7.95)	58.33 (8.12)		
Adjusted Mean Change (SE)	-7.74 (1.76)	-3.69 (1.94)	-4.05 [-9.65; 1.55]	0.142
<b>Center No. 1002</b>				
N'	4	0		
Baseline Mean (SD)	63.75 (5.32)	N.E.		
Week 24 Mean (SD)	56.75 (7.18)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1003</b>				
N'	2	3		
Baseline Mean (SD)	61.50 (3.54)	64.67 (4.73)		
Week 24 Mean (SD)	47.50 (4.95)	53.67 (7.09)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1005</b>				
N'	30	22		
Baseline Mean (SD)	63.47 (4.23)	64.18 (3.50)		
Week 24 Mean (SD)	52.50 (6.75)	51.68 (8.81)		
Adjusted Mean Change (SE)	-11.43 (1.52)	-12.55 (1.72)	1.11 [-3.35; 5.58]	0.618

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1007</b>				
N'	5	7		
Baseline Mean (SD)	62.00 (2.92)	64.29 (2.56)		
Week 24 Mean (SD)	58.50 (5.80)	58.57 (12.59)		
Adjusted Mean Change (SE)	-6.79 (5.33)	-6.78 (5.00)	-0.01 [-16.72; 16.70]	0.999
<b>Center No. 1008</b>				
N'	2	3		
Baseline Mean (SD)	65.00 (1.41)	68.67 (3.51)		
Week 24 Mean (SD)	51.50 (2.12)	52.33 (14.50)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1010</b>				
N'	2	3		
Baseline Mean (SD)	65.00 (2.83)	65.00 (1.73)		
Week 24 Mean (SD)	64.50 (2.12)	64.33 (2.89)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1011</b>				
N'	2	5		
Baseline Mean (SD)	63.50 (4.95)	64.60 (3.44)		
Week 24 Mean (SD)	56.00 (1.41)	58.00 (4.42)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1012</b>				
N'	3	5		
Baseline Mean (SD)	64.67 (3.21)	66.80 (2.17)		
Week 24 Mean (SD)	54.67 (4.51)	58.00 (12.08)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1014</b>				
N'	5	4		
Baseline Mean (SD)	62.60 (1.14)	64.00 (4.32)		
Week 24 Mean (SD)	50.60 (5.18)	54.50 (9.04)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1015</b>				
N'	4	2		
Baseline Mean (SD)	61.00 (4.32)	60.00 (0.00)		
Week 24 Mean (SD)	48.50 (8.85)	45.00 (12.73)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1017</b>				
N'	5	4		
Baseline Mean (SD)	66.80 (2.28)	67.25 (2.50)		
Week 24 Mean (SD)	52.20 (4.76)	59.50 (2.38)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1018</b>				
N'	7	5		
Baseline Mean (SD)	64.43 (1.72)	65.00 (2.55)		
Week 24 Mean (SD)	51.00 (8.39)	55.20 (5.17)		
Adjusted Mean Change (SE)	-7.87 (3.24)	-5.82 (3.56)	-2.05 [-12.40; 8.29]	0.659
<b>Center No. 1019</b>				
N'	2	2		
Baseline Mean (SD)	69.50 (0.71)	65.00 (2.83)		
Week 24 Mean (SD)	53.00 (7.07)	63.00 (2.83)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1021</b>				
N'	15	7		
Baseline Mean (SD)	62.00 (4.34)	66.00 (4.51)		
Week 24 Mean (SD)	52.00 (9.64)	60.50 (10.78)		
Adjusted Mean Change (SE)	-8.58 (2.24)	-6.48 (3.39)	-2.10 [-10.67; 6.47]	0.613
<b>Center No. 1022</b>				
N'	3	3		
Baseline Mean (SD)	64.33 (3.21)	64.67 (6.43)		
Week 24 Mean (SD)	55.00 (2.00)	54.33 (10.21)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1025</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	62.00 (11.31)		
Week 24 Mean (SD)	N.E.	56.00 (14.14)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1027</b>				
N'	3	5		
Baseline Mean (SD)	62.33 (6.66)	64.40 (2.61)		
Week 24 Mean (SD)	47.33 (11.02)	58.00 (10.71)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1028</b>				
N'	11	5		
Baseline Mean (SD)	64.36 (2.06)	66.60 (3.29)		
Week 24 Mean (SD)	52.00 (7.07)	59.80 (8.61)		
Adjusted Mean Change (SE)	-13.54 (2.92)	-5.10 (3.97)	-8.44 [-19.02; 2.15]	0.107
<b>Center No. 1029</b>				
N'	15	9		
Baseline Mean (SD)	64.33 (3.96)	63.67 (3.16)		
Week 24 Mean (SD)	53.07 (7.59)	57.22 (5.31)		
Adjusted Mean Change (SE)	-11.39 (2.30)	-6.91 (2.36)	-4.48 [-11.19; 2.24]	0.180
<b>Center No. 1030</b>				
N'	11	9		
Baseline Mean (SD)	62.00 (3.44)	63.33 (2.18)		
Week 24 Mean (SD)	50.64 (9.79)	56.88 (7.20)		
Adjusted Mean Change (SE)	-13.05 (2.96)	-8.23 (3.17)	-4.82 [-13.83; 4.20]	0.273
<b>Center No. 1032</b>				
N'	2	4		
Baseline Mean (SD)	62.50 (4.95)	65.50 (1.29)		
Week 24 Mean (SD)	51.50 (0.71)	59.67 (5.51)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1033</b>				
N'	4	6		
Baseline Mean (SD)	61.75 (5.91)	63.83 (2.56)		
Week 24 Mean (SD)	48.25 (10.72)	58.00 (7.24)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1034</b>				
N'	4	3		
Baseline Mean (SD)	64.75 (4.27)	60.00 (3.61)		
Week 24 Mean (SD)	55.33 (6.66)	53.00 (6.08)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1035</b>				
N'	27	22		
Baseline Mean (SD)	63.89 (3.48)	63.82 (6.09)		
Week 24 Mean (SD)	49.52 (5.35)	56.32 (8.35)		
Adjusted Mean Change (SE)	-13.23 (1.80)	-6.65 (1.85)	-6.59 [-10.37; -2.81]	0.001

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1036</b>				
N'	7	6		
Baseline Mean (SD)	63.57 (4.58)	63.17 (3.87)		
Week 24 Mean (SD)	51.43 (11.22)	59.83 (5.88)		
Adjusted Mean Change (SE)	-12.02 (2.76)	-4.23 (2.95)	-7.79 [-16.90; 1.32]	0.084
<b>Center No. 1037</b>				
N'	8	11		
Baseline Mean (SD)	64.75 (3.69)	63.27 (3.50)		
Week 24 Mean (SD)	56.75 (7.36)	59.80 (5.98)		
Adjusted Mean Change (SE)	-11.51 (3.03)	-4.48 (2.29)	-7.03 [-14.38; 0.31]	0.059
<b>Center No. 1039</b>				
N'	4	3		
Baseline Mean (SD)	60.00 (7.53)	62.67 (2.08)		
Week 24 Mean (SD)	53.25 (12.63)	56.00 (4.58)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1040</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	63.00 (2.00)		
Week 24 Mean (SD)	N.E.	59.00 (6.56)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1041</b>				
N'	4	5		
Baseline Mean (SD)	63.00 (4.97)	66.80 (2.49)		
Week 24 Mean (SD)	54.75 (7.32)	59.20 (8.58)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1042</b>				
N'	4	5		
Baseline Mean (SD)	65.00 (0.82)	58.80 (6.46)		
Week 24 Mean (SD)	52.25 (6.34)	50.80 (9.15)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1044</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	60.00 (8.49)		
Week 24 Mean (SD)	N.E.	58.00 (0.00)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1046</b>				
N'	1	0		
Baseline Mean (SD)	66.00 (N.E.)	N.E.		
Week 24 Mean (SD)	46.00 (N.E.)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1048</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	68.67 (8.33)		
Week 24 Mean (SD)	N.E.	56.67 (13.32)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1049</b>				
N'	1	0		
Baseline Mean (SD)	63.00 (N.E.)	N.E.		
Week 24 Mean (SD)	51.00 (N.E.)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1050</b>				
N'	6	9		
Baseline Mean (SD)	64.67 (1.37)	63.89 (5.75)		
Week 24 Mean (SD)	52.17 (11.37)	56.33 (10.38)		
Adjusted Mean Change (SE)	-12.94 (4.61)	-9.17 (3.90)	-3.77 [-16.98; 9.45]	0.540
<b>Center No. 1051</b>				
N'	1	1		
Baseline Mean (SD)	60.00 (N.E.)	64.00 (N.E.)		
Week 24 Mean (SD)	54.00 (N.E.)	60.00 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1052</b>				
N'	7	4		
Baseline Mean (SD)	63.71 (4.61)	64.50 (4.04)		
Week 24 Mean (SD)	55.29 (4.92)	58.25 (6.65)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1055</b>				
N'	2	4		
Baseline Mean (SD)	63.50 (0.71)	65.50 (4.12)		
Week 24 Mean (SD)	47.00 (7.07)	56.25 (5.91)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1058</b>				
N'	0	1		
Baseline Mean (SD)	N.E.	65.00 (N.E.)		
Week 24 Mean (SD)	N.E.	50.00 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1059</b>				
N'	7	6		
Baseline Mean (SD)	62.14 (4.95)	63.67 (1.97)		
Week 24 Mean (SD)	56.50 (6.47)	53.17 (7.68)		
Adjusted Mean Change (SE)	-4.26 (2.82)	-10.44 (2.99)	6.17 [-3.15; 15.50]	0.168
<b>Center No. 1061</b>				
N'	9	6		
Baseline Mean (SD)	66.22 (3.67)	64.33 (3.50)		
Week 24 Mean (SD)	58.00 (9.08)	55.50 (5.50)		
Adjusted Mean Change (SE)	-11.73 (3.48)	-13.68 (4.11)	1.95 [-8.32; 12.22]	0.681
<b>Center No. 1063</b>				
N'	4	2		
Baseline Mean (SD)	64.75 (3.30)	64.00 (5.66)		
Week 24 Mean (SD)	56.50 (12.87)	59.50 (2.12)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1064</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	64.00 (1.73)		
Week 24 Mean (SD)	N.E.	55.00 (7.00)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1067</b>				
N'	9	16		
Baseline Mean (SD)	66.67 (2.06)	64.44 (3.27)		
Week 24 Mean (SD)	49.11 (9.25)	53.63 (9.13)		
Adjusted Mean Change (SE)	-16.82 (3.23)	-10.78 (2.70)	-6.05 [-14.60; 2.50]	0.156
<b>Center No. 1068</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	59.00 (1.41)		
Week 24 Mean (SD)	N.E.	59.00 (4.24)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1069</b>				
N'	3	4		
Baseline Mean (SD)	62.33 (3.06)	65.75 (2.06)		
Week 24 Mean (SD)	55.00 (4.24)	62.67 (1.53)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1070</b>				
N'	1	4		
Baseline Mean (SD)	58.00 (N.E.)	63.75 (3.40)		
Week 24 Mean (SD)	60.00 (N.E.)	66.00 (8.49)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1072</b>				
N'	2	1		
Baseline Mean (SD)	58.50 (6.36)	62.00 (N.E.)		
Week 24 Mean (SD)	61.50 (0.71)	62.00 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1073</b>				
N'	11	6		
Baseline Mean (SD)	60.82 (4.94)	62.83 (7.08)		
Week 24 Mean (SD)	51.00 (7.10)	54.00 (10.30)		
Adjusted Mean Change (SE)	-9.20 (1.69)	-7.40 (2.24)	-1.80 [-6.94; 3.33]	0.459
<b>Center No. 1074</b>				
N'	5	3		
Baseline Mean (SD)	64.20 (5.76)	59.33 (4.62)		
Week 24 Mean (SD)	44.60 (8.29)	49.33 (4.62)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1076</b>				
N'	1	5		
Baseline Mean (SD)	68.00 (N.E.)	61.40 (3.65)		
Week 24 Mean (SD)	53.00 (N.E.)	48.40 (9.94)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1077</b>				
N'	3	2		
Baseline Mean (SD)	61.67 (2.52)	58.50 (4.95)		
Week 24 Mean (SD)	48.00 (7.21)	55.00 (11.31)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1079</b>				
N'	4	3		
Baseline Mean (SD)	66.50 (6.19)	66.33 (0.58)		
Week 24 Mean (SD)	49.50 (16.60)	62.33 (5.69)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1080</b>				
N'	3	1		
Baseline Mean (SD)	63.67 (2.08)	57.00 (N.E.)		
Week 24 Mean (SD)	53.67 (13.28)	53.00 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1082</b>				
N'	5	8		
Baseline Mean (SD)	65.40 (2.07)	62.63 (2.72)		
Week 24 Mean (SD)	52.50 (2.38)	52.71 (6.24)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1084</b>				
N'	2	3		
Baseline Mean (SD)	62.50 (3.54)	61.33 (4.51)		
Week 24 Mean (SD)	45.50 (10.61)	57.33 (1.15)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1085</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	64.33 (3.21)		
Week 24 Mean (SD)	N.E.	60.00 (1.41)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1086</b>				
N'	6	9		
Baseline Mean (SD)	66.00 (3.58)	66.11 (1.83)		
Week 24 Mean (SD)	55.83 (7.68)	58.78 (6.00)		
Adjusted Mean Change (SE)	-10.24 (2.69)	-7.15 (2.24)	-3.09 [-10.79; 4.61]	0.396
<b>Center No. 1087</b>				
N'	1	4		
Baseline Mean (SD)	60.00 (N.E.)	63.50 (1.29)		
Week 24 Mean (SD)	49.00 (N.E.)	54.25 (7.23)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1088</b>				
N'	6	6		
Baseline Mean (SD)	64.00 (2.45)	63.17 (2.64)		
Week 24 Mean (SD)	53.83 (4.96)	47.80 (11.05)		
Adjusted Mean Change (SE)	-8.91 (3.92)	-13.92 (4.17)	5.01 [-7.99; 18.01]	0.400
<b>Center No. 1089</b>				
N'	4	4		
Baseline Mean (SD)	66.00 (6.78)	59.00 (3.27)		
Week 24 Mean (SD)	53.00 (5.29)	42.67 (5.77)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1091</b>				
N'	6	5		
Baseline Mean (SD)	60.17 (5.00)	64.40 (2.70)		
Week 24 Mean (SD)	47.60 (9.07)	60.20 (5.40)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1093</b>				
N'	1	4		
Baseline Mean (SD)	66.00 (N.E.)	66.50 (1.00)		
Week 24 Mean (SD)	65.00 (N.E.)	56.75 (6.13)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1095</b>				
N'	5	3		
Baseline Mean (SD)	60.80 (2.95)	62.00 (1.73)		
Week 24 Mean (SD)	52.20 (8.93)	57.00 (6.08)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1096</b>				
N'	2	0		
Baseline Mean (SD)	57.50 (12.02)	N.E.		
Week 24 Mean (SD)	48.50 (0.71)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1100</b>				
N'	1	3		
Baseline Mean (SD)	67.00 (N.E.)	62.33 (3.51)		
Week 24 Mean (SD)	53.00 (N.E.)	51.33 (3.06)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1101</b>				
N'	4	5		
Baseline Mean (SD)	66.25 (7.50)	63.40 (1.82)		
Week 24 Mean (SD)	58.50 (7.55)	52.00 (4.85)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1103</b>				
N'	2	3		
Baseline Mean (SD)	63.00 (2.83)	63.33 (1.53)		
Week 24 Mean (SD)	58.00 (1.41)	56.33 (7.37)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1105</b>				
N'	3	3		
Baseline Mean (SD)	63.33 (2.08)	62.33 (0.58)		
Week 24 Mean (SD)	57.33 (10.02)	61.00 (2.65)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1108</b>				
N'	14	10		
Baseline Mean (SD)	62.71 (5.04)	64.20 (4.26)		
Week 24 Mean (SD)	52.29 (9.19)	52.40 (6.77)		
Adjusted Mean Change (SE)	-10.43 (2.27)	-10.76 (2.78)	0.33 [-7.09; 7.75]	0.927
<b>Center No. 1110</b>				
N'	6	5		
Baseline Mean (SD)	65.33 (5.65)	62.80 (4.87)		
Week 24 Mean (SD)	48.75 (3.20)	50.00 (6.67)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1111</b>				
N'	4	0		
Baseline Mean (SD)	61.50 (3.70)	N.E.		
Week 24 Mean (SD)	53.00 (7.07)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1113</b>				
N'	3	3		
Baseline Mean (SD)	67.00 (1.00)	60.67 (3.21)		
Week 24 Mean (SD)	55.33 (3.21)	50.67 (8.08)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1115</b>				
N'	4	6		
Baseline Mean (SD)	64.75 (2.36)	66.17 (4.88)		
Week 24 Mean (SD)	44.00 (6.00)	49.60 (7.40)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1116</b>				
N'	1	4		
Baseline Mean (SD)	62.00 (N.E.)	64.50 (9.85)		
Week 24 Mean (SD)	53.00 (N.E.)	59.50 (5.69)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1118</b>				
N'	3	2		
Baseline Mean (SD)	64.67 (3.51)	64.00 (2.83)		
Week 24 Mean (SD)	55.50 (13.44)	48.50 (9.19)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1119</b>				
N'	3	5		
Baseline Mean (SD)	68.33 (6.66)	64.40 (0.89)		
Week 24 Mean (SD)	48.33 (7.77)	55.40 (7.89)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1121</b>				
N'	4	4		
Baseline Mean (SD)	62.00 (8.33)	63.25 (2.75)		
Week 24 Mean (SD)	60.25 (4.03)	61.75 (3.77)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1123</b>				
N'	1	1		
Baseline Mean (SD)	61.00 (N.E.)	62.00 (N.E.)		
Week 24 Mean (SD)	50.00 (N.E.)	62.00 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1124</b>				
N'	3	2		
Baseline Mean (SD)	67.67 (3.51)	66.00 (1.41)		
Week 24 Mean (SD)	51.33 (12.06)	62.00 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1502</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	64.67 (0.58)		
Week 24 Mean (SD)	N.E.	66.00 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<p>N': Number of patients in the analysis            CI: Confidence interval            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, baseline value, stratification factor, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup.            If interaction test is N.E., linear mixed model for repeated measures is calculated separately for each subgroup and includes treatment group, baseline value, stratification factor, scheduled visit and interaction between treatment group and scheduled visit.            The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p>				



**Table 14.2-4.2 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 5 points reduction from baseline to week 24, Logistic Regression Model (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Reduction of at least 5 pts from BL</b>					
N'	364	358	2.30	1.34	0.18
n (%)	280 (72.2)	209 (53.9)	[1.70; 3.12] <.001	[1.20; 1.50] <.001	[0.12; 0.25] <.001
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>OR is obtained from a logistic regression model that includes treatment group, baseline value and stratification factor (MMD at baseline).                      RR and RD are calculated directly (without adjustment) and with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-4.2.1 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 5 points reduction from baseline to week 24, Logistic Regression Model by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
< median age, N	186	190			
≥ median age, N	202	198			
<b>Reduction of at least 5 pts from BL</b>					
<b>Interaction test: p=0.010</b>					
<b>&lt; median age</b>					
N'	172	181	1.53	1.15	0.09
n (%)	129 (69.4)	115 (60.5)	[0.99; 2.37] 0.053	[0.99; 1.33] 0.074	[-0.01; 0.18] 0.072
<b>≥ median age</b>					
N'	192	177	3.41	1.57	0.27
n (%)	151 (74.8)	94 (47.5)	[2.21; 5.26] <.001	[1.33; 1.86] <.001	[0.18; 0.36] <.001
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-4.2.2 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 5 points reduction from baseline to week 24, Logistic Regression Model by Gender (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Male, N	57	53			
Female, N	331	335			
<b>Reduction of at least 5 pts from BL</b>					
<b>Interaction test: p=0.826</b>					
<b>Male</b>					
N'	52	48	2.51	1.35	0.19
n (%)	42 (73.7)	29 (54.7)	[1.10; 5.70] 0.028	[1.01; 1.80] 0.044	[0.01; 0.37] 0.035
<b>Female</b>					
N'	312	310	2.27	1.34	0.18
n (%)	238 (71.9)	180 (53.7)	[1.64; 3.15] <.001	[1.19; 1.51] <.001	[0.11; 0.25] <.001
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-4.2.3 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 5 points reduction from baseline to week 24, Logistic Regression Model by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92			
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254			
≥ 15 monthly migraine days at baseline, N	43	42			
<b>Reduction of at least 5 pts from BL</b>					
<b>Interaction test: p=0.107</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
N'	87	84	1.69	1.22	0.12
n (%)	65 (67.7)	51 (55.4)	[0.92; 3.09] 0.090	[0.97; 1.54] 0.088	[-0.02; 0.26] 0.081
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
N'	238	236	2.95	1.44	0.23
n (%)	190 (76.3)	135 (53.1)	[2.00; 4.36] <.001	[1.25; 1.64] <.001	[0.15; 0.31] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
N'	39	38	1.25	1.06	0.03
n (%)	25 (58.1)	23 (54.8)	[0.53; 2.98] 0.612	[0.73; 1.54] 0.754	[-0.18; 0.24] 0.753
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.  <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.                      The stratification factor is not included in the logistic regression model due to collinearity with the subgroups.</p>					

**Table 14.2-4.2.4 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 5 points reduction from baseline to week 24, Logistic Regression Model by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Naïve*, N	232	229			
Prior treatment failure*, N	156	159			
<b>Reduction of at least 5 pts from BL</b>					
<b>Interaction test: p=0.646</b>					
<b>Naïve*</b>					
N'	215	211	2.17	1.29	0.17
n (%)	171 (73.7)	131 (57.2)	[1.45; 3.25] <.001	[1.12; 1.48] <.001	[0.08; 0.25] <.001
<b>Prior treatment failure*</b>					
N'	149	147	2.51	1.42	0.21
n (%)	109 (69.9)	78 (49.1)	[1.57; 4.02] <.001	[1.18; 1.72] <.001	[0.10; 0.31] <.001
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>*: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>					

**Table 14.2-4.2.5 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 5 points reduction from baseline to week 24, Logistic Regression Model by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1001, N	10	8			
Center No. 1002, N	4	0			
Center No. 1003, N	2	3			
Center No. 1005, N	31	22			
Center No. 1007, N	5	7			
Center No. 1008, N	3	3			
Center No. 1010, N	2	3			
Center No. 1011, N	2	5			
Center No. 1012, N	3	5			
Center No. 1014, N	5	4			
Center No. 1015, N	4	2			
Center No. 1017, N	5	4			
Center No. 1018, N	7	6			
Center No. 1019, N	2	2			
Center No. 1021, N	16	10			
Center No. 1022, N	3	3			
Center No. 1025, N	0	2			
Center No. 1027, N	3	5			
Center No. 1028, N	11	5			
Center No. 1029, N	15	9			
Center No. 1030, N	11	9			
Center No. 1032, N	2	4			
Center No. 1033, N	4	6			
Center No. 1034, N	4	3			
Center No. 1035, N	27	22			
Center No. 1036, N	7	7			
Center No. 1037, N	9	11			
Center No. 1039, N	4	3			
Center No. 1040, N	0	3			
Center No. 1041, N	5	5			
Center No. 1042, N	4	5			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1044, N	0	2			
Center No. 1046, N	1	1			
Center No. 1048, N	0	3			
Center No. 1049, N	1	0			
Center No. 1050, N	6	9			
Center No. 1051, N	1	1			
Center No. 1052, N	7	4			
Center No. 1055, N	2	4			
Center No. 1058, N	0	1			
Center No. 1059, N	7	7			
Center No. 1061, N	9	6			
Center No. 1063, N	4	2			
Center No. 1064, N	0	3			
Center No. 1067, N	10	16			
Center No. 1068, N	0	2			
Center No. 1069, N	3	4			
Center No. 1070, N	1	5			
Center No. 1072, N	2	1			
Center No. 1073, N	11	7			
Center No. 1074, N	5	3			
Center No. 1076, N	1	5			
Center No. 1077, N	3	2			
Center No. 1079, N	4	3			
Center No. 1080, N	3	1			
Center No. 1082, N	5	8			
Center No. 1084, N	2	3			
Center No. 1085, N	0	3			
Center No. 1086, N	6	9			
Center No. 1087, N	1	4			
Center No. 1088, N	6	6			
Center No. 1089, N	4	4			
Center No. 1091, N	6	5			
Center No. 1093, N	1	4			
Center No. 1095, N	5	3			
Center No. 1096, N	2	0			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1100, N	1	4			
Center No. 1101, N	4	6			
Center No. 1103, N	2	3			
Center No. 1105, N	3	3			
Center No. 1108, N	15	10			
Center No. 1110, N	6	5			
Center No. 1111, N	5	0			
Center No. 1113, N	3	3			
Center No. 1115, N	5	6			
Center No. 1116, N	1	4			
Center No. 1118, N	3	2			
Center No. 1119, N	3	5			
Center No. 1121, N	4	4			
Center No. 1123, N	1	1			
Center No. 1124, N	3	2			
Center No. 1502, N	0	3			
<b>Reduction of at least 5 pts from BL</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
N'	9	6	14.26	1.87	0.33
n (%)	7 (70.0)	3 (37.5)	[0.72; >99.99] 0.081	[0.70; 4.99] 0.213	[-0.11; 0.76] 0.147
<b>Center No. 1002</b>					
N'	4	0	N.E.	N.E.	N.E.
n (%)	3 (75.0)	0 (0.0)			
<b>Center No. 1003</b>					
N'	2	3	N.E.	1.50	0.33
n (%)	2 (100.0)	2 (66.7)		[0.67; 3.34] 0.321	[-0.20; 0.87] 0.221
<b>Center No. 1005</b>					
N'	28	22	0.82	0.93	-0.05
n (%)	21 (67.7)	16 (72.7)	[0.20; 3.36] 0.780	[0.65; 1.33] 0.693	[-0.30; 0.20] 0.694
<b>Center No. 1007</b>					
N'	4	7	0.37	0.70	-0.17
n (%)	2 (40.0)	4 (57.1)	[0.03; 5.33] 0.465†	[0.20; 2.44] 0.576	[-0.74; 0.39] 0.552



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1008</b>					
N'	2	3	1.00	1.00	0.00
n (%)	2 (66.7)	2 (66.7)	[0.03; 29.81] 1.000‡	[0.32; 3.10] 1.000	[-0.75; 0.75] 1.000
<b>Center No. 1010</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1011</b>					
N'	2	5	N.E.	1.67	0.40
n (%)	2 (100.0)	3 (60.0)		[0.81; 3.41] 0.162	[-0.03; 0.83] 0.068
<b>Center No. 1012</b>					
N'	3	4	N.E.	5.00	0.80
n (%)	3 (100.0)	1 (20.0)		[0.87; 28.86] 0.072	[0.45; 1.15] <.001
<b>Center No. 1014</b>					
N'	5	4	1.54	1.07	0.05
n (%)	4 (80.0)	3 (75.0)	[0.06; 38.11] 0.792†	[0.52; 2.18] 0.860	[-0.50; 0.60] 0.859
<b>Center No. 1015</b>					
N'	4	2	N.E.	0.75	-0.25
n (%)	3 (75.0)	2 (100.0)		[0.43; 1.32] 0.319	[-0.67; 0.17] 0.248
<b>Center No. 1017</b>					
N'	5	4	N.E.	1.33	0.25
n (%)	5 (100.0)	3 (75.0)		[0.76; 2.35] 0.319	[-0.17; 0.67] 0.248
<b>Center No. 1018</b>					
N'	7	5	N.E.	1.50	0.33
n (%)	7 (100.0)	4 (66.7)		[0.85; 2.64] 0.160	[-0.04; 0.71] 0.083
<b>Center No. 1019</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	2 (100.0)	0 (0.0)			
<b>Center No. 1021</b>					
N'	15	6	2.98	2.08	0.33
n (%)	10 (62.5)	3 (30.0)	[0.47; 18.85] 0.247	[0.75; 5.78] 0.158	[-0.05; 0.70] 0.085
<b>Center No. 1022</b>					
N'	3	3	N.E.	1.50	0.33
n (%)	3 (100.0)	2 (66.7)		[0.67; 3.34] 0.321	[-0.20; 0.87] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1025</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (50.0)			
<b>Center No. 1027</b>					
N'	3	4	N.E.	5.00	0.80
n (%)	3 (100.0)	1 (20.0)		[0.87; 28.86] 0.072	[0.45; 1.15] <.001
<b>Center No. 1028</b>					
N'	11	5	1.29	1.36	0.22
n (%)	9 (81.8)	3 (60.0)	[0.08; 21.18] 0.858†	[0.63; 2.94] 0.429	[-0.27; 0.70] 0.379
<b>Center No. 1029</b>					
N'	15	9	10.45	1.95	0.42
n (%)	13 (86.7)	4 (44.4)	[1.03; >99.99] 0.048	[0.91; 4.16] 0.084	[0.05; 0.79] 0.024
<b>Center No. 1030</b>					
N'	11	8	3.37	1.64	0.28
n (%)	8 (72.7)	4 (44.4)	[0.46; 24.99] 0.234	[0.72; 3.70] 0.236	[-0.14; 0.70] 0.185
<b>Center No. 1032</b>					
N'	2	3	N.E.	4.00	0.75
n (%)	2 (100.0)	1 (25.0)		[0.73; 21.84] 0.109	[0.33; 1.17] <.001
<b>Center No. 1033</b>					
N'	4	6	2.54	1.50	0.25
n (%)	3 (75.0)	3 (50.0)	[0.15; 44.46] 0.522†	[0.56; 4.00] 0.417	[-0.33; 0.83] 0.401
<b>Center No. 1034</b>					
N'	3	3	1.57	0.75	-0.17
n (%)	2 (50.0)	2 (66.7)	[0.03; 82.10] 0.824	[0.21; 2.66] 0.656	[-0.89; 0.56] 0.652
<b>Center No. 1035</b>					
N'	27	22	14.56	1.85	0.43
n (%)	25 (92.6)	11 (50.0)	[2.54; 83.37] 0.003†	[1.20; 2.85] 0.005	[0.19; 0.66] <.001
<b>Center No. 1036</b>					
N'	7	6	5.19	2.50	0.43
n (%)	5 (71.4)	2 (28.6)	[0.48; 56.61] 0.177†	[0.71; 8.83] 0.155	[-0.04; 0.90] 0.076

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1037</b>					
N'	8	10	2.12	1.22	0.08
n (%)	4 (44.4)	4 (36.4)	[0.25; 18.06] 0.492	[0.42; 3.56] 0.713	[-0.35; 0.51] 0.714
<b>Center No. 1039</b>					
N'	4	3	0.17	0.38	-0.42
n (%)	1 (25.0)	2 (66.7)	<0.01; 6.88] 0.348†	[0.06; 2.45] 0.306	[-1.10; 0.26] 0.231
<b>Center No. 1040</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (33.3)			
<b>Center No. 1041</b>					
N'	4	5	1.66	1.50	0.20
n (%)	3 (60.0)	2 (40.0)	[0.08; 34.02] 0.742†	[0.41; 5.45] 0.538	[-0.41; 0.81] 0.519
<b>Center No. 1042</b>					
N'	4	5	N.E.	1.67	0.40
n (%)	4 (100.0)	3 (60.0)		[0.81; 3.41] 0.162	[-0.03; 0.83] 0.068
<b>Center No. 1044</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (50.0)			
<b>Center No. 1046</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1048</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	3 (100.0)			
<b>Center No. 1049</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1050</b>					
N'	6	9	0.84	0.90	-0.06
n (%)	3 (50.0)	5 (55.6)	[0.10; 6.82] 0.870†	[0.33; 2.42] 0.835	[-0.57; 0.46] 0.833
<b>Center No. 1051</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1052</b>					
N'	7	4	25.55	1.71	0.36
n (%)	6 (85.7)	2 (50.0)	[0.20; >99.99] 0.192†	[0.61; 4.78] 0.303	[-0.20; 0.91] 0.207
<b>Center No. 1055</b>					
N'	2	4	N.E.	2.00	0.50
n (%)	2 (100.0)	2 (50.0)		[0.75; 5.33] 0.166	[0.01; 0.99] 0.046
<b>Center No. 1058</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (100.0)			
<b>Center No. 1059</b>					
N'	6	6	0.39	0.60	-0.29
n (%)	3 (42.9)	5 (71.4)	[0.04; 4.16] 0.438	[0.23; 1.59] 0.305	[-0.78; 0.21] 0.259
<b>Center No. 1061</b>					
N'	9	6	0.41	0.83	-0.11
n (%)	5 (55.6)	4 (66.7)	[0.04; 4.42] 0.466†	[0.37; 1.88] 0.660	[-0.61; 0.39] 0.662
<b>Center No. 1063</b>					
N'	4	2	2.86	1.50	0.25
n (%)	3 (75.0)	1 (50.0)	[0.05; >99.99] 0.614	[0.34; 6.70] 0.596	[-0.56; 1.06] 0.546
<b>Center No. 1064</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (66.7)			
<b>Center No. 1067</b>					
N'	9	16	2.18	1.20	0.15
n (%)	9 (90.0)	12 (75.0)	[0.17; 28.66] 0.555†	[0.85; 1.70] 0.308	[-0.13; 0.43] 0.297
<b>Center No. 1068</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1069</b>					
N'	2	3	4.86	2.67	0.42
n (%)	2 (66.7)	1 (25.0)	[0.08; >99.99] 0.452†	[0.41; 17.42] 0.306	[-0.26; 1.10] 0.231
<b>Center No. 1070</b>					
N'	1	2	N.E.	1.00	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.06; 15.99] 1.000	[-0.55; 0.15] 0.264

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1072</b>					
N'	2	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1073</b>					
N'	11	6	2.45	1.27	0.19
n (%)	10 (90.9)	5 (71.4)	[0.13; 46.90] 0.552†	[0.77; 2.11] 0.349	[-0.18; 0.57] 0.309
<b>Center No. 1074</b>					
N'	5	3	N.E.	N.E.	N.E.
n (%)	5 (100.0)	3 (100.0)			
<b>Center No. 1076</b>					
N'	1	5	N.E.	1.25	0.20
n (%)	1 (100.0)	4 (80.0)		[0.81; 1.94] 0.318	[-0.15; 0.55] 0.264
<b>Center No. 1077</b>					
N'	3	2	N.E.	2.00	0.50
n (%)	3 (100.0)	1 (50.0)		[0.50; 8.00] 0.327	[-0.19; 1.19] 0.157
<b>Center No. 1079</b>					
N'	4	3	11.43	2.25	0.42
n (%)	3 (75.0)	1 (33.3)	[0.11; >99.99] 0.303†	[0.41; 12.28] 0.349	[-0.26; 1.10] 0.231
<b>Center No. 1080</b>					
N'	3	1	N.E.	2.50	0.67
n (%)	2 (66.7)	0 (0.0)		[0.20; 31.00] 0.476	[0.13; 1.20] 0.014
<b>Center No. 1082</b>					
N'	4	7	0.72	1.07	0.05
n (%)	4 (80.0)	6 (75.0)	[0.03; 18.42] 0.844†	[0.59; 1.93] 0.831	[-0.41; 0.51] 0.832
<b>Center No. 1084</b>					
N'	2	3	N.E.	1.50	0.33
n (%)	2 (100.0)	2 (66.7)		[0.67; 3.34] 0.321	[-0.20; 0.87] 0.221
<b>Center No. 1085</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1086</b>					
N'	6	9	1.62	1.20	0.11
n (%)	4 (66.7)	5 (55.6)	[0.12; 21.98] 0.715	[0.53; 2.71] 0.660	[-0.39; 0.61] 0.662

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1087</b>					
N'	1	4	N.E.	1.33	0.25
n (%)	1 (100.0)	3 (75.0)		[0.76; 2.35] 0.319	[-0.17; 0.67] 0.248
<b>Center No. 1088</b>					
N'	6	5	2.19	1.25	0.17
n (%)	5 (83.3)	4 (66.7)	[0.13; 36.15] 0.585†	[0.64; 2.44] 0.514	[-0.31; 0.65] 0.497
<b>Center No. 1089</b>					
N'	4	3	0.21	1.00	0.00
n (%)	3 (75.0)	3 (75.0)	<0.01; 26.09 0.529†	[0.45; 2.23] 1.000	[-0.60; 0.60] 1.000
<b>Center No. 1091</b>					
N'	5	5	2.47	1.67	0.27
n (%)	4 (66.7)	2 (40.0)	[0.11; 57.58] 0.574	[0.50; 5.61] 0.409	[-0.30; 0.84] 0.360
<b>Center No. 1093</b>					
N'	1	4	N.E.	0.50	-0.50
n (%)	0 (0.0)	2 (50.0)		[0.04; 6.44] 0.595	[-0.99; -0.01] 0.046
<b>Center No. 1095</b>					
N'	5	3	2.57	1.80	0.27
n (%)	3 (60.0)	1 (33.3)	[0.12; 55.89] 0.547†	[0.31; 10.39] 0.511	[-0.42; 0.95] 0.445
<b>Center No. 1096</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	1 (50.0)	0 (0.0)			
<b>Center No. 1100</b>					
N'	1	3	N.E.	1.33	0.25
n (%)	1 (100.0)	3 (75.0)		[0.76; 2.35] 0.319	[-0.17; 0.67] 0.248
<b>Center No. 1101</b>					
N'	4	5	0.20	0.60	-0.33
n (%)	2 (50.0)	5 (83.3)	[0.01; 4.03] 0.297†	[0.21; 1.70] 0.337	[-0.91; 0.24] 0.255
<b>Center No. 1103</b>					
N'	2	3	2.00	1.50	0.17
n (%)	1 (50.0)	1 (33.3)	[0.05; 78.25] 0.711‡	[0.18; 12.46] 0.707	[-0.71; 1.04] 0.709

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1105</b>					
N'	3	3	N.E.	3.00	0.33
n (%)	1 (33.3)	0 (0.0)		[0.17; 53.71] 0.455	[-0.20; 0.87] 0.221
<b>Center No. 1108</b>					
N'	14	10	1.41	0.95	-0.03
n (%)	10 (66.7)	7 (70.0)	[0.20; 9.96] 0.732	[0.55; 1.64] 0.860	[-0.40; 0.34] 0.860
<b>Center No. 1110</b>					
N'	4	5	0.94	1.11	0.07
n (%)	4 (66.7)	3 (60.0)	[0.04; 20.36] 0.971†	[0.45; 2.77] 0.821	[-0.50; 0.64] 0.819
<b>Center No. 1111</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	1 (20.0)	0 (0.0)			
<b>Center No. 1113</b>					
N'	3	3	N.E.	1.50	0.33
n (%)	3 (100.0)	2 (66.7)		[0.67; 3.34] 0.321	[-0.20; 0.87] 0.221
<b>Center No. 1115</b>					
N'	3	5	0.36	0.72	-0.23
n (%)	3 (60.0)	5 (83.3)	[0.01; 9.46] 0.540†	[0.32; 1.60] 0.421	[-0.76; 0.29] 0.382
<b>Center No. 1116</b>					
N'	1	4	N.E.	1.33	0.25
n (%)	1 (100.0)	3 (75.0)		[0.76; 2.35] 0.319	[-0.17; 0.67] 0.248
<b>Center No. 1118</b>					
N'	2	2	N.E.	0.33	-0.67
n (%)	1 (33.3)	2 (100.0)		[0.07; 1.65] 0.178	[-1.20; -0.13] 0.014
<b>Center No. 1119</b>					
N'	3	5	N.E.	1.25	0.20
n (%)	3 (100.0)	4 (80.0)		[0.81; 1.94] 0.318	[-0.15; 0.55] 0.264
<b>Center No. 1121</b>					
N'	4	4	N.E.	3.00	0.25
n (%)	1 (25.0)	0 (0.0)		[0.16; 57.37] 0.466	[-0.17; 0.67] 0.248
<b>Center No. 1123</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1124</b>					
N <sup>†</sup>	3	1	N.E.	3.75	0.67
n (%)	2 (66.7)	0 (0.0)		[0.27; 52.64] 0.327	[0.13; 1.20] 0.014
<b>Center No. 1502</b>					
N <sup>†</sup>	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<p>N<sup>†</sup>: Number of patients with available response value  N-N<sup>†</sup> is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup that include treatment group, baseline value and stratification factor (MMD at baseline).  † The stratification factor is excluded from the model due to non-convergence of the full model.  ‡ The stratification factor and baseline value are excluded from the model due to non-convergence of the full model.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p>					



**Table 14.2-4.3 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 6.3 points reduction from baseline to week 24, Logistic Regression Model (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Reduction of at least 6.3 pts from BL</b>					
N'	364	358	2.23	1.41	0.19
n (%)	251 (64.7)	178 (45.9)	[1.66; 2.99] <.001	[1.24; 1.61] <.001	[0.12; 0.26] <.001
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>OR is obtained from a logistic regression model that includes treatment group, baseline value and stratification factor (MMD at baseline).                      RR and RD are calculated directly (without adjustment) and with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-4.3.1 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 6.3 points reduction from baseline to week 24, Logistic Regression Model by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
< median age, N	186	190			
≥ median age, N	202	198			
<b>Reduction of at least 6.3 pts from BL</b>					
<b>Interaction test: p=0.003</b>					
<b>&lt; median age</b>					
N'	172	181	1.42	1.14	0.08
n (%)	117 (62.9)	105 (55.3)	[0.94; 2.17] 0.098	[0.96; 1.35] 0.133	[-0.02; 0.18] 0.131
<b>≥ median age</b>					
N'	192	177	3.49	1.80	0.29
n (%)	134 (66.3)	73 (36.9)	[2.30; 5.31] <.001	[1.46; 2.21] <.001	[0.20; 0.39] <.001
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-4.3.2 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 6.3 points reduction from baseline to week 24, Logistic Regression Model by Gender (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Male, N	57	53			
Female, N	331	335			
<b>Reduction of at least 6.3 pts from BL</b>					
<b>Interaction test: p=0.636</b>					
<b>Male</b>					
N'	52	48	1.88	1.29	0.14
n (%)	36 (63.2)	26 (49.1)	[0.86; 4.08] 0.112	[0.92; 1.81] 0.143	[-0.04; 0.32] 0.133
<b>Female</b>					
N'	312	310	2.30	1.43	0.20
n (%)	215 (65.0)	152 (45.4)	[1.67; 3.15] <.001	[1.24; 1.65] <.001	[0.12; 0.27] <.001
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-4.3.3 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 6.3 points reduction from baseline to week 24, Logistic Regression Model by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92			
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254			
≥ 15 monthly migraine days at baseline, N	43	42			
<b>Reduction of at least 6.3 pts from BL</b>					
<b>Interaction test: p=0.250</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
N'	87	84	1.91	1.33	0.16
n (%)	61 (63.5)	44 (47.8)	[1.06; 3.45] 0.033	[1.02; 1.73] 0.033	[0.02; 0.30] 0.028
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
N'	238	236	2.63	1.50	0.23
n (%)	169 (67.9)	115 (45.3)	[1.82; 3.81] <.001	[1.28; 1.76] <.001	[0.14; 0.31] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
N'	39	38	1.25	1.08	0.04
n (%)	21 (48.8)	19 (45.2)	[0.53; 2.97] 0.607	[0.69; 1.70] 0.740	[-0.18; 0.25] 0.739
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.  <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.                      The stratification factor is not included in the logistic regression model due to collinearity with the subgroups.</p>					

**Table 14.2-4.3.4 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 6.3 points reduction from baseline to week 24, Logistic Regression Model by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Naïve*, N	232	229			
Prior treatment failure*, N	156	159			
<b>Reduction of at least 6.3 pts from BL</b>					
<b>Interaction test: p=0.315</b>					
<b>Naïve*</b>					
N'	215	211	1.97	1.32	0.16
n (%)	152 (65.5)	114 (49.8)	[1.35; 2.89] <.001	[1.12; 1.54] <.001	[0.07; 0.25] <.001
<b>Prior treatment failure*</b>					
N'	149	147	2.68	1.58	0.23
n (%)	99 (63.5)	64 (40.3)	[1.69; 4.26] <.001	[1.26; 1.97] <.001	[0.12; 0.34] <.001
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>*: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>					

**Table 14.2-4.3.5 HIT-6, Headache Impact Test, Proportion of patients achieving at least a 6.3 points reduction from baseline to week 24, Logistic Regression Model by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1001, N	10	8			
Center No. 1002, N	4	0			
Center No. 1003, N	2	3			
Center No. 1005, N	31	22			
Center No. 1007, N	5	7			
Center No. 1008, N	3	3			
Center No. 1010, N	2	3			
Center No. 1011, N	2	5			
Center No. 1012, N	3	5			
Center No. 1014, N	5	4			
Center No. 1015, N	4	2			
Center No. 1017, N	5	4			
Center No. 1018, N	7	6			
Center No. 1019, N	2	2			
Center No. 1021, N	16	10			
Center No. 1022, N	3	3			
Center No. 1025, N	0	2			
Center No. 1027, N	3	5			
Center No. 1028, N	11	5			
Center No. 1029, N	15	9			
Center No. 1030, N	11	9			
Center No. 1032, N	2	4			
Center No. 1033, N	4	6			
Center No. 1034, N	4	3			
Center No. 1035, N	27	22			
Center No. 1036, N	7	7			
Center No. 1037, N	9	11			
Center No. 1039, N	4	3			
Center No. 1040, N	0	3			
Center No. 1041, N	5	5			
Center No. 1042, N	4	5			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1044, N	0	2			
Center No. 1046, N	1	1			
Center No. 1048, N	0	3			
Center No. 1049, N	1	0			
Center No. 1050, N	6	9			
Center No. 1051, N	1	1			
Center No. 1052, N	7	4			
Center No. 1055, N	2	4			
Center No. 1058, N	0	1			
Center No. 1059, N	7	7			
Center No. 1061, N	9	6			
Center No. 1063, N	4	2			
Center No. 1064, N	0	3			
Center No. 1067, N	10	16			
Center No. 1068, N	0	2			
Center No. 1069, N	3	4			
Center No. 1070, N	1	5			
Center No. 1072, N	2	1			
Center No. 1073, N	11	7			
Center No. 1074, N	5	3			
Center No. 1076, N	1	5			
Center No. 1077, N	3	2			
Center No. 1079, N	4	3			
Center No. 1080, N	3	1			
Center No. 1082, N	5	8			
Center No. 1084, N	2	3			
Center No. 1085, N	0	3			
Center No. 1086, N	6	9			
Center No. 1087, N	1	4			
Center No. 1088, N	6	6			
Center No. 1089, N	4	4			
Center No. 1091, N	6	5			
Center No. 1093, N	1	4			
Center No. 1095, N	5	3			
Center No. 1096, N	2	0			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1100, N	1	4			
Center No. 1101, N	4	6			
Center No. 1103, N	2	3			
Center No. 1105, N	3	3			
Center No. 1108, N	15	10			
Center No. 1110, N	6	5			
Center No. 1111, N	5	0			
Center No. 1113, N	3	3			
Center No. 1115, N	5	6			
Center No. 1116, N	1	4			
Center No. 1118, N	3	2			
Center No. 1119, N	3	5			
Center No. 1121, N	4	4			
Center No. 1123, N	1	1			
Center No. 1124, N	3	2			
Center No. 1502, N	0	3			
<b>Reduction of at least 6.3 pts from BL</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
N'	9	6	N.E.	9.00	0.50
n (%)	5 (50.0)	0 (0.0)		[0.57; 141.89] 0.118	[0.19; 0.81] 0.002
<b>Center No. 1002</b>					
N'	4	0	N.E.	N.E.	N.E.
n (%)	3 (75.0)	0 (0.0)			
<b>Center No. 1003</b>					
N'	2	3	N.E.	3.00	0.67
n (%)	2 (100.0)	1 (33.3)		[0.61; 14.86] 0.178	[0.13; 1.20] 0.014
<b>Center No. 1005</b>					
N'	28	22	0.69	0.90	-0.07
n (%)	19 (61.3)	15 (68.2)	[0.18; 2.65] 0.586	[0.60; 1.34] 0.601	[-0.33; 0.19] 0.603
<b>Center No. 1007</b>					
N'	4	7	0.21	0.35	-0.37
n (%)	1 (20.0)	4 (57.1)	[0.01; 3.64] 0.285†	[0.05; 2.26] 0.270	[-0.88; 0.14] 0.151



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1008</b>					
N'	2	3	1.00	1.00	0.00
n (%)	2 (66.7)	2 (66.7)	[0.03; 29.81] 1.000‡	[0.32; 3.10] 1.000	[-0.75; 0.75] 1.000
<b>Center No. 1010</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1011</b>					
N'	2	5	0.67	0.83	-0.10
n (%)	1 (50.0)	3 (60.0)	[0.02; 18.06] 0.810‡	[0.18; 3.96] 0.819	[-0.92; 0.72] 0.810
<b>Center No. 1012</b>					
N'	3	4	N.E.	5.00	0.80
n (%)	3 (100.0)	1 (20.0)		[0.87; 28.86] 0.072	[0.45; 1.15] <.001
<b>Center No. 1014</b>					
N'	5	4	1.54	1.07	0.05
n (%)	4 (80.0)	3 (75.0)	[0.06; 38.11] 0.792†	[0.52; 2.18] 0.860	[-0.50; 0.60] 0.859
<b>Center No. 1015</b>					
N'	4	2	2.90	1.50	0.25
n (%)	3 (75.0)	1 (50.0)	[0.07; >99.99] 0.573†	[0.34; 6.70] 0.596	[-0.56; 1.06] 0.546
<b>Center No. 1017</b>					
N'	5	4	24.87	1.60	0.30
n (%)	4 (80.0)	2 (50.0)	[0.05; >99.99] 0.304	[0.55; 4.68] 0.391	[-0.30; 0.90] 0.329
<b>Center No. 1018</b>					
N'	7	5	0.60	0.86	-0.10
n (%)	4 (57.1)	4 (66.7)	[0.05; 6.65] 0.677†	[0.36; 2.02] 0.724	[-0.62; 0.43] 0.723
<b>Center No. 1019</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	2 (100.0)	0 (0.0)			
<b>Center No. 1021</b>					
N'	15	6	2.22	1.88	0.26
n (%)	9 (56.3)	3 (30.0)	[0.36; 13.56] 0.387	[0.66; 5.31] 0.236	[-0.11; 0.64] 0.169
<b>Center No. 1022</b>					
N'	3	3	0.26	1.00	0.00
n (%)	2 (66.7)	2 (66.7)	<0.01; 64.15] 0.631†	[0.32; 3.10] 1.000	[-0.75; 0.75] 1.000

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1025</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (50.0)			
<b>Center No. 1027</b>					
N'	3	4	N.E.	5.00	0.80
n (%)	3 (100.0)	1 (20.0)		[0.87; 28.86] 0.072	[0.45; 1.15] <.001
<b>Center No. 1028</b>					
N'	11	5	3.22	2.05	0.42
n (%)	9 (81.8)	2 (40.0)	[0.23; 44.30] 0.381	[0.67; 6.20] 0.206	[-0.07; 0.90] 0.092
<b>Center No. 1029</b>					
N'	15	9	4.44	1.65	0.29
n (%)	11 (73.3)	4 (44.4)	[0.58; 33.87] 0.151	[0.75; 3.64] 0.215	[-0.11; 0.68] 0.151
<b>Center No. 1030</b>					
N'	11	8	5.77	2.86	0.41
n (%)	7 (63.6)	2 (22.2)	[0.76; 43.96] 0.091†	[0.78; 10.52] 0.113	[0.02; 0.81] 0.039
<b>Center No. 1032</b>					
N'	2	3	N.E.	4.00	0.75
n (%)	2 (100.0)	1 (25.0)		[0.73; 21.84] 0.109	[0.33; 1.17] <.001
<b>Center No. 1033</b>					
N'	4	6	5.33	2.25	0.42
n (%)	3 (75.0)	2 (33.3)	[0.30; 94.92] 0.254†	[0.63; 7.97] 0.209	[-0.15; 0.98] 0.150
<b>Center No. 1034</b>					
N'	3	3	1.98	1.50	0.17
n (%)	2 (50.0)	1 (33.3)	[0.04; 96.90] 0.731	[0.23; 9.80] 0.672	[-0.56; 0.89] 0.652
<b>Center No. 1035</b>					
N'	27	22	12.91	2.17	0.48
n (%)	24 (88.9)	9 (40.9)	[2.68; 62.19] 0.001	[1.29; 3.65] 0.003	[0.24; 0.72] <.001
<b>Center No. 1036</b>					
N'	7	6	12.72	5.00	0.57
n (%)	5 (71.4)	1 (14.3)	[0.84; >99.99] 0.067†	[0.77; 32.58] 0.092	[0.15; 0.99] 0.008

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1037</b>					
N'	8	10	5.68	1.63	0.17
n (%)	4 (44.4)	3 (27.3)	[0.45; 71.40] 0.179	[0.49; 5.47] 0.429	[-0.25; 0.59] 0.421
<b>Center No. 1039</b>					
N'	4	3	0.17	0.38	-0.42
n (%)	1 (25.0)	2 (66.7)	<0.01; 6.88] 0.348†	[0.06; 2.45] 0.306	[-1.10; 0.26] 0.231
<b>Center No. 1040</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (33.3)			
<b>Center No. 1041</b>					
N'	4	5	1.66	1.50	0.20
n (%)	3 (60.0)	2 (40.0)	[0.08; 34.02] 0.742†	[0.41; 5.45] 0.538	[-0.41; 0.81] 0.519
<b>Center No. 1042</b>					
N'	4	5	2.83	3.75	0.55
n (%)	3 (75.0)	1 (20.0)	[0.05; >99.99] 0.607†	[0.59; 23.66] 0.160	[-0.00; 1.10] 0.050
<b>Center No. 1044</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (50.0)			
<b>Center No. 1046</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1048</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (66.7)			
<b>Center No. 1049</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1050</b>					
N'	6	9	1.32	1.13	0.06
n (%)	3 (50.0)	4 (44.4)	[0.16; 10.77] 0.793†	[0.38; 3.32] 0.831	[-0.46; 0.57] 0.833
<b>Center No. 1051</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1052</b>					
N'	7	4	3.06	1.43	0.21
n (%)	5 (71.4)	2 (50.0)	[0.20; 46.74] 0.422†	[0.48; 4.23] 0.520	[-0.38; 0.81] 0.479
<b>Center No. 1055</b>					
N'	2	4	N.E.	2.00	0.50
n (%)	2 (100.0)	2 (50.0)		[0.75; 5.33] 0.166	[0.01; 0.99] 0.046
<b>Center No. 1058</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (100.0)			
<b>Center No. 1059</b>					
N'	6	6	0.02	0.50	-0.29
n (%)	2 (28.6)	4 (57.1)	[<0.01; 10.71] 0.214	[0.13; 1.90] 0.309	[-0.78; 0.21] 0.259
<b>Center No. 1061</b>					
N'	9	6	0.41	0.83	-0.11
n (%)	5 (55.6)	4 (66.7)	[0.04; 4.42] 0.466†	[0.37; 1.88] 0.660	[-0.61; 0.39] 0.662
<b>Center No. 1063</b>					
N'	4	2	0.33	0.50	-0.25
n (%)	1 (25.0)	1 (50.0)	[<0.01; 12.10] 0.545	[0.06; 4.47] 0.535	[-1.06; 0.56] 0.546
<b>Center No. 1064</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (66.7)			
<b>Center No. 1067</b>					
N'	9	16	0.82	1.07	0.05
n (%)	8 (80.0)	12 (75.0)	[0.09; 7.67] 0.858†	[0.70; 1.62] 0.763	[-0.28; 0.38] 0.764
<b>Center No. 1068</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1069</b>					
N'	2	3	N.E.	6.25	0.67
n (%)	2 (66.7)	0 (0.0)		[0.40; 96.50] 0.189	[0.13; 1.20] 0.014
<b>Center No. 1070</b>					
N'	1	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1072</b>					
N'	2	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1073</b>					
N'	11	6	0.86	1.11	0.06
n (%)	7 (63.6)	4 (57.1)	[0.10; 7.61] 0.891†	[0.51; 2.43] 0.787	[-0.40; 0.53] 0.784
<b>Center No. 1074</b>					
N'	5	3	N.E.	N.E.	N.E.
n (%)	5 (100.0)	3 (100.0)			
<b>Center No. 1076</b>					
N'	1	5	N.E.	1.25	0.20
n (%)	1 (100.0)	4 (80.0)		[0.81; 1.94] 0.318	[-0.15; 0.55] 0.264
<b>Center No. 1077</b>					
N'	3	2	N.E.	2.00	0.50
n (%)	3 (100.0)	1 (50.0)		[0.50; 8.00] 0.327	[-0.19; 1.19] 0.157
<b>Center No. 1079</b>					
N'	4	3	11.43	2.25	0.42
n (%)	3 (75.0)	1 (33.3)	[0.11; >99.99] 0.303†	[0.41; 12.28] 0.349	[-0.26; 1.10] 0.231
<b>Center No. 1080</b>					
N'	3	1	N.E.	2.50	0.67
n (%)	2 (66.7)	0 (0.0)		[0.20; 31.00] 0.476	[0.13; 1.20] 0.014
<b>Center No. 1082</b>					
N'	4	7	0.72	1.07	0.05
n (%)	4 (80.0)	6 (75.0)	[0.03; 18.42] 0.844†	[0.59; 1.93] 0.831	[-0.41; 0.51] 0.832
<b>Center No. 1084</b>					
N'	2	3	N.E.	3.00	0.67
n (%)	2 (100.0)	1 (33.3)		[0.61; 14.86] 0.178	[0.13; 1.20] 0.014
<b>Center No. 1085</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1086</b>					
N'	6	9	1.62	1.20	0.11
n (%)	4 (66.7)	5 (55.6)	[0.12; 21.98] 0.715	[0.53; 2.71] 0.660	[-0.39; 0.61] 0.662

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1087</b>					
N'	1	4	N.E.	1.33	0.25
n (%)	1 (100.0)	3 (75.0)		[0.76; 2.35] 0.319	[-0.17; 0.67] 0.248
<b>Center No. 1088</b>					
N'	6	5	3.67	1.33	0.17
n (%)	4 (66.7)	3 (50.0)	[0.22; 62.30] 0.369	[0.50; 3.55] 0.565	[-0.38; 0.72] 0.552
<b>Center No. 1089</b>					
N'	4	3	0.21	1.00	0.00
n (%)	3 (75.0)	3 (75.0)	<0.01; 26.09 0.529†	[0.45; 2.23] 1.000	[-0.60; 0.60] 1.000
<b>Center No. 1091</b>					
N'	5	5	0.53	1.25	0.10
n (%)	3 (50.0)	2 (40.0)	[0.02; 12.93] 0.698	[0.33; 4.77] 0.744	[-0.49; 0.69] 0.738
<b>Center No. 1093</b>					
N'	1	4	N.E.	0.50	-0.50
n (%)	0 (0.0)	2 (50.0)		[0.04; 6.44] 0.595	[-0.99; -0.01] 0.046
<b>Center No. 1095</b>					
N'	5	3	2.57	1.80	0.27
n (%)	3 (60.0)	1 (33.3)	[0.12; 55.89] 0.547†	[0.31; 10.39] 0.511	[-0.42; 0.95] 0.445
<b>Center No. 1096</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	1 (50.0)	0 (0.0)			
<b>Center No. 1100</b>					
N'	1	3	N.E.	1.33	0.25
n (%)	1 (100.0)	3 (75.0)		[0.76; 2.35] 0.319	[-0.17; 0.67] 0.248
<b>Center No. 1101</b>					
N'	4	5	0.51	0.75	-0.17
n (%)	2 (50.0)	4 (66.7)	[0.04; 7.40] 0.623†	[0.24; 2.33] 0.618	[-0.79; 0.45] 0.597
<b>Center No. 1103</b>					
N'	2	3	2.00	1.50	0.17
n (%)	1 (50.0)	1 (33.3)	[0.05; 78.25] 0.711‡	[0.18; 12.46] 0.707	[-0.71; 1.04] 0.709

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1105</b>					
N'	3	3	N.E.	3.00	0.33
n (%)	1 (33.3)	0 (0.0)		[0.17; 53.71] 0.455	[-0.20; 0.87] 0.221
<b>Center No. 1108</b>					
N'	14	10	0.93	0.86	-0.10
n (%)	9 (60.0)	7 (70.0)	[0.13; 6.46] 0.943	[0.48; 1.53] 0.602	[-0.48; 0.28] 0.603
<b>Center No. 1110</b>					
N'	4	5	0.94	1.11	0.07
n (%)	4 (66.7)	3 (60.0)	[0.04; 20.36] 0.971†	[0.45; 2.77] 0.821	[-0.50; 0.64] 0.819
<b>Center No. 1111</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	1 (20.0)	0 (0.0)			
<b>Center No. 1113</b>					
N'	3	3	N.E.	1.50	0.33
n (%)	3 (100.0)	2 (66.7)		[0.67; 3.34] 0.321	[-0.20; 0.87] 0.221
<b>Center No. 1115</b>					
N'	3	5	1.07	0.90	-0.07
n (%)	3 (60.0)	4 (66.7)	[0.07; 15.49] 0.959†	[0.36; 2.24] 0.821	[-0.64; 0.50] 0.819
<b>Center No. 1116</b>					
N'	1	4	N.E.	4.00	0.75
n (%)	1 (100.0)	1 (25.0)		[0.73; 21.84] 0.109	[0.33; 1.17] <.001
<b>Center No. 1118</b>					
N'	2	2	N.E.	0.33	-0.67
n (%)	1 (33.3)	2 (100.0)		[0.07; 1.65] 0.178	[-1.20; -0.13] 0.014
<b>Center No. 1119</b>					
N'	3	5	N.E.	1.67	0.40
n (%)	3 (100.0)	3 (60.0)		[0.81; 3.41] 0.162	[-0.03; 0.83] 0.068
<b>Center No. 1121</b>					
N'	4	4	N.E.	3.00	0.25
n (%)	1 (25.0)	0 (0.0)		[0.16; 57.37] 0.466	[-0.17; 0.67] 0.248
<b>Center No. 1123</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1124</b>					
N <sup>†</sup>	3	1	N.E.	3.75	0.67
n (%)	2 (66.7)	0 (0.0)		[0.27; 52.64] 0.327	[0.13; 1.20] 0.014
<b>Center No. 1502</b>					
N <sup>†</sup>	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<p>N<sup>†</sup>: Number of patients with available response value  N-N<sup>†</sup> is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup that include treatment group, baseline value and stratification factor (MMD at baseline).  † The stratification factor is excluded from the model due to non-convergence of the full model.  ‡ The stratification factor and baseline value are excluded from the model due to non-convergence of the full model.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p>					



**Table 14.2-5.0 Return rates in the diary for SF-36v2, Quality of Life, by assessment week (Full analysis set)**

	Treatment Groups		
	AMG334 (N=388) n (%)	Topiramate (N=388) n (%)	Total (N=776) n (%)
<b>Physical component summary</b>			
Day 1	384 (99.0)	381 (98.2)	765 (98.6)
Week 4	369 (95.1)	349 (89.9)	718 (92.5)
Week 8	371 (95.6)	367 (94.6)	738 (95.1)
Week 12	375 (96.6)	364 (93.8)	739 (95.2)
Week 16	371 (95.6)	364 (93.8)	735 (94.7)
Week 20	367 (94.6)	359 (92.5)	726 (93.6)
Week 24	365 (94.1)	362 (93.3)	727 (93.7)
<b>Mental component summary</b>			
Day 1	384 (99.0)	381 (98.2)	765 (98.6)
Week 4	369 (95.1)	349 (89.9)	718 (92.5)
Week 8	371 (95.6)	367 (94.6)	738 (95.1)
Week 12	375 (96.6)	364 (93.8)	739 (95.2)
Week 16	371 (95.6)	364 (93.8)	735 (94.7)
Week 20	367 (94.6)	359 (92.5)	726 (93.6)
Week 24	365 (94.1)	362 (93.3)	727 (93.7)

**Table 14.2-5.1 SF-36v2, Quality of Life, change from baseline to week 24, Linear Mixed Model for Repeated Measures (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Physical component summary</b>				
N'	378	374		
Baseline Mean (SD)	45.26 (7.13)	44.79 (7.26)		
Week 24 Mean (SD)	50.90 (6.57)	48.96 (7.17)		
Adjusted Mean Change (SE)	5.48 (0.36)	3.63 (0.36)	1.86 [0.96; 2.75]	<.001
<b>Mental component summary</b>				
N'	378	374		
Baseline Mean (SD)	51.63 (8.43)	52.07 (8.08)		
Week 24 Mean (SD)	53.00 (8.48)	51.08 (9.72)		
Adjusted Mean Change (SE)	1.00 (0.46)	-1.18 (0.46)	2.19 [1.04; 3.33]	<.001
N': Number of patients in the analysis CI: Confidence interval SD: Standard deviation SE: Standard error  Linear mixed model for repeated measures includes treatment group, baseline value, stratification factor, scheduled visit and interaction between treatment group and scheduled visit. The model utilizes unstructured covariance matrix in the repeated statement.				

**Table 14.2-5.1.1 SF-36v2, Quality of Life, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
< median age, N	186	190		
≥ median age, N	202	198		
<b>Physical component summary</b>				
<b>Interaction test: p=0.062</b>				
<b>&lt; median age</b>				
N'	180	185		
Baseline Mean (SD)	45.42 (6.83)	45.60 (6.82)		
Week 24 Mean (SD)	50.92 (6.73)	49.87 (7.21)		
Adjusted Mean Change (SE)	5.47 (0.48)	4.21 (0.48)	1.26 [-0.02; 2.53]	0.053
<b>≥ median age</b>				
N'	198	189		
Baseline Mean (SD)	45.12 (7.40)	43.99 (7.60)		
Week 24 Mean (SD)	50.88 (6.43)	48.01 (7.02)		
Adjusted Mean Change (SE)	5.45 (0.47)	3.00 (0.49)	2.45 [1.20; 3.70]	<.001
<b>Mental component summary</b>				
<b>Interaction test: p=0.191</b>				
<b>&lt; median age</b>				
N'	180	185		
Baseline Mean (SD)	51.49 (8.40)	51.38 (8.63)		
Week 24 Mean (SD)	52.89 (8.50)	51.45 (9.34)		
Adjusted Mean Change (SE)	0.94 (0.62)	-0.38 (0.61)	1.32 [-0.32; 2.96]	0.115
<b>≥ median age</b>				
N'	198	189		
Baseline Mean (SD)	51.76 (8.48)	52.74 (7.46)		
Week 24 Mean (SD)	53.11 (8.48)	50.71 (10.11)		
Adjusted Mean Change (SE)	1.05 (0.61)	-2.01 (0.63)	3.06 [1.46; 4.66]	<.001
N': Number of patients in the analysis CI: Confidence interval SD: Standard deviation SE: Standard error				
Linear mixed model for repeated measures includes treatment group, baseline value, stratification factor, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup. The model utilizes unstructured covariance matrix in the repeated statement.				
Subgroup analysis results are only displayed for subgroups with N' > 0 in at least one treatment group.				

**Table 14.2-5.1.2 SF-36v2, Quality of Life, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Gender (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Male, N	57	53		
Female, N	331	335		
<b>Physical component summary</b>				
<b>Interaction test: p=0.507</b>				
<b>Male</b>				
N'	54	52		
Baseline Mean (SD)	47.48 (7.53)	47.44 (6.70)		
Week 24 Mean (SD)	51.60 (6.33)	50.19 (7.23)		
Adjusted Mean Change (SE)	5.06 (0.87)	3.38 (0.89)	1.68 [-0.70; 4.07]	0.167
<b>Female</b>				
N'	324	322		
Baseline Mean (SD)	44.89 (7.00)	44.36 (7.27)		
Week 24 Mean (SD)	50.78 (6.61)	48.76 (7.15)		
Adjusted Mean Change (SE)	5.56 (0.38)	3.67 (0.38)	1.89 [0.93; 2.85]	<.001
<b>Mental component summary</b>				
<b>Interaction test: p=0.548</b>				
<b>Male</b>				
N'	54	52		
Baseline Mean (SD)	52.92 (7.77)	51.14 (9.22)		
Week 24 Mean (SD)	53.49 (9.26)	52.24 (8.49)		
Adjusted Mean Change (SE)	0.99 (1.11)	0.45 (1.14)	0.53 [-2.54; 3.60]	0.734
<b>Female</b>				
N'	324	322		
Baseline Mean (SD)	51.42 (8.53)	52.22 (7.88)		
Week 24 Mean (SD)	52.92 (8.36)	50.90 (9.90)		
Adjusted Mean Change (SE)	1.01 (0.49)	-1.44 (0.49)	2.45 [1.21; 3.68]	<.001
N': Number of patients in the analysis CI: Confidence interval SD: Standard deviation SE: Standard error				
Linear mixed model for repeated measures includes treatment group, baseline value, stratification factor, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup. The model utilizes unstructured covariance matrix in the repeated statement.				
Subgroup analysis results are only displayed for subgroups with N' > 0 in at least one treatment group.				

**Table 14.2-5.1.3 SF-36v2, Quality of Life, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92		
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254		
≥ 15 monthly migraine days at baseline, N	43	42		
<b>Physical component summary</b>				
<b>Interaction test: p=0.760</b>				
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>				
N'	91	89		
Baseline Mean (SD)	47.03 (6.64)	45.68 (7.12)		
Week 24 Mean (SD)	52.40 (6.76)	49.58 (7.07)		
Adjusted Mean Change (SE)	6.39 (0.65)	3.88 (0.66)	2.51 [0.69; 4.34]	0.007
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>				
N'	245	246		
Baseline Mean (SD)	44.72 (7.11)	44.71 (7.28)		
Week 24 Mean (SD)	50.67 (6.33)	48.97 (7.10)		
Adjusted Mean Change (SE)	5.83 (0.40)	4.03 (0.40)	1.79 [0.69; 2.89]	0.001
<b>≥ 15 monthly migraine days at baseline</b>				
N'	42	39		
Baseline Mean (SD)	44.62 (7.78)	43.25 (7.40)		
Week 24 Mean (SD)	48.94 (6.99)	47.45 (7.80)		
Adjusted Mean Change (SE)	3.74 (0.96)	2.88 (1.00)	0.86 [-1.87; 3.58]	0.537
<b>Mental component summary</b>				
<b>Interaction test: p=0.634</b>				
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>				
N'	91	89		
Baseline Mean (SD)	51.79 (7.48)	53.70 (6.91)		
Week 24 Mean (SD)	51.32 (9.21)	51.38 (9.04)		
Adjusted Mean Change (SE)	-0.33 (0.84)	-1.63 (0.85)	1.30 [-1.05; 3.65]	0.277
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>				
N'	245	246		
Baseline Mean (SD)	51.93 (8.77)	52.09 (8.09)		
Week 24 Mean (SD)	53.84 (7.86)	51.25 (9.57)		
Adjusted Mean Change (SE)	1.76 (0.51)	-0.96 (0.51)	2.72 [1.30; 4.13]	<.001

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>≥ 15 monthly migraine days at baseline</b>				
N <sup>1</sup>	42	39		
Baseline Mean (SD)	49.55 (8.28)	48.24 (9.32)		
Week 24 Mean (SD)	51.69 (9.83)	49.32 (12.04)		
Adjusted Mean Change (SE)	0.48 (1.24)	-0.49 (1.28)	0.97 [-2.53; 4.47]	0.586
<p>N<sup>1</sup>: Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, baseline value, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup.            The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N<sup>1</sup> &gt; 0 in at least one treatment group.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.  <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.            The stratification factor is not included in the linear mixed model due to collinearity with the subgroups.</p>				

**Table 14.2-5.1.4 SF-36v2, Quality of Life, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Naïve*, N	232	229		
Prior treatment failure*, N	156	159		
<b>Physical component summary</b>				
<b>Interaction test: p=0.416</b>				
<b>Naïve*</b>				
N'	224	221		
Baseline Mean (SD)	45.85 (7.00)	45.21 (7.40)		
Week 24 Mean (SD)	51.32 (6.42)	49.53 (6.99)		
Adjusted Mean Change (SE)	5.64 (0.44)	4.03 (0.44)	1.61 [0.45; 2.77]	0.007
<b>Prior treatment failure*</b>				
N'	154	153		
Baseline Mean (SD)	44.41 (7.25)	44.18 (7.03)		
Week 24 Mean (SD)	50.31 (6.75)	48.13 (7.37)		
Adjusted Mean Change (SE)	5.20 (0.53)	2.98 (0.53)	2.21 [0.82; 3.61]	0.002
<b>Mental component summary</b>				
<b>Interaction test: p=0.119</b>				
<b>Naïve*</b>				
N'	224	221		
Baseline Mean (SD)	52.08 (8.33)	52.04 (8.34)		
Week 24 Mean (SD)	53.35 (8.12)	51.90 (9.47)		
Adjusted Mean Change (SE)	1.04 (0.56)	-0.35 (0.57)	1.40 [-0.09; 2.88]	0.065

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Prior treatment failure*</b>				
N'	154	153		
Baseline Mean (SD)	50.98 (8.57)	52.12 (7.71)		
Week 24 Mean (SD)	52.50 (8.98)	49.89 (9.99)		
Adjusted Mean Change (SE)	0.92 (0.68)	-2.41 (0.68)	3.33 [1.54; 5.12]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, baseline value, stratification factor, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup.            The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p> <p>*: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>				



**Table 14.2-5.1.5 SF-36v2, Quality of Life, change from baseline to week 24, Linear Mixed Model for Repeated Measures by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1001, N	10	8		
Center No. 1002, N	4	0		
Center No. 1003, N	2	3		
Center No. 1005, N	31	22		
Center No. 1007, N	5	7		
Center No. 1008, N	3	3		
Center No. 1010, N	2	3		
Center No. 1011, N	2	5		
Center No. 1012, N	3	5		
Center No. 1014, N	5	4		
Center No. 1015, N	4	2		
Center No. 1017, N	5	4		
Center No. 1018, N	7	6		
Center No. 1019, N	2	2		
Center No. 1021, N	16	10		
Center No. 1022, N	3	3		
Center No. 1025, N	0	2		
Center No. 1027, N	3	5		
Center No. 1028, N	11	5		
Center No. 1029, N	15	9		
Center No. 1030, N	11	9		
Center No. 1032, N	2	4		
Center No. 1033, N	4	6		
Center No. 1034, N	4	3		
Center No. 1035, N	27	22		
Center No. 1036, N	7	7		
Center No. 1037, N	9	11		
Center No. 1039, N	4	3		
Center No. 1040, N	0	3		
Center No. 1041, N	5	5		
Center No. 1042, N	4	5		
Center No. 1044, N	0	2		
Center No. 1046, N	1	1		

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1048, N	0	3		
Center No. 1049, N	1	0		
Center No. 1050, N	6	9		
Center No. 1051, N	1	1		
Center No. 1052, N	7	4		
Center No. 1055, N	2	4		
Center No. 1058, N	0	1		
Center No. 1059, N	7	7		
Center No. 1061, N	9	6		
Center No. 1063, N	4	2		
Center No. 1064, N	0	3		
Center No. 1067, N	10	16		
Center No. 1068, N	0	2		
Center No. 1069, N	3	4		
Center No. 1070, N	1	5		
Center No. 1072, N	2	1		
Center No. 1073, N	11	7		
Center No. 1074, N	5	3		
Center No. 1076, N	1	5		
Center No. 1077, N	3	2		
Center No. 1079, N	4	3		
Center No. 1080, N	3	1		
Center No. 1082, N	5	8		
Center No. 1084, N	2	3		
Center No. 1085, N	0	3		
Center No. 1086, N	6	9		
Center No. 1087, N	1	4		
Center No. 1088, N	6	6		
Center No. 1089, N	4	4		
Center No. 1091, N	6	5		
Center No. 1093, N	1	4		
Center No. 1095, N	5	3		
Center No. 1096, N	2	0		
Center No. 1100, N	1	4		
Center No. 1101, N	4	6		
Center No. 1103, N	2	3		

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1105, N	3	3		
Center No. 1108, N	15	10		
Center No. 1110, N	6	5		
Center No. 1111, N	5	0		
Center No. 1113, N	3	3		
Center No. 1115, N	5	6		
Center No. 1116, N	1	4		
Center No. 1118, N	3	2		
Center No. 1119, N	3	5		
Center No. 1121, N	4	4		
Center No. 1123, N	1	1		
Center No. 1124, N	3	2		
Center No. 1502, N	0	3		
<b>Physical component summary</b>				
<b>Interaction test: N.E.</b>				
<b>Center No. 1001</b>				
N'	10	8		
Baseline Mean (SD)	45.58 (4.85)	42.79 (7.53)		
Week 24 Mean (SD)	47.74 (7.86)	46.24 (7.96)		
Adjusted Mean Change (SE)	2.63 (4.19)	-2.32 (4.59)	4.95 [-8.48; 18.37]	0.440
<b>Center No. 1002</b>				
N'	4	0		
Baseline Mean (SD)	37.94 (13.15)	N.E.		
Week 24 Mean (SD)	46.41 (4.16)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1003</b>				
N'	2	3		
Baseline Mean (SD)	44.66 (7.98)	50.33 (10.84)		
Week 24 Mean (SD)	57.56 (2.09)	59.42 (9.80)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1005</b>				
N'	30	22		
Baseline Mean (SD)	47.18 (7.65)	45.17 (10.28)		
Week 24 Mean (SD)	52.51 (5.69)	49.02 (6.57)		
Adjusted Mean Change (SE)	5.10 (0.97)	3.14 (1.10)	1.95 [-0.84; 4.74]	0.165

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1007</b>				
N'	5	7		
Baseline Mean (SD)	45.54 (3.26)	45.56 (4.30)		
Week 24 Mean (SD)	45.00 (7.91)	47.20 (12.07)		
Adjusted Mean Change (SE)	2.64 (4.99)	5.34 (4.46)	-2.70 [-16.88; 11.49]	0.667
<b>Center No. 1008</b>				
N'	2	3		
Baseline Mean (SD)	45.84 (0.23)	34.76 (12.89)		
Week 24 Mean (SD)	49.60 (1.17)	47.99 (11.19)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1010</b>				
N'	2	2		
Baseline Mean (SD)	41.16 (2.91)	45.39 (3.32)		
Week 24 Mean (SD)	43.34 (1.44)	44.01 (3.90)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1011</b>				
N'	2	5		
Baseline Mean (SD)	43.83 (3.43)	45.21 (4.97)		
Week 24 Mean (SD)	49.44 (5.75)	45.78 (5.65)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1012</b>				
N'	3	5		
Baseline Mean (SD)	47.82 (7.21)	42.47 (4.15)		
Week 24 Mean (SD)	52.64 (6.42)	46.47 (8.31)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1014</b>				
N'	5	4		
Baseline Mean (SD)	48.00 (4.29)	43.85 (9.15)		
Week 24 Mean (SD)	51.49 (5.96)	49.65 (4.89)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1015</b>				
N'	4	2		
Baseline Mean (SD)	47.24 (6.19)	46.71 (17.22)		
Week 24 Mean (SD)	54.64 (5.85)	58.11 (4.13)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1017</b>				
N'	5	4		
Baseline Mean (SD)	47.09 (6.11)	39.43 (7.16)		
Week 24 Mean (SD)	51.22 (4.61)	39.60 (9.44)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1018</b>				
N'	7	5		
Baseline Mean (SD)	43.13 (1.50)	46.65 (7.73)		
Week 24 Mean (SD)	51.74 (3.79)	43.91 (11.07)		
Adjusted Mean Change (SE)	6.55 (3.21)	-2.64 (3.54)	9.19 [-0.36; 18.74]	0.057
<b>Center No. 1019</b>				
N'	2	2		
Baseline Mean (SD)	42.62 (7.78)	42.16 (7.95)		
Week 24 Mean (SD)	50.38 (2.96)	42.67 (2.57)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1021</b>				
N'	15	7		
Baseline Mean (SD)	41.44 (7.80)	44.06 (2.08)		
Week 24 Mean (SD)	49.69 (6.43)	41.29 (14.02)		
Adjusted Mean Change (SE)	7.99 (2.26)	-1.25 (3.37)	9.24 [0.80; 17.68]	0.034
<b>Center No. 1022</b>				
N'	3	3		
Baseline Mean (SD)	43.22 (4.13)	49.11 (2.30)		
Week 24 Mean (SD)	48.20 (5.67)	50.94 (6.39)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1025</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	40.92 (14.20)		
Week 24 Mean (SD)	N.E.	45.69 (9.67)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1027</b>				
N'	3	5		
Baseline Mean (SD)	48.16 (9.96)	42.11 (5.69)		
Week 24 Mean (SD)	50.49 (7.47)	48.17 (5.25)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1028</b>				
N'	11	5		
Baseline Mean (SD)	41.49 (6.08)	41.25 (5.36)		
Week 24 Mean (SD)	48.75 (4.87)	43.84 (6.13)		
Adjusted Mean Change (SE)	6.50 (1.89)	2.02 (2.51)	4.48 [-2.11; 11.07]	0.163
<b>Center No. 1029</b>				
N'	15	9		
Baseline Mean (SD)	44.35 (4.06)	43.54 (7.45)		
Week 24 Mean (SD)	51.24 (7.15)	47.15 (3.12)		
Adjusted Mean Change (SE)	8.93 (1.95)	3.55 (1.85)	5.39 [-0.08; 10.85]	0.053
<b>Center No. 1030</b>				
N'	11	9		
Baseline Mean (SD)	46.81 (5.73)	49.15 (7.31)		
Week 24 Mean (SD)	51.32 (6.01)	51.22 (5.34)		
Adjusted Mean Change (SE)	3.78 (1.73)	2.35 (1.88)	1.43 [-3.78; 6.65]	0.567
<b>Center No. 1032</b>				
N'	2	4		
Baseline Mean (SD)	50.16 (4.14)	44.95 (7.31)		
Week 24 Mean (SD)	56.59 (N.E.)	47.39 (6.48)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1033</b>				
N'	4	6		
Baseline Mean (SD)	48.44 (5.32)	46.56 (5.87)		
Week 24 Mean (SD)	50.17 (9.11)	46.47 (7.12)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1034</b>				
N'	4	3		
Baseline Mean (SD)	45.79 (10.94)	48.01 (9.30)		
Week 24 Mean (SD)	53.59 (1.87)	52.08 (7.73)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1035</b>				
N'	27	22		
Baseline Mean (SD)	45.83 (6.20)	46.25 (4.12)		
Week 24 Mean (SD)	53.09 (4.58)	47.99 (7.22)		
Adjusted Mean Change (SE)	7.57 (1.38)	2.21 (1.44)	5.37 [2.13; 8.60]	0.002

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1036</b>				
N'	7	6		
Baseline Mean (SD)	45.62 (10.05)	41.28 (7.97)		
Week 24 Mean (SD)	51.58 (7.33)	43.35 (5.88)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1037</b>				
N'	8	11		
Baseline Mean (SD)	42.08 (6.49)	43.58 (8.44)		
Week 24 Mean (SD)	44.62 (8.42)	47.55 (7.34)		
Adjusted Mean Change (SE)	1.35 (2.12)	3.43 (1.62)	-2.08 [-7.22; 3.06]	0.403
<b>Center No. 1039</b>				
N'	4	3		
Baseline Mean (SD)	46.40 (10.60)	44.71 (1.05)		
Week 24 Mean (SD)	49.09 (14.28)	51.08 (1.26)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1040</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	43.33 (7.10)		
Week 24 Mean (SD)	N.E.	39.27 (7.96)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1041</b>				
N'	4	5		
Baseline Mean (SD)	48.41 (5.78)	39.14 (5.86)		
Week 24 Mean (SD)	51.80 (3.38)	47.64 (5.02)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1042</b>				
N'	4	5		
Baseline Mean (SD)	43.66 (8.24)	47.57 (3.38)		
Week 24 Mean (SD)	51.33 (2.89)	53.20 (6.10)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1044</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	47.42 (2.43)		
Week 24 Mean (SD)	N.E.	47.69 (4.19)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1046</b>				
N'	1	0		
Baseline Mean (SD)	60.13 (N.E.)	N.E.		
Week 24 Mean (SD)	56.17 (N.E.)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1048</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	40.93 (20.26)		
Week 24 Mean (SD)	N.E.	51.98 (5.27)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1049</b>				
N'	1	0		
Baseline Mean (SD)	48.52 (N.E.)	N.E.		
Week 24 Mean (SD)	58.93 (N.E.)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1050</b>				
N'	6	9		
Baseline Mean (SD)	46.02 (8.20)	47.77 (5.98)		
Week 24 Mean (SD)	51.99 (6.16)	51.22 (8.05)		
Adjusted Mean Change (SE)	1.86 (4.23)	-3.29 (4.24)	5.15 [-6.61; 16.91]	0.353
<b>Center No. 1051</b>				
N'	1	1		
Baseline Mean (SD)	58.58 (N.E.)	53.16 (N.E.)		
Week 24 Mean (SD)	50.44 (N.E.)	55.72 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1052</b>				
N'	7	4		
Baseline Mean (SD)	47.51 (9.87)	46.09 (4.11)		
Week 24 Mean (SD)	51.12 (3.52)	52.19 (6.85)		
Adjusted Mean Change (SE)	0.11 (1.84)	4.93 (2.32)	-4.82 [-12.03; 2.39]	0.153
<b>Center No. 1055</b>				
N'	2	4		
Baseline Mean (SD)	48.85 (2.17)	48.37 (10.17)		
Week 24 Mean (SD)	55.49 (3.95)	49.44 (9.78)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1058</b>				
N'	0	1		
Baseline Mean (SD)	N.E.	42.66 (N.E.)		
Week 24 Mean (SD)	N.E.	50.33 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1059</b>				
N'	7	6		
Baseline Mean (SD)	48.39 (7.33)	41.26 (5.38)		
Week 24 Mean (SD)	51.72 (3.40)	49.30 (9.10)		
Adjusted Mean Change (SE)	6.23 (2.87)	6.43 (3.09)	-0.19 [-9.75; 9.36]	0.964
<b>Center No. 1061</b>				
N'	9	6		
Baseline Mean (SD)	38.42 (5.64)	42.19 (9.45)		
Week 24 Mean (SD)	44.34 (8.00)	47.02 (5.81)		
Adjusted Mean Change (SE)	2.10 (2.85)	1.32 (3.25)	0.78 [-6.80; 8.37]	0.823
<b>Center No. 1063</b>				
N'	4	2		
Baseline Mean (SD)	47.23 (7.52)	45.15 (3.55)		
Week 24 Mean (SD)	52.04 (4.03)	46.83 (2.92)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1064</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	46.20 (2.34)		
Week 24 Mean (SD)	N.E.	53.61 (0.31)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1067</b>				
N'	9	16		
Baseline Mean (SD)	43.41 (6.84)	44.97 (7.23)		
Week 24 Mean (SD)	53.55 (7.30)	51.05 (6.97)		
Adjusted Mean Change (SE)	8.99 (2.44)	7.13 (2.04)	1.86 [-4.56; 8.27]	0.553
<b>Center No. 1068</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	47.89 (1.20)		
Week 24 Mean (SD)	N.E.	42.07 (10.47)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1069</b>				
N'	3	4		
Baseline Mean (SD)	40.78 (20.32)	43.92 (5.74)		
Week 24 Mean (SD)	50.70 (1.15)	44.72 (3.78)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1070</b>				
N'	1	4		
Baseline Mean (SD)	54.67 (N.E.)	38.32 (5.12)		
Week 24 Mean (SD)	50.98 (N.E.)	44.65 (0.61)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1072</b>				
N'	2	1		
Baseline Mean (SD)	46.62 (5.52)	57.11 (N.E.)		
Week 24 Mean (SD)	46.84 (8.00)	53.53 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1073</b>				
N'	11	6		
Baseline Mean (SD)	48.77 (6.25)	45.55 (4.79)		
Week 24 Mean (SD)	50.71 (9.99)	52.47 (3.85)		
Adjusted Mean Change (SE)	-2.13 (2.38)	2.91 (3.13)	-5.04 [-13.33; 3.25]	0.210
<b>Center No. 1074</b>				
N'	5	3		
Baseline Mean (SD)	47.00 (5.54)	52.29 (2.64)		
Week 24 Mean (SD)	56.02 (4.39)	59.04 (3.98)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1076</b>				
N'	1	5		
Baseline Mean (SD)	38.49 (N.E.)	47.92 (4.75)		
Week 24 Mean (SD)	47.38 (N.E.)	55.59 (2.16)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1077</b>				
N'	3	2		
Baseline Mean (SD)	48.18 (2.43)	42.47 (10.96)		
Week 24 Mean (SD)	53.50 (4.26)	44.55 (11.54)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1079</b>				
N'	4	3		
Baseline Mean (SD)	44.00 (6.28)	37.66 (7.47)		
Week 24 Mean (SD)	49.50 (15.28)	49.43 (1.29)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1080</b>				
N'	3	1		
Baseline Mean (SD)	47.84 (3.87)	50.11 (N.E.)		
Week 24 Mean (SD)	47.18 (12.96)	54.50 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1082</b>				
N'	5	8		
Baseline Mean (SD)	42.20 (6.46)	45.63 (4.65)		
Week 24 Mean (SD)	56.56 (1.58)	51.08 (4.76)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1084</b>				
N'	2	3		
Baseline Mean (SD)	41.74 (6.08)	45.34 (3.40)		
Week 24 Mean (SD)	51.58 (0.83)	48.86 (2.53)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1085</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	38.12 (8.59)		
Week 24 Mean (SD)	N.E.	47.84 (1.48)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1086</b>				
N'	6	9		
Baseline Mean (SD)	44.71 (7.55)	41.31 (4.13)		
Week 24 Mean (SD)	49.80 (4.39)	45.14 (8.43)		
Adjusted Mean Change (SE)	7.45 (3.22)	4.61 (2.93)	2.84 [-6.63; 12.30]	0.523
<b>Center No. 1087</b>				
N'	1	4		
Baseline Mean (SD)	47.63 (N.E.)	47.83 (8.12)		
Week 24 Mean (SD)	52.22 (N.E.)	49.12 (5.52)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1088</b>				
N'	6	6		
Baseline Mean (SD)	49.26 (3.69)	46.81 (6.80)		
Week 24 Mean (SD)	52.17 (4.99)	53.51 (5.20)		
Adjusted Mean Change (SE)	1.75 (3.28)	0.20 (3.31)	1.55 [-9.19; 12.30]	0.747
<b>Center No. 1089</b>				
N'	4	4		
Baseline Mean (SD)	47.62 (10.24)	50.46 (3.13)		
Week 24 Mean (SD)	51.16 (8.67)	58.65 (2.26)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1091</b>				
N'	6	5		
Baseline Mean (SD)	48.01 (7.89)	44.17 (2.63)		
Week 24 Mean (SD)	53.89 (5.89)	49.16 (1.42)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1093</b>				
N'	1	4		
Baseline Mean (SD)	53.12 (N.E.)	44.02 (2.62)		
Week 24 Mean (SD)	49.43 (N.E.)	48.08 (4.97)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1095</b>				
N'	5	3		
Baseline Mean (SD)	43.66 (5.63)	44.38 (9.27)		
Week 24 Mean (SD)	44.55 (5.36)	47.05 (5.82)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1096</b>				
N'	2	0		
Baseline Mean (SD)	53.67 (7.65)	N.E.		
Week 24 Mean (SD)	52.35 (2.72)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1100</b>				
N'	1	3		
Baseline Mean (SD)	40.19 (N.E.)	41.38 (15.67)		
Week 24 Mean (SD)	51.47 (N.E.)	51.74 (8.14)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1101</b>				
N'	4	5		
Baseline Mean (SD)	43.67 (4.23)	47.74 (3.94)		
Week 24 Mean (SD)	46.53 (5.78)	52.42 (5.95)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1103</b>				
N'	2	3		
Baseline Mean (SD)	49.66 (2.43)	48.71 (3.55)		
Week 24 Mean (SD)	49.64 (1.44)	49.36 (3.16)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1105</b>				
N'	3	3		
Baseline Mean (SD)	45.25 (3.86)	46.30 (13.84)		
Week 24 Mean (SD)	49.87 (5.92)	53.00 (5.49)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1108</b>				
N'	14	10		
Baseline Mean (SD)	44.74 (8.13)	44.23 (10.94)		
Week 24 Mean (SD)	52.42 (7.89)	52.87 (4.21)		
Adjusted Mean Change (SE)	7.60 (1.64)	8.36 (2.02)	-0.76 [-6.15; 4.63]	0.771
<b>Center No. 1110</b>				
N'	6	4		
Baseline Mean (SD)	44.76 (6.25)	44.53 (4.67)		
Week 24 Mean (SD)	56.13 (4.83)	46.08 (5.61)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1111</b>				
N'	3	0		
Baseline Mean (SD)	44.36 (11.41)	N.E.		
Week 24 Mean (SD)	41.96 (2.35)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1113</b>				
N'	3	3		
Baseline Mean (SD)	39.79 (11.28)	50.34 (6.90)		
Week 24 Mean (SD)	47.43 (4.01)	53.52 (4.13)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1115</b>				
N'	4	6		
Baseline Mean (SD)	43.10 (4.69)	47.53 (10.99)		
Week 24 Mean (SD)	54.88 (1.63)	55.43 (5.52)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1116</b>				
N'	1	4		
Baseline Mean (SD)	48.38 (N.E.)	40.55 (7.84)		
Week 24 Mean (SD)	51.63 (N.E.)	47.68 (2.40)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1118</b>				
N'	3	2		
Baseline Mean (SD)	41.30 (9.66)	46.65 (0.27)		
Week 24 Mean (SD)	47.27 (16.09)	52.64 (7.39)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1119</b>				
N'	3	5		
Baseline Mean (SD)	44.58 (7.29)	43.57 (9.07)		
Week 24 Mean (SD)	54.83 (4.82)	49.80 (7.81)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1121</b>				
N'	4	4		
Baseline Mean (SD)	39.87 (10.59)	48.09 (4.90)		
Week 24 Mean (SD)	46.35 (7.16)	47.04 (5.57)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1123</b>				
N'	1	1		
Baseline Mean (SD)	44.32 (N.E.)	47.07 (N.E.)		
Week 24 Mean (SD)	56.82 (N.E.)	53.18 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1124</b>				
N'	3	2		
Baseline Mean (SD)	43.75 (13.03)	39.66 (0.11)		
Week 24 Mean (SD)	53.21 (6.14)	44.96 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1502</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	40.60 (8.90)		
Week 24 Mean (SD)	N.E.	33.29 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Mental component summary</b>				
<b>Interaction test: N.E.</b>				
<b>Center No. 1001</b>				
N'	10	8		
Baseline Mean (SD)	50.89 (7.11)	54.01 (7.80)		
Week 24 Mean (SD)	51.04 (6.78)	53.47 (14.01)		
Adjusted Mean Change (SE)	0.55 (2.00)	-2.21 (2.23)	2.76 [-3.68; 9.21]	0.371
<b>Center No. 1002</b>				
N'	4	0		
Baseline Mean (SD)	49.08 (11.39)	N.E.		
Week 24 Mean (SD)	54.96 (4.38)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1003</b>				
N'	2	3		
Baseline Mean (SD)	51.58 (10.32)	44.20 (18.03)		
Week 24 Mean (SD)	53.12 (5.61)	49.11 (17.45)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1005</b>				
N'	30	22		
Baseline Mean (SD)	49.25 (7.00)	47.31 (8.62)		
Week 24 Mean (SD)	51.02 (10.25)	50.22 (8.93)		
Adjusted Mean Change (SE)	1.47 (1.71)	1.10 (1.95)	0.37 [-4.69; 5.42]	0.885
<b>Center No. 1007</b>				
N'	5	7		
Baseline Mean (SD)	56.98 (4.69)	57.11 (2.03)		
Week 24 Mean (SD)	55.99 (6.77)	48.01 (15.68)		
Adjusted Mean Change (SE)	-0.04 (6.84)	-6.53 (7.27)	6.48 [-15.03; 27.99]	0.499

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1008</b>				
N'	2	3		
Baseline Mean (SD)	56.62 (5.72)	43.44 (10.04)		
Week 24 Mean (SD)	54.10 (3.47)	58.07 (7.80)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1010</b>				
N'	2	2		
Baseline Mean (SD)	55.49 (6.13)	46.07 (0.53)		
Week 24 Mean (SD)	56.81 (3.90)	40.84 (7.81)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1011</b>				
N'	2	5		
Baseline Mean (SD)	44.61 (17.78)	52.10 (2.92)		
Week 24 Mean (SD)	53.17 (8.00)	53.92 (11.85)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1012</b>				
N'	3	5		
Baseline Mean (SD)	53.65 (8.18)	51.87 (5.98)		
Week 24 Mean (SD)	55.76 (7.07)	50.85 (6.87)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1014</b>				
N'	5	4		
Baseline Mean (SD)	50.85 (4.61)	52.78 (6.30)		
Week 24 Mean (SD)	48.69 (9.70)	49.94 (9.37)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1015</b>				
N'	4	2		
Baseline Mean (SD)	44.35 (12.39)	58.04 (3.95)		
Week 24 Mean (SD)	51.61 (5.60)	57.42 (1.58)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1017</b>				
N'	5	4		
Baseline Mean (SD)	53.38 (5.44)	52.83 (6.42)		
Week 24 Mean (SD)	55.08 (2.89)	45.94 (8.54)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1018</b>				
N'	7	5		
Baseline Mean (SD)	52.46 (7.39)	54.96 (2.76)		
Week 24 Mean (SD)	54.29 (7.19)	53.69 (3.88)		
Adjusted Mean Change (SE)	-1.27 (2.01)	-2.30 (2.19)	1.03 [-5.41; 7.47]	0.722
<b>Center No. 1019</b>				
N'	2	2		
Baseline Mean (SD)	37.09 (11.43)	39.96 (13.27)		
Week 24 Mean (SD)	52.35 (2.40)	41.14 (11.13)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1021</b>				
N'	15	7		
Baseline Mean (SD)	52.12 (9.52)	56.36 (9.09)		
Week 24 Mean (SD)	52.78 (10.51)	59.18 (11.37)		
Adjusted Mean Change (SE)	-0.95 (2.68)	2.63 (3.97)	-3.58 [-13.63; 6.47]	0.464
<b>Center No. 1022</b>				
N'	3	3		
Baseline Mean (SD)	58.11 (3.38)	54.64 (1.83)		
Week 24 Mean (SD)	53.76 (4.20)	51.06 (4.18)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1025</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	46.08 (17.23)		
Week 24 Mean (SD)	N.E.	41.45 (16.41)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1027</b>				
N'	3	5		
Baseline Mean (SD)	47.25 (16.96)	51.82 (8.60)		
Week 24 Mean (SD)	50.89 (16.52)	48.01 (9.75)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1028</b>				
N'	11	5		
Baseline Mean (SD)	52.31 (8.92)	53.03 (8.20)		
Week 24 Mean (SD)	54.06 (6.68)	44.20 (19.26)		
Adjusted Mean Change (SE)	2.49 (4.41)	-8.44 (6.43)	10.93 [-6.10; 27.97]	0.185

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1029</b>				
N'	15	9		
Baseline Mean (SD)	54.98 (5.31)	55.81 (8.10)		
Week 24 Mean (SD)	54.27 (6.30)	53.00 (9.44)		
Adjusted Mean Change (SE)	-1.42 (2.15)	-2.78 (2.40)	1.36 [-5.27; 7.98]	0.674
<b>Center No. 1030</b>				
N'	11	9		
Baseline Mean (SD)	51.66 (11.24)	53.40 (10.92)		
Week 24 Mean (SD)	53.49 (9.12)	51.15 (14.69)		
Adjusted Mean Change (SE)	2.92 (1.66)	-1.92 (1.80)	4.85 [-0.24; 9.93]	0.060
<b>Center No. 1032</b>				
N'	2	4		
Baseline Mean (SD)	48.68 (4.92)	47.11 (16.19)		
Week 24 Mean (SD)	55.34 (N.E.)	42.14 (25.19)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1033</b>				
N'	4	6		
Baseline Mean (SD)	50.44 (11.81)	53.79 (9.55)		
Week 24 Mean (SD)	55.07 (13.00)	51.84 (10.30)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1034</b>				
N'	4	3		
Baseline Mean (SD)	59.21 (6.86)	53.48 (3.93)		
Week 24 Mean (SD)	53.75 (3.88)	55.29 (1.51)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1035</b>				
N'	27	22		
Baseline Mean (SD)	52.56 (8.56)	51.39 (7.05)		
Week 24 Mean (SD)	53.33 (8.48)	50.48 (9.01)		
Adjusted Mean Change (SE)	2.42 (2.08)	0.60 (2.18)	1.83 [-2.87; 6.52]	0.437
<b>Center No. 1036</b>				
N'	7	6		
Baseline Mean (SD)	51.31 (9.30)	53.65 (2.76)		
Week 24 Mean (SD)	53.60 (9.59)	48.26 (4.22)		
Adjusted Mean Change (SE)	3.56 (2.19)	-5.41 (2.42)	8.97 [1.96; 15.98]	0.018

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1037</b>				
N'	8	11		
Baseline Mean (SD)	48.26 (8.35)	50.12 (4.96)		
Week 24 Mean (SD)	51.79 (8.08)	48.25 (8.81)		
Adjusted Mean Change (SE)	3.55 (3.39)	-2.70 (2.70)	6.25 [-2.45; 14.94]	0.146
<b>Center No. 1039</b>				
N'	4	3		
Baseline Mean (SD)	56.67 (5.95)	54.80 (1.86)		
Week 24 Mean (SD)	53.22 (4.54)	58.23 (2.77)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1040</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	48.30 (4.50)		
Week 24 Mean (SD)	N.E.	43.52 (4.48)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1041</b>				
N'	4	5		
Baseline Mean (SD)	49.49 (7.00)	53.79 (10.34)		
Week 24 Mean (SD)	54.31 (5.36)	51.21 (2.44)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1042</b>				
N'	4	5		
Baseline Mean (SD)	52.32 (4.01)	49.45 (7.42)		
Week 24 Mean (SD)	51.49 (5.33)	47.92 (8.18)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1044</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	59.34 (1.54)		
Week 24 Mean (SD)	N.E.	49.92 (10.42)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1046</b>				
N'	1	0		
Baseline Mean (SD)	50.54 (N.E.)	N.E.		
Week 24 Mean (SD)	56.78 (N.E.)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1048</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	58.85 (2.95)		
Week 24 Mean (SD)	N.E.	55.35 (3.14)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1049</b>				
N'	1	0		
Baseline Mean (SD)	61.85 (N.E.)	N.E.		
Week 24 Mean (SD)	59.58 (N.E.)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1050</b>				
N'	6	9		
Baseline Mean (SD)	52.83 (8.85)	48.61 (10.26)		
Week 24 Mean (SD)	54.41 (7.18)	49.83 (10.70)		
Adjusted Mean Change (SE)	1.55 (2.71)	-0.19 (2.77)	1.75 [-5.82; 9.32]	0.618
<b>Center No. 1051</b>				
N'	1	1		
Baseline Mean (SD)	50.14 (N.E.)	49.42 (N.E.)		
Week 24 Mean (SD)	55.89 (N.E.)	43.68 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1052</b>				
N'	7	4		
Baseline Mean (SD)	53.83 (4.96)	51.44 (6.84)		
Week 24 Mean (SD)	50.84 (10.11)	43.28 (9.93)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1055</b>				
N'	2	4		
Baseline Mean (SD)	43.18 (8.97)	51.75 (4.74)		
Week 24 Mean (SD)	51.18 (5.45)	50.61 (2.72)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1058</b>				
N'	0	1		
Baseline Mean (SD)	N.E.	47.21 (N.E.)		
Week 24 Mean (SD)	N.E.	50.84 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1059</b>				
N'	7	6		
Baseline Mean (SD)	48.76 (8.44)	54.25 (3.66)		
Week 24 Mean (SD)	51.31 (6.14)	54.38 (5.55)		
Adjusted Mean Change (SE)	2.11 (3.28)	-0.18 (3.40)	2.29 [-8.43; 13.02]	0.640
<b>Center No. 1061</b>				
N'	9	6		
Baseline Mean (SD)	42.73 (7.68)	51.36 (9.24)		
Week 24 Mean (SD)	47.56 (10.70)	49.74 (13.81)		
Adjusted Mean Change (SE)	4.57 (3.78)	-0.64 (4.41)	5.21 [-6.50; 16.91]	0.345
<b>Center No. 1063</b>				
N'	4	2		
Baseline Mean (SD)	53.71 (3.27)	54.65 (2.40)		
Week 24 Mean (SD)	52.47 (11.01)	53.06 (2.82)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1064</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	54.74 (2.01)		
Week 24 Mean (SD)	N.E.	46.77 (4.67)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1067</b>				
N'	9	16		
Baseline Mean (SD)	51.67 (6.87)	49.39 (9.36)		
Week 24 Mean (SD)	55.77 (5.65)	50.43 (11.51)		
Adjusted Mean Change (SE)	-0.57 (2.88)	-5.90 (2.46)	5.33 [-2.20; 12.87]	0.156
<b>Center No. 1068</b>				
N'	0	2		
Baseline Mean (SD)	N.E.	47.60 (9.89)		
Week 24 Mean (SD)	N.E.	58.31 (3.14)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1069</b>				
N'	3	4		
Baseline Mean (SD)	58.53 (1.91)	53.27 (6.53)		
Week 24 Mean (SD)	54.95 (4.65)	40.51 (3.93)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1070</b>				
N'	1	4		
Baseline Mean (SD)	57.52 (N.E.)	48.42 (8.57)		
Week 24 Mean (SD)	55.60 (N.E.)	50.45 (12.94)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1072</b>				
N'	2	1		
Baseline Mean (SD)	53.93 (5.11)	42.54 (N.E.)		
Week 24 Mean (SD)	56.50 (3.82)	52.04 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1073</b>				
N'	11	6		
Baseline Mean (SD)	53.45 (10.94)	54.32 (5.59)		
Week 24 Mean (SD)	54.77 (11.57)	57.85 (3.95)		
Adjusted Mean Change (SE)	0.90 (2.07)	3.47 (2.78)	-2.57 [-9.78; 4.64]	0.452
<b>Center No. 1074</b>				
N'	5	3		
Baseline Mean (SD)	56.96 (2.96)	59.00 (7.06)		
Week 24 Mean (SD)	58.73 (3.34)	57.49 (9.48)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1076</b>				
N'	1	5		
Baseline Mean (SD)	52.86 (N.E.)	50.83 (8.83)		
Week 24 Mean (SD)	57.42 (N.E.)	51.44 (8.26)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1077</b>				
N'	3	2		
Baseline Mean (SD)	54.33 (4.92)	49.47 (0.05)		
Week 24 Mean (SD)	54.22 (5.38)	41.84 (10.07)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1079</b>				
N'	4	3		
Baseline Mean (SD)	46.18 (10.03)	53.39 (4.44)		
Week 24 Mean (SD)	47.48 (12.18)	50.76 (7.53)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1080</b>				
N'	3	1		
Baseline Mean (SD)	55.73 (4.61)	53.65 (N.E.)		
Week 24 Mean (SD)	59.68 (2.24)	39.65 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1082</b>				
N'	5	8		
Baseline Mean (SD)	56.16 (7.16)	56.66 (3.50)		
Week 24 Mean (SD)	47.71 (15.76)	55.28 (11.15)		
Adjusted Mean Change (SE)	-9.49 (3.89)	2.55 (3.50)	-12.03 [-23.92; -0.14]	0.048
<b>Center No. 1084</b>				
N'	2	3		
Baseline Mean (SD)	60.67 (5.65)	52.56 (6.33)		
Week 24 Mean (SD)	59.61 (0.50)	48.74 (5.29)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1085</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	56.43 (7.55)		
Week 24 Mean (SD)	N.E.	45.31 (20.46)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1086</b>				
N'	6	9		
Baseline Mean (SD)	47.21 (8.89)	50.03 (8.50)		
Week 24 Mean (SD)	48.46 (12.12)	48.95 (8.32)		
Adjusted Mean Change (SE)	0.75 (3.19)	3.12 (2.67)	-2.37 [-11.53; 6.79]	0.581
<b>Center No. 1087</b>				
N'	1	4		
Baseline Mean (SD)	50.18 (N.E.)	55.80 (3.12)		
Week 24 Mean (SD)	61.08 (N.E.)	57.36 (4.28)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1088</b>				
N'	6	6		
Baseline Mean (SD)	47.80 (10.82)	52.90 (5.26)		
Week 24 Mean (SD)	51.64 (7.95)	55.64 (6.34)		
Adjusted Mean Change (SE)	7.62 (4.90)	8.38 (5.04)	-0.76 [-16.89; 15.37]	0.916

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1089</b>				
N'	4	4		
Baseline Mean (SD)	50.47 (8.23)	53.81 (6.66)		
Week 24 Mean (SD)	47.54 (16.27)	58.86 (4.95)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1091</b>				
N'	6	5		
Baseline Mean (SD)	48.57 (10.85)	53.36 (8.37)		
Week 24 Mean (SD)	53.94 (9.81)	53.86 (7.08)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1093</b>				
N'	1	4		
Baseline Mean (SD)	26.94 (N.E.)	39.29 (8.72)		
Week 24 Mean (SD)	40.53 (N.E.)	51.32 (7.23)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1095</b>				
N'	5	3		
Baseline Mean (SD)	52.49 (3.32)	51.63 (8.27)		
Week 24 Mean (SD)	54.89 (5.34)	54.59 (9.72)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1096</b>				
N'	2	0		
Baseline Mean (SD)	55.48 (6.05)	N.E.		
Week 24 Mean (SD)	59.58 (1.50)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1100</b>				
N'	1	3		
Baseline Mean (SD)	60.31 (N.E.)	61.76 (5.05)		
Week 24 Mean (SD)	62.47 (N.E.)	56.13 (3.13)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1101</b>				
N'	4	5		
Baseline Mean (SD)	45.47 (10.06)	50.27 (9.22)		
Week 24 Mean (SD)	48.54 (7.53)	52.36 (6.08)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1103</b>				
N'	2	3		
Baseline Mean (SD)	55.94 (12.88)	52.42 (6.35)		
Week 24 Mean (SD)	59.38 (4.06)	52.82 (4.60)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1105</b>				
N'	3	3		
Baseline Mean (SD)	44.34 (15.46)	55.30 (5.30)		
Week 24 Mean (SD)	51.72 (6.84)	52.47 (7.06)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1108</b>				
N'	14	10		
Baseline Mean (SD)	55.67 (5.23)	56.68 (8.35)		
Week 24 Mean (SD)	54.37 (8.51)	53.37 (9.33)		
Adjusted Mean Change (SE)	-1.51 (2.08)	-5.29 (2.53)	3.79 [-2.99; 10.57]	0.257
<b>Center No. 1110</b>				
N'	6	4		
Baseline Mean (SD)	54.48 (7.39)	56.78 (3.47)		
Week 24 Mean (SD)	58.27 (5.23)	54.85 (5.24)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1111</b>				
N'	3	0		
Baseline Mean (SD)	57.12 (2.88)	N.E.		
Week 24 Mean (SD)	55.31 (9.50)	N.E.		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1113</b>				
N'	3	3		
Baseline Mean (SD)	47.84 (15.52)	58.28 (2.82)		
Week 24 Mean (SD)	51.05 (12.75)	57.07 (1.67)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1115</b>				
N'	4	6		
Baseline Mean (SD)	53.75 (2.64)	55.23 (6.78)		
Week 24 Mean (SD)	55.91 (4.29)	53.04 (11.07)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1116</b>				
N'	1	4		
Baseline Mean (SD)	58.66 (N.E.)	45.63 (12.87)		
Week 24 Mean (SD)	57.91 (N.E.)	46.99 (15.63)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1118</b>				
N'	3	2		
Baseline Mean (SD)	52.78 (6.05)	61.23 (3.32)		
Week 24 Mean (SD)	51.04 (5.59)	61.02 (2.55)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1119</b>				
N'	3	5		
Baseline Mean (SD)	46.67 (8.43)	50.40 (11.53)		
Week 24 Mean (SD)	56.17 (0.83)	47.78 (9.83)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1121</b>				
N'	4	4		
Baseline Mean (SD)	46.74 (14.04)	53.67 (6.57)		
Week 24 Mean (SD)	39.30 (16.55)	51.72 (13.92)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1123</b>				
N'	1	1		
Baseline Mean (SD)	58.24 (N.E.)	38.61 (N.E.)		
Week 24 Mean (SD)	48.12 (N.E.)	49.68 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1124</b>				
N'	3	2		
Baseline Mean (SD)	53.43 (3.94)	53.80 (2.28)		
Week 24 Mean (SD)	55.78 (8.93)	53.27 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1502</b>				
N'	0	3		
Baseline Mean (SD)	N.E.	44.18 (17.07)		
Week 24 Mean (SD)	N.E.	29.65 (N.E.)		
Adjusted Mean Change (SE)	N.E.	N.E.	N.E.	N.E.
<p>N': Number of patients in the analysis            CI: Confidence interval            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, baseline value, stratification factor, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup.            If interaction test is N.E., linear mixed model for repeated measures is calculated separately for each subgroup and includes treatment group, baseline value, stratification factor, scheduled visit and interaction between treatment group and scheduled visit.            The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p>				

**Table 14.2-5.2 SF-36v2, Quality of Life, Proportion of patients achieving at least a 5 points increase from baseline to week 24, Logistic Regression Model (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>PCS increase of at least 5 pts from BL</b>					
N <sup>i</sup>	363	355	1.77	1.28	0.10
n (%)	185 (47.7)	145 (37.4)	[1.29; 2.43] <.001	[1.08; 1.51] 0.004	[0.03; 0.17] 0.003
<b>MCS increase of at least 5 pts from BL</b>					
N <sup>i</sup>	363	355	1.74	1.51	0.09
n (%)	98 (25.3)	65 (16.8)	[1.17; 2.59] 0.006	[1.14; 2.00] 0.004	[0.03; 0.14] 0.003
<p>N<sup>i</sup>: Number of patients with available response value                      N-N<sup>i</sup> is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>OR is obtained from a logistic regression model that includes treatment group, baseline value and stratification factor (MMD at baseline).                      RR and RD are calculated directly (without adjustment) and with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-5.2.1 SF-36v2, Quality of Life, Proportion of patients achieving at least a 5 points increase from baseline to week 24, Logistic Regression Model by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
< median age, N	186	190			
≥ median age, N	202	198			
<b>PCS increase of at least 5 pts from BL</b>					
<b>Interaction test: p=0.008</b>					
<b>&lt; median age</b>					
N'	172	180	1.16	1.07	0.03
n (%)	86 (46.2)	82 (43.2)	[0.74; 1.81] 0.528	[0.86; 1.34] 0.548	[-0.07; 0.13] 0.548
<b>≥ median age</b>					
N'	191	175	2.77	1.54	0.17
n (%)	99 (49.0)	63 (31.8)	[1.75; 4.38] <.001	[1.20; 1.97] <.001	[0.08; 0.27] <.001
<b>MCS increase of at least 5 pts from BL</b>					
<b>Interaction test: p=0.410</b>					
<b>&lt; median age</b>					
N'	172	180	1.51	1.27	0.06
n (%)	51 (27.4)	41 (21.6)	[0.89; 2.59] 0.129	[0.89; 1.82] 0.190	[-0.03; 0.15] 0.187
<b>≥ median age</b>					
N'	191	175	2.12	1.92	0.11
n (%)	47 (23.3)	24 (12.1)	[1.17; 3.85] 0.013	[1.22; 3.01] 0.005	[0.04; 0.19] 0.003
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-5.2.2 SF-36v2, Quality of Life, Proportion of patients achieving at least a 5 points increase from baseline to week 24, Logistic Regression Model by Gender (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Male, N	57	53			
Female, N	331	335			
<b>PCS increase of at least 5 pts from BL</b>					
<b>Interaction test: p=0.595</b>					
<b>Male</b>					
N'	52	48	1.42	1.22	0.07
n (%)	21 (36.8)	16 (30.2)	[0.60; 3.39] 0.428	[0.72; 2.08] 0.463	[-0.11; 0.24] 0.459
<b>Female</b>					
N'	311	307	1.83	1.29	0.11
n (%)	164 (49.5)	129 (38.5)	[1.30; 2.58] <.001	[1.08; 1.53] 0.004	[0.04; 0.19] 0.004
<b>MCS increase of at least 5 pts from BL</b>					
<b>Interaction test: p=0.964</b>					
<b>Male</b>					
N'	52	48	1.78	1.21	0.04
n (%)	13 (22.8)	10 (18.9)	[0.62; 5.13] 0.283	[0.58; 2.52] 0.613	[-0.11; 0.19] 0.610
<b>Female</b>					
N'	311	307	1.74	1.56	0.09
n (%)	85 (25.7)	55 (16.4)	[1.13; 2.66] 0.011	[1.15; 2.12] 0.004	[0.03; 0.15] 0.003
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-5.2.3 SF-36v2, Quality of Life, Proportion of patients achieving at least a 5 points increase from baseline to week 24, Logistic Regression Model by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92			
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254			
≥ 15 monthly migraine days at baseline, N	43	42			
<b>PCS increase of at least 5 pts from BL</b>					
<b>Interaction test: p=0.797</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
N'	87	83	2.13	1.31	0.12
n (%)	48 (50.0)	35 (38.0)	[1.12; 4.04] 0.021	[0.95; 1.83] 0.103	[-0.02; 0.26] 0.096
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
N'	237	235	1.65	1.28	0.10
n (%)	120 (48.2)	96 (37.8)	[1.11; 2.44] 0.013	[1.04; 1.56] 0.019	[0.02; 0.19] 0.018
<b>≥ 15 monthly migraine days at baseline</b>					
N'	39	37	1.74	1.19	0.06
n (%)	17 (39.5)	14 (33.3)	[0.65; 4.63] 0.269	[0.67; 2.09] 0.554	[-0.14; 0.27] 0.552
<b>MCS increase of at least 5 pts from BL</b>					
<b>Interaction test: p=0.445</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
N'	87	83	1.68	1.82	0.09
n (%)	19 (19.8)	10 (10.9)	[0.69; 4.05] 0.252	[0.89; 3.70] 0.098	[-0.01; 0.19] 0.086
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
N'	237	235	1.99	1.61	0.10
n (%)	68 (27.3)	43 (16.9)	[1.22; 3.23] 0.005	[1.15; 2.27] 0.006	[0.03; 0.18] 0.005

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>≥ 15 monthly migraine days at baseline</b>					
N <sup>1</sup>	39	37	0.92	0.90	-0.03
n (%)	11 (25.6)	12 (28.6)	[0.31; 2.73] 0.878	[0.45; 1.80] 0.757	[-0.22; 0.16] 0.756
<p>N<sup>1</sup>: Number of patients with available response value  N-N<sup>1</sup> is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.  <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.  The stratification factor is not included in the logistic regression model due to collinearity with the subgroups.</p>					



**Table 14.2-5.2.4 SF-36v2, Quality of Life, Proportion of patients achieving at least a 5 points increase from baseline to week 24, Logistic Regression Model by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Naïve*, N	232	229			
Prior treatment failure*, N	156	159			
<b>PCS increase of at least 5 pts from BL</b>					
<b>Interaction test: p=0.054</b>					
<b>Naïve*</b>					
N'	214	210	1.37	1.12	0.05
n (%)	104 (44.8)	92 (40.2)	[0.91; 2.06] 0.132	[0.90; 1.38] 0.313	[-0.04; 0.14] 0.312
<b>Prior treatment failure*</b>					
N'	149	145	2.58	1.56	0.19
n (%)	81 (51.9)	53 (33.3)	[1.56; 4.26] <.001	[1.19; 2.03] 0.001	[0.08; 0.29] <.001
<b>MCS increase of at least 5 pts from BL</b>					
<b>Interaction test: p=0.244</b>					
<b>Naïve*</b>					
N'	214	210	1.48	1.26	0.05
n (%)	60 (25.9)	47 (20.5)	[0.90; 2.42] 0.120	[0.90; 1.76] 0.177	[-0.02; 0.13] 0.174
<b>Prior treatment failure*</b>					
N'	149	145	2.44	2.15	0.13
n (%)	38 (24.4)	18 (11.3)	[1.23; 4.82] 0.010	[1.29; 3.60] 0.004	[0.05; 0.21] 0.002
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>*: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>					

**Table 14.2-5.2.5 SF-36v2, Quality of Life, Proportion of patients achieving at least a 5 points increase from baseline to week 24, Logistic Regression Model by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1001, N	10	8			
Center No. 1002, N	4	0			
Center No. 1003, N	2	3			
Center No. 1005, N	31	22			
Center No. 1007, N	5	7			
Center No. 1008, N	3	3			
Center No. 1010, N	2	3			
Center No. 1011, N	2	5			
Center No. 1012, N	3	5			
Center No. 1014, N	5	4			
Center No. 1015, N	4	2			
Center No. 1017, N	5	4			
Center No. 1018, N	7	6			
Center No. 1019, N	2	2			
Center No. 1021, N	16	10			
Center No. 1022, N	3	3			
Center No. 1025, N	0	2			
Center No. 1027, N	3	5			
Center No. 1028, N	11	5			
Center No. 1029, N	15	9			
Center No. 1030, N	11	9			
Center No. 1032, N	2	4			
Center No. 1033, N	4	6			
Center No. 1034, N	4	3			
Center No. 1035, N	27	22			
Center No. 1036, N	7	7			
Center No. 1037, N	9	11			
Center No. 1039, N	4	3			
Center No. 1040, N	0	3			
Center No. 1041, N	5	5			
Center No. 1042, N	4	5			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1044, N	0	2			
Center No. 1046, N	1	1			
Center No. 1048, N	0	3			
Center No. 1049, N	1	0			
Center No. 1050, N	6	9			
Center No. 1051, N	1	1			
Center No. 1052, N	7	4			
Center No. 1055, N	2	4			
Center No. 1058, N	0	1			
Center No. 1059, N	7	7			
Center No. 1061, N	9	6			
Center No. 1063, N	4	2			
Center No. 1064, N	0	3			
Center No. 1067, N	10	16			
Center No. 1068, N	0	2			
Center No. 1069, N	3	4			
Center No. 1070, N	1	5			
Center No. 1072, N	2	1			
Center No. 1073, N	11	7			
Center No. 1074, N	5	3			
Center No. 1076, N	1	5			
Center No. 1077, N	3	2			
Center No. 1079, N	4	3			
Center No. 1080, N	3	1			
Center No. 1082, N	5	8			
Center No. 1084, N	2	3			
Center No. 1085, N	0	3			
Center No. 1086, N	6	9			
Center No. 1087, N	1	4			
Center No. 1088, N	6	6			
Center No. 1089, N	4	4			
Center No. 1091, N	6	5			
Center No. 1093, N	1	4			
Center No. 1095, N	5	3			
Center No. 1096, N	2	0			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1100, N	1	4			
Center No. 1101, N	4	6			
Center No. 1103, N	2	3			
Center No. 1105, N	3	3			
Center No. 1108, N	15	10			
Center No. 1110, N	6	5			
Center No. 1111, N	5	0			
Center No. 1113, N	3	3			
Center No. 1115, N	5	6			
Center No. 1116, N	1	4			
Center No. 1118, N	3	2			
Center No. 1119, N	3	5			
Center No. 1121, N	4	4			
Center No. 1123, N	1	1			
Center No. 1124, N	3	2			
Center No. 1502, N	0	3			
<b>PCS increase of at least 5 pts from BL</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
N'	9	6	2.74	1.20	0.05
n (%)	3 (30.0)	2 (25.0)	[0.15; 51.24] 0.500	[0.26; 5.53] 0.815	[-0.36; 0.46] 0.813
<b>Center No. 1002</b>					
N'	4	0	N.E.	N.E.	N.E.
n (%)	2 (50.0)	0 (0.0)			
<b>Center No. 1003</b>					
N'	2	3	N.E.	1.50	0.33
n (%)	2 (100.0)	2 (66.7)		[0.67; 3.34] 0.321	[-0.20; 0.87] 0.221
<b>Center No. 1005</b>					
N'	28	22	1.70	0.95	-0.02
n (%)	12 (38.7)	9 (40.9)	[0.23; 12.63] 0.604	[0.48; 1.85] 0.872	[-0.29; 0.25] 0.872
<b>Center No. 1007</b>					
N'	4	7	N.E.	0.19	-0.43
n (%)	0 (0.0)	3 (42.9)		[0.01; 3.03] 0.240	[-0.80; -0.06] 0.022

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1008</b>					
N'	2	3	N.E.	0.20	-0.67
n (%)	0 (0.0)	2 (66.7)		[0.01; 2.98] 0.243	[-1.20; -0.13] 0.014
<b>Center No. 1010</b>					
N'	2	2	N.E.	4.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.24; 67.72] 0.337	[-0.19; 1.19] 0.157
<b>Center No. 1011</b>					
N'	2	5	3.78	2.50	0.30
n (%)	1 (50.0)	1 (20.0)	[0.11; >99.99] 0.464†	[0.27; 23.36] 0.422	[-0.48; 1.08] 0.449
<b>Center No. 1012</b>					
N'	3	4	>99.99	3.33	0.47
n (%)	2 (66.7)	1 (20.0)	[<0.01; >99.99] 0.484†	[0.49; 22.90] 0.221	[-0.17; 1.11] 0.152
<b>Center No. 1014</b>					
N'	5	4	0.75	0.80	-0.05
n (%)	1 (20.0)	1 (25.0)	[0.03; 17.51] 0.858‡	[0.07; 9.18] 0.858	[-0.60; 0.50] 0.859
<b>Center No. 1015</b>					
N'	4	2	3.53	1.50	0.25
n (%)	3 (75.0)	1 (50.0)	[0.05; >99.99] 0.562†	[0.34; 6.70] 0.596	[-0.56; 1.06] 0.546
<b>Center No. 1017</b>					
N'	5	4	0.67	0.80	-0.10
n (%)	2 (40.0)	2 (50.0)	[0.05; 9.47] 0.765‡	[0.19; 3.42] 0.764	[-0.75; 0.55] 0.764
<b>Center No. 1018</b>					
N'	7	5	30.74	5.14	0.69
n (%)	6 (85.7)	1 (16.7)	[1.40; >99.99] 0.030†	[0.84; 31.57] 0.077	[0.30; 1.09] <.001
<b>Center No. 1019</b>					
N'	2	2	N.E.	3.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.19; 47.96] 0.437	[-0.19; 1.19] 0.157
<b>Center No. 1021</b>					
N'	15	6	6.61	3.44	0.49
n (%)	11 (68.8)	2 (20.0)	[0.87; 50.02] 0.067	[0.95; 12.40] 0.059	[0.15; 0.82] 0.004

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1022</b>					
N'	3	3	0.05	1.00	0.00
n (%)	2 (66.7)	2 (66.7)	[<0.01; 34.08] 0.365†	[0.32; 3.10] 1.000	[-0.75; 0.75] 1.000
<b>Center No. 1025</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (50.0)			
<b>Center No. 1027</b>					
N'	3	4	2.88	0.83	-0.07
n (%)	1 (33.3)	2 (40.0)	[0.04; >99.99] 0.626†	[0.12; 5.72] 0.853	[-0.75; 0.62] 0.849
<b>Center No. 1028</b>					
N'	11	5	10.05	3.18	0.44
n (%)	7 (63.6)	1 (20.0)	[0.59; >99.99] 0.111†	[0.52; 19.42] 0.210	[-0.02; 0.89] 0.058
<b>Center No. 1029</b>					
N'	15	9	7.61	1.50	0.22
n (%)	10 (66.7)	4 (44.4)	[0.57; >99.99] 0.125	[0.67; 3.38] 0.329	[-0.18; 0.63] 0.280
<b>Center No. 1030</b>					
N'	11	8	0.52	0.82	-0.08
n (%)	4 (36.4)	4 (44.4)	[0.07; 3.75] 0.520	[0.28; 2.39] 0.713	[-0.51; 0.35] 0.714
<b>Center No. 1032</b>					
N'	1	3	N.E.	0.56	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.03; 9.73] 0.687	[-0.67; 0.17] 0.248
<b>Center No. 1033</b>					
N'	4	6	2.03	1.50	0.08
n (%)	1 (25.0)	1 (16.7)	[0.08; 53.85] 0.673†	[0.13; 17.67] 0.747	[-0.44; 0.60] 0.753
<b>Center No. 1034</b>					
N'	3	3	0.13	0.38	-0.42
n (%)	1 (25.0)	2 (66.7)	[<0.01; 4.64] 0.263†	[0.06; 2.45] 0.306	[-1.10; 0.26] 0.231
<b>Center No. 1035</b>					
N'	27	22	11.53	3.67	0.48
n (%)	18 (66.7)	4 (18.2)	[2.57; 51.74] 0.001	[1.45; 9.25] 0.006	[0.24; 0.72] <.001

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1036</b>					
N'	7	6	>99.99	2.50	0.43
n (%)	5 (71.4)	2 (28.6)	[0.32; >99.99] 0.109†	[0.71; 8.83] 0.155	[-0.04; 0.90] 0.076
<b>Center No. 1037</b>					
N'	8	10	2.28	1.22	0.06
n (%)	3 (33.3)	3 (27.3)	[0.19; 27.13] 0.514	[0.32; 4.65] 0.768	[-0.34; 0.47] 0.769
<b>Center No. 1039</b>					
N'	4	3	<0.01	0.38	-0.42
n (%)	1 (25.0)	2 (66.7)	[<0.01; >99.99] 0.418†	[0.06; 2.45] 0.306	[-1.10; 0.26] 0.231
<b>Center No. 1040</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1041</b>					
N'	4	5	0.25	0.25	-0.60
n (%)	1 (20.0)	4 (80.0)	[<0.01; 11.43] 0.477	[0.04; 1.52] 0.133	[-1.10; -0.10] 0.018
<b>Center No. 1042</b>					
N'	4	5	0.50	1.25	0.10
n (%)	2 (50.0)	2 (40.0)	[<0.01; 28.91] 0.737†	[0.29; 5.35] 0.764	[-0.55; 0.75] 0.764
<b>Center No. 1044</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1046</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1048</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (66.7)			
<b>Center No. 1049</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1050</b>					
N'	6	9	1.79	1.50	0.17
n (%)	3 (50.0)	3 (33.3)	[0.19; 16.66] 0.610†	[0.44; 5.09] 0.516	[-0.34; 0.67] 0.518

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1051</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1052</b>					
N'	7	4	0.05	0.38	-0.46
n (%)	2 (28.6)	3 (75.0)	[<0.01; 3.18] 0.160†	[0.10; 1.40] 0.146	[-1.00; 0.08] 0.092
<b>Center No. 1055</b>					
N'	2	4	N.E.	N.E.	N.E.
n (%)	2 (100.0)	0 (0.0)			
<b>Center No. 1058</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (100.0)			
<b>Center No. 1059</b>					
N'	6	6	0.62	0.67	-0.14
n (%)	2 (28.6)	3 (42.9)	[<0.01; 55.52] 0.837	[0.16; 2.84] 0.584	[-0.64; 0.35] 0.573
<b>Center No. 1061</b>					
N'	9	6	7.20	1.67	0.22
n (%)	5 (55.6)	2 (33.3)	[0.11; >99.99] 0.350†	[0.47; 5.96] 0.432	[-0.28; 0.72] 0.381
<b>Center No. 1063</b>					
N'	4	2	N.E.	3.00	0.50
n (%)	2 (50.0)	0 (0.0)		[0.21; 43.66] 0.421	[0.01; 0.99] 0.046
<b>Center No. 1064</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (66.7)			
<b>Center No. 1067</b>					
N'	9	16	1.56	1.37	0.16
n (%)	6 (60.0)	7 (43.8)	[0.27; 8.86] 0.616†	[0.65; 2.91] 0.410	[-0.23; 0.55] 0.413
<b>Center No. 1068</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1069</b>					
N'	2	3	1.50	1.33	0.08
n (%)	1 (33.3)	1 (25.0)	[0.06; 40.63] 0.810‡	[0.13; 13.74] 0.809	[-0.60; 0.76] 0.811



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1070</b>					
N'	1	2	N.E.	1.00	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.06; 15.99] 1.000	[-0.55; 0.15] 0.264
<b>Center No. 1072</b>					
N'	2	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1073</b>					
N'	11	6	0.27	0.51	-0.35
n (%)	4 (36.4)	5 (71.4)	[0.03; 2.16] 0.215†	[0.20; 1.27] 0.147	[-0.79; 0.09] 0.118
<b>Center No. 1074</b>					
N'	5	3	N.E.	1.50	0.33
n (%)	5 (100.0)	2 (66.7)		[0.67; 3.34] 0.321	[-0.20; 0.87] 0.221
<b>Center No. 1076</b>					
N'	1	5	N.E.	1.67	0.40
n (%)	1 (100.0)	3 (60.0)		[0.81; 3.41] 0.162	[-0.03; 0.83] 0.068
<b>Center No. 1077</b>					
N'	3	2	N.E.	2.25	0.33
n (%)	1 (33.3)	0 (0.0)		[0.13; 38.09] 0.574	[-0.20; 0.87] 0.221
<b>Center No. 1079</b>					
N'	4	3	1.06	0.75	-0.17
n (%)	2 (50.0)	2 (66.7)	[0.03; 39.10] 0.973†	[0.21; 2.66] 0.656	[-0.89; 0.56] 0.652
<b>Center No. 1080</b>					
N'	3	1	N.E.	1.50	0.33
n (%)	1 (33.3)	0 (0.0)		[0.10; 22.62] 0.770	[-0.20; 0.87] 0.221
<b>Center No. 1082</b>					
N'	4	7	1.17	1.20	0.10
n (%)	3 (60.0)	4 (50.0)	[0.10; 13.19] 0.902†	[0.44; 3.25] 0.720	[-0.45; 0.65] 0.722
<b>Center No. 1084</b>					
N'	2	3	N.E.	3.00	0.67
n (%)	2 (100.0)	1 (33.3)		[0.61; 14.86] 0.178	[0.13; 1.20] 0.014
<b>Center No. 1085</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (33.3)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1086</b>					
N'	6	9	2.92	1.13	0.06
n (%)	3 (50.0)	4 (44.4)	[0.20; 42.72] 0.435	[0.38; 3.32] 0.831	[-0.46; 0.57] 0.833
<b>Center No. 1087</b>					
N'	1	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1088</b>					
N'	6	5	3.51	1.00	0.00
n (%)	1 (16.7)	1 (16.7)	[0.05; >99.99] 0.561†	[0.08; 12.56] 1.000	[-0.42; 0.42] 1.000
<b>Center No. 1089</b>					
N'	4	3	0.63	1.00	0.00
n (%)	2 (50.0)	2 (50.0)	[0.01; 27.46] 0.810†	[0.25; 4.00] 1.000	[-0.69; 0.69] 1.000
<b>Center No. 1091</b>					
N'	5	5	11.60	1.25	0.10
n (%)	3 (50.0)	2 (40.0)	[0.15; >99.99] 0.268†	[0.33; 4.77] 0.744	[-0.49; 0.69] 0.738
<b>Center No. 1093</b>					
N'	1	4	N.E.	0.50	-0.50
n (%)	0 (0.0)	2 (50.0)		[0.04; 6.44] 0.595	[-0.99; -0.01] 0.046
<b>Center No. 1095</b>					
N'	5	3	N.E.	0.22	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.01; 4.20] 0.316	[-0.87; 0.20] 0.221
<b>Center No. 1096</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1100</b>					
N'	1	3	N.E.	1.33	0.25
n (%)	1 (100.0)	3 (75.0)		[0.76; 2.35] 0.319	[-0.17; 0.67] 0.248
<b>Center No. 1101</b>					
N'	4	5	N.E.	0.28	-0.33
n (%)	0 (0.0)	2 (33.3)		[0.02; 4.66] 0.375	[-0.71; 0.04] 0.083
<b>Center No. 1103</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1105</b>					
N'	3	3	1.17	1.00	0.00
n (%)	1 (33.3)	1 (33.3)	[0.02; 62.14] 0.939†	[0.10; 9.61] 1.000	[-0.75; 0.75] 1.000
<b>Center No. 1108</b>					
N'	14	10	1.58	1.11	0.07
n (%)	10 (66.7)	6 (60.0)	[0.19; 12.80] 0.669	[0.60; 2.07] 0.739	[-0.32; 0.45] 0.735
<b>Center No. 1110</b>					
N'	4	4	2.08	1.67	0.27
n (%)	4 (66.7)	2 (40.0)	[0.15; 28.91] 0.586†	[0.50; 5.61] 0.409	[-0.30; 0.84] 0.360
<b>Center No. 1111</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	1 (20.0)	0 (0.0)			
<b>Center No. 1113</b>					
N'	3	3	4.00	2.00	0.33
n (%)	2 (66.7)	1 (33.3)	[0.13; >99.99] 0.424‡	[0.33; 11.97] 0.448	[-0.42; 1.09] 0.386
<b>Center No. 1115</b>					
N'	3	5	0.55	0.90	-0.07
n (%)	3 (60.0)	4 (66.7)	[0.04; 8.48] 0.666†	[0.36; 2.24] 0.821	[-0.64; 0.50] 0.819
<b>Center No. 1116</b>					
N'	1	4	N.E.	0.36	-0.75
n (%)	0 (0.0)	3 (75.0)		[0.03; 4.21] 0.414	[-1.17; -0.33] <.001
<b>Center No. 1118</b>					
N'	2	2	1.58	0.67	-0.17
n (%)	1 (33.3)	1 (50.0)	[<0.01; >99.99] 0.931†	[0.08; 5.54] 0.707	[-1.04; 0.71] 0.709
<b>Center No. 1119</b>					
N'	3	5	1.63	1.11	0.07
n (%)	2 (66.7)	3 (60.0)	[0.06; 46.68] 0.775†	[0.38; 3.25] 0.847	[-0.62; 0.75] 0.849
<b>Center No. 1121</b>					
N'	4	4	N.E.	5.00	0.50
n (%)	2 (50.0)	0 (0.0)		[0.31; 79.94] 0.255	[0.01; 0.99] 0.046
<b>Center No. 1123</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	1 (100.0)	1 (100.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1124</b>					
N'	3	1	>99.99	1.33	0.17
n (%)	2 (66.7)	1 (50.0)	[<0.01; >99.99] 0.554†	[0.27; 6.61] 0.725	[-0.71; 1.04] 0.709
<b>Center No. 1502</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>MCS increase of at least 5 pts from BL</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
N'	9	6	1.48	1.60	0.08
n (%)	2 (20.0)	1 (12.5)	[0.10; 21.45] 0.772‡	[0.17; 14.63] 0.677	[-0.26; 0.41] 0.663
<b>Center No. 1002</b>					
N'	4	0	N.E.	N.E.	N.E.
n (%)	2 (50.0)	0 (0.0)			
<b>Center No. 1003</b>					
N'	2	3	N.E.	0.27	-0.67
n (%)	0 (0.0)	2 (66.7)		[0.02; 3.74] 0.327	[-1.20; -0.13] 0.014
<b>Center No. 1005</b>					
N'	28	22	1.42	1.06	0.02
n (%)	12 (38.7)	8 (36.4)	[0.34; 5.87] 0.630	[0.52; 2.16] 0.863	[-0.24; 0.29] 0.862
<b>Center No. 1007</b>					
N'	4	7	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1008</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	3 (100.0)			
<b>Center No. 1010</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1011</b>					
N'	2	5	1.50	1.25	0.10
n (%)	1 (50.0)	2 (40.0)	[0.06; 40.63] 0.810‡	[0.22; 7.22] 0.803	[-0.72; 0.92] 0.810
<b>Center No. 1012</b>					
N'	3	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1014</b>					
N'	5	4	N.E.	0.28	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.01; 5.43] 0.398	[-0.67; 0.17] 0.248
<b>Center No. 1015</b>					
N'	4	2	N.E.	3.00	0.50
n (%)	2 (50.0)	0 (0.0)		[0.21; 43.66] 0.421	[0.01; 0.99] 0.046
<b>Center No. 1017</b>					
N'	5	4	N.E.	2.50	0.20
n (%)	1 (20.0)	0 (0.0)		[0.13; 48.85] 0.546	[-0.15; 0.55] 0.264
<b>Center No. 1018</b>					
N'	7	5	N.E.	2.63	0.14
n (%)	1 (14.3)	0 (0.0)		[0.13; 54.64] 0.533	[-0.12; 0.40] 0.280
<b>Center No. 1019</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	2 (100.0)	0 (0.0)			
<b>Center No. 1021</b>					
N'	15	6	2.74	3.13	0.21
n (%)	5 (31.3)	1 (10.0)	[0.17; 44.34] 0.477	[0.42; 23.01] 0.263	[-0.08; 0.51] 0.156
<b>Center No. 1022</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1025</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1027</b>					
N'	3	4	N.E.	0.50	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.03; 9.46] 0.644	[-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
N'	11	5	0.97	0.91	-0.02
n (%)	2 (18.2)	1 (20.0)	[0.02; 54.59] 0.990†	[0.11; 7.85] 0.931	[-0.44; 0.40] 0.932
<b>Center No. 1029</b>					
N'	15	9	18.98	1.80	0.09
n (%)	3 (20.0)	1 (11.1)	[0.10; >99.99] 0.274†	[0.22; 14.80] 0.585	[-0.20; 0.38] 0.546

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1030</b>					
N'	11	8	N.E.	4.17	0.18
n (%)	2 (18.2)	0 (0.0)		[0.23; 77.11] 0.338	[-0.05; 0.41] 0.118
<b>Center No. 1032</b>					
N'	1	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1033</b>					
N'	4	6	1.94	1.50	0.08
n (%)	1 (25.0)	1 (16.7)	[0.08; 48.31] 0.687†	[0.13; 17.67] 0.747	[-0.44; 0.60] 0.753
<b>Center No. 1034</b>					
N'	3	3	N.E.	0.27	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.01; 4.94] 0.375	[-0.87; 0.20] 0.221
<b>Center No. 1035</b>					
N'	27	22	2.30	1.43	0.08
n (%)	7 (25.9)	4 (18.2)	[0.41; 13.05] 0.346	[0.48; 4.25] 0.524	[-0.15; 0.31] 0.511
<b>Center No. 1036</b>					
N'	7	6	N.E.	5.00	0.29
n (%)	2 (28.6)	0 (0.0)		[0.28; 88.53] 0.272	[-0.05; 0.62] 0.094
<b>Center No. 1037</b>					
N'	8	10	5.53	2.44	0.26
n (%)	4 (44.4)	2 (18.2)	[0.41; 74.26] 0.197	[0.57; 10.43] 0.227	[-0.13; 0.66] 0.194
<b>Center No. 1039</b>					
N'	4	3	0.67	0.75	-0.08
n (%)	1 (25.0)	1 (33.3)	[0.02; 18.06] 0.810‡	[0.07; 7.73] 0.809	[-0.76; 0.60] 0.811
<b>Center No. 1040</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1041</b>					
N'	4	5	0.22	1.00	0.00
n (%)	1 (20.0)	1 (20.0)	<0.01; 18.13] 0.501†	[0.08; 11.93] 1.000	[-0.50; 0.50] 1.000
<b>Center No. 1042</b>					
N'	4	5	N.E.	3.60	0.25
n (%)	1 (25.0)	0 (0.0)		[0.18; 70.35] 0.398	[-0.17; 0.67] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1044</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1046</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1048</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1049</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1050</b>					
N'	6	9	60.53	1.50	0.06
n (%)	1 (16.7)	1 (11.1)	[<0.01; >99.99] 0.405†	[0.11; 19.64] 0.757	[-0.31; 0.42] 0.764
<b>Center No. 1051</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1052</b>					
N'	7	4	N.E.	1.88	0.14
n (%)	1 (14.3)	0 (0.0)		[0.09; 37.63] 0.681	[-0.12; 0.40] 0.280
<b>Center No. 1055</b>					
N'	2	4	N.E.	5.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.29; 87.55] 0.271	[-0.19; 1.19] 0.157
<b>Center No. 1058</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1059</b>					
N'	6	6	1.33	2.00	0.14
n (%)	2 (28.6)	1 (14.3)	[0.06; 31.86] 0.861	[0.23; 17.34] 0.529	[-0.28; 0.57] 0.508
<b>Center No. 1061</b>					
N'	9	6	5.46	4.00	0.50
n (%)	6 (66.7)	1 (16.7)	[0.34; 86.94] 0.230†	[0.63; 25.39] 0.141	[0.07; 0.93] 0.022

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1063</b>					
N'	4	2	N.E.	1.80	0.25
n (%)	1 (25.0)	0 (0.0)		[0.10; 31.52] 0.687	[-0.17; 0.67] 0.248
<b>Center No. 1064</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1067</b>					
N'	9	16	2.02	1.28	0.09
n (%)	4 (40.0)	5 (31.3)	[0.33; 12.40] 0.446†	[0.45; 3.66] 0.645	[-0.29; 0.47] 0.651
<b>Center No. 1068</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	2 (100.0)			
<b>Center No. 1069</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1070</b>					
N'	1	2	N.E.	1.00	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.06; 15.99] 1.000	[-0.55; 0.15] 0.264
<b>Center No. 1072</b>					
N'	2	1	N.E.	0.50	-0.50
n (%)	1 (50.0)	1 (100.0)		[0.13; 2.00] 0.327	[-1.19; 0.19] 0.157
<b>Center No. 1073</b>					
N'	11	6	0.37	0.64	-0.10
n (%)	2 (18.2)	2 (28.6)	[0.03; 4.99] 0.453†	[0.11; 3.54] 0.606	[-0.51; 0.30] 0.615
<b>Center No. 1074</b>					
N'	5	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1076</b>					
N'	1	5	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1077</b>					
N'	3	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1079</b>					
N'	4	3	N.E.	4.00	0.50
n (%)	2 (50.0)	0 (0.0)		[0.26; 61.76] 0.321	[0.01; 0.99] 0.046
<b>Center No. 1080</b>					
N'	3	1	N.E.	1.50	0.33
n (%)	1 (33.3)	0 (0.0)		[0.10; 22.62] 0.770	[-0.20; 0.87] 0.221
<b>Center No. 1082</b>					
N'	4	7	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1084</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1085</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1086</b>					
N'	6	9	0.08	0.75	-0.06
n (%)	1 (16.7)	2 (22.2)	[<0.01; 16.17] 0.356†	[0.09; 6.55] 0.795	[-0.46; 0.35] 0.787
<b>Center No. 1087</b>					
N'	1	4	N.E.	4.00	0.75
n (%)	1 (100.0)	1 (25.0)		[0.73; 21.84] 0.109	[0.33; 1.17] <.001
<b>Center No. 1088</b>					
N'	6	5	0.11	0.50	-0.17
n (%)	1 (16.7)	2 (33.3)	[<0.01; 7.40] 0.306†	[0.06; 4.15] 0.521	[-0.65; 0.31] 0.497
<b>Center No. 1089</b>					
N'	4	3	<0.01	1.00	0.00
n (%)	1 (25.0)	1 (25.0)	[<0.01; >99.99] 0.428†	[0.09; 11.03] 1.000	[-0.60; 0.60] 1.000
<b>Center No. 1091</b>					
N'	5	5	N.E.	2.57	0.17
n (%)	1 (16.7)	0 (0.0)		[0.13; 52.13] 0.538	[-0.13; 0.46] 0.273
<b>Center No. 1093</b>					
N'	1	4	N.E.	1.33	0.25
n (%)	1 (100.0)	3 (75.0)		[0.76; 2.35] 0.319	[-0.17; 0.67] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1095</b>					
N'	5	3	0.60	0.60	-0.13
n (%)	1 (20.0)	1 (33.3)	[0.01; 24.89] 0.786†	[0.06; 6.44] 0.673	[-0.77; 0.51] 0.682
<b>Center No. 1096</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	1 (50.0)	0 (0.0)			
<b>Center No. 1100</b>					
N'	1	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1101</b>					
N'	4	5	2.00	1.50	0.17
n (%)	2 (50.0)	2 (33.3)	[0.15; 26.73] 0.600‡	[0.34; 6.70] 0.596	[-0.45; 0.79] 0.597
<b>Center No. 1103</b>					
N'	2	3	N.E.	4.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.24; 67.72] 0.337	[-0.19; 1.19] 0.157
<b>Center No. 1105</b>					
N'	3	3	N.E.	3.00	0.33
n (%)	1 (33.3)	0 (0.0)		[0.17; 53.71] 0.455	[-0.20; 0.87] 0.221
<b>Center No. 1108</b>					
N'	14	10	0.72	0.67	-0.07
n (%)	2 (13.3)	2 (20.0)	[0.06; 8.17] 0.789†	[0.11; 3.99] 0.657	[-0.37; 0.24] 0.665
<b>Center No. 1110</b>					
N'	4	4	N.E.	2.57	0.17
n (%)	1 (16.7)	0 (0.0)		[0.13; 52.13] 0.538	[-0.13; 0.46] 0.273
<b>Center No. 1111</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1113</b>					
N'	3	3	N.E.	3.00	0.33
n (%)	1 (33.3)	0 (0.0)		[0.17; 53.71] 0.455	[-0.20; 0.87] 0.221
<b>Center No. 1115</b>					
N'	3	5	1.30	1.20	0.03
n (%)	1 (20.0)	1 (16.7)	[0.05; 34.12] 0.875†	[0.10; 14.69] 0.887	[-0.43; 0.49] 0.887

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1116</b>					
N'	1	4	N.E.	0.83	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.05; 13.02] 0.897	[-0.67; 0.17] 0.248
<b>Center No. 1118</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1119</b>					
N'	3	5	3.00	1.67	0.27
n (%)	2 (66.7)	2 (40.0)	[0.15; 59.88] 0.472‡	[0.44; 6.36] 0.455	[-0.42; 0.95] 0.445
<b>Center No. 1121</b>					
N'	4	4	1.32	1.00	0.00
n (%)	1 (25.0)	1 (25.0)	[0.05; 37.57] 0.870†	[0.09; 11.03] 1.000	[-0.60; 0.60] 1.000
<b>Center No. 1123</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (100.0)			
<b>Center No. 1124</b>					
N'	3	1	N.E.	3.75	0.67
n (%)	2 (66.7)	0 (0.0)		[0.27; 52.64] 0.327	[0.13; 1.20] 0.014
<b>Center No. 1502</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      N.E.: Not estimable                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup that include treatment group, baseline value and stratification factor (MMD at baseline).                      † The stratification factor is excluded from the model due to non-convergence of the full model.                      ‡ The stratification factor and baseline value are excluded from the model due to non-convergence of the full model.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.                      RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p>					

**Table 14.2-5.3 SF-36v2, Quality of Life, Proportion of patients achieving at least a 9.4/9.6 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>PCS increase of at least 9.4 pts from BL</b>					
N'	363	355	1.50	1.21	0.04
n (%)	93 (24.0)	77 (19.8)	[1.02; 2.21] 0.042	[0.92; 1.58] 0.166	[-0.02; 0.10] 0.164
<b>MCS increase of at least 9.6 pts from BL</b>					
N'	363	355	1.49	1.45	0.04
n (%)	45 (11.6)	31 (8.0)	[0.85; 2.62] 0.165	[0.94; 2.24] 0.093	[-0.01; 0.08] 0.090
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>OR is obtained from a logistic regression model that includes treatment group, baseline value and stratification factor (MMD at baseline).                      RR and RD are calculated directly (without adjustment) and with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-5.3.1 SF-36v2, Quality of Life, Proportion of patients achieving at least a 9.4/9.6 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
< median age, N	186	190			
≥ median age, N	202	198			
<b>PCS increase of at least 9.4 pts from BL</b>					
<b>Interaction test: p=0.240</b>					
<b>&lt; median age</b>					
N'	172	180	1.20	1.12	0.03
n (%)	46 (24.7)	42 (22.1)	[0.70; 2.05] 0.515	[0.78; 1.61] 0.548	[-0.06; 0.11] 0.548
<b>≥ median age</b>					
N'	191	175	1.91	1.32	0.06
n (%)	47 (23.3)	35 (17.7)	[1.08; 3.36] 0.025	[0.89; 1.95] 0.169	[-0.02; 0.13] 0.165
<b>MCS increase of at least 9.6 pts from BL</b>					
<b>Interaction test: p=0.173</b>					
<b>&lt; median age</b>					
N'	172	180	1.03	1.02	0.00
n (%)	20 (10.8)	20 (10.5)	[0.48; 2.23] 0.938	[0.57; 1.84] 0.943	[-0.06; 0.06] 0.943
<b>≥ median age</b>					
N'	191	175	2.29	2.23	0.07
n (%)	25 (12.4)	11 (5.6)	[0.98; 5.36] 0.056	[1.13; 4.40] 0.021	[0.01; 0.12] 0.016
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-5.3.2 SF-36v2, Quality of Life, Proportion of patients achieving at least a 9.4/9.6 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Gender (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Male, N	57	53			
Female, N	331	335			
<b>PCS increase of at least 9.4 pts from BL</b>					
<b>Interaction test: p=0.091</b>					
<b>Male</b>					
N'	52	48	0.62	0.76	-0.05
n (%)	9 (15.8)	11 (20.8)	[0.21; 1.85] 0.389	[0.34; 1.69] 0.502	[-0.19; 0.09] 0.501
<b>Female</b>					
N'	311	307	1.70	1.29	0.06
n (%)	84 (25.4)	66 (19.7)	[1.12; 2.58] 0.013	[0.97; 1.71] 0.081	[-0.01; 0.12] 0.079
<b>MCS increase of at least 9.6 pts from BL</b>					
<b>Interaction test: p=0.525</b>					
<b>Male</b>					
N'	52	48	2.41	1.39	0.03
n (%)	6 (10.5)	4 (7.5)	[0.49; 11.95] 0.280	[0.42; 4.67] 0.590	[-0.08; 0.14] 0.585
<b>Female</b>					
N'	311	307	1.39	1.46	0.04
n (%)	39 (11.8)	27 (8.1)	[0.76; 2.53] 0.286	[0.92; 2.33] 0.111	[-0.01; 0.08] 0.108
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-5.3.3 SF-36v2, Quality of Life, Proportion of patients achieving at least a 9.4/9.6 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92			
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254			
≥ 15 monthly migraine days at baseline, N	43	42			
<b>PCS increase of at least 9.4 pts from BL</b>					
<b>Interaction test: p=0.363</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
N'	87	83	1.08	0.91	-0.02
n (%)	18 (18.8)	19 (20.7)	[0.48; 2.42] 0.850	[0.51; 1.62] 0.743	[-0.13; 0.09] 0.743
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
N'	237	235	1.49	1.26	0.05
n (%)	64 (25.7)	52 (20.5)	[0.93; 2.39] 0.100	[0.91; 1.73] 0.165	[-0.02; 0.13] 0.163
<b>≥ 15 monthly migraine days at baseline</b>					
N'	39	37	3.15	1.79	0.11
n (%)	11 (25.6)	6 (14.3)	[0.92; 10.85] 0.068	[0.73; 4.40] 0.204	[-0.05; 0.28] 0.187
<b>MCS increase of at least 9.6 pts from BL</b>					
<b>Interaction test: p=0.485</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
N'	87	83	1.64	2.40	0.03
n (%)	5 (5.2)	2 (2.2)	[0.29; 9.32] 0.577	[0.48; 12.04] 0.289	[-0.02; 0.08] 0.266
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
N'	237	235	1.77	1.62	0.05
n (%)	35 (14.1)	22 (8.7)	[0.91; 3.45] 0.093	[0.98; 2.69] 0.060	[-0.00; 0.11] 0.056

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>≥ 15 monthly migraine days at baseline</b>					
N <sup>1</sup>	39	37	0.68	0.70	-0.05
n (%)	5 (11.6)	7 (16.7)	[0.16; 2.81] 0.591	[0.24; 2.03] 0.508	[-0.20; 0.10] 0.504
<p>N<sup>1</sup>: Number of patients with available response value  N-N<sup>1</sup> is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.  <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.  The stratification factor is not included in the logistic regression model due to collinearity with the subgroups.</p>					



**Table 14.2-5.3.4 SF-36v2, Quality of Life, Proportion of patients achieving at least a 9.4/9.6 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Naïve*, N	232	229			
Prior treatment failure*, N	156	159			
<b>PCS increase of at least 9.4 pts from BL</b>					
<b>Interaction test: p=0.161</b>					
<b>Naïve*</b>					
N'	214	210	1.20	1.02	0.01
n (%)	55 (23.7)	53 (23.1)	[0.74; 1.97] 0.460	[0.74; 1.42] 0.887	[-0.07; 0.08] 0.887
<b>Prior treatment failure*</b>					
N'	149	145	2.14	1.61	0.09
n (%)	38 (24.4)	24 (15.1)	[1.13; 4.05] 0.019	[1.02; 2.56] 0.042	[0.01; 0.18] 0.038
<b>MCS increase of at least 9.6 pts from BL</b>					
<b>Interaction test: p=0.235</b>					
<b>Naïve*</b>					
N'	214	210	1.14	1.08	0.01
n (%)	24 (10.3)	22 (9.6)	[0.56; 2.35] 0.717	[0.62; 1.86] 0.792	[-0.05; 0.06] 0.792
<b>Prior treatment failure*</b>					
N'	149	145	2.33	2.38	0.08
n (%)	21 (13.5)	9 (5.7)	[0.92; 5.90] 0.074	[1.12; 5.03] 0.023	[0.01; 0.14] 0.018
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>*: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>					

**Table 14.2-5.3.5 SF-36v2, Quality of Life, Proportion of patients achieving at least a 9.4/9.6 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1001, N	10	8			
Center No. 1002, N	4	0			
Center No. 1003, N	2	3			
Center No. 1005, N	31	22			
Center No. 1007, N	5	7			
Center No. 1008, N	3	3			
Center No. 1010, N	2	3			
Center No. 1011, N	2	5			
Center No. 1012, N	3	5			
Center No. 1014, N	5	4			
Center No. 1015, N	4	2			
Center No. 1017, N	5	4			
Center No. 1018, N	7	6			
Center No. 1019, N	2	2			
Center No. 1021, N	16	10			
Center No. 1022, N	3	3			
Center No. 1025, N	0	2			
Center No. 1027, N	3	5			
Center No. 1028, N	11	5			
Center No. 1029, N	15	9			
Center No. 1030, N	11	9			
Center No. 1032, N	2	4			
Center No. 1033, N	4	6			
Center No. 1034, N	4	3			
Center No. 1035, N	27	22			
Center No. 1036, N	7	7			
Center No. 1037, N	9	11			
Center No. 1039, N	4	3			
Center No. 1040, N	0	3			
Center No. 1041, N	5	5			
Center No. 1042, N	4	5			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1044, N	0	2			
Center No. 1046, N	1	1			
Center No. 1048, N	0	3			
Center No. 1049, N	1	0			
Center No. 1050, N	6	9			
Center No. 1051, N	1	1			
Center No. 1052, N	7	4			
Center No. 1055, N	2	4			
Center No. 1058, N	0	1			
Center No. 1059, N	7	7			
Center No. 1061, N	9	6			
Center No. 1063, N	4	2			
Center No. 1064, N	0	3			
Center No. 1067, N	10	16			
Center No. 1068, N	0	2			
Center No. 1069, N	3	4			
Center No. 1070, N	1	5			
Center No. 1072, N	2	1			
Center No. 1073, N	11	7			
Center No. 1074, N	5	3			
Center No. 1076, N	1	5			
Center No. 1077, N	3	2			
Center No. 1079, N	4	3			
Center No. 1080, N	3	1			
Center No. 1082, N	5	8			
Center No. 1084, N	2	3			
Center No. 1085, N	0	3			
Center No. 1086, N	6	9			
Center No. 1087, N	1	4			
Center No. 1088, N	6	6			
Center No. 1089, N	4	4			
Center No. 1091, N	6	5			
Center No. 1093, N	1	4			
Center No. 1095, N	5	3			
Center No. 1096, N	2	0			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1100, N	1	4			
Center No. 1101, N	4	6			
Center No. 1103, N	2	3			
Center No. 1105, N	3	3			
Center No. 1108, N	15	10			
Center No. 1110, N	6	5			
Center No. 1111, N	5	0			
Center No. 1113, N	3	3			
Center No. 1115, N	5	6			
Center No. 1116, N	1	4			
Center No. 1118, N	3	2			
Center No. 1119, N	3	5			
Center No. 1121, N	4	4			
Center No. 1123, N	1	1			
Center No. 1124, N	3	2			
Center No. 1502, N	0	3			
<b>PCS increase of at least 9.4 pts from BL</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
N'	9	6	1.35	0.80	-0.05
n (%)	2 (20.0)	2 (25.0)	[0.09; 20.90] 0.829	[0.14; 4.49] 0.800	[-0.44; 0.34] 0.801
<b>Center No. 1002</b>					
N'	4	0	N.E.	N.E.	N.E.
n (%)	2 (50.0)	0 (0.0)			
<b>Center No. 1003</b>					
N'	2	3	0.50	0.75	-0.17
n (%)	1 (50.0)	2 (66.7)	[0.01; 19.56] 0.711‡	[0.15; 3.72] 0.725	[-1.04; 0.71] 0.709
<b>Center No. 1005</b>					
N'	28	22	1.69	1.06	0.02
n (%)	9 (29.0)	6 (27.3)	[0.34; 8.40] 0.521	[0.44; 2.56] 0.889	[-0.23; 0.26] 0.888
<b>Center No. 1007</b>					
N'	4	7	N.E.	0.27	-0.29
n (%)	0 (0.0)	2 (28.6)		[0.02; 4.59] 0.363	[-0.62; 0.05] 0.094

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1008</b>					
N'	2	3	N.E.	0.20	-0.67
n (%)	0 (0.0)	2 (66.7)		[0.01; 2.98] 0.243	[-1.20; -0.13] 0.014
<b>Center No. 1010</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1011</b>					
N'	2	5	N.E.	0.67	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.04; 11.94] 0.783	[-0.55; 0.15] 0.264
<b>Center No. 1012</b>					
N'	3	4	N.E.	0.50	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.03; 9.46] 0.644	[-0.55; 0.15] 0.264
<b>Center No. 1014</b>					
N'	5	4	N.E.	0.28	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.01; 5.43] 0.398	[-0.67; 0.17] 0.248
<b>Center No. 1015</b>					
N'	4	2	0.33	0.50	-0.25
n (%)	1 (25.0)	1 (50.0)	[<0.01; 11.94] 0.547‡	[0.06; 4.47] 0.535	[-1.06; 0.56] 0.546
<b>Center No. 1017</b>					
N'	5	4	0.67	0.80	-0.10
n (%)	2 (40.0)	2 (50.0)	[0.05; 9.47] 0.765‡	[0.19; 3.42] 0.764	[-0.75; 0.55] 0.764
<b>Center No. 1018</b>					
N'	7	5	4.29	2.57	0.26
n (%)	3 (42.9)	1 (16.7)	[0.24; 77.44] 0.324†	[0.35; 18.68] 0.351	[-0.21; 0.73] 0.277
<b>Center No. 1019</b>					
N'	2	2	N.E.	3.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.19; 47.96] 0.437	[-0.19; 1.19] 0.157
<b>Center No. 1021</b>					
N'	15	6	1.85	2.50	0.15
n (%)	4 (25.0)	1 (10.0)	[0.14; 23.64] 0.636	[0.32; 19.30] 0.380	[-0.13; 0.43] 0.297

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1022</b>					
N'	3	3	N.E.	3.00	0.33
n (%)	1 (33.3)	0 (0.0)		[0.17; 53.71] 0.455	[-0.20; 0.87] 0.221
<b>Center No. 1025</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1027</b>					
N'	3	4	N.E.	0.30	-0.40
n (%)	0 (0.0)	2 (40.0)		[0.02; 4.74] 0.393	[-0.83; 0.03] 0.068
<b>Center No. 1028</b>					
N'	11	5	N.E.	1.50	0.09
n (%)	1 (9.1)	0 (0.0)		[0.07; 31.58] 0.794	[-0.08; 0.26] 0.294
<b>Center No. 1029</b>					
N'	15	9	7.70	1.50	0.11
n (%)	5 (33.3)	2 (22.2)	[0.38; >99.99] 0.183	[0.36; 6.18] 0.575	[-0.25; 0.47] 0.547
<b>Center No. 1030</b>					
N'	11	8	1.43	1.64	0.07
n (%)	2 (18.2)	1 (11.1)	[0.08; 25.86] 0.809†	[0.18; 15.26] 0.666	[-0.24; 0.38] 0.651
<b>Center No. 1032</b>					
N'	1	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1033</b>					
N'	4	6	N.E.	0.47	-0.17
n (%)	0 (0.0)	1 (16.7)		[0.02; 9.26] 0.617	[-0.46; 0.13] 0.273
<b>Center No. 1034</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1035</b>					
N'	27	22	13.11	8.15	0.32
n (%)	10 (37.0)	1 (4.5)	[1.39; >99.99] 0.025†	[1.13; 58.84] 0.038	[0.12; 0.53] 0.002
<b>Center No. 1036</b>					
N'	7	6	0.39	0.50	-0.14
n (%)	1 (14.3)	2 (28.6)	[0.01; 10.82] 0.581†	[0.06; 4.33] 0.529	[-0.57; 0.28] 0.508

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1037</b>					
N'	8	10	3.22	2.44	0.13
n (%)	2 (22.2)	1 (9.1)	[0.21; 48.66] 0.399†	[0.26; 22.80] 0.433	[-0.19; 0.45] 0.422
<b>Center No. 1039</b>					
N'	4	3	N.E.	2.40	0.25
n (%)	1 (25.0)	0 (0.0)		[0.13; 44.42] 0.557	[-0.17; 0.67] 0.248
<b>Center No. 1040</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1041</b>					
N'	4	5	>99.99	1.00	0.00
n (%)	1 (20.0)	1 (20.0)	[0.04; >99.99] 0.235†	[0.08; 11.93] 1.000	[-0.50; 0.50] 1.000
<b>Center No. 1042</b>					
N'	4	5	4.00	2.50	0.30
n (%)	2 (50.0)	1 (20.0)	[0.21; 75.66] 0.355‡	[0.34; 18.63] 0.371	[-0.30; 0.90] 0.329
<b>Center No. 1044</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1046</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1048</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (33.3)			
<b>Center No. 1049</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1050</b>					
N'	6	9	4.07	3.00	0.22
n (%)	2 (33.3)	1 (11.1)	[0.17; 95.59] 0.383†	[0.34; 26.19] 0.320	[-0.21; 0.65] 0.310
<b>Center No. 1051</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1052</b>					
N'	7	4	0.16	0.57	-0.11
n (%)	1 (14.3)	1 (25.0)	<0.01; 16.13 0.436†	[0.05; 6.86] 0.659	[-0.60; 0.39] 0.673
<b>Center No. 1055</b>					
N'	2	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1058</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1059</b>					
N'	6	6	0.85	0.50	-0.14
n (%)	1 (14.3)	2 (28.6)	[0.02; 33.13] 0.928	[0.06; 4.33] 0.529	[-0.57; 0.28] 0.508
<b>Center No. 1061</b>					
N'	9	6	1.57	1.33	0.11
n (%)	4 (44.4)	2 (33.3)	[0.05; 48.90] 0.797†	[0.35; 5.13] 0.675	[-0.39; 0.61] 0.662
<b>Center No. 1063</b>					
N'	4	2	N.E.	1.80	0.25
n (%)	1 (25.0)	0 (0.0)		[0.10; 31.52] 0.687	[-0.17; 0.67] 0.248
<b>Center No. 1064</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1067</b>					
N'	9	16	0.12	1.07	0.03
n (%)	4 (40.0)	6 (37.5)	<0.01; 4.23 0.242†	[0.40; 2.87] 0.898	[-0.36; 0.41] 0.899
<b>Center No. 1068</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1069</b>					
N'	2	3	1.50	1.33	0.08
n (%)	1 (33.3)	1 (25.0)	[0.06; 40.63] 0.810‡	[0.13; 13.74] 0.809	[-0.60; 0.76] 0.811
<b>Center No. 1070</b>					
N'	1	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1072</b>					
N'	2	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1073</b>					
N'	11	6	0.80	0.64	-0.05
n (%)	1 (9.1)	1 (14.3)	[0.03; 18.83] 0.892†	[0.05; 8.61] 0.734	[-0.36; 0.26] 0.743
<b>Center No. 1074</b>					
N'	5	3	0.15	1.20	0.07
n (%)	2 (40.0)	1 (33.3)	<0.01; 78.37] 0.552	[0.17; 8.24] 0.853	[-0.62; 0.75] 0.849
<b>Center No. 1076</b>					
N'	1	5	N.E.	0.60	-0.40
n (%)	0 (0.0)	2 (40.0)		[0.05; 7.92] 0.698	[-0.83; 0.03] 0.068
<b>Center No. 1077</b>					
N'	3	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1079</b>					
N'	4	3	1.06	0.75	-0.17
n (%)	2 (50.0)	2 (66.7)	[0.03; 39.10] 0.973†	[0.21; 2.66] 0.656	[-0.89; 0.56] 0.652
<b>Center No. 1080</b>					
N'	3	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1082</b>					
N'	4	7	8.42	4.80	0.48
n (%)	3 (60.0)	1 (12.5)	[0.49; >99.99] 0.143†	[0.67; 34.36] 0.118	[-0.01; 0.96] 0.056
<b>Center No. 1084</b>					
N'	2	3	N.E.	4.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.24; 67.72] 0.337	[-0.19; 1.19] 0.157
<b>Center No. 1085</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1086</b>					
N'	6	9	1.37	1.00	0.00
n (%)	2 (33.3)	3 (33.3)	[0.12; 16.19] 0.803	[0.23; 4.31] 1.000	[-0.49; 0.49] 1.000

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1087</b>					
N'	1	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1088</b>					
N'	6	5	N.E.	0.33	-0.17
n (%)	0 (0.0)	1 (16.7)		[0.02; 6.86] 0.476	[-0.46; 0.13] 0.273
<b>Center No. 1089</b>					
N'	4	3	N.E.	0.33	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.02; 6.37] 0.466	[-0.67; 0.17] 0.248
<b>Center No. 1091</b>					
N'	5	5	2.03	0.83	-0.03
n (%)	1 (16.7)	1 (20.0)	[0.01; >99.99] 0.783	[0.07; 10.20] 0.887	[-0.49; 0.43] 0.887
<b>Center No. 1093</b>					
N'	1	4	N.E.	0.83	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.05; 13.02] 0.897	[-0.67; 0.17] 0.248
<b>Center No. 1095</b>					
N'	5	3	N.E.	0.22	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.01; 4.20] 0.316	[-0.87; 0.20] 0.221
<b>Center No. 1096</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1100</b>					
N'	1	3	N.E.	4.00	0.75
n (%)	1 (100.0)	1 (25.0)		[0.73; 21.84] 0.109	[0.33; 1.17] <.001
<b>Center No. 1101</b>					
N'	4	5	N.E.	0.47	-0.17
n (%)	0 (0.0)	1 (16.7)		[0.02; 9.26] 0.617	[-0.46; 0.13] 0.273
<b>Center No. 1103</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1105</b>					
N'	3	3	N.E.	0.33	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.02; 5.97] 0.455	[-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1108</b>					
N'	14	10	1.10	0.83	-0.07
n (%)	5 (33.3)	4 (40.0)	[0.13; 9.53] 0.928	[0.29; 2.37] 0.732	[-0.45; 0.32] 0.735
<b>Center No. 1110</b>					
N'	4	4	1.51	1.67	0.13
n (%)	2 (33.3)	1 (20.0)	[0.08; 29.26] 0.785†	[0.21; 13.43] 0.631	[-0.38; 0.65] 0.612
<b>Center No. 1111</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1113</b>					
N'	3	3	1.00	1.00	0.00
n (%)	1 (33.3)	1 (33.3)	[0.03; 29.81] 1.000‡	[0.10; 9.61] 1.000	[-0.75; 0.75] 1.000
<b>Center No. 1115</b>					
N'	3	5	0.50	0.60	-0.13
n (%)	1 (20.0)	2 (33.3)	[0.03; 7.99] 0.624‡	[0.07; 4.83] 0.631	[-0.65; 0.38] 0.612
<b>Center No. 1116</b>					
N'	1	4	N.E.	0.50	-0.50
n (%)	0 (0.0)	2 (50.0)		[0.04; 6.44] 0.595	[-0.99; -0.01] 0.046
<b>Center No. 1118</b>					
N'	2	2	N.E.	0.25	-0.50
n (%)	0 (0.0)	1 (50.0)		[0.01; 4.23] 0.337	[-1.19; 0.19] 0.157
<b>Center No. 1119</b>					
N'	3	5	N.E.	4.50	0.33
n (%)	1 (33.3)	0 (0.0)		[0.24; 85.12] 0.316	[-0.20; 0.87] 0.221
<b>Center No. 1121</b>					
N'	4	4	N.E.	3.00	0.25
n (%)	1 (25.0)	0 (0.0)		[0.16; 57.37] 0.466	[-0.17; 0.67] 0.248
<b>Center No. 1123</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1124</b>					
N'	3	1	N.E.	3.75	0.67
n (%)	2 (66.7)	0 (0.0)		[0.27; 52.64] 0.327	[0.13; 1.20] 0.014

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1502</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>MCS increase of at least 9.6 pts from BL</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
N'	9	6	N.E.	0.27	-0.13
n (%)	0 (0.0)	1 (12.5)		[0.01; 5.92] 0.408	[-0.35; 0.10] 0.285
<b>Center No. 1002</b>					
N'	4	0	N.E.	N.E.	N.E.
n (%)	1 (25.0)	0 (0.0)			
<b>Center No. 1003</b>					
N'	2	3	N.E.	0.44	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.03; 7.52] 0.574	[-0.87; 0.20] 0.221
<b>Center No. 1005</b>					
N'	28	22	0.60	0.59	-0.11
n (%)	5 (16.1)	6 (27.3)	[0.12; 3.04] 0.538	[0.21; 1.70] 0.328	[-0.34; 0.12] 0.335
<b>Center No. 1007</b>					
N'	4	7	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1008</b>					
N'	2	3	N.E.	0.20	-0.67
n (%)	0 (0.0)	2 (66.7)		[0.01; 2.98] 0.243	[-1.20; -0.13] 0.014
<b>Center No. 1010</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1011</b>					
N'	2	5	1.50	1.25	0.10
n (%)	1 (50.0)	2 (40.0)	[0.06; 40.63] 0.810 <sup>‡</sup>	[0.22; 7.22] 0.803	[-0.72; 0.92] 0.810
<b>Center No. 1012</b>					
N'	3	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1014</b>					
N'	5	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1015</b>					
N'	4	2	N.E.	3.00	0.50
n (%)	2 (50.0)	0 (0.0)		[0.21; 43.66] 0.421	[0.01; 0.99] 0.046
<b>Center No. 1017</b>					
N'	5	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1018</b>					
N'	7	5	N.E.	2.63	0.14
n (%)	1 (14.3)	0 (0.0)		[0.13; 54.64] 0.533	[-0.12; 0.40] 0.280
<b>Center No. 1019</b>					
N'	2	2	N.E.	3.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.19; 47.96] 0.437	[-0.19; 1.19] 0.157
<b>Center No. 1021</b>					
N'	15	6	0.45	1.25	0.03
n (%)	2 (12.5)	1 (10.0)	[0.02; 10.98] 0.628†	[0.13; 12.06] 0.847	[-0.22; 0.27] 0.843
<b>Center No. 1022</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1025</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1027</b>					
N'	3	4	N.E.	0.50	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.03; 9.46] 0.644	[-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
N'	11	5	N.E.	1.50	0.09
n (%)	1 (9.1)	0 (0.0)		[0.07; 31.58] 0.794	[-0.08; 0.26] 0.294
<b>Center No. 1029</b>					
N'	15	9	N.E.	1.88	0.07
n (%)	1 (6.7)	0 (0.0)		[0.08; 41.69] 0.691	[-0.06; 0.19] 0.301
<b>Center No. 1030</b>					
N'	11	8	N.E.	2.50	0.09
n (%)	1 (9.1)	0 (0.0)		[0.11; 54.87] 0.561	[-0.08; 0.26] 0.294

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1032</b>					
N'	1	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1033</b>					
N'	4	6	N.E.	4.20	0.25
n (%)	1 (25.0)	0 (0.0)		[0.21; 83.34] 0.346	[-0.17; 0.67] 0.248
<b>Center No. 1034</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1035</b>					
N'	27	22	5.44	3.26	0.10
n (%)	4 (14.8)	1 (4.5)	[0.37; 80.75] 0.218†	[0.39; 27.09] 0.274	[-0.06; 0.26] 0.208
<b>Center No. 1036</b>					
N'	7	6	N.E.	3.00	0.14
n (%)	1 (14.3)	0 (0.0)		[0.14; 63.15] 0.480	[-0.12; 0.40] 0.280
<b>Center No. 1037</b>					
N'	8	10	0.29	1.22	0.02
n (%)	1 (11.1)	1 (9.1)	<0.01; 46.06] 0.630†	[0.09; 16.93] 0.881	[-0.25; 0.29] 0.882
<b>Center No. 1039</b>					
N'	4	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1040</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1041</b>					
N'	4	5	0.22	1.00	0.00
n (%)	1 (20.0)	1 (20.0)	<0.01; 18.13] 0.501†	[0.08; 11.93] 1.000	[-0.50; 0.50] 1.000
<b>Center No. 1042</b>					
N'	4	5	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1044</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1046</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1048</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1049</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1050</b>					
N'	6	9	N.E.	0.48	-0.11
n (%)	0 (0.0)	1 (11.1)		[0.02; 10.07] 0.634	[-0.32; 0.09] 0.289
<b>Center No. 1051</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1052</b>					
N'	7	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1055</b>					
N'	2	4	N.E.	5.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.29; 87.55] 0.271	[-0.19; 1.19] 0.157
<b>Center No. 1058</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1059</b>					
N'	6	6	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1061</b>					
N'	9	6	N.E.	4.90	0.33
n (%)	3 (33.3)	0 (0.0)		[0.30; 80.69] 0.266	[0.03; 0.64] 0.034
<b>Center No. 1063</b>					
N'	4	2	N.E.	1.80	0.25
n (%)	1 (25.0)	0 (0.0)		[0.10; 31.52] 0.687	[-0.17; 0.67] 0.248
<b>Center No. 1064</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1067</b>					
N'	9	16	3.45	1.60	0.08
n (%)	2 (20.0)	2 (12.5)	[0.25; 46.94] 0.352†	[0.27; 9.62] 0.608	[-0.22; 0.37] 0.620

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1068</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (50.0)			
<b>Center No. 1069</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1070</b>					
N'	1	2	N.E.	1.00	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.06; 15.99] 1.000	[-0.55; 0.15] 0.264
<b>Center No. 1072</b>					
N'	2	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1073</b>					
N'	11	6	0.96	1.27	0.04
n (%)	2 (18.2)	1 (14.3)	[0.05; 16.92] 0.980†	[0.14; 11.55] 0.830	[-0.31; 0.38] 0.825
<b>Center No. 1074</b>					
N'	5	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1076</b>					
N'	1	5	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1077</b>					
N'	3	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1079</b>					
N'	4	3	N.E.	2.40	0.25
n (%)	1 (25.0)	0 (0.0)		[0.13; 44.42] 0.557	[-0.17; 0.67] 0.248
<b>Center No. 1080</b>					
N'	3	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1082</b>					
N'	4	7	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1084</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1085</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1086</b>					
N'	6	9	N.E.	4.29	0.17
n (%)	1 (16.7)	0 (0.0)		[0.20; 90.63] 0.350	[-0.13; 0.46] 0.273
<b>Center No. 1087</b>					
N'	1	4	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1088</b>					
N'	6	5	N.E.	3.00	0.17
n (%)	1 (16.7)	0 (0.0)		[0.15; 61.74] 0.476	[-0.13; 0.46] 0.273
<b>Center No. 1089</b>					
N'	4	3	N.E.	3.00	0.25
n (%)	1 (25.0)	0 (0.0)		[0.16; 57.37] 0.466	[-0.17; 0.67] 0.248
<b>Center No. 1091</b>					
N'	5	5	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1093</b>					
N'	1	4	N.E.	2.00	0.50
n (%)	1 (100.0)	2 (50.0)		[0.75; 5.33] 0.166	[0.01; 0.99] 0.046
<b>Center No. 1095</b>					
N'	5	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1096</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1100</b>					
N'	1	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1101</b>					
N'	4	5	5.00	3.00	0.33
n (%)	2 (50.0)	1 (16.7)	[0.27; 91.52] 0.278‡	[0.39; 23.07] 0.291	[-0.24; 0.91] 0.255

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1103</b>					
N'	2	3	N.E.	4.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.24; 67.72] 0.337	[-0.19; 1.19] 0.157
<b>Center No. 1105</b>					
N'	3	3	N.E.	3.00	0.33
n (%)	1 (33.3)	0 (0.0)		[0.17; 53.71] 0.455	[-0.20; 0.87] 0.221
<b>Center No. 1108</b>					
N'	14	10	N.E.	0.23	-0.10
n (%)	0 (0.0)	1 (10.0)		[0.01; 5.12] 0.353	[-0.29; 0.09] 0.292
<b>Center No. 1110</b>					
N'	4	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1111</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1113</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1115</b>					
N'	3	5	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1116</b>					
N'	1	4	N.E.	0.83	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.05; 13.02] 0.897	[-0.67; 0.17] 0.248
<b>Center No. 1118</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1119</b>					
N'	3	5	3.00	1.67	0.27
n (%)	2 (66.7)	2 (40.0)	[0.15; 59.88] 0.472‡	[0.44; 6.36] 0.455	[-0.42; 0.95] 0.445
<b>Center No. 1121</b>					
N'	4	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1123</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (100.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1124</b>					
N <sup>†</sup>	3	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1502</b>					
N <sup>†</sup>	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<p>N<sup>†</sup>: Number of patients with available response value  N-N<sup>†</sup> is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup that include treatment group, baseline value and stratification factor (MMD at baseline).  † The stratification factor is excluded from the model due to non-convergence of the full model.  ‡ The stratification factor and baseline value are excluded from the model due to non-convergence of the full model.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p>					

**Table 14.2-5.4 SF-36v2, Quality of Life, Proportion of patients achieving at least a 11.2/12.5 points (PCS/MCS) increase from baseline to week 24, Logistic Regression Model (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>PCS increase of at least 11.2 pts from BL</b>					
N'	363	355	1.35	1.12	0.02
n (%)	65 (16.8)	58 (14.9)	[0.87; 2.11] 0.181	[0.81; 1.55] 0.492	[-0.03; 0.07] 0.491
<b>MCS increase of at least 12.5 pts from BL</b>					
N'	363	355	1.76	1.71	0.03
n (%)	29 (7.5)	17 (4.4)	[0.84; 3.69] 0.137	[0.95; 3.05] 0.072	[-0.00; 0.06] 0.068
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>OR is obtained from a logistic regression model that includes treatment group, baseline value and stratification factor (MMD at baseline).                      RR and RD are calculated directly (without adjustment) and with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-5.4.1 SF-36v2, Quality of Life, Proportion of patients achieving at least a 11.2/12.5 points(PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
< median age, N	186	190			
≥ median age, N	202	198			
<b>PCS increase of at least 11.2 pts from BL</b>					
<b>Interaction test: p=0.605</b>					
<b>&lt; median age</b>					
N'	172	180	1.21	1.12	0.02
n (%)	34 (18.3)	31 (16.3)	[0.66; 2.22] 0.544	[0.72; 1.74] 0.615	[-0.06; 0.10] 0.615
<b>≥ median age</b>					
N'	191	175	1.53	1.13	0.02
n (%)	31 (15.3)	27 (13.6)	[0.79; 2.94] 0.205	[0.70; 1.81] 0.628	[-0.05; 0.09] 0.627
<b>MCS increase of at least 12.5 pts from BL</b>					
<b>Interaction test: p=0.489</b>					
<b>&lt; median age</b>					
N'	172	180	1.38	1.21	0.01
n (%)	13 (7.0)	11 (5.8)	[0.51; 3.75] 0.532	[0.56; 2.63] 0.635	[-0.04; 0.06] 0.634
<b>≥ median age</b>					
N'	191	175	2.35	2.61	0.05
n (%)	16 (7.9)	6 (3.0)	[0.75; 7.36] 0.141	[1.04; 6.54] 0.040	[0.00; 0.09] 0.030
<p>N': Number of patients with available response value  N-N' is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-5.4.2 SF-36v2, Quality of Life, Proportion of patients achieving at least a 11.2/12.5 points(PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Gender (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Male, N	57	53			
Female, N	331	335			
<b>PCS increase of at least 11.2 pts from BL</b>					
<b>Interaction test: p=0.013</b>					
<b>Male</b>					
N'	52	48	0.25	0.41	-0.10
n (%)	4 (7.0)	9 (17.0)	[0.06; 1.02] 0.054	[0.14; 1.26] 0.121	[-0.22; 0.02] 0.106
<b>Female</b>					
N'	311	307	1.68	1.26	0.04
n (%)	61 (18.4)	49 (14.6)	[1.04; 2.71] 0.034	[0.89; 1.78] 0.188	[-0.02; 0.09] 0.186
<b>MCS increase of at least 12.5 pts from BL</b>					
<b>Interaction test: p=0.705</b>					
<b>Male</b>					
N'	52	48	2.56	1.39	0.01
n (%)	3 (5.3)	2 (3.8)	[0.28; 23.61] 0.408	[0.24; 8.02] 0.709	[-0.06; 0.09] 0.706
<b>Female</b>					
N'	311	307	1.62	1.75	0.03
n (%)	26 (7.9)	15 (4.5)	[0.74; 3.56] 0.228	[0.95; 3.25] 0.074	[-0.00; 0.07] 0.070
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p>					

**Table 14.2-5.4.3 SF-36v2, Quality of Life, Proportion of patients achieving at least a 11.2/12.5 points(PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92			
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254			
≥ 15 monthly migraine days at baseline, N	43	42			
<b>PCS increase of at least 11.2 pts from BL</b>					
<b>Interaction test: p=0.860</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
N'	87	83	1.23	0.96	-0.01
n (%)	14 (14.6)	14 (15.2)	[0.49; 3.07] 0.663	[0.48; 1.90] 0.903	[-0.11; 0.10] 0.903
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
N'	237	235	1.32	1.15	0.02
n (%)	44 (17.7)	39 (15.4)	[0.76; 2.27] 0.323	[0.78; 1.71] 0.485	[-0.04; 0.09] 0.484
<b>≥ 15 monthly migraine days at baseline</b>					
N'	39	37	1.94	1.37	0.04
n (%)	7 (16.3)	5 (11.9)	[0.47; 7.91] 0.358	[0.47; 3.97] 0.565	[-0.10; 0.19] 0.561
<b>MCS increase of at least 12.5 pts from BL</b>					
<b>Interaction test: p=0.585</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
N'	87	83	1.59	2.88	0.02
n (%)	3 (3.1)	1 (1.1)	[0.15; 17.18] 0.702	[0.30; 27.14] 0.357	[-0.02; 0.06] 0.327
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
N'	237	235	2.17	1.96	0.05
n (%)	23 (9.2)	12 (4.7)	[0.89; 5.28] 0.088	[0.99; 3.84] 0.052	[0.00; 0.09] 0.047

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>≥ 15 monthly migraine days at baseline</b>					
N <sup>1</sup>	39	37	0.76	0.73	-0.03
n (%)	3 (7.0)	4 (9.5)	[0.13; 4.55] 0.760	[0.17; 3.08] 0.671	[-0.14; 0.09] 0.670
<p>N<sup>1</sup>: Number of patients with available response value  N-N<sup>1</sup> is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.  <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.  The stratification factor is not included in the logistic regression model due to collinearity with the subgroups.</p>					



**Table 14.2-5.4.4 SF-36v2, Quality of Life, Proportion of patients achieving at least a 11.2/12.5 points(PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Naïve*, N	232	229			
Prior treatment failure*, N	156	159			
<b>PCS increase of at least 11.2 pts from BL</b>					
<b>Interaction test: p=0.474</b>					
<b>Naïve*</b>					
N'	214	210	1.19	0.99	-0.00
n (%)	39 (16.8)	39 (17.0)	[0.68; 2.11] 0.540	[0.66; 1.48] 0.950	[-0.07; 0.07] 0.950
<b>Prior treatment failure*</b>					
N'	149	145	1.67	1.39	0.05
n (%)	26 (16.7)	19 (11.9)	[0.81; 3.45] 0.164	[0.81; 2.41] 0.235	[-0.03; 0.12] 0.231
<b>MCS increase of at least 12.5 pts from BL</b>					
<b>Interaction test: p=0.808</b>					
<b>Naïve*</b>					
N'	214	210	1.58	1.38	0.02
n (%)	14 (6.0)	10 (4.4)	[0.57; 4.34] 0.376	[0.63; 3.05] 0.423	[-0.02; 0.06] 0.420
<b>Prior treatment failure*</b>					
N'	149	145	1.90	2.18	0.05
n (%)	15 (9.6)	7 (4.4)	[0.63; 5.69] 0.252	[0.92; 5.21] 0.078	[-0.00; 0.11] 0.069
<p>N': Number of patients with available response value                      N-N' is the number of values with non-response imputation.                      n (%): Number and percentage of patients with event                      CI: Confidence Interval                      OR: Odds Ratio                      RR: Relative Risk                      RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.                      RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>*: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>					

**Table 14.2-5.4.5 SF-36v2, Quality of Life, Proportion of patients achieving at least a 11.2/12.5 points(PCS/MCS) increase from baseline to week 24, Logistic Regression Model by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1001, N	10	8			
Center No. 1002, N	4	0			
Center No. 1003, N	2	3			
Center No. 1005, N	31	22			
Center No. 1007, N	5	7			
Center No. 1008, N	3	3			
Center No. 1010, N	2	3			
Center No. 1011, N	2	5			
Center No. 1012, N	3	5			
Center No. 1014, N	5	4			
Center No. 1015, N	4	2			
Center No. 1017, N	5	4			
Center No. 1018, N	7	6			
Center No. 1019, N	2	2			
Center No. 1021, N	16	10			
Center No. 1022, N	3	3			
Center No. 1025, N	0	2			
Center No. 1027, N	3	5			
Center No. 1028, N	11	5			
Center No. 1029, N	15	9			
Center No. 1030, N	11	9			
Center No. 1032, N	2	4			
Center No. 1033, N	4	6			
Center No. 1034, N	4	3			
Center No. 1035, N	27	22			
Center No. 1036, N	7	7			
Center No. 1037, N	9	11			
Center No. 1039, N	4	3			
Center No. 1040, N	0	3			
Center No. 1041, N	5	5			
Center No. 1042, N	4	5			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1044, N	0	2			
Center No. 1046, N	1	1			
Center No. 1048, N	0	3			
Center No. 1049, N	1	0			
Center No. 1050, N	6	9			
Center No. 1051, N	1	1			
Center No. 1052, N	7	4			
Center No. 1055, N	2	4			
Center No. 1058, N	0	1			
Center No. 1059, N	7	7			
Center No. 1061, N	9	6			
Center No. 1063, N	4	2			
Center No. 1064, N	0	3			
Center No. 1067, N	10	16			
Center No. 1068, N	0	2			
Center No. 1069, N	3	4			
Center No. 1070, N	1	5			
Center No. 1072, N	2	1			
Center No. 1073, N	11	7			
Center No. 1074, N	5	3			
Center No. 1076, N	1	5			
Center No. 1077, N	3	2			
Center No. 1079, N	4	3			
Center No. 1080, N	3	1			
Center No. 1082, N	5	8			
Center No. 1084, N	2	3			
Center No. 1085, N	0	3			
Center No. 1086, N	6	9			
Center No. 1087, N	1	4			
Center No. 1088, N	6	6			
Center No. 1089, N	4	4			
Center No. 1091, N	6	5			
Center No. 1093, N	1	4			
Center No. 1095, N	5	3			
Center No. 1096, N	2	0			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1100, N	1	4			
Center No. 1101, N	4	6			
Center No. 1103, N	2	3			
Center No. 1105, N	3	3			
Center No. 1108, N	15	10			
Center No. 1110, N	6	5			
Center No. 1111, N	5	0			
Center No. 1113, N	3	3			
Center No. 1115, N	5	6			
Center No. 1116, N	1	4			
Center No. 1118, N	3	2			
Center No. 1119, N	3	5			
Center No. 1121, N	4	4			
Center No. 1123, N	1	1			
Center No. 1124, N	3	2			
Center No. 1502, N	0	3			
<b>PCS increase of at least 11.2 pts from BL</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
N'	9	6	N.E.	0.27	-0.13
n (%)	0 (0.0)	1 (12.5)		[0.01; 5.92] 0.408	[-0.35; 0.10] 0.285
<b>Center No. 1002</b>					
N'	4	0	N.E.	N.E.	N.E.
n (%)	2 (50.0)	0 (0.0)			
<b>Center No. 1003</b>					
N'	2	3	1.68	1.50	0.17
n (%)	1 (50.0)	1 (33.3)	[0.04; 80.39] 0.792	[0.18; 12.46] 0.707	[-0.71; 1.04] 0.709
<b>Center No. 1005</b>					
N'	28	22	1.83	0.99	-0.00
n (%)	7 (22.6)	5 (22.7)	[0.30; 11.01] 0.509	[0.36; 2.73] 0.990	[-0.23; 0.23] 0.990
<b>Center No. 1007</b>					
N'	4	7	N.E.	0.44	-0.14
n (%)	0 (0.0)	1 (14.3)		[0.02; 9.11] 0.599	[-0.40; 0.12] 0.280

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1008</b>					
N'	2	3	N.E.	0.20	-0.67
n (%)	0 (0.0)	2 (66.7)		[0.01; 2.98] 0.243	[-1.20; -0.13] 0.014
<b>Center No. 1010</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1011</b>					
N'	2	5	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1012</b>					
N'	3	4	N.E.	0.50	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.03; 9.46] 0.644	[-0.55; 0.15] 0.264
<b>Center No. 1014</b>					
N'	5	4	N.E.	0.28	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.01; 5.43] 0.398	[-0.67; 0.17] 0.248
<b>Center No. 1015</b>					
N'	4	2	0.33	0.50	-0.25
n (%)	1 (25.0)	1 (50.0)	[<0.01; 11.94] 0.547‡	[0.06; 4.47] 0.535	[-1.06; 0.56] 0.546
<b>Center No. 1017</b>					
N'	5	4	0.75	0.80	-0.05
n (%)	1 (20.0)	1 (25.0)	[0.03; 17.51] 0.858‡	[0.07; 9.18] 0.858	[-0.60; 0.50] 0.859
<b>Center No. 1018</b>					
N'	7	5	1.98	1.71	0.12
n (%)	2 (28.6)	1 (16.7)	[0.13; 30.00] 0.623†	[0.20; 14.55] 0.621	[-0.33; 0.57] 0.603
<b>Center No. 1019</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1021</b>					
N'	15	6	N.E.	4.53	0.19
n (%)	3 (18.8)	0 (0.0)		[0.26; 79.45] 0.301	[-0.00; 0.38] 0.055
<b>Center No. 1022</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1025</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1027</b>					
N'	3	4	N.E.	0.30	-0.40
n (%)	0 (0.0)	2 (40.0)		[0.02; 4.74] 0.393	[-0.83; 0.03] 0.068
<b>Center No. 1028</b>					
N'	11	5	N.E.	1.50	0.09
n (%)	1 (9.1)	0 (0.0)		[0.07; 31.58] 0.794	[-0.08; 0.26] 0.294
<b>Center No. 1029</b>					
N'	15	9	45.34	1.80	0.09
n (%)	3 (20.0)	1 (11.1)	[0.40; >99.99] 0.115	[0.22; 14.80] 0.585	[-0.20; 0.38] 0.546
<b>Center No. 1030</b>					
N'	11	8	<0.01	0.82	-0.02
n (%)	1 (9.1)	1 (11.1)	[<0.01; >99.99] 0.374†	[0.06; 11.33] 0.881	[-0.29; 0.25] 0.882
<b>Center No. 1032</b>					
N'	1	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1033</b>					
N'	4	6	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1034</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1035</b>					
N'	27	22	5.13	4.89	0.18
n (%)	6 (22.2)	1 (4.5)	[0.53; 49.54] 0.157†	[0.64; 37.63] 0.127	[-0.00; 0.36] 0.053
<b>Center No. 1036</b>					
N'	7	6	0.39	0.50	-0.14
n (%)	1 (14.3)	2 (28.6)	[0.01; 10.82] 0.581†	[0.06; 4.33] 0.529	[-0.57; 0.28] 0.508
<b>Center No. 1037</b>					
N'	8	10	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1039</b>					
N'	4	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1040</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1041</b>					
N'	4	5	>99.99	1.00	0.00
n (%)	1 (20.0)	1 (20.0)	[0.04; >99.99] 0.235†	[0.08; 11.93] 1.000	[-0.50; 0.50] 1.000
<b>Center No. 1042</b>					
N'	4	5	1.33	1.25	0.05
n (%)	1 (25.0)	1 (20.0)	[0.06; 31.12] 0.858‡	[0.11; 14.34] 0.858	[-0.50; 0.60] 0.859
<b>Center No. 1044</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1046</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1048</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (33.3)			
<b>Center No. 1049</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1050</b>					
N'	6	9	N.E.	4.29	0.17
n (%)	1 (16.7)	0 (0.0)		[0.20; 90.63] 0.350	[-0.13; 0.46] 0.273
<b>Center No. 1051</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1052</b>					
N'	7	4	0.16	0.57	-0.11
n (%)	1 (14.3)	1 (25.0)	<0.01; 16.13] 0.436†	[0.05; 6.86] 0.659	[-0.60; 0.39] 0.673
<b>Center No. 1055</b>					
N'	2	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1058</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1059</b>					
N'	6	6	N.E.	0.20	-0.29
n (%)	0 (0.0)	2 (28.6)		[0.01; 3.54] 0.272	[-0.62; 0.05] 0.094
<b>Center No. 1061</b>					
N'	9	6	0.21	0.67	-0.11
n (%)	2 (22.2)	2 (33.3)	[<0.01; 6.46] 0.371†	[0.13; 3.53] 0.633	[-0.58; 0.35] 0.639
<b>Center No. 1063</b>					
N'	4	2	N.E.	1.80	0.25
n (%)	1 (25.0)	0 (0.0)		[0.10; 31.52] 0.687	[-0.17; 0.67] 0.248
<b>Center No. 1064</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1067</b>					
N'	9	16	0.12	1.07	0.03
n (%)	4 (40.0)	6 (37.5)	[<0.01; 4.23] 0.242†	[0.40; 2.87] 0.898	[-0.36; 0.41] 0.899
<b>Center No. 1068</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1069</b>					
N'	2	3	1.50	1.33	0.08
n (%)	1 (33.3)	1 (25.0)	[0.06; 40.63] 0.810‡	[0.13; 13.74] 0.809	[-0.60; 0.76] 0.811
<b>Center No. 1070</b>					
N'	1	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1072</b>					
N'	2	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1073</b>					
N'	11	6	0.80	0.64	-0.05
n (%)	1 (9.1)	1 (14.3)	[0.03; 18.83] 0.892†	[0.05; 8.61] 0.734	[-0.36; 0.26] 0.743



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1074</b>					
N'	5	3	N.E.	3.33	0.40
n (%)	2 (40.0)	0 (0.0)		[0.21; 52.68] 0.393	[-0.03; 0.83] 0.068
<b>Center No. 1076</b>					
N'	1	5	N.E.	1.00	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.06; 15.99] 1.000	[-0.55; 0.15] 0.264
<b>Center No. 1077</b>					
N'	3	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1079</b>					
N'	4	3	5.31	1.50	0.17
n (%)	2 (50.0)	1 (33.3)	[0.09; >99.99] 0.422†	[0.23; 9.80] 0.672	[-0.56; 0.89] 0.652
<b>Center No. 1080</b>					
N'	3	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1082</b>					
N'	4	7	N.E.	10.50	0.60
n (%)	3 (60.0)	0 (0.0)		[0.65; 168.80] 0.097	[0.17; 1.03] 0.006
<b>Center No. 1084</b>					
N'	2	3	N.E.	4.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.24; 67.72] 0.337	[-0.19; 1.19] 0.157
<b>Center No. 1085</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1086</b>					
N'	6	9	1.39	0.75	-0.06
n (%)	1 (16.7)	2 (22.2)	[0.07; 29.27] 0.830†	[0.09; 6.55] 0.795	[-0.46; 0.35] 0.787
<b>Center No. 1087</b>					
N'	1	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1088</b>					
N'	6	5	N.E.	0.33	-0.17
n (%)	0 (0.0)	1 (16.7)		[0.02; 6.86] 0.476	[-0.46; 0.13] 0.273

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1089</b>					
N'	4	3	N.E.	0.33	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.02; 6.37] 0.466	[-0.67; 0.17] 0.248
<b>Center No. 1091</b>					
N'	5	5	N.E.	2.57	0.17
n (%)	1 (16.7)	0 (0.0)		[0.13; 52.13] 0.538	[-0.13; 0.46] 0.273
<b>Center No. 1093</b>					
N'	1	4	N.E.	0.83	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.05; 13.02] 0.897	[-0.67; 0.17] 0.248
<b>Center No. 1095</b>					
N'	5	3	N.E.	0.22	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.01; 4.20] 0.316	[-0.87; 0.20] 0.221
<b>Center No. 1096</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1100</b>					
N'	1	3	N.E.	4.00	0.75
n (%)	1 (100.0)	1 (25.0)		[0.73; 21.84] 0.109	[0.33; 1.17] <.001
<b>Center No. 1101</b>					
N'	4	5	N.E.	0.47	-0.17
n (%)	0 (0.0)	1 (16.7)		[0.02; 9.26] 0.617	[-0.46; 0.13] 0.273
<b>Center No. 1103</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1105</b>					
N'	3	3	N.E.	0.33	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.02; 5.97] 0.455	[-0.87; 0.20] 0.221
<b>Center No. 1108</b>					
N'	14	10	0.33	0.50	-0.20
n (%)	3 (20.0)	4 (40.0)	[0.03; 3.94] 0.382	[0.14; 1.77] 0.283	[-0.56; 0.16] 0.283
<b>Center No. 1110</b>					
N'	4	4	N.E.	4.29	0.33
n (%)	2 (33.3)	0 (0.0)		[0.25; 72.90] 0.314	[-0.04; 0.71] 0.083

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1111</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1113</b>					
N'	3	3	1.00	1.00	0.00
n (%)	1 (33.3)	1 (33.3)	[0.03; 29.81] 1.000‡	[0.10; 9.61] 1.000	[-0.75; 0.75] 1.000
<b>Center No. 1115</b>					
N'	3	5	0.50	0.60	-0.13
n (%)	1 (20.0)	2 (33.3)	[0.03; 7.99] 0.624‡	[0.07; 4.83] 0.631	[-0.65; 0.38] 0.612
<b>Center No. 1116</b>					
N'	1	4	N.E.	0.83	-0.25
n (%)	0 (0.0)	1 (25.0)		[0.05; 13.02] 0.897	[-0.67; 0.17] 0.248
<b>Center No. 1118</b>					
N'	2	2	N.E.	0.25	-0.50
n (%)	0 (0.0)	1 (50.0)		[0.01; 4.23] 0.337	[-1.19; 0.19] 0.157
<b>Center No. 1119</b>					
N'	3	5	N.E.	4.50	0.33
n (%)	1 (33.3)	0 (0.0)		[0.24; 85.12] 0.316	[-0.20; 0.87] 0.221
<b>Center No. 1121</b>					
N'	4	4	N.E.	3.00	0.25
n (%)	1 (25.0)	0 (0.0)		[0.16; 57.37] 0.466	[-0.17; 0.67] 0.248
<b>Center No. 1123</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	1 (100.0)	0 (0.0)			
<b>Center No. 1124</b>					
N'	3	1	N.E.	3.75	0.67
n (%)	2 (66.7)	0 (0.0)		[0.27; 52.64] 0.327	[0.13; 1.20] 0.014
<b>Center No. 1502</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>MCS increase of at least 12.5 pts from BL</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
N'	9	6	N.E.	0.27	-0.13
n (%)	0 (0.0)	1 (12.5)		[0.01; 5.92] 0.408	[-0.35; 0.10] 0.285
<b>Center No. 1002</b>					
N'	4	0	N.E.	N.E.	N.E.
n (%)	1 (25.0)	0 (0.0)			
<b>Center No. 1003</b>					
N'	2	3	N.E.	0.44	-0.33
n (%)	0 (0.0)	1 (33.3)		[0.03; 7.52] 0.574	[-0.87; 0.20] 0.221
<b>Center No. 1005</b>					
N'	28	22	0.18	0.18	-0.15
n (%)	1 (3.2)	4 (18.2)	[0.02; 2.27] 0.187†	[0.02; 1.48] 0.110	[-0.32; 0.02] 0.090
<b>Center No. 1007</b>					
N'	4	7	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1008</b>					
N'	2	3	N.E.	0.20	-0.67
n (%)	0 (0.0)	2 (66.7)		[0.01; 2.98] 0.243	[-1.20; -0.13] 0.014
<b>Center No. 1010</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1011</b>					
N'	2	5	N.E.	6.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.34; 107.43] 0.224	[-0.19; 1.19] 0.157
<b>Center No. 1012</b>					
N'	3	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1014</b>					
N'	5	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1015</b>					
N'	4	2	N.E.	1.80	0.25
n (%)	1 (25.0)	0 (0.0)		[0.10; 31.52] 0.687	[-0.17; 0.67] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1017</b>					
N'	5	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1018</b>					
N'	7	5	N.E.	2.63	0.14
n (%)	1 (14.3)	0 (0.0)		[0.13; 54.64] 0.533	[-0.12; 0.40] 0.280
<b>Center No. 1019</b>					
N'	2	2	N.E.	3.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.19; 47.96] 0.437	[-0.19; 1.19] 0.157
<b>Center No. 1021</b>					
N'	15	6	0.45	1.25	0.03
n (%)	2 (12.5)	1 (10.0)	[0.02; 10.98] 0.628†	[0.13; 12.06] 0.847	[-0.22; 0.27] 0.843
<b>Center No. 1022</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1025</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1027</b>					
N'	3	4	N.E.	0.50	-0.20
n (%)	0 (0.0)	1 (20.0)		[0.03; 9.46] 0.644	[-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
N'	11	5	N.E.	1.50	0.09
n (%)	1 (9.1)	0 (0.0)		[0.07; 31.58] 0.794	[-0.08; 0.26] 0.294
<b>Center No. 1029</b>					
N'	15	9	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1030</b>					
N'	11	8	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1032</b>					
N'	1	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1033</b>					
N'	4	6	N.E.	4.20	0.25
n (%)	1 (25.0)	0 (0.0)		[0.21; 83.34] 0.346	[-0.17; 0.67] 0.248
<b>Center No. 1034</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1035</b>					
N'	27	22	N.E.	5.75	0.11
n (%)	3 (11.1)	0 (0.0)		[0.31; 105.71] 0.239	[-0.01; 0.23] 0.066
<b>Center No. 1036</b>					
N'	7	6	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1037</b>					
N'	8	10	N.E.	3.60	0.11
n (%)	1 (11.1)	0 (0.0)		[0.16; 79.01] 0.416	[-0.09; 0.32] 0.289
<b>Center No. 1039</b>					
N'	4	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1040</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1041</b>					
N'	4	5	N.E.	3.00	0.20
n (%)	1 (20.0)	0 (0.0)		[0.15; 59.89] 0.472	[-0.15; 0.55] 0.264
<b>Center No. 1042</b>					
N'	4	5	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1044</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1046</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1048</b>					
N'	0	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1049</b>					
N'	1	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1050</b>					
N'	6	9	N.E.	0.48	-0.11
n (%)	0 (0.0)	1 (11.1)		[0.02; 10.07] 0.634	[-0.32; 0.09] 0.289
<b>Center No. 1051</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1052</b>					
N'	7	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1055</b>					
N'	2	4	N.E.	5.00	0.50
n (%)	1 (50.0)	0 (0.0)		[0.29; 87.55] 0.271	[-0.19; 1.19] 0.157
<b>Center No. 1058</b>					
N'	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1059</b>					
N'	6	6	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1061</b>					
N'	9	6	N.E.	3.50	0.22
n (%)	2 (22.2)	0 (0.0)		[0.20; 62.27] 0.394	[-0.05; 0.49] 0.109
<b>Center No. 1063</b>					
N'	4	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1064</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1067</b>					
N'	9	16	32.10	3.20	0.14
n (%)	2 (20.0)	1 (6.3)	[0.25; >99.99] 0.161†	[0.33; 30.87] 0.315	[-0.14; 0.41] 0.327
<b>Center No. 1068</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	1 (50.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1069</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1070</b>					
N'	1	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1072</b>					
N'	2	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1073</b>					
N'	11	6	N.E.	2.00	0.09
n (%)	1 (9.1)	0 (0.0)		[0.09; 43.22] 0.658	[-0.08; 0.26] 0.294
<b>Center No. 1074</b>					
N'	5	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1076</b>					
N'	1	5	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1077</b>					
N'	3	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1079</b>					
N'	4	3	N.E.	2.40	0.25
n (%)	1 (25.0)	0 (0.0)		[0.13; 44.42] 0.557	[-0.17; 0.67] 0.248
<b>Center No. 1080</b>					
N'	3	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1082</b>					
N'	4	7	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1084</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1085</b>					
N'	0	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1086</b>					
N'	6	9	N.E.	4.29	0.17
n (%)	1 (16.7)	0 (0.0)		[0.20; 90.63] 0.350	[-0.13; 0.46] 0.273
<b>Center No. 1087</b>					
N'	1	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1088</b>					
N'	6	5	N.E.	3.00	0.17
n (%)	1 (16.7)	0 (0.0)		[0.15; 61.74] 0.476	[-0.13; 0.46] 0.273
<b>Center No. 1089</b>					
N'	4	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1091</b>					
N'	5	5	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1093</b>					
N'	1	4	N.E.	2.00	0.50
n (%)	1 (100.0)	2 (50.0)		[0.75; 5.33] 0.166	[0.01; 0.99] 0.046
<b>Center No. 1095</b>					
N'	5	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1096</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1100</b>					
N'	1	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1101</b>					
N'	4	5	1.67	1.50	0.08
n (%)	1 (25.0)	1 (16.7)	[0.07; 37.73] 0.748‡	[0.13; 17.67] 0.747	[-0.44; 0.60] 0.753
<b>Center No. 1103</b>					
N'	2	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1105</b>					
N'	3	3	N.E.	3.00	0.33
n (%)	1 (33.3)	0 (0.0)		[0.17; 53.71] 0.455	[-0.20; 0.87] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1108</b>					
N'	14	10	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1110</b>					
N'	4	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1111</b>					
N'	2	0	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1113</b>					
N'	3	3	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1115</b>					
N'	3	5	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1116</b>					
N'	1	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1118</b>					
N'	2	2	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1119</b>					
N'	3	5	8.00	3.33	0.47
n (%)	2 (66.7)	1 (20.0)	[0.31; >99.99] 0.210‡	[0.49; 22.90] 0.221	[-0.17; 1.11] 0.152
<b>Center No. 1121</b>					
N'	4	4	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1123</b>					
N'	1	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<b>Center No. 1124</b>					
N'	3	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1502</b>					
N <sup>†</sup>	0	1	N.E.	N.E.	N.E.
n (%)	0 (0.0)	0 (0.0)			
<p>N<sup>†</sup>: Number of patients with available response value  N-N<sup>†</sup> is the number of values with non-response imputation.  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, baseline value, stratification factor (MMD at baseline), subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup that include treatment group, baseline value and stratification factor (MMD at baseline).  † The stratification factor is excluded from the model due to non-convergence of the full model.  ‡ The stratification factor and baseline value are excluded from the model due to non-convergence of the full model.  RR and RD are calculated directly (without adjustment) within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Missing values are imputed by non-response.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p>					

**Table 14.2-6.0 Return rates in the diary for TSQM Ver II, Satisfaction with Treatment, at week 6 and 24 (Full analysis set)**

	Treatment Groups		
	AMG334 (N=388) n (%)	Topiramate (N=388) n (%)	Total (N=776) n (%)
<b>Effectiveness</b>			
Week 6	321 ( 82.7)	257 ( 66.2)	578 ( 74.5)
Week 24	330 ( 85.1)	230 ( 59.3)	560 ( 72.2)
<b>Side effects</b>			
Week 6	106 ( 27.3)	163 ( 42.0)	269 ( 34.7)
Week 24	68 ( 17.5)	113 ( 29.1)	181 ( 23.3)
<b>Convenience</b>			
Week 6	321 ( 82.7)	257 ( 66.2)	578 ( 74.5)
Week 24	330 ( 85.1)	230 ( 59.3)	560 ( 72.2)
<b>Global satisfaction</b>			
Week 6	321 ( 82.7)	257 ( 66.2)	578 ( 74.5)
Week 24	330 ( 85.1)	230 ( 59.3)	560 ( 72.2)

**Table 14.2-6.1 TSQM Ver II, Satisfaction with Treatment, at week 24, Linear Mixed Model for Repeated Measures (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Effectiveness</b>				
N'	356	286		
Mean (SD)	75.10 (30.23)	63.73 (32.99)		
Adjusted Mean (SE)	73.88 (1.95)	61.59 (2.24)	12.29 [7.05; 17.53]	<.001
<b>Side effects</b>				
N'	134	196		
Mean (SD)	84.31 (19.41)	73.38 (24.19)		
Adjusted Mean (SE)	84.50 (2.90)	71.46 (2.31)	13.05 [6.46; 19.63]	<.001
<b>Convenience</b>				
N'	356	286		
Mean (SD)	78.13 (24.58)	75.94 (25.47)		
Adjusted Mean (SE)	76.49 (1.54)	73.87 (1.76)	2.62 [-1.51; 6.74]	0.214
<b>Global satisfaction</b>				
N'	356	286		
Mean (SD)	79.65 (27.49)	67.90 (31.99)		
Adjusted Mean (SE)	76.80 (1.84)	63.62 (2.10)	13.19 [8.26; 18.11]	<.001
N': Number of patients in the analysis CI: Confidence interval SD: Standard deviation SE: Standard error  Linear mixed model for repeated measures includes treatment group, stratification factor, scheduled visit and interaction between treatment group and scheduled visit. The model utilizes unstructured covariance matrix in the repeated statement.				

**Table 14.2-6.1.1 TSQM Ver II, Satisfaction with Treatment, at week 24, Linear Mixed Model for Repeated Measures by Age Group (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
< median age, N	186	190		
≥ median age, N	202	198		
<b>Effectiveness</b>				
<b>Interaction test: p=0.031</b>				
<b>&lt; median age</b>				
N'	170	148		
Mean (SD)	73.24 (30.78)	67.91 (30.50)		
Adjusted Mean (SE)	72.20 (2.62)	66.20 (2.95)	6.00 [-1.37; 13.38]	0.110
<b>≥ median age</b>				
N'	186	138		
Mean (SD)	76.77 (29.72)	59.10 (35.11)		
Adjusted Mean (SE)	75.38 (2.57)	56.51 (3.10)	18.87 [11.44; 26.29]	<.001
<b>Side effects</b>				
<b>Interaction test: p=0.420</b>				
<b>&lt; median age</b>				
N'	62	101		
Mean (SD)	86.84 (16.03)	76.72 (22.98)		
Adjusted Mean (SE)	87.00 (5.10)	75.56 (3.01)	11.44 [0.23; 22.65]	0.046
<b>≥ median age</b>				
N'	72	95		
Mean (SD)	83.33 (20.64)	69.85 (25.13)		
Adjusted Mean (SE)	83.10 (3.35)	66.80 (3.17)	16.30 [7.82; 24.78]	<.001
<b>Convenience</b>				
<b>Interaction test: p=0.340</b>				
<b>&lt; median age</b>				
N'	170	148		
Mean (SD)	76.18 (25.93)	74.52 (26.21)		
Adjusted Mean (SE)	74.87 (2.08)	73.15 (2.33)	1.72 [-4.11; 7.55]	0.562
<b>≥ median age</b>				
N'	186	138		
Mean (SD)	79.89 (23.25)	77.52 (24.65)		
Adjusted Mean (SE)	78.11 (2.04)	74.81 (2.45)	3.30 [-2.57; 9.17]	0.271

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Global satisfaction</b>				
<b>Interaction test: p=0.005</b>				
<b>&lt; median age</b>				
N'	170	148		
Mean (SD)	77.94 (29.13)	72.73 (28.67)		
Adjusted Mean (SE)	75.18 (2.46)	69.37 (2.76)	5.82 [-1.10; 12.73]	0.099
<b>≥ median age</b>				
N'	186	138		
Mean (SD)	81.18 (25.92)	62.54 (34.67)		
Adjusted Mean (SE)	78.24 (2.42)	57.27 (2.91)	20.96 [14.00; 27.93]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup.            The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p>				

**Table 14.2-6.1.2 TSQM Ver II, Satisfaction with Treatment, at week 24, Linear Mixed Model for Repeated Measures by Gender (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Male, N	57	53		
Female, N	331	335		
<b>Effectiveness</b>				
<b>Interaction test: p=0.571</b>				
<b>Male</b>				
N'	55	41		
Mean (SD)	76.92 (28.04)	70.70 (28.94)		
Adjusted Mean (SE)	75.59 (4.46)	68.47 (5.62)	7.12 [-6.71; 20.94]	0.312
<b>Female</b>				
N'	301	245		
Mean (SD)	74.76 (30.66)	62.65 (33.51)		
Adjusted Mean (SE)	73.59 (2.08)	60.54 (2.38)	13.05 [7.38; 18.72]	<.001
<b>Side effects</b>				
<b>Interaction test: p=0.717</b>				
<b>Male</b>				
N'	16	22		
Mean (SD)	81.55 (22.03)	78.70 (15.65)		
Adjusted Mean (SE)	81.89 (8.30)	75.18 (7.15)	6.71 [-14.62; 28.04]	0.537
<b>Female</b>				
N'	118	174		
Mean (SD)	84.63 (19.27)	72.92 (24.79)		
Adjusted Mean (SE)	84.80 (3.05)	71.14 (2.41)	13.66 [6.70; 20.62]	<.001
<b>Convenience</b>				
<b>Interaction test: p=0.470</b>				
<b>Male</b>				
N'	55	41		
Mean (SD)	81.30 (23.42)	80.29 (20.88)		
Adjusted Mean (SE)	79.13 (3.53)	77.56 (4.42)	1.57 [-9.31; 12.45]	0.777
<b>Female</b>				
N'	301	245		
Mean (SD)	77.54 (24.79)	75.27 (26.10)		
Adjusted Mean (SE)	76.02 (1.64)	73.29 (1.88)	2.73 [-1.74; 7.19]	0.231



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Global satisfaction</b>				
<b>Interaction test: p=0.228</b>				
<b>Male</b>				
N'	55	41		
Mean (SD)	79.65 (26.22)	75.00 (29.74)		
Adjusted Mean (SE)	76.95 (4.21)	70.94 (5.27)	6.01 [-6.97; 18.99]	0.364
<b>Female</b>				
N'	301	245		
Mean (SD)	79.65 (27.76)	66.79 (32.26)		
Adjusted Mean (SE)	76.81 (1.96)	62.47 (2.23)	14.33 [9.01; 19.66]	<.001
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup.            The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p>				

**Table 14.2-6.1.3 TSQM Ver II, Satisfaction with Treatment, at week 24, Linear Mixed Model for Repeated Measures by Disease Severity (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
4-7 monthly migraine days at baseline <sup>1</sup> , N	96	92		
8-14 monthly migraine days at baseline <sup>2</sup> , N	249	254		
≥ 15 monthly migraine days at baseline, N	43	42		
<b>Effectiveness</b>				
<b>Interaction test: p=0.048</b>				
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>				
N'	90	67		
Mean (SD)	77.29 (28.06)	61.16 (34.28)		
Adjusted Mean (SE)	77.01 (3.45)	60.53 (4.21)	16.48 [5.79; 27.17]	0.003
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>				
N'	228	187		
Mean (SD)	77.52 (28.99)	64.45 (32.60)		
Adjusted Mean (SE)	77.60 (2.11)	63.40 (2.48)	14.20 [7.81; 20.59]	<.001
<b>≥ 15 monthly migraine days at baseline</b>				
N'	38	32		
Mean (SD)	55.24 (35.65)	64.86 (33.71)		
Adjusted Mean (SE)	56.13 (5.22)	64.76 (6.37)	-8.63 [-24.81; 7.56]	0.296
<b>Side effects</b>				
<b>Interaction test: p=0.353</b>				
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>				
N'	33	46		
Mean (SD)	81.94 (23.87)	75.00 (25.69)		
Adjusted Mean (SE)	81.00 (5.55)	74.07 (4.31)	6.93 [-6.90; 20.75]	0.325
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>				
N'	86	127		
Mean (SD)	87.07 (17.04)	72.02 (24.47)		
Adjusted Mean (SE)	86.76 (3.14)	69.75 (2.52)	17.01 [9.09; 24.93]	<.001
<b>≥ 15 monthly migraine days at baseline</b>				
N'	15	23		
Mean (SD)	65.00 (18.07)	77.68 (20.65)		
Adjusted Mean (SE)	67.99 (9.49)	74.06 (5.91)	-6.07 [-28.06; 15.92]	0.588

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Convenience</b>				
<b>Interaction test: p=0.487</b>				
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>				
N'	90	67		
Mean (SD)	78.40 (21.21)	77.36 (23.79)		
Adjusted Mean (SE)	78.34 (2.75)	77.24 (3.35)	1.10 [-7.41; 9.61]	0.799
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>				
N'	228	187		
Mean (SD)	79.41 (24.16)	76.05 (25.83)		
Adjusted Mean (SE)	79.56 (1.69)	75.49 (1.97)	4.07 [-1.03; 9.16]	0.118
<b>≥ 15 monthly migraine days at baseline</b>				
N'	38	32		
Mean (SD)	69.68 (32.29)	71.98 (27.50)		
Adjusted Mean (SE)	69.76 (4.17)	72.55 (5.05)	-2.79 [-15.66; 10.08]	0.670
<b>Global satisfaction</b>				
<b>Interaction test: p=0.066</b>				
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>				
N'	90	67		
Mean (SD)	80.83 (24.28)	65.72 (32.18)		
Adjusted Mean (SE)	79.68 (3.26)	64.78 (3.96)	14.89 [4.82; 24.97]	0.004
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>				
N'	228	187		
Mean (SD)	82.05 (26.09)	68.45 (32.18)		
Adjusted Mean (SE)	81.93 (2.00)	65.98 (2.33)	15.95 [9.92; 21.98]	<.001

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>≥ 15 monthly migraine days at baseline</b>				
N <sup>1</sup>	38	32		
Mean (SD)	62.14 (36.06)	69.20 (31.43)		
Adjusted Mean (SE)	62.13 (4.94)	69.41 (5.98)	-7.28 [-22.52; 7.96]	0.348
<p>N<sup>1</sup>: Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup. The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N<sup>1</sup> &gt; 0 in at least one treatment group.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.  <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.            The stratification factor is not included in the linear mixed model due to collinearity with the subgroups.</p>				

**Table 14.2-6.1.4 TSQM Ver II, Satisfaction with Treatment, at week 24, Linear Mixed Model for Repeated Measures by Prior Treatment Failure Status (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Naïve*, N	232	229		
Prior treatment failure*, N	156	159		
<b>Effectiveness</b>				
<b>Interaction test: p=0.698</b>				
<b>Naïve*</b>				
N'	213	174		
Mean (SD)	76.41 (29.74)	64.78 (33.26)		
Adjusted Mean (SE)	75.30 (2.39)	62.55 (2.80)	12.75 [5.95; 19.55]	<.001
<b>Prior treatment failure*</b>				
N'	143	112		
Mean (SD)	73.21 (30.94)	62.19 (32.71)		
Adjusted Mean (SE)	71.62 (2.87)	59.99 (3.35)	11.63 [3.39; 19.86]	0.006
<b>Side effects</b>				
<b>Interaction test: p=0.819</b>				
<b>Naïve*</b>				
N'	74	121		
Mean (SD)	85.53 (17.08)	72.24 (25.80)		
Adjusted Mean (SE)	85.72 (3.77)	70.27 (2.84)	15.45 [6.67; 24.23]	<.001
<b>Prior treatment failure*</b>				
N'	60	75		
Mean (SD)	82.78 (22.23)	75.09 (21.70)		
Adjusted Mean (SE)	83.41 (4.14)	73.41 (3.48)	9.99 [-0.10; 20.09]	0.052
<b>Convenience</b>				
<b>Interaction test: p=0.144</b>				
<b>Naïve*</b>				
N'	213	174		
Mean (SD)	78.21 (24.55)	73.48 (27.43)		
Adjusted Mean (SE)	76.65 (1.89)	71.42 (2.20)	5.23 [-0.11; 10.57]	0.055
<b>Prior treatment failure*</b>				
N'	143	112		
Mean (SD)	78.02 (24.72)	79.57 (21.92)		
Adjusted Mean (SE)	76.29 (2.27)	77.57 (2.64)	-1.29 [-7.77; 5.20]	0.697

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Global satisfaction</b>				
<b>Interaction test: p=0.604</b>				
<b>Naïve*</b>				
N'	213	174		
Mean (SD)	81.15 (25.97)	67.27 (32.88)		
Adjusted Mean (SE)	78.31 (2.26)	63.16 (2.62)	15.15 [8.76; 21.53]	<.001
<b>Prior treatment failure*</b>				
N'	143	112		
Mean (SD)	77.47 (29.51)	68.82 (30.79)		
Adjusted Mean (SE)	74.52 (2.71)	64.17 (3.15)	10.35 [2.61; 18.10]	0.009
<p>N': Number of patients in the analysis            CI: Confidence interval            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup.            The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p> <p>*: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>				

**Table 14.2-6.1.5 TSQM Ver II, Satisfaction with Treatment, at week 24, Linear Mixed Model for Repeated Measures by Study Center (Full Analysis Set)**

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1001, N	10	8		
Center No. 1002, N	4	0		
Center No. 1003, N	2	3		
Center No. 1005, N	31	22		
Center No. 1007, N	5	7		
Center No. 1008, N	3	3		
Center No. 1010, N	2	3		
Center No. 1011, N	2	5		
Center No. 1012, N	3	5		
Center No. 1014, N	5	4		
Center No. 1015, N	4	2		
Center No. 1017, N	5	4		
Center No. 1018, N	7	6		
Center No. 1019, N	2	2		
Center No. 1021, N	16	10		
Center No. 1022, N	3	3		
Center No. 1025, N	0	2		
Center No. 1027, N	3	5		
Center No. 1028, N	11	5		
Center No. 1029, N	15	9		
Center No. 1030, N	11	9		
Center No. 1032, N	2	4		
Center No. 1033, N	4	6		
Center No. 1034, N	4	3		
Center No. 1035, N	27	22		
Center No. 1036, N	7	7		
Center No. 1037, N	9	11		
Center No. 1039, N	4	3		
Center No. 1040, N	0	3		
Center No. 1041, N	5	5		
Center No. 1042, N	4	5		
Center No. 1044, N	0	2		
Center No. 1046, N	1	1		

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1048, N	0	3		
Center No. 1049, N	1	0		
Center No. 1050, N	6	9		
Center No. 1051, N	1	1		
Center No. 1052, N	7	4		
Center No. 1055, N	2	4		
Center No. 1058, N	0	1		
Center No. 1059, N	7	7		
Center No. 1061, N	9	6		
Center No. 1063, N	4	2		
Center No. 1064, N	0	3		
Center No. 1067, N	10	16		
Center No. 1068, N	0	2		
Center No. 1069, N	3	4		
Center No. 1070, N	1	5		
Center No. 1072, N	2	1		
Center No. 1073, N	11	7		
Center No. 1074, N	5	3		
Center No. 1076, N	1	5		
Center No. 1077, N	3	2		
Center No. 1079, N	4	3		
Center No. 1080, N	3	1		
Center No. 1082, N	5	8		
Center No. 1084, N	2	3		
Center No. 1085, N	0	3		
Center No. 1086, N	6	9		
Center No. 1087, N	1	4		
Center No. 1088, N	6	6		
Center No. 1089, N	4	4		
Center No. 1091, N	6	5		
Center No. 1093, N	1	4		
Center No. 1095, N	5	3		
Center No. 1096, N	2	0		
Center No. 1100, N	1	4		
Center No. 1101, N	4	6		
Center No. 1103, N	2	3		



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
Center No. 1105, N	3	3		
Center No. 1108, N	15	10		
Center No. 1110, N	6	5		
Center No. 1111, N	5	0		
Center No. 1113, N	3	3		
Center No. 1115, N	5	6		
Center No. 1116, N	1	4		
Center No. 1118, N	3	2		
Center No. 1119, N	3	5		
Center No. 1121, N	4	4		
Center No. 1123, N	1	1		
Center No. 1124, N	3	2		
Center No. 1502, N	0	3		
<b>Effectiveness</b>				
<b>Interaction test: p=0.429</b>				
<b>Center No. 1001</b>				
N'	9	6		
Mean (SD)	71.30 (37.29)	55.56 (48.11)		
Adjusted Mean (SE)	71.22 (10.22)	56.97 (17.38)	14.25 [-25.36; 53.86]	0.480
<b>Center No. 1002</b>				
N'	3	0		
Mean (SD)	75.00 (23.57)	N.E.		
Adjusted Mean (SE)	75.73 (21.44)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>				
N'	2	2		
Mean (SD)	50.00 (70.71)	50.00 (70.71)		
Adjusted Mean (SE)	47.24 (21.75)	47.24 (21.75)	-0.00 [-60.23; 60.23]	1.000
<b>Center No. 1005</b>				
N'	25	19		
Mean (SD)	77.17 (24.65)	59.72 (33.49)		
Adjusted Mean (SE)	76.54 (6.42)	56.14 (8.78)	20.41 [-0.81; 41.62]	0.059

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1007</b>				
N'	5	4		
Mean (SD)	86.11 (12.73)	56.25 (42.70)		
Adjusted Mean (SE)	77.74 (17.52)	55.39 (15.37)	22.35 [-23.30; 68.00]	0.337
<b>Center No. 1008</b>				
N'	2	3		
Mean (SD)	87.50 (5.89)	100.00 (0.00)		
Adjusted Mean (SE)	84.74 (21.75)	105.48 (21.36)	-20.74 [-80.71; 39.24]	0.497
<b>Center No. 1010</b>				
N'	2	2		
Mean (SD)	75.00 (N.E.)	58.33 (58.93)		
Adjusted Mean (SE)	77.15 (30.02)	55.57 (21.75)	21.58 [-51.09; 94.25]	0.560
<b>Center No. 1011</b>				
N'	2	3		
Mean (SD)	41.67 (47.14)	45.83 (64.82)		
Adjusted Mean (SE)	39.25 (21.72)	38.13 (21.47)	1.12 [-58.77; 61.01]	0.971
<b>Center No. 1012</b>				
N'	3	4		
Mean (SD)	63.89 (19.25)	45.83 (64.82)		
Adjusted Mean (SE)	61.13 (17.79)	43.63 (21.25)	17.50 [-36.75; 71.75]	0.527
<b>Center No. 1014</b>				
N'	5	2		
Mean (SD)	73.33 (19.00)	66.67 (0.00)		
Adjusted Mean (SE)	72.37 (13.72)	63.91 (21.75)	8.46 [-42.02; 58.94]	0.742
<b>Center No. 1015</b>				
N'	4	2		
Mean (SD)	95.83 (8.33)	8.33 (11.79)		
Adjusted Mean (SE)	93.25 (15.39)	5.57 (21.75)	87.67 [35.49; 139.85]	0.001
<b>Center No. 1017</b>				
N'	4	4		
Mean (SD)	89.58 (20.83)	58.33 (35.36)		
Adjusted Mean (SE)	87.17 (15.39)	54.98 (21.39)	32.19 [-19.44; 83.82]	0.221

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1018</b>				
N'	7	4		
Mean (SD)	86.90 (17.91)	62.50 (41.67)		
Adjusted Mean (SE)	84.15 (11.73)	59.91 (15.39)	24.23 [-13.55; 62.01]	0.208
<b>Center No. 1019</b>				
N'	2	2		
Mean (SD)	95.83 (5.89)	54.17 (17.68)		
Adjusted Mean (SE)	93.42 (21.72)	51.41 (21.75)	42.01 [-18.28; 102.31]	0.172
<b>Center No. 1021</b>				
N'	14	5		
Mean (SD)	55.95 (44.27)	61.67 (24.72)		
Adjusted Mean (SE)	53.44 (8.31)	59.32 (13.79)	-5.88 [-37.29; 25.53]	0.713
<b>Center No. 1022</b>				
N'	3	3		
Mean (SD)	75.00 (25.00)	72.22 (34.69)		
Adjusted Mean (SE)	75.23 (17.72)	69.92 (17.77)	5.31 [-43.94; 54.56]	0.832
<b>Center No. 1025</b>				
N'	0	2		
Mean (SD)	N.E.	37.50 (5.89)		
Adjusted Mean (SE)	N.E.	38.53 (21.70)	N.E.	N.E.
<b>Center No. 1027</b>				
N'	3	4		
Mean (SD)	83.33 (28.87)	27.78 (48.11)		
Adjusted Mean (SE)	80.57 (17.79)	23.61 (17.62)	56.96 [7.77; 106.15]	0.023
<b>Center No. 1028</b>				
N'	11	4		
Mean (SD)	71.97 (29.64)	63.89 (29.27)		
Adjusted Mean (SE)	69.96 (9.34)	60.66 (17.52)	9.31 [-29.62; 48.23]	0.639
<b>Center No. 1029</b>				
N'	13	5		
Mean (SD)	76.39 (35.86)	83.33 (23.57)		
Adjusted Mean (SE)	72.25 (8.98)	80.90 (21.15)	-8.65 [-53.57; 36.27]	0.705

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1030</b>				
N'	10	8		
Mean (SD)	82.41 (24.45)	69.44 (22.77)		
Adjusted Mean (SE)	80.50 (10.25)	67.75 (12.40)	12.75 [-18.77; 44.27]	0.427
<b>Center No. 1032</b>				
N'	2	4		
Mean (SD)	91.67 (N.E.)	27.78 (48.11)		
Adjusted Mean (SE)	97.50 (30.02)	25.25 (17.62)	72.26 [3.98; 140.53]	0.038
<b>Center No. 1033</b>				
N'	4	4		
Mean (SD)	81.25 (32.19)	52.08 (21.92)		
Adjusted Mean (SE)	80.39 (15.37)	49.67 (15.39)	30.72 [-11.99; 73.43]	0.158
<b>Center No. 1034</b>				
N'	4	2		
Mean (SD)	80.56 (12.73)	0.00 (0.00)		
Adjusted Mean (SE)	78.55 (17.58)	-2.07 (21.79)	80.61 [25.71; 135.51]	0.004
<b>Center No. 1035</b>				
N'	24	9		
Mean (SD)	78.41 (33.60)	71.30 (25.38)		
Adjusted Mean (SE)	76.49 (6.64)	68.84 (10.31)	7.64 [-16.20; 31.49]	0.529
<b>Center No. 1036</b>				
N'	7	6		
Mean (SD)	80.95 (32.88)	45.00 (28.63)		
Adjusted Mean (SE)	79.28 (11.66)	42.20 (13.69)	37.08 [1.80; 72.35]	0.039
<b>Center No. 1037</b>				
N'	6	5		
Mean (SD)	66.67 (42.49)	47.92 (29.17)		
Adjusted Mean (SE)	63.58 (13.74)	41.92 (15.26)	21.66 [-18.46; 61.78]	0.289
<b>Center No. 1039</b>				
N'	4	3		
Mean (SD)	91.67 (9.62)	88.89 (9.62)		
Adjusted Mean (SE)	89.25 (15.39)	88.89 (17.70)	0.36 [-45.72; 46.45]	0.988

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1040</b>				
N'	0	2		
Mean (SD)	N.E.	83.33 (N.E.)		
Adjusted Mean (SE)	N.E.	80.57 (30.71)	N.E.	N.E.
<b>Center No. 1041</b>				
N'	4	4		
Mean (SD)	85.42 (14.23)	41.67 (58.93)		
Adjusted Mean (SE)	82.83 (15.39)	40.63 (21.41)	42.20 [-9.44; 93.84]	0.109
<b>Center No. 1042</b>				
N'	4	3		
Mean (SD)	95.83 (8.33)	30.56 (39.38)		
Adjusted Mean (SE)	94.97 (15.37)	30.33 (17.72)	64.65 [18.64; 110.65]	0.006
<b>Center No. 1046</b>				
N'	1	0		
Mean (SD)	83.33 (N.E.)	N.E.		
Adjusted Mean (SE)	81.27 (30.73)	N.E.	N.E.	N.E.
<b>Center No. 1048</b>				
N'	0	2		
Mean (SD)	N.E.	91.67 (11.79)		
Adjusted Mean (SE)	N.E.	89.25 (21.72)	N.E.	N.E.
<b>Center No. 1049</b>				
N'	1	0		
Mean (SD)	0.00 (N.E.)	N.E.		
Adjusted Mean (SE)	-2.76 (30.71)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>				
N'	6	5		
Mean (SD)	86.67 (21.73)	71.67 (39.79)		
Adjusted Mean (SE)	82.11 (13.65)	68.91 (13.83)	13.20 [-24.78; 51.19]	0.495
<b>Center No. 1051</b>				
N'	1	1		
Mean (SD)	41.67 (N.E.)	50.00 (N.E.)		
Adjusted Mean (SE)	38.91 (30.71)	47.24 (30.71)	-8.33 [-93.51; 76.84]	0.848

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1052</b>				
N'	7	3		
Mean (SD)	70.24 (19.16)	41.67 (30.05)		
Adjusted Mean (SE)	67.68 (11.67)	41.90 (17.72)	25.78 [-15.95; 67.51]	0.225
<b>Center No. 1055</b>				
N'	2	3		
Mean (SD)	95.83 (5.89)	54.17 (64.82)		
Adjusted Mean (SE)	93.77 (21.79)	46.49 (21.43)	47.27 [-12.79; 107.33]	0.123
<b>Center No. 1058</b>				
N'	0	1		
Mean (SD)	N.E.	83.33 (N.E.)		
Adjusted Mean (SE)	N.E.	80.57 (30.71)	N.E.	N.E.
<b>Center No. 1059</b>				
N'	7	5		
Mean (SD)	75.00 (10.54)	89.58 (15.77)		
Adjusted Mean (SE)	72.93 (12.51)	85.43 (15.26)	-12.50 [-51.07; 26.07]	0.525
<b>Center No. 1061</b>				
N'	8	4		
Mean (SD)	59.38 (32.87)	64.58 (42.15)		
Adjusted Mean (SE)	56.62 (10.99)	62.00 (15.39)	-5.38 [-42.29; 31.53]	0.775
<b>Center No. 1063</b>				
N'	4	1		
Mean (SD)	79.17 (25.00)	N.E.		
Adjusted Mean (SE)	76.41 (15.43)	N.E.	N.E.	N.E.
<b>Center No. 1064</b>				
N'	0	2		
Mean (SD)	N.E.	83.33 (23.57)		
Adjusted Mean (SE)	N.E.	84.37 (21.70)	N.E.	N.E.
<b>Center No. 1067</b>				
N'	8	14		
Mean (SD)	76.04 (36.03)	65.91 (33.22)		
Adjusted Mean (SE)	73.71 (10.94)	61.61 (9.30)	12.10 [-15.95; 40.15]	0.397

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1068</b>				
N'	0	2		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1069</b>				
N'	3	2		
Mean (SD)	66.67 (23.57)	N.E.		
Adjusted Mean (SE)	61.52 (21.42)	N.E.	N.E.	N.E.
<b>Center No. 1070</b>				
N'	1	4		
Mean (SD)	0.00 (N.E.)	50.00 (35.36)		
Adjusted Mean (SE)	4.83 (30.78)	49.01 (21.42)	-44.18 [-118.02; 29.66]	0.240
<b>Center No. 1072</b>				
N'	2	1		
Mean (SD)	50.00 (N.E.)	N.E.		
Adjusted Mean (SE)	54.61 (30.02)	N.E.	N.E.	N.E.
<b>Center No. 1073</b>				
N'	11	6		
Mean (SD)	71.97 (30.57)	62.50 (32.81)		
Adjusted Mean (SE)	70.03 (9.32)	59.97 (12.59)	10.05 [-20.53; 40.64]	0.519
<b>Center No. 1074</b>				
N'	5	3		
Mean (SD)	86.67 (15.14)	77.78 (38.49)		
Adjusted Mean (SE)	84.32 (13.79)	75.48 (17.77)	8.84 [-35.14; 52.83]	0.693
<b>Center No. 1076</b>				
N'	1	5		
Mean (SD)	100.00 (N.E.)	88.89 (9.62)		
Adjusted Mean (SE)	97.24 (30.71)	89.07 (17.46)	8.17 [-61.19; 77.52]	0.817
<b>Center No. 1077</b>				
N'	3	1		
Mean (SD)	50.00 (46.40)	91.67 (N.E.)		
Adjusted Mean (SE)	47.47 (17.75)	89.60 (30.73)	-42.13 [-111.78; 27.52]	0.235

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1079</b>				
N'	4	2		
Mean (SD)	75.00 (31.91)	62.50 (17.68)		
Adjusted Mean (SE)	74.14 (15.37)	60.09 (21.72)	14.05 [-38.21; 66.31]	0.598
<b>Center No. 1080</b>				
N'	3	1		
Mean (SD)	100.00 (0.00)	100.00 (N.E.)		
Adjusted Mean (SE)	97.47 (17.75)	97.24 (30.71)	0.23 [-69.34; 69.80]	0.995
<b>Center No. 1082</b>				
N'	4	6		
Mean (SD)	70.83 (47.87)	55.56 (28.71)		
Adjusted Mean (SE)	70.32 (15.34)	52.91 (12.61)	17.41 [-21.59; 56.40]	0.381
<b>Center No. 1084</b>				
N'	2	3		
Mean (SD)	83.33 (11.79)	72.22 (34.69)		
Adjusted Mean (SE)	80.57 (21.75)	69.92 (17.77)	10.65 [-44.46; 65.76]	0.704
<b>Center No. 1085</b>				
N'	0	2		
Mean (SD)	N.E.	66.67 (N.E.)		
Adjusted Mean (SE)	N.E.	66.36 (30.02)	N.E.	N.E.
<b>Center No. 1086</b>				
N'	5	8		
Mean (SD)	90.00 (14.91)	36.90 (44.58)		
Adjusted Mean (SE)	87.66 (13.79)	34.21 (11.63)	53.45 [18.16; 88.74]	0.003
<b>Center No. 1087</b>				
N'	1	3		
Mean (SD)	100.00 (N.E.)	75.00 (25.00)		
Adjusted Mean (SE)	97.24 (30.71)	74.77 (17.72)	22.47 [-47.13; 92.07]	0.526



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1088</b>				
N'	6	6		
Mean (SD)	62.50 (31.95)	86.67 (13.94)		
Adjusted Mean (SE)	59.97 (12.59)	85.38 (13.73)	-25.41 [-61.78; 10.97]	0.171
<b>Center No. 1089</b>				
N'	3	4		
Mean (SD)	94.44 (9.62)	94.44 (4.81)		
Adjusted Mean (SE)	91.92 (17.75)	87.34 (17.53)	4.57 [-44.33; 53.48]	0.854
<b>Center No. 1091</b>				
N'	5	3		
Mean (SD)	85.42 (17.18)	37.50 (41.25)		
Adjusted Mean (SE)	84.95 (15.25)	37.00 (21.44)	47.95 [-3.60; 99.49]	0.068
<b>Center No. 1093</b>				
N'	1	2		
Mean (SD)	83.33 (N.E.)	91.67 (N.E.)		
Adjusted Mean (SE)	80.57 (30.71)	86.34 (30.00)	-5.77 [-90.00; 78.47]	0.893
<b>Center No. 1095</b>				
N'	5	2		
Mean (SD)	45.83 (20.97)	33.33 (0.00)		
Adjusted Mean (SE)	46.13 (15.20)	30.57 (21.75)	15.55 [-36.51; 67.62]	0.558
<b>Center No. 1096</b>				
N'	2	0		
Mean (SD)	91.67 (11.79)	N.E.		
Adjusted Mean (SE)	88.91 (21.75)	N.E.	N.E.	N.E.
<b>Center No. 1100</b>				
N'	1	2		
Mean (SD)	100.00 (N.E.)	50.00 (23.57)		
Adjusted Mean (SE)	97.93 (30.73)	47.93 (21.79)	50.00 [-23.76; 123.76]	0.184
<b>Center No. 1101</b>				
N'	4	5		
Mean (SD)	47.92 (41.04)	63.33 (36.13)		
Adjusted Mean (SE)	45.50 (15.39)	62.09 (13.76)	-16.59 [-57.11; 23.93]	0.422

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1103</b>				
N'	2	3		
Mean (SD)	37.50 (29.46)	80.56 (17.35)		
Adjusted Mean (SE)	34.74 (21.75)	78.49 (17.83)	-43.75 [-99.03; 11.53]	0.121
<b>Center No. 1105</b>				
N'	3	2		
Mean (SD)	72.22 (29.27)	33.33 (N.E.)		
Adjusted Mean (SE)	69.69 (17.75)	30.57 (30.02)	39.12 [-29.29; 107.53]	0.262
<b>Center No. 1108</b>				
N'	15	9		
Mean (SD)	82.78 (31.88)	86.11 (18.63)		
Adjusted Mean (SE)	81.77 (7.93)	85.04 (10.28)	-3.27 [-28.74; 22.19]	0.801
<b>Center No. 1110</b>				
N'	5	5		
Mean (SD)	75.00 (50.00)	71.67 (28.63)		
Adjusted Mean (SE)	75.99 (15.23)	69.05 (13.79)	6.94 [-33.44; 47.32]	0.736
<b>Center No. 1111</b>				
N'	5	0		
Mean (SD)	75.00 (11.79)	N.E.		
Adjusted Mean (SE)	72.93 (21.79)	N.E.	N.E.	N.E.
<b>Center No. 1113</b>				
N'	3	3		
Mean (SD)	80.56 (4.81)	80.56 (20.97)		
Adjusted Mean (SE)	80.33 (17.72)	78.26 (17.77)	2.07 [-47.30; 51.43]	0.934
<b>Center No. 1115</b>				
N'	4	4		
Mean (SD)	61.11 (53.58)	97.92 (4.17)		
Adjusted Mean (SE)	60.68 (17.64)	95.16 (15.43)	-34.48 [-80.55; 11.59]	0.142
<b>Center No. 1116</b>				
N'	1	4		
Mean (SD)	100.00 (N.E.)	88.89 (9.62)		
Adjusted Mean (SE)	97.24 (30.71)	86.12 (17.55)	11.12 [-58.29; 80.54]	0.753

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1118</b>				
N'	3	1		
Mean (SD)	100.00 (N.E.)	100.00 (N.E.)		
Adjusted Mean (SE)	94.71 (29.77)	97.24 (30.71)	-2.53 [-86.44; 81.38]	0.953
<b>Center No. 1119</b>				
N'	3	4		
Mean (SD)	94.44 (9.62)	72.92 (24.88)		
Adjusted Mean (SE)	94.44 (17.70)	75.85 (15.44)	18.60 [-27.55; 64.74]	0.429
<b>Center No. 1121</b>				
N'	3	2		
Mean (SD)	36.11 (25.46)	50.00 (0.00)		
Adjusted Mean (SE)	36.11 (17.70)	47.59 (21.72)	-11.47 [-66.52; 43.57]	0.682
<b>Center No. 1123</b>				
N'	1	1		
Mean (SD)	91.67 (N.E.)	16.67 (N.E.)		
Adjusted Mean (SE)	88.91 (30.71)	13.91 (30.71)	75.00 [-10.18; 160.18]	0.084
<b>Center No. 1124</b>				
N'	3	1		
Mean (SD)	52.78 (42.76)	N.E.		
Adjusted Mean (SE)	57.61 (17.91)	N.E.	N.E.	N.E.
<b>Center No. 1502</b>				
N'	0	3		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Side effects</b>				
<b>Interaction test: p=0.890</b>				
<b>Center No. 1001</b>				
N'	7	4		
Mean (SD)	83.33 (23.57)	75.00 (11.79)		
Adjusted Mean (SE)	85.86 (17.05)	70.03 (17.08)	15.83 [-31.64; 63.30]	0.512

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1002</b>				
N'	1	0		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1003</b>				
N'	0	1		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1005</b>				
N'	12	9		
Mean (SD)	85.42 (16.52)	79.17 (17.68)		
Adjusted Mean (SE)	87.25 (8.75)	75.63 (16.99)	11.62 [-26.21; 49.45]	0.546
<b>Center No. 1007</b>				
N'	2	4		
Mean (SD)	N.E.	91.67 (9.62)		
Adjusted Mean (SE)	N.E.	92.11 (12.37)	N.E.	N.E.
<b>Center No. 1008</b>				
N'	0	3		
Mean (SD)	N.E.	75.00 (N.E.)		
Adjusted Mean (SE)	N.E.	73.42 (23.76)	N.E.	N.E.
<b>Center No. 1010</b>				
N'	2	1		
Mean (SD)	100.00 (N.E.)	58.33 (N.E.)		
Adjusted Mean (SE)	101.86 (23.99)	60.20 (24.67)	41.67 [-25.83; 109.17]	0.225
<b>Center No. 1011</b>				
N'	1	3		
Mean (SD)	N.E.	50.00 (70.71)		
Adjusted Mean (SE)	N.E.	51.90 (17.46)	N.E.	N.E.
<b>Center No. 1012</b>				
N'	2	3		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1014</b>				
N'	1	2		
Mean (SD)	N.E.	100.00 (N.E.)		
Adjusted Mean (SE)	N.E.	106.09 (23.99)	N.E.	N.E.
<b>Center No. 1015</b>				
N'	1	2		
Mean (SD)	N.E.	41.67 (58.93)		
Adjusted Mean (SE)	N.E.	43.53 (17.53)	N.E.	N.E.
<b>Center No. 1017</b>				
N'	2	3		
Mean (SD)	91.67 (N.E.)	83.33 (11.79)		
Adjusted Mean (SE)	92.13 (23.95)	84.27 (17.21)	7.86 [-50.09; 65.81]	0.789
<b>Center No. 1018</b>				
N'	2	1		
Mean (SD)	83.33 (N.E.)	100.00 (N.E.)		
Adjusted Mean (SE)	88.01 (23.99)	101.86 (24.67)	-13.85 [-81.35; 53.65]	0.686
<b>Center No. 1019</b>				
N'	1	1		
Mean (SD)	100.00 (N.E.)	75.00 (N.E.)		
Adjusted Mean (SE)	101.86 (24.67)	76.86 (24.67)	25.00 [-43.45; 93.45]	0.472
<b>Center No. 1021</b>				
N'	7	3		
Mean (SD)	91.67 (11.79)	69.44 (17.35)		
Adjusted Mean (SE)	92.26 (12.20)	71.39 (14.50)	20.87 [-16.09; 57.84]	0.267
<b>Center No. 1022</b>				
N'	2	3		
Mean (SD)	25.00 (N.E.)	62.50 (41.25)		
Adjusted Mean (SE)	37.24 (23.95)	68.16 (17.15)	-30.93 [-88.82; 26.97]	0.293

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1025</b>				
N'	0	1		
Mean (SD)	N.E.	75.00 (N.E.)		
Adjusted Mean (SE)	N.E.	71.20 (24.84)	N.E.	N.E.
<b>Center No. 1027</b>				
N'	1	4		
Mean (SD)	N.E.	83.33 (N.E.)		
Adjusted Mean (SE)	N.E.	85.28 (24.74)	N.E.	N.E.
<b>Center No. 1028</b>				
N'	6	3		
Mean (SD)	70.83 (29.70)	87.50 (17.68)		
Adjusted Mean (SE)	71.75 (10.18)	85.39 (17.26)	-13.64 [-52.78; 25.50]	0.493
<b>Center No. 1029</b>				
N'	3	3		
Mean (SD)	83.33 (N.E.)	N.E.		
Adjusted Mean (SE)	85.20 (23.76)	N.E.	N.E.	N.E.
<b>Center No. 1030</b>				
N'	3	6		
Mean (SD)	100.00 (N.E.)	72.50 (29.11)		
Adjusted Mean (SE)	98.11 (23.76)	69.79 (10.93)	28.31 [-23.06; 79.69]	0.278
<b>Center No. 1032</b>				
N'	1	2		
Mean (SD)	100.00 (N.E.)	33.33 (N.E.)		
Adjusted Mean (SE)	101.86 (24.67)	35.28 (24.74)	66.59 [-2.34; 135.51]	0.058
<b>Center No. 1033</b>				
N'	1	3		
Mean (SD)	N.E.	45.83 (5.89)		
Adjusted Mean (SE)	N.E.	49.14 (17.14)	N.E.	N.E.
<b>Center No. 1034</b>				
N'	2	2		
Mean (SD)	N.E.	75.00 (35.36)		
Adjusted Mean (SE)	N.E.	76.94 (17.63)	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1035</b>				
N'	13	7		
Mean (SD)	89.29 (15.19)	79.17 (31.95)		
Adjusted Mean (SE)	90.88 (9.30)	81.55 (10.16)	9.33 [-17.40; 36.06]	0.492
<b>Center No. 1036</b>				
N'	2	6		
Mean (SD)	91.67 (N.E.)	62.50 (28.46)		
Adjusted Mean (SE)	100.57 (23.99)	60.13 (12.21)	40.44 [-12.43; 93.30]	0.133
<b>Center No. 1037</b>				
N'	4	4		
Mean (SD)	87.50 (17.68)	77.78 (31.55)		
Adjusted Mean (SE)	86.69 (17.20)	74.01 (14.12)	12.68 [-30.87; 56.24]	0.567
<b>Center No. 1039</b>				
N'	1	3		
Mean (SD)	N.E.	91.67 (0.00)		
Adjusted Mean (SE)	N.E.	90.74 (17.40)	N.E.	N.E.
<b>Center No. 1040</b>				
N'	0	2		
Mean (SD)	N.E.	75.00 (N.E.)		
Adjusted Mean (SE)	N.E.	76.86 (24.67)	N.E.	N.E.
<b>Center No. 1041</b>				
N'	0	2		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1042</b>				
N'	3	2		
Mean (SD)	79.17 (17.68)	87.50 (5.89)		
Adjusted Mean (SE)	81.98 (17.24)	86.53 (17.43)	-4.55 [-52.82; 43.72]	0.853
<b>Center No. 1046</b>				
N'	1	0		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1048</b>				
N'	0	1		
Mean (SD)	N.E.	83.33 (N.E.)		
Adjusted Mean (SE)	N.E.	85.20 (24.67)	N.E.	N.E.
<b>Center No. 1050</b>				
N'	2	1		
Mean (SD)	N.E.	37.50 (N.E.)		
Adjusted Mean (SE)	N.E.	39.36 (24.67)	N.E.	N.E.
<b>Center No. 1051</b>				
N'	0	1		
Mean (SD)	N.E.	83.33 (N.E.)		
Adjusted Mean (SE)	N.E.	85.20 (24.67)	N.E.	N.E.
<b>Center No. 1052</b>				
N'	2	2		
Mean (SD)	87.50 (5.89)	54.17 (17.68)		
Adjusted Mean (SE)	89.36 (17.53)	53.24 (17.40)	36.13 [-12.83; 85.08]	0.147
<b>Center No. 1055</b>				
N'	0	2		
Mean (SD)	N.E.	75.00 (N.E.)		
Adjusted Mean (SE)	N.E.	64.19 (23.99)	N.E.	N.E.
<b>Center No. 1058</b>				
N'	0	1		
Mean (SD)	N.E.	75.00 (N.E.)		
Adjusted Mean (SE)	N.E.	76.86 (24.67)	N.E.	N.E.
<b>Center No. 1059</b>				
N'	3	4		
Mean (SD)	75.00 (N.E.)	83.33 (8.33)		
Adjusted Mean (SE)	75.99 (23.78)	82.64 (14.10)	-6.65 [-60.93; 47.62]	0.809
<b>Center No. 1061</b>				
N'	3	3		
Mean (SD)	100.00 (N.E.)	75.00 (35.36)		
Adjusted Mean (SE)	98.11 (23.76)	77.57 (17.29)	20.54 [-36.98; 78.05]	0.482



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1063</b>				
N'	2	1		
Mean (SD)	41.67 (N.E.)	N.E.		
Adjusted Mean (SE)	50.57 (23.99)	N.E.	N.E.	N.E.
<b>Center No. 1064</b>				
N'	0	2		
Mean (SD)	N.E.	100.00 (N.E.)		
Adjusted Mean (SE)	N.E.	100.90 (23.93)	N.E.	N.E.
<b>Center No. 1067</b>				
N'	2	7		
Mean (SD)	87.50 (17.68)	100.00 (N.E.)		
Adjusted Mean (SE)	89.44 (17.63)	93.22 (23.48)	-3.77 [-61.67; 54.12]	0.898
<b>Center No. 1068</b>				
N'	0	2		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1069</b>				
N'	0	1		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1070</b>				
N'	0	3		
Mean (SD)	N.E.	79.17 (17.68)		
Adjusted Mean (SE)	N.E.	80.67 (17.29)	N.E.	N.E.
<b>Center No. 1072</b>				
N'	0	1		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1073</b>				
N'	2	2		
Mean (SD)	87.50 (17.68)	79.17 (5.89)		
Adjusted Mean (SE)	89.40 (17.46)	81.03 (17.53)	8.37 [-40.20; 56.94]	0.734

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1074</b>				
N'	0	2		
Mean (SD)	N.E.	50.00 (N.E.)		
Adjusted Mean (SE)	N.E.	57.57 (24.06)	N.E.	N.E.
<b>Center No. 1076</b>				
N'	1	2		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1077</b>				
N'	0	1		
Mean (SD)	N.E.	91.67 (N.E.)		
Adjusted Mean (SE)	N.E.	93.61 (24.74)	N.E.	N.E.
<b>Center No. 1079</b>				
N'	2	2		
Mean (SD)	54.17 (29.46)	50.00 (N.E.)		
Adjusted Mean (SE)	53.20 (17.43)	64.55 (23.95)	-11.35 [-69.79; 47.08]	0.702
<b>Center No. 1080</b>				
N'	0	1		
Mean (SD)	N.E.	41.67 (N.E.)		
Adjusted Mean (SE)	N.E.	43.53 (24.67)	N.E.	N.E.
<b>Center No. 1082</b>				
N'	2	6		
Mean (SD)	95.83 (5.89)	77.78 (27.72)		
Adjusted Mean (SE)	97.74 (17.46)	79.65 (10.24)	18.08 [-21.53; 57.69]	0.369
<b>Center No. 1084</b>				
N'	2	2		
Mean (SD)	100.00 (N.E.)	58.33 (58.93)		
Adjusted Mean (SE)	101.86 (24.67)	60.24 (17.46)	41.63 [-17.79; 101.04]	0.169
<b>Center No. 1085</b>				
N'	0	1		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1086</b>				
N'	2	6		
Mean (SD)	95.83 (5.89)	64.58 (19.69)		
Adjusted Mean (SE)	97.78 (17.63)	63.18 (12.21)	34.60 [-7.53; 76.73]	0.107
<b>Center No. 1087</b>				
N'	0	2		
Mean (SD)	N.E.	50.00 (11.79)		
Adjusted Mean (SE)	N.E.	49.03 (17.43)	N.E.	N.E.
<b>Center No. 1088</b>				
N'	2	5		
Mean (SD)	79.17 (5.89)	93.75 (7.98)		
Adjusted Mean (SE)	81.07 (17.46)	95.81 (12.36)	-14.74 [-56.66; 27.18]	0.489
<b>Center No. 1089</b>				
N'	0	2		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1091</b>				
N'	0	2		
Mean (SD)	N.E.	83.33 (N.E.)		
Adjusted Mean (SE)	N.E.	85.28 (24.74)	N.E.	N.E.
<b>Center No. 1093</b>				
N'	0	1		
Mean (SD)	N.E.	62.50 (N.E.)		
Adjusted Mean (SE)	N.E.	64.36 (24.67)	N.E.	N.E.
<b>Center No. 1095</b>				
N'	2	2		
Mean (SD)	83.33 (11.79)	66.67 (N.E.)		
Adjusted Mean (SE)	82.36 (17.43)	76.98 (23.99)	5.39 [-53.05; 63.82]	0.856
<b>Center No. 1096</b>				
N'	1	0		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1100</b>				
N'	0	1		
Mean (SD)	N.E.	50.00 (N.E.)		
Adjusted Mean (SE)	N.E.	51.94 (24.74)	N.E.	N.E.
<b>Center No. 1101</b>				
N'	2	4		
Mean (SD)	N.E.	85.42 (2.95)		
Adjusted Mean (SE)	N.E.	87.93 (17.20)	N.E.	N.E.
<b>Center No. 1103</b>				
N'	0	2		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1105</b>				
N'	1	2		
Mean (SD)	100.00 (N.E.)	75.00 (N.E.)		
Adjusted Mean (SE)	101.86 (24.67)	78.27 (23.99)	23.59 [-43.91; 91.09]	0.492
<b>Center No. 1108</b>				
N'	5	6		
Mean (SD)	100.00 (0.00)	86.11 (12.73)		
Adjusted Mean (SE)	101.87 (17.13)	89.06 (13.95)	12.81 [-30.31; 55.93]	0.559
<b>Center No. 1110</b>				
N'	2	5		
Mean (SD)	100.00 (N.E.)	61.11 (12.73)		
Adjusted Mean (SE)	101.94 (24.74)	61.27 (14.10)	40.67 [-15.48; 96.81]	0.155
<b>Center No. 1111</b>				
N'	2	0		
Mean (SD)	91.67 (N.E.)	N.E.		
Adjusted Mean (SE)	93.61 (24.74)	N.E.	N.E.	N.E.
<b>Center No. 1113</b>				
N'	1	1		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1115</b>				
N'	1	3		
Mean (SD)	N.E.	50.00 (N.E.)		
Adjusted Mean (SE)	N.E.	49.05 (23.76)	N.E.	N.E.
<b>Center No. 1118</b>				
N'	2	0		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1119</b>				
N'	0	3		
Mean (SD)	N.E.	66.67 (47.14)		
Adjusted Mean (SE)	N.E.	65.70 (17.43)	N.E.	N.E.
<b>Center No. 1121</b>				
N'	2	0		
Mean (SD)	75.00 (35.36)	N.E.		
Adjusted Mean (SE)	76.90 (17.46)	N.E.	N.E.	N.E.
<b>Center No. 1123</b>				
N'	0	1		
Mean (SD)	N.E.	100.00 (N.E.)		
Adjusted Mean (SE)	N.E.	101.86 (24.67)	N.E.	N.E.
<b>Center No. 1124</b>				
N'	2	1		
Mean (SD)	58.33 (N.E.)	N.E.		
Adjusted Mean (SE)	61.57 (24.16)	N.E.	N.E.	N.E.
<b>Center No. 1502</b>				
N'	0	3		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Convenience</b>				
<b>Interaction test: N.E.</b>				
<b>Center No. 1001</b>				
N'	9	6		
Mean (SD)	59.26 (32.87)	61.11 (20.03)		
Adjusted Mean (SE)	58.75 (13.14)	49.66 (17.37)	9.09 [-38.42; 56.60]	0.682

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1002</b>				
N'	3	0		
Mean (SD)	86.11 (3.93)	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1003</b>				
N'	2	2		
Mean (SD)	61.11 (47.14)	63.89 (51.07)		
Adjusted Mean (SE)	61.11 (34.75)	63.89 (34.75)	-2.78 [-214.23; 208.67]	0.960
<b>Center No. 1005</b>				
N'	25	19		
Mean (SD)	78.74 (20.97)	67.59 (29.57)		
Adjusted Mean (SE)	78.24 (5.23)	64.35 (6.96)	13.89 [-2.73; 30.51]	0.099
<b>Center No. 1007</b>				
N'	5	4		
Mean (SD)	83.33 (16.67)	79.17 (24.16)		
Adjusted Mean (SE)	80.48 (13.68)	77.30 (13.85)	3.18 [-40.17; 46.54]	0.858
<b>Center No. 1008</b>				
N'	2	3		
Mean (SD)	94.44 (7.86)	97.22 (3.93)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1010</b>				
N'	2	2		
Mean (SD)	44.44 (N.E.)	75.00 (35.36)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1011</b>				
N'	2	3		
Mean (SD)	30.56 (35.36)	66.67 (15.71)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1012</b>				
N'	3	4		
Mean (SD)	75.93 (13.98)	80.56 (19.64)		
Adjusted Mean (SE)	73.15 (11.21)	80.56 (9.26)	-7.41 [-42.53; 27.72]	0.590

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1014</b>				
N'	5	2		
Mean (SD)	88.89 (15.71)	80.56 (3.93)		
Adjusted Mean (SE)	91.07 (7.39)	81.99 (13.77)	9.08 [-38.94; 57.11]	0.590
<b>Center No. 1015</b>				
N'	4	2		
Mean (SD)	90.28 (8.33)	2.78 (3.93)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1017</b>				
N'	4	4		
Mean (SD)	88.89 (22.22)	75.00 (35.36)		
Adjusted Mean (SE)	88.89 (11.68)	91.15 (14.40)	-2.26 [-49.92; 45.40]	0.908
<b>Center No. 1018</b>				
N'	7	4		
Mean (SD)	91.27 (8.40)	68.06 (45.67)		
Adjusted Mean (SE)	101.60 (19.32)	73.22 (16.23)	28.38 [-16.40; 73.15]	0.182
<b>Center No. 1019</b>				
N'	2	2		
Mean (SD)	83.33 (15.71)	100.00 (0.00)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1021</b>				
N'	14	5		
Mean (SD)	74.21 (29.85)	72.22 (17.12)		
Adjusted Mean (SE)	73.93 (7.50)	72.42 (12.46)	1.51 [-29.42; 32.44]	0.919
<b>Center No. 1022</b>				
N'	3	3		
Mean (SD)	75.93 (12.83)	88.89 (9.62)		
Adjusted Mean (SE)	78.00 (8.49)	91.18 (8.49)	-13.18 [-64.86; 38.50]	0.387
<b>Center No. 1025</b>				
N'	0	2		
Mean (SD)	N.E.	69.44 (3.93)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1027</b>				
N'	3	4		
Mean (SD)	88.89 (14.70)	66.67 (11.11)		
Adjusted Mean (SE)	89.81 (10.64)	65.74 (8.48)	24.07 [-20.44; 68.59]	0.208
<b>Center No. 1028</b>				
N'	11	4		
Mean (SD)	81.31 (26.68)	72.22 (9.62)		
Adjusted Mean (SE)	81.20 (9.58)	77.75 (12.65)	3.45 [-29.44; 36.33]	0.822
<b>Center No. 1029</b>				
N'	13	5		
Mean (SD)	83.33 (28.82)	75.00 (11.79)		
Adjusted Mean (SE)	90.51 (10.09)	84.21 (20.97)	6.30 [-39.84; 52.45]	0.775
<b>Center No. 1030</b>				
N'	10	8		
Mean (SD)	80.25 (28.48)	84.26 (14.66)		
Adjusted Mean (SE)	72.98 (9.87)	81.66 (10.90)	-8.68 [-39.00; 21.65]	0.549
<b>Center No. 1032</b>				
N'	2	4		
Mean (SD)	94.44 (N.E.)	77.78 (29.40)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1033</b>				
N'	4	4		
Mean (SD)	81.94 (23.73)	84.72 (20.97)		
Adjusted Mean (SE)	80.01 (14.82)	94.63 (15.88)	-14.63 [-76.32; 47.07]	0.546
<b>Center No. 1034</b>				
N'	4	2		
Mean (SD)	90.74 (11.56)	33.33 (47.14)		
Adjusted Mean (SE)	93.56 (18.46)	32.45 (28.79)	61.11 [-60.66; 182.89]	0.209
<b>Center No. 1035</b>				
N'	24	9		
Mean (SD)	77.53 (27.08)	85.19 (17.12)		
Adjusted Mean (SE)	53.51 (6.30)	58.85 (8.52)	-5.34 [-22.48; 11.79]	0.529



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1036</b>				
N'	7	6		
Mean (SD)	74.60 (34.52)	86.67 (7.45)		
Adjusted Mean (SE)	58.49 (5.38)	56.87 (6.23)	1.62 [-16.76; 20.00]	0.846
<b>Center No. 1037</b>				
N'	6	5		
Mean (SD)	70.00 (35.05)	69.44 (25.86)		
Adjusted Mean (SE)	61.81 (14.80)	68.45 (15.12)	-6.64 [-55.69; 42.41]	0.763
<b>Center No. 1039</b>				
N'	4	3		
Mean (SD)	80.56 (21.52)	90.74 (11.56)		
Adjusted Mean (SE)	82.41 (10.88)	90.74 (9.74)	-8.33 [-54.81; 38.14]	0.608
<b>Center No. 1040</b>				
N'	0	2		
Mean (SD)	N.E.	44.44 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1041</b>				
N'	4	4		
Mean (SD)	76.39 (13.89)	41.67 (51.07)		
Adjusted Mean (SE)	76.74 (13.38)	32.23 (16.54)	44.51 [-9.40; 98.41]	0.087
<b>Center No. 1042</b>				
N'	4	3		
Mean (SD)	80.56 (11.56)	44.44 (34.69)		
Adjusted Mean (SE)	78.31 (13.10)	42.95 (15.08)	35.36 [-19.97; 90.70]	0.151
<b>Center No. 1046</b>				
N'	1	0		
Mean (SD)	61.11 (N.E.)	N.E.		
Adjusted Mean (SE)	61.11 (0.00)	N.E.	N.E.	N.E.
<b>Center No. 1048</b>				
N'	0	2		
Mean (SD)	N.E.	86.11 (11.79)		
Adjusted Mean (SE)	N.E.	86.11 (0.00)	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1049</b>				
N'	1	0		
Mean (SD)	5.56 (N.E.)	N.E.		
Adjusted Mean (SE)	5.56 (0.00)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>				
N'	6	5		
Mean (SD)	90.00 (8.24)	74.44 (42.24)		
Adjusted Mean (SE)	89.69 (17.87)	75.31 (24.70)	14.38 [-37.10; 65.86]	0.530
<b>Center No. 1051</b>				
N'	1	1		
Mean (SD)	83.33 (N.E.)	66.67 (N.E.)		
Adjusted Mean (SE)	83.33 (0.00)	66.67 (0.00)	16.67 [N.E.; N.E.]	N.E.
<b>Center No. 1052</b>				
N'	7	3		
Mean (SD)	73.81 (24.37)	62.96 (42.43)		
Adjusted Mean (SE)	84.73 (20.26)	68.72 (22.90)	16.01 [-64.34; 96.36]	0.643
<b>Center No. 1055</b>				
N'	2	3		
Mean (SD)	97.22 (3.93)	94.44 (7.86)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1058</b>				
N'	0	1		
Mean (SD)	N.E.	50.00 (N.E.)		
Adjusted Mean (SE)	N.E.	50.00 (0.00)	N.E.	N.E.
<b>Center No. 1059</b>				
N'	7	5		
Mean (SD)	87.04 (6.73)	70.83 (35.54)		
Adjusted Mean (SE)	87.23 (10.13)	79.88 (11.63)	7.36 [-26.89; 41.60]	0.639
<b>Center No. 1061</b>				
N'	8	4		
Mean (SD)	68.06 (26.52)	70.83 (16.59)		
Adjusted Mean (SE)	72.10 (13.65)	72.85 (13.49)	-0.76 [-37.19; 35.68]	0.964

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1063</b>				
N'	4	1		
Mean (SD)	86.11 (16.67)	N.E.		
Adjusted Mean (SE)	86.11 (8.33)	N.E.	N.E.	N.E.
<b>Center No. 1064</b>				
N'	0	2		
Mean (SD)	N.E.	91.67 (11.79)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1067</b>				
N'	8	14		
Mean (SD)	73.61 (33.43)	75.25 (31.46)		
Adjusted Mean (SE)	71.78 (11.57)	81.05 (11.20)	-9.27 [-44.16; 25.62]	0.585
<b>Center No. 1068</b>				
N'	0	2		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1069</b>				
N'	3	2		
Mean (SD)	61.11 (23.57)	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1070</b>				
N'	1	4		
Mean (SD)	55.56 (N.E.)	63.89 (3.93)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1072</b>				
N'	2	1		
Mean (SD)	88.89 (N.E.)	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1073</b>				
N'	11	6		
Mean (SD)	86.87 (13.67)	67.59 (34.68)		
Adjusted Mean (SE)	85.88 (8.84)	67.55 (11.63)	18.33 [-7.71; 44.37]	0.152
<b>Center No. 1074</b>				
N'	5	3		
Mean (SD)	85.56 (22.08)	88.89 (19.25)		
Adjusted Mean (SE)	87.56 (8.68)	92.23 (11.31)	-4.67 [-40.72; 31.38]	0.753

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1076</b>				
N'	1	5		
Mean (SD)	94.44 (N.E.)	88.89 (9.62)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1077</b>				
N'	3	1		
Mean (SD)	79.63 (17.86)	94.44 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1079</b>				
N'	4	2		
Mean (SD)	63.89 (25.05)	58.33 (27.50)		
Adjusted Mean (SE)	73.15 (18.52)	52.31 (22.89)	20.83 [-112.46; 154.13]	0.571
<b>Center No. 1080</b>				
N'	3	1		
Mean (SD)	81.48 (23.13)	100.00 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1082</b>				
N'	4	6		
Mean (SD)	91.67 (7.17)	79.63 (14.34)		
Adjusted Mean (SE)	91.24 (6.92)	78.81 (8.04)	12.43 [-12.44; 37.29]	0.267
<b>Center No. 1084</b>				
N'	2	3		
Mean (SD)	75.00 (27.50)	90.74 (8.49)		
Adjusted Mean (SE)	79.02 (13.49)	89.40 (11.02)	-10.38 [-85.34; 64.57]	0.612
<b>Center No. 1085</b>				
N'	0	2		
Mean (SD)	N.E.	72.22 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1086</b>				
N'	5	8		
Mean (SD)	84.44 (11.39)	69.84 (36.13)		
Adjusted Mean (SE)	83.51 (13.08)	74.35 (11.56)	9.16 [-30.32; 48.65]	0.616

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1087</b>				
N'	1	3		
Mean (SD)	100.00 (N.E.)	81.48 (3.21)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1088</b>				
N'	6	6		
Mean (SD)	63.89 (38.77)	73.33 (36.73)		
Adjusted Mean (SE)	66.28 (15.05)	77.55 (15.13)	-11.27 [-59.00; 36.46]	0.606
<b>Center No. 1089</b>				
N'	3	4		
Mean (SD)	70.37 (27.96)	88.89 (9.62)		
Adjusted Mean (SE)	67.27 (14.19)	85.79 (12.89)	-18.52 [-75.76; 38.73]	0.379
<b>Center No. 1091</b>				
N'	5	3		
Mean (SD)	80.56 (17.27)	66.67 (15.71)		
Adjusted Mean (SE)	82.77 (8.68)	68.51 (12.46)	14.26 [-25.25; 53.78]	0.396
<b>Center No. 1093</b>				
N'	1	2		
Mean (SD)	66.67 (N.E.)	77.78 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1095</b>				
N'	5	2		
Mean (SD)	66.67 (16.36)	75.00 (19.64)		
Adjusted Mean (SE)	70.53 (7.31)	86.51 (12.58)	-15.98 [-58.18; 26.21]	0.314
<b>Center No. 1096</b>				
N'	2	0		
Mean (SD)	100.00 (0.00)	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1100</b>				
N'	1	2		
Mean (SD)	77.78 (N.E.)	91.67 (11.79)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1101</b>				
N'	4	5		
Mean (SD)	75.00 (20.54)	64.44 (14.49)		
Adjusted Mean (SE)	52.12 (16.44)	45.40 (14.71)	6.72 [-49.99; 63.43]	0.773
<b>Center No. 1103</b>				
N'	2	3		
Mean (SD)	77.78 (15.71)	87.04 (17.86)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1105</b>				
N'	3	2		
Mean (SD)	81.48 (6.42)	66.67 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1108</b>				
N'	15	9		
Mean (SD)	81.11 (30.85)	91.98 (10.43)		
Adjusted Mean (SE)	80.19 (6.94)	87.65 (9.71)	-7.47 [-31.87; 16.93]	0.531
<b>Center No. 1110</b>				
N'	5	5		
Mean (SD)	69.44 (46.81)	86.67 (24.09)		
Adjusted Mean (SE)	64.72 (11.21)	62.60 (12.33)	2.12 [-39.86; 44.10]	0.906
<b>Center No. 1111</b>				
N'	5	0		
Mean (SD)	66.67 (0.00)	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1113</b>				
N'	3	3		
Mean (SD)	72.22 (34.69)	88.89 (9.62)		
Adjusted Mean (SE)	78.33 (6.21)	64.44 (6.57)	13.89 [-27.17; 54.94]	0.283
<b>Center No. 1115</b>				
N'	4	4		
Mean (SD)	48.15 (36.99)	100.00 (0.00)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1116</b>				
N'	1	4		
Mean (SD)	83.33 (N.E.)	81.48 (13.98)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1118</b>				
N'	3	1		
Mean (SD)	88.89 (N.E.)	100.00 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1119</b>				
N'	3	4		
Mean (SD)	87.04 (17.86)	52.78 (36.43)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1121</b>				
N'	3	2		
Mean (SD)	90.74 (16.04)	77.78 (31.43)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1123</b>				
N'	1	1		
Mean (SD)	94.44 (N.E.)	94.44 (N.E.)		
Adjusted Mean (SE)	94.44 (0.00)	94.44 (0.00)	0.00 [N.E.; N.E.]	N.E.
<b>Center No. 1124</b>				
N'	3	1		
Mean (SD)	61.11 (34.69)	N.E.		
Adjusted Mean (SE)	61.11 (20.03)	N.E.	N.E.	N.E.
<b>Center No. 1502</b>				
N'	0	3		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Global satisfaction</b>				
<b>Interaction test: N.E.</b>				
<b>Center No. 1001</b>				
N'	9	6		
Mean (SD)	62.96 (36.59)	47.22 (42.76)		
Adjusted Mean (SE)	63.08 (11.42)	47.33 (19.44)	15.75 [-33.79; 65.29]	0.499

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1002</b>				
N'	3	0		
Mean (SD)	91.67 (11.79)	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1003</b>				
N'	2	2		
Mean (SD)	58.33 (58.93)	50.00 (70.71)		
Adjusted Mean (SE)	58.33 (46.02)	50.00 (46.02)	8.33 [-271.71; 288.37]	0.910
<b>Center No. 1005</b>				
N'	25	19		
Mean (SD)	78.99 (24.47)	75.00 (29.52)		
Adjusted Mean (SE)	77.55 (5.75)	70.15 (7.44)	7.40 [-10.29; 25.09]	0.403
<b>Center No. 1007</b>				
N'	5	4		
Mean (SD)	97.22 (4.81)	93.75 (7.98)		
Adjusted Mean (SE)	73.97 (15.85)	68.94 (15.82)	5.03 [-9.21; 19.27]	0.406
<b>Center No. 1008</b>				
N'	2	3		
Mean (SD)	100.00 (0.00)	100.00 (0.00)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1010</b>				
N'	2	2		
Mean (SD)	83.33 (N.E.)	50.00 (70.71)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1011</b>				
N'	2	3		
Mean (SD)	41.67 (58.93)	50.00 (70.71)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1012</b>				
N'	3	4		
Mean (SD)	50.00 (50.00)	50.00 (70.71)		
Adjusted Mean (SE)	56.94 (41.55)	29.12 (32.33)	27.83 [-112.45; 168.11]	0.611



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1014</b>				
N'	5	2		
Mean (SD)	86.67 (13.94)	66.67 (0.00)		
Adjusted Mean (SE)	86.55 (7.00)	69.43 (13.85)	17.12 [-29.88; 64.12]	0.330
<b>Center No. 1015</b>				
N'	4	2		
Mean (SD)	95.83 (8.33)	45.83 (29.46)		
Adjusted Mean (SE)	97.22 (10.20)	48.61 (15.87)	48.61 [-3.53; 100.76]	0.059
<b>Center No. 1017</b>				
N'	4	4		
Mean (SD)	87.50 (19.84)	58.33 (47.14)		
Adjusted Mean (SE)	87.50 (9.36)	59.09 (10.17)	28.41 [-7.10; 63.93]	0.095
<b>Center No. 1018</b>				
N'	7	4		
Mean (SD)	89.29 (12.47)	66.67 (44.62)		
Adjusted Mean (SE)	105.72 (18.99)	74.88 (15.90)	30.84 [-12.98; 74.65]	0.143
<b>Center No. 1019</b>				
N'	2	2		
Mean (SD)	95.83 (5.89)	54.17 (17.68)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1021</b>				
N'	14	5		
Mean (SD)	67.86 (37.53)	63.33 (26.74)		
Adjusted Mean (SE)	66.91 (9.86)	64.00 (16.30)	2.91 [-37.70; 43.52]	0.881
<b>Center No. 1022</b>				
N'	3	3		
Mean (SD)	77.78 (25.46)	63.89 (41.11)		
Adjusted Mean (SE)	29.74 (22.43)	55.39 (22.43)	-25.65 [-162.11; 110.81]	0.504
<b>Center No. 1025</b>				
N'	0	2		
Mean (SD)	N.E.	50.00 (23.57)		
Adjusted Mean (SE)	N.E.	50.00 (0.00)	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1027</b>				
N'	3	4		
Mean (SD)	83.33 (28.87)	75.00 (43.30)		
Adjusted Mean (SE)	112.50 (28.01)	45.83 (24.03)	66.67 [-51.82; 185.15]	0.193
<b>Center No. 1028</b>				
N'	11	4		
Mean (SD)	77.27 (28.65)	63.89 (29.27)		
Adjusted Mean (SE)	66.39 (12.68)	49.49 (19.19)	16.90 [-30.73; 64.52]	0.451
<b>Center No. 1029</b>				
N'	13	5		
Mean (SD)	82.64 (28.97)	83.33 (23.57)		
Adjusted Mean (SE)	93.21 (10.37)	92.86 (21.74)	0.35 [-45.38; 46.09]	0.987
<b>Center No. 1030</b>				
N'	10	8		
Mean (SD)	75.00 (30.62)	68.06 (30.92)		
Adjusted Mean (SE)	74.85 (12.52)	65.87 (13.74)	8.98 [-29.24; 47.20]	0.622
<b>Center No. 1032</b>				
N'	2	4		
Mean (SD)	91.67 (N.E.)	27.78 (48.11)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1033</b>				
N'	4	4		
Mean (SD)	79.17 (31.55)	56.25 (29.17)		
Adjusted Mean (SE)	86.33 (18.31)	59.00 (18.92)	27.32 [-46.57; 101.22]	0.363
<b>Center No. 1034</b>				
N'	4	2		
Mean (SD)	88.89 (9.62)	8.33 (11.79)		
Adjusted Mean (SE)	87.22 (5.76)	12.22 (9.06)	75.00 [36.45; 113.55]	0.008
<b>Center No. 1035</b>				
N'	24	9		
Mean (SD)	81.44 (31.38)	75.93 (15.84)		
Adjusted Mean (SE)	60.38 (6.82)	56.89 (9.19)	3.49 [-14.84; 21.82]	0.700

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1036</b>				
N'	7	6		
Mean (SD)	80.95 (36.55)	46.67 (26.74)		
Adjusted Mean (SE)	75.51 (7.33)	5.72 (8.56)	69.79 [44.77; 94.81]	<.001
<b>Center No. 1037</b>				
N'	6	5		
Mean (SD)	88.33 (16.24)	43.75 (38.11)		
Adjusted Mean (SE)	58.87 (20.91)	28.18 (17.32)	30.69 [-29.00; 90.38]	0.270
<b>Center No. 1039</b>				
N'	4	3		
Mean (SD)	89.58 (15.77)	86.11 (17.35)		
Adjusted Mean (SE)	92.36 (9.71)	86.11 (8.69)	6.25 [-35.21; 47.71]	0.664
<b>Center No. 1040</b>				
N'	0	2		
Mean (SD)	N.E.	83.33 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1041</b>				
N'	4	4		
Mean (SD)	91.67 (11.79)	54.17 (29.46)		
Adjusted Mean (SE)	92.10 (10.16)	61.00 (12.08)	31.10 [-5.19; 67.39]	0.079
<b>Center No. 1042</b>				
N'	4	3		
Mean (SD)	91.67 (11.79)	36.11 (41.11)		
Adjusted Mean (SE)	99.59 (10.71)	41.39 (11.86)	58.20 [15.48; 100.91]	0.019
<b>Center No. 1046</b>				
N'	1	0		
Mean (SD)	91.67 (N.E.)	N.E.		
Adjusted Mean (SE)	91.67 (0.00)	N.E.	N.E.	N.E.
<b>Center No. 1048</b>				
N'	0	2		
Mean (SD)	N.E.	100.00 (0.00)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1049</b>				
N'	1	0		
Mean (SD)	0.00 (N.E.)	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1050</b>				
N'	6	5		
Mean (SD)	86.67 (11.18)	80.00 (27.39)		
Adjusted Mean (SE)	57.87 (16.00)	47.41 (17.67)	10.46 [-21.66; 42.58]	0.466
<b>Center No. 1051</b>				
N'	1	1		
Mean (SD)	50.00 (N.E.)	66.67 (N.E.)		
Adjusted Mean (SE)	50.00 (0.00)	66.67 (0.00)	-16.67 [N.E.; N.E.]	N.E.
<b>Center No. 1052</b>				
N'	7	3		
Mean (SD)	77.38 (23.92)	38.89 (19.25)		
Adjusted Mean (SE)	78.96 (16.03)	39.24 (16.36)	39.72 [-21.82; 101.25]	0.165
<b>Center No. 1055</b>				
N'	2	3		
Mean (SD)	100.00 (0.00)	95.83 (5.89)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1058</b>				
N'	0	1		
Mean (SD)	N.E.	83.33 (N.E.)		
Adjusted Mean (SE)	N.E.	83.33 (0.00)	N.E.	N.E.
<b>Center No. 1059</b>				
N'	7	5		
Mean (SD)	77.78 (10.09)	89.58 (15.77)		
Adjusted Mean (SE)	76.00 (6.10)	87.08 (7.56)	-11.08 [-32.49; 10.32]	0.272
<b>Center No. 1061</b>				
N'	8	4		
Mean (SD)	70.83 (36.73)	68.75 (36.24)		
Adjusted Mean (SE)	70.73 (19.43)	68.70 (20.01)	2.03 [-52.21; 56.27]	0.934

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1063</b>				
N'	4	1		
Mean (SD)	81.25 (32.19)	N.E.		
Adjusted Mean (SE)	81.25 (16.09)	N.E.	N.E.	N.E.
<b>Center No. 1064</b>				
N'	0	2		
Mean (SD)	N.E.	91.67 (11.79)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1067</b>				
N'	8	14		
Mean (SD)	83.33 (35.63)	74.24 (31.94)		
Adjusted Mean (SE)	83.77 (12.24)	70.90 (11.71)	12.87 [-23.73; 49.48]	0.471
<b>Center No. 1068</b>				
N'	0	2		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1069</b>				
N'	3	2		
Mean (SD)	62.50 (5.89)	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1070</b>				
N'	1	4		
Mean (SD)	0.00 (N.E.)	54.17 (29.46)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1072</b>				
N'	2	1		
Mean (SD)	50.00 (N.E.)	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1073</b>				
N'	11	6		
Mean (SD)	90.15 (9.73)	65.28 (35.91)		
Adjusted Mean (SE)	87.44 (7.97)	62.90 (10.55)	24.54 [-0.50; 49.58]	0.054

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1074</b>				
N'	5	3		
Mean (SD)	86.67 (15.14)	83.33 (28.87)		
Adjusted Mean (SE)	89.02 (8.94)	87.26 (11.64)	1.76 [-35.37; 38.90]	0.908
<b>Center No. 1076</b>				
N'	1	5		
Mean (SD)	100.00 (N.E.)	91.67 (8.33)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1077</b>				
N'	3	1		
Mean (SD)	69.44 (38.49)	83.33 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1079</b>				
N'	4	2		
Mean (SD)	66.67 (40.82)	75.00 (35.36)		
Adjusted Mean (SE)	88.10 (20.08)	63.39 (27.24)	24.70 [-123.21; 172.62]	0.547
<b>Center No. 1080</b>				
N'	3	1		
Mean (SD)	97.22 (4.81)	33.33 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1082</b>				
N'	4	6		
Mean (SD)	93.75 (7.98)	61.11 (20.86)		
Adjusted Mean (SE)	91.29 (9.37)	61.04 (11.66)	30.26 [-5.88; 66.40]	0.086
<b>Center No. 1084</b>				
N'	2	3		
Mean (SD)	87.50 (5.89)	63.89 (48.83)		
Adjusted Mean (SE)	126.39 (44.56)	50.93 (36.34)	75.46 [-172.10; 323.03]	0.320
<b>Center No. 1085</b>				
N'	0	2		
Mean (SD)	N.E.	83.33 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1086</b>				
N'	5	8		
Mean (SD)	91.67 (11.79)	44.05 (43.22)		
Adjusted Mean (SE)	93.31 (16.21)	31.24 (13.55)	62.07 [14.65; 109.50]	0.015
<b>Center No. 1087</b>				
N'	1	3		
Mean (SD)	100.00 (N.E.)	61.11 (20.97)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1088</b>				
N'	6	6		
Mean (SD)	68.06 (16.17)	91.67 (8.33)		
Adjusted Mean (SE)	70.36 (5.46)	99.13 (6.29)	-28.77 [-46.47; - 11.06]	0.005
<b>Center No. 1089</b>				
N'	3	4		
Mean (SD)	88.89 (9.62)	94.44 (9.62)		
Adjusted Mean (SE)	58.33 (8.11)	63.89 (7.84)	-5.56 [-35.75; 24.64]	0.599
<b>Center No. 1091</b>				
N'	5	3		
Mean (SD)	87.50 (14.43)	58.33 (11.79)		
Adjusted Mean (SE)	89.19 (6.01)	60.13 (8.00)	29.06 [2.92; 55.20]	0.036
<b>Center No. 1093</b>				
N'	1	2		
Mean (SD)	91.67 (N.E.)	91.67 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1095</b>				
N'	5	2		
Mean (SD)	64.58 (32.90)	33.33 (0.00)		
Adjusted Mean (SE)	69.04 (16.20)	41.53 (29.58)	27.51 [-64.94; 119.97]	0.413
<b>Center No. 1096</b>				
N'	2	0		
Mean (SD)	95.83 (5.89)	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1100</b>				
N'	1	2		
Mean (SD)	100.00 (N.E.)	66.67 (47.14)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1101</b>				
N'	4	5		
Mean (SD)	75.00 (28.87)	58.33 (33.33)		
Adjusted Mean (SE)	76.76 (18.26)	46.46 (16.34)	30.30 [-32.69; 93.28]	0.271
<b>Center No. 1103</b>				
N'	2	3		
Mean (SD)	50.00 (23.57)	77.78 (9.62)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1105</b>				
N'	3	2		
Mean (SD)	72.22 (9.62)	33.33 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1108</b>				
N'	15	9		
Mean (SD)	82.22 (32.86)	87.04 (20.88)		
Adjusted Mean (SE)	79.38 (7.99)	77.77 (11.13)	1.61 [-26.45; 29.67]	0.906
<b>Center No. 1110</b>				
N'	5	5		
Mean (SD)	75.00 (50.00)	58.33 (40.82)		
Adjusted Mean (SE)	80.87 (23.27)	57.97 (23.46)	22.90 [-56.59; 102.40]	0.507
<b>Center No. 1111</b>				
N'	5	0		
Mean (SD)	75.00 (11.79)	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1113</b>				
N'	3	3		
Mean (SD)	77.78 (4.81)	91.67 (8.33)		
Adjusted Mean (SE)	72.78 (4.36)	97.50 (4.92)	-24.72 [-56.24; 6.80]	0.078



	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1115</b>				
N'	4	4		
Mean (SD)	55.56 (50.92)	97.92 (4.17)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1116</b>				
N'	1	4		
Mean (SD)	100.00 (N.E.)	61.11 (53.58)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1118</b>				
N'	3	1		
Mean (SD)	100.00 (N.E.)	100.00 (N.E.)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1119</b>				
N'	3	4		
Mean (SD)	94.44 (9.62)	58.33 (44.10)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1121</b>				
N'	3	2		
Mean (SD)	55.56 (29.27)	70.83 (5.89)		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<b>Center No. 1123</b>				
N'	1	1		
Mean (SD)	100.00 (N.E.)	83.33 (N.E.)		
Adjusted Mean (SE)	100.00 (0.00)	83.33 (0.00)	16.67 [N.E.; N.E.]	N.E.
<b>Center No. 1124</b>				
N'	3	1		
Mean (SD)	86.11 (24.06)	N.E.		
Adjusted Mean (SE)	86.11 (13.89)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison	
	AMG334 (N=388)	Topiramate (N=388)	Mean Difference [95% CI]	p-value
<b>Center No. 1502</b>				
N'	0	3		
Mean (SD)	N.E.	N.E.		
Adjusted Mean (SE)	N.E.	N.E.	N.E.	N.E.
<p>N': Number of patients in the analysis            CI: Confidence interval            N.E.: Not estimable            SD: Standard deviation            SE: Standard error</p> <p>Linear mixed model for repeated measures includes treatment group, stratification factor, scheduled visit, subgroup, interaction between treatment group and scheduled visit, interaction between treatment group and subgroup and interaction between treatment group, scheduled visit and subgroup.</p> <p>If interaction test is N.E., linear mixed model for repeated measures is calculated separately for each subgroup and includes treatment group, stratification factor, scheduled visit and interaction between treatment group and scheduled visit.            The model utilizes unstructured covariance matrix in the repeated statement.</p> <p>Subgroup analysis results are only displayed for subgroups with N' &gt; 0 in at least one treatment group.</p>				

## Safety Analysis

**Table 14.3.1-1.1 Overview of treatment-emergent adverse events occurring during study (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
<b>Any AE</b>					
n (%)	338 (87.1)	361 (93.0)	0.51 [0.31; 0.83] 0.006	0.94 [0.89; 0.98] 0.006	-0.06 [-0.10; -0.02] 0.006
<b>Any SAE</b>					
n (%)	10 (2.6)	19 (4.9)	0.51 [0.24; 1.12] 0.094	0.53 [0.25; 1.12] 0.095	-0.02 [-0.05; 0.00] 0.088
<b>Any AE leading to discontinuation of study treatment</b>					
n (%)	41 (10.6)	151 (38.9)	0.19 [0.13; 0.27] <.001	0.27 [0.20; 0.37] <.001	-0.28 [-0.34; -0.23] <.001
<b>Any SAE leading to discontinuation of study treatment</b>					
n (%)	0 (0.0)	3 (0.8)	N.E.	0.14 [0.01; 2.76] 0.198	-0.01 [-0.02; 0.00] 0.082
<b>Any non-severe AE</b>					
n (%)	317 (81.7)	323 (83.2)	0.90 [0.62; 1.30] 0.571	0.98 [0.92; 1.05] 0.571	-0.02 [-0.07; 0.04] 0.571
<b>Any severe AE</b>					
n (%)	21 (5.4)	38 (9.8)	0.53 [0.30; 0.92] 0.023	0.55 [0.33; 0.92] 0.024	-0.04 [-0.08; -0.01] 0.021
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR is obtained from a logistic regression model with treatment group as predictor.  RR and RD are calculated directly with CI and p-value based on the Wald statistic.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.</p> <p>The severity grade refers to the maximum observed severity per patient.</p>					

**Table 14.3.1-1.1.1 Overview of treatment-emergent adverse events occurring during study by Age Group (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
< median age, N'	186	190			
≥ median age, N'	202	198			
<b>Any AE</b>					
<b>Interaction test: p=0.498</b>					
<b>&lt; median age</b>					
n (%)	157 (84.4)	176 (92.6)	0.43 [0.22; 0.84] 0.014	0.91 [0.85; 0.98] 0.013	-0.08 [-0.15; -0.02] 0.012
<b>≥ median age</b>					
n (%)	181 (89.6)	185 (93.4)	0.61 [0.29; 1.25] 0.173	0.96 [0.90; 1.02] 0.170	-0.04 [-0.09; 0.02] 0.168
<b>Any SAE</b>					
<b>Interaction test: p=0.492</b>					
<b>&lt; median age</b>					
n (%)	8 (4.3)	13 (6.8)	0.61 [0.25; 1.51] 0.287	0.63 [0.27; 1.48] 0.288	-0.03 [-0.07; 0.02] 0.282
<b>≥ median age</b>					
n (%)	2 (1.0)	6 (3.0)	0.32 [0.06; 1.60] 0.166	0.33 [0.07; 1.60] 0.167	-0.02 [-0.05; 0.01] 0.146
<b>Any AE leading to discontinuation of study treatment</b>					
<b>Interaction test: p=0.275</b>					
<b>&lt; median age</b>					
n (%)	20 (10.8)	65 (34.2)	0.23 [0.13; 0.40] <.001	0.31 [0.20; 0.50] <.001	-0.23 [-0.32; -0.15] <.001
<b>≥ median age</b>					
n (%)	21 (10.4)	86 (43.4)	0.15 [0.09; 0.26] <.001	0.24 [0.15; 0.37] <.001	-0.33 [-0.41; -0.25] <.001

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Any SAE leading to discontinuation of study treatment</b>					
<b>Interaction test: N.E.</b>					
<b>&lt; median age</b>					
n (%)	0 (0.0)	3 (1.6)	N.E.	0.15 [0.01; 2.81] 0.202	-0.02 [-0.03; 0.00] 0.081
<b>Any non-severe AE</b>					
<b>Interaction test: p=0.639</b>					
<b>&lt; median age</b>					
n (%)	146 (78.5)	155 (81.6)	0.82 [0.50; 1.37] 0.454	0.96 [0.87; 1.06] 0.455	-0.03 [-0.11; 0.05] 0.454
<b>≥ median age</b>					
n (%)	171 (84.7)	168 (84.8)	0.99 [0.57; 1.70] 0.957	1.00 [0.92; 1.08] 0.957	-0.00 [-0.07; 0.07] 0.957
<b>Any severe AE</b>					
<b>Interaction test: p=0.871</b>					
<b>&lt; median age</b>					
n (%)	11 (5.9)	21 (11.1)	0.51 [0.24; 1.08] 0.079	0.54 [0.27; 1.08] 0.080	-0.05 [-0.11; 0.00] 0.072
<b>≥ median age</b>					
n (%)	10 (5.0)	17 (8.6)	0.55 [0.25; 1.24] 0.152	0.58 [0.27; 1.23] 0.153	-0.04 [-0.09; 0.01] 0.147
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.</p> <p>Only subgroups with at least one event are displayed.</p> <p>The severity grade refers to the maximum observed severity per patient.</p>					

**Table 14.3.1-1.1.2 Overview of treatment-emergent adverse events occurring during study by Gender (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
Male, N'	57	53			
Female, N'	331	335			
<b>Any AE</b>					
<b>Interaction test: p=0.973</b>					
<b>Male</b>					
n (%)	44 (77.2)	46 (86.8)	0.51 [0.19; 1.41] 0.196	0.89 [0.75; 1.06] 0.192	-0.10 [-0.24; 0.05] 0.185
<b>Female</b>					
n (%)	294 (88.8)	315 (94.0)	0.50 [0.29; 0.89] 0.018	0.94 [0.90; 0.99] 0.017	-0.05 [-0.09; -0.01] 0.016
<b>Any SAE</b>					
<b>Interaction test: N.E.</b>					
<b>Female</b>					
n (%)	10 (3.0)	19 (5.7)	0.52 [0.24; 1.13] 0.099	0.53 [0.25; 1.13] 0.100	-0.03 [-0.06; 0.00] 0.093
<b>Any AE leading to discontinuation of study treatment</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	0 (0.0)	19 (35.8)	N.E.	0.02 [0.00; 0.39] 0.009	-0.36 [-0.49; -0.23] <.001
<b>Female</b>					
n (%)	41 (12.4)	132 (39.4)	0.22 [0.15; 0.32] <.001	0.31 [0.23; 0.43] <.001	-0.27 [-0.33; -0.21] <.001
<b>Any SAE leading to discontinuation of study treatment</b>					
<b>Interaction test: N.E.</b>					
<b>Female</b>					
n (%)	0 (0.0)	3 (0.9)	N.E.	0.14 [0.01; 2.79] 0.200	-0.01 [-0.02; 0.00] 0.082

Treatment Groups			Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Any non-severe AE</b>					
<b>Interaction test: p=0.438</b>					
<b>Male</b>					
n (%)	42 (73.7)	43 (81.1)	0.65 [0.26; 1.61] 0.353	0.91 [0.74; 1.11] 0.351	-0.07 [-0.23; 0.08] 0.348
<b>Female</b>					
n (%)	275 (83.1)	280 (83.6)	0.96 [0.64; 1.45] 0.862	0.99 [0.93; 1.06] 0.862	-0.01 [-0.06; 0.05] 0.862
<b>Any severe AE</b>					
<b>Interaction test: p=0.879</b>					
<b>Male</b>					
n (%)	2 (3.5)	3 (5.7)	0.61 [0.10; 3.78] 0.592	0.62 [0.11; 3.57] 0.592	-0.02 [-0.10; 0.06] 0.591
<b>Female</b>					
n (%)	19 (5.7)	35 (10.4)	0.52 [0.29; 0.93] 0.028	0.55 [0.32; 0.94] 0.029	-0.05 [-0.09; -0.01] 0.025
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup with treatment group as predictor.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.</p> <p>Only subgroups with at least one event are displayed.</p> <p>The severity grade refers to the maximum observed severity per patient.</p>					

**Table 14.3.1-1.1.3 Overview of treatment-emergent adverse events occurring during study by Disease Severity (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
4-7 monthly migraine days at baseline <sup>1</sup> , N'	96	92			
8-14 monthly migraine days at baseline <sup>2</sup> , N'	249	254			
≥ 15 monthly migraine days at baseline, N'	43	42			
<b>Any AE</b>					
<b>Interaction test: p=0.125</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	81 (84.4)	89 (96.7)	0.18 [0.05; 0.65] 0.009	0.87 [0.79; 0.96] 0.004	-0.12 [-0.20; -0.04] 0.003
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	220 (88.4)	232 (91.3)	0.72 [0.40; 1.29] 0.269	0.97 [0.91; 1.03] 0.269	-0.03 [-0.08; 0.02] 0.267
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	37 (86.0)	40 (95.2)	0.31 [0.06; 1.62] 0.165	0.90 [0.79; 1.04] 0.150	-0.09 [-0.21; 0.03] 0.140
<b>Any SAE</b>					
<b>Interaction test: p=0.377</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	1 (1.0)	2 (2.2)	0.47 [0.04; 5.31] 0.545	0.48 [0.04; 5.20] 0.545	-0.01 [-0.05; 0.02] 0.538
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	5 (2.0)	14 (5.5)	0.35 [0.12; 0.99] 0.048	0.36 [0.13; 1.00] 0.049	-0.04 [-0.07; -0.00] 0.038
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	4 (9.3)	3 (7.1)	1.33 [0.28; 6.35] 0.718	1.30 [0.31; 5.47] 0.718	0.02 [-0.10; 0.14] 0.717



Treatment Groups			Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Any AE leading to discontinuation of study treatment</b>					
<b>Interaction test: p=0.693</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	8 (8.3)	37 (40.2)	0.14 [0.06; 0.31] <.001	0.21 [0.10; 0.42] <.001	-0.32 [-0.43; -0.20] <.001
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	28 (11.2)	97 (38.2)	0.21 [0.13; 0.33] <.001	0.29 [0.20; 0.43] <.001	-0.27 [-0.34; -0.20] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	5 (11.6)	17 (40.5)	0.19 [0.06; 0.59] 0.004	0.29 [0.12; 0.71] 0.007	-0.29 [-0.47; -0.11] 0.001
<b>Any SAE leading to discontinuation of study treatment</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	1 (1.1)	N.E.	0.32 [0.01; 7.75] 0.483	-0.01 [-0.03; 0.01] 0.315
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	0 (0.0)	2 (0.8)	N.E.	0.20 [0.01; 4.23] 0.304	-0.01 [-0.02; 0.00] 0.156
<b>Any non-severe AE</b>					
<b>Interaction test: p=0.018</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	74 (77.1)	81 (88.0)	0.46 [0.21; 1.01] 0.052	0.88 [0.77; 1.00] 0.049	-0.11 [-0.22; -0.00] 0.045
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	209 (83.9)	203 (79.9)	1.31 [0.83; 2.07] 0.243	1.05 [0.97; 1.14] 0.242	0.04 [-0.03; 0.11] 0.241
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	34 (79.1)	39 (92.9)	0.29 [0.07; 1.16] 0.080	0.85 [0.71; 1.01] 0.072	-0.14 [-0.28; 0.01] 0.061

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Any severe AE</b>					
<b>Interaction test: p=0.132</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	7 (7.3)	8 (8.7)	0.83 [0.29; 2.38] 0.723	0.84 [0.32; 2.22] 0.723	-0.01 [-0.09; 0.06] 0.723
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	11 (4.4)	29 (11.4)	0.36 [0.17; 0.73] 0.005	0.39 [0.20; 0.76] 0.006	-0.07 [-0.12; -0.02] 0.003
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	3 (7.0)	1 (2.4)	3.07 [0.31; 30.81] 0.339	2.93 [0.32; 27.06] 0.343	0.05 [-0.04; 0.13] 0.312
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.</p> <p>Only subgroups with at least one event are displayed.</p> <p>The severity grade refers to the maximum observed severity per patient.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.  <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.</p>					

**Table 14.3.1-1.1.4 Overview of treatment-emergent adverse events occurring during study by Prior Treatment Failure Status (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
Naïve*, N'	232	229			
Prior treatment failure*, N'	156	159			
<b>Any AE</b>					
<b>Interaction test: p=0.336</b>					
<b>Naïve*</b>					
n (%)	197 (84.9)	213 (93.0)	0.42 [0.23; 0.79] 0.007	0.91 [0.86; 0.97] 0.006	-0.08 [-0.14; -0.02] 0.005
<b>Prior treatment failure*</b>					
n (%)	141 (90.4)	148 (93.1)	0.70 [0.31; 1.57] 0.386	0.97 [0.91; 1.04] 0.386	-0.03 [-0.09; 0.03] 0.385
<b>Any SAE</b>					
<b>Interaction test: p=0.727</b>					
<b>Naïve*</b>					
n (%)	6 (2.6)	10 (4.4)	0.58 [0.21; 1.63] 0.302	0.59 [0.22; 1.60] 0.302	-0.02 [-0.05; 0.02] 0.297
<b>Prior treatment failure*</b>					
n (%)	4 (2.6)	9 (5.7)	0.44 [0.13; 1.46] 0.178	0.45 [0.14; 1.44] 0.180	-0.03 [-0.07; 0.01] 0.164
<b>Any AE leading to discontinuation of study treatment</b>					
<b>Interaction test: p=0.837</b>					
<b>Naïve*</b>					
n (%)	24 (10.3)	86 (37.6)	0.19 [0.12; 0.32] <.001	0.28 [0.18; 0.42] <.001	-0.27 [-0.35; -0.20] <.001
<b>Prior treatment failure*</b>					
n (%)	17 (10.9)	65 (40.9)	0.18 [0.10; 0.32] <.001	0.27 [0.16; 0.43] <.001	-0.30 [-0.39; -0.21] <.001

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Any SAE leading to discontinuation of study treatment</b>					
<b>Interaction test: N.E.</b>					
<b>Naïve*</b>					
n (%)	0 (0.0)	2 (0.9)	N.E.	0.20 [0.01; 4.09] 0.294	-0.01 [-0.02; 0.00] 0.155
<b>Prior treatment failure*</b>					
n (%)	0 (0.0)	1 (0.6)	N.E.	0.34 [0.01; 8.28] 0.507	-0.01 [-0.02; 0.01] 0.316
<b>Any non-severe AE</b>					
<b>Interaction test: p=0.258</b>					
<b>Naïve*</b>					
n (%)	186 (80.2)	193 (84.3)	0.75 [0.47; 1.22] 0.250	0.95 [0.87; 1.04] 0.249	-0.04 [-0.11; 0.03] 0.248
<b>Prior treatment failure*</b>					
n (%)	131 (84.0)	130 (81.8)	1.17 [0.65; 2.10] 0.602	1.03 [0.93; 1.14] 0.602	0.02 [-0.06; 0.11] 0.602
<b>Any severe AE</b>					
<b>Interaction test: p=0.956</b>					
<b>Naïve*</b>					
n (%)	11 (4.7)	20 (8.7)	0.52 [0.24; 1.11] 0.092	0.54 [0.27; 1.11] 0.093	-0.04 [-0.09; 0.01] 0.087

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Prior treatment failure*</b>					
n (%)	10 (6.4)	18 (11.3)	0.54 [0.24; 1.20] 0.130	0.57 [0.27; 1.19] 0.132	-0.05 [-0.11; 0.01] 0.123
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.</p> <p>Only subgroups with at least one event are displayed.</p> <p>The severity grade refers to the maximum observed severity per patient.</p> <p>*: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>					

**Table 14.3.1-1.1.5 Overview of treatment-emergent adverse events occurring during study by Study Center (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
Center No. 1001, N'	10	8			
Center No. 1002, N'	4	0			
Center No. 1003, N'	2	3			
Center No. 1005, N'	31	22			
Center No. 1007, N'	5	7			
Center No. 1008, N'	3	3			
Center No. 1010, N'	2	3			
Center No. 1011, N'	2	5			
Center No. 1012, N'	3	5			
Center No. 1014, N'	5	4			
Center No. 1015, N'	4	2			
Center No. 1017, N'	5	4			
Center No. 1018, N'	7	6			
Center No. 1019, N'	2	2			
Center No. 1021, N'	16	10			
Center No. 1022, N'	3	3			
Center No. 1025, N'	0	2			
Center No. 1027, N'	3	5			
Center No. 1028, N'	11	5			
Center No. 1029, N'	15	9			
Center No. 1030, N'	11	9			
Center No. 1032, N'	2	4			
Center No. 1033, N'	4	6			
Center No. 1034, N'	4	3			
Center No. 1035, N'	27	22			
Center No. 1036, N'	7	7			
Center No. 1037, N'	9	11			
Center No. 1039, N'	4	3			
Center No. 1040, N'	0	3			
Center No. 1041, N'	5	5			
Center No. 1042, N'	4	5			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1044, N <sup>a</sup>	0	2			
Center No. 1046, N <sup>a</sup>	1	1			
Center No. 1048, N <sup>a</sup>	0	3			
Center No. 1049, N <sup>a</sup>	1	0			
Center No. 1050, N <sup>a</sup>	6	9			
Center No. 1051, N <sup>a</sup>	1	1			
Center No. 1052, N <sup>a</sup>	7	4			
Center No. 1055, N <sup>a</sup>	2	4			
Center No. 1058, N <sup>a</sup>	0	1			
Center No. 1059, N <sup>a</sup>	7	7			
Center No. 1061, N <sup>a</sup>	9	6			
Center No. 1063, N <sup>a</sup>	4	2			
Center No. 1064, N <sup>a</sup>	0	3			
Center No. 1067, N <sup>a</sup>	10	16			
Center No. 1068, N <sup>a</sup>	0	2			
Center No. 1069, N <sup>a</sup>	3	4			
Center No. 1070, N <sup>a</sup>	1	5			
Center No. 1072, N <sup>a</sup>	2	1			
Center No. 1073, N <sup>a</sup>	11	7			
Center No. 1074, N <sup>a</sup>	5	3			
Center No. 1076, N <sup>a</sup>	1	5			
Center No. 1077, N <sup>a</sup>	3	2			
Center No. 1079, N <sup>a</sup>	4	3			
Center No. 1080, N <sup>a</sup>	3	1			
Center No. 1082, N <sup>a</sup>	5	8			
Center No. 1084, N <sup>a</sup>	2	3			
Center No. 1085, N <sup>a</sup>	0	3			
Center No. 1086, N <sup>a</sup>	6	9			
Center No. 1087, N <sup>a</sup>	1	4			
Center No. 1088, N <sup>a</sup>	6	6			
Center No. 1089, N <sup>a</sup>	4	4			
Center No. 1091, N <sup>a</sup>	6	5			
Center No. 1093, N <sup>a</sup>	1	4			
Center No. 1095, N <sup>a</sup>	5	3			
Center No. 1096, N <sup>a</sup>	2	0			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1100, N <sup>a</sup>	1	4			
Center No. 1101, N <sup>a</sup>	4	6			
Center No. 1103, N <sup>a</sup>	2	3			
Center No. 1105, N <sup>a</sup>	3	3			
Center No. 1108, N <sup>a</sup>	15	10			
Center No. 1110, N <sup>a</sup>	6	5			
Center No. 1111, N <sup>a</sup>	5	0			
Center No. 1113, N <sup>a</sup>	3	3			
Center No. 1115, N <sup>a</sup>	5	6			
Center No. 1116, N <sup>a</sup>	1	4			
Center No. 1118, N <sup>a</sup>	3	2			
Center No. 1119, N <sup>a</sup>	3	5			
Center No. 1121, N <sup>a</sup>	4	4			
Center No. 1123, N <sup>a</sup>	1	1			
Center No. 1124, N <sup>a</sup>	3	2			
Center No. 1502, N <sup>a</sup>	0	3			
<b>Any AE</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	9 (90.0)	8 (100.0)	N.E.	0.90 [0.73; 1.11] 0.318	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1002</b>					
n (%)	4 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	2 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1005</b>					
n (%)	28 (90.3)	19 (86.4)	1.47 [0.27; 8.09] 0.655	1.05 [0.85; 1.28] 0.664	0.04 [-0.14; 0.22] 0.661
<b>Center No. 1007</b>					
n (%)	5 (100.0)	7 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1008</b>					
n (%)	2 (66.7)	3 (100.0)	N.E.	0.67 [0.30; 1.48] 0.321	-0.33 [-0.87; 0.20] 0.221



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1010</b>					
n (%)	2 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1011</b>					
n (%)	2 (100.0)	5 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1012</b>					
n (%)	3 (100.0)	5 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1014</b>					
n (%)	5 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1015</b>					
n (%)	3 (75.0)	2 (100.0)	N.E.	0.75 [0.43; 1.32] 0.319	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1017</b>					
n (%)	5 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1018</b>					
n (%)	7 (100.0)	5 (83.3)	N.E.	1.20 [0.84; 1.72] 0.318	0.17 [-0.13; 0.46] 0.273
<b>Center No. 1019</b>					
n (%)	1 (50.0)	2 (100.0)	N.E.	0.50 [0.13; 2.00] 0.327	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1021</b>					
n (%)	16 (100.0)	10 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1022</b>					
n (%)	2 (66.7)	2 (66.7)	1.00 [0.03; 29.81] 1.000	1.00 [0.32; 3.10] 1.000	0.00 [-0.75; 0.75] 1.000
<b>Center No. 1025</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1027</b>					
n (%)	3 (100.0)	5 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1028</b>					
n (%)	11 (100.0)	5 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1029</b>					
n (%)	10 (66.7)	8 (88.9)	0.25 [0.02; 2.59] 0.246	0.75 [0.49; 1.15] 0.186	-0.22 [-0.54; 0.09] 0.166

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1030</b>					
n (%)	10 (90.9)	9 (100.0)	N.E.	0.91 [0.75; 1.10] 0.317	-0.09 [-0.26; 0.08] 0.294
<b>Center No. 1032</b>					
n (%)	2 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1033</b>					
n (%)	4 (100.0)	6 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1034</b>					
n (%)	4 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1035</b>					
n (%)	25 (92.6)	22 (100.0)	N.E.	0.93 [0.83; 1.03] 0.157	-0.07 [-0.17; 0.02] 0.142
<b>Center No. 1036</b>					
n (%)	6 (85.7)	7 (100.0)	N.E.	0.86 [0.63; 1.16] 0.318	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1037</b>					
n (%)	8 (88.9)	11 (100.0)	N.E.	0.89 [0.71; 1.12] 0.318	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1039</b>					
n (%)	3 (75.0)	3 (100.0)	N.E.	0.75 [0.43; 1.32] 0.319	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1040</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1041</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.14 [0.01; 2.21] 0.164	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1042</b>					
n (%)	4 (100.0)	5 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1044</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1046</b>					
n (%)	1 (100.0)	1 (100.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1048</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	6 (100.0)	9 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1051</b>					
n (%)	1 (100.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1052</b>					
n (%)	7 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1055</b>					
n (%)	2 (100.0)	3 (75.0)	N.E.	1.33 [0.76; 2.35] 0.319	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1058</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1059</b>					
n (%)	6 (85.7)	7 (100.0)	N.E.	0.86 [0.63; 1.16] 0.318	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1061</b>					
n (%)	8 (88.9)	6 (100.0)	N.E.	0.89 [0.71; 1.12] 0.318	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1063</b>					
n (%)	4 (100.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1064</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	7 (70.0)	13 (81.3)	0.54 [0.09; 3.41] 0.511	0.86 [0.54; 1.38] 0.533	-0.11 [-0.45; 0.23] 0.520
<b>Center No. 1068</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1069</b>					
n (%)	2 (66.7)	4 (100.0)	N.E.	0.67 [0.30; 1.48] 0.321	-0.33 [-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1070</b>					
n (%)	1 (100.0)	4 (80.0)	N.E.	1.25 [0.81; 1.94] 0.318	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1072</b>					
n (%)	2 (100.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1073</b>					
n (%)	11 (100.0)	6 (85.7)	N.E.	1.17 [0.86; 1.58] 0.318	0.14 [-0.12; 0.40] 0.280
<b>Center No. 1074</b>					
n (%)	5 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1076</b>					
n (%)	1 (100.0)	2 (40.0)	N.E.	2.50 [0.85; 7.31] 0.094	0.60 [0.17; 1.03] 0.006
<b>Center No. 1077</b>					
n (%)	3 (100.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1079</b>					
n (%)	2 (50.0)	3 (100.0)	N.E.	0.50 [0.19; 1.33] 0.166	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1080</b>					
n (%)	3 (100.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1082</b>					
n (%)	4 (80.0)	8 (100.0)	N.E.	0.80 [0.52; 1.24] 0.318	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1084</b>					
n (%)	1 (50.0)	3 (100.0)	N.E.	0.50 [0.13; 2.00] 0.327	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1085</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1086</b>					
n (%)	5 (83.3)	9 (100.0)	N.E.	0.83 [0.58; 1.19] 0.318	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1087</b>					
n (%)	1 (100.0)	4 (100.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1088</b>					
n (%)	3 (50.0)	3 (50.0)	1.00 [0.10; 9.61] 1.000	1.00 [0.32; 3.10] 1.000	0.00 [-0.57; 0.57] 1.000
<b>Center No. 1089</b>					
n (%)	4 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1091</b>					
n (%)	4 (66.7)	5 (100.0)	N.E.	0.67 [0.38; 1.17] 0.160	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1093</b>					
n (%)	1 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1095</b>					
n (%)	5 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1096</b>					
n (%)	2 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1100</b>					
n (%)	1 (100.0)	3 (75.0)	N.E.	1.33 [0.76; 2.35] 0.319	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1101</b>					
n (%)	1 (25.0)	4 (66.7)	0.17 [<0.01; 2.82] 0.214	0.38 [0.06; 2.24] 0.283	-0.42 [-0.98; 0.15] 0.150
<b>Center No. 1103</b>					
n (%)	2 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1105</b>					
n (%)	3 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1108</b>					
n (%)	15 (100.0)	9 (90.0)	N.E.	1.11 [0.90; 1.37] 0.318	0.10 [-0.09; 0.29] 0.292
<b>Center No. 1110</b>					
n (%)	5 (83.3)	5 (100.0)	N.E.	0.83 [0.58; 1.19] 0.318	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1111</b>					
n (%)	5 (100.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1113</b>					
n (%)	3 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1115</b>					
n (%)	4 (80.0)	6 (100.0)	N.E.	0.80 [0.52; 1.24] 0.318	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1116</b>					
n (%)	0 (0.0)	3 (75.0)	N.E.	0.36 [0.03; 4.21] 0.414	-0.75 [-1.17; -0.33] <.001
<b>Center No. 1118</b>					
n (%)	3 (100.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1119</b>					
n (%)	2 (66.7)	5 (100.0)	N.E.	0.67 [0.30; 1.48] 0.321	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1121</b>					
n (%)	3 (75.0)	3 (75.0)	1.00 [0.04; 24.55] 1.000	1.00 [0.45; 2.23] 1.000	0.00 [-0.60; 0.60] 1.000
<b>Center No. 1123</b>					
n (%)	1 (100.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1124</b>					
n (%)	2 (66.7)	2 (100.0)	N.E.	0.67 [0.30; 1.48] 0.321	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1502</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Any SAE</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	1 (10.0)	1 (12.5)	0.78 [0.04; 14.75] 0.867	0.80 [0.06; 10.89] 0.867	-0.03 [-0.32; 0.27] 0.868
<b>Center No. 1003</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1005</b>					
n (%)	1 (3.2)	0 (0.0)	N.E.	2.16 [0.09; 50.60] 0.633	0.03 [-0.03; 0.09] 0.309
<b>Center No. 1007</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.27 [0.02; 4.59] 0.363	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1014</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.50 [0.13; 48.85] 0.546	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1021</b>					
n (%)	1 (6.3)	1 (10.0)	0.60 [0.03; 10.82] 0.729	0.63 [0.04; 8.91] 0.729	-0.04 [-0.26; 0.18] 0.739
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1035</b>					
n (%)	0 (0.0)	3 (13.6)	N.E.	0.12 [0.01; 2.16] 0.149	-0.14 [-0.28; 0.01] 0.062
<b>Center No. 1036</b>					
n (%)	1 (14.3)	0 (0.0)	N.E.	3.00 [0.14; 63.15] 0.480	0.14 [-0.12; 0.40] 0.280
<b>Center No. 1040</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1059</b>					
n (%)	1 (14.3)	0 (0.0)	N.E.	3.00 [0.14; 63.15] 0.480	0.14 [-0.12; 0.40] 0.280
<b>Center No. 1061</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.23 [0.01; 4.93] 0.350	-0.17 [-0.46; 0.13] 0.273

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1067</b>					
n (%)	1 (10.0)	0 (0.0)	N.E.	4.64 [0.21; 103.90] 0.334	0.10 [-0.09; 0.29] 0.292
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1072</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1073</b>					
n (%)	1 (9.1)	0 (0.0)	N.E.	2.00 [0.09; 43.22] 0.658	0.09 [-0.08; 0.26] 0.294
<b>Center No. 1091</b>					
n (%)	1 (16.7)	0 (0.0)	N.E.	2.57 [0.13; 52.13] 0.538	0.17 [-0.13; 0.46] 0.273
<b>Center No. 1093</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1108</b>					
n (%)	0 (0.0)	1 (10.0)	N.E.	0.23 [0.01; 5.12] 0.353	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1113</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1115</b>					
n (%)	1 (20.0)	1 (16.7)	1.25 [0.06; 26.87] 0.887	1.20 [0.10; 14.69] 0.887	0.03 [-0.43; 0.49] 0.887
<b>Center No. 1118</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Any AE leading to discontinuation of study treatment</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	1 (10.0)	4 (50.0)	0.11 [<0.01; 1.34] 0.083	0.20 [0.03; 1.45] 0.112	-0.40 [-0.79; -0.01] 0.046
<b>Center No. 1002</b>					
n (%)	2 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1005</b>					
n (%)	5 (16.1)	10 (45.5)	0.23 [0.06; 0.82] 0.024	0.35 [0.14; 0.89] 0.028	-0.29 [-0.54; -0.05] 0.019
<b>Center No. 1007</b>					
n (%)	2 (40.0)	3 (42.9)	0.89 [0.09; 9.16] 0.921	0.93 [0.24; 3.68] 0.922	-0.03 [-0.59; 0.54] 0.921
<b>Center No. 1008</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1010</b>					
n (%)	1 (50.0)	1 (33.3)	2.00 [0.05; 78.25] 0.711	1.50 [0.18; 12.46] 0.707	0.17 [-0.71; 1.04] 0.709
<b>Center No. 1011</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.29 [0.02; 3.92] 0.349	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1012</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.21 [0.01; 3.12] 0.260	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1014</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.17 [0.01; 2.73] 0.209	-0.50 [-0.99; -0.01] 0.046

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1017</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1021</b>					
n (%)	3 (18.8)	5 (50.0)	0.23 [0.04; 1.35] 0.103	0.38 [0.11; 1.24] 0.107	-0.31 [-0.68; 0.05] 0.093
<b>Center No. 1027</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.30 [0.02; 4.74] 0.393	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1028</b>					
n (%)	1 (9.1)	2 (40.0)	0.15 [<0.01; 2.29] 0.172	0.23 [0.03; 1.96] 0.178	-0.31 [-0.77; 0.15] 0.190
<b>Center No. 1029</b>					
n (%)	3 (20.0)	7 (77.8)	0.07 [<0.01; 0.54] 0.010	0.26 [0.09; 0.75] 0.013	-0.58 [-0.92; -0.24] <.001
<b>Center No. 1030</b>					
n (%)	1 (9.1)	2 (22.2)	0.35 [0.03; 4.65] 0.426	0.41 [0.04; 3.82] 0.433	-0.13 [-0.45; 0.19] 0.422
<b>Center No. 1032</b>					
n (%)	0 (0.0)	3 (75.0)	N.E.	0.24 [0.02; 3.19] 0.278	-0.75 [-1.17; -0.33] <.001
<b>Center No. 1033</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.28 [0.02; 4.66] 0.375	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1034</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1035</b>					
n (%)	5 (18.5)	13 (59.1)	0.16 [0.04; 0.57] 0.005	0.31 [0.13; 0.74] 0.009	-0.41 [-0.66; -0.15] 0.002
<b>Center No. 1036</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.20 [0.01; 3.54] 0.272	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1037</b>					
n (%)	3 (33.3)	7 (63.6)	0.29 [0.04; 1.82] 0.185	0.52 [0.19; 1.46] 0.217	-0.30 [-0.72; 0.12] 0.156
<b>Center No. 1040</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1041</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.14 [0.01; 2.21] 0.164	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1042</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.24 [0.01; 3.93] 0.317	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1044</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1046</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1048</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	1 (16.7)	4 (44.4)	0.25 [0.02; 3.10] 0.280	0.38 [0.05; 2.59] 0.320	-0.28 [-0.72; 0.16] 0.217
<b>Center No. 1052</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.21 [0.01; 4.18] 0.305	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1055</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.33 [0.02; 4.85] 0.421	-0.50 [-0.99; -0.01] 0.046

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1059</b>					
n (%)	1 (14.3)	3 (42.9)	0.22 [0.02; 2.97] 0.256	0.33 [0.04; 2.48] 0.283	-0.29 [-0.73; 0.16] 0.212
<b>Center No. 1061</b>					
n (%)	1 (11.1)	2 (33.3)	0.25 [0.02; 3.66] 0.311	0.33 [0.04; 2.91] 0.320	-0.22 [-0.65; 0.21] 0.310
<b>Center No. 1063</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1064</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	1 (10.0)	5 (31.3)	0.24 [0.02; 2.49] 0.234	0.32 [0.04; 2.36] 0.263	-0.21 [-0.51; 0.08] 0.156
<b>Center No. 1068</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1069</b>					
n (%)	0 (0.0)	3 (75.0)	N.E.	0.18 [0.01; 2.54] 0.204	-0.75 [-1.17; -0.33] <.001
<b>Center No. 1070</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.43 [0.04; 5.19] 0.505	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1072</b>					
n (%)	1 (50.0)	1 (100.0)	N.E.	0.50 [0.13; 2.00] 0.327	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1076</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1077</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1079</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1082</b>					
n (%)	1 (20.0)	2 (25.0)	0.75 [0.05; 11.31] 0.835	0.80 [0.10; 6.70] 0.837	-0.05 [-0.51; 0.41] 0.832
<b>Center No. 1085</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1086</b>					
n (%)	1 (16.7)	2 (22.2)	0.70 [0.05; 10.01] 0.793	0.75 [0.09; 6.55] 0.795	-0.06 [-0.46; 0.35] 0.787
<b>Center No. 1087</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1088</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.33 [0.02; 6.86] 0.476	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1089</b>					
n (%)	1 (25.0)	1 (25.0)	1.00 [0.04; 24.55] 1.000	1.00 [0.09; 11.03] 1.000	0.00 [-0.60; 0.60] 1.000
<b>Center No. 1091</b>					
n (%)	1 (16.7)	3 (60.0)	0.13 [<0.01; 2.18] 0.158	0.28 [0.04; 1.91] 0.193	-0.43 [-0.96; 0.09] 0.104
<b>Center No. 1093</b>					
n (%)	0 (0.0)	3 (75.0)	N.E.	0.36 [0.03; 4.21] 0.414	-0.75 [-1.17; -0.33] <.001
<b>Center No. 1095</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.22 [0.01; 4.20] 0.316	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1100</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.50 [0.04; 6.44] 0.595	-0.50 [-0.99; -0.01] 0.046

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1105</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.20 [0.01; 2.98] 0.243	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1108</b>					
n (%)	0 (0.0)	1 (10.0)	N.E.	0.23 [0.01; 5.12] 0.353	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1110</b>					
n (%)	1 (16.7)	0 (0.0)	N.E.	2.57 [0.13; 52.13] 0.538	0.17 [-0.13; 0.46] 0.273
<b>Center No. 1115</b>					
n (%)	1 (20.0)	2 (33.3)	0.50 [0.03; 7.99] 0.624	0.60 [0.07; 4.83] 0.631	-0.13 [-0.65; 0.38] 0.612
<b>Center No. 1118</b>					
n (%)	2 (66.7)	1 (50.0)	2.00 [0.05; 78.25] 0.711	1.33 [0.27; 6.61] 0.725	0.17 [-0.71; 1.04] 0.709
<b>Center No. 1119</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1121</b>					
n (%)	1 (25.0)	2 (50.0)	0.33 [0.02; 6.65] 0.472	0.50 [0.07; 3.55] 0.488	-0.25 [-0.90; 0.40] 0.450
<b>Center No. 1124</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1502</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Any SAE leading to discontinuation of study treatment</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1007</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.44 [0.02; 9.11] 0.599	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1035</b>					
n (%)	0 (0.0)	1 (4.5)	N.E.	0.27 [0.01; 6.41] 0.421	-0.05 [-0.13; 0.04] 0.306
<b>Any non-severe AE</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	7 (70.0)	8 (100.0)	N.E.	0.70 [0.47; 1.05] 0.085	-0.30 [-0.58; -0.02] 0.038
<b>Center No. 1002</b>					
n (%)	4 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	2 (100.0)	2 (66.7)	N.E.	1.50 [0.67; 3.34] 0.321	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1005</b>					
n (%)	28 (90.3)	19 (86.4)	1.47 [0.27; 8.09] 0.655	1.05 [0.85; 1.28] 0.664	0.04 [-0.14; 0.22] 0.661
<b>Center No. 1007</b>					
n (%)	4 (80.0)	4 (57.1)	3.00 [0.21; 42.62] 0.417	1.40 [0.64; 3.04] 0.396	0.23 [-0.28; 0.74] 0.377
<b>Center No. 1008</b>					
n (%)	2 (66.7)	3 (100.0)	N.E.	0.67 [0.30; 1.48] 0.321	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1010</b>					
n (%)	2 (100.0)	3 (100.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1011</b>					
n (%)	2 (100.0)	5 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1012</b>					
n (%)	3 (100.0)	5 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1014</b>					
n (%)	5 (100.0)	3 (75.0)	N.E.	1.33 [0.76; 2.35] 0.319	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1015</b>					
n (%)	3 (75.0)	2 (100.0)	N.E.	0.75 [0.43; 1.32] 0.319	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1017</b>					
n (%)	5 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1018</b>					
n (%)	7 (100.0)	5 (83.3)	N.E.	1.20 [0.84; 1.72] 0.318	0.17 [-0.13; 0.46] 0.273
<b>Center No. 1019</b>					
n (%)	1 (50.0)	2 (100.0)	N.E.	0.50 [0.13; 2.00] 0.327	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1021</b>					
n (%)	15 (93.8)	9 (90.0)	1.67 [0.09; 30.06] 0.729	1.04 [0.82; 1.33] 0.741	0.04 [-0.18; 0.26] 0.739
<b>Center No. 1022</b>					
n (%)	1 (33.3)	2 (66.7)	0.25 [<0.01; 7.45] 0.424	0.50 [0.08; 2.99] 0.448	-0.33 [-1.09; 0.42] 0.386
<b>Center No. 1025</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1027</b>					
n (%)	3 (100.0)	4 (80.0)	N.E.	1.25 [0.81; 1.94] 0.318	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1028</b>					
n (%)	11 (100.0)	5 (100.0)	N.E.	N.E.	N.E.



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1029</b>					
n (%)	7 (46.7)	3 (33.3)	1.75 [0.31; 9.75] 0.523	1.40 [0.48; 4.08] 0.538	0.13 [-0.26; 0.53] 0.512
<b>Center No. 1030</b>					
n (%)	10 (90.9)	9 (100.0)	N.E.	0.91 [0.75; 1.10] 0.317	-0.09 [-0.26; 0.08] 0.294
<b>Center No. 1032</b>					
n (%)	2 (100.0)	2 (50.0)	N.E.	2.00 [0.75; 5.33] 0.166	0.50 [0.01; 0.99] 0.046
<b>Center No. 1033</b>					
n (%)	3 (75.0)	3 (50.0)	3.00 [0.19; 47.96] 0.437	1.50 [0.56; 4.00] 0.417	0.25 [-0.33; 0.83] 0.401
<b>Center No. 1034</b>					
n (%)	4 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1035</b>					
n (%)	24 (88.9)	18 (81.8)	1.78 [0.35; 8.96] 0.486	1.09 [0.86; 1.38] 0.495	0.07 [-0.13; 0.27] 0.489
<b>Center No. 1036</b>					
n (%)	5 (71.4)	7 (100.0)	N.E.	0.71 [0.45; 1.14] 0.159	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1037</b>					
n (%)	8 (88.9)	10 (90.9)	0.80 [0.04; 14.89] 0.881	0.98 [0.73; 1.32] 0.882	-0.02 [-0.29; 0.25] 0.882
<b>Center No. 1039</b>					
n (%)	3 (75.0)	3 (100.0)	N.E.	0.75 [0.43; 1.32] 0.319	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1040</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1041</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.14 [0.01; 2.21] 0.164	-0.60 [-1.03; -0.17] 0.006

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1042</b>					
n (%)	4 (100.0)	5 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1044</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1046</b>					
n (%)	1 (100.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1048</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	6 (100.0)	8 (88.9)	N.E.	1.13 [0.89; 1.42] 0.318	0.11 [-0.09; 0.32] 0.289
<b>Center No. 1051</b>					
n (%)	1 (100.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1052</b>					
n (%)	7 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1055</b>					
n (%)	2 (100.0)	3 (75.0)	N.E.	1.33 [0.76; 2.35] 0.319	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1058</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1059</b>					
n (%)	2 (28.6)	2 (28.6)	1.00 [0.10; 10.17] 1.000	1.00 [0.19; 5.24] 1.000	0.00 [-0.47; 0.47] 1.000
<b>Center No. 1061</b>					
n (%)	8 (88.9)	5 (83.3)	1.60 [0.08; 31.77] 0.758	1.07 [0.70; 1.63] 0.766	0.06 [-0.31; 0.42] 0.764
<b>Center No. 1063</b>					
n (%)	4 (100.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1064</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	6 (60.0)	11 (68.8)	0.68 [0.13; 3.55] 0.649	0.87 [0.48; 1.60] 0.659	-0.09 [-0.47; 0.29] 0.651

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1068</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1069</b>					
n (%)	2 (66.7)	3 (75.0)	0.67 [0.02; 18.06] 0.810	0.89 [0.33; 2.37] 0.814	-0.08 [-0.76; 0.60] 0.811
<b>Center No. 1070</b>					
n (%)	1 (100.0)	4 (80.0)	N.E.	1.25 [0.81; 1.94] 0.318	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1072</b>					
n (%)	2 (100.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1073</b>					
n (%)	11 (100.0)	6 (85.7)	N.E.	1.17 [0.86; 1.58] 0.318	0.14 [-0.12; 0.40] 0.280
<b>Center No. 1074</b>					
n (%)	2 (40.0)	3 (100.0)	N.E.	0.40 [0.14; 1.17] 0.094	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1076</b>					
n (%)	1 (100.0)	2 (40.0)	N.E.	2.50 [0.85; 7.31] 0.094	0.60 [0.17; 1.03] 0.006
<b>Center No. 1077</b>					
n (%)	3 (100.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1079</b>					
n (%)	2 (50.0)	3 (100.0)	N.E.	0.50 [0.19; 1.33] 0.166	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1080</b>					
n (%)	3 (100.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1082</b>					
n (%)	4 (80.0)	8 (100.0)	N.E.	0.80 [0.52; 1.24] 0.318	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1084</b>					
n (%)	1 (50.0)	3 (100.0)	N.E.	0.50 [0.13; 2.00] 0.327	-0.50 [-1.19; 0.19] 0.157

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1085</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1086</b>					
n (%)	5 (83.3)	9 (100.0)	N.E.	0.83 [0.58; 1.19] 0.318	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1087</b>					
n (%)	1 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1088</b>					
n (%)	3 (50.0)	3 (50.0)	1.00 [0.10; 9.61] 1.000	1.00 [0.32; 3.10] 1.000	0.00 [-0.57; 0.57] 1.000
<b>Center No. 1089</b>					
n (%)	4 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1091</b>					
n (%)	3 (50.0)	5 (100.0)	N.E.	0.50 [0.22; 1.11] 0.090	-0.50 [-0.90; -0.10] 0.014
<b>Center No. 1093</b>					
n (%)	1 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1095</b>					
n (%)	5 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1096</b>					
n (%)	2 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1100</b>					
n (%)	1 (100.0)	3 (75.0)	N.E.	1.33 [0.76; 2.35] 0.319	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1101</b>					
n (%)	1 (25.0)	4 (66.7)	0.17 [<0.01; 2.82] 0.214	0.38 [0.06; 2.24] 0.283	-0.42 [-0.98; 0.15] 0.150
<b>Center No. 1103</b>					
n (%)	2 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1105</b>					
n (%)	3 (100.0)	3 (100.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1108</b>					
n (%)	15 (100.0)	8 (80.0)	N.E.	1.25 [0.92; 1.70] 0.158	0.20 [-0.05; 0.45] 0.114
<b>Center No. 1110</b>					
n (%)	5 (83.3)	4 (80.0)	1.25 [0.06; 26.87] 0.887	1.04 [0.59; 1.83] 0.888	0.03 [-0.43; 0.49] 0.887
<b>Center No. 1111</b>					
n (%)	5 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1113</b>					
n (%)	3 (100.0)	2 (66.7)	N.E.	1.50 [0.67; 3.34] 0.321	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1115</b>					
n (%)	3 (60.0)	6 (100.0)	N.E.	0.60 [0.29; 1.23] 0.162	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1116</b>					
n (%)	0 (0.0)	3 (75.0)	N.E.	0.36 [0.03; 4.21] 0.414	-0.75 [-1.17; -0.33] <.001
<b>Center No. 1118</b>					
n (%)	3 (100.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1119</b>					
n (%)	2 (66.7)	5 (100.0)	N.E.	0.67 [0.30; 1.48] 0.321	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1121</b>					
n (%)	3 (75.0)	3 (75.0)	1.00 [0.04; 24.55] 1.000	1.00 [0.45; 2.23] 1.000	0.00 [-0.60; 0.60] 1.000
<b>Center No. 1123</b>					
n (%)	1 (100.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1124</b>					
n (%)	2 (66.7)	2 (100.0)	N.E.	0.67 [0.30; 1.48] 0.321	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1502</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Any severe AE</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	2 (20.0)	0 (0.0)	N.E.	4.09 [0.22; 74.78] 0.342	0.20 [-0.05; 0.45] 0.114
<b>Center No. 1003</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1007</b>					
n (%)	1 (20.0)	3 (42.9)	0.33 [0.02; 4.74] 0.417	0.47 [0.07; 3.28] 0.444	-0.23 [-0.74; 0.28] 0.377
<b>Center No. 1014</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1021</b>					
n (%)	1 (6.3)	1 (10.0)	0.60 [0.03; 10.82] 0.729	0.63 [0.04; 8.91] 0.729	-0.04 [-0.26; 0.18] 0.739
<b>Center No. 1022</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	3.00 [0.17; 53.71] 0.455	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1029</b>					
n (%)	3 (20.0)	5 (55.6)	0.20 [0.03; 1.24] 0.084	0.36 [0.11; 1.16] 0.087	-0.36 [-0.74; 0.03] 0.069
<b>Center No. 1032</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.33 [0.02; 4.85] 0.421	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1033</b>					
n (%)	1 (25.0)	3 (50.0)	0.33 [0.02; 5.33] 0.437	0.50 [0.08; 3.27] 0.469	-0.25 [-0.83; 0.33] 0.401

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1035</b>					
n (%)	1 (3.7)	4 (18.2)	0.17 [0.02; 1.68] 0.130	0.20 [0.02; 1.69] 0.141	-0.14 [-0.32; 0.03] 0.107
<b>Center No. 1036</b>					
n (%)	1 (14.3)	0 (0.0)	N.E.	3.00 [0.14; 63.15] 0.480	0.14 [-0.12; 0.40] 0.280
<b>Center No. 1037</b>					
n (%)	0 (0.0)	1 (9.1)	N.E.	0.40 [0.02; 8.78] 0.561	-0.09 [-0.26; 0.08] 0.294
<b>Center No. 1040</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1059</b>					
n (%)	4 (57.1)	5 (71.4)	0.53 [0.06; 4.91] 0.579	0.80 [0.36; 1.77] 0.582	-0.14 [-0.64; 0.35] 0.573
<b>Center No. 1061</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.23 [0.01; 4.93] 0.350	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1064</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	1 (10.0)	2 (12.5)	0.78 [0.06; 9.88] 0.846	0.80 [0.08; 7.72] 0.847	-0.03 [-0.27; 0.22] 0.843
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1074</b>					
n (%)	3 (60.0)	0 (0.0)	N.E.	4.67 [0.32; 68.03] 0.260	0.60 [0.17; 1.03] 0.006

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1085</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1091</b>					
n (%)	1 (16.7)	0 (0.0)	N.E.	2.57 [0.13; 52.13] 0.538	0.17 [-0.13; 0.46] 0.273
<b>Center No. 1108</b>					
n (%)	0 (0.0)	1 (10.0)	N.E.	0.23 [0.01; 5.12] 0.353	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1113</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1115</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	3.50 [0.17; 70.95] 0.415	0.20 [-0.15; 0.55] 0.264
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup with treatment group as predictor.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p> <p>Only subgroups with at least one event are displayed.</p> <p>The severity grade refers to the maximum observed severity per patient.</p>					



**Table 14.3.1-2.1 Treatment-emergent adverse events (TEAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N <sup>a</sup>	388	388			
<b>Any AE</b>					
Total, n (%)	338 (87.1)	361 (93.0)	0.51 [0.31; 0.83] 0.006	0.94 [0.89; 0.98] 0.006	-0.06 [-0.10; -0.02] 0.006
Non-severe, n (%)	317 (81.7)	323 (83.2)	0.90 [0.62; 1.30] 0.571	0.98 [0.92; 1.05] 0.571	-0.02 [-0.07; 0.04] 0.571
Severe, n (%)	21 (5.4)	38 (9.8)	0.53 [0.30; 0.92] 0.023	0.55 [0.33; 0.92] 0.024	-0.04 [-0.08; -0.01] 0.021
<b>Nervous system disorders</b>					
Total, n (%)	96 (24.7)	253 (65.2)	0.18 [0.13; 0.24] <.001	0.38 [0.31; 0.46] <.001	-0.40 [-0.47; -0.34] <.001
Non-severe, n (%)	91 (23.5)	244 (62.9)	0.18 [0.13; 0.25] <.001	0.37 [0.31; 0.45] <.001	-0.39 [-0.46; -0.33] <.001
Severe, n (%)	5 (1.3)	9 (2.3)	0.55 [0.18; 1.66] 0.287	0.56 [0.19; 1.64] 0.288	-0.01 [-0.03; 0.01] 0.280
<b>Paraesthesia</b>					
Total, n (%)	17 (4.4)	159 (41.0)	0.07 [0.04; 0.11] <.001	0.11 [0.07; 0.17] <.001	-0.37 [-0.42; -0.31] <.001
Non-severe, n (%)	17 (4.4)	155 (39.9)	0.07 [0.04; 0.12] <.001	0.11 [0.07; 0.18] <.001	-0.36 [-0.41; -0.30] <.001
Severe, n (%)	0 (0.0)	4 (1.0)	N.E.	0.11 [0.01; 2.06] 0.140	-0.01 [-0.02; -0.00] 0.044

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Disturbance in attention</b>					
Total, n (%)	18 (4.6)	63 (16.2)	0.25 [0.15; 0.43] <.001	0.29 [0.17; 0.47] <.001	-0.12 [-0.16; -0.07] <.001
Non-severe, n (%)	17 (4.4)	61 (15.7)	0.25 [0.14; 0.43] <.001	0.28 [0.17; 0.47] <.001	-0.11 [-0.15; -0.07] <.001
Severe, n (%)	1 (0.3)	2 (0.5)	0.50 [0.05; 5.52] 0.571	0.50 [0.05; 5.49] 0.571	-0.00 [-0.01; 0.01] 0.563
<b>Dizziness</b>					
Total, n (%)	28 (7.2)	60 (15.5)	0.43 [0.26; 0.68] <.001	0.47 [0.30; 0.71] <.001	-0.08 [-0.13; -0.04] <.001
Non-severe, n (%)	27 (7.0)	58 (14.9)	0.43 [0.26; 0.69] <.001	0.47 [0.30; 0.72] <.001	-0.08 [-0.12; -0.04] <.001
Severe, n (%)	1 (0.3)	2 (0.5)	0.50 [0.05; 5.52] 0.571	0.50 [0.05; 5.49] 0.571	-0.00 [-0.01; 0.01] 0.563
<b>Taste disorder</b>					
Total, n (%)	0 (0.0)	26 (6.7)	N.E.	0.02 [0.00; 0.31] 0.005	-0.07 [-0.09; -0.04] <.001
Non-severe, n (%)	0 (0.0)	26 (6.7)	N.E.	0.02 [0.00; 0.31] 0.005	-0.07 [-0.09; -0.04] <.001
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Dysgeusia</b>					
Total, n (%)	3 (0.8)	23 (5.9)	0.12 [0.04; 0.42] <.001	0.13 [0.04; 0.43] <.001	-0.05 [-0.08; -0.03] <.001
Non-severe, n (%)	3 (0.8)	23 (5.9)	0.12 [0.04; 0.42] <.001	0.13 [0.04; 0.43] <.001	-0.05 [-0.08; -0.03] <.001
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Headache</b>					
Total, n (%)	6 (1.5)	13 (3.4)	0.45 [0.17; 1.20] 0.113	0.46 [0.18; 1.20] 0.113	-0.02 [-0.04; 0.00] 0.103
Non-severe, n (%)	6 (1.5)	13 (3.4)	0.45 [0.17; 1.20] 0.113	0.46 [0.18; 1.20] 0.113	-0.02 [-0.04; 0.00] 0.103
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Hypoaesthesia</b>					
Total, n (%)	3 (0.8)	13 (3.4)	0.22 [0.06; 0.80] 0.021	0.23 [0.07; 0.80] 0.021	-0.03 [-0.05; -0.01] 0.011
Non-severe, n (%)	3 (0.8)	12 (3.1)	0.24 [0.07; 0.87] 0.030	0.25 [0.07; 0.88] 0.031	-0.02 [-0.04; -0.00] 0.019
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<b>Aphasia</b>					
Total, n (%)	2 (0.5)	11 (2.8)	0.18 [0.04; 0.81] 0.025	0.18 [0.04; 0.81] 0.026	-0.02 [-0.04; -0.01] 0.011
Non-severe, n (%)	2 (0.5)	11 (2.8)	0.18 [0.04; 0.81] 0.025	0.18 [0.04; 0.81] 0.026	-0.02 [-0.04; -0.01] 0.011
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Memory impairment</b>					
Total, n (%)	1 (0.3)	10 (2.6)	0.10 [0.01; 0.77] 0.027	0.10 [0.01; 0.78] 0.028	-0.02 [-0.04; -0.01] 0.006
Non-severe, n (%)	1 (0.3)	10 (2.6)	0.10 [0.01; 0.77] 0.027	0.10 [0.01; 0.78] 0.028	-0.02 [-0.04; -0.01] 0.006
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Infections and infestations</b>					
Total, n (%)	199 (51.3)	185 (47.7)	1.16 [0.87; 1.53] 0.315	1.08 [0.93; 1.24] 0.315	0.04 [-0.03; 0.11] 0.314
Non-severe, n (%)	198 (51.0)	179 (46.1)	1.22 [0.92; 1.61] 0.173	1.11 [0.96; 1.28] 0.173	0.05 [-0.02; 0.12] 0.172
Severe, n (%)	1 (0.3)	6 (1.5)	0.16 [0.02; 1.37] 0.095	0.17 [0.02; 1.38] 0.096	-0.01 [-0.03; 0.00] 0.057
<b>Nasopharyngitis</b>					
Total, n (%)	145 (37.4)	150 (38.7)	0.95 [0.71; 1.27] 0.712	0.97 [0.81; 1.16] 0.712	-0.01 [-0.08; 0.06] 0.712
Non-severe, n (%)	144 (37.1)	148 (38.1)	0.96 [0.72; 1.28] 0.767	0.97 [0.81; 1.17] 0.767	-0.01 [-0.08; 0.06] 0.767
Severe, n (%)	1 (0.3)	2 (0.5)	0.50 [0.05; 5.52] 0.571	0.50 [0.05; 5.49] 0.571	-0.00 [-0.01; 0.01] 0.563
<b>Gastroenteritis</b>					
Total, n (%)	14 (3.6)	8 (2.1)	1.78 [0.74; 4.29] 0.200	1.75 [0.74; 4.12] 0.201	0.02 [-0.01; 0.04] 0.194
Non-severe, n (%)	14 (3.6)	8 (2.1)	1.78 [0.74; 4.29] 0.200	1.75 [0.74; 4.12] 0.201	0.02 [-0.01; 0.04] 0.194
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Bronchitis</b>					
Total, n (%)	10 (2.6)	11 (2.8)	0.91 [0.38; 2.16] 0.825	0.91 [0.39; 2.12] 0.825	-0.00 [-0.03; 0.02] 0.825
Non-severe, n (%)	10 (2.6)	11 (2.8)	0.91 [0.38; 2.16] 0.825	0.91 [0.39; 2.12] 0.825	-0.00 [-0.03; 0.02] 0.825
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Gastrointestinal infection</b>					
Total, n (%)	4 (1.0)	11 (2.8)	0.36 [0.11; 1.13] 0.080	0.36 [0.12; 1.13] 0.081	-0.02 [-0.04; 0.00] 0.067
Non-severe, n (%)	4 (1.0)	10 (2.6)	0.39 [0.12; 1.27] 0.118	0.40 [0.13; 1.26] 0.119	-0.02 [-0.03; 0.00] 0.105
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<b>Sinusitis</b>					
Total, n (%)	11 (2.8)	3 (0.8)	3.74 [1.04; 13.53] 0.044	3.67 [1.03; 13.04] 0.045	0.02 [0.00; 0.04] 0.030
Non-severe, n (%)	11 (2.8)	3 (0.8)	3.74 [1.04; 13.53] 0.044	3.67 [1.03; 13.04] 0.045	0.02 [0.00; 0.04] 0.030
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Cystitis</b>					
Total, n (%)	10 (2.6)	10 (2.6)	1.00 [0.41; 2.43] 1.000	1.00 [0.42; 2.38] 1.000	0.00 [-0.02; 0.02] 1.000
Non-severe, n (%)	10 (2.6)	10 (2.6)	1.00 [0.41; 2.43] 1.000	1.00 [0.42; 2.38] 1.000	0.00 [-0.02; 0.02] 1.000
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Gastrointestinal disorders</b>					
Total, n (%)	146 (37.6)	147 (37.9)	0.99 [0.74; 1.32] 0.941	0.99 [0.83; 1.19] 0.941	-0.00 [-0.07; 0.07] 0.941
Non-severe, n (%)	143 (36.9)	143 (36.9)	1.00 [0.75; 1.34] 1.000	1.00 [0.83; 1.20] 1.000	0.00 [-0.07; 0.07] 1.000
Severe, n (%)	3 (0.8)	4 (1.0)	0.75 [0.17; 3.36] 0.705	0.75 [0.17; 3.33] 0.705	-0.00 [-0.02; 0.01] 0.704

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Nausea</b>					
Total, n (%)	36 (9.3)	71 (18.3)	0.46 [0.30; 0.70] <.001	0.51 [0.35; 0.74] <.001	-0.09 [-0.14; -0.04] <.001
Non-severe, n (%)	35 (9.0)	70 (18.0)	0.45 [0.29; 0.69] <.001	0.50 [0.34; 0.73] <.001	-0.09 [-0.14; -0.04] <.001
Severe, n (%)	1 (0.3)	1 (0.3)	1.00 [0.06; 16.04] 1.000	1.00 [0.06; 15.93] 1.000	0.00 [-0.01; 0.01] 1.000
<b>Constipation</b>					
Total, n (%)	48 (12.4)	12 (3.1)	4.42 [2.31; 8.47] <.001	4.00 [2.16; 7.41] <.001	0.09 [0.06; 0.13] <.001
Non-severe, n (%)	48 (12.4)	12 (3.1)	4.42 [2.31; 8.47] <.001	4.00 [2.16; 7.41] <.001	0.09 [0.06; 0.13] <.001
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Diarrhoea</b>					
Total, n (%)	20 (5.2)	29 (7.5)	0.67 [0.37; 1.21] 0.186	0.69 [0.40; 1.20] 0.187	-0.02 [-0.06; 0.01] 0.184
Non-severe, n (%)	20 (5.2)	28 (7.2)	0.70 [0.39; 1.26] 0.235	0.71 [0.41; 1.25] 0.236	-0.02 [-0.05; 0.01] 0.233
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<b>Abdominal pain upper</b>					
Total, n (%)	22 (5.7)	23 (5.9)	0.95 [0.52; 1.74] 0.878	0.96 [0.54; 1.69] 0.878	-0.00 [-0.04; 0.03] 0.878
Non-severe, n (%)	22 (5.7)	22 (5.7)	1.00 [0.54; 1.84] 1.000	1.00 [0.56; 1.78] 1.000	0.00 [-0.03; 0.03] 1.000
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Dry mouth</b>					
Total, n (%)	8 (2.1)	19 (4.9)	0.41 [0.18; 0.95] 0.037	0.42 [0.19; 0.95] 0.037	-0.03 [-0.05; -0.00] 0.031
Non-severe, n (%)	8 (2.1)	18 (4.6)	0.43 [0.19; 1.01] 0.052	0.44 [0.20; 1.01] 0.053	-0.03 [-0.05; -0.00] 0.046
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<b>Dyspepsia</b>					
Total, n (%)	12 (3.1)	11 (2.8)	1.09 [0.48; 2.51] 0.832	1.09 [0.49; 2.44] 0.832	0.00 [-0.02; 0.03] 0.832
Non-severe, n (%)	12 (3.1)	11 (2.8)	1.09 [0.48; 2.51] 0.832	1.09 [0.49; 2.44] 0.832	0.00 [-0.02; 0.03] 0.832
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Vomiting</b>					
Total, n (%)	9 (2.3)	11 (2.8)	0.81 [0.33; 1.99] 0.651	0.82 [0.34; 1.95] 0.651	-0.01 [-0.03; 0.02] 0.650
Non-severe, n (%)	9 (2.3)	11 (2.8)	0.81 [0.33; 1.99] 0.651	0.82 [0.34; 1.95] 0.651	-0.01 [-0.03; 0.02] 0.650
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Psychiatric disorders</b>					
Total, n (%)	72 (18.6)	114 (29.4)	0.55 [0.39; 0.77] <.001	0.63 [0.49; 0.82] <.001	-0.11 [-0.17; -0.05] <.001
Non-severe, n (%)	70 (18.0)	111 (28.6)	0.55 [0.39; 0.77] <.001	0.63 [0.48; 0.82] <.001	-0.11 [-0.16; -0.05] <.001
Severe, n (%)	2 (0.5)	3 (0.8)	0.67 [0.11; 4.00] 0.656	0.67 [0.11; 3.97] 0.656	-0.00 [-0.01; 0.01] 0.654

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Sleep disorder</b>					
Total, n (%)	20 (5.2)	8 (2.1)	2.58 [1.12; 5.93] 0.026	2.50 [1.11; 5.61] 0.026	0.03 [0.00; 0.06] 0.020
Non-severe, n (%)	20 (5.2)	8 (2.1)	2.58 [1.12; 5.93] 0.026	2.50 [1.11; 5.61] 0.026	0.03 [0.00; 0.06] 0.020
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Depression</b>					
Total, n (%)	11 (2.8)	19 (4.9)	0.57 [0.27; 1.21] 0.141	0.58 [0.28; 1.20] 0.142	-0.02 [-0.05; 0.01] 0.136
Non-severe, n (%)	11 (2.8)	18 (4.6)	0.60 [0.28; 1.29] 0.190	0.61 [0.29; 1.28] 0.190	-0.02 [-0.04; 0.01] 0.185
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<b>Irritability</b>					
Total, n (%)	5 (1.3)	19 (4.9)	0.25 [0.09; 0.69] 0.007	0.26 [0.10; 0.70] 0.007	-0.04 [-0.06; -0.01] 0.004
Non-severe, n (%)	5 (1.3)	19 (4.9)	0.25 [0.09; 0.69] 0.007	0.26 [0.10; 0.70] 0.007	-0.04 [-0.06; -0.01] 0.004
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Mood swings</b>					
Total, n (%)	10 (2.6)	16 (4.1)	0.62 [0.28; 1.37] 0.235	0.63 [0.29; 1.36] 0.236	-0.02 [-0.04; 0.01] 0.231
Non-severe, n (%)	10 (2.6)	16 (4.1)	0.62 [0.28; 1.37] 0.235	0.63 [0.29; 1.36] 0.236	-0.02 [-0.04; 0.01] 0.231
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Depressed mood</b>					
Total, n (%)	2 (0.5)	15 (3.9)	0.13 [0.03; 0.57] 0.007	0.13 [0.03; 0.58] 0.007	-0.03 [-0.05; -0.01] 0.001
Non-severe, n (%)	2 (0.5)	14 (3.6)	0.14 [0.03; 0.61] 0.009	0.14 [0.03; 0.62] 0.010	-0.03 [-0.05; -0.01] 0.002
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<b>Insomnia</b>					
Total, n (%)	8 (2.1)	13 (3.4)	0.61 [0.25; 1.48] 0.273	0.62 [0.26; 1.47] 0.274	-0.01 [-0.04; 0.01] 0.268
Non-severe, n (%)	8 (2.1)	13 (3.4)	0.61 [0.25; 1.48] 0.273	0.62 [0.26; 1.47] 0.274	-0.01 [-0.04; 0.01] 0.268
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Restlessness</b>					
Total, n (%)	4 (1.0)	11 (2.8)	0.36 [0.11; 1.13] 0.080	0.36 [0.12; 1.13] 0.081	-0.02 [-0.04; 0.00] 0.067
Non-severe, n (%)	4 (1.0)	10 (2.6)	0.39 [0.12; 1.27] 0.118	0.40 [0.13; 1.26] 0.119	-0.02 [-0.03; 0.00] 0.105
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<b>General disorders and administration site conditions</b>					
Total, n (%)	77 (19.8)	103 (26.5)	0.69 [0.49; 0.96] 0.027	0.75 [0.58; 0.97] 0.028	-0.07 [-0.13; -0.01] 0.027
Non-severe, n (%)	73 (18.8)	98 (25.3)	0.69 [0.49; 0.97] 0.031	0.74 [0.57; 0.97] 0.031	-0.06 [-0.12; -0.01] 0.030
Severe, n (%)	4 (1.0)	5 (1.3)	0.80 [0.21; 2.99] 0.738	0.80 [0.22; 2.96] 0.738	-0.00 [-0.02; 0.01] 0.737

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Fatigue</b>					
Total, n (%)	44 (11.3)	74 (19.1)	0.54 [0.36; 0.81] 0.003	0.59 [0.42; 0.84] 0.003	-0.08 [-0.13; -0.03] 0.003
Non-severe, n (%)	40 (10.3)	69 (17.8)	0.53 [0.35; 0.81] 0.003	0.58 [0.40; 0.83] 0.003	-0.07 [-0.12; -0.03] 0.003
Severe, n (%)	4 (1.0)	5 (1.3)	0.80 [0.21; 2.99] 0.738	0.80 [0.22; 2.96] 0.738	-0.00 [-0.02; 0.01] 0.737
<b>Influenza like illness</b>					
Total, n (%)	3 (0.8)	11 (2.8)	0.27 [0.07; 0.96] 0.044	0.27 [0.08; 0.97] 0.045	-0.02 [-0.04; -0.00] 0.030
Non-severe, n (%)	3 (0.8)	11 (2.8)	0.27 [0.07; 0.96] 0.044	0.27 [0.08; 0.97] 0.045	-0.02 [-0.04; -0.00] 0.030
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Musculoskeletal and connective tissue disorders</b>					
Total, n (%)	64 (16.5)	61 (15.7)	1.06 [0.72; 1.55] 0.770	1.05 [0.76; 1.45] 0.770	0.01 [-0.04; 0.06] 0.770
Non-severe, n (%)	61 (15.7)	58 (14.9)	1.06 [0.72; 1.57] 0.765	1.05 [0.76; 1.46] 0.765	0.01 [-0.04; 0.06] 0.765
Severe, n (%)	3 (0.8)	3 (0.8)	1.00 [0.20; 4.99] 1.000	1.00 [0.20; 4.92] 1.000	0.00 [-0.01; 0.01] 1.000
<b>Back pain</b>					
Total, n (%)	21 (5.4)	20 (5.2)	1.05 [0.56; 1.98] 0.873	1.05 [0.58; 1.91] 0.873	0.00 [-0.03; 0.03] 0.873
Non-severe, n (%)	19 (4.9)	20 (5.2)	0.95 [0.50; 1.80] 0.870	0.95 [0.52; 1.75] 0.870	-0.00 [-0.03; 0.03] 0.869
Severe, n (%)	2 (0.5)	0 (0.0)	N.E.	5.00 [0.24; 103.81] 0.298	0.01 [-0.00; 0.01] 0.156

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Metabolism and nutrition disorders</b>					
Total, n (%)	12 (3.1)	49 (12.6)	0.22 [0.12; 0.42] <.001	0.24 [0.13; 0.45] <.001	-0.10 [-0.13; -0.06] <.001
Non-severe, n (%)	12 (3.1)	48 (12.4)	0.23 [0.12; 0.43] <.001	0.25 [0.13; 0.46] <.001	-0.09 [-0.13; -0.06] <.001
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<b>Decreased appetite</b>					
Total, n (%)	8 (2.1)	40 (10.3)	0.18 [0.08; 0.40] <.001	0.20 [0.09; 0.42] <.001	-0.08 [-0.12; -0.05] <.001
Non-severe, n (%)	8 (2.1)	39 (10.1)	0.19 [0.09; 0.41] <.001	0.21 [0.10; 0.43] <.001	-0.08 [-0.11; -0.05] <.001
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<b>Respiratory, thoracic and mediastinal disorders</b>					
Total, n (%)	35 (9.0)	45 (11.6)	0.76 [0.47; 1.20] 0.239	0.78 [0.51; 1.18] 0.239	-0.03 [-0.07; 0.02] 0.237
Non-severe, n (%)	35 (9.0)	43 (11.1)	0.80 [0.50; 1.27] 0.340	0.81 [0.53; 1.24] 0.341	-0.02 [-0.06; 0.02] 0.339
Severe, n (%)	0 (0.0)	2 (0.5)	N.E.	0.20 [0.01; 4.15] 0.298	-0.01 [-0.01; 0.00] 0.156
<b>Cough</b>					
Total, n (%)	6 (1.5)	16 (4.1)	0.37 [0.14; 0.94] 0.037	0.38 [0.15; 0.95] 0.038	-0.03 [-0.05; -0.00] 0.030
Non-severe, n (%)	6 (1.5)	15 (3.9)	0.39 [0.15; 1.02] 0.054	0.40 [0.16; 1.02] 0.055	-0.02 [-0.05; -0.00] 0.046
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Oropharyngeal pain</b>					
Total, n (%)	14 (3.6)	10 (2.6)	1.41 [0.62; 3.23] 0.409	1.40 [0.63; 3.11] 0.409	0.01 [-0.01; 0.03] 0.407
Non-severe, n (%)	14 (3.6)	10 (2.6)	1.41 [0.62; 3.23] 0.409	1.40 [0.63; 3.11] 0.409	0.01 [-0.01; 0.03] 0.407
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Investigations</b>					
Total, n (%)	26 (6.7)	42 (10.8)	0.59 [0.36; 0.99] 0.044	0.62 [0.39; 0.99] 0.045	-0.04 [-0.08; -0.00] 0.042
Non-severe, n (%)	26 (6.7)	41 (10.6)	0.61 [0.36; 1.02] 0.057	0.63 [0.40; 1.02] 0.058	-0.04 [-0.08; 0.00] 0.055
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<b>Weight decreased</b>					
Total, n (%)	5 (1.3)	23 (5.9)	0.21 [0.08; 0.55] 0.002	0.22 [0.08; 0.57] 0.002	-0.05 [-0.07; -0.02] <.001
Non-severe, n (%)	5 (1.3)	22 (5.7)	0.22 [0.08; 0.58] 0.002	0.23 [0.09; 0.59] 0.003	-0.04 [-0.07; -0.02] <.001
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<b>Skin and subcutaneous tissue disorders</b>					
Total, n (%)	40 (10.3)	33 (8.5)	1.24 [0.76; 2.01] 0.390	1.21 [0.78; 1.88] 0.390	0.02 [-0.02; 0.06] 0.389
Non-severe, n (%)	39 (10.1)	32 (8.2)	1.24 [0.76; 2.03] 0.384	1.22 [0.78; 1.90] 0.384	0.02 [-0.02; 0.06] 0.383
Severe, n (%)	1 (0.3)	1 (0.3)	1.00 [0.06; 16.04] 1.000	1.00 [0.06; 15.93] 1.000	0.00 [-0.01; 0.01] 1.000

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Pruritus</b>					
Total, n (%)	13 (3.4)	6 (1.5)	2.21 [0.83; 5.87] 0.113	2.17 [0.83; 5.64] 0.113	0.02 [-0.00; 0.04] 0.103
Non-severe, n (%)	13 (3.4)	6 (1.5)	2.21 [0.83; 5.87] 0.113	2.17 [0.83; 5.64] 0.113	0.02 [-0.00; 0.04] 0.103
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Ear and labyrinth disorders</b>					
Total, n (%)	31 (8.0)	33 (8.5)	0.93 [0.56; 1.56] 0.794	0.94 [0.59; 1.50] 0.794	-0.01 [-0.04; 0.03] 0.794
Non-severe, n (%)	29 (7.5)	28 (7.2)	1.04 [0.61; 1.78] 0.891	1.04 [0.63; 1.71] 0.891	0.00 [-0.03; 0.04] 0.891
Severe, n (%)	2 (0.5)	5 (1.3)	0.40 [0.08; 2.06] 0.271	0.40 [0.08; 2.05] 0.272	-0.01 [-0.02; 0.01] 0.254
<b>Vertigo</b>					
Total, n (%)	20 (5.2)	24 (6.2)	0.82 [0.45; 1.52] 0.535	0.83 [0.47; 1.48] 0.535	-0.01 [-0.04; 0.02] 0.535
Non-severe, n (%)	18 (4.6)	19 (4.9)	0.94 [0.49; 1.83] 0.866	0.95 [0.50; 1.78] 0.866	-0.00 [-0.03; 0.03] 0.866
Severe, n (%)	2 (0.5)	5 (1.3)	0.40 [0.08; 2.06] 0.271	0.40 [0.08; 2.05] 0.272	-0.01 [-0.02; 0.01] 0.254
<b>Eye disorders</b>					
Total, n (%)	12 (3.1)	32 (8.2)	0.36 [0.18; 0.70] 0.003	0.38 [0.20; 0.72] 0.003	-0.05 [-0.08; -0.02] 0.002
Non-severe, n (%)	12 (3.1)	30 (7.7)	0.38 [0.19; 0.76] 0.006	0.40 [0.21; 0.77] 0.006	-0.05 [-0.08; -0.01] 0.004
Severe, n (%)	0 (0.0)	2 (0.5)	N.E.	0.20 [0.01; 4.15] 0.298	-0.01 [-0.01; 0.00] 0.156

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b><i>Injury, poisoning and procedural complications</i></b>					
Total, n (%)	27 (7.0)	31 (8.0)	0.86 [0.50; 1.47] 0.585	0.87 [0.53; 1.43] 0.585	-0.01 [-0.05; 0.03] 0.585
Non-severe, n (%)	25 (6.4)	30 (7.7)	0.82 [0.47; 1.43] 0.485	0.83 [0.50; 1.39] 0.485	-0.01 [-0.05; 0.02] 0.484
Severe, n (%)	2 (0.5)	1 (0.3)	2.01 [0.18; 22.21] 0.571	2.00 [0.18; 21.97] 0.571	0.00 [-0.01; 0.01] 0.563
<b><i>Cardiac disorders</i></b>					
Total, n (%)	12 (3.1)	20 (5.2)	0.59 [0.28; 1.22] 0.153	0.60 [0.30; 1.21] 0.154	-0.02 [-0.05; 0.01] 0.148
Non-severe, n (%)	12 (3.1)	19 (4.9)	0.62 [0.30; 1.30] 0.203	0.63 [0.31; 1.28] 0.204	-0.02 [-0.05; 0.01] 0.199
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<b><i>Vascular disorders</i></b>					
Total, n (%)	16 (4.1)	19 (4.9)	0.84 [0.42; 1.65] 0.604	0.84 [0.44; 1.61] 0.604	-0.01 [-0.04; 0.02] 0.604
Non-severe, n (%)	16 (4.1)	19 (4.9)	0.84 [0.42; 1.65] 0.604	0.84 [0.44; 1.61] 0.604	-0.01 [-0.04; 0.02] 0.604
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b><i>Reproductive system and breast disorders</i></b>					
Total, n (%)	15 (3.9)	17 (4.4)	0.88 [0.43; 1.78] 0.718	0.88 [0.45; 1.74] 0.718	-0.01 [-0.03; 0.02] 0.718
Non-severe, n (%)	14 (3.6)	17 (4.4)	0.82 [0.40; 1.68] 0.583	0.82 [0.41; 1.65] 0.583	-0.01 [-0.04; 0.02] 0.582
Severe, n (%)	1 (0.3)	0 (0.0)	N.E.	3.00 [0.12; 73.42] 0.501	0.00 [-0.00; 0.01] 0.317

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b><i>Immune system disorders</i></b>					
Total, n (%)	5 (1.3)	10 (2.6)	0.49 [0.17; 1.46] 0.201	0.50 [0.17; 1.45] 0.202	-0.01 [-0.03; 0.01] 0.192
Non-severe, n (%)	5 (1.3)	8 (2.1)	0.62 [0.20; 1.91] 0.406	0.63 [0.21; 1.89] 0.406	-0.01 [-0.03; 0.01] 0.401
Severe, n (%)	0 (0.0)	2 (0.5)	N.E.	0.20 [0.01; 4.15] 0.298	-0.01 [-0.01; 0.00] 0.156
<b><i>Renal and urinary disorders</i></b>					
Total, n (%)	4 (1.0)	10 (2.6)	0.39 [0.12; 1.27] 0.118	0.40 [0.13; 1.26] 0.119	-0.02 [-0.03; 0.00] 0.105
Non-severe, n (%)	4 (1.0)	10 (2.6)	0.39 [0.12; 1.27] 0.118	0.40 [0.13; 1.26] 0.119	-0.02 [-0.03; 0.00] 0.105
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR is obtained from a logistic regression model with treatment group as predictor.  RR and RD are calculated directly with CI and p-value based on the Wald statistic.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p> <p>The table displays system organ classes (<i>italic/bold</i>) and preferred terms (<b>bold</b>) with a prevalence <math>\geq 10\%</math> or a prevalence <math>\geq 10</math> patients AND <math>\geq 1\%</math> in at least one treatment arm. The severity grade refers to the maximum observed severity per patient.</p>					

**Table 14.3.1-2.1.1 Treatment-emergent adverse events (TEAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade by Age Group (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
< median age, N'	186	190			
≥ median age, N'	202	198			
<b>Any AE</b>					
<b>Interaction test: p=0.498</b>					
<b>&lt; median age</b>					
n (%)	157 (84.4)	176 (92.6)	0.43 [0.22; 0.84] 0.014	0.91 [0.85; 0.98] 0.013	-0.08 [-0.15; -0.02] 0.012
<b>≥ median age</b>					
n (%)	181 (89.6)	185 (93.4)	0.61 [0.29; 1.25] 0.173	0.96 [0.90; 1.02] 0.170	-0.04 [-0.09; 0.02] 0.168
<b>Any AE - severe</b>					
<b>Interaction test: p=0.871</b>					
<b>&lt; median age</b>					
n (%)	11 (5.9)	21 (11.1)	0.51 [0.24; 1.08] 0.079	0.54 [0.27; 1.08] 0.080	-0.05 [-0.11; 0.00] 0.072
<b>≥ median age</b>					
n (%)	10 (5.0)	17 (8.6)	0.55 [0.25; 1.24] 0.152	0.58 [0.27; 1.23] 0.153	-0.04 [-0.09; 0.01] 0.147
<b>Nervous system disorders</b>					
<b>Interaction test: p=0.394</b>					
<b>&lt; median age</b>					
n (%)	51 (27.4)	124 (65.3)	0.20 [0.13; 0.31] <.001	0.42 [0.33; 0.54] <.001	-0.38 [-0.47; -0.29] <.001
<b>≥ median age</b>					
n (%)	45 (22.3)	129 (65.2)	0.15 [0.10; 0.24] <.001	0.34 [0.26; 0.45] <.001	-0.43 [-0.52; -0.34] <.001



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Nervous system disorders - non-severe</b>					
<b>Interaction test: p=0.320</b>					
<b>&lt; median age</b>					
n (%)	48 (25.8)	118 (62.1)	0.21 [0.14; 0.33] <.001	0.42 [0.32; 0.54] <.001	-0.36 [-0.46; -0.27] <.001
<b>≥ median age</b>					
n (%)	43 (21.3)	126 (63.6)	0.15 [0.10; 0.24] <.001	0.33 [0.25; 0.44] <.001	-0.42 [-0.51; -0.34] <.001
<b>Paraesthesia</b>					
<b>Interaction test: p=0.526</b>					
<b>&lt; median age</b>					
n (%)	8 (4.3)	85 (44.7)	0.06 [0.03; 0.12] <.001	0.10 [0.05; 0.19] <.001	-0.40 [-0.48; -0.33] <.001
<b>≥ median age</b>					
n (%)	9 (4.5)	74 (37.4)	0.08 [0.04; 0.16] <.001	0.12 [0.06; 0.23] <.001	-0.33 [-0.40; -0.26] <.001
<b>Paraesthesia - non-severe</b>					
<b>Interaction test: p=0.578</b>					
<b>&lt; median age</b>					
n (%)	8 (4.3)	82 (43.2)	0.06 [0.03; 0.13] <.001	0.10 [0.05; 0.20] <.001	-0.39 [-0.46; -0.31] <.001
<b>≥ median age</b>					
n (%)	9 (4.5)	73 (36.9)	0.08 [0.04; 0.17] <.001	0.12 [0.06; 0.23] <.001	-0.32 [-0.40; -0.25] <.001
<b>Disturbance in attention</b>					
<b>Interaction test: p=0.412</b>					
<b>&lt; median age</b>					
n (%)	8 (4.3)	23 (12.1)	0.33 [0.14; 0.75] 0.008	0.36 [0.16; 0.77] 0.009	-0.08 [-0.13; -0.02] 0.005
<b>≥ median age</b>					
n (%)	10 (5.0)	40 (20.2)	0.21 [0.10; 0.42] <.001	0.25 [0.13; 0.48] <.001	-0.15 [-0.22; -0.09] <.001

		Treatment Groups		Comparison		
		AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Disturbance in attention - non-severe</b>						
<b>Interaction test: p=0.304</b>						
<b>&lt; median age</b>						
n (%)	8 (4.3)	22 (11.6)	0.34 [0.15; 0.79] 0.012	0.37 [0.17; 0.81] 0.013	-0.07 [-0.13; -0.02] 0.008	
<b>≥ median age</b>						
n (%)	9 (4.5)	39 (19.7)	0.19 [0.09; 0.40] <.001	0.23 [0.11; 0.45] <.001	-0.15 [-0.21; -0.09] <.001	
<b>Dizziness</b>						
<b>Interaction test: p=0.125</b>						
<b>&lt; median age</b>						
n (%)	16 (8.6)	25 (13.2)	0.62 [0.32; 1.21] 0.159	0.65 [0.36; 1.18] 0.161	-0.05 [-0.11; 0.02] 0.155	
<b>≥ median age</b>						
n (%)	12 (5.9)	35 (17.7)	0.29 [0.15; 0.59] <.001	0.34 [0.18; 0.63] <.001	-0.12 [-0.18; -0.06] <.001	
<b>Dizziness - non-severe</b>						
<b>Interaction test: p=0.087</b>						
<b>&lt; median age</b>						
n (%)	16 (8.6)	24 (12.6)	0.65 [0.33; 1.27] 0.208	0.68 [0.37; 1.24] 0.209	-0.04 [-0.10; 0.02] 0.203	
<b>≥ median age</b>						
n (%)	11 (5.4)	34 (17.2)	0.28 [0.14; 0.57] <.001	0.32 [0.17; 0.61] <.001	-0.12 [-0.18; -0.06] <.001	
<b>Taste disorder</b>						
<b>Interaction test: N.E.</b>						
<b>&lt; median age</b>						
n (%)	0 (0.0)	10 (5.3)	N.E.	0.05 [0.00; 0.82] 0.036	-0.05 [-0.08; -0.02] 0.001	
<b>≥ median age</b>						
n (%)	0 (0.0)	16 (8.1)	N.E.	0.03 [0.00; 0.49] 0.014	-0.08 [-0.12; -0.04] <.001	

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Taste disorder - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>&lt; median age</b>					
n (%)	0 (0.0)	10 (5.3)	N.E.	0.05 [0.00; 0.82] 0.036	-0.05 [-0.08; -0.02] 0.001
<b>≥ median age</b>					
n (%)	0 (0.0)	16 (8.1)	N.E.	0.03 [0.00; 0.49] 0.014	-0.08 [-0.12; -0.04] <.001
<b>Dysgeusia</b>					
<b>Interaction test: p=0.770</b>					
<b>&lt; median age</b>					
n (%)	1 (0.5)	10 (5.3)	0.10 [0.01; 0.77] 0.027	0.10 [0.01; 0.79] 0.029	-0.05 [-0.08; -0.01] 0.006
<b>≥ median age</b>					
n (%)	2 (1.0)	13 (6.6)	0.14 [0.03; 0.64] 0.011	0.15 [0.03; 0.66] 0.012	-0.06 [-0.09; -0.02] 0.003
<b>Dysgeusia - non-severe</b>					
<b>Interaction test: p=0.770</b>					
<b>&lt; median age</b>					
n (%)	1 (0.5)	10 (5.3)	0.10 [0.01; 0.77] 0.027	0.10 [0.01; 0.79] 0.029	-0.05 [-0.08; -0.01] 0.006
<b>≥ median age</b>					
n (%)	2 (1.0)	13 (6.6)	0.14 [0.03; 0.64] 0.011	0.15 [0.03; 0.66] 0.012	-0.06 [-0.09; -0.02] 0.003
<b>Hypoaesthesia</b>					
<b>Interaction test: p=0.719</b>					
<b>&lt; median age</b>					
n (%)	2 (1.1)	10 (5.3)	0.20 [0.04; 0.91] 0.037	0.20 [0.05; 0.92] 0.039	-0.04 [-0.08; -0.01] 0.019
<b>≥ median age</b>					
n (%)	1 (0.5)	3 (1.5)	0.32 [0.03; 3.14] 0.330	0.33 [0.03; 3.11] 0.331	-0.01 [-0.03; 0.01] 0.307

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Hypoaesthesia - non-severe</b>					
<b>Interaction test: p=0.531</b>					
<b>&lt; median age</b>					
n (%)	2 (1.1)	10 (5.3)	0.20 [0.04; 0.91] 0.037	0.20 [0.05; 0.92] 0.039	-0.04 [-0.08; -0.01] 0.019
<b>≥ median age</b>					
n (%)	1 (0.5)	2 (1.0)	0.49 [0.04; 5.42] 0.559	0.49 [0.04; 5.36] 0.559	-0.01 [-0.02; 0.01] 0.552
<b>Aphasia</b>					
<b>Interaction test: N.E.</b>					
<b>&lt; median age</b>					
n (%)	2 (1.1)	2 (1.1)	1.02 [0.14; 7.33] 0.983	1.02 [0.15; 7.18] 0.983	0.00 [-0.02; 0.02] 0.983
<b>≥ median age</b>					
n (%)	0 (0.0)	9 (4.5)	N.E.	0.05 [0.00; 0.88] 0.041	-0.05 [-0.07; -0.02] 0.002
<b>Aphasia - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>&lt; median age</b>					
n (%)	2 (1.1)	2 (1.1)	1.02 [0.14; 7.33] 0.983	1.02 [0.15; 7.18] 0.983	0.00 [-0.02; 0.02] 0.983
<b>≥ median age</b>					
n (%)	0 (0.0)	9 (4.5)	N.E.	0.05 [0.00; 0.88] 0.041	-0.05 [-0.07; -0.02] 0.002
<b>Memory impairment</b>					
<b>Interaction test: N.E.</b>					
<b>&lt; median age</b>					
n (%)	1 (0.5)	5 (2.6)	0.20 [0.02; 1.73] 0.144	0.20 [0.02; 1.73] 0.145	-0.02 [-0.05; 0.00] 0.102
<b>≥ median age</b>					
n (%)	0 (0.0)	5 (2.5)	N.E.	0.09 [0.00; 1.60] 0.101	-0.03 [-0.05; -0.00] 0.024

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Memory impairment - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>&lt; median age</b>					
n (%)	1 (0.5)	5 (2.6)	0.20 [0.02; 1.73] 0.144	0.20 [0.02; 1.73] 0.145	-0.02 [-0.05; 0.00] 0.102
<b>≥ median age</b>					
n (%)	0 (0.0)	5 (2.5)	N.E.	0.09 [0.00; 1.60] 0.101	-0.03 [-0.05; -0.00] 0.024
<b>Sinusitis</b>					
<b>Interaction test: p=0.954</b>					
<b>&lt; median age</b>					
n (%)	7 (3.8)	2 (1.1)	3.68 [0.75; 17.93] 0.107	3.58 [0.75; 16.99] 0.109	0.03 [-0.00; 0.06] 0.086
<b>≥ median age</b>					
n (%)	4 (2.0)	1 (0.5)	3.98 [0.44; 35.92] 0.219	3.92 [0.44; 34.77] 0.220	0.01 [-0.01; 0.04] 0.181
<b>Sinusitis - non-severe</b>					
<b>Interaction test: p=0.954</b>					
<b>&lt; median age</b>					
n (%)	7 (3.8)	2 (1.1)	3.68 [0.75; 17.93] 0.107	3.58 [0.75; 16.99] 0.109	0.03 [-0.00; 0.06] 0.086
<b>≥ median age</b>					
n (%)	4 (2.0)	1 (0.5)	3.98 [0.44; 35.92] 0.219	3.92 [0.44; 34.77] 0.220	0.01 [-0.01; 0.04] 0.181
<b>Nausea</b>					
<b>Interaction test: p=0.215</b>					
<b>&lt; median age</b>					
n (%)	19 (10.2)	30 (15.8)	0.61 [0.33; 1.12] 0.111	0.65 [0.38; 1.11] 0.113	-0.06 [-0.12; 0.01] 0.107
<b>≥ median age</b>					
n (%)	17 (8.4)	41 (20.7)	0.35 [0.19; 0.64] <.001	0.41 [0.24; 0.69] <.001	-0.12 [-0.19; -0.05] <.001

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Nausea - non-severe</b>					
<b>Interaction test: p=0.306</b>					
<b>&lt; median age</b>					
n (%)	18 (9.7)	30 (15.8)	0.57 [0.31; 1.07] 0.078	0.61 [0.35; 1.06] 0.080	-0.06 [-0.13; 0.01] 0.074
<b>≥ median age</b>					
n (%)	17 (8.4)	40 (20.2)	0.36 [0.20; 0.67] 0.001	0.42 [0.24; 0.71] 0.001	-0.12 [-0.19; -0.05] <.001
<b>Constipation</b>					
<b>Interaction test: p=0.158</b>					
<b>&lt; median age</b>					
n (%)	14 (7.5)	6 (3.2)	2.50 [0.94; 6.64] 0.067	2.38 [0.94; 6.07] 0.069	0.04 [-0.00; 0.09] 0.059
<b>≥ median age</b>					
n (%)	34 (16.8)	6 (3.0)	6.48 [2.65; 15.81] <.001	5.55 [2.38; 12.94] <.001	0.14 [0.08; 0.19] <.001
<b>Constipation - non-severe</b>					
<b>Interaction test: p=0.158</b>					
<b>&lt; median age</b>					
n (%)	14 (7.5)	6 (3.2)	2.50 [0.94; 6.64] 0.067	2.38 [0.94; 6.07] 0.069	0.04 [-0.00; 0.09] 0.059
<b>≥ median age</b>					
n (%)	34 (16.8)	6 (3.0)	6.48 [2.65; 15.81] <.001	5.55 [2.38; 12.94] <.001	0.14 [0.08; 0.19] <.001
<b>Dry mouth</b>					
<b>Interaction test: p=0.859</b>					
<b>&lt; median age</b>					
n (%)	4 (2.2)	9 (4.7)	0.44 [0.13; 1.46] 0.181	0.45 [0.14; 1.45] 0.182	-0.03 [-0.06; 0.01] 0.167
<b>≥ median age</b>					
n (%)	4 (2.0)	10 (5.1)	0.38 [0.12; 1.23] 0.107	0.39 [0.13; 1.23] 0.108	-0.03 [-0.07; 0.01] 0.095

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Psychiatric disorders</b>					
<b>Interaction test: p=0.516</b>					
<b>&lt; median age</b>					
n (%)	35 (18.8)	52 (27.4)	0.62 [0.38; 1.00] 0.050	0.69 [0.47; 1.00] 0.052	-0.09 [-0.17; -0.00] 0.048
<b>≥ median age</b>					
n (%)	37 (18.3)	62 (31.3)	0.49 [0.31; 0.78] 0.003	0.58 [0.41; 0.84] 0.003	-0.13 [-0.21; -0.05] 0.002
<b>Psychiatric disorders - non-severe</b>					
<b>Interaction test: p=0.284</b>					
<b>&lt; median age</b>					
n (%)	35 (18.8)	49 (25.8)	0.67 [0.41; 1.09] 0.106	0.73 [0.50; 1.07] 0.107	-0.07 [-0.15; 0.01] 0.103
<b>≥ median age</b>					
n (%)	35 (17.3)	62 (31.3)	0.46 [0.29; 0.74] 0.001	0.55 [0.38; 0.80] 0.001	-0.14 [-0.22; -0.06] <.001
<b>Sleep disorder</b>					
<b>Interaction test: p=0.113</b>					
<b>&lt; median age</b>					
n (%)	8 (4.3)	6 (3.2)	1.38 [0.47; 4.05] 0.560	1.36 [0.48; 3.85] 0.560	0.01 [-0.03; 0.05] 0.559
<b>≥ median age</b>					
n (%)	12 (5.9)	2 (1.0)	6.19 [1.37; 28.02] 0.018	5.88 [1.33; 25.94] 0.019	0.05 [0.01; 0.08] 0.006
<b>Sleep disorder - non-severe</b>					
<b>Interaction test: p=0.113</b>					
<b>&lt; median age</b>					
n (%)	8 (4.3)	6 (3.2)	1.38 [0.47; 4.05] 0.560	1.36 [0.48; 3.85] 0.560	0.01 [-0.03; 0.05] 0.559
<b>≥ median age</b>					
n (%)	12 (5.9)	2 (1.0)	6.19 [1.37; 28.02] 0.018	5.88 [1.33; 25.94] 0.019	0.05 [0.01; 0.08] 0.006

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Irritability</b>					
<b>Interaction test: p=0.448</b>					
<b>&lt; median age</b>					
n (%)	3 (1.6)	8 (4.2)	0.37 [0.10; 1.43] 0.150	0.38 [0.10; 1.42] 0.152	-0.03 [-0.06; 0.01] 0.132
<b>≥ median age</b>					
n (%)	2 (1.0)	11 (5.6)	0.17 [0.04; 0.78] 0.022	0.18 [0.04; 0.79] 0.024	-0.05 [-0.08; -0.01] 0.010
<b>Irritability - non-severe</b>					
<b>Interaction test: p=0.448</b>					
<b>&lt; median age</b>					
n (%)	3 (1.6)	8 (4.2)	0.37 [0.10; 1.43] 0.150	0.38 [0.10; 1.42] 0.152	-0.03 [-0.06; 0.01] 0.132
<b>≥ median age</b>					
n (%)	2 (1.0)	11 (5.6)	0.17 [0.04; 0.78] 0.022	0.18 [0.04; 0.79] 0.024	-0.05 [-0.08; -0.01] 0.010
<b>Depressed mood</b>					
<b>Interaction test: p=0.906</b>					
<b>&lt; median age</b>					
n (%)	1 (0.5)	7 (3.7)	0.14 [0.02; 1.16] 0.068	0.15 [0.02; 1.17] 0.070	-0.03 [-0.06; -0.00] 0.032
<b>≥ median age</b>					
n (%)	1 (0.5)	8 (4.0)	0.12 [0.01; 0.95] 0.045	0.12 [0.02; 0.97] 0.047	-0.04 [-0.06; -0.01] 0.017
<b>Depressed mood - non-severe</b>					
<b>Interaction test: p=0.824</b>					
<b>&lt; median age</b>					
n (%)	1 (0.5)	6 (3.2)	0.17 [0.02; 1.39] 0.098	0.17 [0.02; 1.40] 0.100	-0.03 [-0.05; 0.00] 0.057
<b>≥ median age</b>					
n (%)	1 (0.5)	8 (4.0)	0.12 [0.01; 0.95] 0.045	0.12 [0.02; 0.97] 0.047	-0.04 [-0.06; -0.01] 0.017



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>General disorders and administration site conditions</b>					
<b>Interaction test: p=0.084</b>					
<b>&lt; median age</b>					
n (%)	40 (21.5)	43 (22.6)	0.94 [0.58; 1.53] 0.792	0.95 [0.65; 1.39] 0.792	-0.01 [-0.10; 0.07] 0.792
<b>≥ median age</b>					
n (%)	37 (18.3)	60 (30.3)	0.52 [0.32; 0.82] 0.006	0.60 [0.42; 0.87] 0.006	-0.12 [-0.20; -0.04] 0.005
<b>General disorders and administration site conditions - non-severe</b>					
<b>Interaction test: p=0.094</b>					
<b>&lt; median age</b>					
n (%)	38 (20.4)	41 (21.6)	0.93 [0.57; 1.53] 0.785	0.95 [0.64; 1.40] 0.785	-0.01 [-0.09; 0.07] 0.784
<b>≥ median age</b>					
n (%)	35 (17.3)	57 (28.8)	0.52 [0.32; 0.84] 0.007	0.60 [0.41; 0.87] 0.008	-0.11 [-0.20; -0.03] 0.006
<b>Fatigue</b>					
<b>Interaction test: p=0.185</b>					
<b>&lt; median age</b>					
n (%)	23 (12.4)	31 (16.3)	0.72 [0.40; 1.30] 0.276	0.76 [0.46; 1.25] 0.277	-0.04 [-0.11; 0.03] 0.273
<b>≥ median age</b>					
n (%)	21 (10.4)	43 (21.7)	0.42 [0.24; 0.74] 0.002	0.48 [0.30; 0.78] 0.003	-0.11 [-0.18; -0.04] 0.002
<b>Fatigue - non-severe</b>					
<b>Interaction test: p=0.204</b>					
<b>&lt; median age</b>					
n (%)	21 (11.3)	29 (15.3)	0.71 [0.39; 1.29] 0.258	0.74 [0.44; 1.25] 0.259	-0.04 [-0.11; 0.03] 0.255
<b>≥ median age</b>					
n (%)	19 (9.4)	40 (20.2)	0.41 [0.23; 0.74] 0.003	0.47 [0.28; 0.78] 0.003	-0.11 [-0.18; -0.04] 0.002

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Influenza like illness</b>					
<b>Interaction test: p=0.500</b>					
<b>&lt; median age</b>					
n (%)	2 (1.1)	5 (2.6)	0.40 [0.08; 2.10] 0.280	0.41 [0.08; 2.08] 0.281	-0.02 [-0.04; 0.01] 0.261
<b>≥ median age</b>					
n (%)	1 (0.5)	6 (3.0)	0.16 [0.02; 1.33] 0.090	0.16 [0.02; 1.34] 0.092	-0.03 [-0.05; 0.00] 0.054
<b>Influenza like illness - non-severe</b>					
<b>Interaction test: p=0.500</b>					
<b>&lt; median age</b>					
n (%)	2 (1.1)	5 (2.6)	0.40 [0.08; 2.10] 0.280	0.41 [0.08; 2.08] 0.281	-0.02 [-0.04; 0.01] 0.261
<b>≥ median age</b>					
n (%)	1 (0.5)	6 (3.0)	0.16 [0.02; 1.33] 0.090	0.16 [0.02; 1.34] 0.092	-0.03 [-0.05; 0.00] 0.054
<b>Metabolism and nutrition disorders</b>					
<b>Interaction test: p=0.101</b>					
<b>&lt; median age</b>					
n (%)	9 (4.8)	24 (12.6)	0.35 [0.16; 0.78] 0.010	0.38 [0.18; 0.80] 0.011	-0.08 [-0.13; -0.02] 0.007
<b>≥ median age</b>					
n (%)	3 (1.5)	25 (12.6)	0.10 [0.03; 0.35] <.001	0.12 [0.04; 0.38] <.001	-0.11 [-0.16; -0.06] <.001
<b>Metabolism and nutrition disorders - non-severe</b>					
<b>Interaction test: p=0.089</b>					
<b>&lt; median age</b>					
n (%)	9 (4.8)	23 (12.1)	0.37 [0.17; 0.82] 0.015	0.40 [0.19; 0.84] 0.016	-0.07 [-0.13; -0.02] 0.011
<b>≥ median age</b>					
n (%)	3 (1.5)	25 (12.6)	0.10 [0.03; 0.35] <.001	0.12 [0.04; 0.38] <.001	-0.11 [-0.16; -0.06] <.001

		Treatment Groups		Comparison		
		AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Decreased appetite</b>						
<b>Interaction test: p=0.407</b>						
<b>&lt; median age</b>						
n (%)	5 (2.7)	19 (10.0)	0.25 [0.09; 0.68] 0.007	0.27 [0.10; 0.71] 0.008	-0.07 [-0.12; -0.02] 0.003	
<b>≥ median age</b>						
n (%)	3 (1.5)	21 (10.6)	0.13 [0.04; 0.43] <.001	0.14 [0.04; 0.46] 0.001	-0.09 [-0.14; -0.05] <.001	
<b>Decreased appetite - non-severe</b>						
<b>Interaction test: p=0.368</b>						
<b>&lt; median age</b>						
n (%)	5 (2.7)	18 (9.5)	0.26 [0.10; 0.73] 0.010	0.28 [0.11; 0.75] 0.011	-0.07 [-0.12; -0.02] 0.005	
<b>≥ median age</b>						
n (%)	3 (1.5)	21 (10.6)	0.13 [0.04; 0.43] <.001	0.14 [0.04; 0.46] 0.001	-0.09 [-0.14; -0.05] <.001	
<b>Cough</b>						
<b>Interaction test: p=0.634</b>						
<b>&lt; median age</b>						
n (%)	4 (2.2)	9 (4.7)	0.44 [0.13; 1.46] 0.181	0.45 [0.14; 1.45] 0.182	-0.03 [-0.06; 0.01] 0.167	
<b>≥ median age</b>						
n (%)	2 (1.0)	7 (3.5)	0.27 [0.06; 1.33] 0.108	0.28 [0.06; 1.33] 0.110	-0.03 [-0.05; 0.00] 0.087	
<b>Investigations</b>						
<b>Interaction test: p=0.266</b>						
<b>&lt; median age</b>						
n (%)	13 (7.0)	16 (8.4)	0.82 [0.38; 1.75] 0.603	0.83 [0.41; 1.68] 0.604	-0.01 [-0.07; 0.04] 0.602	
<b>≥ median age</b>						
n (%)	13 (6.4)	26 (13.1)	0.46 [0.23; 0.91] 0.027	0.49 [0.26; 0.93] 0.028	-0.07 [-0.12; -0.01] 0.024	

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Weight decreased</b>					
<b>Interaction test: p=0.135</b>					
<b>&lt; median age</b>					
n (%)	3 (1.6)	6 (3.2)	0.50 [0.12; 2.04] 0.336	0.51 [0.13; 2.01] 0.337	-0.02 [-0.05; 0.02] 0.325
<b>≥ median age</b>					
n (%)	2 (1.0)	17 (8.6)	0.11 [0.02; 0.47] 0.003	0.12 [0.03; 0.49] 0.004	-0.08 [-0.12; -0.03] <.001
<b>Weight decreased - non-severe</b>					
<b>Interaction test: p=0.099</b>					
<b>&lt; median age</b>					
n (%)	3 (1.6)	5 (2.6)	0.61 [0.14; 2.58] 0.498	0.61 [0.15; 2.53] 0.498	-0.01 [-0.04; 0.02] 0.492
<b>≥ median age</b>					
n (%)	2 (1.0)	17 (8.6)	0.11 [0.02; 0.47] 0.003	0.12 [0.03; 0.49] 0.004	-0.08 [-0.12; -0.03] <.001
<b>Eye disorders</b>					
<b>Interaction test: p=0.644</b>					
<b>&lt; median age</b>					
n (%)	4 (2.2)	9 (4.7)	0.44 [0.13; 1.46] 0.181	0.45 [0.14; 1.45] 0.182	-0.03 [-0.06; 0.01] 0.167
<b>≥ median age</b>					
n (%)	8 (4.0)	23 (11.6)	0.31 [0.14; 0.72] 0.006	0.34 [0.16; 0.74] 0.007	-0.08 [-0.13; -0.02] 0.004
<b>Eye disorders - non-severe</b>					
<b>Interaction test: p=0.581</b>					
<b>&lt; median age</b>					
n (%)	4 (2.2)	8 (4.2)	0.50 [0.15; 1.69] 0.265	0.51 [0.16; 1.67] 0.266	-0.02 [-0.06; 0.01] 0.253

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>≥ median age</b>					
n (%)	8 (4.0)	22 (11.1)	0.33 [0.14; 0.76] 0.009	0.36 [0.16; 0.78] 0.010	-0.07 [-0.12; -0.02] 0.006
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup with treatment group as predictor.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.</p> <p>Only subgroups with at least one event are displayed.</p> <p>The table displays system organ classes, preferred terms and severity grades with a p-value &lt;0.05 for RR in the total analysis set. The severity grade refers to the maximum observed severity per patient.</p>					

**Table 14.3.1-2.1.2 Treatment-emergent adverse events (TEAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade by Gender (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
Male, N'	57	53			
Female, N'	331	335			
<b>Any AE</b>					
<b>Interaction test: p=0.973</b>					
<b>Male</b>					
n (%)	44 (77.2)	46 (86.8)	0.51 [0.19; 1.41] 0.196	0.89 [0.75; 1.06] 0.192	-0.10 [-0.24; 0.05] 0.185
<b>Female</b>					
n (%)	294 (88.8)	315 (94.0)	0.50 [0.29; 0.89] 0.018	0.94 [0.90; 0.99] 0.017	-0.05 [-0.09; -0.01] 0.016
<b>Any AE - severe</b>					
<b>Interaction test: p=0.879</b>					
<b>Male</b>					
n (%)	2 (3.5)	3 (5.7)	0.61 [0.10; 3.78] 0.592	0.62 [0.11; 3.57] 0.592	-0.02 [-0.10; 0.06] 0.591
<b>Female</b>					
n (%)	19 (5.7)	35 (10.4)	0.52 [0.29; 0.93] 0.028	0.55 [0.32; 0.94] 0.029	-0.05 [-0.09; -0.01] 0.025
<b>Nervous system disorders</b>					
<b>Interaction test: p=0.640</b>					
<b>Male</b>					
n (%)	9 (15.8)	25 (47.2)	0.21 [0.09; 0.51] <.001	0.33 [0.17; 0.65] 0.001	-0.31 [-0.48; -0.15] <.001
<b>Female</b>					
n (%)	87 (26.3)	228 (68.1)	0.17 [0.12; 0.23] <.001	0.39 [0.32; 0.47] <.001	-0.42 [-0.49; -0.35] <.001

		Treatment Groups		Comparison		
		AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Nervous system disorders - non-severe</b>						
<b>Interaction test: p=0.703</b>						
<b>Male</b>						
n (%)	9 (15.8)	25 (47.2)	0.21 [0.09; 0.51] <.001	0.33 [0.17; 0.65] 0.001	-0.31 [-0.48; -0.15] <.001	
<b>Female</b>						
n (%)	82 (24.8)	219 (65.4)	0.17 [0.12; 0.24] <.001	0.38 [0.31; 0.46] <.001	-0.41 [-0.47; -0.34] <.001	
<b>Paraesthesia</b>						
<b>Interaction test: p=0.956</b>						
<b>Male</b>						
n (%)	1 (1.8)	11 (20.8)	0.07 [<0.01; 0.55] 0.012	0.08 [0.01; 0.63] 0.016	-0.19 [-0.30; -0.08] 0.001	
<b>Female</b>						
n (%)	16 (4.8)	148 (44.2)	0.06 [0.04; 0.11] <.001	0.11 [0.07; 0.18] <.001	-0.39 [-0.45; -0.34] <.001	
<b>Paraesthesia - non-severe</b>						
<b>Interaction test: p=0.991</b>						
<b>Male</b>						
n (%)	1 (1.8)	11 (20.8)	0.07 [<0.01; 0.55] 0.012	0.08 [0.01; 0.63] 0.016	-0.19 [-0.30; -0.08] 0.001	
<b>Female</b>						
n (%)	16 (4.8)	144 (43.0)	0.07 [0.04; 0.12] <.001	0.11 [0.07; 0.18] <.001	-0.38 [-0.44; -0.32] <.001	
<b>Disturbance in attention</b>						
<b>Interaction test: p=0.460</b>						
<b>Male</b>						
n (%)	1 (1.8)	7 (13.2)	0.12 [0.01; 0.99] 0.049	0.13 [0.02; 1.04] 0.055	-0.11 [-0.21; -0.02] 0.021	
<b>Female</b>						
n (%)	17 (5.1)	56 (16.7)	0.27 [0.15; 0.48] <.001	0.31 [0.18; 0.52] <.001	-0.12 [-0.16; -0.07] <.001	

		Treatment Groups		Comparison		
		AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Disturbance in attention - non-severe</b>						
<b>Interaction test: p=0.472</b>						
<b>Male</b>						
n (%)	1 (1.8)	7 (13.2)	0.12 [0.01; 0.99] 0.049	0.13 [0.02; 1.04] 0.055	-0.11 [-0.21; -0.02] 0.021	
<b>Female</b>						
n (%)	16 (4.8)	54 (16.1)	0.26 [0.15; 0.47] <.001	0.30 [0.18; 0.51] <.001	-0.11 [-0.16; -0.07] <.001	
<b>Dizziness</b>						
<b>Interaction test: p=0.755</b>						
<b>Male</b>						
n (%)	3 (5.3)	5 (9.4)	0.53 [0.12; 2.35] 0.406	0.56 [0.14; 2.22] 0.408	-0.04 [-0.14; 0.06] 0.403	
<b>Female</b>						
n (%)	25 (7.6)	55 (16.4)	0.42 [0.25; 0.69] <.001	0.46 [0.29; 0.72] <.001	-0.09 [-0.14; -0.04] <.001	
<b>Dizziness - non-severe</b>						
<b>Interaction test: p=0.756</b>						
<b>Male</b>						
n (%)	3 (5.3)	5 (9.4)	0.53 [0.12; 2.35] 0.406	0.56 [0.14; 2.22] 0.408	-0.04 [-0.14; 0.06] 0.403	
<b>Female</b>						
n (%)	24 (7.3)	53 (15.8)	0.42 [0.25; 0.69] <.001	0.46 [0.29; 0.72] <.001	-0.09 [-0.13; -0.04] <.001	
<b>Taste disorder</b>						
<b>Interaction test: N.E.</b>						
<b>Male</b>						
n (%)	0 (0.0)	4 (7.5)	N.E.	0.10 [0.01; 1.88] 0.125	-0.08 [-0.15; -0.00] 0.038	
<b>Female</b>						
n (%)	0 (0.0)	22 (6.6)	N.E.	0.02 [0.00; 0.37] 0.008	-0.07 [-0.09; -0.04] <.001	



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Taste disorder - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	0 (0.0)	4 (7.5)	N.E.	0.10 [0.01; 1.88] 0.125	-0.08 [-0.15; -0.00] 0.038
<b>Female</b>					
n (%)	0 (0.0)	22 (6.6)	N.E.	0.02 [0.00; 0.37] 0.008	-0.07 [-0.09; -0.04] <.001
<b>Dysgeusia</b>					
<b>Interaction test: p=0.265</b>					
<b>Male</b>					
n (%)	1 (1.8)	2 (3.8)	0.46 [0.04; 5.17] 0.526	0.46 [0.04; 4.98] 0.527	-0.02 [-0.08; 0.04] 0.521
<b>Female</b>					
n (%)	2 (0.6)	21 (6.3)	0.09 [0.02; 0.39] 0.001	0.10 [0.02; 0.41] 0.001	-0.06 [-0.08; -0.03] <.001
<b>Dysgeusia - non-severe</b>					
<b>Interaction test: p=0.265</b>					
<b>Male</b>					
n (%)	1 (1.8)	2 (3.8)	0.46 [0.04; 5.17] 0.526	0.46 [0.04; 4.98] 0.527	-0.02 [-0.08; 0.04] 0.521
<b>Female</b>					
n (%)	2 (0.6)	21 (6.3)	0.09 [0.02; 0.39] 0.001	0.10 [0.02; 0.41] 0.001	-0.06 [-0.08; -0.03] <.001
<b>Hypoaesthesia</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	0 (0.0)	1 (1.9)	N.E.	0.31 [0.01; 7.46] 0.471	-0.02 [-0.06; 0.02] 0.313
<b>Female</b>					
n (%)	3 (0.9)	12 (3.6)	0.25 [0.07; 0.88] 0.031	0.25 [0.07; 0.89] 0.032	-0.03 [-0.05; -0.00] 0.019

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Hypoaesthesia - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	0 (0.0)	1 (1.9)	N.E.	0.31 [0.01; 7.46] 0.471	-0.02 [-0.06; 0.02] 0.313
<b>Female</b>					
n (%)	3 (0.9)	11 (3.3)	0.27 [0.07; 0.97] 0.046	0.28 [0.08; 0.98] 0.047	-0.02 [-0.05; -0.00] 0.031
<b>Aphasia</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	0 (0.0)	1 (1.9)	N.E.	0.31 [0.01; 7.46] 0.471	-0.02 [-0.06; 0.02] 0.313
<b>Female</b>					
n (%)	2 (0.6)	10 (3.0)	0.20 [0.04; 0.91] 0.037	0.20 [0.04; 0.92] 0.038	-0.02 [-0.04; -0.00] 0.020
<b>Aphasia - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	0 (0.0)	1 (1.9)	N.E.	0.31 [0.01; 7.46] 0.471	-0.02 [-0.06; 0.02] 0.313
<b>Female</b>					
n (%)	2 (0.6)	10 (3.0)	0.20 [0.04; 0.91] 0.037	0.20 [0.04; 0.92] 0.038	-0.02 [-0.04; -0.00] 0.020
<b>Memory impairment</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	0 (0.0)	3 (5.7)	N.E.	0.13 [0.01; 2.52] 0.179	-0.06 [-0.12; 0.01] 0.075
<b>Female</b>					
n (%)	1 (0.3)	7 (2.1)	0.14 [0.02; 1.16] 0.069	0.14 [0.02; 1.17] 0.070	-0.02 [-0.03; -0.00] 0.033

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Memory impairment - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	0 (0.0)	3 (5.7)	N.E.	0.13 [0.01; 2.52] 0.179	-0.06 [-0.12; 0.01] 0.075
<b>Female</b>					
n (%)	1 (0.3)	7 (2.1)	0.14 [0.02; 1.16] 0.069	0.14 [0.02; 1.17] 0.070	-0.02 [-0.03; -0.00] 0.033
<b>Sinusitis</b>					
<b>Interaction test: N.E.</b>					
<b>Female</b>					
n (%)	11 (3.3)	3 (0.9)	3.80 [1.05; 13.76] 0.042	3.71 [1.04; 13.18] 0.043	0.02 [0.00; 0.05] 0.029
<b>Sinusitis - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Female</b>					
n (%)	11 (3.3)	3 (0.9)	3.80 [1.05; 13.76] 0.042	3.71 [1.04; 13.18] 0.043	0.02 [0.00; 0.05] 0.029
<b>Nausea</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	0 (0.0)	10 (18.9)	N.E.	0.04 [0.00; 0.74] 0.030	-0.19 [-0.29; -0.08] <.001
<b>Female</b>					
n (%)	36 (10.9)	61 (18.2)	0.55 [0.35; 0.85] 0.008	0.60 [0.41; 0.88] 0.008	-0.07 [-0.13; -0.02] 0.007
<b>Nausea - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	0 (0.0)	10 (18.9)	N.E.	0.04 [0.00; 0.74] 0.030	-0.19 [-0.29; -0.08] <.001

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Female</b>					
n (%)	35 (10.6)	60 (17.9)	0.54 [0.35; 0.85] 0.007	0.59 [0.40; 0.87] 0.008	-0.07 [-0.13; -0.02] 0.006
<b>Constipation</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	3 (5.3)	0 (0.0)	N.E.	6.52 [0.34; 123.28] 0.211	0.05 [-0.01; 0.11] 0.075
<b>Female</b>					
n (%)	45 (13.6)	12 (3.6)	4.24 [2.20; 8.16] <.001	3.80 [2.04; 7.04] <.001	0.10 [0.06; 0.14] <.001
<b>Constipation - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	3 (5.3)	0 (0.0)	N.E.	6.52 [0.34; 123.28] 0.211	0.05 [-0.01; 0.11] 0.075
<b>Female</b>					
n (%)	45 (13.6)	12 (3.6)	4.24 [2.20; 8.16] <.001	3.80 [2.04; 7.04] <.001	0.10 [0.06; 0.14] <.001
<b>Dry mouth</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	1 (1.8)	0 (0.0)	N.E.	2.79 [0.12; 67.11] 0.527	0.02 [-0.02; 0.05] 0.313
<b>Female</b>					
n (%)	7 (2.1)	19 (5.7)	0.36 [0.15; 0.87] 0.023	0.37 [0.16; 0.88] 0.023	-0.04 [-0.06; -0.01] 0.017
<b>Psychiatric disorders</b>					
<b>Interaction test: p=0.929</b>					
<b>Male</b>					
n (%)	6 (10.5)	9 (17.0)	0.58 [0.19; 1.74] 0.328	0.62 [0.24; 1.62] 0.330	-0.06 [-0.19; 0.06] 0.326

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Female</b>					
n (%)	66 (19.9)	105 (31.3)	0.55 [0.38; 0.78] <.001	0.64 [0.49; 0.83] <.001	-0.11 [-0.18; -0.05] <.001
<i>Psychiatric disorders - non-severe</i>					
<b>Interaction test: p=0.934</b>					
<b>Male</b>					
n (%)	6 (10.5)	9 (17.0)	0.58 [0.19; 1.74] 0.328	0.62 [0.24; 1.62] 0.330	-0.06 [-0.19; 0.06] 0.326
<b>Female</b>					
n (%)	64 (19.3)	102 (30.4)	0.55 [0.38; 0.78] <.001	0.64 [0.48; 0.83] 0.001	-0.11 [-0.18; -0.05] <.001
<b>Sleep disorder</b>					
<b>Interaction test: p=0.788</b>					
<b>Male</b>					
n (%)	2 (3.5)	1 (1.9)	1.89 [0.17; 21.48] 0.607	1.86 [0.17; 19.92] 0.608	0.02 [-0.04; 0.08] 0.597
<b>Female</b>					
n (%)	18 (5.4)	7 (2.1)	2.69 [1.11; 6.54] 0.028	2.60 [1.10; 6.15] 0.029	0.03 [0.00; 0.06] 0.023
<b>Sleep disorder - non-severe</b>					
<b>Interaction test: p=0.788</b>					
<b>Male</b>					
n (%)	2 (3.5)	1 (1.9)	1.89 [0.17; 21.48] 0.607	1.86 [0.17; 19.92] 0.608	0.02 [-0.04; 0.08] 0.597
<b>Female</b>					
n (%)	18 (5.4)	7 (2.1)	2.69 [1.11; 6.54] 0.028	2.60 [1.10; 6.15] 0.029	0.03 [0.00; 0.06] 0.023
<b>Irritability</b>					
<b>Interaction test: p=0.613</b>					
<b>Male</b>					
n (%)	1 (1.8)	2 (3.8)	0.46 [0.04; 5.17] 0.526	0.46 [0.04; 4.98] 0.527	-0.02 [-0.08; 0.04] 0.521

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Female</b>					
n (%)	4 (1.2)	17 (5.1)	0.23 [0.08; 0.69] 0.009	0.24 [0.08; 0.70] 0.009	-0.04 [-0.06; -0.01] 0.004
<b>Irritability - non-severe</b>					
<b>Interaction test: p=0.613</b>					
<b>Male</b>					
n (%)	1 (1.8)	2 (3.8)	0.46 [0.04; 5.17] 0.526	0.46 [0.04; 4.98] 0.527	-0.02 [-0.08; 0.04] 0.521
<b>Female</b>					
n (%)	4 (1.2)	17 (5.1)	0.23 [0.08; 0.69] 0.009	0.24 [0.08; 0.70] 0.009	-0.04 [-0.06; -0.01] 0.004
<b>Depressed mood</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	0 (0.0)	1 (1.9)	N.E.	0.31 [0.01; 7.46] 0.471	-0.02 [-0.06; 0.02] 0.313
<b>Female</b>					
n (%)	2 (0.6)	14 (4.2)	0.14 [0.03; 0.62] 0.010	0.14 [0.03; 0.63] 0.010	-0.04 [-0.06; -0.01] 0.002
<b>Depressed mood - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Male</b>					
n (%)	0 (0.0)	1 (1.9)	N.E.	0.31 [0.01; 7.46] 0.471	-0.02 [-0.06; 0.02] 0.313
<b>Female</b>					
n (%)	2 (0.6)	13 (3.9)	0.15 [0.03; 0.67] 0.013	0.16 [0.04; 0.68] 0.014	-0.03 [-0.06; -0.01] 0.004
<b>General disorders and administration site conditions</b>					
<b>Interaction test: p=0.048</b>					
<b>Male</b>					
n (%)	5 (8.8)	15 (28.3)	0.24 [0.08; 0.73] 0.012	0.31 [0.12; 0.79] 0.015	-0.20 [-0.34; -0.05] 0.007

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Female</b>					
n (%)	72 (21.8)	88 (26.3)	0.78 [0.55; 1.11] 0.173	0.83 [0.63; 1.09] 0.174	-0.05 [-0.11; 0.02] 0.172
<i>General disorders and administration site conditions - non-severe</i>					
<b>Interaction test: p=0.037</b>					
<b>Male</b>					
n (%)	4 (7.0)	14 (26.4)	0.21 [0.06; 0.69] 0.010	0.27 [0.09; 0.76] 0.013	-0.19 [-0.33; -0.06] 0.005
<b>Female</b>					
n (%)	69 (20.8)	84 (25.1)	0.79 [0.55; 1.13] 0.195	0.83 [0.63; 1.10] 0.196	-0.04 [-0.11; 0.02] 0.194
<b>Fatigue</b>					
<b>Interaction test: p=0.095</b>					
<b>Male</b>					
n (%)	3 (5.3)	12 (22.6)	0.19 [0.05; 0.72] 0.014	0.23 [0.07; 0.78] 0.018	-0.17 [-0.30; -0.05] 0.007
<b>Female</b>					
n (%)	41 (12.4)	62 (18.5)	0.62 [0.41; 0.95] 0.030	0.67 [0.47; 0.96] 0.031	-0.06 [-0.12; -0.01] 0.028
<b>Fatigue - non-severe</b>					
<b>Interaction test: p=0.070</b>					
<b>Male</b>					
n (%)	2 (3.5)	11 (20.8)	0.14 [0.03; 0.66] 0.013	0.17 [0.04; 0.73] 0.017	-0.17 [-0.29; -0.05] 0.005
<b>Female</b>					
n (%)	38 (11.5)	58 (17.3)	0.62 [0.40; 0.96] 0.033	0.66 [0.45; 0.97] 0.034	-0.06 [-0.11; -0.01] 0.031
<b>Influenza like illness</b>					
<b>Interaction test: N.E.</b>					
<b>Female</b>					
n (%)	3 (0.9)	11 (3.3)	0.27 [0.07; 0.97] 0.046	0.28 [0.08; 0.98] 0.047	-0.02 [-0.05; -0.00] 0.031

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Influenza like illness - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Female</b>					
n (%)	3 (0.9)	11 (3.3)	0.27 [0.07; 0.97] 0.046	0.28 [0.08; 0.98] 0.047	-0.02 [-0.05; -0.00] 0.031
<b>Metabolism and nutrition disorders</b>					
<b>Interaction test: p=0.258</b>					
<b>Male</b>					
n (%)	2 (3.5)	3 (5.7)	0.61 [0.10; 3.78] 0.592	0.62 [0.11; 3.57] 0.592	-0.02 [-0.10; 0.06] 0.591
<b>Female</b>					
n (%)	10 (3.0)	46 (13.7)	0.20 [0.10; 0.39] <.001	0.22 [0.11; 0.43] <.001	-0.11 [-0.15; -0.07] <.001
<b>Metabolism and nutrition disorders - non-severe</b>					
<b>Interaction test: p=0.269</b>					
<b>Male</b>					
n (%)	2 (3.5)	3 (5.7)	0.61 [0.10; 3.78] 0.592	0.62 [0.11; 3.57] 0.592	-0.02 [-0.10; 0.06] 0.591
<b>Female</b>					
n (%)	10 (3.0)	45 (13.4)	0.20 [0.10; 0.41] <.001	0.22 [0.12; 0.44] <.001	-0.10 [-0.15; -0.06] <.001
<b>Decreased appetite</b>					
<b>Interaction test: p=0.175</b>					
<b>Male</b>					
n (%)	2 (3.5)	3 (5.7)	0.61 [0.10; 3.78] 0.592	0.62 [0.11; 3.57] 0.592	-0.02 [-0.10; 0.06] 0.591
<b>Female</b>					
n (%)	6 (1.8)	37 (11.0)	0.15 [0.06; 0.36] <.001	0.16 [0.07; 0.38] <.001	-0.09 [-0.13; -0.06] <.001



		Treatment Groups		Comparison		
		AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Decreased appetite - non-severe</b>						
<b>Interaction test: p=0.184</b>						
<b>Male</b>						
n (%)	2 (3.5)	3 (5.7)	0.61 [0.10; 3.78] 0.592	0.62 [0.11; 3.57] 0.592	-0.02 [-0.10; 0.06] 0.591	
<b>Female</b>						
n (%)	6 (1.8)	36 (10.7)	0.15 [0.06; 0.37] <.001	0.17 [0.07; 0.39] <.001	-0.09 [-0.13; -0.05] <.001	
<b>Cough</b>						
<b>Interaction test: p=0.306</b>						
<b>Male</b>						
n (%)	2 (3.5)	2 (3.8)	0.93 [0.13; 6.83] 0.941	0.93 [0.14; 6.37] 0.941	-0.00 [-0.07; 0.07] 0.941	
<b>Female</b>						
n (%)	4 (1.2)	14 (4.2)	0.28 [0.09; 0.86] 0.026	0.29 [0.10; 0.87] 0.027	-0.03 [-0.05; -0.01] 0.017	
<b>Investigations</b>						
<b>Interaction test: p=0.313</b>						
<b>Male</b>						
n (%)	4 (7.0)	3 (5.7)	1.26 [0.27; 5.90] 0.771	1.24 [0.29; 5.28] 0.771	0.01 [-0.08; 0.10] 0.770	
<b>Female</b>						
n (%)	22 (6.6)	39 (11.6)	0.54 [0.31; 0.93] 0.027	0.57 [0.35; 0.94] 0.028	-0.05 [-0.09; -0.01] 0.025	
<b>Weight decreased</b>						
<b>Interaction test: p=0.501</b>						
<b>Male</b>						
n (%)	1 (1.8)	2 (3.8)	0.46 [0.04; 5.17] 0.526	0.46 [0.04; 4.98] 0.527	-0.02 [-0.08; 0.04] 0.521	
<b>Female</b>						
n (%)	4 (1.2)	21 (6.3)	0.18 [0.06; 0.54] 0.002	0.19 [0.07; 0.56] 0.002	-0.05 [-0.08; -0.02] <.001	

Treatment Groups		Comparison			
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Weight decreased - non-severe</b>					
<b>Interaction test: p=0.526</b>					
<b>Male</b>					
n (%)	1 (1.8)	2 (3.8)	0.46 [0.04; 5.17] 0.526	0.46 [0.04; 4.98] 0.527	-0.02 [-0.08; 0.04] 0.521
<b>Female</b>					
n (%)	4 (1.2)	20 (6.0)	0.19 [0.07; 0.57] 0.003	0.20 [0.07; 0.59] 0.003	-0.05 [-0.08; -0.02] <.001
<b>Eye disorders</b>					
<b>Interaction test: p=0.355</b>					
<b>Male</b>					
n (%)	1 (1.8)	6 (11.3)	0.14 [0.02; 1.20] 0.073	0.15 [0.02; 1.25] 0.079	-0.10 [-0.19; -0.00] 0.041
<b>Female</b>					
n (%)	11 (3.3)	26 (7.8)	0.41 [0.20; 0.84] 0.015	0.43 [0.22; 0.85] 0.016	-0.04 [-0.08; -0.01] 0.012
<b>Eye disorders - non-severe</b>					
<b>Interaction test: p=0.318</b>					
<b>Male</b>					
n (%)	1 (1.8)	6 (11.3)	0.14 [0.02; 1.20] 0.073	0.15 [0.02; 1.25] 0.079	-0.10 [-0.19; -0.00] 0.041

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Female</b>					
n (%)	11 (3.3)	24 (7.2)	0.45 [0.21; 0.92] 0.030	0.46 [0.23; 0.93] 0.031	-0.04 [-0.07; -0.00] 0.025
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup with treatment group as predictor.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.</p> <p>Only subgroups with at least one event are displayed.</p> <p>The table displays system organ classes, preferred terms and severity grades with a p-value &lt;0.05 for RR in the total analysis set. The severity grade refers to the maximum observed severity per patient.</p>					

**Table 14.3.1-2.1.3 Treatment-emergent adverse events (TEAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade by Disease Severity (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
4-7 monthly migraine days at baseline <sup>1</sup> , N'	96	92			
8-14 monthly migraine days at baseline <sup>2</sup> , N'	249	254			
≥ 15 monthly migraine days at baseline, N'	43	42			
<b>Any AE</b>					
<b>Interaction test: p=0.125</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	81 (84.4)	89 (96.7)	0.18 [0.05; 0.65] 0.009	0.87 [0.79; 0.96] 0.004	-0.12 [-0.20; -0.04] 0.003
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	220 (88.4)	232 (91.3)	0.72 [0.40; 1.29] 0.269	0.97 [0.91; 1.03] 0.269	-0.03 [-0.08; 0.02] 0.267
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	37 (86.0)	40 (95.2)	0.31 [0.06; 1.62] 0.165	0.90 [0.79; 1.04] 0.150	-0.09 [-0.21; 0.03] 0.140
<b>Any AE - severe</b>					
<b>Interaction test: p=0.132</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	7 (7.3)	8 (8.7)	0.83 [0.29; 2.38] 0.723	0.84 [0.32; 2.22] 0.723	-0.01 [-0.09; 0.06] 0.723
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	11 (4.4)	29 (11.4)	0.36 [0.17; 0.73] 0.005	0.39 [0.20; 0.76] 0.006	-0.07 [-0.12; -0.02] 0.003
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	3 (7.0)	1 (2.4)	3.07 [0.31; 30.81] 0.339	2.93 [0.32; 27.06] 0.343	0.05 [-0.04; 0.13] 0.312

Treatment Groups			Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Nervous system disorders</b>					
<b>Interaction test: p=0.792</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	20 (20.8)	60 (65.2)	0.14 [0.07; 0.27] <.001	0.32 [0.21; 0.48] <.001	-0.44 [-0.57; -0.32] <.001
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	59 (23.7)	160 (63.0)	0.18 [0.12; 0.27] <.001	0.38 [0.30; 0.48] <.001	-0.39 [-0.47; -0.31] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	17 (39.5)	33 (78.6)	0.18 [0.07; 0.46] <.001	0.50 [0.34; 0.75] <.001	-0.39 [-0.58; -0.20] <.001
<b>Nervous system disorders - non-severe</b>					
<b>Interaction test: p=0.907</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	19 (19.8)	56 (60.9)	0.16 [0.08; 0.31] <.001	0.33 [0.21; 0.50] <.001	-0.41 [-0.54; -0.28] <.001
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	56 (22.5)	155 (61.0)	0.19 [0.13; 0.27] <.001	0.37 [0.29; 0.47] <.001	-0.39 [-0.46; -0.31] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	16 (37.2)	33 (78.6)	0.16 [0.06; 0.42] <.001	0.47 [0.31; 0.72] <.001	-0.41 [-0.60; -0.22] <.001
<b>Paraesthesia</b>					
<b>Interaction test: p=0.852</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	4 (4.2)	33 (35.9)	0.08 [0.03; 0.23] <.001	0.12 [0.04; 0.31] <.001	-0.32 [-0.42; -0.21] <.001
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	10 (4.0)	106 (41.7)	0.06 [0.03; 0.12] <.001	0.10 [0.05; 0.18] <.001	-0.38 [-0.44; -0.31] <.001

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	3 (7.0)	20 (47.6)	0.08 [0.02; 0.31] <.001	0.15 [0.05; 0.46] <.001	-0.41 [-0.58; -0.24] <.001
<b>Paraesthesia - non-severe</b>					
<b>Interaction test: p=0.832</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	4 (4.2)	31 (33.7)	0.09 [0.03; 0.25] <.001	0.12 [0.05; 0.34] <.001	-0.30 [-0.40; -0.19] <.001
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	10 (4.0)	104 (40.9)	0.06 [0.03; 0.12] <.001	0.10 [0.05; 0.18] <.001	-0.37 [-0.43; -0.30] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	3 (7.0)	20 (47.6)	0.08 [0.02; 0.31] <.001	0.15 [0.05; 0.46] <.001	-0.41 [-0.58; -0.24] <.001
<b>Disturbance in attention</b>					
<b>Interaction test: p=0.099</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	6 (6.3)	8 (8.7)	0.70 [0.23; 2.10] 0.525	0.72 [0.26; 1.99] 0.525	-0.02 [-0.10; 0.05] 0.524
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	10 (4.0)	42 (16.5)	0.21 [0.10; 0.43] <.001	0.24 [0.12; 0.47] <.001	-0.13 [-0.18; -0.07] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	2 (4.7)	13 (31.0)	0.11 [0.02; 0.52] 0.005	0.15 [0.04; 0.63] 0.009	-0.26 [-0.42; -0.11] <.001
<b>Disturbance in attention - non-severe</b>					
<b>Interaction test: p=0.204</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	5 (5.2)	8 (8.7)	0.58 [0.18; 1.83] 0.351	0.60 [0.20; 1.76] 0.352	-0.03 [-0.11; 0.04] 0.347

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	10 (4.0)	40 (15.7)	0.22 [0.11; 0.46] <.001	0.26 [0.13; 0.50] <.001	-0.12 [-0.17; -0.07] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	2 (4.7)	13 (31.0)	0.11 [0.02; 0.52] 0.005	0.15 [0.04; 0.63] 0.009	-0.26 [-0.42; -0.11] <.001
<b>Dizziness</b>					
<b>Interaction test: p=0.704</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	5 (5.2)	13 (14.1)	0.33 [0.11; 0.98] 0.045	0.37 [0.14; 0.99] 0.048	-0.09 [-0.17; -0.01] 0.037
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	16 (6.4)	37 (14.6)	0.40 [0.22; 0.74] 0.004	0.44 [0.25; 0.77] 0.004	-0.08 [-0.13; -0.03] 0.003
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	7 (16.3)	10 (23.8)	0.62 [0.21; 1.83] 0.388	0.68 [0.29; 1.63] 0.390	-0.08 [-0.24; 0.09] 0.384
<b>Dizziness - non-severe</b>					
<b>Interaction test: p=0.728</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	5 (5.2)	11 (12.0)	0.40 [0.13; 1.21] 0.107	0.44 [0.16; 1.21] 0.110	-0.07 [-0.15; 0.01] 0.098
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	15 (6.0)	37 (14.6)	0.38 [0.20; 0.70] 0.002	0.41 [0.23; 0.73] 0.003	-0.09 [-0.14; -0.03] 0.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	7 (16.3)	10 (23.8)	0.62 [0.21; 1.83] 0.388	0.68 [0.29; 1.63] 0.390	-0.08 [-0.24; 0.09] 0.384

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Taste disorder</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	6 (6.5)	N.E.	0.07 [0.00; 1.29] 0.074	-0.07 [-0.12; -0.01] 0.011
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	0 (0.0)	16 (6.3)	N.E.	0.03 [0.00; 0.51] 0.015	-0.06 [-0.09; -0.03] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	0 (0.0)	4 (9.5)	N.E.	0.11 [0.01; 1.96] 0.132	-0.10 [-0.18; -0.01] 0.035
<b>Taste disorder - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	6 (6.5)	N.E.	0.07 [0.00; 1.29] 0.074	-0.07 [-0.12; -0.01] 0.011
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	0 (0.0)	16 (6.3)	N.E.	0.03 [0.00; 0.51] 0.015	-0.06 [-0.09; -0.03] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	0 (0.0)	4 (9.5)	N.E.	0.11 [0.01; 1.96] 0.132	-0.10 [-0.18; -0.01] 0.035
<b>Dysgeusia</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	2 (2.1)	5 (5.4)	0.37 [0.07; 1.96] 0.242	0.38 [0.08; 1.93] 0.244	-0.03 [-0.09; 0.02] 0.227
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	1 (0.4)	15 (5.9)	0.06 [<0.01; 0.49] 0.008	0.07 [0.01; 0.51] 0.009	-0.06 [-0.09; -0.03] <.001



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	0 (0.0)	3 (7.1)	N.E.	0.14 [0.01; 2.62] 0.188	-0.07 [-0.15; 0.01] 0.072
<b>Dysgeusia - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	2 (2.1)	5 (5.4)	0.37 [0.07; 1.96] 0.242	0.38 [0.08; 1.93] 0.244	-0.03 [-0.09; 0.02] 0.227
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	1 (0.4)	15 (5.9)	0.06 [<0.01; 0.49] 0.008	0.07 [0.01; 0.51] 0.009	-0.06 [-0.09; -0.03] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	0 (0.0)	3 (7.1)	N.E.	0.14 [0.01; 2.62] 0.188	-0.07 [-0.15; 0.01] 0.072
<b>Hypoaesthesia</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	4 (4.3)	N.E.	0.11 [0.01; 1.95] 0.131	-0.04 [-0.09; -0.00] 0.041
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	3 (1.2)	7 (2.8)	0.43 [0.11; 1.68] 0.226	0.44 [0.11; 1.67] 0.227	-0.02 [-0.04; 0.01] 0.210
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	0 (0.0)	2 (4.8)	N.E.	0.20 [0.01; 3.95] 0.287	-0.05 [-0.11; 0.02] 0.147
<b>Hypoaesthesia - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	3 (3.3)	N.E.	0.14 [0.01; 2.62] 0.186	-0.03 [-0.07; 0.00] 0.078

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	3 (1.2)	7 (2.8)	0.43 [0.11; 1.68] 0.226	0.44 [0.11; 1.67] 0.227	-0.02 [-0.04; 0.01] 0.210
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	0 (0.0)	2 (4.8)	N.E.	0.20 [0.01; 3.95] 0.287	-0.05 [-0.11; 0.02] 0.147
<b>Aphasia</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	1 (1.0)	2 (2.2)	0.47 [0.04; 5.31] 0.545	0.48 [0.04; 5.20] 0.545	-0.01 [-0.05; 0.02] 0.538
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	0 (0.0)	8 (3.1)	N.E.	0.06 [0.00; 1.03] 0.053	-0.03 [-0.05; -0.01] 0.004
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	1 (2.3)	1 (2.4)	0.98 [0.06; 16.13] 0.987	0.98 [0.06; 15.11] 0.987	-0.00 [-0.07; 0.06] 0.987
<b>Aphasia - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	1 (1.0)	2 (2.2)	0.47 [0.04; 5.31] 0.545	0.48 [0.04; 5.20] 0.545	-0.01 [-0.05; 0.02] 0.538
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	0 (0.0)	8 (3.1)	N.E.	0.06 [0.00; 1.03] 0.053	-0.03 [-0.05; -0.01] 0.004
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	1 (2.3)	1 (2.4)	0.98 [0.06; 16.13] 0.987	0.98 [0.06; 15.11] 0.987	-0.00 [-0.07; 0.06] 0.987

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Memory impairment</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	1 (1.0)	4 (4.3)	0.23 [0.03; 2.11] 0.195	0.24 [0.03; 2.10] 0.197	-0.03 [-0.08; 0.01] 0.162
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	0 (0.0)	3 (1.2)	N.E.	0.15 [0.01; 2.81] 0.202	-0.01 [-0.03; 0.00] 0.081
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	0 (0.0)	3 (7.1)	N.E.	0.14 [0.01; 2.62] 0.188	-0.07 [-0.15; 0.01] 0.072
<b>Memory impairment - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	1 (1.0)	4 (4.3)	0.23 [0.03; 2.11] 0.195	0.24 [0.03; 2.10] 0.197	-0.03 [-0.08; 0.01] 0.162
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	0 (0.0)	3 (1.2)	N.E.	0.15 [0.01; 2.81] 0.202	-0.01 [-0.03; 0.00] 0.081
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	0 (0.0)	3 (7.1)	N.E.	0.14 [0.01; 2.62] 0.188	-0.07 [-0.15; 0.01] 0.072
<b>Sinusitis</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	1 (1.1)	N.E.	0.32 [0.01; 7.75] 0.483	-0.01 [-0.03; 0.01] 0.315
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	7 (2.8)	1 (0.4)	7.32 [0.89; 59.91] 0.064	7.14 [0.88; 57.62] 0.065	0.02 [0.00; 0.05] 0.031

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	4 (9.3)	1 (2.4)	4.21 [0.45; 39.29] 0.208	3.91 [0.46; 33.53] 0.214	0.07 [-0.03; 0.17] 0.168
<b>Sinusitis - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	1 (1.1)	N.E.	0.32 [0.01; 7.75] 0.483	-0.01 [-0.03; 0.01] 0.315
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	7 (2.8)	1 (0.4)	7.32 [0.89; 59.91] 0.064	7.14 [0.88; 57.62] 0.065	0.02 [0.00; 0.05] 0.031
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	4 (9.3)	1 (2.4)	4.21 [0.45; 39.29] 0.208	3.91 [0.46; 33.53] 0.214	0.07 [-0.03; 0.17] 0.168
<b>Nausea</b>					
<b>Interaction test: p=0.993</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	7 (7.3)	13 (14.1)	0.48 [0.18; 1.26] 0.135	0.52 [0.22; 1.24] 0.138	-0.07 [-0.16; 0.02] 0.128
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	25 (10.0)	50 (19.7)	0.46 [0.27; 0.76] 0.003	0.51 [0.33; 0.80] 0.003	-0.10 [-0.16; -0.03] 0.002
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	4 (9.3)	8 (19.0)	0.44 [0.12; 1.58] 0.205	0.49 [0.16; 1.50] 0.211	-0.10 [-0.24; 0.05] 0.194
<b>Nausea - non-severe</b>					
<b>Interaction test: p=0.991</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	7 (7.3)	13 (14.1)	0.48 [0.18; 1.26] 0.135	0.52 [0.22; 1.24] 0.138	-0.07 [-0.16; 0.02] 0.128

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	24 (9.6)	49 (19.3)	0.45 [0.26; 0.75] 0.003	0.50 [0.32; 0.79] 0.003	-0.10 [-0.16; -0.04] 0.002
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	4 (9.3)	8 (19.0)	0.44 [0.12; 1.58] 0.205	0.49 [0.16; 1.50] 0.211	-0.10 [-0.24; 0.05] 0.194
<b>Constipation</b>					
<b>Interaction test: p=0.167</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	14 (14.6)	1 (1.1)	15.54 [2.00; >99.99] 0.009	13.42 [1.80; 99.99] 0.011	0.13 [0.06; 0.21] <.001
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	32 (12.9)	9 (3.5)	4.01 [1.87; 8.60] <.001	3.63 [1.77; 7.44] <.001	0.09 [0.05; 0.14] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	2 (4.7)	2 (4.8)	0.98 [0.13; 7.27] 0.981	0.98 [0.14; 6.62] 0.981	-0.00 [-0.09; 0.09] 0.981
<b>Constipation - non-severe</b>					
<b>Interaction test: p=0.167</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	14 (14.6)	1 (1.1)	15.54 [2.00; >99.99] 0.009	13.42 [1.80; 99.99] 0.011	0.13 [0.06; 0.21] <.001
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	32 (12.9)	9 (3.5)	4.01 [1.87; 8.60] <.001	3.63 [1.77; 7.44] <.001	0.09 [0.05; 0.14] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	2 (4.7)	2 (4.8)	0.98 [0.13; 7.27] 0.981	0.98 [0.14; 6.62] 0.981	-0.00 [-0.09; 0.09] 0.981

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Dry mouth</b>					
<b>Interaction test: p=0.142</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	5 (5.2)	4 (4.3)	1.21 [0.31; 4.65] 0.783	1.20 [0.33; 4.32] 0.783	0.01 [-0.05; 0.07] 0.782
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	2 (0.8)	12 (4.7)	0.16 [0.04; 0.74] 0.018	0.17 [0.04; 0.75] 0.019	-0.04 [-0.07; -0.01] 0.007
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	1 (2.3)	3 (7.1)	0.31 [0.03; 3.10] 0.319	0.33 [0.04; 3.01] 0.322	-0.05 [-0.14; 0.04] 0.294
<b>Psychiatric disorders</b>					
<b>Interaction test: p=0.917</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	16 (16.7)	27 (29.3)	0.48 [0.24; 0.97] 0.041	0.57 [0.33; 0.98] 0.043	-0.13 [-0.25; -0.01] 0.037
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	46 (18.5)	72 (28.3)	0.57 [0.38; 0.87] 0.009	0.65 [0.47; 0.90] 0.010	-0.10 [-0.17; -0.03] 0.008
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	10 (23.3)	15 (35.7)	0.55 [0.21; 1.41] 0.210	0.65 [0.33; 1.28] 0.215	-0.12 [-0.32; 0.07] 0.204
<b>Psychiatric disorders - non-severe</b>					
<b>Interaction test: p=0.846</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	16 (16.7)	27 (29.3)	0.48 [0.24; 0.97] 0.041	0.57 [0.33; 0.98] 0.043	-0.13 [-0.25; -0.01] 0.037
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	45 (18.1)	69 (27.2)	0.59 [0.39; 0.90] 0.015	0.67 [0.48; 0.93] 0.016	-0.09 [-0.16; -0.02] 0.014

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	9 (20.9)	15 (35.7)	0.48 [0.18; 1.26] 0.134	0.59 [0.29; 1.19] 0.139	-0.15 [-0.34; 0.04] 0.126
<b>Sleep disorder</b>					
<b>Interaction test: p=0.259</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	6 (6.3)	5 (5.4)	1.16 [0.34; 3.94] 0.812	1.15 [0.36; 3.64] 0.812	0.01 [-0.06; 0.08] 0.812
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	11 (4.4)	2 (0.8)	5.82 [1.28; 26.54] 0.023	5.61 [1.26; 25.06] 0.024	0.04 [0.01; 0.06] 0.010
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	3 (7.0)	1 (2.4)	3.08 [0.31; 30.82] 0.339	2.93 [0.32; 27.06] 0.343	0.05 [-0.04; 0.13] 0.312
<b>Sleep disorder - non-severe</b>					
<b>Interaction test: p=0.259</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	6 (6.3)	5 (5.4)	1.16 [0.34; 3.94] 0.812	1.15 [0.36; 3.64] 0.812	0.01 [-0.06; 0.08] 0.812
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	11 (4.4)	2 (0.8)	5.82 [1.28; 26.54] 0.023	5.61 [1.26; 25.06] 0.024	0.04 [0.01; 0.06] 0.010
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	3 (7.0)	1 (2.4)	3.08 [0.31; 30.82] 0.339	2.93 [0.32; 27.06] 0.343	0.05 [-0.04; 0.13] 0.312
<b>Irritability</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	5 (5.4)	N.E.	0.09 [0.00; 1.55] 0.097	-0.05 [-0.10; -0.01] 0.021

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	4 (1.6)	11 (4.3)	0.36 [0.11; 1.15] 0.084	0.37 [0.12; 1.15] 0.086	-0.03 [-0.06; 0.00] 0.070
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	1 (2.3)	3 (7.1)	0.31 [0.03; 3.10] 0.319	0.33 [0.04; 3.01] 0.322	-0.05 [-0.14; 0.04] 0.294
<b>Irritability - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	5 (5.4)	N.E.	0.09 [0.00; 1.55] 0.097	-0.05 [-0.10; -0.01] 0.021
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	4 (1.6)	11 (4.3)	0.36 [0.11; 1.15] 0.084	0.37 [0.12; 1.15] 0.086	-0.03 [-0.06; 0.00] 0.070
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	1 (2.3)	3 (7.1)	0.31 [0.03; 3.10] 0.319	0.33 [0.04; 3.01] 0.322	-0.05 [-0.14; 0.04] 0.294
<b>Depressed mood</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	3 (3.3)	N.E.	0.14 [0.01; 2.62] 0.186	-0.03 [-0.07; 0.00] 0.078
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	2 (0.8)	12 (4.7)	0.16 [0.04; 0.74] 0.018	0.17 [0.04; 0.75] 0.019	-0.04 [-0.07; -0.01] 0.007
<b>Depressed mood - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	3 (3.3)	N.E.	0.14 [0.01; 2.62] 0.186	-0.03 [-0.07; 0.00] 0.078



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	2 (0.8)	11 (4.3)	0.18 [0.04; 0.82] 0.026	0.19 [0.04; 0.83] 0.027	-0.04 [-0.06; -0.01] 0.012
<i>General disorders and administration site conditions</i>					
<b>Interaction test: p=0.791</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	18 (18.8)	20 (21.7)	0.83 [0.41; 1.69] 0.610	0.86 [0.49; 1.52] 0.610	-0.03 [-0.14; 0.09] 0.610
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	49 (19.7)	71 (28.0)	0.63 [0.42; 0.96] 0.030	0.70 [0.51; 0.97] 0.031	-0.08 [-0.16; -0.01] 0.029
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	10 (23.3)	12 (28.6)	0.76 [0.29; 2.01] 0.576	0.81 [0.39; 1.68] 0.577	-0.05 [-0.24; 0.13] 0.575
<i>General disorders and administration site conditions - non-severe</i>					
<b>Interaction test: p=0.823</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	16 (16.7)	18 (19.6)	0.82 [0.39; 1.73] 0.607	0.85 [0.46; 1.57] 0.606	-0.03 [-0.14; 0.08] 0.606
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	47 (18.9)	68 (26.8)	0.64 [0.42; 0.97] 0.036	0.71 [0.51; 0.98] 0.037	-0.08 [-0.15; -0.01] 0.034
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	10 (23.3)	12 (28.6)	0.76 [0.29; 2.01] 0.576	0.81 [0.39; 1.68] 0.577	-0.05 [-0.24; 0.13] 0.575
<b>Fatigue</b>					
<b>Interaction test: p=0.687</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	11 (11.5)	14 (15.2)	0.72 [0.31; 1.68] 0.449	0.75 [0.36; 1.57] 0.450	-0.04 [-0.13; 0.06] 0.448

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	26 (10.4)	50 (19.7)	0.48 [0.29; 0.79] 0.004	0.53 [0.34; 0.82] 0.005	-0.09 [-0.15; -0.03] 0.003
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	7 (16.3)	10 (23.8)	0.62 [0.21; 1.83] 0.388	0.68 [0.29; 1.63] 0.390	-0.08 [-0.24; 0.09] 0.384
<b>Fatigue - non-severe</b>					
<b>Interaction test: p=0.739</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	9 (9.4)	12 (13.0)	0.69 [0.28; 1.72] 0.427	0.72 [0.32; 1.62] 0.427	-0.04 [-0.13; 0.05] 0.425
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	24 (9.6)	47 (18.5)	0.47 [0.28; 0.80] 0.005	0.52 [0.33; 0.82] 0.005	-0.09 [-0.15; -0.03] 0.004
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	7 (16.3)	10 (23.8)	0.62 [0.21; 1.83] 0.388	0.68 [0.29; 1.63] 0.390	-0.08 [-0.24; 0.09] 0.384
<b>Influenza like illness</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	2 (2.2)	N.E.	0.19 [0.01; 3.94] 0.284	-0.02 [-0.05; 0.01] 0.153
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	3 (1.2)	8 (3.1)	0.38 [0.10; 1.43] 0.151	0.38 [0.10; 1.43] 0.152	-0.02 [-0.04; 0.01] 0.133
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	0 (0.0)	1 (2.4)	N.E.	0.33 [0.01; 7.78] 0.488	-0.02 [-0.07; 0.02] 0.311

		Treatment Groups		Comparison		
		AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Influenza like illness - non-severe</b>						
<b>Interaction test: N.E.</b>						
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>						
n (%)	0 (0.0)	2 (2.2)	N.E.	0.19 [0.01; 3.94] 0.284	-0.02 [-0.05; 0.01] 0.153	
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>						
n (%)	3 (1.2)	8 (3.1)	0.38 [0.10; 1.43] 0.151	0.38 [0.10; 1.43] 0.152	-0.02 [-0.04; 0.01] 0.133	
<b>≥ 15 monthly migraine days at baseline</b>						
n (%)	0 (0.0)	1 (2.4)	N.E.	0.33 [0.01; 7.78] 0.488	-0.02 [-0.07; 0.02] 0.311	
<b>Metabolism and nutrition disorders</b>						
<b>Interaction test: p=0.576</b>						
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>						
n (%)	1 (1.0)	10 (10.9)	0.09 [0.01; 0.69] 0.021	0.10 [0.01; 0.73] 0.024	-0.10 [-0.17; -0.03] 0.004	
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>						
n (%)	10 (4.0)	34 (13.4)	0.27 [0.13; 0.56] <.001	0.30 [0.15; 0.59] <.001	-0.09 [-0.14; -0.05] <.001	
<b>≥ 15 monthly migraine days at baseline</b>						
n (%)	1 (2.3)	5 (11.9)	0.18 [0.02; 1.58] 0.121	0.20 [0.02; 1.60] 0.128	-0.10 [-0.20; 0.01] 0.082	
<b>Metabolism and nutrition disorders - non-severe</b>						
<b>Interaction test: p=0.554</b>						
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>						
n (%)	1 (1.0)	10 (10.9)	0.09 [0.01; 0.69] 0.021	0.10 [0.01; 0.73] 0.024	-0.10 [-0.17; -0.03] 0.004	
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>						
n (%)	10 (4.0)	33 (13.0)	0.28 [0.13; 0.58] <.001	0.31 [0.16; 0.61] <.001	-0.09 [-0.14; -0.04] <.001	

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	1 (2.3)	5 (11.9)	0.18 [0.02; 1.58] 0.121	0.20 [0.02; 1.60] 0.128	-0.10 [-0.20; 0.01] 0.082
<b>Decreased appetite</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	9 (9.8)	N.E.	0.05 [0.00; 0.85] 0.039	-0.10 [-0.16; -0.04] 0.002
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	7 (2.8)	27 (10.6)	0.24 [0.10; 0.57] 0.001	0.26 [0.12; 0.60] 0.001	-0.08 [-0.12; -0.04] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	1 (2.3)	4 (9.5)	0.23 [0.02; 2.11] 0.192	0.24 [0.03; 2.10] 0.199	-0.07 [-0.17; 0.03] 0.156
<b>Decreased appetite - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	9 (9.8)	N.E.	0.05 [0.00; 0.85] 0.039	-0.10 [-0.16; -0.04] 0.002
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	7 (2.8)	26 (10.2)	0.25 [0.11; 0.60] 0.002	0.27 [0.12; 0.62] 0.002	-0.07 [-0.12; -0.03] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	1 (2.3)	4 (9.5)	0.23 [0.02; 2.11] 0.192	0.24 [0.03; 2.10] 0.199	-0.07 [-0.17; 0.03] 0.156
<b>Cough</b>					
<b>Interaction test: p=0.971</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	1 (1.0)	3 (3.3)	0.31 [0.03; 3.06] 0.317	0.32 [0.03; 3.02] 0.319	-0.02 [-0.06; 0.02] 0.296

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	4 (1.6)	10 (3.9)	0.40 [0.12; 1.29] 0.124	0.41 [0.13; 1.28] 0.125	-0.02 [-0.05; 0.01] 0.110
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	1 (2.3)	3 (7.1)	0.31 [0.03; 3.10] 0.319	0.33 [0.04; 3.01] 0.322	-0.05 [-0.14; 0.04] 0.294
<b>Investigations</b>					
<b>Interaction test: p=0.974</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	6 (6.3)	9 (9.8)	0.61 [0.21; 1.80] 0.375	0.64 [0.24; 1.72] 0.376	-0.04 [-0.11; 0.04] 0.373
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	16 (6.4)	26 (10.2)	0.60 [0.31; 1.15] 0.126	0.63 [0.35; 1.14] 0.127	-0.04 [-0.09; 0.01] 0.121
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	4 (9.3)	7 (16.7)	0.51 [0.14; 1.90] 0.318	0.56 [0.18; 1.77] 0.321	-0.07 [-0.22; 0.07] 0.310
<b>Weight decreased</b>					
<b>Interaction test: p=0.387</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	1 (1.0)	4 (4.3)	0.23 [0.03; 2.11] 0.195	0.24 [0.03; 2.10] 0.197	-0.03 [-0.08; 0.01] 0.162
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	2 (0.8)	16 (6.3)	0.12 [0.03; 0.53] 0.005	0.13 [0.03; 0.55] 0.006	-0.05 [-0.09; -0.02] <.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	2 (4.7)	3 (7.1)	0.63 [0.10; 4.00] 0.628	0.65 [0.11; 3.70] 0.629	-0.02 [-0.13; 0.08] 0.626

Treatment Groups		Comparison			
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Weight decreased - non-severe</b>					
<b>Interaction test: p=0.419</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	1 (1.0)	4 (4.3)	0.23 [0.03; 2.11] 0.195	0.24 [0.03; 2.10] 0.197	-0.03 [-0.08; 0.01] 0.162
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	2 (0.8)	15 (5.9)	0.13 [0.03; 0.57] 0.007	0.14 [0.03; 0.59] 0.008	-0.05 [-0.08; -0.02] 0.001
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	2 (4.7)	3 (7.1)	0.63 [0.10; 4.00] 0.628	0.65 [0.11; 3.70] 0.629	-0.02 [-0.13; 0.08] 0.626
<b>Eye disorders</b>					
<b>Interaction test: p=0.292</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	1 (1.0)	10 (10.9)	0.09 [0.01; 0.69] 0.021	0.10 [0.01; 0.73] 0.024	-0.10 [-0.17; -0.03] 0.004
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	9 (3.6)	19 (7.5)	0.46 [0.21; 1.05] 0.064	0.48 [0.22; 1.05] 0.065	-0.04 [-0.08; 0.00] 0.057
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	2 (4.7)	3 (7.1)	0.63 [0.10; 4.00] 0.628	0.65 [0.11; 3.70] 0.629	-0.02 [-0.13; 0.08] 0.626
<b>Eye disorders - non-severe</b>					
<b>Interaction test: p=0.262</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	1 (1.0)	10 (10.9)	0.09 [0.01; 0.69] 0.021	0.10 [0.01; 0.73] 0.024	-0.10 [-0.17; -0.03] 0.004
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	9 (3.6)	17 (6.7)	0.52 [0.23; 1.20] 0.125	0.54 [0.25; 1.19] 0.126	-0.03 [-0.07; 0.01] 0.117

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	2 (4.7)	3 (7.1)	0.63 [0.10; 4.00] 0.628	0.65 [0.11; 3.70] 0.629	-0.02 [-0.13; 0.08] 0.626
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup with treatment group as predictor.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.</p> <p>Only subgroups with at least one event are displayed.</p> <p>The table displays system organ classes, preferred terms and severity grades with a p-value &lt;0.05 for RR in the total analysis set. The severity grade refers to the maximum observed severity per patient.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline.  <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.</p>					

**Table 14.3.1-2.1.4 Treatment-emergent adverse events (TEAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade by Prior Treatment Failure Status (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
Naïve*, N'	232	229			
Prior treatment failure*, N'	156	159			
<b>Any AE</b>					
<b>Interaction test: p=0.336</b>					
<b>Naïve*</b>					
n (%)	197 (84.9)	213 (93.0)	0.42 [0.23; 0.79] 0.007	0.91 [0.86; 0.97] 0.006	-0.08 [-0.14; -0.02] 0.005
<b>Prior treatment failure*</b>					
n (%)	141 (90.4)	148 (93.1)	0.70 [0.31; 1.57] 0.386	0.97 [0.91; 1.04] 0.386	-0.03 [-0.09; 0.03] 0.385
<b>Any AE - severe</b>					
<b>Interaction test: p=0.956</b>					
<b>Naïve*</b>					
n (%)	11 (4.7)	20 (8.7)	0.52 [0.24; 1.11] 0.092	0.54 [0.27; 1.11] 0.093	-0.04 [-0.09; 0.01] 0.087
<b>Prior treatment failure*</b>					
n (%)	10 (6.4)	18 (11.3)	0.54 [0.24; 1.20] 0.130	0.57 [0.27; 1.19] 0.132	-0.05 [-0.11; 0.01] 0.123
<b>Nervous system disorders</b>					
<b>Interaction test: p=0.885</b>					
<b>Naïve*</b>					
n (%)	53 (22.8)	145 (63.3)	0.17 [0.11; 0.26] <.001	0.36 [0.28; 0.47] <.001	-0.40 [-0.49; -0.32] <.001
<b>Prior treatment failure*</b>					
n (%)	43 (27.6)	108 (67.9)	0.18 [0.11; 0.29] <.001	0.41 [0.31; 0.53] <.001	-0.40 [-0.50; -0.30] <.001



Treatment Groups			Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Nervous system disorders - non-severe</b>					
<b>Interaction test: p=0.956</b>					
<b>Naïve*</b>					
n (%)	51 (22.0)	140 (61.1)	0.18 [0.12; 0.27] <.001	0.36 [0.28; 0.47] <.001	-0.39 [-0.47; -0.31] <.001
<b>Prior treatment failure*</b>					
n (%)	40 (25.6)	104 (65.4)	0.18 [0.11; 0.30] <.001	0.39 [0.29; 0.52] <.001	-0.40 [-0.50; -0.30] <.001
<b>Paraesthesia</b>					
<b>Interaction test: p=0.256</b>					
<b>Naïve*</b>					
n (%)	7 (3.0)	90 (39.3)	0.05 [0.02; 0.11] <.001	0.08 [0.04; 0.16] <.001	-0.36 [-0.43; -0.30] <.001
<b>Prior treatment failure*</b>					
n (%)	10 (6.4)	69 (43.4)	0.09 [0.04; 0.18] <.001	0.15 [0.08; 0.28] <.001	-0.37 [-0.46; -0.28] <.001
<b>Paraesthesia - non-severe</b>					
<b>Interaction test: p=0.245</b>					
<b>Naïve*</b>					
n (%)	7 (3.0)	88 (38.4)	0.05 [0.02; 0.11] <.001	0.08 [0.04; 0.17] <.001	-0.35 [-0.42; -0.29] <.001
<b>Prior treatment failure*</b>					
n (%)	10 (6.4)	67 (42.1)	0.09 [0.05; 0.19] <.001	0.15 [0.08; 0.28] <.001	-0.36 [-0.44; -0.27] <.001
<b>Disturbance in attention</b>					
<b>Interaction test: p=0.661</b>					
<b>Naïve*</b>					
n (%)	10 (4.3)	38 (16.6)	0.23 [0.11; 0.47] <.001	0.26 [0.13; 0.51] <.001	-0.12 [-0.18; -0.07] <.001
<b>Prior treatment failure*</b>					
n (%)	8 (5.1)	25 (15.7)	0.29 [0.13; 0.66] 0.003	0.33 [0.15; 0.70] 0.004	-0.11 [-0.17; -0.04] 0.002

Treatment Groups			Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Disturbance in attention - non-severe</b>					
<b>Interaction test: p=0.832</b>					
<b>Naïve*</b>					
n (%)	10 (4.3)	37 (16.2)	0.23 [0.11; 0.48] <.001	0.27 [0.14; 0.52] <.001	-0.12 [-0.17; -0.06] <.001
<b>Prior treatment failure*</b>					
n (%)	7 (4.5)	24 (15.1)	0.26 [0.11; 0.63] 0.003	0.30 [0.13; 0.67] 0.003	-0.11 [-0.17; -0.04] 0.001
<b>Dizziness</b>					
<b>Interaction test: p=0.627</b>					
<b>Naïve*</b>					
n (%)	16 (6.9)	31 (13.5)	0.47 [0.25; 0.89] 0.021	0.51 [0.29; 0.91] 0.022	-0.07 [-0.12; -0.01] 0.018
<b>Prior treatment failure*</b>					
n (%)	12 (7.7)	29 (18.2)	0.37 [0.18; 0.76] 0.007	0.42 [0.22; 0.80] 0.008	-0.11 [-0.18; -0.03] 0.005
<b>Dizziness - non-severe</b>					
<b>Interaction test: p=0.512</b>					
<b>Naïve*</b>					
n (%)	16 (6.9)	30 (13.1)	0.49 [0.26; 0.93] 0.029	0.53 [0.30; 0.94] 0.030	-0.06 [-0.12; -0.01] 0.026
<b>Prior treatment failure*</b>					
n (%)	11 (7.1)	28 (17.6)	0.35 [0.17; 0.74] 0.006	0.40 [0.21; 0.78] 0.007	-0.11 [-0.18; -0.03] 0.004
<b>Taste disorder</b>					
<b>Interaction test: N.E.</b>					
<b>Naïve*</b>					
n (%)	0 (0.0)	18 (7.9)	N.E.	0.03 [0.00; 0.44] 0.011	-0.08 [-0.11; -0.04] <.001
<b>Prior treatment failure*</b>					
n (%)	0 (0.0)	8 (5.0)	N.E.	0.06 [0.00; 1.03] 0.052	-0.05 [-0.08; -0.02] 0.004

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Taste disorder - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Naïve*</b>					
n (%)	0 (0.0)	18 (7.9)	N.E.	0.03 [0.00; 0.44] 0.011	-0.08 [-0.11; -0.04] <.001
<b>Prior treatment failure*</b>					
n (%)	0 (0.0)	8 (5.0)	N.E.	0.06 [0.00; 1.03] 0.052	-0.05 [-0.08; -0.02] 0.004
<b>Dysgeusia</b>					
<b>Interaction test: p=0.854</b>					
<b>Naïve*</b>					
n (%)	1 (0.4)	9 (3.9)	0.11 [0.01; 0.84] 0.034	0.11 [0.01; 0.86] 0.035	-0.03 [-0.06; -0.01] 0.010
<b>Prior treatment failure*</b>					
n (%)	2 (1.3)	14 (8.8)	0.13 [0.03; 0.60] 0.009	0.15 [0.03; 0.63] 0.010	-0.08 [-0.12; -0.03] 0.002
<b>Dysgeusia - non-severe</b>					
<b>Interaction test: p=0.854</b>					
<b>Naïve*</b>					
n (%)	1 (0.4)	9 (3.9)	0.11 [0.01; 0.84] 0.034	0.11 [0.01; 0.86] 0.035	-0.03 [-0.06; -0.01] 0.010
<b>Prior treatment failure*</b>					
n (%)	2 (1.3)	14 (8.8)	0.13 [0.03; 0.60] 0.009	0.15 [0.03; 0.63] 0.010	-0.08 [-0.12; -0.03] 0.002
<b>Hypoaesthesia</b>					
<b>Interaction test: p=0.906</b>					
<b>Naïve*</b>					
n (%)	2 (0.9)	9 (3.9)	0.21 [0.05; 0.99] 0.049	0.22 [0.05; 1.00] 0.051	-0.03 [-0.06; -0.00] 0.031
<b>Prior treatment failure*</b>					
n (%)	1 (0.6)	4 (2.5)	0.25 [0.03; 2.26] 0.217	0.25 [0.03; 2.25] 0.219	-0.02 [-0.05; 0.01] 0.180

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Hypoaesthesia - non-severe</b>					
<b>Interaction test: p=0.745</b>					
<b>Naïve*</b>					
n (%)	2 (0.9)	9 (3.9)	0.21 [0.05; 0.99] 0.049	0.22 [0.05; 1.00] 0.051	-0.03 [-0.06; -0.00] 0.031
<b>Prior treatment failure*</b>					
n (%)	1 (0.6)	3 (1.9)	0.34 [0.03; 3.26] 0.347	0.34 [0.04; 3.23] 0.348	-0.01 [-0.04; 0.01] 0.321
<b>Aphasia</b>					
<b>Interaction test: N.E.</b>					
<b>Naïve*</b>					
n (%)	0 (0.0)	1 (0.4)	N.E.	0.33 [0.01; 8.04] 0.495	-0.00 [-0.01; 0.00] 0.316
<b>Prior treatment failure*</b>					
n (%)	2 (1.3)	10 (6.3)	0.19 [0.04; 0.90] 0.036	0.20 [0.05; 0.92] 0.038	-0.05 [-0.09; -0.01] 0.018
<b>Aphasia - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Naïve*</b>					
n (%)	0 (0.0)	1 (0.4)	N.E.	0.33 [0.01; 8.04] 0.495	-0.00 [-0.01; 0.00] 0.316
<b>Prior treatment failure*</b>					
n (%)	2 (1.3)	10 (6.3)	0.19 [0.04; 0.90] 0.036	0.20 [0.05; 0.92] 0.038	-0.05 [-0.09; -0.01] 0.018
<b>Memory impairment</b>					
<b>Interaction test: N.E.</b>					
<b>Naïve*</b>					
n (%)	1 (0.4)	7 (3.1)	0.14 [0.02; 1.12] 0.064	0.14 [0.02; 1.14] 0.066	-0.03 [-0.05; -0.00] 0.031
<b>Prior treatment failure*</b>					
n (%)	0 (0.0)	3 (1.9)	N.E.	0.15 [0.01; 2.80] 0.201	-0.02 [-0.04; 0.00] 0.080

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Memory impairment - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Naïve*</b>					
n (%)	1 (0.4)	7 (3.1)	0.14 [0.02; 1.12] 0.064	0.14 [0.02; 1.14] 0.066	-0.03 [-0.05; -0.00] 0.031
<b>Prior treatment failure*</b>					
n (%)	0 (0.0)	3 (1.9)	N.E.	0.15 [0.01; 2.80] 0.201	-0.02 [-0.04; 0.00] 0.080
<b>Sinusitis</b>					
<b>Interaction test: p=0.906</b>					
<b>Naïve*</b>					
n (%)	7 (3.0)	2 (0.9)	3.53 [0.73; 17.18] 0.118	3.45 [0.73; 16.45] 0.120	0.02 [-0.00; 0.05] 0.094
<b>Prior treatment failure*</b>					
n (%)	4 (2.6)	1 (0.6)	4.16 [0.46; 37.62] 0.205	4.08 [0.46; 36.07] 0.206	0.02 [-0.01; 0.05] 0.171
<b>Sinusitis - non-severe</b>					
<b>Interaction test: p=0.906</b>					
<b>Naïve*</b>					
n (%)	7 (3.0)	2 (0.9)	3.53 [0.73; 17.18] 0.118	3.45 [0.73; 16.45] 0.120	0.02 [-0.00; 0.05] 0.094
<b>Prior treatment failure*</b>					
n (%)	4 (2.6)	1 (0.6)	4.16 [0.46; 37.62] 0.205	4.08 [0.46; 36.07] 0.206	0.02 [-0.01; 0.05] 0.171
<b>Nausea</b>					
<b>Interaction test: p=0.292</b>					
<b>Naïve*</b>					
n (%)	15 (6.5)	37 (16.2)	0.36 [0.19; 0.67] 0.001	0.40 [0.23; 0.71] 0.002	-0.10 [-0.15; -0.04] <.001
<b>Prior treatment failure*</b>					
n (%)	21 (13.5)	34 (21.4)	0.57 [0.32; 1.04] 0.066	0.63 [0.38; 1.03] 0.068	-0.08 [-0.16; 0.00] 0.062

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Nausea - non-severe</b>					
<b>Interaction test: p=0.198</b>					
<b>Naïve*</b>					
n (%)	14 (6.0)	37 (16.2)	0.33 [0.17; 0.64] <.001	0.37 [0.21; 0.67] 0.001	-0.10 [-0.16; -0.04] <.001
<b>Prior treatment failure*</b>					
n (%)	21 (13.5)	33 (20.8)	0.59 [0.33; 1.08] 0.088	0.65 [0.39; 1.07] 0.090	-0.07 [-0.16; 0.01] 0.084
<b>Constipation</b>					
<b>Interaction test: p=0.171</b>					
<b>Naïve*</b>					
n (%)	26 (11.2)	9 (3.9)	3.09 [1.41; 6.74] 0.005	2.85 [1.37; 5.95] 0.005	0.07 [0.03; 0.12] 0.003
<b>Prior treatment failure*</b>					
n (%)	22 (14.1)	3 (1.9)	8.54 [2.50; 29.15] <.001	7.47 [2.28; 24.47] <.001	0.12 [0.06; 0.18] <.001
<b>Constipation - non-severe</b>					
<b>Interaction test: p=0.171</b>					
<b>Naïve*</b>					
n (%)	26 (11.2)	9 (3.9)	3.09 [1.41; 6.74] 0.005	2.85 [1.37; 5.95] 0.005	0.07 [0.03; 0.12] 0.003
<b>Prior treatment failure*</b>					
n (%)	22 (14.1)	3 (1.9)	8.54 [2.50; 29.15] <.001	7.47 [2.28; 24.47] <.001	0.12 [0.06; 0.18] <.001
<b>Dry mouth</b>					
<b>Interaction test: p=0.082</b>					
<b>Naïve*</b>					
n (%)	6 (2.6)	7 (3.1)	0.84 [0.28; 2.54] 0.761	0.85 [0.29; 2.48] 0.761	-0.00 [-0.03; 0.03] 0.760
<b>Prior treatment failure*</b>					
n (%)	2 (1.3)	12 (7.5)	0.16 [0.04; 0.72] 0.017	0.17 [0.04; 0.75] 0.019	-0.06 [-0.11; -0.02] 0.006

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Psychiatric disorders</b>					
<b>Interaction test: p=0.719</b>					
<b>Naïve*</b>					
n (%)	41 (17.7)	62 (27.1)	0.58 [0.37; 0.90] 0.016	0.65 [0.46; 0.93] 0.017	-0.09 [-0.17; -0.02] 0.015
<b>Prior treatment failure*</b>					
n (%)	31 (19.9)	52 (32.7)	0.51 [0.31; 0.85] 0.010	0.61 [0.41; 0.89] 0.011	-0.13 [-0.22; -0.03] 0.009
<b>Psychiatric disorders - non-severe</b>					
<b>Interaction test: p=0.775</b>					
<b>Naïve*</b>					
n (%)	40 (17.2)	61 (26.6)	0.57 [0.37; 0.90] 0.015	0.65 [0.45; 0.92] 0.016	-0.09 [-0.17; -0.02] 0.014
<b>Prior treatment failure*</b>					
n (%)	30 (19.2)	50 (31.4)	0.52 [0.31; 0.87] 0.013	0.61 [0.41; 0.91] 0.015	-0.12 [-0.22; -0.03] 0.012
<b>Sleep disorder</b>					
<b>Interaction test: p=0.846</b>					
<b>Naïve*</b>					
n (%)	11 (4.7)	4 (1.7)	2.80 [0.88; 8.92] 0.082	2.71 [0.88; 8.40] 0.083	0.03 [-0.00; 0.06] 0.068
<b>Prior treatment failure*</b>					
n (%)	9 (5.8)	4 (2.5)	2.37 [0.72; 7.87] 0.158	2.29 [0.72; 7.29] 0.160	0.03 [-0.01; 0.08] 0.147
<b>Sleep disorder - non-severe</b>					
<b>Interaction test: p=0.846</b>					
<b>Naïve*</b>					
n (%)	11 (4.7)	4 (1.7)	2.80 [0.88; 8.92] 0.082	2.71 [0.88; 8.40] 0.083	0.03 [-0.00; 0.06] 0.068
<b>Prior treatment failure*</b>					
n (%)	9 (5.8)	4 (2.5)	2.37 [0.72; 7.87] 0.158	2.29 [0.72; 7.29] 0.160	0.03 [-0.01; 0.08] 0.147

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Irritability</b>					
<b>Interaction test: p=0.250</b>					
<b>Naïve*</b>					
n (%)	3 (1.3)	6 (2.6)	0.49 [0.12; 1.97] 0.313	0.49 [0.12; 1.95] 0.314	-0.01 [-0.04; 0.01] 0.304
<b>Prior treatment failure*</b>					
n (%)	2 (1.3)	13 (8.2)	0.15 [0.03; 0.66] 0.012	0.16 [0.04; 0.68] 0.014	-0.07 [-0.12; -0.02] 0.003
<b>Irritability - non-severe</b>					
<b>Interaction test: p=0.250</b>					
<b>Naïve*</b>					
n (%)	3 (1.3)	6 (2.6)	0.49 [0.12; 1.97] 0.313	0.49 [0.12; 1.95] 0.314	-0.01 [-0.04; 0.01] 0.304
<b>Prior treatment failure*</b>					
n (%)	2 (1.3)	13 (8.2)	0.15 [0.03; 0.66] 0.012	0.16 [0.04; 0.68] 0.014	-0.07 [-0.12; -0.02] 0.003
<b>Depressed mood</b>					
<b>Interaction test: p=0.790</b>					
<b>Naïve*</b>					
n (%)	1 (0.4)	6 (2.6)	0.16 [0.02; 1.35] 0.092	0.16 [0.02; 1.36] 0.094	-0.02 [-0.04; 0.00] 0.055
<b>Prior treatment failure*</b>					
n (%)	1 (0.6)	9 (5.7)	0.11 [0.01; 0.86] 0.035	0.11 [0.01; 0.88] 0.038	-0.05 [-0.09; -0.01] 0.010
<b>Depressed mood - non-severe</b>					
<b>Interaction test: p=0.855</b>					
<b>Naïve*</b>					
n (%)	1 (0.4)	6 (2.6)	0.16 [0.02; 1.35] 0.092	0.16 [0.02; 1.36] 0.094	-0.02 [-0.04; 0.00] 0.055
<b>Prior treatment failure*</b>					
n (%)	1 (0.6)	8 (5.0)	0.12 [0.02; 0.99] 0.048	0.13 [0.02; 1.01] 0.051	-0.04 [-0.08; -0.01] 0.017



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>General disorders and administration site conditions</b>					
<b>Interaction test: p=0.538</b>					
<b>Naïve*</b>					
n (%)	43 (18.5)	61 (26.6)	0.63 [0.40; 0.98] 0.038	0.70 [0.49; 0.98] 0.039	-0.08 [-0.16; -0.01] 0.037
<b>Prior treatment failure*</b>					
n (%)	34 (21.8)	42 (26.4)	0.78 [0.46; 1.30] 0.338	0.83 [0.56; 1.22] 0.340	-0.05 [-0.14; 0.05] 0.337
<b>General disorders and administration site conditions - non-severe</b>					
<b>Interaction test: p=0.274</b>					
<b>Naïve*</b>					
n (%)	39 (16.8)	59 (25.8)	0.58 [0.37; 0.92] 0.020	0.65 [0.45; 0.94] 0.020	-0.09 [-0.16; -0.02] 0.018
<b>Prior treatment failure*</b>					
n (%)	34 (21.8)	39 (24.5)	0.86 [0.51; 1.45] 0.566	0.89 [0.59; 1.33] 0.566	-0.03 [-0.12; 0.07] 0.565
<b>Fatigue</b>					
<b>Interaction test: p=0.637</b>					
<b>Naïve*</b>					
n (%)	24 (10.3)	43 (18.8)	0.50 [0.29; 0.85] 0.011	0.55 [0.35; 0.88] 0.012	-0.08 [-0.15; -0.02] 0.010
<b>Prior treatment failure*</b>					
n (%)	20 (12.8)	31 (19.5)	0.61 [0.33; 1.12] 0.110	0.66 [0.39; 1.10] 0.112	-0.07 [-0.15; 0.01] 0.106
<b>Fatigue - non-severe</b>					
<b>Interaction test: p=0.281</b>					
<b>Naïve*</b>					
n (%)	20 (8.6)	41 (17.9)	0.43 [0.24; 0.76] 0.004	0.48 [0.29; 0.80] 0.004	-0.09 [-0.15; -0.03] 0.003
<b>Prior treatment failure*</b>					
n (%)	20 (12.8)	28 (17.6)	0.69 [0.37; 1.28] 0.239	0.73 [0.43; 1.24] 0.240	-0.05 [-0.13; 0.03] 0.235

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Influenza like illness</b>					
<b>Interaction test: p=0.943</b>					
<b>Naïve*</b>					
n (%)	2 (0.9)	7 (3.1)	0.28 [0.06; 1.34] 0.111	0.28 [0.06; 1.34] 0.112	-0.02 [-0.05; 0.00] 0.089
<b>Prior treatment failure*</b>					
n (%)	1 (0.6)	4 (2.5)	0.25 [0.03; 2.26] 0.217	0.25 [0.03; 2.25] 0.219	-0.02 [-0.05; 0.01] 0.180
<b>Influenza like illness - non-severe</b>					
<b>Interaction test: p=0.943</b>					
<b>Naïve*</b>					
n (%)	2 (0.9)	7 (3.1)	0.28 [0.06; 1.34] 0.111	0.28 [0.06; 1.34] 0.112	-0.02 [-0.05; 0.00] 0.089
<b>Prior treatment failure*</b>					
n (%)	1 (0.6)	4 (2.5)	0.25 [0.03; 2.26] 0.217	0.25 [0.03; 2.25] 0.219	-0.02 [-0.05; 0.01] 0.180
<b>Metabolism and nutrition disorders</b>					
<b>Interaction test: p=0.885</b>					
<b>Naïve*</b>					
n (%)	8 (3.4)	31 (13.5)	0.23 [0.10; 0.51] <.001	0.25 [0.12; 0.54] <.001	-0.10 [-0.15; -0.05] <.001
<b>Prior treatment failure*</b>					
n (%)	4 (2.6)	18 (11.3)	0.21 [0.07; 0.62] 0.005	0.23 [0.08; 0.65] 0.006	-0.09 [-0.14; -0.03] 0.002
<b>Metabolism and nutrition disorders - non-severe</b>					
<b>Interaction test: p=0.958</b>					
<b>Naïve*</b>					
n (%)	8 (3.4)	31 (13.5)	0.23 [0.10; 0.51] <.001	0.25 [0.12; 0.54] <.001	-0.10 [-0.15; -0.05] <.001
<b>Prior treatment failure*</b>					
n (%)	4 (2.6)	17 (10.7)	0.22 [0.07; 0.67] 0.008	0.24 [0.08; 0.70] 0.009	-0.08 [-0.14; -0.03] 0.003

		Treatment Groups		Comparison		
		AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Decreased appetite</b>						
<b>Interaction test: p=0.839</b>						
<b>Naïve*</b>						
n (%)	5 (2.2)	26 (11.4)	0.17 [0.06; 0.46] <.001	0.19 [0.07; 0.49] <.001	-0.09 [-0.14; -0.05] <.001	
<b>Prior treatment failure*</b>						
n (%)	3 (1.9)	14 (8.8)	0.20 [0.06; 0.72] 0.014	0.22 [0.06; 0.75] 0.015	-0.07 [-0.12; -0.02] 0.006	
<b>Decreased appetite - non-severe</b>						
<b>Interaction test: p=0.763</b>						
<b>Naïve*</b>						
n (%)	5 (2.2)	26 (11.4)	0.17 [0.06; 0.46] <.001	0.19 [0.07; 0.49] <.001	-0.09 [-0.14; -0.05] <.001	
<b>Prior treatment failure*</b>						
n (%)	3 (1.9)	13 (8.2)	0.22 [0.06; 0.79] 0.020	0.24 [0.07; 0.81] 0.022	-0.06 [-0.11; -0.01] 0.010	
<b>Cough</b>						
<b>Interaction test: p=0.185</b>						
<b>Naïve*</b>						
n (%)	5 (2.2)	8 (3.5)	0.61 [0.20; 1.89] 0.390	0.62 [0.20; 1.86] 0.390	-0.01 [-0.04; 0.02] 0.386	
<b>Prior treatment failure*</b>						
n (%)	1 (0.6)	8 (5.0)	0.12 [0.02; 0.99] 0.048	0.13 [0.02; 1.01] 0.051	-0.04 [-0.08; -0.01] 0.017	
<b>Investigations</b>						
<b>Interaction test: p=0.826</b>						
<b>Naïve*</b>						
n (%)	15 (6.5)	25 (10.9)	0.56 [0.29; 1.10] 0.093	0.59 [0.32; 1.09] 0.094	-0.04 [-0.10; 0.01] 0.089	
<b>Prior treatment failure*</b>						
n (%)	11 (7.1)	17 (10.7)	0.63 [0.29; 1.40] 0.259	0.66 [0.32; 1.36] 0.261	-0.04 [-0.10; 0.03] 0.254	

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Weight decreased</b>					
<b>Interaction test: p=0.943</b>					
<b>Naïve*</b>					
n (%)	3 (1.3)	14 (6.1)	0.20 [0.06; 0.71] 0.013	0.21 [0.06; 0.73] 0.014	-0.05 [-0.08; -0.01] 0.006
<b>Prior treatment failure*</b>					
n (%)	2 (1.3)	9 (5.7)	0.22 [0.05; 1.02] 0.053	0.23 [0.05; 1.03] 0.055	-0.04 [-0.08; -0.00] 0.032
<b>Weight decreased - non-severe</b>					
<b>Interaction test: p=0.847</b>					
<b>Naïve*</b>					
n (%)	3 (1.3)	14 (6.1)	0.20 [0.06; 0.71] 0.013	0.21 [0.06; 0.73] 0.014	-0.05 [-0.08; -0.01] 0.006
<b>Prior treatment failure*</b>					
n (%)	2 (1.3)	8 (5.0)	0.25 [0.05; 1.17] 0.078	0.25 [0.05; 1.18] 0.081	-0.04 [-0.08; 0.00] 0.055
<b>Eye disorders</b>					
<b>Interaction test: p=0.416</b>					
<b>Naïve*</b>					
n (%)	6 (2.6)	20 (8.7)	0.28 [0.11; 0.70] 0.007	0.30 [0.12; 0.72] 0.008	-0.06 [-0.10; -0.02] 0.004
<b>Prior treatment failure*</b>					
n (%)	6 (3.8)	12 (7.5)	0.49 [0.18; 1.34] 0.165	0.51 [0.20; 1.32] 0.166	-0.04 [-0.09; 0.01] 0.155
<b>Eye disorders - non-severe</b>					
<b>Interaction test: p=0.391</b>					
<b>Naïve*</b>					
n (%)	6 (2.6)	19 (8.3)	0.29 [0.12; 0.75] 0.010	0.31 [0.13; 0.77] 0.011	-0.06 [-0.10; -0.02] 0.007

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Prior treatment failure*</b>					
n (%)	6 (3.8)	11 (6.9)	0.54 [0.19; 1.49] 0.234	0.56 [0.21; 1.47] 0.235	-0.03 [-0.08; 0.02] 0.225
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup with treatment group as predictor.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>The interaction test is N.E. if the incidence of events is zero or 100% in one or more subgroup*treatment groups.  OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.</p> <p>Only subgroups with at least one event are displayed.</p> <p>The table displays system organ classes, preferred terms and severity grades with a p-value &lt;0.05 for RR in the total analysis set. The severity grade refers to the maximum observed severity per patient.</p> <p>*: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>					

**Table 14.3.1-2.1.5 Treatment-emergent adverse events (TEAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade by Study Center (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N <sup>a</sup>	388	388			
Center No. 1001, N <sup>a</sup>	10	8			
Center No. 1002, N <sup>a</sup>	4	0			
Center No. 1003, N <sup>a</sup>	2	3			
Center No. 1005, N <sup>a</sup>	31	22			
Center No. 1007, N <sup>a</sup>	5	7			
Center No. 1008, N <sup>a</sup>	3	3			
Center No. 1010, N <sup>a</sup>	2	3			
Center No. 1011, N <sup>a</sup>	2	5			
Center No. 1012, N <sup>a</sup>	3	5			
Center No. 1014, N <sup>a</sup>	5	4			
Center No. 1015, N <sup>a</sup>	4	2			
Center No. 1017, N <sup>a</sup>	5	4			
Center No. 1018, N <sup>a</sup>	7	6			
Center No. 1019, N <sup>a</sup>	2	2			
Center No. 1021, N <sup>a</sup>	16	10			
Center No. 1022, N <sup>a</sup>	3	3			
Center No. 1025, N <sup>a</sup>	0	2			
Center No. 1027, N <sup>a</sup>	3	5			
Center No. 1028, N <sup>a</sup>	11	5			
Center No. 1029, N <sup>a</sup>	15	9			
Center No. 1030, N <sup>a</sup>	11	9			
Center No. 1032, N <sup>a</sup>	2	4			
Center No. 1033, N <sup>a</sup>	4	6			
Center No. 1034, N <sup>a</sup>	4	3			
Center No. 1035, N <sup>a</sup>	27	22			
Center No. 1036, N <sup>a</sup>	7	7			
Center No. 1037, N <sup>a</sup>	9	11			
Center No. 1039, N <sup>a</sup>	4	3			
Center No. 1040, N <sup>a</sup>	0	3			
Center No. 1041, N <sup>a</sup>	5	5			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1042, N <sup>a</sup>	4	5			
Center No. 1044, N <sup>a</sup>	0	2			
Center No. 1046, N <sup>a</sup>	1	1			
Center No. 1048, N <sup>a</sup>	0	3			
Center No. 1049, N <sup>a</sup>	1	0			
Center No. 1050, N <sup>a</sup>	6	9			
Center No. 1051, N <sup>a</sup>	1	1			
Center No. 1052, N <sup>a</sup>	7	4			
Center No. 1055, N <sup>a</sup>	2	4			
Center No. 1058, N <sup>a</sup>	0	1			
Center No. 1059, N <sup>a</sup>	7	7			
Center No. 1061, N <sup>a</sup>	9	6			
Center No. 1063, N <sup>a</sup>	4	2			
Center No. 1064, N <sup>a</sup>	0	3			
Center No. 1067, N <sup>a</sup>	10	16			
Center No. 1068, N <sup>a</sup>	0	2			
Center No. 1069, N <sup>a</sup>	3	4			
Center No. 1070, N <sup>a</sup>	1	5			
Center No. 1072, N <sup>a</sup>	2	1			
Center No. 1073, N <sup>a</sup>	11	7			
Center No. 1074, N <sup>a</sup>	5	3			
Center No. 1076, N <sup>a</sup>	1	5			
Center No. 1077, N <sup>a</sup>	3	2			
Center No. 1079, N <sup>a</sup>	4	3			
Center No. 1080, N <sup>a</sup>	3	1			
Center No. 1082, N <sup>a</sup>	5	8			
Center No. 1084, N <sup>a</sup>	2	3			
Center No. 1085, N <sup>a</sup>	0	3			
Center No. 1086, N <sup>a</sup>	6	9			
Center No. 1087, N <sup>a</sup>	1	4			
Center No. 1088, N <sup>a</sup>	6	6			
Center No. 1089, N <sup>a</sup>	4	4			
Center No. 1091, N <sup>a</sup>	6	5			
Center No. 1093, N <sup>a</sup>	1	4			
Center No. 1095, N <sup>a</sup>	5	3			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1096, N <sup>a</sup>	2	0			
Center No. 1100, N <sup>a</sup>	1	4			
Center No. 1101, N <sup>a</sup>	4	6			
Center No. 1103, N <sup>a</sup>	2	3			
Center No. 1105, N <sup>a</sup>	3	3			
Center No. 1108, N <sup>a</sup>	15	10			
Center No. 1110, N <sup>a</sup>	6	5			
Center No. 1111, N <sup>a</sup>	5	0			
Center No. 1113, N <sup>a</sup>	3	3			
Center No. 1115, N <sup>a</sup>	5	6			
Center No. 1116, N <sup>a</sup>	1	4			
Center No. 1118, N <sup>a</sup>	3	2			
Center No. 1119, N <sup>a</sup>	3	5			
Center No. 1121, N <sup>a</sup>	4	4			
Center No. 1123, N <sup>a</sup>	1	1			
Center No. 1124, N <sup>a</sup>	3	2			
Center No. 1502, N <sup>a</sup>	0	3			
<b>Any AE</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	9 (90.0)	8 (100.0)	N.E.	0.90 [0.73; 1.11] 0.318	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1002</b>					
n (%)	4 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	2 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1005</b>					
n (%)	28 (90.3)	19 (86.4)	1.47 [0.27; 8.09] 0.655	1.05 [0.85; 1.28] 0.664	0.04 [-0.14; 0.22] 0.661
<b>Center No. 1007</b>					
n (%)	5 (100.0)	7 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1008</b>					
n (%)	2 (66.7)	3 (100.0)	N.E.	0.67 [0.30; 1.48] 0.321	-0.33 [-0.87; 0.20] 0.221



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1010</b>					
n (%)	2 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1011</b>					
n (%)	2 (100.0)	5 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1012</b>					
n (%)	3 (100.0)	5 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1014</b>					
n (%)	5 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1015</b>					
n (%)	3 (75.0)	2 (100.0)	N.E.	0.75 [0.43; 1.32] 0.319	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1017</b>					
n (%)	5 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1018</b>					
n (%)	7 (100.0)	5 (83.3)	N.E.	1.20 [0.84; 1.72] 0.318	0.17 [-0.13; 0.46] 0.273
<b>Center No. 1019</b>					
n (%)	1 (50.0)	2 (100.0)	N.E.	0.50 [0.13; 2.00] 0.327	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1021</b>					
n (%)	16 (100.0)	10 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1022</b>					
n (%)	2 (66.7)	2 (66.7)	1.00 [0.03; 29.81] 1.000	1.00 [0.32; 3.10] 1.000	0.00 [-0.75; 0.75] 1.000
<b>Center No. 1025</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1027</b>					
n (%)	3 (100.0)	5 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1028</b>					
n (%)	11 (100.0)	5 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1029</b>					
n (%)	10 (66.7)	8 (88.9)	0.25 [0.02; 2.59] 0.246	0.75 [0.49; 1.15] 0.186	-0.22 [-0.54; 0.09] 0.166

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1030</b>					
n (%)	10 (90.9)	9 (100.0)	N.E.	0.91 [0.75; 1.10] 0.317	-0.09 [-0.26; 0.08] 0.294
<b>Center No. 1032</b>					
n (%)	2 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1033</b>					
n (%)	4 (100.0)	6 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1034</b>					
n (%)	4 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1035</b>					
n (%)	25 (92.6)	22 (100.0)	N.E.	0.93 [0.83; 1.03] 0.157	-0.07 [-0.17; 0.02] 0.142
<b>Center No. 1036</b>					
n (%)	6 (85.7)	7 (100.0)	N.E.	0.86 [0.63; 1.16] 0.318	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1037</b>					
n (%)	8 (88.9)	11 (100.0)	N.E.	0.89 [0.71; 1.12] 0.318	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1039</b>					
n (%)	3 (75.0)	3 (100.0)	N.E.	0.75 [0.43; 1.32] 0.319	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1040</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1041</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.14 [0.01; 2.21] 0.164	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1042</b>					
n (%)	4 (100.0)	5 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1044</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1046</b>					
n (%)	1 (100.0)	1 (100.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1048</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	6 (100.0)	9 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1051</b>					
n (%)	1 (100.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1052</b>					
n (%)	7 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1055</b>					
n (%)	2 (100.0)	3 (75.0)	N.E.	1.33 [0.76; 2.35] 0.319	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1058</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1059</b>					
n (%)	6 (85.7)	7 (100.0)	N.E.	0.86 [0.63; 1.16] 0.318	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1061</b>					
n (%)	8 (88.9)	6 (100.0)	N.E.	0.89 [0.71; 1.12] 0.318	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1063</b>					
n (%)	4 (100.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1064</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	7 (70.0)	13 (81.3)	0.54 [0.09; 3.41] 0.511	0.86 [0.54; 1.38] 0.533	-0.11 [-0.45; 0.23] 0.520
<b>Center No. 1068</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1069</b>					
n (%)	2 (66.7)	4 (100.0)	N.E.	0.67 [0.30; 1.48] 0.321	-0.33 [-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1070</b>					
n (%)	1 (100.0)	4 (80.0)	N.E.	1.25 [0.81; 1.94] 0.318	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1072</b>					
n (%)	2 (100.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1073</b>					
n (%)	11 (100.0)	6 (85.7)	N.E.	1.17 [0.86; 1.58] 0.318	0.14 [-0.12; 0.40] 0.280
<b>Center No. 1074</b>					
n (%)	5 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1076</b>					
n (%)	1 (100.0)	2 (40.0)	N.E.	2.50 [0.85; 7.31] 0.094	0.60 [0.17; 1.03] 0.006
<b>Center No. 1077</b>					
n (%)	3 (100.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1079</b>					
n (%)	2 (50.0)	3 (100.0)	N.E.	0.50 [0.19; 1.33] 0.166	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1080</b>					
n (%)	3 (100.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1082</b>					
n (%)	4 (80.0)	8 (100.0)	N.E.	0.80 [0.52; 1.24] 0.318	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1084</b>					
n (%)	1 (50.0)	3 (100.0)	N.E.	0.50 [0.13; 2.00] 0.327	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1085</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1086</b>					
n (%)	5 (83.3)	9 (100.0)	N.E.	0.83 [0.58; 1.19] 0.318	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1087</b>					
n (%)	1 (100.0)	4 (100.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1088</b>					
n (%)	3 (50.0)	3 (50.0)	1.00 [0.10; 9.61] 1.000	1.00 [0.32; 3.10] 1.000	0.00 [-0.57; 0.57] 1.000
<b>Center No. 1089</b>					
n (%)	4 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1091</b>					
n (%)	4 (66.7)	5 (100.0)	N.E.	0.67 [0.38; 1.17] 0.160	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1093</b>					
n (%)	1 (100.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1095</b>					
n (%)	5 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1096</b>					
n (%)	2 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1100</b>					
n (%)	1 (100.0)	3 (75.0)	N.E.	1.33 [0.76; 2.35] 0.319	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1101</b>					
n (%)	1 (25.0)	4 (66.7)	0.17 [<0.01; 2.82] 0.214	0.38 [0.06; 2.24] 0.283	-0.42 [-0.98; 0.15] 0.150
<b>Center No. 1103</b>					
n (%)	2 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1105</b>					
n (%)	3 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1108</b>					
n (%)	15 (100.0)	9 (90.0)	N.E.	1.11 [0.90; 1.37] 0.318	0.10 [-0.09; 0.29] 0.292
<b>Center No. 1110</b>					
n (%)	5 (83.3)	5 (100.0)	N.E.	0.83 [0.58; 1.19] 0.318	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1111</b>					
n (%)	5 (100.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1113</b>					
n (%)	3 (100.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1115</b>					
n (%)	4 (80.0)	6 (100.0)	N.E.	0.80 [0.52; 1.24] 0.318	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1116</b>					
n (%)	0 (0.0)	3 (75.0)	N.E.	0.36 [0.03; 4.21] 0.414	-0.75 [-1.17; -0.33] <.001
<b>Center No. 1118</b>					
n (%)	3 (100.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1119</b>					
n (%)	2 (66.7)	5 (100.0)	N.E.	0.67 [0.30; 1.48] 0.321	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1121</b>					
n (%)	3 (75.0)	3 (75.0)	1.00 [0.04; 24.55] 1.000	1.00 [0.45; 2.23] 1.000	0.00 [-0.60; 0.60] 1.000
<b>Center No. 1123</b>					
n (%)	1 (100.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1124</b>					
n (%)	2 (66.7)	2 (100.0)	N.E.	0.67 [0.30; 1.48] 0.321	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1502</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Any AE - severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	2 (20.0)	0 (0.0)	N.E.	4.09 [0.22; 74.78] 0.342	0.20 [-0.05; 0.45] 0.114
<b>Center No. 1003</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1007</b>					
n (%)	1 (20.0)	3 (42.9)	0.33 [0.02; 4.74] 0.417	0.47 [0.07; 3.28] 0.444	-0.23 [-0.74; 0.28] 0.377
<b>Center No. 1014</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1021</b>					
n (%)	1 (6.3)	1 (10.0)	0.60 [0.03; 10.82] 0.729	0.63 [0.04; 8.91] 0.729	-0.04 [-0.26; 0.18] 0.739
<b>Center No. 1022</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	3.00 [0.17; 53.71] 0.455	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1029</b>					
n (%)	3 (20.0)	5 (55.6)	0.20 [0.03; 1.24] 0.084	0.36 [0.11; 1.16] 0.087	-0.36 [-0.74; 0.03] 0.069
<b>Center No. 1032</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.33 [0.02; 4.85] 0.421	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1033</b>					
n (%)	1 (25.0)	3 (50.0)	0.33 [0.02; 5.33] 0.437	0.50 [0.08; 3.27] 0.469	-0.25 [-0.83; 0.33] 0.401
<b>Center No. 1035</b>					
n (%)	1 (3.7)	4 (18.2)	0.17 [0.02; 1.68] 0.130	0.20 [0.02; 1.69] 0.141	-0.14 [-0.32; 0.03] 0.107
<b>Center No. 1036</b>					
n (%)	1 (14.3)	0 (0.0)	N.E.	3.00 [0.14; 63.15] 0.480	0.14 [-0.12; 0.40] 0.280

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1037</b>					
n (%)	0 (0.0)	1 (9.1)	N.E.	0.40 [0.02; 8.78] 0.561	-0.09 [-0.26; 0.08] 0.294
<b>Center No. 1040</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1059</b>					
n (%)	4 (57.1)	5 (71.4)	0.53 [0.06; 4.91] 0.579	0.80 [0.36; 1.77] 0.582	-0.14 [-0.64; 0.35] 0.573
<b>Center No. 1061</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.23 [0.01; 4.93] 0.350	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1064</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	1 (10.0)	2 (12.5)	0.78 [0.06; 9.88] 0.846	0.80 [0.08; 7.72] 0.847	-0.03 [-0.27; 0.22] 0.843
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1074</b>					
n (%)	3 (60.0)	0 (0.0)	N.E.	4.67 [0.32; 68.03] 0.260	0.60 [0.17; 1.03] 0.006
<b>Center No. 1085</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1091</b>					
n (%)	1 (16.7)	0 (0.0)	N.E.	2.57 [0.13; 52.13] 0.538	0.17 [-0.13; 0.46] 0.273



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1108</b>					
n (%)	0 (0.0)	1 (10.0)	N.E.	0.23 [0.01; 5.12] 0.353	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1113</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1115</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	3.50 [0.17; 70.95] 0.415	0.20 [-0.15; 0.55] 0.264
<i>Nervous system disorders</i>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	4 (40.0)	6 (75.0)	0.22 [0.03; 1.71] 0.148	0.53 [0.23; 1.26] 0.151	-0.35 [-0.78; 0.08] 0.108
<b>Center No. 1002</b>					
n (%)	2 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	1 (50.0)	3 (100.0)	N.E.	0.50 [0.13; 2.00] 0.327	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1005</b>					
n (%)	7 (22.6)	12 (54.5)	0.24 [0.07; 0.80] 0.020	0.41 [0.19; 0.88] 0.022	-0.32 [-0.57; -0.06] 0.014
<b>Center No. 1007</b>					
n (%)	2 (40.0)	6 (85.7)	0.11 [<0.01; 1.78] 0.120	0.47 [0.15; 1.42] 0.180	-0.46 [-0.96; 0.04] 0.074
<b>Center No. 1008</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1010</b>					
n (%)	1 (50.0)	2 (66.7)	0.50 [0.01; 19.56] 0.711	0.75 [0.15; 3.72] 0.725	-0.17 [-1.04; 0.71] 0.709
<b>Center No. 1011</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.29 [0.02; 3.92] 0.349	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1012</b>					
n (%)	1 (33.3)	3 (60.0)	0.33 [0.02; 6.65] 0.472	0.56 [0.10; 3.21] 0.511	-0.27 [-0.95; 0.42] 0.445
<b>Center No. 1014</b>					
n (%)	2 (40.0)	4 (100.0)	N.E.	0.40 [0.14; 1.17] 0.094	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1015</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	1.80 [0.10; 31.52] 0.687	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1017</b>					
n (%)	2 (40.0)	4 (100.0)	N.E.	0.40 [0.14; 1.17] 0.094	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1018</b>					
n (%)	0 (0.0)	4 (66.7)	N.E.	0.10 [0.01; 1.51] 0.095	-0.67 [-1.04; -0.29] <.001
<b>Center No. 1019</b>					
n (%)	1 (50.0)	2 (100.0)	N.E.	0.50 [0.13; 2.00] 0.327	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1021</b>					
n (%)	6 (37.5)	9 (90.0)	0.07 [<0.01; 0.67] 0.021	0.42 [0.21; 0.81] 0.010	-0.53 [-0.83; -0.22] <.001
<b>Center No. 1022</b>					
n (%)	1 (33.3)	1 (33.3)	1.00 [0.03; 29.81] 1.000	1.00 [0.10; 9.61] 1.000	0.00 [-0.75; 0.75] 1.000

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1027</b>					
n (%)	1 (33.3)	2 (40.0)	0.75 [0.04; 14.97] 0.851	0.83 [0.12; 5.72] 0.853	-0.07 [-0.75; 0.62] 0.849
<b>Center No. 1028</b>					
n (%)	2 (18.2)	5 (100.0)	N.E.	0.18 [0.05; 0.64] 0.008	-0.82 [-1.05; -0.59] <.001
<b>Center No. 1029</b>					
n (%)	1 (6.7)	6 (66.7)	0.04 [<0.01; 0.42] 0.008	0.10 [0.01; 0.70] 0.021	-0.60 [-0.93; -0.27] <.001
<b>Center No. 1030</b>					
n (%)	4 (36.4)	8 (88.9)	0.07 [<0.01; 0.80] 0.032	0.41 [0.18; 0.92] 0.032	-0.53 [-0.88; -0.17] 0.003
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1033</b>					
n (%)	3 (75.0)	5 (83.3)	0.60 [0.03; 13.58] 0.748	0.90 [0.46; 1.76] 0.758	-0.08 [-0.60; 0.44] 0.753
<b>Center No. 1034</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1035</b>					
n (%)	6 (22.2)	15 (68.2)	0.13 [0.04; 0.48] 0.002	0.33 [0.15; 0.70] 0.004	-0.46 [-0.71; -0.21] <.001
<b>Center No. 1036</b>					
n (%)	3 (42.9)	6 (85.7)	0.13 [<0.01; 1.67] 0.116	0.50 [0.20; 1.24] 0.134	-0.43 [-0.88; 0.02] 0.061
<b>Center No. 1037</b>					
n (%)	3 (33.3)	9 (81.8)	0.11 [0.01; 0.88] 0.037	0.41 [0.16; 1.07] 0.068	-0.48 [-0.87; -0.10] 0.013
<b>Center No. 1039</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1040</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1041</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.20 [0.01; 3.35] 0.263	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1042</b>					
n (%)	1 (25.0)	2 (40.0)	0.50 [0.03; 8.95] 0.638	0.63 [0.08; 4.66] 0.646	-0.15 [-0.75; 0.45] 0.626
<b>Center No. 1044</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1046</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	2 (33.3)	5 (55.6)	0.40 [0.05; 3.42] 0.403	0.60 [0.17; 2.14] 0.432	-0.22 [-0.72; 0.28] 0.381
<b>Center No. 1051</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1052</b>					
n (%)	2 (28.6)	2 (50.0)	0.40 [0.03; 5.15] 0.482	0.57 [0.12; 2.63] 0.473	-0.21 [-0.81; 0.38] 0.479
<b>Center No. 1055</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1058</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1059</b>					
n (%)	2 (28.6)	6 (85.7)	0.07 [<0.01; 0.97] 0.047	0.33 [0.10; 1.12] 0.075	-0.57 [-0.99; -0.15] 0.008
<b>Center No. 1061</b>					
n (%)	6 (66.7)	3 (50.0)	2.00 [0.24; 16.61] 0.521	1.33 [0.53; 3.36] 0.542	0.17 [-0.34; 0.67] 0.518

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1063</b>					
n (%)	2 (50.0)	2 (100.0)	N.E.	0.50 [0.19; 1.33] 0.166	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1064</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	3 (30.0)	9 (56.3)	0.33 [0.06; 1.78] 0.199	0.53 [0.19; 1.51] 0.236	-0.26 [-0.64; 0.11] 0.169
<b>Center No. 1068</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1069</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.25 [0.02; 3.86] 0.321	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1070</b>					
n (%)	0 (0.0)	4 (80.0)	N.E.	0.33 [0.03; 3.84] 0.378	-0.80 [-1.15; -0.45] <.001
<b>Center No. 1072</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1073</b>					
n (%)	1 (9.1)	3 (42.9)	0.13 [0.01; 1.70] 0.120	0.21 [0.03; 1.66] 0.139	-0.34 [-0.74; 0.07] 0.101
<b>Center No. 1074</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1076</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1077</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1079</b>					
n (%)	1 (25.0)	3 (100.0)	N.E.	0.25 [0.05; 1.36] 0.109	-0.75 [-1.17; -0.33] <.001

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1080</b>					
n (%)	1 (33.3)	1 (100.0)	N.E.	0.33 [0.07; 1.65] 0.178	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1082</b>					
n (%)	0 (0.0)	8 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1086</b>					
n (%)	3 (50.0)	8 (88.9)	0.13 [<0.01; 1.72] 0.120	0.56 [0.24; 1.29] 0.176	-0.39 [-0.84; 0.06] 0.090
<b>Center No. 1087</b>					
n (%)	0 (0.0)	4 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1088</b>					
n (%)	1 (16.7)	3 (50.0)	0.20 [0.01; 2.91] 0.239	0.33 [0.05; 2.37] 0.272	-0.33 [-0.83; 0.17] 0.190
<b>Center No. 1089</b>					
n (%)	1 (25.0)	3 (75.0)	0.11 [<0.01; 2.73] 0.178	0.33 [0.06; 1.99] 0.229	-0.50 [-1.10; 0.10] 0.102
<b>Center No. 1091</b>					
n (%)	1 (16.7)	5 (100.0)	N.E.	0.17 [0.03; 1.00] 0.050	-0.83 [-1.13; -0.54] <.001
<b>Center No. 1093</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.50 [0.04; 6.44] 0.595	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1095</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.13 [0.01; 2.11] 0.153	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1096</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1100</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1101</b>					
n (%)	0 (0.0)	3 (50.0)	N.E.	0.20 [0.01; 3.07] 0.248	-0.50 [-0.90; -0.10] 0.014
<b>Center No. 1103</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1105</b>					
n (%)	1 (33.3)	2 (66.7)	0.25 [<0.01; 7.45] 0.424	0.50 [0.08; 2.99] 0.448	-0.33 [-1.09; 0.42] 0.386
<b>Center No. 1108</b>					
n (%)	6 (40.0)	9 (90.0)	0.07 [<0.01; 0.75] 0.027	0.44 [0.23; 0.85] 0.015	-0.50 [-0.81; -0.19] 0.002
<b>Center No. 1110</b>					
n (%)	3 (50.0)	3 (60.0)	0.67 [0.06; 7.35] 0.741	0.83 [0.28; 2.44] 0.739	-0.10 [-0.69; 0.49] 0.738
<b>Center No. 1111</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1113</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1115</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.23 [0.01; 3.97] 0.314	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1118</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1119</b>					
n (%)	0 (0.0)	4 (80.0)	N.E.	0.17 [0.01; 2.32] 0.182	-0.80 [-1.15; -0.45] <.001
<b>Center No. 1121</b>					
n (%)	1 (25.0)	3 (75.0)	0.11 [<0.01; 2.73] 0.178	0.33 [0.06; 1.99] 0.229	-0.50 [-1.10; 0.10] 0.102

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1123</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1124</b>					
n (%)	2 (66.7)	1 (50.0)	2.00 [0.05; 78.25] 0.711	1.33 [0.27; 6.61] 0.725	0.17 [-0.71; 1.04] 0.709
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<i>Nervous system disorders - non-severe</i>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	3 (30.0)	6 (75.0)	0.14 [0.02; 1.16] 0.069	0.40 [0.14; 1.12] 0.081	-0.45 [-0.86; -0.04] 0.033
<b>Center No. 1002</b>					
n (%)	2 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	1 (50.0)	3 (100.0)	N.E.	0.50 [0.13; 2.00] 0.327	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1005</b>					
n (%)	7 (22.6)	12 (54.5)	0.24 [0.07; 0.80] 0.020	0.41 [0.19; 0.88] 0.022	-0.32 [-0.57; -0.06] 0.014
<b>Center No. 1007</b>					
n (%)	1 (20.0)	6 (85.7)	0.04 [<0.01; 0.88] 0.041	0.23 [0.04; 1.38] 0.109	-0.66 [-1.09; -0.22] 0.003
<b>Center No. 1008</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1010</b>					
n (%)	1 (50.0)	2 (66.7)	0.50 [0.01; 19.56] 0.711	0.75 [0.15; 3.72] 0.725	-0.17 [-1.04; 0.71] 0.709
<b>Center No. 1011</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.29 [0.02; 3.92] 0.349	-0.60 [-1.03; -0.17] 0.006



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1012</b>					
n (%)	1 (33.3)	3 (60.0)	0.33 [0.02; 6.65] 0.472	0.56 [0.10; 3.21] 0.511	-0.27 [-0.95; 0.42] 0.445
<b>Center No. 1014</b>					
n (%)	2 (40.0)	4 (100.0)	N.E.	0.40 [0.14; 1.17] 0.094	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1015</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	1.80 [0.10; 31.52] 0.687	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1017</b>					
n (%)	2 (40.0)	4 (100.0)	N.E.	0.40 [0.14; 1.17] 0.094	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1018</b>					
n (%)	0 (0.0)	4 (66.7)	N.E.	0.10 [0.01; 1.51] 0.095	-0.67 [-1.04; -0.29] <.001
<b>Center No. 1019</b>					
n (%)	1 (50.0)	2 (100.0)	N.E.	0.50 [0.13; 2.00] 0.327	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1021</b>					
n (%)	6 (37.5)	9 (90.0)	0.07 [<0.01; 0.67] 0.021	0.42 [0.21; 0.81] 0.010	-0.53 [-0.83; -0.22] <.001
<b>Center No. 1022</b>					
n (%)	1 (33.3)	1 (33.3)	1.00 [0.03; 29.81] 1.000	1.00 [0.10; 9.61] 1.000	0.00 [-0.75; 0.75] 1.000
<b>Center No. 1027</b>					
n (%)	1 (33.3)	2 (40.0)	0.75 [0.04; 14.97] 0.851	0.83 [0.12; 5.72] 0.853	-0.07 [-0.75; 0.62] 0.849
<b>Center No. 1028</b>					
n (%)	2 (18.2)	5 (100.0)	N.E.	0.18 [0.05; 0.64] 0.008	-0.82 [-1.05; -0.59] <.001

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1029</b>					
n (%)	0 (0.0)	4 (44.4)	N.E.	0.07 [0.00; 1.16] 0.063	-0.44 [-0.77; -0.12] 0.007
<b>Center No. 1030</b>					
n (%)	4 (36.4)	8 (88.9)	0.07 [<0.01; 0.80] 0.032	0.41 [0.18; 0.92] 0.032	-0.53 [-0.88; -0.17] 0.003
<b>Center No. 1033</b>					
n (%)	2 (50.0)	2 (33.3)	2.00 [0.15; 26.73] 0.600	1.50 [0.34; 6.70] 0.596	0.17 [-0.45; 0.79] 0.597
<b>Center No. 1034</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1035</b>					
n (%)	6 (22.2)	15 (68.2)	0.13 [0.04; 0.48] 0.002	0.33 [0.15; 0.70] 0.004	-0.46 [-0.71; -0.21] <.001
<b>Center No. 1036</b>					
n (%)	3 (42.9)	6 (85.7)	0.13 [<0.01; 1.67] 0.116	0.50 [0.20; 1.24] 0.134	-0.43 [-0.88; 0.02] 0.061
<b>Center No. 1037</b>					
n (%)	3 (33.3)	9 (81.8)	0.11 [0.01; 0.88] 0.037	0.41 [0.16; 1.07] 0.068	-0.48 [-0.87; -0.10] 0.013
<b>Center No. 1039</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1040</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1041</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.20 [0.01; 3.35] 0.263	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1042</b>					
n (%)	1 (25.0)	2 (40.0)	0.50 [0.03; 8.95] 0.638	0.63 [0.08; 4.66] 0.646	-0.15 [-0.75; 0.45] 0.626

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1044</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1046</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	2 (33.3)	5 (55.6)	0.40 [0.05; 3.42] 0.403	0.60 [0.17; 2.14] 0.432	-0.22 [-0.72; 0.28] 0.381
<b>Center No. 1051</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1052</b>					
n (%)	2 (28.6)	2 (50.0)	0.40 [0.03; 5.15] 0.482	0.57 [0.12; 2.63] 0.473	-0.21 [-0.81; 0.38] 0.479
<b>Center No. 1055</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1058</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1059</b>					
n (%)	2 (28.6)	5 (71.4)	0.16 [0.02; 1.63] 0.121	0.40 [0.11; 1.41] 0.155	-0.43 [-0.90; 0.04] 0.076
<b>Center No. 1061</b>					
n (%)	6 (66.7)	3 (50.0)	2.00 [0.24; 16.61] 0.521	1.33 [0.53; 3.36] 0.542	0.17 [-0.34; 0.67] 0.518
<b>Center No. 1063</b>					
n (%)	2 (50.0)	2 (100.0)	N.E.	0.50 [0.19; 1.33] 0.166	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1064</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	2 (20.0)	9 (56.3)	0.19 [0.03; 1.22] 0.081	0.36 [0.10; 1.32] 0.123	-0.36 [-0.71; -0.02] 0.041
<b>Center No. 1068</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1069</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.25 [0.02; 3.86] 0.321	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1070</b>					
n (%)	0 (0.0)	4 (80.0)	N.E.	0.33 [0.03; 3.84] 0.378	-0.80 [-1.15; -0.45] <.001
<b>Center No. 1072</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1073</b>					
n (%)	1 (9.1)	3 (42.9)	0.13 [0.01; 1.70] 0.120	0.21 [0.03; 1.66] 0.139	-0.34 [-0.74; 0.07] 0.101
<b>Center No. 1074</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1076</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1077</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1079</b>					
n (%)	1 (25.0)	3 (100.0)	N.E.	0.25 [0.05; 1.36] 0.109	-0.75 [-1.17; -0.33] <.001
<b>Center No. 1080</b>					
n (%)	1 (33.3)	1 (100.0)	N.E.	0.33 [0.07; 1.65] 0.178	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1082</b>					
n (%)	0 (0.0)	8 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1086</b>					
n (%)	3 (50.0)	8 (88.9)	0.13 [<0.01; 1.72] 0.120	0.56 [0.24; 1.29] 0.176	-0.39 [-0.84; 0.06] 0.090
<b>Center No. 1087</b>					
n (%)	0 (0.0)	4 (100.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1088</b>					
n (%)	1 (16.7)	3 (50.0)	0.20 [0.01; 2.91] 0.239	0.33 [0.05; 2.37] 0.272	-0.33 [-0.83; 0.17] 0.190
<b>Center No. 1089</b>					
n (%)	1 (25.0)	3 (75.0)	0.11 [<0.01; 2.73] 0.178	0.33 [0.06; 1.99] 0.229	-0.50 [-1.10; 0.10] 0.102
<b>Center No. 1091</b>					
n (%)	1 (16.7)	5 (100.0)	N.E.	0.17 [0.03; 1.00] 0.050	-0.83 [-1.13; -0.54] <.001
<b>Center No. 1093</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.50 [0.04; 6.44] 0.595	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1095</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.13 [0.01; 2.11] 0.153	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1096</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1100</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1101</b>					
n (%)	0 (0.0)	3 (50.0)	N.E.	0.20 [0.01; 3.07] 0.248	-0.50 [-0.90; -0.10] 0.014
<b>Center No. 1103</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1105</b>					
n (%)	1 (33.3)	2 (66.7)	0.25 [<0.01; 7.45] 0.424	0.50 [0.08; 2.99] 0.448	-0.33 [-1.09; 0.42] 0.386
<b>Center No. 1108</b>					
n (%)	6 (40.0)	8 (80.0)	0.17 [0.03; 1.07] 0.059	0.50 [0.25; 1.00] 0.050	-0.40 [-0.75; -0.05] 0.025

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1110</b>					
n (%)	3 (50.0)	2 (40.0)	1.50 [0.14; 16.54] 0.741	1.25 [0.33; 4.77] 0.744	0.10 [-0.49; 0.69] 0.738
<b>Center No. 1111</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1113</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1115</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.23 [0.01; 3.97] 0.314	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1118</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1119</b>					
n (%)	0 (0.0)	4 (80.0)	N.E.	0.17 [0.01; 2.32] 0.182	-0.80 [-1.15; -0.45] <.001
<b>Center No. 1121</b>					
n (%)	1 (25.0)	3 (75.0)	0.11 [<0.01; 2.73] 0.178	0.33 [0.06; 1.99] 0.229	-0.50 [-1.10; 0.10] 0.102
<b>Center No. 1123</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1124</b>					
n (%)	2 (66.7)	1 (50.0)	2.00 [0.05; 78.25] 0.711	1.33 [0.27; 6.61] 0.725	0.17 [-0.71; 1.04] 0.709
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Paraesthesia</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	5 (62.5)	N.E.	0.07 [0.00; 1.17] 0.065	-0.63 [-0.96; -0.29] <.001

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1002</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.27 [0.02; 3.74] 0.327	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1005</b>					
n (%)	2 (6.5)	6 (27.3)	0.18 [0.03; 1.02] 0.053	0.24 [0.05; 1.06] 0.060	-0.21 [-0.41; -0.00] 0.047
<b>Center No. 1007</b>					
n (%)	0 (0.0)	6 (85.7)	N.E.	0.10 [0.01; 1.49] 0.095	-0.86 [-1.12; -0.60] <.001
<b>Center No. 1008</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.20 [0.01; 2.98] 0.243	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1011</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.29 [0.02; 3.92] 0.349	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1012</b>					
n (%)	1 (33.3)	2 (40.0)	0.75 [0.04; 14.97] 0.851	0.83 [0.12; 5.72] 0.853	-0.07 [-0.75; 0.62] 0.849
<b>Center No. 1014</b>					
n (%)	0 (0.0)	3 (75.0)	N.E.	0.12 [0.01; 1.80] 0.124	-0.75 [-1.17; -0.33] <.001
<b>Center No. 1018</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.18 [0.01; 3.06] 0.233	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1019</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1021</b>					
n (%)	2 (12.5)	4 (40.0)	0.21 [0.03; 1.50] 0.121	0.31 [0.07; 1.40] 0.129	-0.28 [-0.62; 0.07] 0.117

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1022</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.07 [0.00; 1.17] 0.064	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1029</b>					
n (%)	0 (0.0)	5 (55.6)	N.E.	0.06 [0.00; 0.92] 0.044	-0.56 [-0.88; -0.23] <.001
<b>Center No. 1030</b>					
n (%)	0 (0.0)	6 (66.7)	N.E.	0.06 [0.00; 1.00] 0.050	-0.67 [-0.97; -0.36] <.001
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1034</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1035</b>					
n (%)	1 (3.7)	11 (50.0)	0.04 [<0.01; 0.34] 0.003	0.07 [0.01; 0.53] 0.010	-0.46 [-0.68; -0.24] <.001
<b>Center No. 1036</b>					
n (%)	1 (14.3)	5 (71.4)	0.07 [<0.01; 0.97] 0.047	0.20 [0.03; 1.30] 0.092	-0.57 [-0.99; -0.15] 0.008
<b>Center No. 1037</b>					
n (%)	0 (0.0)	7 (63.6)	N.E.	0.08 [0.01; 1.24] 0.070	-0.64 [-0.92; -0.35] <.001
<b>Center No. 1039</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1040</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1042</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.40 [0.02; 7.82] 0.546	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1046</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	0 (0.0)	3 (33.3)	N.E.	0.20 [0.01; 3.36] 0.266	-0.33 [-0.64; -0.03] 0.034
<b>Center No. 1051</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1052</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.21 [0.01; 4.18] 0.305	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1058</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1059</b>					
n (%)	1 (14.3)	5 (71.4)	0.07 [<0.01; 0.97] 0.047	0.20 [0.03; 1.30] 0.092	-0.57 [-0.99; -0.15] 0.008
<b>Center No. 1061</b>					
n (%)	2 (22.2)	2 (33.3)	0.57 [0.06; 5.77] 0.635	0.67 [0.13; 3.53] 0.633	-0.11 [-0.58; 0.35] 0.639
<b>Center No. 1063</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1064</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	0 (0.0)	3 (18.8)	N.E.	0.22 [0.01; 3.87] 0.301	-0.19 [-0.38; 0.00] 0.055
<b>Center No. 1068</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1070</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1072</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1073</b>					
n (%)	0 (0.0)	3 (42.9)	N.E.	0.10 [0.01; 1.61] 0.103	-0.43 [-0.80; -0.06] 0.022
<b>Center No. 1074</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1079</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1080</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1082</b>					
n (%)	0 (0.0)	6 (75.0)	N.E.	0.12 [0.01; 1.69] 0.115	-0.75 [-1.05; -0.45] <.001
<b>Center No. 1086</b>					
n (%)	1 (16.7)	4 (44.4)	0.25 [0.02; 3.10] 0.280	0.38 [0.05; 2.59] 0.320	-0.28 [-0.72; 0.16] 0.217
<b>Center No. 1087</b>					
n (%)	0 (0.0)	3 (75.0)	N.E.	0.36 [0.03; 4.21] 0.414	-0.75 [-1.17; -0.33] <.001
<b>Center No. 1088</b>					
n (%)	0 (0.0)	3 (50.0)	N.E.	0.14 [0.01; 2.28] 0.169	-0.50 [-0.90; -0.10] 0.014
<b>Center No. 1089</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.20 [0.01; 3.20] 0.255	-0.50 [-0.99; -0.01] 0.046

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1091</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.12 [0.01; 1.93] 0.135	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1093</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1095</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.13 [0.01; 2.11] 0.153	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1100</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1103</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1105</b>					
n (%)	1 (33.3)	1 (33.3)	1.00 [0.03; 29.81] 1.000	1.00 [0.10; 9.61] 1.000	0.00 [-0.75; 0.75] 1.000
<b>Center No. 1108</b>					
n (%)	3 (20.0)	6 (60.0)	0.17 [0.03; 1.00] 0.050	0.33 [0.11; 1.03] 0.057	-0.40 [-0.76; -0.04] 0.032
<b>Center No. 1110</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.17 [0.01; 2.92] 0.223	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1113</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1115</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.23 [0.01; 3.97] 0.314	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1124</b>					
n (%)	1 (33.3)	1 (50.0)	0.50 [0.01; 19.56] 0.711	0.67 [0.08; 5.54] 0.707	-0.17 [-1.04; 0.71] 0.709
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Paraesthesia - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	5 (62.5)	N.E.	0.07 [0.00; 1.17] 0.065	-0.63 [-0.96; -0.29] <.001
<b>Center No. 1002</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.27 [0.02; 3.74] 0.327	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1005</b>					
n (%)	2 (6.5)	6 (27.3)	0.18 [0.03; 1.02] 0.053	0.24 [0.05; 1.06] 0.060	-0.21 [-0.41; -0.00] 0.047
<b>Center No. 1007</b>					
n (%)	0 (0.0)	6 (85.7)	N.E.	0.10 [0.01; 1.49] 0.095	-0.86 [-1.12; -0.60] <.001
<b>Center No. 1008</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.20 [0.01; 2.98] 0.243	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1011</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.29 [0.02; 3.92] 0.349	-0.60 [-1.03; -0.17] 0.006

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1012</b>					
n (%)	1 (33.3)	2 (40.0)	0.75 [0.04; 14.97] 0.851	0.83 [0.12; 5.72] 0.853	-0.07 [-0.75; 0.62] 0.849
<b>Center No. 1014</b>					
n (%)	0 (0.0)	3 (75.0)	N.E.	0.12 [0.01; 1.80] 0.124	-0.75 [-1.17; -0.33] <.001
<b>Center No. 1018</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.18 [0.01; 3.06] 0.233	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1019</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1021</b>					
n (%)	2 (12.5)	4 (40.0)	0.21 [0.03; 1.50] 0.121	0.31 [0.07; 1.40] 0.129	-0.28 [-0.62; 0.07] 0.117
<b>Center No. 1022</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.07 [0.00; 1.17] 0.064	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1029</b>					
n (%)	0 (0.0)	3 (33.3)	N.E.	0.09 [0.01; 1.55] 0.097	-0.33 [-0.64; -0.03] 0.034
<b>Center No. 1030</b>					
n (%)	0 (0.0)	6 (66.7)	N.E.	0.06 [0.00; 1.00] 0.050	-0.67 [-0.97; -0.36] <.001
<b>Center No. 1034</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1035</b>					
n (%)	1 (3.7)	11 (50.0)	0.04 [<0.01; 0.34] 0.003	0.07 [0.01; 0.53] 0.010	-0.46 [-0.68; -0.24] <.001
<b>Center No. 1036</b>					
n (%)	1 (14.3)	5 (71.4)	0.07 [<0.01; 0.97] 0.047	0.20 [0.03; 1.30] 0.092	-0.57 [-0.99; -0.15] 0.008
<b>Center No. 1037</b>					
n (%)	0 (0.0)	7 (63.6)	N.E.	0.08 [0.01; 1.24] 0.070	-0.64 [-0.92; -0.35] <.001
<b>Center No. 1039</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1040</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1042</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.40 [0.02; 7.82] 0.546	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1046</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	0 (0.0)	3 (33.3)	N.E.	0.20 [0.01; 3.36] 0.266	-0.33 [-0.64; -0.03] 0.034
<b>Center No. 1051</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1052</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.21 [0.01; 4.18] 0.305	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1058</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1059</b>					
n (%)	1 (14.3)	4 (57.1)	0.13 [<0.01; 1.67] 0.116	0.25 [0.04; 1.71] 0.158	-0.43 [-0.88; 0.02] 0.061

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1061</b>					
n (%)	2 (22.2)	2 (33.3)	0.57 [0.06; 5.77] 0.635	0.67 [0.13; 3.53] 0.633	-0.11 [-0.58; 0.35] 0.639
<b>Center No. 1063</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1064</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	0 (0.0)	3 (18.8)	N.E.	0.22 [0.01; 3.87] 0.301	-0.19 [-0.38; 0.00] 0.055
<b>Center No. 1068</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1070</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1072</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1073</b>					
n (%)	0 (0.0)	3 (42.9)	N.E.	0.10 [0.01; 1.61] 0.103	-0.43 [-0.80; -0.06] 0.022
<b>Center No. 1074</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1079</b>					
n (%)	0 (0.0)	3 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1080</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1082</b>					
n (%)	0 (0.0)	6 (75.0)	N.E.	0.12 [0.01; 1.69] 0.115	-0.75 [-1.05; -0.45] <.001

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1086</b>					
n (%)	1 (16.7)	4 (44.4)	0.25 [0.02; 3.10] 0.280	0.38 [0.05; 2.59] 0.320	-0.28 [-0.72; 0.16] 0.217
<b>Center No. 1087</b>					
n (%)	0 (0.0)	3 (75.0)	N.E.	0.36 [0.03; 4.21] 0.414	-0.75 [-1.17; -0.33] <.001
<b>Center No. 1088</b>					
n (%)	0 (0.0)	3 (50.0)	N.E.	0.14 [0.01; 2.28] 0.169	-0.50 [-0.90; -0.10] 0.014
<b>Center No. 1089</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.20 [0.01; 3.20] 0.255	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1091</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.12 [0.01; 1.93] 0.135	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1093</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1095</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.13 [0.01; 2.11] 0.153	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1100</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1103</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1105</b>					
n (%)	1 (33.3)	1 (33.3)	1.00 [0.03; 29.81] 1.000	1.00 [0.10; 9.61] 1.000	0.00 [-0.75; 0.75] 1.000
<b>Center No. 1108</b>					
n (%)	3 (20.0)	6 (60.0)	0.17 [0.03; 1.00] 0.050	0.33 [0.11; 1.03] 0.057	-0.40 [-0.76; -0.04] 0.032
<b>Center No. 1110</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.17 [0.01; 2.92] 0.223	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1113</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1115</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.23 [0.01; 3.97] 0.314	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1124</b>					
n (%)	1 (33.3)	1 (50.0)	0.50 [0.01; 19.56] 0.711	0.67 [0.08; 5.54] 0.707	-0.17 [-1.04; 0.71] 0.709
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Disturbance in attention</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	1 (10.0)	2 (25.0)	0.33 [0.02; 4.55] 0.410	0.40 [0.04; 3.66] 0.417	-0.15 [-0.50; 0.20] 0.405
<b>Center No. 1002</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	4.00 [0.24; 67.72] 0.337	0.50 [-0.19; 1.19] 0.157

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1005</b>					
n (%)	4 (12.9)	8 (36.4)	0.26 [0.07; 1.01] 0.052	0.35 [0.12; 1.03] 0.057	-0.23 [-0.47; -0.00] 0.049
<b>Center No. 1007</b>					
n (%)	1 (20.0)	2 (28.6)	0.63 [0.04; 9.65] 0.736	0.70 [0.09; 5.76] 0.740	-0.09 [-0.57; 0.40] 0.729
<b>Center No. 1008</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1012</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1019</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.33 [0.02; 5.33] 0.437	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1021</b>					
n (%)	1 (6.3)	2 (20.0)	0.27 [0.02; 3.41] 0.310	0.31 [0.03; 3.01] 0.315	-0.14 [-0.41; 0.14] 0.327
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1030</b>					
n (%)	2 (18.2)	3 (33.3)	0.44 [0.06; 3.51] 0.442	0.55 [0.11; 2.59] 0.446	-0.15 [-0.53; 0.23] 0.438
<b>Center No. 1033</b>					
n (%)	1 (25.0)	3 (50.0)	0.33 [0.02; 5.33] 0.437	0.50 [0.08; 3.27] 0.469	-0.25 [-0.83; 0.33] 0.401

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1035</b>					
n (%)	1 (3.7)	3 (13.6)	0.24 [0.02; 2.53] 0.237	0.27 [0.03; 2.43] 0.244	-0.10 [-0.26; 0.06] 0.224
<b>Center No. 1036</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.20 [0.01; 3.54] 0.272	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1037</b>					
n (%)	1 (11.1)	2 (18.2)	0.56 [0.04; 7.44] 0.662	0.61 [0.07; 5.70] 0.666	-0.07 [-0.38; 0.24] 0.651
<b>Center No. 1040</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1041</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.33 [0.02; 6.65] 0.472	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1050</b>					
n (%)	1 (16.7)	2 (22.2)	0.70 [0.05; 10.01] 0.793	0.75 [0.09; 6.55] 0.795	-0.06 [-0.46; 0.35] 0.787
<b>Center No. 1059</b>					
n (%)	0 (0.0)	3 (42.9)	N.E.	0.14 [0.01; 2.34] 0.173	-0.43 [-0.80; -0.06] 0.022
<b>Center No. 1063</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1067</b>					
n (%)	0 (0.0)	2 (12.5)	N.E.	0.31 [0.02; 5.85] 0.434	-0.13 [-0.29; 0.04] 0.131
<b>Center No. 1068</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1070</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1073</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.22 [0.01; 4.80] 0.337	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1079</b>					
n (%)	1 (25.0)	1 (33.3)	0.67 [0.02; 18.06] 0.810	0.75 [0.07; 7.73] 0.809	-0.08 [-0.76; 0.60] 0.811
<b>Center No. 1080</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1082</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.30 [0.02; 5.21] 0.409	-0.25 [-0.55; 0.05] 0.102
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1087</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1089</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1091</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1096</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1105</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.20 [0.01; 2.98] 0.243	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1108</b>					
n (%)	0 (0.0)	2 (20.0)	N.E.	0.14 [0.01; 2.60] 0.186	-0.20 [-0.45; 0.05] 0.114

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1110</b>					
n (%)	1 (16.7)	2 (40.0)	0.30 [0.02; 4.91] 0.398	0.42 [0.05; 3.36] 0.411	-0.23 [-0.76; 0.29] 0.382
<b>Center No. 1119</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Disturbance in attention - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	1 (10.0)	2 (25.0)	0.33 [0.02; 4.55] 0.410	0.40 [0.04; 3.66] 0.417	-0.15 [-0.50; 0.20] 0.405
<b>Center No. 1002</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	4.00 [0.24; 67.72] 0.337	0.50 [-0.19; 1.19] 0.157
<b>Center No. 1005</b>					
n (%)	4 (12.9)	8 (36.4)	0.26 [0.07; 1.01] 0.052	0.35 [0.12; 1.03] 0.057	-0.23 [-0.47; -0.00] 0.049
<b>Center No. 1007</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.27 [0.02; 4.59] 0.363	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1008</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1012</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1019</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.33 [0.02; 5.33] 0.437	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1021</b>					
n (%)	1 (6.3)	2 (20.0)	0.27 [0.02; 3.41] 0.310	0.31 [0.03; 3.01] 0.315	-0.14 [-0.41; 0.14] 0.327
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1030</b>					
n (%)	2 (18.2)	3 (33.3)	0.44 [0.06; 3.51] 0.442	0.55 [0.11; 2.59] 0.446	-0.15 [-0.53; 0.23] 0.438
<b>Center No. 1033</b>					
n (%)	1 (25.0)	1 (16.7)	1.67 [0.07; 37.73] 0.748	1.50 [0.13; 17.67] 0.747	0.08 [-0.44; 0.60] 0.753
<b>Center No. 1035</b>					
n (%)	1 (3.7)	3 (13.6)	0.24 [0.02; 2.53] 0.237	0.27 [0.03; 2.43] 0.244	-0.10 [-0.26; 0.06] 0.224
<b>Center No. 1036</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.20 [0.01; 3.54] 0.272	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1037</b>					
n (%)	1 (11.1)	2 (18.2)	0.56 [0.04; 7.44] 0.662	0.61 [0.07; 5.70] 0.666	-0.07 [-0.38; 0.24] 0.651
<b>Center No. 1040</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1041</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.33 [0.02; 6.65] 0.472	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1050</b>					
n (%)	1 (16.7)	2 (22.2)	0.70 [0.05; 10.01] 0.793	0.75 [0.09; 6.55] 0.795	-0.06 [-0.46; 0.35] 0.787
<b>Center No. 1059</b>					
n (%)	0 (0.0)	3 (42.9)	N.E.	0.14 [0.01; 2.34] 0.173	-0.43 [-0.80; -0.06] 0.022
<b>Center No. 1063</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1067</b>					
n (%)	0 (0.0)	2 (12.5)	N.E.	0.31 [0.02; 5.85] 0.434	-0.13 [-0.29; 0.04] 0.131
<b>Center No. 1068</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1070</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1073</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.22 [0.01; 4.80] 0.337	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1079</b>					
n (%)	1 (25.0)	1 (33.3)	0.67 [0.02; 18.06] 0.810	0.75 [0.07; 7.73] 0.809	-0.08 [-0.76; 0.60] 0.811
<b>Center No. 1080</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1082</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.30 [0.02; 5.21] 0.409	-0.25 [-0.55; 0.05] 0.102

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1087</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1089</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1091</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1096</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1105</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.20 [0.01; 2.98] 0.243	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1108</b>					
n (%)	0 (0.0)	2 (20.0)	N.E.	0.14 [0.01; 2.60] 0.186	-0.20 [-0.45; 0.05] 0.114
<b>Center No. 1110</b>					
n (%)	1 (16.7)	2 (40.0)	0.30 [0.02; 4.91] 0.398	0.42 [0.05; 3.36] 0.411	-0.23 [-0.76; 0.29] 0.382
<b>Center No. 1119</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Dizziness</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.16 [0.01; 2.99] 0.222	-0.25 [-0.55; 0.05] 0.102
<b>Center No. 1003</b>					
n (%)	1 (50.0)	2 (66.7)	0.50 [0.01; 19.56] 0.711	0.75 [0.15; 3.72] 0.725	-0.17 [-1.04; 0.71] 0.709
<b>Center No. 1005</b>					
n (%)	0 (0.0)	2 (9.1)	N.E.	0.14 [0.01; 2.86] 0.203	-0.09 [-0.21; 0.03] 0.138
<b>Center No. 1007</b>					
n (%)	1 (20.0)	3 (42.9)	0.33 [0.02; 4.74] 0.417	0.47 [0.07; 3.28] 0.444	-0.23 [-0.74; 0.28] 0.377
<b>Center No. 1012</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	4.50 [0.24; 85.12] 0.316	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1014</b>					
n (%)	1 (20.0)	3 (75.0)	0.08 [<0.01; 1.95] 0.122	0.27 [0.04; 1.68] 0.160	-0.55 [-1.10; 0.00] 0.050
<b>Center No. 1017</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.17 [0.01; 2.73] 0.209	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1021</b>					
n (%)	2 (12.5)	3 (30.0)	0.33 [0.04; 2.48] 0.283	0.42 [0.08; 2.07] 0.285	-0.18 [-0.50; 0.15] 0.294
<b>Center No. 1022</b>					
n (%)	1 (33.3)	1 (33.3)	1.00 [0.03; 29.81] 1.000	1.00 [0.10; 9.61] 1.000	0.00 [-0.75; 0.75] 1.000

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1027</b>					
n (%)	1 (33.3)	1 (20.0)	2.00 [0.08; 51.59] 0.676	1.67 [0.16; 17.89] 0.673	0.13 [-0.51; 0.77] 0.682
<b>Center No. 1029</b>					
n (%)	1 (6.7)	0 (0.0)	N.E.	1.88 [0.08; 41.69] 0.691	0.07 [-0.06; 0.19] 0.301
<b>Center No. 1030</b>					
n (%)	1 (9.1)	2 (22.2)	0.35 [0.03; 4.65] 0.426	0.41 [0.04; 3.82] 0.433	-0.13 [-0.45; 0.19] 0.422
<b>Center No. 1034</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1035</b>					
n (%)	3 (11.1)	1 (4.5)	2.62 [0.25; 27.19] 0.418	2.44 [0.27; 21.89] 0.424	0.07 [-0.08; 0.21] 0.382
<b>Center No. 1036</b>					
n (%)	1 (14.3)	3 (42.9)	0.22 [0.02; 2.97] 0.256	0.33 [0.04; 2.48] 0.283	-0.29 [-0.73; 0.16] 0.212
<b>Center No. 1037</b>					
n (%)	1 (11.1)	1 (9.1)	1.25 [0.07; 23.26] 0.881	1.22 [0.09; 16.93] 0.881	0.02 [-0.25; 0.29] 0.882
<b>Center No. 1040</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1042</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.40 [0.02; 7.82] 0.546	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1044</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	1 (16.7)	3 (33.3)	0.40 [0.03; 5.15] 0.482	0.50 [0.07; 3.75] 0.500	-0.17 [-0.60; 0.26] 0.446

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1052</b>					
n (%)	1 (14.3)	1 (25.0)	0.50 [0.02; 11.09] 0.661	0.57 [0.05; 6.86] 0.659	-0.11 [-0.60; 0.39] 0.673
<b>Center No. 1061</b>					
n (%)	2 (22.2)	2 (33.3)	0.57 [0.06; 5.77] 0.635	0.67 [0.13; 3.53] 0.633	-0.11 [-0.58; 0.35] 0.639
<b>Center No. 1063</b>					
n (%)	1 (25.0)	1 (50.0)	0.33 [<0.01; 11.94] 0.547	0.50 [0.06; 4.47] 0.535	-0.25 [-1.06; 0.56] 0.546
<b>Center No. 1064</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	0 (0.0)	2 (12.5)	N.E.	0.31 [0.02; 5.85] 0.434	-0.13 [-0.29; 0.04] 0.131
<b>Center No. 1068</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1070</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1073</b>					
n (%)	1 (9.1)	0 (0.0)	N.E.	2.00 [0.09; 43.22] 0.658	0.09 [-0.08; 0.26] 0.294
<b>Center No. 1079</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1080</b>					
n (%)	1 (33.3)	1 (100.0)	N.E.	0.33 [0.07; 1.65] 0.178	-0.67 [-1.20; -0.13] 0.014

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1086</b>					
n (%)	1 (16.7)	1 (11.1)	1.60 [0.08; 31.77] 0.758	1.50 [0.11; 19.64] 0.757	0.06 [-0.31; 0.42] 0.764
<b>Center No. 1091</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1093</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1108</b>					
n (%)	2 (13.3)	1 (10.0)	1.38 [0.11; 17.67] 0.802	1.33 [0.14; 12.82] 0.803	0.03 [-0.22; 0.29] 0.796
<b>Center No. 1110</b>					
n (%)	2 (33.3)	2 (40.0)	0.75 [0.06; 8.83] 0.819	0.83 [0.18; 3.96] 0.819	-0.07 [-0.64; 0.50] 0.819
<b>Center No. 1113</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1119</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1121</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.20 [0.01; 3.20] 0.255	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1124</b>					
n (%)	1 (33.3)	1 (50.0)	0.50 [0.01; 19.56] 0.711	0.67 [0.08; 5.54] 0.707	-0.17 [-1.04; 0.71] 0.709
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Dizziness - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.16 [0.01; 2.99] 0.222	-0.25 [-0.55; 0.05] 0.102
<b>Center No. 1003</b>					
n (%)	1 (50.0)	2 (66.7)	0.50 [0.01; 19.56] 0.711	0.75 [0.15; 3.72] 0.725	-0.17 [-1.04; 0.71] 0.709
<b>Center No. 1005</b>					
n (%)	0 (0.0)	2 (9.1)	N.E.	0.14 [0.01; 2.86] 0.203	-0.09 [-0.21; 0.03] 0.138
<b>Center No. 1007</b>					
n (%)	1 (20.0)	3 (42.9)	0.33 [0.02; 4.74] 0.417	0.47 [0.07; 3.28] 0.444	-0.23 [-0.74; 0.28] 0.377
<b>Center No. 1012</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	4.50 [0.24; 85.12] 0.316	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1014</b>					
n (%)	1 (20.0)	3 (75.0)	0.08 [<0.01; 1.95] 0.122	0.27 [0.04; 1.68] 0.160	-0.55 [-1.10; 0.00] 0.050
<b>Center No. 1017</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.17 [0.01; 2.73] 0.209	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1021</b>					
n (%)	2 (12.5)	3 (30.0)	0.33 [0.04; 2.48] 0.283	0.42 [0.08; 2.07] 0.285	-0.18 [-0.50; 0.15] 0.294
<b>Center No. 1022</b>					
n (%)	1 (33.3)	1 (33.3)	1.00 [0.03; 29.81] 1.000	1.00 [0.10; 9.61] 1.000	0.00 [-0.75; 0.75] 1.000

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1027</b>					
n (%)	1 (33.3)	1 (20.0)	2.00 [0.08; 51.59] 0.676	1.67 [0.16; 17.89] 0.673	0.13 [-0.51; 0.77] 0.682
<b>Center No. 1030</b>					
n (%)	1 (9.1)	2 (22.2)	0.35 [0.03; 4.65] 0.426	0.41 [0.04; 3.82] 0.433	-0.13 [-0.45; 0.19] 0.422
<b>Center No. 1034</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1035</b>					
n (%)	3 (11.1)	1 (4.5)	2.62 [0.25; 27.19] 0.418	2.44 [0.27; 21.89] 0.424	0.07 [-0.08; 0.21] 0.382
<b>Center No. 1036</b>					
n (%)	1 (14.3)	3 (42.9)	0.22 [0.02; 2.97] 0.256	0.33 [0.04; 2.48] 0.283	-0.29 [-0.73; 0.16] 0.212
<b>Center No. 1037</b>					
n (%)	1 (11.1)	1 (9.1)	1.25 [0.07; 23.26] 0.881	1.22 [0.09; 16.93] 0.881	0.02 [-0.25; 0.29] 0.882
<b>Center No. 1040</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1042</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.40 [0.02; 7.82] 0.546	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1044</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	1 (16.7)	3 (33.3)	0.40 [0.03; 5.15] 0.482	0.50 [0.07; 3.75] 0.500	-0.17 [-0.60; 0.26] 0.446
<b>Center No. 1052</b>					
n (%)	1 (14.3)	1 (25.0)	0.50 [0.02; 11.09] 0.661	0.57 [0.05; 6.86] 0.659	-0.11 [-0.60; 0.39] 0.673

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1061</b>					
n (%)	2 (22.2)	2 (33.3)	0.57 [0.06; 5.77] 0.635	0.67 [0.13; 3.53] 0.633	-0.11 [-0.58; 0.35] 0.639
<b>Center No. 1063</b>					
n (%)	1 (25.0)	1 (50.0)	0.33 [<0.01; 11.94] 0.547	0.50 [0.06; 4.47] 0.535	-0.25 [-1.06; 0.56] 0.546
<b>Center No. 1064</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	0 (0.0)	2 (12.5)	N.E.	0.31 [0.02; 5.85] 0.434	-0.13 [-0.29; 0.04] 0.131
<b>Center No. 1068</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1070</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1073</b>					
n (%)	1 (9.1)	0 (0.0)	N.E.	2.00 [0.09; 43.22] 0.658	0.09 [-0.08; 0.26] 0.294
<b>Center No. 1079</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1080</b>					
n (%)	1 (33.3)	1 (100.0)	N.E.	0.33 [0.07; 1.65] 0.178	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1086</b>					
n (%)	1 (16.7)	1 (11.1)	1.60 [0.08; 31.77] 0.758	1.50 [0.11; 19.64] 0.757	0.06 [-0.31; 0.42] 0.764

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1091</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1093</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1108</b>					
n (%)	2 (13.3)	0 (0.0)	N.E.	3.44 [0.18; 64.88] 0.410	0.13 [-0.04; 0.31] 0.129
<b>Center No. 1110</b>					
n (%)	2 (33.3)	1 (20.0)	2.00 [0.13; 31.98] 0.624	1.67 [0.21; 13.43] 0.631	0.13 [-0.38; 0.65] 0.612
<b>Center No. 1113</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1119</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1121</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.20 [0.01; 3.20] 0.255	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1124</b>					
n (%)	1 (33.3)	1 (50.0)	0.50 [0.01; 19.56] 0.711	0.67 [0.08; 5.54] 0.707	-0.17 [-1.04; 0.71] 0.709
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Taste disorder</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1007</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.44 [0.02; 9.11] 0.599	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1010</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.27 [0.02; 3.74] 0.327	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1017</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.17 [0.01; 2.73] 0.209	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1021</b>					
n (%)	0 (0.0)	2 (20.0)	N.E.	0.13 [0.01; 2.45] 0.173	-0.20 [-0.45; 0.05] 0.114
<b>Center No. 1028</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.17 [0.01; 3.51] 0.249	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1067</b>					
n (%)	0 (0.0)	3 (18.8)	N.E.	0.22 [0.01; 3.87] 0.301	-0.19 [-0.38; 0.00] 0.055
<b>Center No. 1068</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1079</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1087</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1091</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.17 [0.01; 2.92] 0.223	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1108</b>					
n (%)	0 (0.0)	2 (20.0)	N.E.	0.14 [0.01; 2.60] 0.186	-0.20 [-0.45; 0.05] 0.114
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1119</b>					
n (%)	0 (0.0)	4 (80.0)	N.E.	0.17 [0.01; 2.32] 0.182	-0.80 [-1.15; -0.45] <.001
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Taste disorder - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1007</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.44 [0.02; 9.11] 0.599	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1010</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.27 [0.02; 3.74] 0.327	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1017</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.17 [0.01; 2.73] 0.209	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1021</b>					
n (%)	0 (0.0)	2 (20.0)	N.E.	0.13 [0.01; 2.45] 0.173	-0.20 [-0.45; 0.05] 0.114
<b>Center No. 1028</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.17 [0.01; 3.51] 0.249	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1067</b>					
n (%)	0 (0.0)	3 (18.8)	N.E.	0.22 [0.01; 3.87] 0.301	-0.19 [-0.38; 0.00] 0.055
<b>Center No. 1068</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1079</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1087</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1091</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.17 [0.01; 2.92] 0.223	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1108</b>					
n (%)	0 (0.0)	2 (20.0)	N.E.	0.14 [0.01; 2.60] 0.186	-0.20 [-0.45; 0.05] 0.114
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1119</b>					
n (%)	0 (0.0)	4 (80.0)	N.E.	0.17 [0.01; 2.32] 0.182	-0.80 [-1.15; -0.45] <.001

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Dysgeusia</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.16 [0.01; 2.99] 0.222	-0.25 [-0.55; 0.05] 0.102
<b>Center No. 1003</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1014</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1028</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.17 [0.01; 3.51] 0.249	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1035</b>					
n (%)	0 (0.0)	4 (18.2)	N.E.	0.09 [0.01; 1.61] 0.102	-0.18 [-0.34; -0.02] 0.027
<b>Center No. 1036</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1046</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1061</b>					
n (%)	1 (11.1)	1 (16.7)	0.62 [0.03; 12.41] 0.758	0.67 [0.05; 8.73] 0.757	-0.06 [-0.42; 0.31] 0.764

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1067</b>					
n (%)	0 (0.0)	1 (6.3)	N.E.	0.52 [0.02; 11.54] 0.676	-0.06 [-0.18; 0.06] 0.302
<b>Center No. 1074</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.22 [0.01; 4.20] 0.316	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1076</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1082</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.30 [0.02; 5.21] 0.409	-0.25 [-0.55; 0.05] 0.102
<b>Center No. 1086</b>					
n (%)	1 (16.7)	2 (22.2)	0.70 [0.05; 10.01] 0.793	0.75 [0.09; 6.55] 0.795	-0.06 [-0.46; 0.35] 0.787
<b>Center No. 1091</b>					
n (%)	1 (16.7)	0 (0.0)	N.E.	2.57 [0.13; 52.13] 0.538	0.17 [-0.13; 0.46] 0.273
<b>Center No. 1093</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Dysgeusia - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.16 [0.01; 2.99] 0.222	-0.25 [-0.55; 0.05] 0.102
<b>Center No. 1003</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1014</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1028</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.17 [0.01; 3.51] 0.249	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1035</b>					
n (%)	0 (0.0)	4 (18.2)	N.E.	0.09 [0.01; 1.61] 0.102	-0.18 [-0.34; -0.02] 0.027
<b>Center No. 1036</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1046</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1061</b>					
n (%)	1 (11.1)	1 (16.7)	0.62 [0.03; 12.41] 0.758	0.67 [0.05; 8.73] 0.757	-0.06 [-0.42; 0.31] 0.764
<b>Center No. 1067</b>					
n (%)	0 (0.0)	1 (6.3)	N.E.	0.52 [0.02; 11.54] 0.676	-0.06 [-0.18; 0.06] 0.302
<b>Center No. 1074</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.22 [0.01; 4.20] 0.316	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1076</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1082</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.30 [0.02; 5.21] 0.409	-0.25 [-0.55; 0.05] 0.102

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1086</b>					
n (%)	1 (16.7)	2 (22.2)	0.70 [0.05; 10.01] 0.793	0.75 [0.09; 6.55] 0.795	-0.06 [-0.46; 0.35] 0.787
<b>Center No. 1091</b>					
n (%)	1 (16.7)	0 (0.0)	N.E.	2.57 [0.13; 52.13] 0.538	0.17 [-0.13; 0.46] 0.273
<b>Center No. 1093</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Hypoaesthesia</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1003</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1007</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.27 [0.02; 4.59] 0.363	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1010</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1011</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.67 [0.04; 11.94] 0.783	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1017</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.50 [0.13; 48.85] 0.546	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1019</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	3.00 [0.19; 47.96] 0.437	0.50 [-0.19; 1.19] 0.157

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1029</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.21 [0.01; 4.63] 0.322	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1034</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1052</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.21 [0.01; 4.18] 0.305	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1063</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1105</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	3.00 [0.17; 53.71] 0.455	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Hypoaesthesia - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1003</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1007</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.27 [0.02; 4.59] 0.363	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1010</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1011</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.67 [0.04; 11.94] 0.783	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1017</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.50 [0.13; 48.85] 0.546	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1019</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	3.00 [0.19; 47.96] 0.437	0.50 [-0.19; 1.19] 0.157
<b>Center No. 1034</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1052</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.21 [0.01; 4.18] 0.305	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1063</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1105</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	3.00 [0.17; 53.71] 0.455	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Aphasia</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1010</b>					
n (%)	1 (50.0)	1 (33.3)	2.00 [0.05; 78.25] 0.711	1.50 [0.18; 12.46] 0.707	0.17 [-0.71; 1.04] 0.709
<b>Center No. 1035</b>					
n (%)	0 (0.0)	1 (4.5)	N.E.	0.27 [0.01; 6.41] 0.421	-0.05 [-0.13; 0.04] 0.306
<b>Center No. 1036</b>					
n (%)	0 (0.0)	4 (57.1)	N.E.	0.11 [0.01; 1.74] 0.118	-0.57 [-0.94; -0.20] 0.002
<b>Center No. 1037</b>					
n (%)	0 (0.0)	1 (9.1)	N.E.	0.40 [0.02; 8.78] 0.561	-0.09 [-0.26; 0.08] 0.294
<b>Center No. 1044</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1061</b>					
n (%)	1 (11.1)	0 (0.0)	N.E.	2.10 [0.10; 44.41] 0.634	0.11 [-0.09; 0.32] 0.289
<b>Center No. 1067</b>					
n (%)	0 (0.0)	1 (6.3)	N.E.	0.52 [0.02; 11.54] 0.676	-0.06 [-0.18; 0.06] 0.302

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1070</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1105</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Aphasia - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1010</b>					
n (%)	1 (50.0)	1 (33.3)	2.00 [0.05; 78.25] 0.711	1.50 [0.18; 12.46] 0.707	0.17 [-0.71; 1.04] 0.709
<b>Center No. 1035</b>					
n (%)	0 (0.0)	1 (4.5)	N.E.	0.27 [0.01; 6.41] 0.421	-0.05 [-0.13; 0.04] 0.306
<b>Center No. 1036</b>					
n (%)	0 (0.0)	4 (57.1)	N.E.	0.11 [0.01; 1.74] 0.118	-0.57 [-0.94; -0.20] 0.002
<b>Center No. 1037</b>					
n (%)	0 (0.0)	1 (9.1)	N.E.	0.40 [0.02; 8.78] 0.561	-0.09 [-0.26; 0.08] 0.294
<b>Center No. 1044</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1061</b>					
n (%)	1 (11.1)	0 (0.0)	N.E.	2.10 [0.10; 44.41] 0.634	0.11 [-0.09; 0.32] 0.289
<b>Center No. 1067</b>					
n (%)	0 (0.0)	1 (6.3)	N.E.	0.52 [0.02; 11.54] 0.676	-0.06 [-0.18; 0.06] 0.302
<b>Center No. 1070</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1105</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Memory impairment</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1007</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.44 [0.02; 9.11] 0.599	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1035</b>					
n (%)	0 (0.0)	1 (4.5)	N.E.	0.27 [0.01; 6.41] 0.421	-0.05 [-0.13; 0.04] 0.306
<b>Center No. 1036</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1037</b>					
n (%)	1 (11.1)	1 (9.1)	1.25 [0.07; 23.26] 0.881	1.22 [0.09; 16.93] 0.881	0.02 [-0.25; 0.29] 0.882
<b>Center No. 1050</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1080</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1087</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1088</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.33 [0.02; 6.86] 0.476	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Memory impairment - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1007</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.44 [0.02; 9.11] 0.599	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1035</b>					
n (%)	0 (0.0)	1 (4.5)	N.E.	0.27 [0.01; 6.41] 0.421	-0.05 [-0.13; 0.04] 0.306
<b>Center No. 1036</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1037</b>					
n (%)	1 (11.1)	1 (9.1)	1.25 [0.07; 23.26] 0.881	1.22 [0.09; 16.93] 0.881	0.02 [-0.25; 0.29] 0.882
<b>Center No. 1050</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1080</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1087</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1088</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.33 [0.02; 6.86] 0.476	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Sinusitis</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1007</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	4.00 [0.20; 82.01] 0.368	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1011</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.67 [0.04; 11.94] 0.783	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1012</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1017</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1019</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	3.00 [0.19; 47.96] 0.437	0.50 [-0.19; 1.19] 0.157
<b>Center No. 1030</b>					
n (%)	1 (9.1)	0 (0.0)	N.E.	2.50 [0.11; 54.87] 0.561	0.09 [-0.08; 0.26] 0.294
<b>Center No. 1035</b>					
n (%)	1 (3.7)	0 (0.0)	N.E.	2.46 [0.11; 57.67] 0.575	0.04 [-0.03; 0.11] 0.308
<b>Center No. 1036</b>					
n (%)	1 (14.3)	0 (0.0)	N.E.	3.00 [0.14; 63.15] 0.480	0.14 [-0.12; 0.40] 0.280
<b>Center No. 1050</b>					
n (%)	3 (50.0)	0 (0.0)	N.E.	10.00 [0.61; 164.68] 0.107	0.50 [0.10; 0.90] 0.014

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1073</b>					
n (%)	2 (18.2)	0 (0.0)	N.E.	3.33 [0.18; 60.68] 0.416	0.18 [-0.05; 0.41] 0.118
<b>Center No. 1074</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.00 [0.11; 37.83] 0.644	0.20 [-0.15; 0.55] 0.264
<b>Sinusitis - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1007</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	4.00 [0.20; 82.01] 0.368	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1011</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.67 [0.04; 11.94] 0.783	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1012</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1017</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1019</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	3.00 [0.19; 47.96] 0.437	0.50 [-0.19; 1.19] 0.157
<b>Center No. 1030</b>					
n (%)	1 (9.1)	0 (0.0)	N.E.	2.50 [0.11; 54.87] 0.561	0.09 [-0.08; 0.26] 0.294
<b>Center No. 1035</b>					
n (%)	1 (3.7)	0 (0.0)	N.E.	2.46 [0.11; 57.67] 0.575	0.04 [-0.03; 0.11] 0.308
<b>Center No. 1036</b>					
n (%)	1 (14.3)	0 (0.0)	N.E.	3.00 [0.14; 63.15] 0.480	0.14 [-0.12; 0.40] 0.280

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1050</b>					
n (%)	3 (50.0)	0 (0.0)	N.E.	10.00 [0.61; 164.68] 0.107	0.50 [0.10; 0.90] 0.014
<b>Center No. 1073</b>					
n (%)	2 (18.2)	0 (0.0)	N.E.	3.33 [0.18; 60.68] 0.416	0.18 [-0.05; 0.41] 0.118
<b>Center No. 1074</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.00 [0.11; 37.83] 0.644	0.20 [-0.15; 0.55] 0.264
<b>Nausea</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.16 [0.01; 2.99] 0.222	-0.25 [-0.55; 0.05] 0.102
<b>Center No. 1003</b>					
n (%)	1 (50.0)	1 (33.3)	2.00 [0.05; 78.25] 0.711	1.50 [0.18; 12.46] 0.707	0.17 [-0.71; 1.04] 0.709
<b>Center No. 1005</b>					
n (%)	3 (9.7)	2 (9.1)	1.07 [0.16; 7.01] 0.943	1.06 [0.19; 5.85] 0.943	0.01 [-0.15; 0.16] 0.942
<b>Center No. 1007</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.44 [0.02; 9.11] 0.599	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1008</b>					
n (%)	1 (33.3)	2 (66.7)	0.25 [<0.01; 7.45] 0.424	0.50 [0.08; 2.99] 0.448	-0.33 [-1.09; 0.42] 0.386
<b>Center No. 1010</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	4.00 [0.24; 67.72] 0.337	0.50 [-0.19; 1.19] 0.157
<b>Center No. 1011</b>					
n (%)	1 (50.0)	1 (20.0)	4.00 [0.12; >99.99] 0.442	2.50 [0.27; 23.36] 0.422	0.30 [-0.48; 1.08] 0.449



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1012</b>					
n (%)	2 (66.7)	3 (60.0)	1.33 [0.07; 26.62] 0.851	1.11 [0.38; 3.25] 0.847	0.07 [-0.62; 0.75] 0.849
<b>Center No. 1014</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.50 [0.13; 48.85] 0.546	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1015</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1017</b>					
n (%)	1 (20.0)	2 (50.0)	0.25 [0.01; 4.73] 0.355	0.40 [0.05; 2.98] 0.371	-0.30 [-0.90; 0.30] 0.329
<b>Center No. 1021</b>					
n (%)	2 (12.5)	3 (30.0)	0.33 [0.04; 2.48] 0.283	0.42 [0.08; 2.07] 0.285	-0.18 [-0.50; 0.15] 0.294
<b>Center No. 1022</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1027</b>					
n (%)	1 (33.3)	2 (40.0)	0.75 [0.04; 14.97] 0.851	0.83 [0.12; 5.72] 0.853	-0.07 [-0.75; 0.62] 0.849
<b>Center No. 1028</b>					
n (%)	3 (27.3)	2 (40.0)	0.56 [0.06; 5.22] 0.613	0.68 [0.16; 2.89] 0.603	-0.13 [-0.63; 0.38] 0.620
<b>Center No. 1029</b>					
n (%)	1 (6.7)	1 (11.1)	0.57 [0.03; 10.43] 0.706	0.60 [0.04; 8.46] 0.705	-0.04 [-0.29; 0.20] 0.718
<b>Center No. 1030</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.28 [0.01; 6.10] 0.416	-0.11 [-0.32; 0.09] 0.289

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1033</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1034</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	2.40 [0.13; 44.42] 0.557	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1035</b>					
n (%)	3 (11.1)	6 (27.3)	0.33 [0.07; 1.53] 0.158	0.41 [0.11; 1.45] 0.165	-0.16 [-0.38; 0.06] 0.151
<b>Center No. 1036</b>					
n (%)	0 (0.0)	3 (42.9)	N.E.	0.14 [0.01; 2.34] 0.173	-0.43 [-0.80; -0.06] 0.022
<b>Center No. 1037</b>					
n (%)	1 (11.1)	3 (27.3)	0.33 [0.03; 3.93] 0.383	0.41 [0.05; 3.28] 0.399	-0.16 [-0.50; 0.17] 0.343
<b>Center No. 1040</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1042</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.24 [0.01; 3.93] 0.317	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1050</b>					
n (%)	1 (16.7)	2 (22.2)	0.70 [0.05; 10.01] 0.793	0.75 [0.09; 6.55] 0.795	-0.06 [-0.46; 0.35] 0.787
<b>Center No. 1052</b>					
n (%)	1 (14.3)	2 (50.0)	0.17 [<0.01; 2.98] 0.224	0.29 [0.04; 2.25] 0.234	-0.36 [-0.91; 0.20] 0.207
<b>Center No. 1059</b>					
n (%)	0 (0.0)	3 (42.9)	N.E.	0.14 [0.01; 2.34] 0.173	-0.43 [-0.80; -0.06] 0.022
<b>Center No. 1067</b>					
n (%)	0 (0.0)	2 (12.5)	N.E.	0.31 [0.02; 5.85] 0.434	-0.13 [-0.29; 0.04] 0.131

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1077</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1079</b>					
n (%)	1 (25.0)	1 (33.3)	0.67 [0.02; 18.06] 0.810	0.75 [0.07; 7.73] 0.809	-0.08 [-0.76; 0.60] 0.811
<b>Center No. 1080</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1085</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1087</b>					
n (%)	1 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1089</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	3.00 [0.16; 57.37] 0.466	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1093</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.50 [0.04; 6.44] 0.595	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1095</b>					
n (%)	1 (20.0)	1 (33.3)	0.50 [0.02; 12.90] 0.676	0.60 [0.06; 6.44] 0.673	-0.13 [-0.77; 0.51] 0.682
<b>Center No. 1103</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1105</b>					
n (%)	1 (33.3)	1 (33.3)	1.00 [0.03; 29.81] 1.000	1.00 [0.10; 9.61] 1.000	0.00 [-0.75; 0.75] 1.000

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1108</b>					
n (%)	1 (6.7)	0 (0.0)	N.E.	2.06 [0.09; 46.12] 0.648	0.07 [-0.06; 0.19] 0.301
<b>Center No. 1110</b>					
n (%)	2 (33.3)	0 (0.0)	N.E.	4.29 [0.25; 72.90] 0.314	0.33 [-0.04; 0.71] 0.083
<b>Center No. 1113</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1115</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.39 [0.02; 7.88] 0.538	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1116</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1118</b>					
n (%)	1 (33.3)	1 (50.0)	0.50 [0.01; 19.56] 0.711	0.67 [0.08; 5.54] 0.707	-0.17 [-1.04; 0.71] 0.709
<b>Center No. 1119</b>					
n (%)	1 (33.3)	1 (20.0)	2.00 [0.08; 51.59] 0.676	1.67 [0.16; 17.89] 0.673	0.13 [-0.51; 0.77] 0.682
<b>Center No. 1124</b>					
n (%)	1 (33.3)	1 (50.0)	0.50 [0.01; 19.56] 0.711	0.67 [0.08; 5.54] 0.707	-0.17 [-1.04; 0.71] 0.709
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Nausea - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.16 [0.01; 2.99] 0.222	-0.25 [-0.55; 0.05] 0.102

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1003</b>					
n (%)	1 (50.0)	1 (33.3)	2.00 [0.05; 78.25] 0.711	1.50 [0.18; 12.46] 0.707	0.17 [-0.71; 1.04] 0.709
<b>Center No. 1005</b>					
n (%)	3 (9.7)	2 (9.1)	1.07 [0.16; 7.01] 0.943	1.06 [0.19; 5.85] 0.943	0.01 [-0.15; 0.16] 0.942
<b>Center No. 1007</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.44 [0.02; 9.11] 0.599	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1008</b>					
n (%)	1 (33.3)	2 (66.7)	0.25 [<0.01; 7.45] 0.424	0.50 [0.08; 2.99] 0.448	-0.33 [-1.09; 0.42] 0.386
<b>Center No. 1010</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	4.00 [0.24; 67.72] 0.337	0.50 [-0.19; 1.19] 0.157
<b>Center No. 1011</b>					
n (%)	1 (50.0)	1 (20.0)	4.00 [0.12; >99.99] 0.442	2.50 [0.27; 23.36] 0.422	0.30 [-0.48; 1.08] 0.449
<b>Center No. 1012</b>					
n (%)	2 (66.7)	3 (60.0)	1.33 [0.07; 26.62] 0.851	1.11 [0.38; 3.25] 0.847	0.07 [-0.62; 0.75] 0.849
<b>Center No. 1014</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.50 [0.13; 48.85] 0.546	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1015</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1017</b>					
n (%)	1 (20.0)	2 (50.0)	0.25 [0.01; 4.73] 0.355	0.40 [0.05; 2.98] 0.371	-0.30 [-0.90; 0.30] 0.329

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1021</b>					
n (%)	2 (12.5)	3 (30.0)	0.33 [0.04; 2.48] 0.283	0.42 [0.08; 2.07] 0.285	-0.18 [-0.50; 0.15] 0.294
<b>Center No. 1022</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1027</b>					
n (%)	1 (33.3)	2 (40.0)	0.75 [0.04; 14.97] 0.851	0.83 [0.12; 5.72] 0.853	-0.07 [-0.75; 0.62] 0.849
<b>Center No. 1028</b>					
n (%)	3 (27.3)	2 (40.0)	0.56 [0.06; 5.22] 0.613	0.68 [0.16; 2.89] 0.603	-0.13 [-0.63; 0.38] 0.620
<b>Center No. 1029</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.21 [0.01; 4.63] 0.322	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1030</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.28 [0.01; 6.10] 0.416	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1033</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1034</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	2.40 [0.13; 44.42] 0.557	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1035</b>					
n (%)	3 (11.1)	6 (27.3)	0.33 [0.07; 1.53] 0.158	0.41 [0.11; 1.45] 0.165	-0.16 [-0.38; 0.06] 0.151
<b>Center No. 1036</b>					
n (%)	0 (0.0)	3 (42.9)	N.E.	0.14 [0.01; 2.34] 0.173	-0.43 [-0.80; -0.06] 0.022

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1037</b>					
n (%)	1 (11.1)	3 (27.3)	0.33 [0.03; 3.93] 0.383	0.41 [0.05; 3.28] 0.399	-0.16 [-0.50; 0.17] 0.343
<b>Center No. 1040</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1042</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.24 [0.01; 3.93] 0.317	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1050</b>					
n (%)	1 (16.7)	2 (22.2)	0.70 [0.05; 10.01] 0.793	0.75 [0.09; 6.55] 0.795	-0.06 [-0.46; 0.35] 0.787
<b>Center No. 1052</b>					
n (%)	1 (14.3)	2 (50.0)	0.17 [<0.01; 2.98] 0.224	0.29 [0.04; 2.25] 0.234	-0.36 [-0.91; 0.20] 0.207
<b>Center No. 1059</b>					
n (%)	0 (0.0)	3 (42.9)	N.E.	0.14 [0.01; 2.34] 0.173	-0.43 [-0.80; -0.06] 0.022
<b>Center No. 1067</b>					
n (%)	0 (0.0)	2 (12.5)	N.E.	0.31 [0.02; 5.85] 0.434	-0.13 [-0.29; 0.04] 0.131
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1077</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1079</b>					
n (%)	1 (25.0)	1 (33.3)	0.67 [0.02; 18.06] 0.810	0.75 [0.07; 7.73] 0.809	-0.08 [-0.76; 0.60] 0.811
<b>Center No. 1080</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1085</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1087</b>					
n (%)	1 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1089</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	3.00 [0.16; 57.37] 0.466	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1093</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.50 [0.04; 6.44] 0.595	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1095</b>					
n (%)	1 (20.0)	1 (33.3)	0.50 [0.02; 12.90] 0.676	0.60 [0.06; 6.44] 0.673	-0.13 [-0.77; 0.51] 0.682
<b>Center No. 1103</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1105</b>					
n (%)	1 (33.3)	1 (33.3)	1.00 [0.03; 29.81] 1.000	1.00 [0.10; 9.61] 1.000	0.00 [-0.75; 0.75] 1.000
<b>Center No. 1108</b>					
n (%)	1 (6.7)	0 (0.0)	N.E.	2.06 [0.09; 46.12] 0.648	0.07 [-0.06; 0.19] 0.301
<b>Center No. 1110</b>					
n (%)	2 (33.3)	0 (0.0)	N.E.	4.29 [0.25; 72.90] 0.314	0.33 [-0.04; 0.71] 0.083
<b>Center No. 1113</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1115</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.39 [0.02; 7.88] 0.538	-0.17 [-0.46; 0.13] 0.273



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1116</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1118</b>					
n (%)	1 (33.3)	1 (50.0)	0.50 [0.01; 19.56] 0.711	0.67 [0.08; 5.54] 0.707	-0.17 [-1.04; 0.71] 0.709
<b>Center No. 1119</b>					
n (%)	1 (33.3)	1 (20.0)	2.00 [0.08; 51.59] 0.676	1.67 [0.16; 17.89] 0.673	0.13 [-0.51; 0.77] 0.682
<b>Center No. 1124</b>					
n (%)	1 (33.3)	1 (50.0)	0.50 [0.01; 19.56] 0.711	0.67 [0.08; 5.54] 0.707	-0.17 [-1.04; 0.71] 0.709
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Constipation</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	2 (20.0)	0 (0.0)	N.E.	4.09 [0.22; 74.78] 0.342	0.20 [-0.05; 0.45] 0.114
<b>Center No. 1002</b>					
n (%)	2 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	4.00 [0.24; 67.72] 0.337	0.50 [-0.19; 1.19] 0.157
<b>Center No. 1005</b>					
n (%)	2 (6.5)	0 (0.0)	N.E.	3.59 [0.18; 71.38] 0.402	0.06 [-0.02; 0.15] 0.144
<b>Center No. 1007</b>					
n (%)	1 (20.0)	2 (28.6)	0.63 [0.04; 9.65] 0.736	0.70 [0.09; 5.76] 0.740	-0.09 [-0.57; 0.40] 0.729

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1015</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	1.80 [0.10; 31.52] 0.687	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1018</b>					
n (%)	1 (14.3)	0 (0.0)	N.E.	2.63 [0.13; 54.64] 0.533	0.14 [-0.12; 0.40] 0.280
<b>Center No. 1021</b>					
n (%)	5 (31.3)	0 (0.0)	N.E.	7.12 [0.44; 116.35] 0.169	0.31 [0.09; 0.54] 0.007
<b>Center No. 1028</b>					
n (%)	3 (27.3)	0 (0.0)	N.E.	3.50 [0.21; 57.36] 0.380	0.27 [0.01; 0.54] 0.042
<b>Center No. 1029</b>					
n (%)	3 (20.0)	0 (0.0)	N.E.	4.38 [0.25; 76.09] 0.311	0.20 [-0.00; 0.40] 0.053
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1035</b>					
n (%)	5 (18.5)	1 (4.5)	4.77 [0.51; 44.33] 0.169	4.07 [0.51; 32.35] 0.184	0.14 [-0.03; 0.31] 0.108
<b>Center No. 1037</b>					
n (%)	2 (22.2)	1 (9.1)	2.86 [0.21; 37.99] 0.426	2.44 [0.26; 22.80] 0.433	0.13 [-0.19; 0.45] 0.422
<b>Center No. 1042</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	3.60 [0.18; 70.35] 0.398	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1050</b>					
n (%)	1 (16.7)	0 (0.0)	N.E.	4.29 [0.20; 90.63] 0.350	0.17 [-0.13; 0.46] 0.273

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1052</b>					
n (%)	1 (14.3)	1 (25.0)	0.50 [0.02; 11.09] 0.661	0.57 [0.05; 6.86] 0.659	-0.11 [-0.60; 0.39] 0.673
<b>Center No. 1059</b>					
n (%)	2 (28.6)	1 (14.3)	2.40 [0.16; 34.93] 0.522	2.00 [0.23; 17.34] 0.529	0.14 [-0.28; 0.57] 0.508
<b>Center No. 1061</b>					
n (%)	1 (11.1)	3 (50.0)	0.13 [<0.01; 1.72] 0.120	0.22 [0.03; 1.66] 0.143	-0.39 [-0.84; 0.06] 0.090
<b>Center No. 1063</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	1.80 [0.10; 31.52] 0.687	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1072</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	2.00 [0.14; 28.42] 0.609	0.50 [-0.19; 1.19] 0.157
<b>Center No. 1073</b>					
n (%)	2 (18.2)	0 (0.0)	N.E.	3.33 [0.18; 60.68] 0.416	0.18 [-0.05; 0.41] 0.118
<b>Center No. 1080</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	1.50 [0.10; 22.62] 0.770	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1082</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	4.50 [0.22; 93.08] 0.330	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1086</b>					
n (%)	2 (33.3)	0 (0.0)	N.E.	7.14 [0.40; 127.08] 0.181	0.33 [-0.04; 0.71] 0.083

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1091</b>					
n (%)	2 (33.3)	0 (0.0)	N.E.	4.29 [0.25; 72.90] 0.314	0.33 [-0.04; 0.71] 0.083
<b>Center No. 1105</b>					
n (%)	1 (33.3)	1 (33.3)	1.00 [0.03; 29.81] 1.000	1.00 [0.10; 9.61] 1.000	0.00 [-0.75; 0.75] 1.000
<b>Center No. 1108</b>					
n (%)	1 (6.7)	0 (0.0)	N.E.	2.06 [0.09; 46.12] 0.648	0.07 [-0.06; 0.19] 0.301
<b>Center No. 1111</b>					
n (%)	2 (40.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Constipation - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	2 (20.0)	0 (0.0)	N.E.	4.09 [0.22; 74.78] 0.342	0.20 [-0.05; 0.45] 0.114
<b>Center No. 1002</b>					
n (%)	2 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	4.00 [0.24; 67.72] 0.337	0.50 [-0.19; 1.19] 0.157
<b>Center No. 1005</b>					
n (%)	2 (6.5)	0 (0.0)	N.E.	3.59 [0.18; 71.38] 0.402	0.06 [-0.02; 0.15] 0.144
<b>Center No. 1007</b>					
n (%)	1 (20.0)	2 (28.6)	0.63 [0.04; 9.65] 0.736	0.70 [0.09; 5.76] 0.740	-0.09 [-0.57; 0.40] 0.729
<b>Center No. 1015</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	1.80 [0.10; 31.52] 0.687	0.25 [-0.17; 0.67] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1018</b>					
n (%)	1 (14.3)	0 (0.0)	N.E.	2.63 [0.13; 54.64] 0.533	0.14 [-0.12; 0.40] 0.280
<b>Center No. 1021</b>					
n (%)	5 (31.3)	0 (0.0)	N.E.	7.12 [0.44; 116.35] 0.169	0.31 [0.09; 0.54] 0.007
<b>Center No. 1028</b>					
n (%)	3 (27.3)	0 (0.0)	N.E.	3.50 [0.21; 57.36] 0.380	0.27 [0.01; 0.54] 0.042
<b>Center No. 1029</b>					
n (%)	3 (20.0)	0 (0.0)	N.E.	4.38 [0.25; 76.09] 0.311	0.20 [-0.00; 0.40] 0.053
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1035</b>					
n (%)	5 (18.5)	1 (4.5)	4.77 [0.51; 44.33] 0.169	4.07 [0.51; 32.35] 0.184	0.14 [-0.03; 0.31] 0.108
<b>Center No. 1037</b>					
n (%)	2 (22.2)	1 (9.1)	2.86 [0.21; 37.99] 0.426	2.44 [0.26; 22.80] 0.433	0.13 [-0.19; 0.45] 0.422
<b>Center No. 1042</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	3.60 [0.18; 70.35] 0.398	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1050</b>					
n (%)	1 (16.7)	0 (0.0)	N.E.	4.29 [0.20; 90.63] 0.350	0.17 [-0.13; 0.46] 0.273
<b>Center No. 1052</b>					
n (%)	1 (14.3)	1 (25.0)	0.50 [0.02; 11.09] 0.661	0.57 [0.05; 6.86] 0.659	-0.11 [-0.60; 0.39] 0.673

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1059</b>					
n (%)	2 (28.6)	1 (14.3)	2.40 [0.16; 34.93] 0.522	2.00 [0.23; 17.34] 0.529	0.14 [-0.28; 0.57] 0.508
<b>Center No. 1061</b>					
n (%)	1 (11.1)	3 (50.0)	0.13 [<0.01; 1.72] 0.120	0.22 [0.03; 1.66] 0.143	-0.39 [-0.84; 0.06] 0.090
<b>Center No. 1063</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	1.80 [0.10; 31.52] 0.687	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1072</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	2.00 [0.14; 28.42] 0.609	0.50 [-0.19; 1.19] 0.157
<b>Center No. 1073</b>					
n (%)	2 (18.2)	0 (0.0)	N.E.	3.33 [0.18; 60.68] 0.416	0.18 [-0.05; 0.41] 0.118
<b>Center No. 1080</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	1.50 [0.10; 22.62] 0.770	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1082</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	4.50 [0.22; 93.08] 0.330	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1086</b>					
n (%)	2 (33.3)	0 (0.0)	N.E.	7.14 [0.40; 127.08] 0.181	0.33 [-0.04; 0.71] 0.083
<b>Center No. 1091</b>					
n (%)	2 (33.3)	0 (0.0)	N.E.	4.29 [0.25; 72.90] 0.314	0.33 [-0.04; 0.71] 0.083

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1105</b>					
n (%)	1 (33.3)	1 (33.3)	1.00 [0.03; 29.81] 1.000	1.00 [0.10; 9.61] 1.000	0.00 [-0.75; 0.75] 1.000
<b>Center No. 1108</b>					
n (%)	1 (6.7)	0 (0.0)	N.E.	2.06 [0.09; 46.12] 0.648	0.07 [-0.06; 0.19] 0.301
<b>Center No. 1111</b>					
n (%)	2 (40.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Dry mouth</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1005</b>					
n (%)	1 (3.2)	1 (4.5)	0.70 [0.04; 11.83] 0.805	0.71 [0.05; 10.75] 0.805	-0.01 [-0.12; 0.09] 0.809
<b>Center No. 1007</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.44 [0.02; 9.11] 0.599	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1010</b>					
n (%)	1 (50.0)	1 (33.3)	2.00 [0.05; 78.25] 0.711	1.50 [0.18; 12.46] 0.707	0.17 [-0.71; 1.04] 0.709
<b>Center No. 1015</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	1.80 [0.10; 31.52] 0.687	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1021</b>					
n (%)	1 (6.3)	0 (0.0)	N.E.	1.94 [0.09; 43.50] 0.676	0.06 [-0.06; 0.18] 0.302
<b>Center No. 1028</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.17 [0.01; 3.51] 0.249	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1033</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.28 [0.02; 4.66] 0.375	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1036</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1042</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.40 [0.02; 7.82] 0.546	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1061</b>					
n (%)	1 (11.1)	0 (0.0)	N.E.	2.10 [0.10; 44.41] 0.634	0.11 [-0.09; 0.32] 0.289
<b>Center No. 1067</b>					
n (%)	0 (0.0)	1 (6.3)	N.E.	0.52 [0.02; 11.54] 0.676	-0.06 [-0.18; 0.06] 0.302
<b>Center No. 1068</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1073</b>					
n (%)	1 (9.1)	1 (14.3)	0.60 [0.03; 11.47] 0.734	0.64 [0.05; 8.61] 0.734	-0.05 [-0.36; 0.26] 0.743
<b>Center No. 1074</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.22 [0.01; 4.20] 0.316	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1076</b>					
n (%)	1 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1080</b>					
n (%)	1 (33.3)	1 (100.0)	N.E.	0.33 [0.07; 1.65] 0.178	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1091</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1105</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1119</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.30 [0.02; 4.74] 0.393	-0.40 [-0.83; 0.03] 0.068
<i>Psychiatric disorders</i>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	2 (20.0)	4 (50.0)	0.25 [0.03; 2.00] 0.191	0.40 [0.10; 1.66] 0.206	-0.30 [-0.73; 0.13] 0.168
<b>Center No. 1002</b>					
n (%)	2 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	1 (50.0)	1 (33.3)	2.00 [0.05; 78.25] 0.711	1.50 [0.18; 12.46] 0.707	0.17 [-0.71; 1.04] 0.709
<b>Center No. 1005</b>					
n (%)	10 (32.3)	2 (9.1)	4.76 [0.93; 24.48] 0.062	3.55 [0.86; 14.63] 0.080	0.23 [0.03; 0.44] 0.026
<b>Center No. 1007</b>					
n (%)	3 (60.0)	2 (28.6)	3.75 [0.33; 42.47] 0.286	2.10 [0.53; 8.29] 0.289	0.31 [-0.23; 0.86] 0.258
<b>Center No. 1008</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1010</b>					
n (%)	1 (50.0)	1 (33.3)	2.00 [0.05; 78.25] 0.711	1.50 [0.18; 12.46] 0.707	0.17 [-0.71; 1.04] 0.709

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1011</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.40 [0.03; 5.96] 0.506	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1014</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1017</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.17 [0.01; 2.73] 0.209	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1021</b>					
n (%)	4 (25.0)	3 (30.0)	0.78 [0.13; 4.54] 0.780	0.83 [0.23; 2.97] 0.779	-0.05 [-0.40; 0.30] 0.782
<b>Center No. 1022</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1027</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.30 [0.02; 4.74] 0.393	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1028</b>					
n (%)	3 (27.3)	2 (40.0)	0.56 [0.06; 5.22] 0.613	0.68 [0.16; 2.89] 0.603	-0.13 [-0.63; 0.38] 0.620
<b>Center No. 1030</b>					
n (%)	3 (27.3)	2 (22.2)	1.31 [0.17; 10.26] 0.796	1.23 [0.26; 5.82] 0.797	0.05 [-0.33; 0.43] 0.794
<b>Center No. 1032</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.33 [0.02; 4.85] 0.421	-0.50 [-0.99; -0.01] 0.046

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1033</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1034</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1035</b>					
n (%)	9 (33.3)	9 (40.9)	0.72 [0.22; 2.32] 0.585	0.81 [0.39; 1.70] 0.584	-0.08 [-0.35; 0.20] 0.585
<b>Center No. 1036</b>					
n (%)	0 (0.0)	4 (57.1)	N.E.	0.11 [0.01; 1.74] 0.118	-0.57 [-0.94; -0.20] 0.002
<b>Center No. 1037</b>					
n (%)	5 (55.6)	6 (54.5)	1.04 [0.18; 6.12] 0.964	1.02 [0.46; 2.26] 0.964	0.01 [-0.43; 0.45] 0.964
<b>Center No. 1040</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1041</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.20 [0.01; 3.35] 0.263	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1042</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.40 [0.02; 7.82] 0.546	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1044</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1046</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1048</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	3 (50.0)	3 (33.3)	2.00 [0.24; 16.61] 0.521	1.50 [0.44; 5.09] 0.516	0.17 [-0.34; 0.67] 0.518

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1052</b>					
n (%)	2 (28.6)	2 (50.0)	0.40 [0.03; 5.15] 0.482	0.57 [0.12; 2.63] 0.473	-0.21 [-0.81; 0.38] 0.479
<b>Center No. 1055</b>					
n (%)	1 (50.0)	1 (25.0)	3.00 [0.08; >99.99] 0.547	2.00 [0.22; 17.89] 0.535	0.25 [-0.56; 1.06] 0.546
<b>Center No. 1059</b>					
n (%)	1 (14.3)	3 (42.9)	0.22 [0.02; 2.97] 0.256	0.33 [0.04; 2.48] 0.283	-0.29 [-0.73; 0.16] 0.212
<b>Center No. 1063</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	1.80 [0.10; 31.52] 0.687	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1067</b>					
n (%)	0 (0.0)	2 (12.5)	N.E.	0.31 [0.02; 5.85] 0.434	-0.13 [-0.29; 0.04] 0.131
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1070</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.43 [0.04; 5.19] 0.505	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1072</b>					
n (%)	1 (50.0)	1 (100.0)	N.E.	0.50 [0.13; 2.00] 0.327	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1073</b>					
n (%)	1 (9.1)	2 (28.6)	0.25 [0.02; 3.47] 0.301	0.32 [0.04; 2.89] 0.309	-0.19 [-0.57; 0.18] 0.309
<b>Center No. 1074</b>					
n (%)	1 (20.0)	1 (33.3)	0.50 [0.02; 12.90] 0.676	0.60 [0.06; 6.44] 0.673	-0.13 [-0.77; 0.51] 0.682

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1076</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1079</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1080</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1082</b>					
n (%)	1 (20.0)	4 (50.0)	0.25 [0.02; 3.34] 0.295	0.40 [0.06; 2.63] 0.341	-0.30 [-0.79; 0.19] 0.233
<b>Center No. 1084</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1086</b>					
n (%)	1 (16.7)	4 (44.4)	0.25 [0.02; 3.10] 0.280	0.38 [0.05; 2.59] 0.320	-0.28 [-0.72; 0.16] 0.217
<b>Center No. 1087</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1089</b>					
n (%)	1 (25.0)	1 (25.0)	1.00 [0.04; 24.55] 1.000	1.00 [0.09; 11.03] 1.000	0.00 [-0.60; 0.60] 1.000
<b>Center No. 1091</b>					
n (%)	1 (16.7)	1 (20.0)	0.80 [0.04; 17.20] 0.887	0.83 [0.07; 10.20] 0.887	-0.03 [-0.49; 0.43] 0.887
<b>Center No. 1093</b>					
n (%)	1 (100.0)	1 (25.0)	N.E.	4.00 [0.73; 21.84] 0.109	0.75 [0.33; 1.17] <.001
<b>Center No. 1095</b>					
n (%)	2 (40.0)	2 (66.7)	0.33 [0.02; 6.65] 0.472	0.60 [0.16; 2.29] 0.455	-0.27 [-0.95; 0.42] 0.445

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1096</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1100</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1103</b>					
n (%)	1 (50.0)	1 (33.3)	2.00 [0.05; 78.25] 0.711	1.50 [0.18; 12.46] 0.707	0.17 [-0.71; 1.04] 0.709
<b>Center No. 1108</b>					
n (%)	2 (13.3)	1 (10.0)	1.38 [0.11; 17.67] 0.802	1.33 [0.14; 12.82] 0.803	0.03 [-0.22; 0.29] 0.796
<b>Center No. 1110</b>					
n (%)	2 (33.3)	0 (0.0)	N.E.	4.29 [0.25; 72.90] 0.314	0.33 [-0.04; 0.71] 0.083
<b>Center No. 1111</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1113</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	3.00 [0.17; 53.71] 0.455	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1115</b>					
n (%)	2 (40.0)	4 (66.7)	0.33 [0.03; 3.93] 0.383	0.60 [0.18; 2.02] 0.409	-0.27 [-0.84; 0.30] 0.360
<b>Center No. 1118</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1119</b>					
n (%)	0 (0.0)	4 (80.0)	N.E.	0.17 [0.01; 2.32] 0.182	-0.80 [-1.15; -0.45] <.001

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1121</b>					
n (%)	1 (25.0)	2 (50.0)	0.33 [0.02; 6.65] 0.472	0.50 [0.07; 3.55] 0.488	-0.25 [-0.90; 0.40] 0.450
<b>Center No. 1124</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1502</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<i>Psychiatric disorders - non-severe</i>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	2 (20.0)	4 (50.0)	0.25 [0.03; 2.00] 0.191	0.40 [0.10; 1.66] 0.206	-0.30 [-0.73; 0.13] 0.168
<b>Center No. 1002</b>					
n (%)	2 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	4.00 [0.24; 67.72] 0.337	0.50 [-0.19; 1.19] 0.157
<b>Center No. 1005</b>					
n (%)	10 (32.3)	2 (9.1)	4.76 [0.93; 24.48] 0.062	3.55 [0.86; 14.63] 0.080	0.23 [0.03; 0.44] 0.026
<b>Center No. 1007</b>					
n (%)	3 (60.0)	2 (28.6)	3.75 [0.33; 42.47] 0.286	2.10 [0.53; 8.29] 0.289	0.31 [-0.23; 0.86] 0.258
<b>Center No. 1008</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1010</b>					
n (%)	1 (50.0)	1 (33.3)	2.00 [0.05; 78.25] 0.711	1.50 [0.18; 12.46] 0.707	0.17 [-0.71; 1.04] 0.709

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1011</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.40 [0.03; 5.96] 0.506	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1014</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1017</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.17 [0.01; 2.73] 0.209	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1021</b>					
n (%)	4 (25.0)	3 (30.0)	0.78 [0.13; 4.54] 0.780	0.83 [0.23; 2.97] 0.779	-0.05 [-0.40; 0.30] 0.782
<b>Center No. 1022</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1027</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.30 [0.02; 4.74] 0.393	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1028</b>					
n (%)	3 (27.3)	2 (40.0)	0.56 [0.06; 5.22] 0.613	0.68 [0.16; 2.89] 0.603	-0.13 [-0.63; 0.38] 0.620
<b>Center No. 1030</b>					
n (%)	3 (27.3)	2 (22.2)	1.31 [0.17; 10.26] 0.796	1.23 [0.26; 5.82] 0.797	0.05 [-0.33; 0.43] 0.794
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1034</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1035</b>					
n (%)	9 (33.3)	9 (40.9)	0.72 [0.22; 2.32] 0.585	0.81 [0.39; 1.70] 0.584	-0.08 [-0.35; 0.20] 0.585
<b>Center No. 1036</b>					
n (%)	0 (0.0)	4 (57.1)	N.E.	0.11 [0.01; 1.74] 0.118	-0.57 [-0.94; -0.20] 0.002
<b>Center No. 1037</b>					
n (%)	5 (55.6)	6 (54.5)	1.04 [0.18; 6.12] 0.964	1.02 [0.46; 2.26] 0.964	0.01 [-0.43; 0.45] 0.964
<b>Center No. 1040</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1041</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.20 [0.01; 3.35] 0.263	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1042</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.40 [0.02; 7.82] 0.546	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1044</b>					
n (%)	0 (0.0)	2 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1046</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1048</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	3 (50.0)	3 (33.3)	2.00 [0.24; 16.61] 0.521	1.50 [0.44; 5.09] 0.516	0.17 [-0.34; 0.67] 0.518
<b>Center No. 1052</b>					
n (%)	2 (28.6)	2 (50.0)	0.40 [0.03; 5.15] 0.482	0.57 [0.12; 2.63] 0.473	-0.21 [-0.81; 0.38] 0.479

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1055</b>					
n (%)	1 (50.0)	1 (25.0)	3.00 [0.08; >99.99] 0.547	2.00 [0.22; 17.89] 0.535	0.25 [-0.56; 1.06] 0.546
<b>Center No. 1059</b>					
n (%)	0 (0.0)	3 (42.9)	N.E.	0.14 [0.01; 2.34] 0.173	-0.43 [-0.80; -0.06] 0.022
<b>Center No. 1063</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	1.80 [0.10; 31.52] 0.687	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1067</b>					
n (%)	0 (0.0)	2 (12.5)	N.E.	0.31 [0.02; 5.85] 0.434	-0.13 [-0.29; 0.04] 0.131
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1070</b>					
n (%)	0 (0.0)	3 (60.0)	N.E.	0.43 [0.04; 5.19] 0.505	-0.60 [-1.03; -0.17] 0.006
<b>Center No. 1072</b>					
n (%)	1 (50.0)	1 (100.0)	N.E.	0.50 [0.13; 2.00] 0.327	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1073</b>					
n (%)	1 (9.1)	2 (28.6)	0.25 [0.02; 3.47] 0.301	0.32 [0.04; 2.89] 0.309	-0.19 [-0.57; 0.18] 0.309
<b>Center No. 1074</b>					
n (%)	1 (20.0)	1 (33.3)	0.50 [0.02; 12.90] 0.676	0.60 [0.06; 6.44] 0.673	-0.13 [-0.77; 0.51] 0.682
<b>Center No. 1076</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1079</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1080</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1082</b>					
n (%)	1 (20.0)	4 (50.0)	0.25 [0.02; 3.34] 0.295	0.40 [0.06; 2.63] 0.341	-0.30 [-0.79; 0.19] 0.233
<b>Center No. 1084</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1086</b>					
n (%)	1 (16.7)	4 (44.4)	0.25 [0.02; 3.10] 0.280	0.38 [0.05; 2.59] 0.320	-0.28 [-0.72; 0.16] 0.217
<b>Center No. 1087</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1089</b>					
n (%)	1 (25.0)	1 (25.0)	1.00 [0.04; 24.55] 1.000	1.00 [0.09; 11.03] 1.000	0.00 [-0.60; 0.60] 1.000
<b>Center No. 1091</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1093</b>					
n (%)	1 (100.0)	1 (25.0)	N.E.	4.00 [0.73; 21.84] 0.109	0.75 [0.33; 1.17] <.001
<b>Center No. 1095</b>					
n (%)	2 (40.0)	2 (66.7)	0.33 [0.02; 6.65] 0.472	0.60 [0.16; 2.29] 0.455	-0.27 [-0.95; 0.42] 0.445
<b>Center No. 1096</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1100</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1103</b>					
n (%)	1 (50.0)	1 (33.3)	2.00 [0.05; 78.25] 0.711	1.50 [0.18; 12.46] 0.707	0.17 [-0.71; 1.04] 0.709
<b>Center No. 1108</b>					
n (%)	2 (13.3)	1 (10.0)	1.38 [0.11; 17.67] 0.802	1.33 [0.14; 12.82] 0.803	0.03 [-0.22; 0.29] 0.796
<b>Center No. 1110</b>					
n (%)	2 (33.3)	0 (0.0)	N.E.	4.29 [0.25; 72.90] 0.314	0.33 [-0.04; 0.71] 0.083
<b>Center No. 1111</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1113</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	3.00 [0.17; 53.71] 0.455	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1115</b>					
n (%)	2 (40.0)	4 (66.7)	0.33 [0.03; 3.93] 0.383	0.60 [0.18; 2.02] 0.409	-0.27 [-0.84; 0.30] 0.360
<b>Center No. 1118</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1119</b>					
n (%)	0 (0.0)	4 (80.0)	N.E.	0.17 [0.01; 2.32] 0.182	-0.80 [-1.15; -0.45] <.001
<b>Center No. 1121</b>					
n (%)	1 (25.0)	2 (50.0)	0.33 [0.02; 6.65] 0.472	0.50 [0.07; 3.55] 0.488	-0.25 [-0.90; 0.40] 0.450

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1124</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1502</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Sleep disorder</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	2 (20.0)	1 (12.5)	1.75 [0.13; 23.70] 0.674	1.60 [0.17; 14.63] 0.677	0.08 [-0.26; 0.41] 0.663
<b>Center No. 1005</b>					
n (%)	3 (9.7)	0 (0.0)	N.E.	5.03 [0.27; 92.76] 0.277	0.10 [-0.01; 0.20] 0.068
<b>Center No. 1028</b>					
n (%)	2 (18.2)	0 (0.0)	N.E.	2.50 [0.14; 44.27] 0.532	0.18 [-0.05; 0.41] 0.118
<b>Center No. 1035</b>					
n (%)	7 (25.9)	2 (9.1)	3.50 [0.65; 18.95] 0.146	2.85 [0.66; 12.37] 0.162	0.17 [-0.04; 0.37] 0.106
<b>Center No. 1037</b>					
n (%)	2 (22.2)	3 (27.3)	0.76 [0.10; 5.96] 0.796	0.81 [0.17; 3.87] 0.797	-0.05 [-0.43; 0.33] 0.794
<b>Center No. 1052</b>					
n (%)	1 (14.3)	0 (0.0)	N.E.	1.88 [0.09; 37.63] 0.681	0.14 [-0.12; 0.40] 0.280
<b>Center No. 1063</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	1.80 [0.10; 31.52] 0.687	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1074</b>					
n (%)	1 (20.0)	1 (33.3)	0.50 [0.02; 12.90] 0.676	0.60 [0.06; 6.44] 0.673	-0.13 [-0.77; 0.51] 0.682

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1096</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1118</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157
<b>Sleep disorder - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	2 (20.0)	1 (12.5)	1.75 [0.13; 23.70] 0.674	1.60 [0.17; 14.63] 0.677	0.08 [-0.26; 0.41] 0.663
<b>Center No. 1005</b>					
n (%)	3 (9.7)	0 (0.0)	N.E.	5.03 [0.27; 92.76] 0.277	0.10 [-0.01; 0.20] 0.068
<b>Center No. 1028</b>					
n (%)	2 (18.2)	0 (0.0)	N.E.	2.50 [0.14; 44.27] 0.532	0.18 [-0.05; 0.41] 0.118
<b>Center No. 1035</b>					
n (%)	7 (25.9)	2 (9.1)	3.50 [0.65; 18.95] 0.146	2.85 [0.66; 12.37] 0.162	0.17 [-0.04; 0.37] 0.106
<b>Center No. 1037</b>					
n (%)	2 (22.2)	3 (27.3)	0.76 [0.10; 5.96] 0.796	0.81 [0.17; 3.87] 0.797	-0.05 [-0.43; 0.33] 0.794
<b>Center No. 1052</b>					
n (%)	1 (14.3)	0 (0.0)	N.E.	1.88 [0.09; 37.63] 0.681	0.14 [-0.12; 0.40] 0.280
<b>Center No. 1063</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	1.80 [0.10; 31.52] 0.687	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1074</b>					
n (%)	1 (20.0)	1 (33.3)	0.50 [0.02; 12.90] 0.676	0.60 [0.06; 6.44] 0.673	-0.13 [-0.77; 0.51] 0.682

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1096</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1118</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157
<b>Irritability</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	3 (37.5)	N.E.	0.12 [0.01; 1.98] 0.137	-0.38 [-0.71; -0.04] 0.028
<b>Center No. 1021</b>					
n (%)	2 (12.5)	3 (30.0)	0.33 [0.04; 2.48] 0.283	0.42 [0.08; 2.07] 0.285	-0.18 [-0.50; 0.15] 0.294
<b>Center No. 1030</b>					
n (%)	1 (9.1)	0 (0.0)	N.E.	2.50 [0.11; 54.87] 0.561	0.09 [-0.08; 0.26] 0.294
<b>Center No. 1035</b>					
n (%)	0 (0.0)	2 (9.1)	N.E.	0.16 [0.01; 3.25] 0.236	-0.09 [-0.21; 0.03] 0.138
<b>Center No. 1036</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.20 [0.01; 3.54] 0.272	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1037</b>					
n (%)	1 (11.1)	1 (9.1)	1.25 [0.07; 23.26] 0.881	1.22 [0.09; 16.93] 0.881	0.02 [-0.25; 0.29] 0.882
<b>Center No. 1052</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.21 [0.01; 4.18] 0.305	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1059</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.20 [0.01; 3.54] 0.272	-0.29 [-0.62; 0.05] 0.094

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1070</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1082</b>					
n (%)	0 (0.0)	1 (12.5)	N.E.	0.50 [0.02; 10.34] 0.654	-0.13 [-0.35; 0.10] 0.285
<b>Center No. 1095</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.00 [0.11; 37.83] 0.644	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1115</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.39 [0.02; 7.88] 0.538	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1124</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Irritability - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	3 (37.5)	N.E.	0.12 [0.01; 1.98] 0.137	-0.38 [-0.71; -0.04] 0.028
<b>Center No. 1021</b>					
n (%)	2 (12.5)	3 (30.0)	0.33 [0.04; 2.48] 0.283	0.42 [0.08; 2.07] 0.285	-0.18 [-0.50; 0.15] 0.294
<b>Center No. 1030</b>					
n (%)	1 (9.1)	0 (0.0)	N.E.	2.50 [0.11; 54.87] 0.561	0.09 [-0.08; 0.26] 0.294
<b>Center No. 1035</b>					
n (%)	0 (0.0)	2 (9.1)	N.E.	0.16 [0.01; 3.25] 0.236	-0.09 [-0.21; 0.03] 0.138



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1036</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.20 [0.01; 3.54] 0.272	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1037</b>					
n (%)	1 (11.1)	1 (9.1)	1.25 [0.07; 23.26] 0.881	1.22 [0.09; 16.93] 0.881	0.02 [-0.25; 0.29] 0.882
<b>Center No. 1052</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.21 [0.01; 4.18] 0.305	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1059</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.20 [0.01; 3.54] 0.272	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1070</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1082</b>					
n (%)	0 (0.0)	1 (12.5)	N.E.	0.50 [0.02; 10.34] 0.654	-0.13 [-0.35; 0.10] 0.285
<b>Center No. 1095</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.00 [0.11; 37.83] 0.644	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1115</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.39 [0.02; 7.88] 0.538	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1124</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.25 [0.01; 4.23] 0.337	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Depressed mood</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	1 (12.5)	N.E.	0.27 [0.01; 5.92] 0.408	-0.13 [-0.35; 0.10] 0.285
<b>Center No. 1003</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1007</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	4.00 [0.20; 82.01] 0.368	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1011</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.40 [0.03; 5.96] 0.506	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1021</b>					
n (%)	0 (0.0)	1 (10.0)	N.E.	0.22 [0.01; 4.83] 0.334	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
n (%)	1 (9.1)	1 (20.0)	0.40 [0.02; 8.07] 0.550	0.45 [0.04; 5.89] 0.546	-0.11 [-0.50; 0.28] 0.583
<b>Center No. 1041</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.33 [0.02; 6.65] 0.472	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1044</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	0 (0.0)	1 (6.3)	N.E.	0.52 [0.02; 11.54] 0.676	-0.06 [-0.18; 0.06] 0.302

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1115</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.23 [0.01; 3.97] 0.314	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1119</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Depressed mood - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	1 (12.5)	N.E.	0.27 [0.01; 5.92] 0.408	-0.13 [-0.35; 0.10] 0.285
<b>Center No. 1007</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	4.00 [0.20; 82.01] 0.368	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1011</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.40 [0.03; 5.96] 0.506	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1021</b>					
n (%)	0 (0.0)	1 (10.0)	N.E.	0.22 [0.01; 4.83] 0.334	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
n (%)	1 (9.1)	1 (20.0)	0.40 [0.02; 8.07] 0.550	0.45 [0.04; 5.89] 0.546	-0.11 [-0.50; 0.28] 0.583

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1041</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.33 [0.02; 6.65] 0.472	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1044</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	0 (0.0)	1 (6.3)	N.E.	0.52 [0.02; 11.54] 0.676	-0.06 [-0.18; 0.06] 0.302
<b>Center No. 1115</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.23 [0.01; 3.97] 0.314	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1119</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1502</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>General disorders and administration site conditions</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	4 (40.0)	2 (25.0)	2.00 [0.26; 15.38] 0.506	1.60 [0.39; 6.62] 0.517	0.15 [-0.28; 0.58] 0.491
<b>Center No. 1003</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1005</b>					
n (%)	9 (29.0)	8 (36.4)	0.72 [0.22; 2.29] 0.574	0.80 [0.37; 1.74] 0.572	-0.07 [-0.33; 0.18] 0.576

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1007</b>					
n (%)	1 (20.0)	2 (28.6)	0.63 [0.04; 9.65] 0.736	0.70 [0.09; 5.76] 0.740	-0.09 [-0.57; 0.40] 0.729
<b>Center No. 1008</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1010</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.27 [0.02; 3.74] 0.327	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1011</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.40 [0.03; 5.96] 0.506	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1012</b>					
n (%)	2 (66.7)	1 (20.0)	8.00 [0.31; >99.99] 0.210	3.33 [0.49; 22.90] 0.221	0.47 [-0.17; 1.11] 0.152
<b>Center No. 1014</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.17 [0.01; 2.73] 0.209	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1015</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1017</b>					
n (%)	2 (40.0)	1 (25.0)	2.00 [0.11; 35.80] 0.638	1.60 [0.21; 11.92] 0.646	0.15 [-0.45; 0.75] 0.626
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1021</b>					
n (%)	6 (37.5)	2 (20.0)	2.40 [0.38; 15.28] 0.354	1.88 [0.47; 7.54] 0.376	0.18 [-0.17; 0.52] 0.317

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1022</b>					
n (%)	2 (66.7)	2 (66.7)	1.00 [0.03; 29.81] 1.000	1.00 [0.32; 3.10] 1.000	0.00 [-0.75; 0.75] 1.000
<b>Center No. 1027</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.30 [0.02; 4.74] 0.393	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1028</b>					
n (%)	2 (18.2)	0 (0.0)	N.E.	2.50 [0.14; 44.27] 0.532	0.18 [-0.05; 0.41] 0.118
<b>Center No. 1029</b>					
n (%)	3 (20.0)	1 (11.1)	2.00 [0.18; 22.80] 0.577	1.80 [0.22; 14.80] 0.585	0.09 [-0.20; 0.38] 0.546
<b>Center No. 1030</b>					
n (%)	3 (27.3)	3 (33.3)	0.75 [0.11; 5.11] 0.769	0.82 [0.22; 3.11] 0.768	-0.06 [-0.47; 0.34] 0.769
<b>Center No. 1032</b>					
n (%)	1 (50.0)	1 (25.0)	3.00 [0.08; >99.99] 0.547	2.00 [0.22; 17.89] 0.535	0.25 [-0.56; 1.06] 0.546
<b>Center No. 1034</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	2.40 [0.13; 44.42] 0.557	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1035</b>					
n (%)	3 (11.1)	9 (40.9)	0.18 [0.04; 0.79] 0.023	0.27 [0.08; 0.88] 0.030	-0.30 [-0.54; -0.06] 0.014
<b>Center No. 1036</b>					
n (%)	1 (14.3)	3 (42.9)	0.22 [0.02; 2.97] 0.256	0.33 [0.04; 2.48] 0.283	-0.29 [-0.73; 0.16] 0.212
<b>Center No. 1037</b>					
n (%)	3 (33.3)	1 (9.1)	5.00 [0.42; 59.64] 0.203	3.67 [0.46; 29.49] 0.222	0.24 [-0.11; 0.59] 0.177

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1039</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1040</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1042</b>					
n (%)	1 (25.0)	3 (60.0)	0.22 [0.01; 3.98] 0.307	0.42 [0.07; 2.63] 0.352	-0.35 [-0.95; 0.25] 0.256
<b>Center No. 1044</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1046</b>					
n (%)	1 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1048</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	3 (50.0)	4 (44.4)	1.25 [0.16; 9.92] 0.833	1.13 [0.38; 3.32] 0.831	0.06 [-0.46; 0.57] 0.833
<b>Center No. 1052</b>					
n (%)	1 (14.3)	3 (75.0)	0.06 [<0.01; 1.23] 0.068	0.19 [0.03; 1.27] 0.087	-0.61 [-1.10; -0.11] 0.017
<b>Center No. 1059</b>					
n (%)	3 (42.9)	4 (57.1)	0.56 [0.07; 4.67] 0.594	0.75 [0.26; 2.18] 0.598	-0.14 [-0.66; 0.38] 0.589
<b>Center No. 1061</b>					
n (%)	2 (22.2)	0 (0.0)	N.E.	3.50 [0.20; 62.27] 0.394	0.22 [-0.05; 0.49] 0.109
<b>Center No. 1063</b>					
n (%)	1 (25.0)	1 (50.0)	0.33 [<0.01; 11.94] 0.547	0.50 [0.06; 4.47] 0.535	-0.25 [-1.06; 0.56] 0.546
<b>Center No. 1067</b>					
n (%)	3 (30.0)	3 (18.8)	1.86 [0.29; 11.76] 0.511	1.60 [0.40; 6.43] 0.508	0.11 [-0.23; 0.45] 0.520

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1068</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1069</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.25 [0.02; 3.86] 0.321	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1070</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1073</b>					
n (%)	4 (36.4)	0 (0.0)	N.E.	6.00 [0.37; 96.86] 0.207	0.36 [0.08; 0.65] 0.012
<b>Center No. 1079</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.16 [0.01; 2.47] 0.189	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1080</b>					
n (%)	2 (66.7)	1 (100.0)	N.E.	0.67 [0.30; 1.48] 0.321	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1082</b>					
n (%)	0 (0.0)	4 (50.0)	N.E.	0.17 [0.01; 2.56] 0.199	-0.50 [-0.85; -0.15] 0.005
<b>Center No. 1085</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1086</b>					
n (%)	3 (50.0)	5 (55.6)	0.80 [0.10; 6.35] 0.833	0.90 [0.33; 2.42] 0.835	-0.06 [-0.57; 0.46] 0.833
<b>Center No. 1087</b>					
n (%)	1 (100.0)	2 (50.0)	N.E.	2.00 [0.75; 5.33] 0.166	0.50 [0.01; 0.99] 0.046
<b>Center No. 1088</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.33 [0.02; 6.86] 0.476	-0.17 [-0.46; 0.13] 0.273



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1089</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	3.00 [0.16; 57.37] 0.466	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1093</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1095</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.00 [0.11; 37.83] 0.644	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1100</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.50 [0.04; 6.44] 0.595	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1103</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.27 [0.02; 3.74] 0.327	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1110</b>					
n (%)	2 (33.3)	0 (0.0)	N.E.	4.29 [0.25; 72.90] 0.314	0.33 [-0.04; 0.71] 0.083
<b>Center No. 1113</b>					
n (%)	2 (66.7)	0 (0.0)	N.E.	5.00 [0.34; 74.52] 0.243	0.67 [0.13; 1.20] 0.014
<b>Center No. 1115</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.39 [0.02; 7.88] 0.538	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1118</b>					
n (%)	2 (66.7)	0 (0.0)	N.E.	3.75 [0.27; 52.64] 0.327	0.67 [0.13; 1.20] 0.014
<b>Center No. 1123</b>					
n (%)	1 (100.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1502</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<i>General disorders and administration site conditions - non-severe</i>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	4 (40.0)	2 (25.0)	2.00 [0.26; 15.38] 0.506	1.60 [0.39; 6.62] 0.517	0.15 [-0.28; 0.58] 0.491
<b>Center No. 1003</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1005</b>					
n (%)	9 (29.0)	8 (36.4)	0.72 [0.22; 2.29] 0.574	0.80 [0.37; 1.74] 0.572	-0.07 [-0.33; 0.18] 0.576
<b>Center No. 1007</b>					
n (%)	1 (20.0)	2 (28.6)	0.63 [0.04; 9.65] 0.736	0.70 [0.09; 5.76] 0.740	-0.09 [-0.57; 0.40] 0.729
<b>Center No. 1008</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1010</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.27 [0.02; 3.74] 0.327	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1011</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.40 [0.03; 5.96] 0.506	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1012</b>					
n (%)	2 (66.7)	1 (20.0)	8.00 [0.31; >99.99] 0.210	3.33 [0.49; 22.90] 0.221	0.47 [-0.17; 1.11] 0.152
<b>Center No. 1014</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.17 [0.01; 2.73] 0.209	-0.50 [-0.99; -0.01] 0.046

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1015</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1017</b>					
n (%)	2 (40.0)	1 (25.0)	2.00 [0.11; 35.80] 0.638	1.60 [0.21; 11.92] 0.646	0.15 [-0.45; 0.75] 0.626
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1021</b>					
n (%)	6 (37.5)	2 (20.0)	2.40 [0.38; 15.28] 0.354	1.88 [0.47; 7.54] 0.376	0.18 [-0.17; 0.52] 0.317
<b>Center No. 1022</b>					
n (%)	1 (33.3)	2 (66.7)	0.25 [<0.01; 7.45] 0.424	0.50 [0.08; 2.99] 0.448	-0.33 [-1.09; 0.42] 0.386
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
n (%)	2 (18.2)	0 (0.0)	N.E.	2.50 [0.14; 44.27] 0.532	0.18 [-0.05; 0.41] 0.118
<b>Center No. 1029</b>					
n (%)	1 (6.7)	0 (0.0)	N.E.	1.88 [0.08; 41.69] 0.691	0.07 [-0.06; 0.19] 0.301
<b>Center No. 1030</b>					
n (%)	3 (27.3)	3 (33.3)	0.75 [0.11; 5.11] 0.769	0.82 [0.22; 3.11] 0.768	-0.06 [-0.47; 0.34] 0.769
<b>Center No. 1032</b>					
n (%)	1 (50.0)	1 (25.0)	3.00 [0.08; >99.99] 0.547	2.00 [0.22; 17.89] 0.535	0.25 [-0.56; 1.06] 0.546

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1034</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	2.40 [0.13; 44.42] 0.557	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1035</b>					
n (%)	3 (11.1)	6 (27.3)	0.33 [0.07; 1.53] 0.158	0.41 [0.11; 1.45] 0.165	-0.16 [-0.38; 0.06] 0.151
<b>Center No. 1036</b>					
n (%)	1 (14.3)	3 (42.9)	0.22 [0.02; 2.97] 0.256	0.33 [0.04; 2.48] 0.283	-0.29 [-0.73; 0.16] 0.212
<b>Center No. 1037</b>					
n (%)	3 (33.3)	1 (9.1)	5.00 [0.42; 59.64] 0.203	3.67 [0.46; 29.49] 0.222	0.24 [-0.11; 0.59] 0.177
<b>Center No. 1039</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1040</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1042</b>					
n (%)	1 (25.0)	3 (60.0)	0.22 [0.01; 3.98] 0.307	0.42 [0.07; 2.63] 0.352	-0.35 [-0.95; 0.25] 0.256
<b>Center No. 1044</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1046</b>					
n (%)	1 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1048</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	3 (50.0)	4 (44.4)	1.25 [0.16; 9.92] 0.833	1.13 [0.38; 3.32] 0.831	0.06 [-0.46; 0.57] 0.833
<b>Center No. 1052</b>					
n (%)	1 (14.3)	3 (75.0)	0.06 [<0.01; 1.23] 0.068	0.19 [0.03; 1.27] 0.087	-0.61 [-1.10; -0.11] 0.017

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1059</b>					
n (%)	2 (28.6)	4 (57.1)	0.30 [0.03; 2.76] 0.288	0.50 [0.13; 1.90] 0.309	-0.29 [-0.78; 0.21] 0.259
<b>Center No. 1061</b>					
n (%)	2 (22.2)	0 (0.0)	N.E.	3.50 [0.20; 62.27] 0.394	0.22 [-0.05; 0.49] 0.109
<b>Center No. 1063</b>					
n (%)	1 (25.0)	1 (50.0)	0.33 [<0.01; 11.94] 0.547	0.50 [0.06; 4.47] 0.535	-0.25 [-1.06; 0.56] 0.546
<b>Center No. 1067</b>					
n (%)	3 (30.0)	3 (18.8)	1.86 [0.29; 11.76] 0.511	1.60 [0.40; 6.43] 0.508	0.11 [-0.23; 0.45] 0.520
<b>Center No. 1068</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1069</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.25 [0.02; 3.86] 0.321	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1070</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1073</b>					
n (%)	4 (36.4)	0 (0.0)	N.E.	6.00 [0.37; 96.86] 0.207	0.36 [0.08; 0.65] 0.012
<b>Center No. 1079</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.16 [0.01; 2.47] 0.189	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1080</b>					
n (%)	2 (66.7)	1 (100.0)	N.E.	0.67 [0.30; 1.48] 0.321	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1082</b>					
n (%)	0 (0.0)	4 (50.0)	N.E.	0.17 [0.01; 2.56] 0.199	-0.50 [-0.85; -0.15] 0.005

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1085</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1086</b>					
n (%)	3 (50.0)	5 (55.6)	0.80 [0.10; 6.35] 0.833	0.90 [0.33; 2.42] 0.835	-0.06 [-0.57; 0.46] 0.833
<b>Center No. 1087</b>					
n (%)	1 (100.0)	2 (50.0)	N.E.	2.00 [0.75; 5.33] 0.166	0.50 [0.01; 0.99] 0.046
<b>Center No. 1088</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.33 [0.02; 6.86] 0.476	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1089</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	3.00 [0.16; 57.37] 0.466	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1093</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1095</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.00 [0.11; 37.83] 0.644	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1100</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.50 [0.04; 6.44] 0.595	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1101</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.47 [0.02; 9.26] 0.617	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1103</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.27 [0.02; 3.74] 0.327	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1110</b>					
n (%)	2 (33.3)	0 (0.0)	N.E.	4.29 [0.25; 72.90] 0.314	0.33 [-0.04; 0.71] 0.083

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1113</b>					
n (%)	2 (66.7)	0 (0.0)	N.E.	5.00 [0.34; 74.52] 0.243	0.67 [0.13; 1.20] 0.014
<b>Center No. 1115</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.39 [0.02; 7.88] 0.538	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1118</b>					
n (%)	2 (66.7)	0 (0.0)	N.E.	3.75 [0.27; 52.64] 0.327	0.67 [0.13; 1.20] 0.014
<b>Center No. 1123</b>					
n (%)	1 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1502</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Fatigue</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	2 (20.0)	1 (12.5)	1.75 [0.13; 23.70] 0.674	1.60 [0.17; 14.63] 0.677	0.08 [-0.26; 0.41] 0.663
<b>Center No. 1005</b>					
n (%)	7 (22.6)	6 (27.3)	0.78 [0.22; 2.74] 0.696	0.83 [0.32; 2.13] 0.695	-0.05 [-0.28; 0.19] 0.698
<b>Center No. 1007</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.27 [0.02; 4.59] 0.363	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1008</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1010</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.27 [0.02; 3.74] 0.327	-0.67 [-1.20; -0.13] 0.014

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1011</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.40 [0.03; 5.96] 0.506	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1012</b>					
n (%)	2 (66.7)	1 (20.0)	8.00 [0.31; >99.99] 0.210	3.33 [0.49; 22.90] 0.221	0.47 [-0.17; 1.11] 0.152
<b>Center No. 1014</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1015</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1017</b>					
n (%)	2 (40.0)	1 (25.0)	2.00 [0.11; 35.80] 0.638	1.60 [0.21; 11.92] 0.646	0.15 [-0.45; 0.75] 0.626
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1021</b>					
n (%)	5 (31.3)	1 (10.0)	4.09 [0.40; 41.64] 0.234	3.13 [0.42; 23.01] 0.263	0.21 [-0.08; 0.51] 0.156
<b>Center No. 1022</b>					
n (%)	2 (66.7)	2 (66.7)	1.00 [0.03; 29.81] 1.000	1.00 [0.32; 3.10] 1.000	0.00 [-0.75; 0.75] 1.000
<b>Center No. 1027</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.30 [0.02; 4.74] 0.393	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1028</b>					
n (%)	1 (9.1)	0 (0.0)	N.E.	1.50 [0.07; 31.58] 0.794	0.09 [-0.08; 0.26] 0.294



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1029</b>					
n (%)	3 (20.0)	1 (11.1)	2.00 [0.18; 22.80] 0.577	1.80 [0.22; 14.80] 0.585	0.09 [-0.20; 0.38] 0.546
<b>Center No. 1030</b>					
n (%)	1 (9.1)	2 (22.2)	0.35 [0.03; 4.65] 0.426	0.41 [0.04; 3.82] 0.433	-0.13 [-0.45; 0.19] 0.422
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1035</b>					
n (%)	0 (0.0)	5 (22.7)	N.E.	0.07 [0.00; 1.28] 0.074	-0.23 [-0.40; -0.05] 0.011
<b>Center No. 1036</b>					
n (%)	0 (0.0)	3 (42.9)	N.E.	0.14 [0.01; 2.34] 0.173	-0.43 [-0.80; -0.06] 0.022
<b>Center No. 1037</b>					
n (%)	2 (22.2)	1 (9.1)	2.86 [0.21; 37.99] 0.426	2.44 [0.26; 22.80] 0.433	0.13 [-0.19; 0.45] 0.422
<b>Center No. 1039</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1040</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1042</b>					
n (%)	1 (25.0)	1 (20.0)	1.33 [0.06; 31.12] 0.858	1.25 [0.11; 14.34] 0.858	0.05 [-0.50; 0.60] 0.859
<b>Center No. 1048</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	3 (50.0)	3 (33.3)	2.00 [0.24; 16.61] 0.521	1.50 [0.44; 5.09] 0.516	0.17 [-0.34; 0.67] 0.518

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1052</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.21 [0.01; 4.18] 0.305	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1059</b>					
n (%)	2 (28.6)	4 (57.1)	0.30 [0.03; 2.76] 0.288	0.50 [0.13; 1.90] 0.309	-0.29 [-0.78; 0.21] 0.259
<b>Center No. 1063</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1067</b>					
n (%)	1 (10.0)	2 (12.5)	0.78 [0.06; 9.88] 0.846	0.80 [0.08; 7.72] 0.847	-0.03 [-0.27; 0.22] 0.843
<b>Center No. 1068</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1070</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1073</b>					
n (%)	2 (18.2)	0 (0.0)	N.E.	3.33 [0.18; 60.68] 0.416	0.18 [-0.05; 0.41] 0.118
<b>Center No. 1079</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1082</b>					
n (%)	0 (0.0)	4 (50.0)	N.E.	0.17 [0.01; 2.56] 0.199	-0.50 [-0.85; -0.15] 0.005
<b>Center No. 1085</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1086</b>					
n (%)	1 (16.7)	2 (22.2)	0.70 [0.05; 10.01] 0.793	0.75 [0.09; 6.55] 0.795	-0.06 [-0.46; 0.35] 0.787
<b>Center No. 1087</b>					
n (%)	1 (100.0)	1 (25.0)	N.E.	4.00 [0.73; 21.84] 0.109	0.75 [0.33; 1.17] <.001
<b>Center No. 1088</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.33 [0.02; 6.86] 0.476	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1093</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1095</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.00 [0.11; 37.83] 0.644	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1100</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.50 [0.04; 6.44] 0.595	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1103</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1110</b>					
n (%)	2 (33.3)	0 (0.0)	N.E.	4.29 [0.25; 72.90] 0.314	0.33 [-0.04; 0.71] 0.083
<b>Center No. 1113</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	3.00 [0.17; 53.71] 0.455	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1118</b>					
n (%)	2 (66.7)	0 (0.0)	N.E.	3.75 [0.27; 52.64] 0.327	0.67 [0.13; 1.20] 0.014
<b>Center No. 1502</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Fatigue - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	2 (20.0)	1 (12.5)	1.75 [0.13; 23.70] 0.674	1.60 [0.17; 14.63] 0.677	0.08 [-0.26; 0.41] 0.663
<b>Center No. 1005</b>					
n (%)	7 (22.6)	6 (27.3)	0.78 [0.22; 2.74] 0.696	0.83 [0.32; 2.13] 0.695	-0.05 [-0.28; 0.19] 0.698
<b>Center No. 1007</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.27 [0.02; 4.59] 0.363	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1008</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1010</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.27 [0.02; 3.74] 0.327	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1011</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.40 [0.03; 5.96] 0.506	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1012</b>					
n (%)	2 (66.7)	1 (20.0)	8.00 [0.31; >99.99] 0.210	3.33 [0.49; 22.90] 0.221	0.47 [-0.17; 1.11] 0.152
<b>Center No. 1014</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1015</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1017</b>					
n (%)	2 (40.0)	1 (25.0)	2.00 [0.11; 35.80] 0.638	1.60 [0.21; 11.92] 0.646	0.15 [-0.45; 0.75] 0.626

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1021</b>					
n (%)	5 (31.3)	1 (10.0)	4.09 [0.40; 41.64] 0.234	3.13 [0.42; 23.01] 0.263	0.21 [-0.08; 0.51] 0.156
<b>Center No. 1022</b>					
n (%)	1 (33.3)	2 (66.7)	0.25 [<0.01; 7.45] 0.424	0.50 [0.08; 2.99] 0.448	-0.33 [-1.09; 0.42] 0.386
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
n (%)	1 (9.1)	0 (0.0)	N.E.	1.50 [0.07; 31.58] 0.794	0.09 [-0.08; 0.26] 0.294
<b>Center No. 1029</b>					
n (%)	1 (6.7)	0 (0.0)	N.E.	1.88 [0.08; 41.69] 0.691	0.07 [-0.06; 0.19] 0.301
<b>Center No. 1030</b>					
n (%)	1 (9.1)	2 (22.2)	0.35 [0.03; 4.65] 0.426	0.41 [0.04; 3.82] 0.433	-0.13 [-0.45; 0.19] 0.422
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1035</b>					
n (%)	0 (0.0)	2 (9.1)	N.E.	0.16 [0.01; 3.25] 0.236	-0.09 [-0.21; 0.03] 0.138
<b>Center No. 1036</b>					
n (%)	0 (0.0)	3 (42.9)	N.E.	0.14 [0.01; 2.34] 0.173	-0.43 [-0.80; -0.06] 0.022

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1037</b>					
n (%)	2 (22.2)	1 (9.1)	2.86 [0.21; 37.99] 0.426	2.44 [0.26; 22.80] 0.433	0.13 [-0.19; 0.45] 0.422
<b>Center No. 1039</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1040</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1042</b>					
n (%)	1 (25.0)	1 (20.0)	1.33 [0.06; 31.12] 0.858	1.25 [0.11; 14.34] 0.858	0.05 [-0.50; 0.60] 0.859
<b>Center No. 1048</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	3 (50.0)	3 (33.3)	2.00 [0.24; 16.61] 0.521	1.50 [0.44; 5.09] 0.516	0.17 [-0.34; 0.67] 0.518
<b>Center No. 1052</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.21 [0.01; 4.18] 0.305	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1059</b>					
n (%)	1 (14.3)	4 (57.1)	0.13 [<0.01; 1.67] 0.116	0.25 [0.04; 1.71] 0.158	-0.43 [-0.88; 0.02] 0.061
<b>Center No. 1063</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1067</b>					
n (%)	1 (10.0)	2 (12.5)	0.78 [0.06; 9.88] 0.846	0.80 [0.08; 7.72] 0.847	-0.03 [-0.27; 0.22] 0.843
<b>Center No. 1068</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1070</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1073</b>					
n (%)	2 (18.2)	0 (0.0)	N.E.	3.33 [0.18; 60.68] 0.416	0.18 [-0.05; 0.41] 0.118
<b>Center No. 1079</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1082</b>					
n (%)	0 (0.0)	4 (50.0)	N.E.	0.17 [0.01; 2.56] 0.199	-0.50 [-0.85; -0.15] 0.005
<b>Center No. 1085</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1086</b>					
n (%)	1 (16.7)	2 (22.2)	0.70 [0.05; 10.01] 0.793	0.75 [0.09; 6.55] 0.795	-0.06 [-0.46; 0.35] 0.787
<b>Center No. 1087</b>					
n (%)	1 (100.0)	1 (25.0)	N.E.	4.00 [0.73; 21.84] 0.109	0.75 [0.33; 1.17] <.001
<b>Center No. 1088</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.33 [0.02; 6.86] 0.476	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1093</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1095</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.00 [0.11; 37.83] 0.644	0.20 [-0.15; 0.55] 0.264

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1100</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.50 [0.04; 6.44] 0.595	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1103</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1110</b>					
n (%)	2 (33.3)	0 (0.0)	N.E.	4.29 [0.25; 72.90] 0.314	0.33 [-0.04; 0.71] 0.083
<b>Center No. 1113</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	3.00 [0.17; 53.71] 0.455	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1118</b>					
n (%)	2 (66.7)	0 (0.0)	N.E.	3.75 [0.27; 52.64] 0.327	0.67 [0.13; 1.20] 0.014
<b>Center No. 1502</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Influenza like illness</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	2 (20.0)	1 (12.5)	1.75 [0.13; 23.70] 0.674	1.60 [0.17; 14.63] 0.677	0.08 [-0.26; 0.41] 0.663
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1035</b>					
n (%)	0 (0.0)	1 (4.5)	N.E.	0.27 [0.01; 6.41] 0.421	-0.05 [-0.13; 0.04] 0.306
<b>Center No. 1042</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.24 [0.01; 3.93] 0.317	-0.40 [-0.83; 0.03] 0.068



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1052</b>					
n (%)	1 (14.3)	2 (50.0)	0.17 [<0.01; 2.98] 0.224	0.29 [0.04; 2.25] 0.234	-0.36 [-0.91; 0.20] 0.207
<b>Center No. 1059</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1086</b>					
n (%)	0 (0.0)	2 (22.2)	N.E.	0.29 [0.02; 5.08] 0.394	-0.22 [-0.49; 0.05] 0.109
<b>Center No. 1087</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<b>Influenza like illness - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	2 (20.0)	1 (12.5)	1.75 [0.13; 23.70] 0.674	1.60 [0.17; 14.63] 0.677	0.08 [-0.26; 0.41] 0.663
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1035</b>					
n (%)	0 (0.0)	1 (4.5)	N.E.	0.27 [0.01; 6.41] 0.421	-0.05 [-0.13; 0.04] 0.306
<b>Center No. 1042</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.24 [0.01; 3.93] 0.317	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1052</b>					
n (%)	1 (14.3)	2 (50.0)	0.17 [<0.01; 2.98] 0.224	0.29 [0.04; 2.25] 0.234	-0.36 [-0.91; 0.20] 0.207
<b>Center No. 1059</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1086</b>					
n (%)	0 (0.0)	2 (22.2)	N.E.	0.29 [0.02; 5.08] 0.394	-0.22 [-0.49; 0.05] 0.109
<b>Center No. 1087</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.83 [0.05; 13.02] 0.897	-0.25 [-0.67; 0.17] 0.248
<i>Metabolism and nutrition disorders</i>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	3 (37.5)	N.E.	0.12 [0.01; 1.98] 0.137	-0.38 [-0.71; -0.04] 0.028
<b>Center No. 1002</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.27 [0.02; 3.74] 0.327	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1005</b>					
n (%)	0 (0.0)	2 (9.1)	N.E.	0.14 [0.01; 2.86] 0.203	-0.09 [-0.21; 0.03] 0.138
<b>Center No. 1007</b>					
n (%)	3 (60.0)	2 (28.6)	3.75 [0.33; 42.47] 0.286	2.10 [0.53; 8.29] 0.289	0.31 [-0.23; 0.86] 0.258
<b>Center No. 1008</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.20 [0.01; 2.98] 0.243	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1014</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1015</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1017</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.50 [0.13; 48.85] 0.546	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1021</b>					
n (%)	0 (0.0)	1 (10.0)	N.E.	0.22 [0.01; 4.83] 0.334	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1025</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.17 [0.01; 3.51] 0.249	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1029</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.21 [0.01; 4.63] 0.322	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1030</b>					
n (%)	1 (9.1)	3 (33.3)	0.20 [0.02; 2.39] 0.203	0.27 [0.03; 2.19] 0.222	-0.24 [-0.59; 0.11] 0.177
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1035</b>					
n (%)	1 (3.7)	3 (13.6)	0.24 [0.02; 2.53] 0.237	0.27 [0.03; 2.43] 0.244	-0.10 [-0.26; 0.06] 0.224
<b>Center No. 1036</b>					
n (%)	1 (14.3)	2 (28.6)	0.42 [0.03; 6.06] 0.522	0.50 [0.06; 4.33] 0.529	-0.14 [-0.57; 0.28] 0.508
<b>Center No. 1037</b>					
n (%)	0 (0.0)	4 (36.4)	N.E.	0.13 [0.01; 2.19] 0.158	-0.36 [-0.65; -0.08] 0.012

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1055</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1059</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1067</b>					
n (%)	0 (0.0)	2 (12.5)	N.E.	0.31 [0.02; 5.85] 0.434	-0.13 [-0.29; 0.04] 0.131
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1070</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1073</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.13 [0.01; 2.43] 0.174	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1074</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.22 [0.01; 4.20] 0.316	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1093</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.50 [0.04; 6.44] 0.595	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1105</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	3.00 [0.17; 53.71] 0.455	0.33 [-0.20; 0.87] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1108</b>					
n (%)	1 (6.7)	1 (10.0)	0.64 [0.04; 11.63] 0.765	0.67 [0.05; 9.47] 0.765	-0.03 [-0.26; 0.19] 0.771
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1115</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.23 [0.01; 3.97] 0.314	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1118</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	2.25 [0.13; 38.09] 0.574	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1124</b>					
n (%)	1 (33.3)	1 (50.0)	0.50 [0.01; 19.56] 0.711	0.67 [0.08; 5.54] 0.707	-0.17 [-1.04; 0.71] 0.709
<b>Metabolism and nutrition disorders - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	3 (37.5)	N.E.	0.12 [0.01; 1.98] 0.137	-0.38 [-0.71; -0.04] 0.028
<b>Center No. 1002</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.27 [0.02; 3.74] 0.327	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1005</b>					
n (%)	0 (0.0)	2 (9.1)	N.E.	0.14 [0.01; 2.86] 0.203	-0.09 [-0.21; 0.03] 0.138

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1007</b>					
n (%)	3 (60.0)	2 (28.6)	3.75 [0.33; 42.47] 0.286	2.10 [0.53; 8.29] 0.289	0.31 [-0.23; 0.86] 0.258
<b>Center No. 1008</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.20 [0.01; 2.98] 0.243	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1014</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1015</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1017</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.50 [0.13; 48.85] 0.546	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1021</b>					
n (%)	0 (0.0)	1 (10.0)	N.E.	0.22 [0.01; 4.83] 0.334	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1025</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.17 [0.01; 3.51] 0.249	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1029</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.21 [0.01; 4.63] 0.322	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1030</b>					
n (%)	1 (9.1)	3 (33.3)	0.20 [0.02; 2.39] 0.203	0.27 [0.03; 2.19] 0.222	-0.24 [-0.59; 0.11] 0.177

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1035</b>					
n (%)	1 (3.7)	3 (13.6)	0.24 [0.02; 2.53] 0.237	0.27 [0.03; 2.43] 0.244	-0.10 [-0.26; 0.06] 0.224
<b>Center No. 1036</b>					
n (%)	1 (14.3)	2 (28.6)	0.42 [0.03; 6.06] 0.522	0.50 [0.06; 4.33] 0.529	-0.14 [-0.57; 0.28] 0.508
<b>Center No. 1037</b>					
n (%)	0 (0.0)	4 (36.4)	N.E.	0.13 [0.01; 2.19] 0.158	-0.36 [-0.65; -0.08] 0.012
<b>Center No. 1055</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1059</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1067</b>					
n (%)	0 (0.0)	2 (12.5)	N.E.	0.31 [0.02; 5.85] 0.434	-0.13 [-0.29; 0.04] 0.131
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1070</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1073</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.13 [0.01; 2.43] 0.174	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1074</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.22 [0.01; 4.20] 0.316	-0.33 [-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1093</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.50 [0.04; 6.44] 0.595	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1105</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	3.00 [0.17; 53.71] 0.455	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1108</b>					
n (%)	1 (6.7)	1 (10.0)	0.64 [0.04; 11.63] 0.765	0.67 [0.05; 9.47] 0.765	-0.03 [-0.26; 0.19] 0.771
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1115</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.23 [0.01; 3.97] 0.314	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1118</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	2.25 [0.13; 38.09] 0.574	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1124</b>					
n (%)	1 (33.3)	1 (50.0)	0.50 [0.01; 19.56] 0.711	0.67 [0.08; 5.54] 0.707	-0.17 [-1.04; 0.71] 0.709
<b>Decreased appetite</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.16 [0.01; 2.99] 0.222	-0.25 [-0.55; 0.05] 0.102



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1002</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1005</b>					
n (%)	0 (0.0)	2 (9.1)	N.E.	0.14 [0.01; 2.86] 0.203	-0.09 [-0.21; 0.03] 0.138
<b>Center No. 1007</b>					
n (%)	2 (40.0)	2 (28.6)	1.67 [0.15; 18.87] 0.680	1.40 [0.29; 6.86] 0.678	0.11 [-0.43; 0.66] 0.681
<b>Center No. 1008</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.20 [0.01; 2.98] 0.243	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1015</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1021</b>					
n (%)	0 (0.0)	1 (10.0)	N.E.	0.22 [0.01; 4.83] 0.334	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1025</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.17 [0.01; 3.51] 0.249	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1030</b>					
n (%)	1 (9.1)	3 (33.3)	0.20 [0.02; 2.39] 0.203	0.27 [0.03; 2.19] 0.222	-0.24 [-0.59; 0.11] 0.177

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1035</b>					
n (%)	1 (3.7)	2 (9.1)	0.38 [0.03; 4.55] 0.448	0.41 [0.04; 4.20] 0.451	-0.05 [-0.19; 0.09] 0.450
<b>Center No. 1036</b>					
n (%)	1 (14.3)	2 (28.6)	0.42 [0.03; 6.06] 0.522	0.50 [0.06; 4.33] 0.529	-0.14 [-0.57; 0.28] 0.508
<b>Center No. 1037</b>					
n (%)	0 (0.0)	4 (36.4)	N.E.	0.13 [0.01; 2.19] 0.158	-0.36 [-0.65; -0.08] 0.012
<b>Center No. 1059</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1067</b>					
n (%)	0 (0.0)	1 (6.3)	N.E.	0.52 [0.02; 11.54] 0.676	-0.06 [-0.18; 0.06] 0.302
<b>Center No. 1070</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1073</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.13 [0.01; 2.43] 0.174	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1074</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.22 [0.01; 4.20] 0.316	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1093</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.50 [0.04; 6.44] 0.595	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1105</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	3.00 [0.17; 53.71] 0.455	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1108</b>					
n (%)	0 (0.0)	1 (10.0)	N.E.	0.23 [0.01; 5.12] 0.353	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1115</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.39 [0.02; 7.88] 0.538	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1124</b>					
n (%)	1 (33.3)	1 (50.0)	0.50 [0.01; 19.56] 0.711	0.67 [0.08; 5.54] 0.707	-0.17 [-1.04; 0.71] 0.709
<b>Decreased appetite - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.16 [0.01; 2.99] 0.222	-0.25 [-0.55; 0.05] 0.102
<b>Center No. 1002</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Center No. 1003</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1005</b>					
n (%)	0 (0.0)	2 (9.1)	N.E.	0.14 [0.01; 2.86] 0.203	-0.09 [-0.21; 0.03] 0.138
<b>Center No. 1007</b>					
n (%)	2 (40.0)	2 (28.6)	1.67 [0.15; 18.87] 0.680	1.40 [0.29; 6.86] 0.678	0.11 [-0.43; 0.66] 0.681
<b>Center No. 1008</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.20 [0.01; 2.98] 0.243	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1015</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.20 [0.01; 3.50] 0.271	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1021</b>					
n (%)	0 (0.0)	1 (10.0)	N.E.	0.22 [0.01; 4.83] 0.334	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1025</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.17 [0.01; 3.51] 0.249	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1030</b>					
n (%)	1 (9.1)	3 (33.3)	0.20 [0.02; 2.39] 0.203	0.27 [0.03; 2.19] 0.222	-0.24 [-0.59; 0.11] 0.177
<b>Center No. 1035</b>					
n (%)	1 (3.7)	2 (9.1)	0.38 [0.03; 4.55] 0.448	0.41 [0.04; 4.20] 0.451	-0.05 [-0.19; 0.09] 0.450
<b>Center No. 1036</b>					
n (%)	1 (14.3)	2 (28.6)	0.42 [0.03; 6.06] 0.522	0.50 [0.06; 4.33] 0.529	-0.14 [-0.57; 0.28] 0.508

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1037</b>					
n (%)	0 (0.0)	4 (36.4)	N.E.	0.13 [0.01; 2.19] 0.158	-0.36 [-0.65; -0.08] 0.012
<b>Center No. 1059</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1067</b>					
n (%)	0 (0.0)	1 (6.3)	N.E.	0.52 [0.02; 11.54] 0.676	-0.06 [-0.18; 0.06] 0.302
<b>Center No. 1070</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1073</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.13 [0.01; 2.43] 0.174	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1074</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.22 [0.01; 4.20] 0.316	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1093</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.50 [0.04; 6.44] 0.595	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1105</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	3.00 [0.17; 53.71] 0.455	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1108</b>					
n (%)	0 (0.0)	1 (10.0)	N.E.	0.23 [0.01; 5.12] 0.353	-0.10 [-0.29; 0.09] 0.292

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1115</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.39 [0.02; 7.88] 0.538	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1121</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1124</b>					
n (%)	1 (33.3)	1 (50.0)	0.50 [0.01; 19.56] 0.711	0.67 [0.08; 5.54] 0.707	-0.17 [-1.04; 0.71] 0.709
<b>Cough</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1003</b>					
n (%)	1 (50.0)	1 (33.3)	2.00 [0.05; 78.25] 0.711	1.50 [0.18; 12.46] 0.707	0.17 [-0.71; 1.04] 0.709
<b>Center No. 1014</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1017</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.17 [0.01; 2.73] 0.209	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1029</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.21 [0.01; 4.63] 0.322	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1033</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	4.20 [0.21; 83.34] 0.346	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1036</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1039</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1052</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.21 [0.01; 4.18] 0.305	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1059</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1070</b>					
n (%)	0 (0.0)	2 (40.0)	N.E.	0.60 [0.05; 7.92] 0.698	-0.40 [-0.83; 0.03] 0.068
<b>Center No. 1074</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.00 [0.11; 37.83] 0.644	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1089</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.33 [0.02; 6.37] 0.466	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1095</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.00 [0.11; 37.83] 0.644	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1103</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1108</b>					
n (%)	2 (13.3)	0 (0.0)	N.E.	3.44 [0.18; 64.88] 0.410	0.13 [-0.04; 0.31] 0.129

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1113</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.33 [0.02; 5.97] 0.455	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1115</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.39 [0.02; 7.88] 0.538	-0.17 [-0.46; 0.13] 0.273
<b>Investigations</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	4 (50.0)	N.E.	0.09 [0.01; 1.47] 0.092	-0.50 [-0.85; -0.15] 0.005
<b>Center No. 1005</b>					
n (%)	1 (3.2)	1 (4.5)	0.70 [0.04; 11.83] 0.805	0.71 [0.05; 10.75] 0.805	-0.01 [-0.12; 0.09] 0.809
<b>Center No. 1007</b>					
n (%)	1 (20.0)	2 (28.6)	0.63 [0.04; 9.65] 0.736	0.70 [0.09; 5.76] 0.740	-0.09 [-0.57; 0.40] 0.729
<b>Center No. 1008</b>					
n (%)	1 (33.3)	3 (100.0)	N.E.	0.33 [0.07; 1.65] 0.178	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1021</b>					
n (%)	3 (18.8)	1 (10.0)	2.08 [0.19; 23.30] 0.553	1.88 [0.22; 15.63] 0.561	0.09 [-0.18; 0.35] 0.520
<b>Center No. 1027</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1028</b>					
n (%)	1 (9.1)	1 (20.0)	0.40 [0.02; 8.07] 0.550	0.45 [0.04; 5.89] 0.546	-0.11 [-0.50; 0.28] 0.583



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1030</b>					
n (%)	1 (9.1)	1 (11.1)	0.80 [0.04; 14.89] 0.881	0.82 [0.06; 11.33] 0.881	-0.02 [-0.29; 0.25] 0.882
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1035</b>					
n (%)	2 (7.4)	2 (9.1)	0.80 [0.10; 6.19] 0.831	0.81 [0.12; 5.33] 0.831	-0.02 [-0.17; 0.14] 0.832
<b>Center No. 1036</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.33 [0.02; 7.02] 0.480	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1037</b>					
n (%)	0 (0.0)	3 (27.3)	N.E.	0.17 [0.01; 2.94] 0.224	-0.27 [-0.54; -0.01] 0.042
<b>Center No. 1039</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	2.40 [0.13; 44.42] 0.557	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1040</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	2 (33.3)	0 (0.0)	N.E.	7.14 [0.40; 127.08] 0.181	0.33 [-0.04; 0.71] 0.083
<b>Center No. 1051</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1067</b>					
n (%)	2 (20.0)	4 (25.0)	0.75 [0.11; 5.11] 0.769	0.80 [0.18; 3.59] 0.771	-0.05 [-0.38; 0.28] 0.764
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1070</b>					
n (%)	1 (100.0)	2 (40.0)	N.E.	2.50 [0.85; 7.31] 0.094	0.60 [0.17; 1.03] 0.006
<b>Center No. 1072</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1073</b>					
n (%)	2 (18.2)	0 (0.0)	N.E.	3.33 [0.18; 60.68] 0.416	0.18 [-0.05; 0.41] 0.118
<b>Center No. 1080</b>					
n (%)	1 (33.3)	1 (100.0)	N.E.	0.33 [0.07; 1.65] 0.178	-0.67 [-1.20; -0.13] 0.014
<b>Center No. 1082</b>					
n (%)	1 (20.0)	2 (25.0)	0.75 [0.05; 11.31] 0.835	0.80 [0.10; 6.70] 0.837	-0.05 [-0.51; 0.41] 0.832
<b>Center No. 1085</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	N.E.	N.E.
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1089</b>					
n (%)	2 (50.0)	0 (0.0)	N.E.	5.00 [0.31; 79.94] 0.255	0.50 [0.01; 0.99] 0.046
<b>Center No. 1091</b>					
n (%)	1 (16.7)	0 (0.0)	N.E.	2.57 [0.13; 52.13] 0.538	0.17 [-0.13; 0.46] 0.273
<b>Center No. 1095</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.22 [0.01; 4.20] 0.316	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1108</b>					
n (%)	2 (13.3)	1 (10.0)	1.38 [0.11; 17.67] 0.802	1.33 [0.14; 12.82] 0.803	0.03 [-0.22; 0.29] 0.796

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1115</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.39 [0.02; 7.88] 0.538	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1124</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	2.25 [0.13; 38.09] 0.574	0.33 [-0.20; 0.87] 0.221
<b>Weight decreased</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	3 (37.5)	N.E.	0.12 [0.01; 1.98] 0.137	-0.38 [-0.71; -0.04] 0.028
<b>Center No. 1007</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.27 [0.02; 4.59] 0.363	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1008</b>					
n (%)	1 (33.3)	2 (66.7)	0.25 [<0.01; 7.45] 0.424	0.50 [0.08; 2.99] 0.448	-0.33 [-1.09; 0.42] 0.386
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1028</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.17 [0.01; 3.51] 0.249	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1030</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.28 [0.01; 6.10] 0.416	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1035</b>					
n (%)	1 (3.7)	1 (4.5)	0.81 [0.05; 13.70] 0.882	0.81 [0.05; 12.30] 0.882	-0.01 [-0.12; 0.10] 0.883
<b>Center No. 1037</b>					
n (%)	0 (0.0)	1 (9.1)	N.E.	0.40 [0.02; 8.78] 0.561	-0.09 [-0.26; 0.08] 0.294
<b>Center No. 1040</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.
<b>Center No. 1050</b>					
n (%)	1 (16.7)	0 (0.0)	N.E.	4.29 [0.20; 90.63] 0.350	0.17 [-0.13; 0.46] 0.273
<b>Center No. 1051</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1070</b>					
n (%)	1 (100.0)	1 (20.0)	N.E.	5.00 [0.87; 28.86] 0.072	0.80 [0.45; 1.15] <.001
<b>Center No. 1080</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1082</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.30 [0.02; 5.21] 0.409	-0.25 [-0.55; 0.05] 0.102
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1095</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.22 [0.01; 4.20] 0.316	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1124</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	2.25 [0.13; 38.09] 0.574	0.33 [-0.20; 0.87] 0.221
<b>Weight decreased - non-severe</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	3 (37.5)	N.E.	0.12 [0.01; 1.98] 0.137	-0.38 [-0.71; -0.04] 0.028
<b>Center No. 1007</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.27 [0.02; 4.59] 0.363	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1008</b>					
n (%)	1 (33.3)	2 (66.7)	0.25 [<0.01; 7.45] 0.424	0.50 [0.08; 2.99] 0.448	-0.33 [-1.09; 0.42] 0.386
<b>Center No. 1018</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.29 [0.01; 6.07] 0.426	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1028</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.17 [0.01; 3.51] 0.249	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1030</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.28 [0.01; 6.10] 0.416	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1035</b>					
n (%)	1 (3.7)	1 (4.5)	0.81 [0.05; 13.70] 0.882	0.81 [0.05; 12.30] 0.882	-0.01 [-0.12; 0.10] 0.883
<b>Center No. 1037</b>					
n (%)	0 (0.0)	1 (9.1)	N.E.	0.40 [0.02; 8.78] 0.561	-0.09 [-0.26; 0.08] 0.294
<b>Center No. 1040</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1050</b>					
n (%)	1 (16.7)	0 (0.0)	N.E.	4.29 [0.20; 90.63] 0.350	0.17 [-0.13; 0.46] 0.273
<b>Center No. 1051</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1070</b>					
n (%)	1 (100.0)	1 (20.0)	N.E.	5.00 [0.87; 28.86] 0.072	0.80 [0.45; 1.15] <.001
<b>Center No. 1080</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.
<b>Center No. 1082</b>					
n (%)	0 (0.0)	2 (25.0)	N.E.	0.30 [0.02; 5.21] 0.409	-0.25 [-0.55; 0.05] 0.102
<b>Center No. 1086</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.48 [0.02; 10.07] 0.634	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1095</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.22 [0.01; 4.20] 0.316	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1124</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	2.25 [0.13; 38.09] 0.574	0.33 [-0.20; 0.87] 0.221
<b>Eye disorders</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1005</b>					
n (%)	1 (3.2)	0 (0.0)	N.E.	2.16 [0.09; 50.60] 0.633	0.03 [-0.03; 0.09] 0.309

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1007</b>					
n (%)	0 (0.0)	3 (42.9)	N.E.	0.19 [0.01; 3.03] 0.240	-0.43 [-0.80; -0.06] 0.022
<b>Center No. 1010</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	4.00 [0.24; 67.72] 0.337	0.50 [-0.19; 1.19] 0.157
<b>Center No. 1012</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1017</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1021</b>					
n (%)	1 (6.3)	0 (0.0)	N.E.	1.94 [0.09; 43.50] 0.676	0.06 [-0.06; 0.18] 0.302
<b>Center No. 1028</b>					
n (%)	1 (9.1)	1 (20.0)	0.40 [0.02; 8.07] 0.550	0.45 [0.04; 5.89] 0.546	-0.11 [-0.50; 0.28] 0.583
<b>Center No. 1029</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.21 [0.01; 4.63] 0.322	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1030</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.28 [0.01; 6.10] 0.416	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1034</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1036</b>					
n (%)	1 (14.3)	0 (0.0)	N.E.	3.00 [0.14; 63.15] 0.480	0.14 [-0.12; 0.40] 0.280
<b>Center No. 1037</b>					
n (%)	0 (0.0)	3 (27.3)	N.E.	0.17 [0.01; 2.94] 0.224	-0.27 [-0.54; -0.01] 0.042
<b>Center No. 1042</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.40 [0.02; 7.82] 0.546	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1052</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.21 [0.01; 4.18] 0.305	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1061</b>					
n (%)	1 (11.1)	0 (0.0)	N.E.	2.10 [0.10; 44.41] 0.634	0.11 [-0.09; 0.32] 0.289
<b>Center No. 1068</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1069</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.25 [0.02; 3.86] 0.321	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1070</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1073</b>					
n (%)	1 (9.1)	0 (0.0)	N.E.	2.00 [0.09; 43.22] 0.658	0.09 [-0.08; 0.26] 0.294
<b>Center No. 1074</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.22 [0.01; 4.20] 0.316	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1077</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	2.25 [0.13; 38.09] 0.574	0.33 [-0.20; 0.87] 0.221



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1082</b>					
n (%)	0 (0.0)	1 (12.5)	N.E.	0.50 [0.02; 10.34] 0.654	-0.13 [-0.35; 0.10] 0.285
<b>Center No. 1084</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1086</b>					
n (%)	1 (16.7)	2 (22.2)	0.70 [0.05; 10.01] 0.793	0.75 [0.09; 6.55] 0.795	-0.06 [-0.46; 0.35] 0.787
<b>Center No. 1088</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.33 [0.02; 6.86] 0.476	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1089</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.20 [0.01; 3.20] 0.255	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1095</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.00 [0.11; 37.83] 0.644	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1115</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.23 [0.01; 3.97] 0.314	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1118</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	2.25 [0.13; 38.09] 0.574	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1121</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.20 [0.01; 3.20] 0.255	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1123</b>					
n (%)	1 (100.0)	0 (0.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<i>Eye disorders - non-severe</i>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1005</b>					
n (%)	1 (3.2)	0 (0.0)	N.E.	2.16 [0.09; 50.60] 0.633	0.03 [-0.03; 0.09] 0.309
<b>Center No. 1007</b>					
n (%)	0 (0.0)	2 (28.6)	N.E.	0.27 [0.02; 4.59] 0.363	-0.29 [-0.62; 0.05] 0.094
<b>Center No. 1010</b>					
n (%)	1 (50.0)	0 (0.0)	N.E.	4.00 [0.24; 67.72] 0.337	0.50 [-0.19; 1.19] 0.157
<b>Center No. 1012</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.50 [0.03; 9.46] 0.644	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1017</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.28 [0.01; 5.43] 0.398	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1021</b>					
n (%)	1 (6.3)	0 (0.0)	N.E.	1.94 [0.09; 43.50] 0.676	0.06 [-0.06; 0.18] 0.302
<b>Center No. 1028</b>					
n (%)	1 (9.1)	1 (20.0)	0.40 [0.02; 8.07] 0.550	0.45 [0.04; 5.89] 0.546	-0.11 [-0.50; 0.28] 0.583
<b>Center No. 1029</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.21 [0.01; 4.63] 0.322	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1030</b>					
n (%)	0 (0.0)	1 (11.1)	N.E.	0.28 [0.01; 6.10] 0.416	-0.11 [-0.32; 0.09] 0.289
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1034</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.27 [0.01; 4.94] 0.375	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1036</b>					
n (%)	1 (14.3)	0 (0.0)	N.E.	3.00 [0.14; 63.15] 0.480	0.14 [-0.12; 0.40] 0.280
<b>Center No. 1037</b>					
n (%)	0 (0.0)	3 (27.3)	N.E.	0.17 [0.01; 2.94] 0.224	-0.27 [-0.54; -0.01] 0.042
<b>Center No. 1042</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.40 [0.02; 7.82] 0.546	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1052</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.21 [0.01; 4.18] 0.305	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1061</b>					
n (%)	1 (11.1)	0 (0.0)	N.E.	2.10 [0.10; 44.41] 0.634	0.11 [-0.09; 0.32] 0.289
<b>Center No. 1068</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	N.E.	N.E.
<b>Center No. 1069</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.42 [0.02; 7.71] 0.557	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1070</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	1.00 [0.06; 15.99] 1.000	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1073</b>					
n (%)	1 (9.1)	0 (0.0)	N.E.	2.00 [0.09; 43.22] 0.658	0.09 [-0.08; 0.26] 0.294
<b>Center No. 1074</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.22 [0.01; 4.20] 0.316	-0.33 [-0.87; 0.20] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1077</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	2.25 [0.13; 38.09] 0.574	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1082</b>					
n (%)	0 (0.0)	1 (12.5)	N.E.	0.50 [0.02; 10.34] 0.654	-0.13 [-0.35; 0.10] 0.285
<b>Center No. 1084</b>					
n (%)	0 (0.0)	1 (33.3)	N.E.	0.44 [0.03; 7.52] 0.574	-0.33 [-0.87; 0.20] 0.221
<b>Center No. 1086</b>					
n (%)	1 (16.7)	2 (22.2)	0.70 [0.05; 10.01] 0.793	0.75 [0.09; 6.55] 0.795	-0.06 [-0.46; 0.35] 0.787
<b>Center No. 1088</b>					
n (%)	0 (0.0)	1 (16.7)	N.E.	0.33 [0.02; 6.86] 0.476	-0.17 [-0.46; 0.13] 0.273
<b>Center No. 1089</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.20 [0.01; 3.20] 0.255	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1095</b>					
n (%)	1 (20.0)	0 (0.0)	N.E.	2.00 [0.11; 37.83] 0.644	0.20 [-0.15; 0.55] 0.264
<b>Center No. 1110</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.29 [0.01; 5.79] 0.415	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1115</b>					
n (%)	0 (0.0)	2 (33.3)	N.E.	0.23 [0.01; 3.97] 0.314	-0.33 [-0.71; 0.04] 0.083
<b>Center No. 1118</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	2.25 [0.13; 38.09] 0.574	0.33 [-0.20; 0.87] 0.221

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1121</b>					
n (%)	0 (0.0)	2 (50.0)	N.E.	0.20 [0.01; 3.20] 0.255	-0.50 [-0.99; -0.01] 0.046
<b>Center No. 1123</b>					
n (%)	1 (100.0)	0 (0.0)	N.E.	N.E.	N.E.
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup with treatment group as predictor.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p> <p>Only subgroups with at least one event are displayed.</p> <p>The table displays system organ classes, preferred terms and severity grades with a p-value &lt;0.05 for RR in the total analysis set. The severity grade refers to the maximum observed severity per patient.</p>					

**Table 14.3.1-2.3 Adverse events leading to discontinuation of study treatment, during the study, by primary system organ class, preferred term and maximum severity grade (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N <sup>a</sup>	388	388			
<b>Any AE leading to discontinuation of study treatment</b>					
Total, n (%)	41 (10.6)	151 (38.9)	0.19 [0.13; 0.27] <.001	0.27 [0.20; 0.37] <.001	-0.28 [-0.34; -0.23] <.001
Non-severe, n (%)	34 (8.8)	133 (34.3)	0.18 [0.12; 0.28] <.001	0.26 [0.18; 0.36] <.001	-0.26 [-0.31; -0.20] <.001
Severe, n (%)	7 (1.8)	18 (4.6)	0.38 [0.16; 0.91] 0.031	0.39 [0.16; 0.92] 0.032	-0.03 [-0.05; -0.00] 0.025
<b><i>Nervous system disorders</i></b>					
Total, n (%)	16 (4.1)	91 (23.5)	0.14 [0.08; 0.24] <.001	0.18 [0.11; 0.29] <.001	-0.19 [-0.24; -0.15] <.001
Non-severe, n (%)	13 (3.4)	85 (21.9)	0.12 [0.07; 0.23] <.001	0.15 [0.09; 0.27] <.001	-0.19 [-0.23; -0.14] <.001
Severe, n (%)	3 (0.8)	6 (1.5)	0.50 [0.12; 2.00] 0.324	0.50 [0.13; 1.99] 0.324	-0.01 [-0.02; 0.01] 0.314
<b>Paraesthesia</b>					
Total, n (%)	0 (0.0)	38 (9.8)	N.E.	0.01 [0.00; 0.21] 0.002	-0.10 [-0.13; -0.07] <.001
Non-severe, n (%)	0 (0.0)	35 (9.0)	N.E.	0.01 [0.00; 0.23] 0.003	-0.09 [-0.12; -0.06] <.001
Severe, n (%)	0 (0.0)	3 (0.8)	N.E.	0.14 [0.01; 2.76] 0.198	-0.01 [-0.02; 0.00] 0.082

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Disturbance in attention</b>					
Total, n (%)	7 (1.8)	36 (9.3)	0.18 [0.08; 0.41] <.001	0.19 [0.09; 0.43] <.001	-0.07 [-0.11; -0.04] <.001
Non-severe, n (%)	6 (1.5)	35 (9.0)	0.16 [0.07; 0.38] <.001	0.17 [0.07; 0.40] <.001	-0.07 [-0.11; -0.04] <.001
Severe, n (%)	1 (0.3)	1 (0.3)	1.00 [0.06; 16.04] 1.000	1.00 [0.06; 15.93] 1.000	0.00 [-0.01; 0.01] 1.000
<b>Dizziness</b>					
Total, n (%)	4 (1.0)	21 (5.4)	0.18 [0.06; 0.54] 0.002	0.19 [0.07; 0.55] 0.002	-0.04 [-0.07; -0.02] <.001
Non-severe, n (%)	3 (0.8)	20 (5.2)	0.14 [0.04; 0.49] 0.002	0.15 [0.04; 0.50] 0.002	-0.04 [-0.07; -0.02] <.001
Severe, n (%)	1 (0.3)	1 (0.3)	1.00 [0.06; 16.04] 1.000	1.00 [0.06; 15.93] 1.000	0.00 [-0.01; 0.01] 1.000
<b>Dysgeusia</b>					
Total, n (%)	0 (0.0)	10 (2.6)	N.E.	0.05 [0.00; 0.81] 0.035	-0.03 [-0.04; -0.01] 0.001
Non-severe, n (%)	0 (0.0)	10 (2.6)	N.E.	0.05 [0.00; 0.81] 0.035	-0.03 [-0.04; -0.01] 0.001
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Psychiatric disorders</b>					
Total, n (%)	15 (3.9)	54 (13.9)	0.25 [0.14; 0.45] <.001	0.28 [0.16; 0.48] <.001	-0.10 [-0.14; -0.06] <.001
Non-severe, n (%)	14 (3.6)	51 (13.1)	0.25 [0.13; 0.45] <.001	0.27 [0.15; 0.49] <.001	-0.10 [-0.13; -0.06] <.001
Severe, n (%)	1 (0.3)	3 (0.8)	0.33 [0.03; 3.20] 0.340	0.33 [0.03; 3.19] 0.340	-0.01 [-0.02; 0.00] 0.316

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Depression</b>					
Total, n (%)	3 (0.8)	14 (3.6)	0.21 [0.06; 0.73] 0.014	0.21 [0.06; 0.74] 0.015	-0.03 [-0.05; -0.01] 0.007
Non-severe, n (%)	3 (0.8)	13 (3.4)	0.22 [0.06; 0.80] 0.021	0.23 [0.07; 0.80] 0.021	-0.03 [-0.05; -0.01] 0.011
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<b>Irritability</b>					
Total, n (%)	0 (0.0)	10 (2.6)	N.E.	0.05 [0.00; 0.81] 0.035	-0.03 [-0.04; -0.01] 0.001
Non-severe, n (%)	0 (0.0)	10 (2.6)	N.E.	0.05 [0.00; 0.81] 0.035	-0.03 [-0.04; -0.01] 0.001
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Gastrointestinal disorders</b>					
Total, n (%)	13 (3.4)	43 (11.1)	0.28 [0.15; 0.53] <.001	0.30 [0.17; 0.55] <.001	-0.08 [-0.11; -0.04] <.001
Non-severe, n (%)	12 (3.1)	42 (10.8)	0.26 [0.14; 0.51] <.001	0.29 [0.15; 0.53] <.001	-0.08 [-0.11; -0.04] <.001
Severe, n (%)	1 (0.3)	1 (0.3)	1.00 [0.06; 16.04] 1.000	1.00 [0.06; 15.93] 1.000	0.00 [-0.01; 0.01] 1.000
<b>Nausea</b>					
Total, n (%)	8 (2.1)	26 (6.7)	0.29 [0.13; 0.66] 0.003	0.31 [0.14; 0.67] 0.003	-0.05 [-0.08; -0.02] 0.001
Non-severe, n (%)	7 (1.8)	25 (6.4)	0.27 [0.11; 0.62] 0.002	0.28 [0.12; 0.64] 0.003	-0.05 [-0.07; -0.02] 0.001
Severe, n (%)	1 (0.3)	1 (0.3)	1.00 [0.06; 16.04] 1.000	1.00 [0.06; 15.93] 1.000	0.00 [-0.01; 0.01] 1.000



	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>General disorders and administration site conditions</b>					
Total, n (%)	10 (2.6)	37 (9.5)	0.25 [0.12; 0.51] <.001	0.27 [0.14; 0.54] <.001	-0.07 [-0.10; -0.04] <.001
Non-severe, n (%)	8 (2.1)	34 (8.8)	0.22 [0.10; 0.48] <.001	0.24 [0.11; 0.50] <.001	-0.07 [-0.10; -0.04] <.001
Severe, n (%)	2 (0.5)	3 (0.8)	0.67 [0.11; 4.00] 0.656	0.67 [0.11; 3.97] 0.656	-0.00 [-0.01; 0.01] 0.654
<b>Fatigue</b>					
Total, n (%)	9 (2.3)	29 (7.5)	0.29 [0.14; 0.63] 0.002	0.31 [0.15; 0.65] 0.002	-0.05 [-0.08; -0.02] <.001
Non-severe, n (%)	7 (1.8)	26 (6.7)	0.26 [0.11; 0.60] 0.002	0.27 [0.12; 0.61] 0.002	-0.05 [-0.08; -0.02] <.001
Severe, n (%)	2 (0.5)	3 (0.8)	0.67 [0.11; 4.00] 0.656	0.67 [0.11; 3.97] 0.656	-0.00 [-0.01; 0.01] 0.654
<b>Ear and labyrinth disorders</b>					
Total, n (%)	5 (1.3)	14 (3.6)	0.35 [0.12; 0.98] 0.045	0.36 [0.13; 0.98] 0.046	-0.02 [-0.04; -0.00] 0.036
Non-severe, n (%)	4 (1.0)	11 (2.8)	0.36 [0.11; 1.13] 0.080	0.36 [0.12; 1.13] 0.081	-0.02 [-0.04; 0.00] 0.067
Severe, n (%)	1 (0.3)	3 (0.8)	0.33 [0.03; 3.20] 0.340	0.33 [0.03; 3.19] 0.340	-0.01 [-0.02; 0.00] 0.316
<b>Vertigo</b>					
Total, n (%)	4 (1.0)	13 (3.4)	0.30 [0.10; 0.93] 0.037	0.31 [0.10; 0.94] 0.038	-0.02 [-0.04; -0.00] 0.027
Non-severe, n (%)	3 (0.8)	10 (2.6)	0.29 [0.08; 1.08] 0.065	0.30 [0.08; 1.08] 0.066	-0.02 [-0.04; -0.00] 0.050
Severe, n (%)	1 (0.3)	3 (0.8)	0.33 [0.03; 3.20] 0.340	0.33 [0.03; 3.19] 0.340	-0.01 [-0.02; 0.00] 0.316

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b><i>Eye disorders</i></b>					
Total, n (%)	2 (0.5)	10 (2.6)	0.20 [0.04; 0.90] 0.036	0.20 [0.04; 0.91] 0.037	-0.02 [-0.04; -0.00] 0.020
Non-severe, n (%)	2 (0.5)	9 (2.3)	0.22 [0.05; 1.02] 0.052	0.22 [0.05; 1.02] 0.053	-0.02 [-0.03; -0.00] 0.033
Severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR is obtained from a logistic regression model with treatment group as predictor.  RR and RD are calculated directly with CI and p-value based on the Wald statistic.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p> <p>The table displays system organ classes (<i>italic/bold</i>) and preferred terms (<b>bold</b>) with a prevalence <math>\geq 5\%</math> or a prevalence <math>\geq 10</math> patients AND <math>\geq 1\%</math> in at least one treatment arm. The severity grade refers to the maximum observed severity per patient.</p>					

**Table 14.3.1-2.6 Serious adverse events (SAE), regardless of study treatment relationship, during the study, by primary system organ class, preferred term and maximum severity grade (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N <sup>1</sup>	388	388			
<b>Any SAE</b>					
Total, n (%)	10 (2.6)	19 (4.9)	0.51 [0.24; 1.12] 0.094	0.53 [0.25; 1.12] 0.095	-0.02 [-0.05; 0.00] 0.088
Non-severe, n (%)	3 (0.8)	11 (2.8)	0.27 [0.07; 0.96] 0.044	0.27 [0.08; 0.97] 0.045	-0.02 [-0.04; -0.00] 0.030
Severe, n (%)	7 (1.8)	8 (2.1)	0.87 [0.31; 2.43] 0.794	0.88 [0.32; 2.39] 0.794	-0.00 [-0.02; 0.02] 0.794
<p>N<sup>1</sup>: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR is obtained from a logistic regression model with treatment group as predictor.  RR and RD are calculated directly with CI and p-value based on the Wald statistic.</p> <p>The table displays system organ classes (<i>italic/bold</i>) and preferred terms (<b>bold</b>) with a prevalence <math>\geq 5\%</math> or a prevalence <math>\geq 10</math> patients AND <math>\geq 1\%</math> in at least one treatment arm. The severity grade refers to the maximum observed severity per patient.</p>					

**Table 14.3.1-2.8 Serious adverse events (SAE) leading to discontinuation of study treatment, during the study, by primary system organ class, preferred term and maximum severity grade (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N <sup>1</sup>	388	388			
<b>Any SAE leading to discontinuation of study treatment</b>					
Total, n (%)	0 (0.0)	3 (0.8)	N.E.	0.14 [0.01; 2.76] 0.198	-0.01 [-0.02; 0.00] 0.082
Non-severe, n (%)	0 (0.0)	1 (0.3)	N.E.	0.33 [0.01; 8.16] 0.501	-0.00 [-0.01; 0.00] 0.317
Severe, n (%)	0 (0.0)	2 (0.5)	N.E.	0.20 [0.01; 4.15] 0.298	-0.01 [-0.01; 0.00] 0.156
<p>N<sup>1</sup>: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>OR is obtained from a logistic regression model with treatment group as predictor.  RR and RD are calculated directly with CI and p-value based on the Wald statistic.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.</p> <p>The table displays system organ classes (<i>italic/bold</i>) and preferred terms (<b>bold</b>) with a prevalence <math>\geq 5\%</math> or a prevalence <math>\geq 10</math> patients AND <math>\geq 1\%</math> in at least one treatment arm. The severity grade refers to the maximum observed severity per patient.</p>					

**Table 14.3.1-2.9 Adverse events of special interest (AESI), during the study, by maximum severity grade (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
<b>Ischaemic heart disease</b>					
Total, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Non-severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Ischaemic central nervous vascular conditions</b>					
Total, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Non-severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<b>Hypertension</b>					
Total, n (%)	9 (2.3)	12 (3.1)	0.74 [0.31; 1.79] 0.508	0.75 [0.32; 1.76] 0.508	-0.01 [-0.03; 0.02] 0.507
Non-severe, n (%)	9 (2.3)	12 (3.1)	0.74 [0.31; 1.79] 0.508	0.75 [0.32; 1.76] 0.508	-0.01 [-0.03; 0.02] 0.507
Severe, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	N.E.	N.E.	N.E.
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>OR is obtained from a logistic regression model with treatment group as predictor. RR and RD are calculated directly with CI and p-value based on the Wald statistic.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups. RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p> <p>The severity grade refers to the maximum observed severity per patient.</p>					

**Table 14.3.1-2.9.1 Adverse events of special interest (AESI), during the study, by Age Group (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
< median age, N'	186	190			
≥ median age, N'	202	198			
<b>Hypertension</b>					
<b>Interaction test: p=0.919</b>					
<b>&lt; median age</b>					
n (%)	2 (1.1)	3 (1.6)	0.68 [0.11; 4.10] 0.672	0.68 [0.12; 4.03] 0.672	-0.01 [-0.03; 0.02] 0.669
<b>≥ median age</b>					
n (%)	7 (3.5)	9 (4.5)	0.75 [0.28; 2.07] 0.583	0.76 [0.29; 2.01] 0.583	-0.01 [-0.05; 0.03] 0.582
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Only subgroups with at least one event are displayed.</p>					

**Table 14.3.1-2.9.2 Adverse events of special interest (AESI), during the study, by Gender (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
Male, N'	57	53			
Female, N'	331	335			
<b>Hypertension</b>					
<b>Interaction test: N.E.</b>					
<b>Female</b>					
n (%)	9 (2.7)	12 (3.6)	0.75 [0.31; 1.81] 0.525	0.76 [0.32; 1.78] 0.525	-0.01 [-0.04; 0.02] 0.523
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup with treatment group as predictor.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Only subgroups with at least one event are displayed.</p>					

**Table 14.3.1-2.9.3 Adverse events of special interest (AESI), during the study, by Disease Severity (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
4-7 monthly migraine days at baseline <sup>1</sup> , N'	96	92			
8-14 monthly migraine days at baseline <sup>2</sup> , N'	249	254			
≥ 15 monthly migraine days at baseline, N'	43	42			
<b>Hypertension</b>					
<b>Interaction test: N.E.</b>					
<b>4-7 monthly migraine days at baseline<sup>1</sup></b>					
n (%)	0 (0.0)	5 (5.4)	N.E.	0.09 [0.00; 1.55] 0.097	-0.05 [-0.10; -0.01] 0.021
<b>8-14 monthly migraine days at baseline<sup>2</sup></b>					
n (%)	9 (3.6)	5 (2.0)	1.87 [0.62; 5.65] 0.269	1.84 [0.62; 5.40] 0.270	0.02 [-0.01; 0.05] 0.263
<b>≥ 15 monthly migraine days at baseline</b>					
n (%)	0 (0.0)	2 (4.8)	N.E.	0.20 [0.01; 3.95] 0.287	-0.05 [-0.11; 0.02] 0.147
<p>N': Number of patients in the analysis n (%): Number and percentage of patients with event CI: Confidence Interval N.E.: Not estimable OR: Odds Ratio RR: Relative Risk RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction. If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup with treatment group as predictor. RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.</p> <p>Only subgroups with at least one event are displayed.</p> <p><sup>1</sup> Subgroup '4-7 monthly migraine days at baseline' includes 2 subjects in the AMG334 arm with less than 4 monthly migraine days at baseline. <sup>2</sup> Subgroup '8-14 monthly migraine days at baseline' includes 1 subject in the AMG334 arm for whom monthly migraine days at baseline could not be calculated. This subject was assigned to this subgroup based on the stratification factor selected by the study center at randomization.</p>					



**Table 14.3.1-2.9.4 Adverse events of special interest (AESI), during the study, by Prior Treatment Failure Status (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
Naïve*, N'	232	229			
Prior treatment failure*, N'	156	159			
<b>Hypertension</b>					
<b>Interaction test: p=0.502</b>					
<b>Naïve*</b>					
n (%)	4 (1.7)	7 (3.1)	0.56 [0.16; 1.93] 0.355	0.56 [0.17; 1.90] 0.356	-0.01 [-0.04; 0.01] 0.349
<b>Prior treatment failure*</b>					
n (%)	5 (3.2)	5 (3.1)	1.02 [0.29; 3.59] 0.976	1.02 [0.30; 3.45] 0.976	0.00 [-0.04; 0.04] 0.976
<p>N': Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>Only subgroups with at least one event are displayed.</p> <p>*: 'Naïve'/Prior treatment failure' relates to propranolol/metoprolol, amitriptyline, flunarizine.</p>					

**Table 14.3.1-2.9.5 Adverse events of special interest (AESI), during the study, by Study Center (Safety Analysis Set)**

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
N'	388	388			
Center No. 1001, N'	10	8			
Center No. 1002, N'	4	0			
Center No. 1003, N'	2	3			
Center No. 1005, N'	31	22			
Center No. 1007, N'	5	7			
Center No. 1008, N'	3	3			
Center No. 1010, N'	2	3			
Center No. 1011, N'	2	5			
Center No. 1012, N'	3	5			
Center No. 1014, N'	5	4			
Center No. 1015, N'	4	2			
Center No. 1017, N'	5	4			
Center No. 1018, N'	7	6			
Center No. 1019, N'	2	2			
Center No. 1021, N'	16	10			
Center No. 1022, N'	3	3			
Center No. 1025, N'	0	2			
Center No. 1027, N'	3	5			
Center No. 1028, N'	11	5			
Center No. 1029, N'	15	9			
Center No. 1030, N'	11	9			
Center No. 1032, N'	2	4			
Center No. 1033, N'	4	6			
Center No. 1034, N'	4	3			
Center No. 1035, N'	27	22			
Center No. 1036, N'	7	7			
Center No. 1037, N'	9	11			
Center No. 1039, N'	4	3			
Center No. 1040, N'	0	3			
Center No. 1041, N'	5	5			
Center No. 1042, N'	4	5			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1044, N <sup>a</sup>	0	2			
Center No. 1046, N <sup>a</sup>	1	1			
Center No. 1048, N <sup>a</sup>	0	3			
Center No. 1049, N <sup>a</sup>	1	0			
Center No. 1050, N <sup>a</sup>	6	9			
Center No. 1051, N <sup>a</sup>	1	1			
Center No. 1052, N <sup>a</sup>	7	4			
Center No. 1055, N <sup>a</sup>	2	4			
Center No. 1058, N <sup>a</sup>	0	1			
Center No. 1059, N <sup>a</sup>	7	7			
Center No. 1061, N <sup>a</sup>	9	6			
Center No. 1063, N <sup>a</sup>	4	2			
Center No. 1064, N <sup>a</sup>	0	3			
Center No. 1067, N <sup>a</sup>	10	16			
Center No. 1068, N <sup>a</sup>	0	2			
Center No. 1069, N <sup>a</sup>	3	4			
Center No. 1070, N <sup>a</sup>	1	5			
Center No. 1072, N <sup>a</sup>	2	1			
Center No. 1073, N <sup>a</sup>	11	7			
Center No. 1074, N <sup>a</sup>	5	3			
Center No. 1076, N <sup>a</sup>	1	5			
Center No. 1077, N <sup>a</sup>	3	2			
Center No. 1079, N <sup>a</sup>	4	3			
Center No. 1080, N <sup>a</sup>	3	1			
Center No. 1082, N <sup>a</sup>	5	8			
Center No. 1084, N <sup>a</sup>	2	3			
Center No. 1085, N <sup>a</sup>	0	3			
Center No. 1086, N <sup>a</sup>	6	9			
Center No. 1087, N <sup>a</sup>	1	4			
Center No. 1088, N <sup>a</sup>	6	6			
Center No. 1089, N <sup>a</sup>	4	4			
Center No. 1091, N <sup>a</sup>	6	5			
Center No. 1093, N <sup>a</sup>	1	4			
Center No. 1095, N <sup>a</sup>	5	3			
Center No. 1096, N <sup>a</sup>	2	0			

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Center No. 1100, N <sup>a</sup>	1	4			
Center No. 1101, N <sup>a</sup>	4	6			
Center No. 1103, N <sup>a</sup>	2	3			
Center No. 1105, N <sup>a</sup>	3	3			
Center No. 1108, N <sup>a</sup>	15	10			
Center No. 1110, N <sup>a</sup>	6	5			
Center No. 1111, N <sup>a</sup>	5	0			
Center No. 1113, N <sup>a</sup>	3	3			
Center No. 1115, N <sup>a</sup>	5	6			
Center No. 1116, N <sup>a</sup>	1	4			
Center No. 1118, N <sup>a</sup>	3	2			
Center No. 1119, N <sup>a</sup>	3	5			
Center No. 1121, N <sup>a</sup>	4	4			
Center No. 1123, N <sup>a</sup>	1	1			
Center No. 1124, N <sup>a</sup>	3	2			
Center No. 1502, N <sup>a</sup>	0	3			
<b>Hypertension</b>					
<b>Interaction test: N.E.</b>					
<b>Center No. 1001</b>					
n (%)	0 (0.0)	1 (12.5)	N.E.	0.27 [0.01; 5.92] 0.408	-0.13 [-0.35; 0.10] 0.285
<b>Center No. 1012</b>					
n (%)	1 (33.3)	0 (0.0)	N.E.	4.50 [0.24; 85.12] 0.316	0.33 [-0.20; 0.87] 0.221
<b>Center No. 1019</b>					
n (%)	0 (0.0)	1 (50.0)	N.E.	0.33 [0.02; 5.33] 0.437	-0.50 [-1.19; 0.19] 0.157
<b>Center No. 1021</b>					
n (%)	0 (0.0)	1 (10.0)	N.E.	0.22 [0.01; 4.83] 0.334	-0.10 [-0.29; 0.09] 0.292
<b>Center No. 1027</b>					
n (%)	1 (33.3)	1 (20.0)	2.00 [0.08; 51.59] 0.676	1.67 [0.16; 17.89] 0.673	0.13 [-0.51; 0.77] 0.682


	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1028</b>					
n (%)	1 (9.1)	0 (0.0)	N.E.	1.50 [0.07; 31.58] 0.794	0.09 [-0.08; 0.26] 0.294
<b>Center No. 1030</b>					
n (%)	1 (9.1)	0 (0.0)	N.E.	2.50 [0.11; 54.87] 0.561	0.09 [-0.08; 0.26] 0.294
<b>Center No. 1032</b>					
n (%)	0 (0.0)	1 (25.0)	N.E.	0.56 [0.03; 9.73] 0.687	-0.25 [-0.67; 0.17] 0.248
<b>Center No. 1035</b>					
n (%)	1 (3.7)	1 (4.5)	0.81 [0.05; 13.70] 0.882	0.81 [0.05; 12.30] 0.882	-0.01 [-0.12; 0.10] 0.883
<b>Center No. 1042</b>					
n (%)	0 (0.0)	1 (20.0)	N.E.	0.40 [0.02; 7.82] 0.546	-0.20 [-0.55; 0.15] 0.264
<b>Center No. 1050</b>					
n (%)	1 (16.7)	0 (0.0)	N.E.	4.29 [0.20; 90.63] 0.350	0.17 [-0.13; 0.46] 0.273
<b>Center No. 1063</b>					
n (%)	1 (25.0)	0 (0.0)	N.E.	1.80 [0.10; 31.52] 0.687	0.25 [-0.17; 0.67] 0.248
<b>Center No. 1067</b>					
n (%)	1 (10.0)	0 (0.0)	N.E.	4.64 [0.21; 103.90] 0.334	0.10 [-0.09; 0.29] 0.292
<b>Center No. 1069</b>					
n (%)	1 (33.3)	1 (25.0)	1.50 [0.06; 40.63] 0.810	1.33 [0.13; 13.74] 0.809	0.08 [-0.60; 0.76] 0.811
<b>Center No. 1073</b>					
n (%)	0 (0.0)	1 (14.3)	N.E.	0.22 [0.01; 4.80] 0.337	-0.14 [-0.40; 0.12] 0.280
<b>Center No. 1080</b>					
n (%)	0 (0.0)	1 (100.0)	N.E.	N.E.	N.E.

	Treatment Groups		Comparison		
	AMG334 (N=388)	Topiramate (N=388)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
<b>Center No. 1084</b>					
n (%)	0 (0.0)	2 (66.7)	N.E.	0.27 [0.02; 3.74] 0.327	-0.67 [-1.20; -0.13] 0.014
<p>N: Number of patients in the analysis  n (%): Number and percentage of patients with event  CI: Confidence Interval  N.E.: Not estimable  OR: Odds Ratio  RR: Relative Risk  RD: Risk Difference</p> <p>Interaction test and OR are obtained from a logistic regression model that includes treatment group, subgroup factor and treatment by subgroup factor interaction.  If the interaction test is N.E., OR are obtained from separate logistic regression models for each subgroup with treatment group as predictor.  RR and RD are calculated directly within subgroups, with CI and p-value based on the Wald statistic.</p> <p>OR is N.E. if the incidence of events is zero or 100% in one or both treatment groups.  RR and RD are N.E. if the incidence of events is zero or 100% in both treatment groups or if there are no subjects in one of the treatment groups.</p> <p>Only subgroups with at least one event are displayed.</p>					


## Figures

### Efficacy Analysis

Figure 14.2-2.1 Monthly Migraine Days - Boxplot (Full Analysis Set)




**Figure 14.2-4.1 HIT-6, Headache Impact Test - Boxplot (Full Analysis Set)**







**Figure 14.2-5.1a SF-36v2, Quality of Life, Physical Component Summary - Boxplot (Full Analysis Set)**




**Figure 14.2-5.1b SF-36v2, Quality of Life, Mental Component Summary - Boxplot (Full Analysis Set)**




**Figure 14.2-6.1a TSQM Ver II, Satisfaction with Treatment, Effectiveness - Boxplot  
(Full Analysis Set)**



**Figure 14.2-6.1b TSQM Ver II, Satisfaction with Treatment, Side effects - Boxplot (Full Analysis Set)**



**Figure 14.2-6.1c TSQM Ver II, Satisfaction with Treatment, Convenience - Boxplot  
(Full Analysis Set)**



**Figure 14.2-6.1d TSQM Ver II, Satisfaction with Treatment, Global satisfaction - Boxplot (Full Analysis Set)**

